

8. The fusion protein of claim 7, wherein the fusion protein comprises a sequence selected from the group consisting of:

- (a) sequences provided in SEQ ID NO: 682, 692, 695, 699, 703 and 709; and
- (b) sequences encoded by SEQ ID NO: 679, 691, 696, 700, 704 and 708.

9. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 or 786-788 under moderately stringent conditions.

10. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polypeptide according to claim 1,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

11. An isolated T cell population, comprising T cells prepared according to the method of claim 10.

12. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 11; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

13. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 12.

14. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 12.

15. A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 9;
- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and
- (d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

16. A diagnostic kit comprising at least one oligonucleotide according to claim 9.

17. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.


18. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate; and



(b) administering to the patient an effective amount of the proliferated T cells,

thereby inhibiting the development of a cancer in the patient.

1/10

*Fig. 1*

2/10

*Fig. 2A**Fig. 2B*

3/10








Fig. 3

4/10

*Fig. 4**Fig. 5*


5/10

*Fig. 6A**Fig. 6B*

SUBSTITUTE SHEET (RULE 26)

6/10

Expression of P501S
by the Baculovirus Expression System



C 6 million high 5 cells in 6-well plate were infected with an unrelated control virus BV/ECD_PD (lane 2), without virus (lane 3), or with recombinant baculovirus for P501 at different MOIs (lane 4-8). Cell lysates were run on SDS-PAGE under the reducing conditions and analyzed by Western blot with a monoclonal antibody against P501S (P501S-10E3-G4D3). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

Fig. 7

7/10

FIGURE 8. Mapping of the epitope recognized by 10E3-G4-D3




Fig. 8

8/10

Schematic of P501S with predicted
transmembrane, cytoplasmic, and extracellular regions

MVQRLWVSRLLRHRK AQLLLVNLLTFGLEVCLAAGIT **YVPPLLLEVGVEEKFM**
TMVLGIGPVLGLVCYPLLGSAS

DHWRGRYGRRRP FIWALSLGILLSLFLIPRAGWL AGLLCPDPRPLE LALLILGVGLLDFCGQVCFTPL

EALISDLFRDPDHCRQ AYSVYAFMISLGGCLGYLLPAI **DWDT****SALAPYLGTQEE**

CLFGLLTLIFLTCVAATLLV *AEEAALGPTEPAEGLSAPSLSPHCCPCRARLAFRNLGALLPRL*

HQLCCRMPTLRR LFVAELCSWMALMTFTLFYTD VGEGLYQGVPRAE**PGTEARRHYDEGVR**

MGSLGLFLQCAISLVFSLVM *DRLVQRF***GTRAVYLAS** VAAFPVAAGATCLSHSVAVVTA **SAA**

LTGFTFSALQILPYTLASLY *HREKQVFLPKYRGDTGGASSED***SLMTSFLPGPKPGAPFPNGHVGAGGSGL**

*LPPPPALCGASACDVSVRVVVGEPT***EARVVPGRG** ICLDLAILDSAFLLSQVAPSLF **MG****SIVQLSQS**

VTAYMVSAAGLGLVAIFYAT *QVVFDK***SDLAKYSA**

Underlined sequence: Predicted transmembrane domain; **Bold sequence**:
Predicted extracellular domain; *Italic sequence*: Predicted intracellular
domain. Sequence in bold/underlined: used generate polyclonal rabbit
serum

Localization of domains predicted using HMMTOP (G.E. Tusnady and I. Simon
(1998) Principles Governing Amino Acid Composition of Integral Membrane
Proteins: Applications to topology Prediction. J. Mol Biol. 283, 489-506.

Fig. 9

9/10

Genomic Map of (5) Corixa Candidate Genes




Fig. 10

10/10




Fig. 11

SEQUENCE LISTING

<110> Corixa Corporation
 Smithkline Beechan Biologicals S.A.
Xu, Jiangchun
 Dillon, Davin C.
 Mitcham, Jennifer L.
 Harlocker, Susan L.
 Jiang, Yuqui
 Reed, Steven G.
 Kalos, Michael D.
 Fanger, Gary R.
 Retter, Marc W.
 Stolk, John A.
 Day, Craig H.
 Skeiky, Yasir A.W.
 Wang, Aijun
 Meagher, Medeleine Joy
 Vanderbrugge, Didier
 Dewerchin, Marianne
 Dehottay, Ph.
 de Rop, Philippe

<120> COMPOSITIONS AND METHODS FOR THE THERAPY AND
 DIAGNOSIS OF PROSTATE CANCER

<130> 210121.42722PC

<140> PCT

<141> 2001-01-16

<160> 792

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 814

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(814)

<223> n = A,T,C or G

<400> 1

tttttttttt	tttttcacag	tataacagct	ctttatttct	gtgagttcta	ctaggaaatc	60
atcaaatctg	aggggtgtct	ggaggacttc	aatacacctc	cccccatagt	gaatcagctt	120
ccaggggggc	cagtcacctc	ccttacttca	tccccatccc	atgccaaagg	aagacctccc	180
ctcettggct	cacagccttc	tctaggtctc	ccagtgcctc	caggacagag	tgggttatgt	240
tttcagctcc	atccttgctg	tgagtgtctg	gtgcgttggtg	cctccagctt	ctgctcagtg	300
cttcatggac	agtgtccagc	acatgtcact	ctccactctc	tcagtgtgga	tccactagtt	360
ctagagcggc	cgccaccgcg	gtggagctcc	agcttttggt	cccttttagtg	agggttaatt	420
gcgcgcttgg	cgtaatcatg	gtcataactg	tttcctgtgt	gaaattgtta	tccgctcaca	480
attccacaca	acatacgagc	cggaagcata	aagtgtaaag	cctgggggtgc	ctaatgagtg	540
anctaactca	cattaattgc	gttgcgctca	ctgnccgctt	tccagtcngg	aaaactgtcg	600
tgccagctgc	attaatgaat	cggccaacgc	ncgggggaaaa	gcggtttgcg	ttttgggggc	660

```

tcttgcgctt ctcgctcact nantcctgcg ctcggctcctt cggtctgcggg gaaacgggtatc 720
actcctcaaaa gngggtatta cgggttatccn naaatcnggg gatacccnngg aaaaaanttt 780
aacaaaaggg cancaaaggg cngaaacgta aaaa 814

```

```

<210> 2
<211> 816
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(816)
<223> n = A,T,C or G

```

```

<400> 2
acagaaatgt tggatggtgg agcacctttc tatacgactt acaggacagc agatggggaa 60
ttcatggctg ttggagcaat agaaccccag ttctacgagc tgctgatcaa aggacttggg 120
ctaaagtctg atgaacttcc caatcagatg agcatggatg attggccaga aatgaagaag 180
aagtttgcag atgtatttgc aaagaagacg aaggcagagt ggtgtcaaat ctttgacggc 240
acagatgcct gtgtgactcc ggttctgact tttagaggag ttgttcatca tgatcacaaac 300
aaggaaacggg gctcgtttat caccagttag gagcaggacg tgagcccccg ccttgcacct 360
ctgctgttaa acaccccagc catcccttct ttcaaaaggg atccactagt tctagaagcg 420
gcccacacgg cgggtggagct ccagcttttg ttcccttttag tgagggttaa ttgcgcgctt 480
ggcgtaataca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccccc 540
aacatacgag ccggaacata aagtgttaag cctgggggtgc ctaatgantg agctaactcn 600
cattaattgc gttgcgctca ctgcccgtt tccagtcggg aaaactgtcg tgccactgcn 660
ttantgaatc ngccaccccc cgggaaaagg cggttgcctt ttgggcctct tccgctttcc 720
tcgctcattg atcctngcnc ccggtcttcg gctgcggnga acggttcaact cctcaaaggc 780
ggtntnccgg ttatccccaac acnggggata cccnga 816

```

```

<210> 3
<211> 773
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(773)
<223> n = A,T,C or G

```

```

<400> 3
ctttlgaaag aagggatggc tggggtgttt aacagcagag gtgcaggggc ggggctcacg 60
tctgtctcct cactgggtgat aaacgagccc cgttccttgt tgtgatcatg atgaacaacc 120
tctcaaaaag tcagaaccgg agtcacacag gcatctgtgc cgtcaaagat ttgacaccac 180
tctgccttcg tcttcttttg aaatacatct gcaaacttct tcttcatttc tggccaatca 240
tccatgctca tctgattggg aagttcatca gacttttagt canntccttt gatcagcagc 300
tcgtagaact ggggttctat tgctccaaca gccatgaatt ccccatctgc tgtcctgtaa 360
gtcgtataga aaggtgctcc accatccaac atgttctgtc ctgcaggggg ggcccggtag 420
ccaattcgcc ctatantgag tcgtattacg cgcgctcact ggccgtcgtt ttacaacgtc 480
gtgactggga aaaccctggg cgtaaccaac ttaatcgctt tgcagacat ccccttttcg 540
ccagctgggc gtaatancca aaaggcccgc accgatcgcc cttccaacag ttgcgcacct 600
gaatgggnaa atgggacccc cctgttaccg cgcattnaac ccccgcnngg tttngttgtt 660
acccccacnt nnaccgctta cactttgccg gcgccttanc gcccgctccc ttttnccttt 720
cttcccttcc ttttncnccn ctctcccccg gggtttcccc cntcaaacc cna 773

```

```

<210> 4
<211> 828
<212> DNA

```

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(828)

<223> n = A,T,C or G

<400> 4

cctcctgagt	cctactgacc	tgtgctttct	ggtgtggagt	ccagggctgc	taggaaaagg	60
aatgggcaga	cacaggtgta	tgccaatggt	tctgaaatgg	gtataatttc	gtcctctcct	120
tcggaacact	ggctgtctct	gaagacttct	cgctcagttt	cagtgaggac	acacacaaaag	180
acgtgggtga	ccatgttggt	tgtgggggtgc	agagatggga	gggggtggggc	ccaccctgga	240
agagtggaca	gtgacacaag	gtggacactc	tctacagatc	actgaggata	agctggagcc	300
acaatgcatg	aggcacacac	acagcaagga	tgacnctgta	aacatagccc	acgtgtcct	360
gnngggactg	ggaagcctan	atnaggccgt	gagcanaaag	aaggggagga	tccactagtt	420
ctanagcggc	cgccaccgcg	gtgganctcc	ancttttggt	cccttttagtg	aggggttaatt	480
gcgcgcttgg	cntaatcatg	gtcatanctn	tttctgtgt	gaaattgtta	tccgtccaca	540
attccacaca	acatacganc	cggaaacata	aantgtaaac	ctgggggtgcc	taatgantga	600
ctaactcaca	ttaattgcgt	tgcgctcaact	gcccgccttc	caatcnggaa	acctgtcttg	660
ccncttgcat	tnatgaatcn	gccaaacccc	ggggaaaagc	gtttgcgttt	tgggcgctct	720
tccgcttcct	cnctcantta	ntccctncnc	tcgggtcattc	cggtcgcngc	aaaccggttc	780
accnctcca	aagggggtat	tccggtttcc	ccnaatccgg	gganancc		828

<210> 5

<211> 834

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(834)

<223> n = A,T,C or G

<400> 5

tttttttttt	tttttactga	tagatggaat	ttattaagct	tttcacatgt	gatagcacat	60
agttttaatt	gcatccaaag	tactaacaaa	aactctagca	atcaagaatg	gcagcatggt	120
attttataac	aatcaacacc	tgtggctttt	aaaatttggt	tttcataaga	taattttatac	180
tgaagtaaat	ctagccatgc	ttttaaaaaa	tgttttaggt	cactccaagc	ttggcagtta	240
acattttggca	taaacaataa	taaaacaatc	acaatttaat	aaataacaaa	tacaacattg	300
taggccataa	tcatatacag	tataaggaaa	aggtggtagt	gttgagtaag	cagttattag	360
aatagaatac	cttgccctct	atgcaaatat	gtctagacac	tttgattcac	tcagccctga	420
cattcagttt	tcaaagtagg	agacagggtc	tacagtatca	ttttacagtt	tccaacacat	480
tgaaaacaag	tagaaaatga	tgagttgatt	tttattaatg	cattacatcc	tcaagagtta	540
tcaccaaccc	ctcagttata	aaaaattttc	aagttatatt	agtcataata	cttggtgtgc	600
ttatttttaa	ttagtgtctaa	atggattaag	tgaagacaac	aatgggtccc	taatgtgatt	660
gatattggto	atttttacca	gcttctaaat	ctnaactttc	aggcttttga	actggaacat	720
tgnatnacag	tgttccanag	ttncaaccta	ctggaacatt	acagtgtgct	tgattcaaaa	780
tgttattttg	ttaaaaatta	aattttaacc	tggtggaaaa	ataatttgaa	atna	834

<210> 6

<211> 818

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(818)

<223> n = A,T,C or G

<400> 6

tttttttttt	tttttttttt	aagacctca	tcaatagatg	gagacataca	gaaatagtca	60
aaacacatct	acaaaaatgcc	agtatcaggc	ggcggttcg	aagccaaagt	gatgtttgga	120
tgtaaagtga	aattattagtt	ggcggatgaa	gcagatagtg	aggaaagttg	agccaataat	180
gacgtgaagt	ccgtggaagc	ctgtggctac	aaaaaatgtt	gagccgtaga	tgcctgcgga	240
aattggtgaag	ggagactcga	agtactctga	ggctttagtg	agggtaaaat	agagacccag	300
taaaattgta	ataagcagtg	cttgaattat	ttggtttcgg	ttgttttcta	ttagactatg	360
gtgagctcag	gtgattgata	ctcctgatgc	gagtaatacg	gatgtgttta	ggagtgggac	420
ttctagggga	tttagcgggg	tgatgcctgt	tgggggccag	tgcctccta	gttggggggt	480
ccggtctagg	ctggagtggg	aaaaggctca	gaaaaatcct	gcgaagaaaa	aaacttctga	540
ggtaataaat	aggattatcc	cgtatcgaag	gcctttttgg	acaggtgggtg	tgtggtggcc	600
ttggtatgtg	ctttctcgtg	ttacatcgcg	ccatcattgg	tatatgggta	gtgtgttggg	660
ttantanggc	ctantatgaa	gaacttttgg	antggaatta	aatcaatngc	ttggccggaa	720
gtcattarqa	nggctnaaaa	ggccctgtta	ngggtctggg	ctnggtttta	cccnacccat	780
ggaatnncnc	ccccggacna	ntgnatccct	attcttaa			818

<210> 7

<211> 817

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(817)

<223> n = A,T,C or G

<400> 7

tttttttttt	tttttttttt	tggtctetaga	gggggtagag	ggggtgctat	agggtaaata	60
cgggccctat	ttcaaagatt	tttaggggaa	ttaattctag	gacgatgggt	atgaaactgt	120
ggtttgctcc	acagatttca	gagcattgac	cgtagtatac	ccccggtcgt	gtagcgggtga	180
aagtggtttg	gtttagacgt	ccgggaattg	catctgtttt	taagcctaata	gtggggacag	240
ctcatgagtg	caagacgtct	tgtgatgtaa	ttattatacn	aatgggggct	tcaatcggga	300
gtactactcg	attgtcaacg	tcaaggagtc	gcaggtcgcc	tggttctagg	aataatgggg	360
gaagtatgta	ggaattgaag	attaatccgc	cgtagtcggt	gttctcctag	gttcaataacc	420
attggtggcc	aattgatttg	atggtaaggg	gagggatcgt	tgaactcgtc	tgttatgtaa	480
aggatnccct	ngggatggga	aggcnatnaa	ggactangga	tnaatggcgg	gcangatatt	540
tcaaacngtc	tctanttcct	gaaacgtctg	aaatgttaat	aanaattaan	tttngttatt	600
gaatnttnng	gaaaagggct	tacaggacta	gaaaccaaata	angaaaanta	atnntaangg	660
cnttatcntn	aaaggtnata	accnctccta	tnatcccacc	caatngnatt	ccccacnncn	720
acnattggat	nccccanttc	canaaanggc	cnccccccg	tgnannccnc	cttttgttcc	780
cttnantgan	ggttattenc	cctngcntt	atcancc			817

<210> 8

<211> 799

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(799)

<223> n = A,T,C or G

<400> 8

catttccggg	tttactttct	aaggaaagcc	gagcggaagc	tgctaacgtg	ggaatcggtg	60
cataaggaga	actttctgct	ggcacgcgct	agggacaagc	gggagagcga	ctccgagcgt	120
ctgaagcgca	cgtcccagaa	ggtggacttg	gcactgaaac	agctgggaca	catccgcgag	180
Laogaacagc	gcctgaaaagt	gctggagcgg	gaggtccagc	agtgtagccg	cgctcctggg	240

tgggtggcgc	angcctganc	cgctctgcct	tgctgcccc	angtgggcgc	ccacccctg	300
acctgcctg	gtccaaacac	tgagccctgc	tgggcgactt	caagganaac	ccccacangg	360
ggattttgct	cctanantaa	ggctcatctg	ggcctcggcc	ccccacctg	gttggccttg	420
tctttgagt	gagccccatg	tccatctggg	ccactgtcng	gaccaccttt	ngggagtgtt	480
ctccttacia	ccacannatg	cccggtcct	cccggaacc	antcccancc	tgngaaggat	540
caagnectgn	atccactnnt	netanaaccg	gcncncnccg	cngtggaaac	cnccttntgt	600
tccttttct	tnagggttaa	tnncgccttg	gccttnccan	ngtctncnc	nttttccnnt	660
gttnaaattg	ttangcnccc	nccnntcccn	cnnncnnan	cccgaaccnn	annttnnann	720
nectgggggt	nccnncngat	tgaccenncc	nccctntant	tgcnttnggg	nncnntgccc	780
ctttccctct	nggganncg					799

<210> 9

<211> 801

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(801)

<223> n = A,T,C or G

<400> 9

acgccttgat	cctcccaggc	tgggactggg	tctgggagga	gccgggcatg	ctgtggtttg	60
taangatgac	actcccaaag	gtggtcctga	cagtggccca	gatggacatg	gggctcacct	120
caaggacaag	gccaccaggt	gcgggggccc	aagccacat	gaccttact	ctatgagcaa	180
aatccctgt	gggggcttct	cctgaagtc	cgccancagg	gctcagtctt	tggacccang	240
caggtcattg	ggttgtngnc	caactggggg	ccncaacgca	aaanggcnc	gggcctcngn	300
cacccatccc	angacgcggc	tacactnctg	gacctccnc	tccaccactt	tcattgcctg	360
ttctaccgg	cgatntgtc	ccanctgttt	cngtgcncac	tccancttct	nggacgtgcg	420
ctacatacgc	ccggantcnc	netccgcctt	tgctccctatc	cacgtncan	caacaaattt	480
cncctantg	caccnattec	cacttttnc	agntttccnc	nncngcttc	cttntaaaag	540
ggttgancce	cggaaaatnc	cccaaagggg	gggggcccng	tacccaaactn	ccccctnata	600
gctgaantcc	ccatnacenn	gnctnatgg	ancntccnt	tttaannacn	ttctnaactt	660
gggaanance	ctcgnccntn	ccccnttaa	tccncccttg	cnangnnent	cccccnntcc	720
ncccnntng	gcntntnann	cnaaaaaggc	ccnnnancaa	tctcctnnnc	cctcanttcg	780
ccanccctcg	aatcggccn	c				801

<210> 10

<211> 789

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(789)

<223> n = A,T,C or G

<400> 10

cagtctatnt	ggccagtgtg	gcagctttcc	ctgtggtctg	cggtgccaca	tgctgtccc	60
acagtgtggc	cgtggtgaca	gcttcagccg	ccctcaccgg	gttcaccttc	tcagccctgc	120
agatccctgc	ctacacactg	gctccctct	accacccggga	gaagcaggtg	ttcctgcca	180
aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	cctgatgacc	agcttcctgc	240
caggccctaa	gcctggagct	cccttcccta	atggacacgt	gggtgctgga	ggcagtggcc	300
tgctcccacc	tccaccgcg	ctctgcgggg	cctctgcctg	tgatgtctcc	gtacgtgtgg	360
tggtgggtga	gcccaccgan	gccagggtgg	ttccggggccg	gggcatctgc	ctggacctcg	420
ccatccctgga	tagtgcttcc	tgctgtccca	ngtggcccca	tccctgttta	tgggctccat	480
tgtccagctc	agccagtctg	tactgccta	tatggtgtct	gccgcaggcc	tgggtctggt	540
cccatttact	ttgtacaca	ggtantattt	gacaagaacg	anttggccaa	atactcagcg	600

```

ttaaaaaatt ccagcaacat tgggggtgga aggcctgcct cactgggtcc aactccccgc 660
tccgtgttaac cccatggggc tgcgggcttg gccgccaaatt tctgttgctg ccaaantnat 720
gtgactctct gctgccacct gttgctggct gaagtgcnta cngcncanct nggggggtng 780
gnggttccc

```

```

<210> 11
<211> 772
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(772)
<223> n = A,T,C or G

```

```

<400> 11
ccacccctac ccaaatatta gacaccaaca cagaaaagct agcaatggat tcccttctac 60
tttgtttaaat aaataagtta aatattttaa tgccctgtgtc tctgtgatgg caacagaagg 120
accaacagggc cacatcctga taaaaggtaa gaggggggtg gatcagcaaa aagacagtgc 180
tgtgggctga ggggacctgg ttcttgtgtg ttgcccctca ggactcttcc cctacaaata 240
actttcatat gttcaaatcc catggaggag tgtttcatcc tagaaactcc catgcaagag 300
ctacattaaa cgaagctgca ggtaagggg cttanagatg ggaaaccagg tgactgagtt 360
tattcagctc ccaaaaaccc ttctctaggt gtgtctcaac taggaggcta gctgttaacc 420
ctgagcctgg gtaatccacc tgcagagtc ccccatccca gtgcatggaa ccttctggc 480
ctccctgtat aagtcagac tgaaccccc ttggaaggnc tccagtcagg cagccctana 540
aactggggaa aaaagaaaag gacgcccacn ccccagctg tgcantacg cacctcaaca 600
gcacaggggtg gcagcaaaaa aaccacttta ctttggcaca aacaaaaact ngggggggca 660
accccgccac ccnangggg gttaacagga ancgggnaa cntggaacct aatnaggca 720
ggcccnccac ccnaatntt gctgggaaat ttttctccc ctaaattntt tc 772

```

```

<210> 12
<211> 751
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(751)
<223> n = A,T,C or G

```

```

<400> 12
gccccattc cagctgccac accacccacg gtgactgcat tagttcggat gtcatacaaa 60
agctgattga agcaaccctc tactttttgg tctgtagcct ttgtcttggg gcaggtttca 120
ttggctgtgt tgggtgacgtt gtcattgcaa cagaatgggg gaaaggcact gttctctttg 180
aagtanggtg agtcctcaaa atccgtatag ttggtgaagc cacagcactt gagcccttc 240
atggtggtgt tccacacttg agtgaagtct tccctgggaa cataatcttt cttgatggca 300
ggcactacca gcaacgtcag ggaagtgtc agccattgtg gtgtacacca aggcgaccac 360
agcagctgcn acctcagcaa tgaagatgan gaggangatg aagaagaacg tcncgagggc 420
acacttgctc tcagtcttan caccatanca gccctgaaa accaananca aagaccacna 480
cncgggctgc gatgaagaaa tnaccccneg ttgacaaaact tgcattggcac tggganccac 540
agtggccnna aaaatcttca aaaaggatgc cccatcnatt gaccccccaa atgcccactg 600
ccaacagggg ctgccccacn cncnnaacga tgancnatt gnacaagatc tncntggctc 660
tnatnaacnt gaacctgcn tngtggctcc tgttcaggnc cngggcctga cttctnaann 720
aanggaactn gaagncccca cngganannc g
751

```

```

<210> 13
<211> 729
<212> DNA

```

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(729)

<223> n = A,T,C or G

<400> 13

gagccaggcg	tccctctgcc	tgcccaactca	gtggcaaacac	ccgggagctg	ttttgtcctt	60
tgtggancct	cagcagtncc	ctctttcaga	actcantgcc	aaganccctg	aacaggagcc	120
accatgcagt	gcttcagctt	cattaagacc	atgatgatcc	tcttcaattt	gctcatcttt	180
ctgtgtggtg	cagccctggt	ggcagtgggc	atctgggtgt	caatcgatgg	ggcatccttt	240
ctgaagatct	tcgggccact	gtcgtccagt	gccatgcagt	ttgtcaacgt	gggctacttc	300
ctcatcgcaq	ccggcggttg	ggtcttagct	ctagggtttcc	tgggctgcta	tgggtgctaag	360
actgagagca	agtatgccct	cgtgacgttc	ttcttcatcc	tcctcctcat	cttcattgct	420
gaggttgcaa	tqctgtggtc	gccttggtgt	acaccacaat	ggctgagcac	ttcctgacgt	480
tgctggtaat	gcctgccatc	aanaaaagat	tatgggttcc	caggaanact	tcactcaagt	540
gttggaacac	caccatgaaa	gggctcaagt	gctgtggctt	cnnccaacta	tacggatttt	600
gaagantcac	ctacttcaaa	gaaaaanagt	cctttccccc	atttctgttg	caattgacaa	660
acgtccccaa	cacagccaat	tgaaaacctg	cacccaaccc	aaangggtec	ccaaccanaa	720
attnaaggg						729

<210> 14

<211> 816

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(816)

<223> n = A,T,C or G

<400> 14

tgctcttctt	caaagttggt	cttggttgcca	taacaaccac	cataggtaaa	gcggggcgag	60
tgttcgctga	aggggttgta	gtaccagcgc	gggatgctct	cettgcagag	tcctgtgtct	120
ggcaggtcga	cgcagtgccc	tttgtcactg	gggaaatgga	tgcgctggag	ctcgtaaaag	180
ccactcgtgt	atttttcaca	ggcagcctcg	tccgacgcgt	cggggcagtt	gggggtgtct	240
tcacactcca	ggaaaactgtc	natgcagcag	ccattgctgc	agcggaaactg	ggtgggctga	300
cangtgccag	agcacactgg	atgggcgcctt	tccatgnnan	gggccctgng	ggaaagtccc	360
tgancccan	anctgcctct	caaangcccc	accttgacac	ccccgacagg	ctagaatgga	420
atcttcttcc	cgaaaggtag	ttnttcttgt	tgcccaancc	ancccntaa	acaaactctt	480
gcanatctgc	tccngggggg	tctantacc	ancgtgggaa	aagaacccca	ggcngcgaac	540
caancttggt	tggatncgaa	genataatct	netnttctgc	ttggtggaca	gcaccantna	600
ctgtnnanct	ttagnccntg	gtcctontgg	gttgnncttg	aacctaatcn	ccnntcaact	660
gggacaagg	aantngccnt	cctttnaatt	cccnancntn	ccccctggtt	tgggggttttn	720
cncnctccta	ccccagaaan	nccgtgttcc	cccccaacta	ggggccnaaa	ccnnttnttc	780
cacaaccctn	ccccaccac	gggttcngnt	ggttng			816

<210> 15

<211> 783

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(783)

<223> n = A,T,C or G

<400> 15

ccaaggcctg	ggcaggcata	nacttgaagg	tacaacccca	ggaacccctg	gtgctgaagg	60
atgtggaaaa	cacagattgg	cgctactgc	gggtgacac	ggatgtcagg	gtagagagga	120
aagacccaaa	ccaggtggaa	ctgtggggac	tcaaggaang	cacctacctg	ttccagctga	180
cagtgaactag	ctcagaccac	ccagaggaca	cggccaaagt	cacagtcact	gtgctgtcca	240
ccaagcagac	agaagactac	tgcctcgcac	ccaacaangt	gggtcgtctg	cggggtcttt	300
tcaccagctg	gtactatgac	cccacggagc	agatctgcaa	gagtttctgt	tatggaggct	360
cttggggcaa	caagaacaac	taccttcggg	aagaagagt	cattctance	tgtcnggggt	420
tgaagggtgg	gcctttgana	ngcanctctg	gggtctcangc	gactttcccc	caggggccctt	480
ccatggaaaag	gcgccatcca	ntgttctctg	gcacctgtca	gcccacccag	ttccgctgca	540
ccatgggtg	ctgcactnac	antttcctng	aattgtgaca	acacccccca	ntgcccccaa	600
ccctcccaac	aaagcttccc	tgttnaaaaa	tacnccantt	ggcttttnac	aaacnccccg	660
cnctctcctt	ttccccnntn	aacaaagggc	ncnngccttt	gaactgccc	aaccnnggaa	720
ctnccnngg	aaaaantncc	ccccctggtt	cctnnaance	cctccncnaa	anctncccc	780
ccc						783

<210> 16

<211> 801

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(801)

<223> n = A,T,C or G

<400> 16

gccccaatc	cagctgccac	accacccacg	gtgactgcat	tagttcggat	gtcatataaa	60
agctgattga	agcaaccctc	tacttttttg	tcgtgagcct	tttgcttggg	gcagggtttca	120
ttggctgtgt	tggtgacgtt	gtcattgcaa	cagaatgggg	gaaaggcact	gttctctttg	180
aagtaggggtg	agtcctcaaa	atccgtatag	ttggtgaagc	cacagcactt	gagccctttc	240
atggtgggtg	tcacacttg	agtgaagtct	tcctgggaac	cataatcttt	cttgatggca	300
ggcactacca	gcaacgtcag	gaagtgtca	gccattgtgg	tgtacaccaa	ggcgaccaca	360
gcagctgcaa	cctcagcaat	gaagatgagg	aggaggatga	agaagaacgt	cncgagggca	420
cacttgctct	ccgtcttagc	accatagcag	ccangaaac	caagagcaaa	gaccacaacg	480
ccngctgcga	atgaaagaaa	ntacccacgt	tgacaaaactg	catggccact	ggacgacagt	540
tggcccgaa	atcttcagaa	aagggatgcc	ccatcgattg	aacacccana	tgcccaactgc	600
cnacaggggt	gcnccnccn	gaaagaatga	gccattgaag	aaggatcttc	ntggtcttaa	660
tgaactgaaa	ccntgcatgg	tggccctgt	tcagggctct	tggcagtga	ttctganaaa	720
aaggaaacngc	ntnagcccc	ccaaangana	aaacaccccc	gggtgttgcc	ctgaattggc	780
ggccaaggan	ccctgccccn	g				801

<210> 17

<211> 740

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(740)

<223> n = A,T,C or G

<400> 17

gtcagagcca	ggcgtccctc	tgcctgccca	ctcagtgcca	acacccggga	gctgttttgt	60
cctttgtgga	gcctcagcag	ttccctcttt	cagaactcac	tgccaagagc	cctgaacagg	120
agccaccatg	cagtgcctta	gtttcattaa	gaccatgatg	atcctcttca	atttgcctat	180
ctttctgtgt	ggtgcagccc	tggtggcagt	gggcactctg	gtgtcaatcg	atggggcactc	240
ctttctgaag	atcttcgggc	cactgtcgtc	cagtgcctatg	cagtttgtca	acgtgggcta	300

cttcctcadc	gcagccggcg	ttgtggtctt	tgtctttggt	ttcctgggct	gctatgggtgc	360
taagacggag	agcaagtgtg	ccctcgtgac	gttcttcttc	atcctcctcc	tcctcttcat	420
tgtctgaagt	gcagctgctg	tggtcgcctt	ggtgtacacc	acaatggctg	aaccattcct	480
gacgttgctg	gtantgcctg	ccatcaanaa	agattatggg	ttcccaggaa	aaattcactc	540
aantntggaa	caccnccatg	aaaagggctc	caatttctgn	tggtctcccc	aactataccg	600
gaattttgaa	agantcnccc	tacttccaaa	aaaaaanant	tgcctttnc	ccntttctgt	660
tgcaatgaaa	acntcccaan	acngccaatn	aaaacctgcc	cnnncaaaaa	ggntcncaaa	720
caaaaaaant	nnaagggttn					740

<210> 18
 <211> 802
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(802)
 <223> n = A,T,C or G

<400> 18	
ccgctggttg	cgctgggtcca gngnagccac gaagcacgtc agcatacaca gcctcaatca 60
caaggtcttc	cagctgccgc acattacgca gggcaagagc ctccagcaac actgcatatg 120
ggatacactt	tacttttagca gccaggggtga caactgagag gtgtcgaagc ttattcttct 180
gagcctctgt	tagtggagga agattccggg cttcagctaa gtagtcagcg tatgtcccat 240
aagcaaacac	tgtgagcagc cggaaggtag agggcaaagtc actctcagcc agctctctaa 300
cattgggcat	gtccagcagt tctccaaaca cgtagacacc agnggcctcc agcacctgat 360
ggatgagtgt	ggccagcgtt gcccccttgg ccgacttggc taggagcaga aattgctcct 420
ggttctgccc	tgtcaccttc acttccgcac tcatcactgc actgagtgtg ggggacttgg 480
gctcaggatg	tccagagacg tggttccgcc cctcncctta atgacaccgn ccanncaacc 540
gtcggctccc	gccgantngt ttctgtctnc ctgggtcagg gtctgctggc cnetacttgc 600
aancttcgtc	nggccatgg aattcacenc accggaactn gtangatcca ctntttctat 660
aaccggnccg	caccgcnnnt ggaaactccac tcttnttnc tttacttgag ggtaagggtc 720
accctttncc	ttactttggt ccaaaccntn cntgtgtctg anatngtnaa tcnngnccna 780
tnccancnc	atangaagcc ng 802

<210> 19
 <211> 731
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(731)
 <223> n = A,T,C or G

<400> 19	
cnaagcttcc	aggtnacggg ccgcnaancc tgaccnagg tancanaang cagnncgcgg 60
gagccacccg	tcacngngng gngtctttat nggagggggc ggagccacat cnetggacnt 120
cntgacccca	actccccnc ncncantgca gtgatgagtg cagaactgaa ggtnacgtgg 180
caggaacca	gancaaannc tgetcnnct caagtcggcn nagggggcgg ggctggccac 240
gcncatcct	cnagtgtctn aaagcccn cctgtctact tgtttggaga acngcnnga 300
catgcccagn	gttanataac nggcngagag tnannttgcc tctcccttcc ggctgcgcgn 360
cgngtntgct	tagnggacat aacctgacta cttaactgaa ccnngaate tncnccct 420
ccactaagct	cagaacaaaa aacttcgaca ccactcantt gtcacctgnc tgctcaagta 480
aagtgtaccc	catncccaat gtntgctnga ngctctgncc tgcnttangt tcggtcctgg 540
gaagacctat	caattnaagc tatgtttctg actgcctctt gctccctgna acaancnacc 600
cnnctntcca	aggggggggnc ggcccccaat ccccccaacc ntnaattnan tttancccn 660
cccccnnggc	cggcctttta cnancntcnn nnacngggna aaaccnnngc tttncccaac 720

nnaatecnc t

731

<210> 20
 <211> 754
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(754)
 <223> n = A,T,C or G

<400> 20

tttttttttt	tttttttttt	taaaaacccc	ctccattnaa	tgnaaaacttc	cgaaattgtc	60
caacccccc	ntccaaatnn	ccntttccgg	gnngggggttc	caaacccean	ttanntttgg	120
annttaaatt	aaatnttnt	tgnggggnna	ancenaatgt	nangaaagt	naaccanta	180
tnancttnaa	tnccctggaaa	ccngtngntt	ccaaaaatnt	ttaaccotta	antccctccg	240
aaatngttna	nggaaaacccc	aantttctnt	aaggttggtt	gaaggntnaa	tnaaaaanccc	300
nnccaattgt	tttngccac	gcctgaatta	attggnttcc	gntgttttcc	nttaaaanaa	360
ggnnancccc	ggttantnaa	tccccccnnc	cccaattata	ccganttttt	ttngaattgg	420
gancccnccg	gaattaacgg	ggnnntccc	tnntgggggg	cnngnncccc	ccccntccgg	480
ggttngggnc	aggnccnaat	tgtttaagg	tccgaaaaat	ccctccnaga	aaaaaanctc	540
ccaggntgag	nnnngggttt	ncccccccc	canggccct	ctcgnaag	tggggtttgg	600
ggggccctgg	attttntttc	ccctnttnc	tcccccccc	ccnggganag	aggttngngt	660
tttgnctnnc	ggcccnccn	aaganccttn	ccganttnan	ttaaatecnt	gcctnggcga	720
agtccttgn	aggntaaan	ggccccctnn	cggg			754

<210> 21
 <211> 755
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(755)
 <223> n = A,T,C or G

<400> 21

atcancat	gacccnaac	nngggaccnc	tcancggnc	nnncnaccnc	cggccnatca	60
nngtnagnnc	actncnnttn	natcacnccc	cncnactac	gcccncnanc	cnacgcncta	120
nncanatncc	actganngcg	cgangtngan	ngagaaanct	nataccanag	ncaccanacn	180
ccagctgtcc	nanaangcct	nnnatacngg	nnnatecaat	ntgnancctc	cnaagtattn	240
nncnncan	gattttctn	anccgattac	ccntncccc	tanccctcc	cccccaacna	300
cgaaggcnc	ggncnnaagg	nngcgncc	ccgctagntc	cccnncnaag	cncnnccta	360
aactcancn	nattacnccg	ttcntgagta	tcactccccg	aatctcaccc	tactcaactc	420
aaaaanaten	gatacaaaat	aatncaagcc	tgnttatnac	actntgactg	ggtctctatt	480
ttagnngtcc	ntnaancntc	ctaatacttc	cagctctncc	tcnccaattt	ccnaanggct	540
ctttcngaca	gcantttttg	gttcccnntt	gggttcttan	ngaattgcc	ttcntngaac	600
gggctcntct	tttccctcgg	ttancctgg	ttcnccggc	cagttattat	ttccentttt	660
aaattcntnc	cntttanttt	tggnctttna	aaccccgcc	cttgaaaacg	gccccctggt	720
aaaagggtgt	tttganaaaa	tttttgtttt	gttcc			755

<210> 22
 <211> 849
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(849)
 <223> n = A,T,C or G

<400> 22
 tttttttttt tttttangtg tngtcgtgca ggtagaggct tactacaant gtgaanaagct 60
 acgctnggan taangcgacc cgantttctag gannncctt aaaatcanac tgtgaagatn 120
 atcctgnnna cggaanggtc accggnngat nntgctaggg tgncnctcc cannncttn 180
 cataactcng nggacctgcc caccaccttc ggcgcccgng ngncggggcc cgggtcattn 240
 gnnttaaccn cactnngcna ncggtttccn nccccnng acccnggcga tccgggggtnc 300
 tctgtcttcc cctgnagncn anaaantggg ccnccgnccc ctttaccct nnacaagcca 360
 cngccntcta ncncngccc cccctccant nngggggact gccnanggt ccgttncnng 420
 nnaccccnng gggtncctcg gttgtcgant cnaccgnang ccanggattc cnaaggaagg 480
 tgcgttnttg gcccttacc ttcgctncgg nncaccttc ccgacnanga nccgtccccg 540
 cncnccgnng cctcncctcg caacacccgc nctentngt nccgnnnccc cccaccccg 600
 nccctcncnc ngncgnancn ctcncncnc gtctcannca ccaccccgcc ccgccaggcc 660
 ntcanccacn ggngacnng nagnncntc gcncccgcn gcgnccct ccgcnngaa 720
 ctncntcng ccantnncgc tcaanccna cnaaacgcg ctgcggggcc cgnagcgncc 780
 nccctcncga gtccctcccg cttccnacc angnnttcn cgaggacaen nnaccccgcc 840
 nncangcgg 849

<210> 23
 <211> 872
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(872)
 <223> n = A,T,C or G

<400> 23
 gcgcgaacta tacttcgctc gnactcgtgc gectcgetnc tcttttcttc cgcaaccatg 60
 tctgacnanc ccgattnggc ngatatchan aagntcganc agtccaaact gantaacaca 120
 cacacnncn aganaaatcc nctgccttcc anagtancn attgaacnng agaaccangc 180
 nggcgaatcg taatnaggcg tgcgcgcga atntgtcnc gtttatttn ccagctcnc 240
 ctncnacc cactctctn nactgtcnn accctngtn cgnaccccc naggtcgga 300
 tccgggtttn nntgaccgng cnccectcc cccctccat nacganccnc ccgcaccacc 360
 nanngcncgc nccccgnct cttgcncnc ctgtccttn cccctgtngc ctggcncnng 420
 accgcattga cctcgcncn ctncnngaaa ncgnanacgt ccgggttggn annancgtg 480
 tgggnnngcg tctgcncgc gttccttcn ncncttcca ccatcttct tacnggggtc 540
 ccncgcctc tcnnncacnc cctgggaagc tntcctntgc ccccttnac tccccccct 600
 cgnccgtgnc cgncccaacc ntcatttnca nacgntcttc acaannccct ggntnnctcc 660
 cnancngncn gtcancncag ggaagggng ggncncttg nttgacgtg ngngangtc 720
 cgaanantcc tcnccntcan cctaccct cggcggnct ctngttnc aacttancaa 780
 ntctccccg ngncnctc tcagcctcnc cnccecnct ctctgcantg tncctctgctc 840
 tnaccnntac gantnttcg cncctcttt cc 872

<210> 24
 <211> 815
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(815)
 <223> n = A,T,C or G

```

<400> 24
gcctgcaagc ttgagtattc tatagngtca cctaaatanc ttggcntaat catggtcnta      60
nctgncttcc tctgtcaaat gtatacnaaa tanatatgaa tctnatntga caaganngta      120
tctnctatta gtaacaantg tntgtccat cctgtengan canattccca tnnattncgr      180
cgcattcnch gencantatn taatngggaa nctnnntnnn ncaccnncat ctatcntncc      240
genccttgac tggagagat ggatnanttc tntntgacc nacatgttca tcttggattn      300
aanancccc cggngnccac cggttngnng cnagecnntc ccaagacctc ctgtggaggt      360
aacctgcgtc aganncatca aacntgggaa acccgcnnc angtnnaagt ngnnncanar      420
gatcccgtec aggnntnacc atcccttenc agcgccccct ttngtgcctt anagnngnagc      480
gtgtccnanc cncacaacat ganacgcgcc agnccanccg caattnggca caatgtcgnc      540
gaacccccca gggggantna tncaaanccc caggattgtc cncncangaa atcccnanc      600
ccnccctac cennctttgg gacngtgacc aantcccgga gtncaggtcc gcccnngctc      660
ccccaccggt nncntgggg ggggtgaanct cngnntcanc cngncgaggn ntcgnaagga      720
accggncctn ggcgaanng ancnntcnga agngccnct cgtataaccc cccctcncca      780
nccnaengnt agntcccccc cngggtncgg aangg                                815

```

```

<210> 25
<211> 775
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(775)
<223> n = A,T,C or G

```

```

<400> 25
ccgagatgtc tcgtccgtg gccttagctg tgctcgcgct actctctctt tctggcctgg      60
aggctatcca gcgtactcca aagattcagg ttactcaag tcatccagca gagaatggaa      120
agtcaaatct cctgaattgc tatgtgtctg ggttccatcc atccgacatt gaanttgact      180
tactgaagaa tgganagaga attgaaaaag tggagcattc agacttgtct ttcagcaagg      240
actggtcttt ctatctcntg tactacactg aattcacccc cactgaaaaa gatgagtag      300
cctgccgtgt gaaccatgtg actttgtcac agcccaagat agttaagtgg gatcgagaca      360
tgttaagcag cncatggaa gtttgaagat gcgcatttg gattggatga attccaaatt      420
ctgcttgctt genttttaat antgatatgc ntataacccc taccctttat gncccaaat      480
tgtaggggtt acatnantgt tcnctnngga catgatcttc ctttataant ccnccnttcg      540
aattgccgt cncnngttn ngaatgttcc cnaaaccacg gttaggctccc ccaggtcncc      600
tcttacggaa gggcctgggc cnccttncaa ggttggggga accnaaaatt tcnctntgc      660
ccncccncca cncctttgng nncncanttt ggaaccttc cnattccctc tggcctenna      720
nctttncta anaaaacttn aaancgtngc naaanntttt acttcccccc ttacc              775

```

```

<210> 26
<211> 820
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(820)
<223> n = A,T,C or G

```

```

<400> 26
anattantac agtgtaatct tttccagag gtgtgtanag ggaacggggc ctgagggcat      60
cccnagata ncttatanca acagtgtctt gaccaagagc tgctgggcac atttctgca      120
gaaaagggtg cggccccat cactcctcct ctcccatagc catcccagag gggtagtag      180
ccatcangcc ttcggtggga gggagtcang gaaacaacan accacagagc anacagacca      240
ntgatgacca tggcgggag cgagcctctt cctgnaccg gggtaggana nganagccta      300
nctgaggggt cacactataa acgttaacga ccnagatnan cacctgcttc aagtgcaccc      360

```

```

ttectacctg acnaccagn accnnnaact gngcctggg gacagcctg ggancagcta 420
acnnagcact cacctgcccc cccatggccg tncgntccc tggtectgnc aagggaagct 480
ccctgttgga attncgggga naccaaggga nccccctect ccanctgtga aggaaaaann 540
gatggaattt tnccttccg gccntcccc tcttccttta cagccccct nntactctc 600
tccctctntt ntccctgncnc acttttnacc ccnnnatttc ccttnattga tcggannctn 660
ganattccac tnnccctnc cntcnatcng naanacnaaa nactntctna ccnggggat 720
gggnccctcg ntcatcctct ctttttctct accncnntt ctttgectct ccttngatca 780
tccaacntc gntggccntn ccccccnntt tccttttccc 820

```

```

<210> 27
<211> 818
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(818)
<223> n = A,T,C or G

```

```

<400> 27
tctgggtgat ggcctcttcc tctcagggga cctctgactg ctctgggcca aagaatctct 60
tgtttcttct ccgagcccca ggcagcgggtg attcagccct gcccaacctg attctgatga 120
ctgaggatgc tgtgacggac ccaaggggca aatagggtcc cagggtccag ggaggggcgc 180
ctgetgagca ctccgcccc tcacctgcc cagccccctgc catgagctct gggctgggtc 240
tcgcctcca gggttctgct ctccangca ngccancaa tggcgtggg ccacactggc 300
ttcttctgc ccntccctg gctctganc tctgtcttcc tgcctgtgc angnccttg 360
gatctcagtt tccctcnctc anngaactct gttctgann tcttcantta actntgantt 420
tatnaccnan tggnetgtnc tgcnnactt taatgggcn gaccggctaa tccctccctc 480
netcccttcc anttcnnna accngcttnc cntctctcc centancccg ccngggaanc 540
ctcctttgcc ctaccangg gccnnnaccg ccctnnctn ggggggcnng gttnctnnc 600
ctgntnccc cncctcnnt tncctcgtcc cncncnccn nngcanntc ncngtcccn 660
tnnetcttct ngntcgnaa ngntcnctn tnnnnngcn ngntnnctn tccctctcnc 720
cnnntgnang tnnntnnnc ncnngncccc nnnnnnnnn nggnntnnn tctnncngc 780
cccncccc ngnattaagg cctcnnctc ccggccnc 818

```

```

<210> 28
<211> 731
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(731)
<223> n = A,T,C or G

```

```

<400> 28
aggaagggcg gagggatatt gtangggatt gagggatagg agnataangg gggaggtgtg 60
tcccaacatg anggtgnngt tctcttttga angaggggtg ngtttttann ccnggtgggt 120
gattnaaccc cattgtatgg agnnaaagg ttnagggtat ttttcggctc ttatcagtat 180
ntanattcct gtnaatcgga aaatnatntt tcnnccggaa aatnttgctc ccatacgnaa 240
attnctccc ggtagtgc atntnggggn cngccangtt tccaggctg ctanaatcgt 300
actaaagntt naagtggan tncaaatgaa aacctnnac agagnatccn taccgcactg 360
tnnnntnct tgcctctntg actctgcng agcccaatac ccngngnat gtcnccngn 420
nnngcgnnc tgaaannnnc tcnggctnn gancatcang gggtttcgca tcaaaagcnn 480
cgtttcnat naaggcactt tngcctcatc caaccnctng ccctcncca tttngccgctc 540
nggttencct acgctnnntg cncctnnntn ganattttnc ccgctnggg naancctcct 600
gnaatgggta gggnccttntc ttttnaccnn gnggtntact aatcnctnc acgcntnctt 660
tctcnacccc cccctttttt caatcccanc ggcnaatggg gtctcccnng cgangggggg 720

```

nnnccannnc c

731

<210> 29
 <211> 822
 <212> DNA
 <213> Homo sapien

 <220>
 <221> misc_feature
 <222> (1)...(822)
 <223> n = A,T,C or G

<400> 29

actagtcacag	tgtgggtggaa	ttccattgtg	ttggggncnc	ttctatgant	antnttagat	60
cgctcanacc	tcacancctc	ccnacnangc	ctataangaa	nannaataga	netgtncnnt	120
atntntacnc	tcatanncct	cnnnacccac	tcctctctaa	ccentactgt	gcctatngcn	180
tnnctantct	ntgcgcctn	cnanccaccn	gtggggcnac	cncnngnatt	ctcnatctcc	240
tcnccatntn	gcctananta	ngtncatacc	ctatacctac	nccaatgcta	nnnctaanch	300
tcocatnatt	annntaacta	ccactgacnt	ngaactttcnc	atnanctcct	aatttgaatc	360
tactctgact	cccacngcct	annnattagc	ancntccccc	nacnatntct	caacccaaatc	420
ntcaacaacc	tatctanctg	ttcnccaacc	nttnccctccg	atccccnnac	aacccccctc	480
ccaaataccc	nccacctgac	ncctaaccen	caccatcccg	gcaagccnan	ggncatttan	540
ccactggaat	cacnatngga	naaaaaaac	ccnaactctc	tancncnnat	ctccctaana	600
aatnctcctn	naatttactn	ncantnccat	caancccaen	tgaaaacnaa	ccctgtttt	660
tanatecctt	ctttcgaaaa	ccnacccttt	annncccaac	ctttnggggc	ccccnctnc	720
ccnaatgaag	gncncccaat	cnangaaacg	nccttgaaaa	ancnaggcna	anannntccg	780
canatectat	cccttanttn	ggggncctt	nccengggcc	cc		822

<210> 30
 <211> 787
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(787)
 <223> n = A,T,C or G

<400> 30

cggccgcctg	ctctggcaca	tgcctcctga	atggcatcaa	aagtgatgga	ctgcccattg	60
ctagagaaga	ccttctctcc	tactgtcatt	atggagccct	gcagactgag	ggctccccct	120
gtctgcagga	tttgatgtct	gaagtctgtg	agtgtggctt	ggagctcctc	atctacatna	180
gctggaagcc	ctggagggcc	tctctcgcca	gcctccccct	tctctccacg	ctctccangg	240
acaccagggg	ctccaggcag	cccattatc	ccagnangac	atgggtgttc	tcacgcgga	300
cccatggggc	ctgnaaggcc	agggtctcct	ttgacacat	ctctcccgtc	ctgcttgcca	360
ggcgtgga	tcactantt	ctanaacggg	cgccaccncc	gtgggagctc	cagcttttgt	420
tcccnttaat	gaagggtaat	tgcncgcttg	gcgtaatcat	nggtcanaac	tntttcctgt	480
gtgaaattgt	ttntccccct	ncnattccnc	ncnacatacn	aacccggaan	cataaagtgt	540
taaagcctgg	gggtngcctn	nngaathaac	tnaactcaat	taattgcgtt	ggctcatggc	600
ccgctttccn	ttcnggaaaa	ctgtctctcc	ctgcnttnnt	gaatcgggca	ccccccnggg	660
aaaagcgggt	tgcnttttng	ggggntcctt	ccncttcccc	cctcnctaan	ccctnccgct	720
eggctgttnc	nggtngcggg	gaangggnat	nnnctccncc	naagggggng	agnnngntat	780
ccccaaa						822

<210> 31
 <211> 799
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(799)
 <223> n = A,T,C or G

<400> 31
 tttttttttt ttttttttggc gatgctactg ttttaattgca ggaggtgggg gtgtgtgtac 60
 catgtaccag ggctattaga agcaagaagg aaggaggagg ggcagagcgc cctgctgagc 120
 aacaaaggac tcctgcagcc ttctctgtct gtctcttggc gcaggcacat ggggaggcct 180
 cccgcagggt gggggccacc agtccagggg tgggagcact acanggggtg ggagtgggtg 240
 gtggctggtg cnaatggcct gncacanatc cctacgattc ttgacacctg gatttcacca 300
 ggggaccttc tgttctccca nggnaacttc nttnatctcn aaagaacaca actgtttctt 360
 cngcanttct ggctgttcat ggaaagcaca ggtgtccnat ttnggctggg acttgggtaca 420
 tatggttccg gccacacctc ccntcnaa aagtaattca ccccccccn cntctnttg 480
 cctgggccct taantaccca caccggaact canttantta ttcatcttng gntgggcttg 540
 ntatnccn cctgaangcg ccaagttgaa aggccacgcc gtnccnctc cccatagnan 600
 nttttnnct canctaatac cccccnggc aacnatacaa tcccccccn tgggggcccc 660
 agcccanggc ccccgctcg ggnnccngn cncgnantcc ccaggntctc ccantcngnc 720
 ccnnngcncc cccgcacgca gaacanaagg ntngagcnc cgcannnnnn nggttnccnac 780
 ctcgcccccc ccnnccngg 799

<210> 32
 <211> 789
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(789)
 <223> n = A,T,C or G

<400> 32
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
 ttttnccnag ggcaggttta ttgacaacct cncgggacac aancaggctg gggacaggac 120
 ggcaacaggc tccggcgcg gggcgggcg ccctacctgc ggtaccaaata ntgcagcctc 180
 cgctcccgc tgaatnccct ctgcagctgc aggatgcctt aaaacagggc ctcggccntn 240
 ggtgggcacc ctgggatttn aatttccacg ggcacaatgc ggtcgcancc cctcaccacc 300
 nattaggaat agtggnttta ccnccnccg ttggcncact cccntggaa accacttntc 360
 gcggctccgg catctgtct taaaccttgc aaacnctggg gccctctttt tgggttantn 420
 nccngccaca atcatnactc agactggcnc gggctggccc caaaaaancn ccccaaaacc 480
 ggnccatgtc tttnccgggt tgcctgenatn tncatcacct cccgggcnc naaggncac 540
 ccaaaagtgc ttngggccn caaaaaanct ccggggggnc ccagtttcaa caaagtcac 600
 ccccttggcc cccaaatcct cccccgntt nctgggttg ggaacccacg cctctnnctt 660
 tggngggcaa gntggntccc ccttcgggccc cccgggtggc ccnctctaa ngaaaacncc 720
 ntctnnnca ccatcccccc nngnnacgnc tancaangna tccctttttt tanaaacggg 780
 cccccnccg 799

<210> 33
 <211> 793
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(793)
 <223> n = A,T,C or G

<400> 33

gacagaaacat	gttggatggt	ggagcacctt	tctataacgac	ttacaggaca	gcagatgggg	60
aattcatggc	tgttgagca	atanaacccc	agttctacga	gctgctgac	aaaggacttg	120
gactaaagtc	tgatgaactt	cccaatcaga	tgagcatgga	tgattggcca	gaaatgaana	180
agaagtttgc	agatgtatct	gcaaagaaga	cgaaggcaga	gtggtgtcaa	atctttgacg	240
gcacagatgc	ctgtgtgact	ccggttctga	cttttgagga	ggttggttcat	catgatcaca	300
acaangaacg	gggtctggtt	atcaccantg	aggagcagga	cgtgagcccc	cgccctgcac	360
ctctgctgtt	aaacaccccc	gccatccctt	ctttcaaaaag	ggatccacta	cttctagagc	420
ggncgccacc	gcggtggagc	tccagctttt	gttcccttta	gtgaggggta	attgcgcgct	480
tggcgtaatc	atggtcatan	ctgtttcctg	tgtgaaattg	ttatccgctc	acaattccac	540
gcaacatacg	anccggaagc	atnaaaatctt	aaagcctggn	ggtngcctaa	tgantgaact	600
naactcacatt	aattggcttt	gcgctcactg	cccgctttcc	agtcgggaaa	acctgtcctt	660
gccagctgcc	nttaatgaat	cnggccaccc	ccgggggaaa	aggcngtttg	cttnttgggg	720
cgencttccc	gctttctcgc	ttcctgaant	ccttcccccc	ggtctttcgg	cttgcggcna	780
acggtatcna	cct					793

<210> 34

<211> 756

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(756)

<223> n = A,T,C or G

<400> 34

gcgcgacccg	gcattgacga	gcaactcaag	ggcgagtggg	accgtaaaag	ccccaatctt	60
ancaagtgcg	gggaanagct	gggtcgactc	aagctagtct	ttctggagct	caacttcttg	120
ccaaccacag	ggaccaagct	gaccaaacag	cagctaattc	tggcccgatg	catactggag	180
atcgggggcc	aattggagcat	cctacgcaan	gacatccctt	ccttcgagcg	ctacatggcc	240
cagctcaaat	gctactactt	tgattacaan	gagcagctcc	cagagtcagc	ctatatgcac	300
cagctcttgg	gcttcaacct	cctcttctct	ctgtcccaga	acgggggtgg	tgantnccac	360
acgganttgg	anccgctgcc	tgcccaanga	catacanacc	aatgtctaca	tcnaccacca	420
gtgtcctgga	gcaatactga	tgganggcag	ctaccncaaa	gtnttctctg	ccnagggtaa	480
cateccccgc	cgagagctac	accttcttca	ttgacatcct	gctcgacact	atcagggatg	540
aaaatcgng	ggttgctcca	gaaaggctnc	aanaanatec	ttttcncctg	aggcccccg	600
atncnctagt	ncatagaatc	gcccgcctac	gcggtgganc	ctccaacctt	tcgttncctt	660
ttactgaggg	tttattgccg	cccttgccgt	tatcatggtc	acnccngttn	cctgtgttga	720
aattnttaac	ccccacaaat	tccacgcena	catnng			756

<210> 35

<211> 834

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(834)

<223> n = A,T,C or G

<400> 35

ggggtatctct	anactnacct	gnatgcatgg	ttgtcggtgt	ggtcgctgtc	gatgaanatg	60
aaacagratct	tgcccttgaa	gctctcggtc	gctgtnttta	agttgctcag	tctgcggtca	120
tagtcagaca	cncctttggg	caaaaaacan	caggatntga	gtcttgattt	cacctccaat	180
aatcttctng	gctgtctgct	cggtgaactc	gatgaacnang	ggcagctggt	tgtgtntgat	240
aaantccanc	angttctcct	tggtgacctc	cccttcaaaag	ttgttccggc	cttcatcaaa	300
cttctnnaan	angannancc	cancctttgtc	gagctggnat	ttgganaaca	cgctactggt	360

```

ggaaaactgat cccaaatggt atgtcatcca tgcctctgc tgcctgcaaa aaacttgctt 420
ggcncaaact cgactcccn tccttgaaag aagccnatca cccccccctc cctggactcc 480
nncaangact ctncgcgtnc ccntccnng caggggttggg ggcanncgg gccntgcgc 540
ttcttcagcc agttcacnat ntcatcagc ccctctgcc gctgtntat tccttggggg 600
ggaanccgtc tctcccttcc tgaannaact ttgaccgtng gaatagccgc gcntcncnt 660
acntnctggg ccgggttcaa antccctccn ttgncntcn cctcgggcca ttctggattt 720
nccnaacttt ttccttcccc cncnccnng ngtttggnnt tttcatnggg ccccaactct 780
gctnttgccc antccctgg gggcntntan cncnccntnt ggtcccntng ggcc 834

```

<210> 36

<211> 814

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(814)

<223> n = A,T,C or G

<400> 36

```

cggncgcttt cncgcgcgc ccggtttcca tgacnaaggc tcccttcang ttaaatacnn 60
cctagnaaac attaatgggt tgctctacta atacatcata cnaaccagta agcctgcca 120
naacgccaac tcaggccatt cctaccaaag gaagaaaggc tggctctctc acccctgta 180
ggaaaggcct gccttgtaag acaccacaat ncggctgaat ctnaagtctt gtgttttact 240
aatggaaaaa aaaaataaac aanaggtttt gttctcatgg ctgccaccg cagcctggca 300
ctaaaacanc ccagcgtca cttctgcttg ganaaatatt ctttgcctt ttggacatca 360
ggcttgatgg tatcactgcc acntttccac ccagctgggc ncccttcccc catntttgtc 420
antganctgg aaggcctgaa ncttagtctc caaaagtctc ngcccacaag accggccacc 480
aggggangtc nttncagtg gatctgcaa anantaccn tatcatcnnt gaataaaaag 540
gcccctgaac ganatgcttc cancanctt taagaccat aatcctngaa ccatgggtgcc 600
cttccggtct gatccnaaag gaatgttctt ggggtccant ccctccttig ttncttacgt 660
tgtnttgga cctgtctnng atnaccaan tganatcccc ngaagcacc tncnccctggc 720
atttganttt cntaaattct ctgccctacn netgaaagca cnaltccctn ggcncnnaan 780
ggngaactca agaaggtctn ngaaaaacca cncn 814

```

<210> 37

<211> 760

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(760)

<223> n = A,T,C or G

<400> 37

```

gcatgctgct cttcctcaaa gttgttcttg ttgccataac aaccaccata ggtaaagcgg 60
gcgcagtggt cgctgaagg gttgtagtac cagcgcggga tgctctcctt gcagagtctt 120
gtgtctggca ggtccacgca atgcccttg tctactggga aatggatgcg ctggagctcg 180
tcnaanccac tcgtgtatth ttcacangca gcctcctccg aagcntccg gcagttgggg 240
gtgtcgtcac actccactaa actgtcgatn cancagccca ttgctgcagc ggaactgggt 300
gggctgacag gtgccagaac acactggatn ggcctttcca tggaaaggcc tgggggaaat 360
cncctnancc caaactgcct ctcaaaggcc accttgaca ccccgacag ctagaaatgc 420
actcttcttc ccaaaggtag ttgttcttg tgcceaagca ncctccanca aaccaaaanc 480
ttgcaaaatc tgctccgtgg gggatcatnn taccanggtt ggggaaanaa acccggcngn 540
ganccnctt gtttgaatgc naaggnaata atcctcctgt cttgcttggg tggaaanagca 600
caattgaact gttaacnttg ggccgngttc cncnnggtg gtctgaaact aatcacgcgc 660
actggaaaaa ggtangtgcc ttccttgaat tcccaaant cccctngntt tgggtntttt 720

```


<221> misc_feature
 <222> (1)...(753)
 <223> n = A,T,C or G

<400> 40

gtggtatttt	ctgtaagatc	agggtgttcct	ccctcgtagg	tttagaggaa	acaccctcat	60
agatgaaaac	ccccccgaga	cagcagcact	gcaactgcc	agcagccggg	gtaggagggg	120
cgccctatgc	acagctgggc	ccttgagaca	gcagggttc	gatgtcaggc	tcgatgtcaa	180
tggctctggaa	gcggcggctg	tacctgcgta	ggggcacacc	gtcaggggcc	accaggaact	240
tctcaaagtt	ccaggcaacn	tcgttgcgac	acaccggaga	ccagggtgatn	agcttgggggt	300
cggtcataan	cgcggtggcg	tcgtcgtggg	gagctggcag	ggcctcccgc	aggaaggcna	360
ataaaagggtg	cgcccccgca	ccgttcanc	cgcaacttctc	naanaccatg	angttgggct	420
cnaaccaccc	accannccgg	acttccttga	nggaattccc	aaatctcttc	gntcttgggc	480
ttctnctgat	gccctanctg	gttgcccngn	atgccaanca	nccccaancc	ccgggggtcct	540
aaanccccc	cctcctcctt	tcctctgggt	tnttntcccc	ggaccntggg	tcctctcaag	600
ggancccata	tctcnaccan	tactcacct	ccccccccnt	gnnaccanc	cttctanngn	660
ttcccncccg	ncctctggcc	cntcaaan	gcttncacna	cctgggtctg	ccttcccccc	720
tnccctatct	gnaccccn	tttgtctcan	tnt			753

<210> 41
 <211> 341
 <212> DNA
 <213> Homo sapien

<400> 41

actatatcca	tcacaacaga	catgcttcat	cccatagact	tcttgacata	gcttcaaagt	60
agtgaaccca	tccttgattt	atatacatat	atgttctcag	tattttggga	gcctttccac	120
ttctttaaac	cttggttcatt	atgaacactg	aaaataggaa	tttgtgaaga	gttaaaaagt	180
tatagcttgt	ttacgtagta	agtttttgaa	gtctacattc	aatccagaca	cttagttgag	240
tggtaaactg	tgatttttaa	aaaatatcat	ttgagaatat	tctttcagag	gtattttcat	300
ttttactttt	tgattaattg	tgttttatat	attagggtag	t		341

<210> 42
 <211> 101
 <212> DNA
 <213> Homo sapien

<400> 42

acttactgaa	tttagttctg	tgctcttcc	tatttagtgt	tgtatcataa	atactttgat	60
gtttcaaaca	ttctaaataa	ataattttca	gtggcttcat	a		101

<210> 43
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 43

acatctttgt	tacagtctaa	gatgtgttct	taaatcacca	ttccttctctg	gtcctcaccc	60
tccagggtgg	tctcacactg	taattagagc	tattgaggag	tctttacagc	aaattaagat	120
tcagatgcct	tgctaagtct	agagttctag	agttatgttt	cagaaagtct	aagaaaccca	180
cctcttgaga	ggtcagtaaa	gaggacttaa	tatttcatat	ctacaaaatg	accacaggat	240
tgatacaga	acgagagtta	tcctggataa	ctcagagctg	agtacctgcc	cggggggccgc	300
tcgaa						305

<210> 44
 <211> 852
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(852)
 <223> n = A,T,C or G

<400> 44
 acataaatat cagagaaaag tagtctttga aatattttacg tccaggagtt ctttgtttct 60
 gattattttgg tgtgtgtttt ggtttgtgtc caaagtattg gcagottcag ttttcattct 120
 ctctccatcc tcgggcattc ttcccaaatt tatataccag tottcgtcca tccacacgct 180
 ccagaatttc tctttttag taatatctca tagctcggt gagcttttca taggtcatgc 240
 tgtgtgtgtt cttcttttta ccccatagct gagccactgc ctctgatttc aagaacctga 300
 agaagccctc agatcggtct tcccatttta ttaatcctgg gttcttgtct gggttcaaga 360
 ggatgtcgcg gatgaattcc cataagttag tccctctcgg gttgtgcttt ttgggtgtggc 420
 acttggcagg ggggtcttgc tcttttttca tatcagggtga ctctgcaaca ggaaggtgac 480
 tgggtggtgt catggagatc tgagcccgcc agaaagtttt gctgtccaac aaatctactg 540
 tgcaccata gttggtgtca tataaatagt tctngtcttt ccagggtgtc atgatggaag 600
 gctcagtttg ttcagtcttg acaatgacat tgtgtgtgga ctggaacagg tcactactgc 660
 actggccgtt ccacttcaga tgcctgcaagt tgcctgtagag gagntgcccc gccgtccctg 720
 ccgccgggt gaactcctgc aaactcatgc tgcaaagggt ctgcgccgtg atgtcgaact 780
 cntggaaggg gatacaattg gcatccagct ggttggtgtc caggaggtga tggagccact 840
 cccacacctg gt 852

<210> 45
 <211> 234
 <212> DNA
 <213> Homo sapien

<400> 45
 acaacagacc ctgtctcgt aaagacctca tgcctatcaa gttggacgaa tccgtgtccg 60
 agtctgacac catccggagc atcagcattg ctctgcagtg ccctaccgcg gggaactctt 120
 gctcgttttc tggctggggc ctgctggcga acggcagaat gcctaccgtg ctgcagtgcg 180
 tgaacgtgtc ggtggtgtct gaggaggtct gcagtaagct ctatgaccgg ctgt 234

<210> 46
 <211> 590
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(590)
 <223> n = A,T,C or G

<400> 46
 actttttatt taaatgttta taaggcagat ctatgagaat gatagaaaac atgggtgtgta 60
 atttgatagc aatatttttg agattacaga gttttagtaa ttaccaatta cacagttaaa 120
 aagaagataa tatattccaa gcanatacaa aatatctaata gaaagatcaa ggcaggaaaa 180
 tgantataac taattgacaa tggaaaaatca attttaatgt gaattgcaca ttatccttta 240
 aaagctttca aaanaanaa ttattgcagt ctanttaatt caaacagtg taaatgggtat 300
 caggataaan aactgaagg canaaaagaat taattttcac ttcattgtaac ncacccanat 360
 ttacaatggc ttaaatgcan ggaaaaagca gtggaagtag ggaagtantc aaggtctttc 420
 tggctctctaa tctgccttac tctttgggtg tggctttgat cctctggaga cagctgccag 480
 ggctcctgtt atatccacaa tcccagcagc aagatgaagg gatgaaaaag gacacatgct 540
 gcttctcttt gaggagactt catctcactg gccaacactc agtcacatgt 590

<210> 47
 <211> 774

<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(774)
<223> n = A,T,C or G

<400> 47
acaagggggc ataatgaagg agtggggana gatttttaaag aaggaaaaaa aacgaggccc 60
tgaacagaat tttcctgnac aacggggcctt caaaataatt ttcttgggga ggttcaagac 120
gcttcactgc ttgaaactta aatggatgtg ggacanaatt ttctgtaatg accctgaggg 180
cattacagac gggactcttg gaggaaggat aaacagaaaag gggacaaaag ctaatcccaa 240
aacatcaaaag aaaggaaggt ggcgtcatac ctcccagcct acacagttct ccagggtctt 300
cctcatccct ggaggacgac agtggaggaa caactgacca tgtccccagg ctctgtgtg 360
ctggctcctg gtcttcagcc cccagctctg gaagcccacc ctctgtgat cctgcgtggc 420
ccacactcct tgaacacaca tccccaggtt atattccttg acatggctga acctcctatt 480
cctacttccg agatgccttg ctccctgcag cctgtcaaaa tcccactcac cctccaaacc 540
acggcatggg aagcctttct gacttgccctg attactccag catcttggaa caatccctga 600
ttccccactc cttagaggca agataggggtg gttaagagta gggctggacc acttggagcc 660
aggctgctgg cttcaaattn tggctcattt acgagctatg ggaccttggg caagtnatct 720
tcacttctat gggcntcatt ttgttctacc tgcaaaatgg gggataataa tagt 774

<210> 48
<211> 124
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(124)
<223> n = A,T,C or G

<400> 48
canaaattga aattttataa aaaggcattt ttctcttata tccataaaat gatataattt 60
ttgcaantat anaaatgtgt cataaattat aatgttcctt aattacagct caacgcaact 120
tggt 124

<210> 49
<211> 147
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(147)
<223> n = A,T,C or G

<400> 49
gccgatgcta ctattttatt gcaggaggtg ggggtgtttt tattattctc tcaacagctt 60
tgtggctaca ggtggtgtct gactgcatna aaaanttttt tacgggtgat tgcaaaaatt 120
ttagggcacc catatcccaa gcantgt 147

<210> 50
<211> 107
<212> DNA
<213> Homo sapien

<400> 50
 acattaaatt aataaaagga ctgttggggt tctgctaaaa cacatggctt gatattttgc 60
 atgttttgag gttaggagga gttaggcata tgttttggga gaggggt 107

<210> 51
 <211> 204
 <212> DNA
 <213> Homo sapien

<400> 51
 gtctttaggga cacacgactc tggggtcacg gggccgacac acttgcacgg 60
 ggggaaggaa aggcagagaa gtgacaccgt cagggggaaa tgacagaaaag gaaaaatcaag 120
 gccttgcaag gtcagaaaag ggactcaggg ctccaccac agccctgccc cacttgccca 180
 ccttctttt gggaccagca atgt 204

<210> 52
 <211> 491
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(491)
 <223> n = A,T,C or G

<400> 52
 acaaagataa catttatctt ataacaaaaa tttgatagtt tttaaaggta gtatttgtta 60
 gggatatttt caaaagacta aagagataac tcaggtaaaa agttagaaat gtataaaaca 120
 ccatcagaca ggTTTTTaaa aaacaacata ttacaaaatt agacaatcat ccttaaaaaa 180
 aaaactttt gtatcaattt cttttgttca aaatgactga cttaantatt tttaaattatt 240
 tcanaaacac ttctcaaaaa attttcaana tggtagcttt canatgtnc ctcagtccca 300
 atgttgttca gataaataaa tctcgtgaga acttaccacc caccacaagc tttctggggc 360
 atgcaacagt gtcttttctt tnttttttct tttttttttt ttacaggcac agaaactcat 420
 ccttttttatt tggataacaa agggcttcca aattatattg aaaaataaat ccaagttaat 480
 atcacttttg t 491

<210> 53
 <211> 484
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(484)
 <223> n = A,T,C or G

<400> 53
 acataattta gcagggctaa ttaccataag atgctattta ttaanaggtn tatgatctga 60
 gtattaaacag ttgctgaagt ttggtatttt tatgcagcat tttctttttg ctttgataac 120
 actacagaac ccttaaggac actgaaaatt agtaagtaaa gttcagaaac attagctgct 180
 caatcaaatc tctacataac actatagtaa ttaaaacggt aaaaaaaagt gttgaaatct 240
 gcactagtat anaccgctcc tgtcaggata anactgcttt ggaacagaaa gggaaaaanc 300
 agcttttgant ttctttgtgc tgatangagg aaaggctgaa ttaccttggt gcctctccct 360
 gatgattggc aggtcnggta aatnccaaaa catattccaa ctcaacactt cttttccncc 420
 tancttgant ctgtgtatcc caggancagg cggatggaat gggccagccc ncggatgttc 480
 cant 484

<210> 54

<211> 151
 <212> DNA
 <213> Homo sapien

<400> 54
 actaaacctc gtgcttgtga actccatata gaaaacgggtg ccatccctga acacggctgg 60
 ccactgggta tactgctgac aaccgcaaca acaaaaacac aaatccttgg cactggctag 120
 tctatgtcct ctcaagtgcc tttttgtttg t 151

<210> 55
 <211> 91
 <212> DNA
 <213> Homo sapien

<400> 55
 acctggcttg tctccgggtg gttcccggtg cccccacgg tccccagaac ggacactttc 60
 gcctccagt ggatactga gccaaagtgg t 91

<210> 56
 <211> 133
 <212> DNA
 <213> Homo sapien

<400> 56
 ggcggtatgt cgttggttat atacaaatat gtcattttat gtaagggact tgagtatact 60
 tggatttttg gtatctgtgg gttgggggga cgggtccagga accaatacce catggatacc 120
 aagggacaac tgt 133

<210> 57
 <211> 147
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(147)
 <223> n = A,T,C or G

<400> 57
 actctggaga acctgagccg ctgctccgcc totgggatga ggtgatgcan gcngtggcgc 60
 gactgggagc tgagcccttc cctttgcgcc tgccctcagag gattgttgcc gacntgcana 120
 tctcantggg ctggatncat gcagggt 147

<210> 58
 <211> 198
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(198)
 <223> n = A,T,C or G

<400> 58
 acagggatat aggttttnaag ttattgtnat tgtaaaatac attgaatttt ctgtatactc 60
 tgattacata catttatcct ttaaaaaaga tgtaaatcctt aatttttatg ccatctatta 120
 atttaccat gagttacctt gtaaatgaga agtcatgata gcactgaatt ttaactagtt 180
 ttgacttcta agtttggt 198

<210> 59
 <211> 330
 <212> DNA
 <213> Homo sapien

<400> 59
 acacacaaatg gggttgagg aagtcttata agcaaaactg gtgatggcta ctgaaaagat 60
 ccattgaaaa ttatcattaa tgattttaaa tgacaagtta tcaaaaactc actcaatttt 120
 caactgtgct agcttgctaa aatgggagtt aactctagag caaatatagt atcttctgaa 180
 tacagtcaat aaatgacaaa gccagggcct acaggtggtt tccagacttt ccagaccag 240
 cagaggaat ctattttata acatggatct ccgtctgtgc tcaaaatacc taatgatatt 300
 ttctgtcttt attggacttc ttgaagagt 330

<210> 60
 <211> 175
 <212> DNA
 <213> Homo sapien

<400> 60
 accgtgggtg ctttctacat tcttgacggc tcttccacca acatctggtt ctacttcggc 60
 gtcgtgggtc ctttctctt catcctcacc cagctgggtg tgctcaccga ctttgccgac 120
 tcttggaacc agcgttggtt gggcaaggcc gaggagtgcg attcccgctg ctggt 175

<210> 61
 <211> 154
 <212> DNA
 <213> Homo sapien

<400> 61
 accccacttt tctcctgtg agcagctctg acttctcact gctacatgat gaggggtgagt 60
 ggttggtgct cttcaacagt atctccctt tcccgatct gctgagccgg acagcagtg 120
 tgaatgcac agccccgggg ctccacattg ctgt 154

<210> 62
 <211> 30
 <212> DNA
 <213> Homo sapien

<400> 62
 cgctcgagcc ctatagttag tctgattaga 30

<210> 63
 <211> 89
 <212> DNA
 <213> Homo sapien

<400> 63
 acaagtcatt tcagaccct ttgctcttca aaactgacca tcttttatat ttaatgcttc 60
 ctgtatgaat aaaaatgggt atgtcaagt 89

<210> 64
 <211> 97
 <212> DNA
 <213> Homo sapien

<400> 64
 acgggagtaa ctgagtcggg acgctgaatc tgaatccacc aataaataaa ggttctgcag 60

aatcagtgc tccaggattg gtccttggat ctgggggt

97

<210> 65
 <211> 377
 <212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(377)
 <223> n = A,T,C or G

<400> 65
 acaacaanaa ntcccttctt taggccactg atggaaacct ggaacccctt ttgatggca 60
 gcatggcgct ctaggccttg acacagcggc tggggtttgg gctntcccaa accgcacacc 120
 ccaaccctgg tctaccaca nttctggcta tgggctgtct ctgccactga acatcagggt 180
 tcggtcataa natgaaatcc caanggggac agaggtcagt agaggaagct caatgagaaa 240
 ggtgctgttt gctcagccag aaaacagctg cctggcattc gccgctgaac tatgaacccg 300
 tgggggtgaa ctaccccan gaggaatcat gcctgggcga tgcaanggtg ccaacaggag 360
 gggcgggagg agcatgt 377

<210> 66
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 66
 acgcctttcc ctcagaattc agggaagaga ctgtgcctg ccttctcccg ttgttgcggtg 60
 agaaccctgt tgcccttcc caccatatcc accctcgctc catctttgaa ctcaaacaag 120
 aggaactaac tgcacctgg tcctctcccc agtccccagt tcacctcca tccctcacct 180
 tcctccactc taagggatat caacactgcc cagcacaggg gccctgaatt tatgtggttt 240
 ttatatattt ttaataaga tgcactttat gtcatttttt aataaagtct gaagaattac 300
 tgttt 305

<210> 67
 <211> 385
 <212> DNA
 <213> Homo sapien

<400> 67
 actacacaca ctccacttgc ccttgtgaga cactttgtcc cagcacttta ggaatgctga 60
 ggtcggacca gccacatctc atgtgcaaga ttgccagca gacatcaggt ctgagagttc 120
 cccttttaaa aaaggggact tgcttaaaaa agaagtctag ccacgattgt gtagagcagc 180
 tgtgctgtgc tggagattca cttttgagag agttctcctc tgagacctga tctttagagg 240
 ctgggcagtc ttgcacatga gatggggctg gtctgatctc agcactcctt agtctgcttg 300
 cctctcccag ggccccagcc tggccacacc tgcttacagg gcactctcag atgcccatac 360
 catagtttct gtgctagtgg accgt 385

<210> 68
 <211> 73
 <212> DNA
 <213> Homo sapien

<400> 68
 acttaaccag atatattttt accccagatg gggatattct ttgtaaaaaa tgaaaataaa 60
 gtttttttaa tgg 73

<210> 69

<211> 536
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(536)
 <223> n = A,T,C or G

<400> 69
 actagtcacg tgtgggtgaa ttccattgtg ttggggggctc tcaccctcct ctccctgcagc 60
 tccagctttg tgctctgcct ctgaggagac catgggccag catctgagta cctgtctgct 120
 cctgtctggcc accctagctg tggccctggc ctggagcccc aaggaggagg ataggataat 180
 cccgggtggc atctataacg cagacctcaa tgatgagtgg gtacagcgtg cccttcactt 240
 cgccatcagc gagtataaca aggccaccaa agatgactac tacagacgtc cgctgcgggt 300
 actaagagcc aggcaacaga ccgttggggg ggtgaattac ttcttcgacg tagaggtggg 360
 ccgaaccata tgtaccaagt cccagcccaa cttggacacc tgtgccttcc atgaacagcc 420
 agaactgcag aagaaacagt tgtgtctctt cgagatctac gaagtccct ggggagaaca 480
 gaangtcctt gggtgaaatc caggtgtcaa gaaatcctan ggaatctgtt ccaggc 536

<210> 70
 <211> 477
 <212> DNA
 <213> Homo sapien

<400> 70
 atgacccta acagggggccc tctcagccct cctaattgacc tccggcctag ccatgtgatt 60
 tcaattccac tccataacgc tctcataact aggcctacta accaacacac taaccatata 120
 ccaatgatgg cgcgatgtaa cagagaaaag cacataccaa ggccaccaca caccacctgt 180
 ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt ttttcttcgc 240
 agggattttt ctgagccctt taccactcca gcctagcccc tccccccaa ctaggagggc 300
 actggccccc aacaggcctc accccgctaa atccctctaga agtccactc ctaaaccat 360
 cgttattact cgcacagga gtatcaatca cctgagctca ccatagtcta atagaaaaca 420
 accgaaacca aattattcaa agcactgctt attacaattt tactgggtct ctatttt 477

<210> 71
 <211> 533
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(533)
 <223> n = A,T,C or G

<400> 71
 agagctatag gtacagtgtg atctcagctt tgcaaacaca ttttctacat agatagtact 60
 aggtattaat agatatgtaa agaaagaaat cacaccatta ataatggtaa gattgggtta 120
 tgtgatttta gtggtatttt tggcaccctt atatatgttt tccaaacttt cagcagtgat 180
 attatttcca taacttaaaa agtgagtttg aaaaagaaaa tctccagcaa gcattctcatt 240
 taaataaagg tttgtcatct ttaaaaatac agcaatatgt gactttttta aaaagctgtc 300
 aaataggtgt gaccctacta ataattatta gaaatacatt taaaaacatc gattacctca 360
 agtcagtttg ccttgaaaaa tatcaaatat aactcttaga gaaatgtaca taaaagaatg 420
 ctctgtaatt ttggagtang aggttccttc ctcaattttg tattttttaa aagtacatgg 480
 taaaaaaaaa aattcacaac agtatataag gctgtaaaat gaagaattct gcc 533

<210> 72
 <211> 511

<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(511)
<223> n = A,T,C or G

<400> 72
tattacggaa aaacacacca cataattcaa ctancaaaga anactgcttc agggcgtgta 60
aatgaaagg cticcaggca gttatctgat taaagaacac taaaagaggg acaaggctaa 120
aagccgcagg atgtctacac tatancaggc gctatttggg ttggctggag gagctgtgga 180
aaacatggan agattggtgc tgganacgc cgtggctatt cctcattggt attacanagt 240
gaggttctct gtgtgccac tggtttgaaa accgttctnc aataatgata gaatagtaca 300
cacatgagaa ctgaaatggc ccaaaccag aaagaaagcc caactagatc ctcagaanac 360
gcttctaggg acaataaccg atgaagaaaa gatggcctcc ttgtgcccc gtctgttatg 420
atttctctcc attgcagcna naaaccggtt ctctaaagca aacncagggtg atgatggcna 480
aaatacaccc cctcttgaag naccnggagg a 511

<210> 73
<211> 499
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(499)
<223> n = A,T,C or G

<400> 73
cagtgccagc actggtgcc gtaccagtac caataacagt gccagtgcc gtgccagcac 60
cagtgggtggc ttcagtgtg gtgccagcct gaccgccact ctacatttg ggctcttcgc 120
tggccttggg ggagctggtg ccagcaccag tggcagctct ggtgcctgig gtttctccta 180
caagtgagat tttagatatt gttaatcctg ccagtcttct tcttcaagcc aggggtgcac 240
ctcagaaaacc tactcaacac agcactctag gcagccacta tcaatcaatt gaagttgaca 300
ctctgcatta aatctatttg ccatttctga aaaaaaaaaa aaaaaaaggg cggcgcctcg 360
antctagagg gcccggttaa acccgctgat cagcctcgac tgtgccttct anttgccagc 420
catctgttgt ttgccctcc cccgntgcct tccttgacct tggaaagtgc cactcccact 480
gtcctttcct aantaaat 499

<210> 74
<211> 537
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(537)
<223> n = A,T,C or G

<400> 74
tttcatagga gaacacactg aggagatact tgaagaattt ggattcagcc gcgaagagat 60
ttatcagctt aactcagata aaatcattga aagtaataag gtaaaagcta gtctctaact 120
tccaggccca cggtcaagt gaatttgaat actgcattta cagtgtagag taacacataa 180
cattgtatgc atggaacat ggaggaacag tattacagtg tcttaccact ctaatcaaga 240
aaagaattac agactctgat tctacagtga tgattgaatt ctaaaaatgg taatcattag 300
ggcttttgat ttataanact ttgggtactt atactaaatt atggtagtta tactgccttc 360
cagtttgctt gatataattg ttgatattaa gattcttgac ttatatattg aatgggttct 420

acigaaaaan gaatgatata ttcttgaaga catcgatata catttattta cactcttgat 480
tctacaatgt agaaaatgaa ggaaatgccc caaattgtat ggtgataaaa gtcccg 537

<210> 75
<211> 467
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(467)
<223> n = A,T,C or G

<400> 75
caaanacaat tgttcaaaag atgcaaatga tacactactg ctgcagctca caaacacctc 60
tgcataattac acgtacctcc tctgtctcct caagtagtgt ggtctatttt gccatcatca 120
cctgctgtct gcttagaaga acggttttct gctgcaangg agagaaatca taacagacgg 180
tggcacaagg aggccatctt ttctcctcgc gttattgtcc ctagaagcgt cttctgagga 240
tctagtggg ctttctttct gggtttgggc catttcantt ctcagtgtgt tactattcta 300
tcattattgt ataacgggtt tcaaaccong gggcacncag agaacctcac totgtaataa 360
caatgaggaa tagccacggg gatctccagc accaaatctc tccatgttnt tccagagctc 420
ctccagccaa cccaaatagc cgctgctatn gtgtagaaca tccctgn 467

<210> 76
<211> 400
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(400)
<223> n = A,T,C or G

<400> 76
aagctgacag cattcgggcc gagatgtctc gctccgtggc cttagctgtg ctgcgcctac 60
tctctctttc tggcctggag gctatccagc gtactccaaa gattcagggt tactcaegtc 120
atccagcaga gaatggaaag tcaaatttcc tgaattgcta tgtgtctggg ttcatccat 180
ccgacattga agttgactta ctgaagaatg gagagagaat tgaaaaagt gagcattcag 240
acttctcttt cagcaaggac tggctcttct atctcttgta ctacactgaa ttcaccccca 300
ctgaaaaaga tgagtatgcc tggcgtgtga accatgtgac tttgtcacag cccaagatng 360
ttnagtggga teganacatg taagcagcan catggggaggt 400

<210> 77
<211> 248
<212> DNA
<213> Homo sapien

<400> 77
ctggagtgcc ttggtgttcc aagcccctgc aggaagcaga atgcaccttc tgaggcacct 60
ccagctgccc cggcggggga tgcgaggctc ggagcaccct tgcccggctg tgattgctgc 120
caggcactgt tcatctcagc tttctgtcc ctttgcctcc ggcaagcgt tctgctgaaa 180
gttcatactt ggagcctgat gtcttaacga ataaaggctc catgctccac ccgaaaaaaa 240
aaaaaaa 248

<210> 78
<211> 201
<212> DNA
<213> Homo sapien

```

<400> 78
actagtcacg tgtgggtggaa ttccattgtg ttggggcccaa cacaatggct acctttaaca      60
tcacccagac cccgccctgc ccggtgcccc cgtgctgct aacgacagta tgatgottac      120
tctgctactc ggaaactatt tttatgtaat taatgtatgc tttcttggtt ataaatgcct      180
gatttaaaaa aaaaaaaaaa a                                201

```

```

<210> 79
<211> 552
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(552)
<223> n = A,T,C or G

```

```

<400> 79
tccttttgtt aggtttttga gacaacccta gacctaaact gtgtcacaga cttctgaatg      60
tttaggcagt gctagtaatt tcctcgtaat gattctgtta ttactttcct attctttatt      120
cctctttcct ctgaagatta atgaagttga aaattgaggt ggataaatac aaaaaggtag      180
tgtgatagta taagtatcta agtgcagatg aaagtgtgtt atatatatcc attcaaaatt      240
atgcaagtta gtaattactc agggttaact aaattacttt aatatgctgt tgaacctact      300
ctgttccttg gctagaaaaa attataaaca ggactttgtt agtttgggaa gccaaattga      360
taatattcta tgttctaaaa gtgggctat acataaanta tnaagaaata tggaaatttta      420
ttcccaggaa tatgggggtt atttatgaat antaccggg anagaagttt tgantnaaac      480
cngttttgtt taatacgtta atatgtcctn aatnaacaag gcntgactta tttccaaaaa      540
aaaaaaaaaa aa                                          552

```

```

<210> 80
<211> 476
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(476)
<223> n = A,T,C or G

```

```

<400> 80
acaggggattt gagatgctaa ggccccagag atcgtttgat ccaaccctct tattttcaga      60
ggggaaaatg gggcctagaa gttacagagc atctagctgg tgcgctggca cccctggcct      120
cacacagact ccagagtagc tgggactaca ggcacacagt cactgaagca ggcctgttt      180
gcaattcacg ttgccacctc caacttaaac attcttcata tgtgatgtcc ttagtcacta      240
aggtttaaact ttcccaccca gaaaaggcaa cttagataaa atcttagagt actttcatac      300
tcttctaagt cctcttccag cctcactttg agtcctcctt ggggggttgat aggaantntc      360
tcttggtttt ctcaataaaa tctctatcca tctcatgttt aatttggtac gcntaaaaat      420
gctgaaaaaa ttaaaatgtt ctggtttcnc tttaaaaaaa aaaaaaaaaa aaaaaa      476

```

```

<210> 81
<211> 232
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(232)
<223> n = A,T,C or G

```

```

<400> 81
tttttttttg tatgccttctn ctgtggngtt attgttgctg ccaccttga ggagccagct    60
tttttttgta tttttttttt ctggggggtc ttcttggtc tgccctcca ttccagcct    120
ctcatcccca ttttgcactt ttgctagggg tggaggcgt ttctggtag cccctcagag    180
actagtcag cgggaataag tcttaggggt ggggggtgtg gcaagccggc ct          232

```

```

<210> 82
<211> 383
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(383)
<223> n = A,T,C or G

```

```

<400> 82
aggcgggagc aagaactaaa gccaaagccc aagaagagtg gcagtgccag cactggtgcc    60
agtaccagta ccaataacat gccagtgccg gtgccagcac cagtgggtggc ttcagtgtctg    120
gtgccagcct gacggccact ctacatttg ggctcttcgc tggccttggg ggagctggtg    180
ccagcaccag tggcagctct ggtgcctgtg gtttctccta caagtgagat tttagatatt    240
gttaatcctg ccagtccttc tttcaagcc aggggtgcac ctcagaaacc tactcaacac    300
agcactctng gcagccacta tcaatcaatt gaagttgaca ctctgcatta aatctatttg    360
ccatttcaaa aaaaaaaaaa aaa          383

```

```

<210> 83
<211> 494
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(494)
<223> n = A,T,C or G

```

```

<400> 83
accgaattgg gaccgctggc ttataagcga tcatgtctc cagtattacc tcaacgagca    60
gggagatcga gtctatacgc tgaagaaatt tgaccgatg ggacaacaga cctgctcagc    120
ccatctctgt cggttctccc cagatgacaa atactctcga cacogaatca ccatcaagaa    180
acgtttcaag gtgtctatga ccagcaacc gcgcctgtc ctctgagggt ccttaaactg    240
atgtcttttc tgccacctgt taccctctcg agactccgta accaaactct tcggactgtg    300
agccctgatg cctttttgcc agccatactc ttgggntcc agtctctctg ggcgattgat    360
tatgcttgtg tgaggcaatc atggtggcat caccatnaa gggaacacat ttganttttt    420
tttncatat tttaaattac naccagaata nttcagaata aatgaattga aaaactctta    480
aaaaaaaaaa aaaa          494

```

```

<210> 84
<211> 380
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(380)
<223> n = A,T,C or G

```

```

<400> 84

```

```

gctggtagcc tatggcgtgg ccacggangg gctcctgagg cacgggacag tgacttccca      60
agtatcctgc gccgcgtctt ctaccgtccc tacctgcaga tcttcgggca gattccccag      120
gaggacatgg acgtggccct catggagcac agcaactgct cgtcggagcc cggttcttgg      180
gcacaccctc ctggggccca ggccggcacc tgcgtctccc agtatgccaa ctggctggtg      240
gtgctgctcc tgcgtcatctt cctgctcgtg gccaacatcc tgctggtcac ttgctcattg      300
ccatgttcag ttacacattc ggcaaagtac agggcaacag cnatctctac tgggaaggcc      360
agcgttnccg cctcatccgg                                     380

```

```

<210> 85
<211> 481
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(481)
<223> n = A,T,C or G

```

```

<400> 85
gagttagctc ctccacaacc ttgatgaggt cgtctgcagt ggctctctgc ttcataccgc      60
tnccatcgtc atactgtagg ttigccacca cctcctgcat cttggggcgg ctaatatcca      120
ggaaactctc aatcaagtca ccgtcnatna aacctgtggc tggttctgtc ttccgctcgg      180
tgtgaaagga tctccagaag gagtgtctga tcttccccac acttttgatg actttattga      240
gtcgattctg catgtccagc aggaggttgt accagctctc tgacagttag gtcaccagcc      300
ctatcatgcc nttgaacgtg ccgaagaaca ccgagccttg tgtggggggg gnagtctcac      360
ccagattctg cattaccaga nagccgtggc aaaaganatt gacaactcgc ccaggnngaa      420
aaagaacacc tcttgaagt gctngccgct cctcgtecnt tggtggnngc gcntnccttt      480
t                                     481

```

```

<210> 86
<211> 472
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(472)
<223> n = A,T,C or G

```

```

<400> 86
aacatcttcc tgtataatgc tgtgtaatat cgatccgatn ttgtctgctg agaattcatt      60
acttggaana gcaacttnaa gcctggacac tggattataa attcacaata tgcaacactt      120
taaacagtgt gtcaatctgc tcccttactt tgtcatcacc agtctgggaa taagggtatg      180
ccctattcac acctgttaaa agggcgctaa gcatttttga ttcaacatct ttttttttga      240
cacaagtccg aaaaaagcaa aagtaaacag ttnttaattt gttagccaat tcactttctt      300
catgggacag agccatttga tttaaaaagc aaattgcata atattgagct ttgggagctg      360
atatntgagc ggaagantag cctttctact tcaccagaca caactccttt catattggga      420
tgttnacnaa agttatgtct cttacagatg ggatgctttt gtggcaattc tg                                     472

```

```

<210> 87
<211> 413
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(413)
<223> n = A,T,C or G

```



```

<400> 87
agaaacacagt atctctnaaa acaacctctc atacctgttg gacctaatit tgtgtgcgtg      60
tgtgtgtgcg cgcatattat atagacaggc acatcttttt tacttttgta aaagcttatg      120
cctcttttgt atctatatct gtgaaagttt taatgatctg ccataatgtc ttggggacct      180
ttgtcttctg tgtaaatggt actagagaaa acacctatnt tatgagtcaa tctagttngt      240
tttattcgac atgaaggaaa ttccagatn acaacactna caaactctcc cttgactagg      300
ggggacaaaag aaaagcnaaa ctgaacatna gaaacaattn cctggtgaga aattncataa      360
acagaaattg ggtngtatat tgaaanannng catcattnaa acgttttttt ttt              413

```

```

<210> 88
<211> 448
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(448)
<223> n = A,T,C or G

```

```

<400> 88
cgcagcgggt cctctctatc tagctccagc ctctgcctg ccccaactccc cgcgtcccgc      60
qtcctagccn accatggccg ggcccctgcg cgcctccttg ctctgtctgg ccctcctggc      120
cgtggccctg gccgtgagcc ccgcggcccg ctccagtcce ggcaagccgc cgcgcctggt      180
gggaggccca tggaccccgc gtggaagaag aagggtgtgc gcgtgcactg gactttgcgc      240
tcggcnanta caacaaaccc gcaacnaact ttaccnagcn cgcgtgcagc gttgtgccgc      300
cccaancaaa ttgttactng gggtaanata ttcttggaag ttgaacctgg gccaaacnng      360
tttaccagaa ccnagccaat tngaacaatt nccccccat aacagccccc tttaaaaagg      420
gaancantcc tgntcttttc caaatittt              448

```

```

<210> 89
<211> 463
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(463)
<223> n = A,T,C or G

```

```

<400> 89
gaattttgtg cactggccac tgtgatggaa ccattgggcc aggatgcttt gagtttatca      60
gtagtatttc tgccaaagtt ggtgttgtaa catgagtatg taaaatgtca aaaaattagc      120
agaggtctag gtctgcatat cagcagacag ttgtccgtg tattttgtag ccttgaagtt      180
ctcagtgaca agttntttct gatgcgaagt tctnattcca gtgttttagt cctttgcac      240
tttatgttn agacttgccct ctntnaaatt gcttttgtnt tctgcaggta ctatctgtgg      300
ttaacaaaa tagaannact tctctgcttn gaanatttga atatcttaca tctnaaaatn      360
aattctctcc ccatannaaa acccangccc ttggganaat ttgaaaaang gntccttcnn      420
aattcnnana anttcagntn tcatacaaca naacnggancc ccc              463

```

```

<210> 90
<211> 400
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(400)

```

<223> n = A,T,C or G

```

<400> 90
agggattgaa ggtctnttnt actgtcggac tgttcancca ccaactctac aagttgctgt      60
cttccactca ctgtctgtaa gcntnttaac ccagactgta tcttcataaa tagaacaaat      120
tcttcaccag tcacatcttc taggaccttt ttggattcag ttagtataag ctcttccact      180
tcctttgtta agacttcato tggtaaagtc ttaagttttg tagaaaggaa ttttaattgct      240
cgttctctaa caatgtcttc tccttgaagt atttggtgta acaaccacc tnaagtcctt      300
ttgtgcatcc attttaaata tacttaatag ggcattggtt cactagggtt aattctgcaa      360
gagtcactctg tctgcaaaag ttgcgttagt atatctgcaa      400

```

<210> 91

<211> 480

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(480)

<223> n = A,T,C or G

```

<400> 91
gagctcggat ccaataatct ttgtctgagg gcagcacaca tatncagtgc catggnaact      60
ggtctacccc acatgggagc agcatgccgt agntatataa ggtcattoce tgagtcagac      120
atgcctcttt gactaccgtg tgccagtgtt ggtgattctc acacacctcc nnccgctctt      180
tgtggaaaaa ctggcacttg nctggaacta gcaagacatc acttaciaat tcaccacga      240
gacacttgaa aggtgtaaca aagcgactct tgcattgctt tttgtccctc cggcaccagt      300
tgtcaatact aaccgcgtgg tttgcctcca tcacatttgt gatctgtagc tctggataca      360
tctcctgaca gtactgaaga acttctcttt ttgtttcaaa agcaactctt ggtgcctgtt      420
ngatcagggtt cccatttccc agtccgaatg ttcacatggc atatnttact tcccacaaaa      480

```

<210> 92

<211> 477

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(477)

<223> n = A,T,C or G

```

<400> 92
atacagccca natcccacca cgaagatgcg cttgttgact gagaacctga tgcggtcact      60
ggtcccgttg tagccccagc gactctccac ctgctggaag cggttgatgc tgcactcctt      120
cccacgcagg cagcagcggg gccgggtcaat gaactccact cgtggcttgg gggtgacggg      180
taantgcagg aagaggctga ccacctcgcg gtccaccagg atgcccgaact gtgcgggacc      240
tgacgcgaaa ctctctgatg gtcattgagc ggaagcgaat gangcccagg gccttgccca      300
gaaccttccg cctgttctct ggcgtcacct gcagctgctg ccgctnacac tcggcctcgg      360
accagcggac aaacggcggt gaacagccgc acctcacgga tgcccantgt gtcgcgctcc      420
aggaacggcn ccagcgtgtc cagggtcaatg tcgggtgaanc ctccgcgggt aatggcg      477

```

<210> 93

<211> 377

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(377)

<223> n = A,T,C or G

<400> 93

gaaaggctgg accitgctc gcattgtgt	gotggcagga ataccttggc aagcagctcc	60
agtcagagca gcccagacc gctgcgcgc	gaagctaagc ctgcctctgg ccttcccctc	120
cgcctcaatg cagaaccant agtgggagca	ctgtgttttag agttaagagt gaacaactgt	180
tgattttact tgggaatttc ctctgttata	tagcttttcc caatgctaata tccaaaacaa	240
caacaacaaa ataacatggt tgctgttina	gttggtataaa agtangtgat tctgtatnta	300
agagaaatat tactgttaca tatactgctt	gcaantctctg tatttattgg tncctcggaa	360
ataactatat tattaaa		377

<210> 94

<211> 495

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(495)

<223> n = A,T,C or G

<400> 94

ccctttgagg ggtaggggc cagttccag	tggaagaaac aggccaggag aantgcgtgc	60
cgagctgang cagatttccc acagtgacc	cagagccctg ggctatagtc tctgaccctc	120
ccaaggaaag accaccttct ggggacatg	gctggagggc aggcactaga ggcaccaagg	180
gaaggcccca ttccggggct gtcccccag	gaggaaggga aggggctctg tgtgccccc	240
acgaggaana ggccctgant cctgggatca	nacaccctt cactgtatc cccacacaaa	300
tgcaagctca ccaagggtccc ctctcagtc	cttccctaca cctgaacgg nactggccc	360
acacccaccc agancancca cccgccatg	ggaatgtnt caaggaatcg cngggcaacg	420
tggactctng tcccnnaagg ggcagaatc	tccaatagan gganngaacc cttgctnana	480
aaaaaaaaana aaaaa		495

<210> 95

<211> 472

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(472)

<223> n = A,T,C or G

<400> 95

ggttacttgg ttctattgcc accaattagt	ggatgtcatt tagaaccatt ttgtctgctc	60
cctctggaag ccttgcgcag agcggacttt	gtaattgttg gagaataact gotgaatttt	120
tagctgtttt gagttgatcc gcaccactgc	accacaactc aatatgaaaa ctatttnact	180
tatttattat cttgtgaaaa gtatacaatg	aaaattttgt tcatactgta tttatcaagt	240
atgatgaaaa gcaatagata tatattcttt	tattatgttn aattatgatt gccattatta	300
atcggcaaaa tgtggagtgt atgttctttt	cacagtaata tatgcctttt gtaacttcac	360
ttggttattt tattgtaaat gaattacaaa	attcttaatt taagaaaatg gtangttata	420
tttanttcan taatttcttt ccttgtttac	gtaatttttg aaaagaatgc at	472

<210> 96

<211> 476

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(476)

<223> n = A,T,C or G

<400> 96

ctgaagcatt	tcttcaaact	tntctacttt	tgtcattgat	acctgtagta	agttgacaat	60
gtggtgaaat	ttcaaaatta	tatgtaactt	ctactagttt	tactttctcc	cccaagtctt	120
ttttaactca	tgattttttac	acacacaatc	cagaacttat	tatatagcct	ctaagtcttt	180
attcttcaca	gtagatgatg	aaagagtcc	ccagtgtctt	gngcanaatg	ttctagntat	240
agctggatac	atacngtggg	agttctataa	actcatacct	cagtgggact	naacccaaat	300
tgtgttagtc	tcaattccta	ccacactgag	ggagcctccc	aaatcactat	attcttatct	360
gcaggtactc	ctccagaaaa	acngacaggg	caggcttgca	tgaaaaagtn	acatctgcgt	420
tacaaagtct	atcttctcca	nangtctgtg	aaggaacaat	ttaatcttct	agcttt	476

<210> 97

<211> 479

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(479)

<223> n = A,T,C or G

<400> 97

actctttcta	atgctgatat	gatcttgagt	ataagaatgc	atatgtcact	agaatggata	60
aaataatgct	gcaaacttaa	tgttcttatg	caaaatggaa	cgctaatagaa	acacagctta	120
caatcgcaaa	tcaaaaactca	caagtgtctca	tctgtttagag	atttagtgta	ataagactta	180
gattgtgctc	cttcggatata	gattgtttct	canatcttgg	gcaatnttcc	ttagtcaaata	240
caggctacta	gaattctggt	attggatatn	tgagagcatg	aaatttttaa	naatacactt	300
gtgattatna	aattaatcac	aaatttccact	tatacctgct	atcagcagct	agaaaaacat	360
ntnnttttta	natcaaaagta	ttttgtgttt	ggaantgtgn	aatgaaatc	tgaatgtggg	420
ttnatctta	ttttttcccn	gacnactant	tnctttttta	gggnctattc	tganccatc	479

<210> 98

<211> 461

<212> DNA

<213> Homo sapien

<400> 98

agtgacttgt	cctccaacaa	aacccttga	tcaagtttgt	ggcactgaca	atcagacctta	60
tgctagtctc	tgctactat	tcgctactaa	atgcagactg	gaggggacca	aaaaggggca	120
tcaactccag	ctggattatt	ttggagcctg	caaacttatt	cctacttgta	cggactttga	180
agtgattcag	tttctctac	ggatgagaga	ctggctcaag	aatatcctca	tgcagcttta	240
tgaagccact	ctgaacacgc	tggttatcta	gatgagaaca	gagaaataaa	gtcagaaaaat	300
ttacctggag	aaaagaggct	ttggctgggg	accatcccat	tgaaccttct	cttaaggact	360
ttaagaaaaa	ctaccacatg	ttgtgtatcc	tggtgccggc	cgtttatgaa	ctgaccaccc	420
tttgaataa	tcttgacgct	cctgaacttg	ctcctctgcg	a		461

<210> 99

<211> 171

<212> DNA

<213> Homo sapien

<400> 99

gtggccgcgc	gcagggtgtt	cctcgtaaccg	cagggccccc	tcccttcccc	aggcgctccct	60
cggcgccctc	gcgggcccga	ggaggagcgg	ctggcgggtg	gggggagtgt	gaccacacct	120

cggtgagaaa agccttctct agcgatctga gaggcgtgcc ttgggggtac c 171

<210> 100
<211> 269
<212> DNA
<213> Homo sapien

<400> 100
cggcgcgaag tgcaactcca gctggggcgc tgccgacgaa gattctgcca gcagttggtc 60
cgactgcgac gacggcggcg ggcacagtcg cagggtgcagc gcgggcgcct ggggtcttgc 120
aaggctgagc tgacgcgcga gaggtcgtgt cagctccac gaccttgacg ccgtcgggga 180
cagccgggaa agagcccggg gaagcgggag gcctcgggga gcccctcggg aagggcggcc 240
cgagagatac gcaggtgcag gtggccgcc 269

<210> 101
<211> 405
<212> DNA
<213> Homo sapien

<400> 101
tttttttttt ttgtggaatc tactgcgagc acagcaggtc agcaacaagt ttattttgca 60
gctagcaagg taacagggta gggcatggtt acatgttcag gtcaacttcc ttgtcgttg 120
ttgattgggt tgtctttatg gggcgggggt ggggtagggg aaacgaagca aataacatgg 180
agtgggtgca cctccctgt agaacctggt taaaaagctt ggggcagttc acctggctctg 240
tgaccgtcat ttctttgaca tcaatgttat tagaagtcag gatattcttt agagagtcca 300
ctgttctgga gggagattag ggtttcttgc caaatccaac aaaatccact gaaaaagtgt 360
gatgatcagt acgaataccg aggcattatc tcatatcggg ggcca 405

<210> 102
<211> 470
<212> DNA
<213> Homo sapien

<400> 102
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
ggcacttaat ccattttttat ttcaaaatgt ctacaaattt aatcccatta tacggtattt 120
tcaaaatcta aattattcaa attagccaaa tctttaccaa ataataccca aaaatcaaaa 180
atatacttct ttccagcaaac ttgttacata aattaaaaaa atatatacgg ctggtgtttt 240
caaagtacaa ttatcttaac actgcaaaaca ttttaaggaa ctaaaataaa aaaaaacact 300
ccgcaaagggt taaagggaac aacaaattct tttacaacac cattataaaa atcatatctc 360
aaatcttagg ggaatatata cttcacacgg gatcttaact tttactcact ttgtttattt 420
ttttaaacca ttgtttgggc ccaacacaat ggaatcccc ctggactagt 470

<210> 103
<211> 581
<212> DNA
<213> Homo sapien

<400> 103
tttttttttt ttttttttga cccccctctt ataaaaaaca agttaccatt ttatttttact 60
tacacatatt tattttataa ttggtatttag atattcaaaa ggcagctttt aaaatcaaac 120
taaatggaaa ctgccttaga tacataattc ttaggaaata gcttaaaaac tgcctaaagt 180
gaaaatcttc totagctctt ttgaactgaa atttttgact cttgtaaaaac atccaaattc 240
atttttcttg tottttaaat tatctaactt ttccattttt tccctattcc aagtcaattt 300
gcttctctag cctcatttcc tagctcttat ctactattag taagtggctt ttttccataa 360
agggaaaaaca ggaagagaaa tggcacacaa aacaaacatt ttatattcat atttctacct 420
acgttaataa aatagcattt tgtgaagcca gctcaaaaaga aggcttagat ccttttatgt 480
ccattttagt cactaaacga tatcaaaagt ccagaatgca aaagggttgt gaacatttat 540

tcaaaagcta atataagata tttcacatac tcatctttct g

581

<210> 104
 <211> 578
 <212> DNA
 <213> Homo sapien

<400> 104
 tttttttttt tttttttttt tttttctctt cttttttttt gaaatgagga tctgagtttt 60
 cactctctag atagggcatg aagaaaactc atctttccag ctttaaaata acaatcaaat 120
 ctcttatgct atatcatatt ttaagttaaa ctaatgagtc actggcttat ctctctctga 180
 aggaaatctg ttcattcttc tcattcatat agttatatca agtactacct tgcataattga 240
 gaggtttttc ttctctatct acacatatat ttccatgtga atttgtatca aacctttatt 300
 ttcattgcaa ctagaaaata atgtttcttt tgcataagag aagagaacaa tatagcatta 360
 caaaactgct caaattgttt gttaagttat ccattataat tagttggcag gagctaatac 420
 aaatcacatt tacgacagca ataataaaac tgaagtacca gttaaatata caaaataatt 480
 aaaggaacat ttttagcctg ggtataatta gctaattcac tttacaagca tttattagaa 540
 tgaattcaca tgttattatt cctagcccaa cacaatgg 578

<210> 105
 <211> 538
 <212> DNA
 <213> Homo sapien

<400> 105
 tttttttttt tttttcagta ataatacagaa caatatattat ttttatattt aaaattcata 60
 gaaaagtgcc ttacatttaa taaaagtgtg tttctcaaag tgatcagagg aattagatat 120
 gtcttgaaca ccaatattaa tttgaggaaa atacacaaa atacattaag taaattattt 180
 aagatcatag agcttgtaag tgaaaagata aaatttgacc tcagaaactc tgagcattaa 240
 aaatccacta ttagcaaata aattactatg gacttcttgc ttttaattttg tgatgaatat 300
 ggggtgtcac tggtaaacca acacattctg aaggatacat tacttagtga tagattctta 360
 tgtactttgc taatacgtgg atatgagttg acaagtttct ctttcttcaa tcttttaagg 420
 ggcgagaaat gaggaagaaa agaaaaggat tacgcatact gttctttcta tgggaaggatt 480
 agatatgttt cttttgccaa tattaataaaa ataataatgt ttactactag tgaaaccc 538

<210> 106
 <211> 473
 <212> DNA
 <213> Homo sapien

<400> 106
 tttttttttt ttttttagtc aagtttctat ttttattata attaaagtct tggtcatttc 60
 atttatttagc tctgcaactt acatatttaa attaaagaaa cgttttagac aactgtacaa 120
 tttataaatg taagggtcca ttattgagta atatatctct ccaagagtgg atgtgtccct 180
 tctccacca actaatgaac agcaacatta gttaattttt attagtagat atacactgct 240
 gcaaacgcta attctcttct ccatcccat gtgatattgt gtatatgtgt gagttggtag 300
 aatgcatcac aatctacaat caacagcaag atgaagctag gctgggcttt cggtgaaaat 360
 agactgtgtc tgtctgaatc aaatgatctg acctatcctc ggtggcaaga actcttcgaa 420
 ccgcttctc aaaggcgctg ccacatttgt ggctctttgc acttgtttca aaa 473

<210> 107
 <211> 1621
 <212> DNA
 <213> Homo sapien

<400> 107
 cgccatggca ctgcagggca tctcggtcat ggagctgtcc ggccctggccc cgggcccgtt 60
 ctgtgctatg gtctggctg acttcggggc gcgtgtggtta cgcgtggacc ggcccggctc 120

```

ccgetacgac gtgagccgct tgggccgggg caagcgctcg ctagtgctgg acctgaagca 180
gcccggggga gccgccgtgc tggccgctcc gtgcaagcgg tcggatgtgc tgctggagcc 240
cttcggccgc ggtgtcatgg agaaactcca gctgggcccga gagattctgc agcgggaaaa 300
tccaaggctt atttatgcca ggctgagtggt atttgccag tcaggaagct tctgccggtt 360
agetggccac gatatacaact atttggcttt gtcagggtgtt ctctcaaaaa ttggcagaag 420
tgggtgagaat ccgtatgccc cgttgaatct cctggctgac tttgctggtg gtggccttat 480
gtgtgcactg ggcattataa tggctctttt tgaccgcaca cgcactgaca agggtcaggt 540
cattgatgca aatatggtgg aaggaacagc atatttaagt tcttttctgt ggaaaactca 600
gaaatcgagt ctgtgggaag cactcgagg acagaacatg ttggatggtg gacacacctt 660
ctatacgact tacaggacag cagatgggga attcatggct gtggagcaa tagaacccca 720
gttctacgag ctgctgatca aaggacttgg actaaagtct gatgaacttc ccaatcgat 780
gagcatggat gattggccag aaatgaagaa gaagtttgca gatgtatttg caaagaagac 840
gaaggcagag tgggtgtcaaa tctttgacgg cacagatgcc tgtgtgactc cggttctgac 900
ttttgaggag gttgttcata atgatcacia caaggaaacgg ggtcgttta tcaccagtga 960
ggagcaggac gtgagccccc gccctgcacc tctgctgtta aacaccccag ccatcccttc 1020
tttcaaaagg gatcctttca taggagaaca cactgaggag atacttgaag aatttggatt 1080
cagccgcgaa gagattttatc agcttaactc agataaaatc attgaaagta ataaggtaaa 1140
agctagtctc taacttccag gccacggct caagtgaatt tgaatactgc atttacagtg 1200
tagagtaaca cataacattg tatgcatgga aacatggagg aacagtatta cagtgtccta 1260
ccactctaata caagaaaaaga attacagact ctgattctac agtgaatgatt gaattctaaa 1320
aatggttata attagggtt ttgatttata aaactttggg tacttatact aaattatggt 1380
agttattctg ccttccagtt tgcttgatat atttggtgat attaagattc ttgacttata 1440
tttgaatgg gttctagtga aaaaggaatg atatatctt gaagacatcg atatacat 1500
atttacactc ttgattctac aatgtagaaa atgaggaaat gccacaaatt gtatggtgat 1560
aaaagtcacg tgaacaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
a 1621

```

<210> 108
 <211> 382
 <212> PRT
 <213> Homo sapien

<400> 108
 Met Ala Leu Gln Gly Ile Ser Val Met Glu Leu Ser Gly Leu Ala Pro
 1 5 10 15
 Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val
 20 25 30
 Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg
 35 40 45
 Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gln Pro Arg Gly Ala Ala
 50 55 60
 Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe
 65 70 75 80
 Arg Arg Gly Val Met Glu Lys Leu Gln Leu Gly Pro Glu Ile Leu Gln
 85 90 95
 Arg Glu Asn Pro Arg Leu Ile Tyr Ala Arg Leu Ser Gly Phe Gly Gln
 100 105 110
 Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp Ile Asn Tyr Leu Ala
 115 120 125
 Leu Ser Gly Val Leu Ser Lys Ile Gly Arg Ser Gly Glu Asn Pro Tyr
 130 135 140
 Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Leu Met Cys
 145 150 155 160
 Ala Leu Gly Ile Ile Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys
 165 170 175
 Gly Gln Val Ile Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser
 180 185 190
 Ser Phe Leu Trp Lys Thr Gln Lys Ser Ser Leu Trp Glu Ala Pro Arg

195	200	205
Gly Gln Asn Met Leu Asp	Gly Gly Ala Pro Phe	Tyr Thr Thr Tyr Arg
210	215	220
Thr Ala Asp Gly Glu Phe Met	Ala Val Gly Ala Ile Glu Pro Gln Phe	240
225	230	235
Tyr Glu Leu Leu Ile Lys Gly Leu Gly Leu Lys Ser Asp Glu Leu Pro	245	250
255	260	265
Asn Gln Met Ser Met Asp Asp Trp Pro Glu Met Lys Lys Lys Phe Ala	270	275
280	285	290
Asp Val Phe Ala Lys Lys Thr Lys Ala Glu Trp Cys Gln Ile Phe Asp	295	300
305	310	315
Gly Thr Asp Ala Cys Val Thr Pro Val Leu Thr Phe Glu Glu Val Val	320	325
330	335	340
His His Asp His Asn Lys Glu Arg Gly Ser Phe Ile Thr Ser Glu Glu	345	350
355	360	365
Gln Asp Val Ser Pro Arg Pro Ala Pro Leu Leu Leu Asn Thr Pro Ala	370	375
380	385	390
Ile Pro Ser Phe Lys Arg Asp Pro Phe Ile Gly Glu His Thr Glu Glu	395	400
405	410	415
Ile Leu Glu Glu Phe Gly Phe Ser Arg Glu Glu Ile Tyr Gln Leu Asn	420	425
430	435	440
Ser Asp Lys Ile Ile Glu Ser Asn Lys Val Lys Ala Ser Leu	445	450

<210> 109
 <211> 1524
 <212> DNA
 <213> Homo sapien

<400> 109

ggcacgaggg	tgcgccaggg	cctgagcgga	ggcgggggca	gcctcgccag	cgggggcccc	60
gggcctggcc	atgcctcaact	gagccagcgc	ctgcgcctct	acctcgccga	cagctggaac	120
cagtgcgacc	tagtggctct	caactgcttc	ctcctgggcg	tgggctgccc	gctgaccccg	180
ggttttgtacc	acctgggccc	cactgtcctc	tgcctcgact	tcattggttt	cacggtgccg	240
ctgcttcaca	tcttcacggt	caacaaacag	ctggggccca	agatcgatcat	cgtgagcaag	300
atgatgaagg	acgtgttctt	cttccctctt	ttcctcgccg	tgtggctggg	agcctatggc	360
gtggccacgg	aggggctcct	gaggccacgg	gacagtgaat	tcccaagtat	cctgcgcgcg	420
gtcttctacc	gtccctacct	gcagatcttc	gggcagattc	cccaggagga	catggacgtg	480
gcccctcatgg	agcacagcaa	ctgctcgctg	gagcccggtt	tctgggcaca	ccctcctggg	540
gcccaggcgg	gcacctgcgt	ctcccagtat	gccaactggc	tgggtggtgct	gctcctcgtc	600
atcttctctgc	tctgtggcca	catcctgctg	gtcaacttgc	tcattgccat	gttcagttac	660
acattcggca	aagtaacagg	caacagcgat	ctctactgga	aggcgagcgc	ttaccgcctc	720
atccgggaat	tccactctcg	gcccgcgctg	gccccgccct	ttatcgatcat	ctcccacttg	780
cgccctcctgc	tcaggcaatt	gtgcaggcga	ccccggagcc	cccagccgct	ctccccggcc	840
ctcgagcatt	tccgggttta	cctttctaa	gaagccgagc	ggaagctgct	aacgtgggaa	900
tccgtgcata	aggagaactt	tctgctggca	cgcgtaggga	acaagcggga	gagcgactcc	960
gagcgtctga	agcgacgctc	ccagaagggtg	gacttggcac	tgaacagct	gggacacatc	1020
cgcgagtagc	aacagcgctt	gaaagtgtctg	gagcgggagg	tccagcagtg	tagccgcgtc	1080
ctgggggtggg	tggccgaggg	cctgagccgc	tctgccttgc	tgcccccagg	tgggcccga	1140
ccccctgacc	tgcctgggtc	caaagactga	gcccgtgtgg	cggacttcaa	ggagaagccc	1200
ccacagggga	ttttgctcct	agagtaaggc	tcattctggg	ctcgcccccc	gcacctgggtg	1260
gccttgtcct	tgaggtgagc	cccatgtcca	tctggggcac	tgtcaggacc	acctttggga	1320
gtgtcatcct	tacaaaccac	agcatgcccc	gctcctccca	gaaccagtcc	cagcctggga	1380
ggatcaaggc	ctggatcccg	ggccgttatc	catctggagg	ctgcagggtc	cttggggtaa	1440
cagggaccac	agacccctca	ccactcacag	attcctcaca	ctgggggaaat	aaagccattt	1500
cagaggaaaa	aaaaaaaaaa	aaaa				1524

<210> 110

<211> 3410

<212> DNA

<213> Homo sapien

<400> 110

gggaaccagc	ctgcacgcgc	tggetccggg	tgacagccgc	gcgcctcggc	caggatctga	60
gtgatgagac	gtgtcccccac	tgaggtgccc	cacagcagca	gggtgttgagc	atgggtgag	120
aagctggacc	ggcaccaaaag	ggctggcaga	aatgggcgcc	tggttgattc	ctaggcagtt	180
ggcggcagca	aggaggagag	gcgcagctt	ctggagcaga	gocgagaoga	agcagttctg	240
gagtgcctga	acggcccccct	gagccctacc	cgccctggccc	actatgggtcc	agaggctgtg	300
ggtgagccgc	ctgctgcggc	accggaaaagc	ccagctcttg	ctgggtcaacc	tgctaaacctt	360
tggcctggag	gtgtgttttg	ccgcaggcat	caacctatgtg	ccgcctctgc	tgctggaagt	420
gggggtagag	gagaagtcca	tgacctgggt	gctgggcatt	gggtccagtgc	tgggcctggt	480
ctgtgtcccg	ctcctaggct	cagccagtga	ccactggcgt	ggacgctatg	gccgccgccg	540
gcccttcac	tgggcactgt	ccttgggcat	cctgctgagc	ctctttctca	tcccaagggc	600
cggttggtta	gcagggtgct	tgtgcccga	tcccaggccc	ctggagctgg	cactgctcat	660
cctgggcgtg	gggtgctgg	acttctgtg	ccagggtgtg	ttcactccac	tggaggccct	720
gctctctgac	ctcttcggg	acccggacca	ctgtcgccag	gcctactctg	tctatgcctt	780
catgatcagt	cctgggggt	gcctgggcta	cctcctgcct	gccattgact	gggacaccag	840
tgccttgccc	cctacctgg	gcaccagga	ggagtgcctc	tttggcctgc	tcacctcat	900
cttccctacc	tgcgtagcag	ccacactgct	gggtggctgag	gaggcagcgc	tgggccccac	960
cgagccagca	gaagggtgt	cgccccctc	cttgtcgccc	cactgctgtc	catgcccggc	1020
ccgcttggt	ttccggaacc	tgggcgccct	gcttccccgg	ctgcaccagc	tgtgtgcgcg	1080
catgccccgc	accctgcgcc	ggctcttctg	ggctgagctg	tgcagctgga	tggcactcat	1140
gaccttcacg	ctgttttaca	cggatttctg	gggcgagggg	ctgtaccagg	gcgtgcccag	1200
agctgagccg	ggcaccgagg	cccggagaca	ctatgatgaa	ggcgttcgga	tgggcagcct	1260
gggctgttcc	ctgcagtgcg	ccatctccct	ggctctctct	ctggctcatgg	accggctgggt	1320
gcagcgattc	ggcactcgag	cagtctatct	ggccagtgtg	gcagctttcc	ctgtggctgc	1380
cggtgccaca	tgcctgtccc	acagtgtggc	cgtggtgaca	gcttcagccg	cctcaccggg	1440
gttcaccttc	tcagccctgc	agatcctgcc	ctacacactg	gcctccctct	accaccggga	1500
gaagcaggtg	ttcctgccc	aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	1560
cctgatgacc	agcttcctgc	caggccctaa	gcctggagct	cccttcctta	atggacacgt	1620
gggtgctgga	ggcagtggcc	tgtcccacc	tccaccgcgc	ctctgcgggg	cctctgcctg	1680
tgatgtctcc	gtacgtgtgg	tgggtgggtga	gcccaccgag	gccagggtgg	ttccggggccg	1740
ggccatctgc	ctggacctgc	ccatcctgga	tagtgccttc	ctgctgtccc	aggtggcccc	1800
atccctgttt	atgggtccca	ttgtccagct	cagccagtct	gtcactgcct	atatggtgtc	1860
tgcgcagggc	ctgggtctgg	tgcacctta	ctttgtctaca	caggtagtat	ttgacaagag	1920
cgacttgccc	aaatactcag	cgtagaaaac	ttccagcaca	ttgggggtgga	gggcctgcct	1980
cactgggtcc	cagctccccg	ctcctgttag	ccccatgggg	ctgccgggct	ggccgccagt	2040
ttctgttgct	gccaaagtaa	tgtggctctc	tgtgcccacc	ctgtgctgct	gaggtgcgta	2100
gctgcacagc	tgggggtgg	ggcgtccctc	tcctctctcc	ccagtctcta	gggctgcctg	2160
actggaggcc	ttccaagggg	gtttcagttc	ggacttatac	agggaggcca	gaagggtccc	2220
atgcactgga	atgcggggac	tctgcagggt	gattacccag	gctcagggtt	aacagctagc	2280
ctcctagtgt	agacacacct	agagaagggt	ttttgggagc	tgaataaaact	cagtcacctg	2340
gtttcccatc	tctaagcccc	ttaacctgca	gcttcgttta	atgtagctct	tgcattggag	2400
tttctaggat	gaaacactcc	tccatgggat	ttgaacatat	gacttatttg	taggggaaga	2460
gtcctgaggg	gcaacacaca	agaaccaggt	ccctcagcc	cacagcactg	tctttttgct	2520
gatccacccc	cctcttacct	tttatcagga	tgtggcctgt	tgggtcctct	gttgccatca	2580
cagagacaca	ggcatttaaa	tatttaactt	atttatttta	caaagtagaa	gggaatccat	2640
tgtctagctt	tctgtgtttg	tgtctaata	ttgggtaggg	tgggggatcc	ccaacaatca	2700
ggtccctga	gatagctgg	cattggctg	atcattgcca	gaatcttctt	ctcctgggggt	2760
ctggcccccc	aaaatgccta	accaggacc	ttggaaatc	tactatccc	aaatgataat	2820
tccaaatgct	gttaccacaag	gttaggggtg	tgaagggaag	tagagggtgg	ggcttcagggt	2880
ctcaacggct	tccctaacca	ccctcttct	cttggcccag	cctgggtccc	ccacttcca	2940
ctccccctta	ctctctctag	gactgggtg	atgaaggcac	tgccccaaat	ttccccctacc	3000
cccaactttc	cctaccccc	aactttcccc	accagctcca	caaccctgtt	tggagctact	3060
gcaggaccag	aagcacaag	tgcgtttcc	caagcctttg	tccatctcag	ccccagagt	3120
atatctgtgc	ttgggggaatc	tcacacagaa	actcaggagc	acccctgccc	tgagctaaag	3180

gaggtcttat	ctctcagggg	gggtttaagt	gccgtttgca	ataatgtcgt	cttattttatt	3240
tagcgggggtg	aatatttttat	actgtaagtg	agcaatcaga	gtataatgtt	tatgggtgaca	3300
aaattaaagg	ctttcttata	tgtttaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3360
aaaaaaaaara	aaaaaaaaaa	aaaaaaaaaa	aaaaaaataa	aaaaaaaaaa		3410

<210> 111
 <211> 1289
 <212> DNA
 <213> Homo sapien

<400> 111						
agccaggcgt	ccctctgcct	gcccactcag	tggcaacacc	cgggagctgt	tttgtccttt	60
gtggagcctc	agcagttccc	tctttcagaa	ctcactgcca	agagccctga	acaggagcca	120
ccatgcagtg	cttcagcttc	attaagacca	tgatgatcct	cttcaatttg	ctcatctttc	180
tgtgtgggtg	agccctgttg	gcagtgggca	tctgggtgtc	aatcgatggg	gcatcctttc	240
tgaagatctt	cgggccactg	tcgtccagtg	ccatgcagtt	tgtcaacgtg	ggctacttcc	300
tcatcgcagc	cggcgttggtg	gtctttgtct	ttggtttccct	gggctgctat	gggtgctaaga	360
ctgagagcaa	gtgtgccttc	gtgacgttct	tcttcactct	cctcctcatc	ttcattgctg	420
agggtgcagc	tgctgtggtc	gccttgggtg	acaccacaat	ggctgagcac	ttcctgacgt	480
tgctggtagt	gcctgccatc	aagaaagatt	atggttccca	ggaagacttc	actcaagtgt	540
ggaacaccac	catgaaagg	ctcaagtgtc	gtggcttcac	caactatacg	gattttgagg	600
actcacccta	cttcaaagag	aacagtgcct	ttccccatt	ctgttgcaat	gacaacgtca	660
ccaacacagc	caatgaaacc	tgcaccaagc	aaaaggctca	cgacaaaaaa	gtagagggtt	720
gcttcaatca	gcttttgtat	gacatccgaa	ctaattgcagt	caccgtgggt	gggtgtggcag	780
ctggaattgg	gggcctcgag	ctggctgcca	tgattgtgtc	catgtatctg	tactgcaatc	840
tacaataagt	ccacttctgc	ctctgccact	actgctgcca	catgggaact	gtgaagaggc	900
accctggcaa	gcagcagtg	ttgggggagg	ggacaggatc	taacaatgtc	acttgggcca	960
gaatggacct	gccctttctg	ctccagactt	ggggctagat	agggaccact	ccttttagcg	1020
atgcctgact	ttccttccat	tggtgggtgg	atgggtgggg	ggcattccag	agcctctaag	1080
gtagccagtt	ctgttgccca	ttccccagt	ctattaaacc	cttgatatgc	cccctaggcc	1140
tagtgggtgat	cccagtgctc	tactggggga	tgagagaaa	gcattttata	gcctgggcat	1200
aagtgaaatc	agcagagcct	ctgggtggat	gtgtagaagg	cacttcaaaa	tgcataaacc	1260
tgttacaatg	ttaaaaaaaa	aaaaaaaaaa				1289

<210> 112
 <211> 315
 <212> PRT
 <213> Homo sapien

<400> 112															
Met	Val	Phe	Thr	Val	Arg	Leu	Leu	His	Ile	Phe	Thr	Val	Asn	Lys	Gln
1				5				10					15		
Leu	Gly	Pro	Lys	Ile	Val	Ile	Val	Ser	Lys	Met	Met	Lys	Asp	Val	Phe
			20					25					30		
Phe	Phe	Leu	Phe	Phe	Leu	Gly	Val	Trp	Leu	Val	Ala	Tyr	Gly	Val	Ala
		35				40					45				
Thr	Glu	Gly	Leu	Leu	Arg	Pro	Arg	Asp	Ser	Asp	Phe	Pro	Ser	Ile	Leu
		50			55						60				
Arg	Arg	Val	Phe	Tyr	Arg	Pro	Tyr	Leu	Gln	Ile	Phe	Gly	Gln	Ile	Pro
65				70				75						80	
Gln	Glu	Asp	Met	Asp	Val	Ala	Leu	Met	Glu	His	Ser	Asn	Cys	Ser	Ser
			85					90					95		
Glu	Pro	Gly	Phe	Trp	Ala	His	Pro	Pro	Gly	Ala	Gln	Ala	Gly	Thr	Cys
		100					105				110				
Val	Ser	Gln	Tyr	Ala	Asn	Trp	Leu	Val	Val	Leu	Leu	Leu	Val	Ile	Phe
		115				120					125				
Leu	Leu	Val	Ala	Asn	Ile	Leu	Leu	Val	Asn	Leu	Leu	Ile	Ala	Met	Phe
		130				135					140				

Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys
 145 150 155 160
 Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu
 165 170 175
 Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln
 180 185 190
 Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu
 195 200 205
 His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr
 210 215 220
 Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp
 225 230 235 240
 Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val
 245 250 255
 Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg
 260 265 270
 Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly
 275 280 285
 Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly
 290 295 300
 Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp
 305 310 315

<210> 113
 <211> 553
 <212> PRT
 <213> Homo sapien

<400> 113
 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
 1 5 10 15
 Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu
 20 25 30
 Ala Ala Gly Ile Thr Tyr Val Pro Leu Leu Leu Glu Val Gly Val
 35 40 45
 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly
 50 55 60
 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly
 65 70 75 80
 Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile
 85 90 95
 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu
 100 105 110
 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly
 115 120 125
 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu
 130 135 140
 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala
 145 150 155 160
 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr
 165 170 175
 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu
 180 185 190
 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu
 195 200 205
 Thr Cys Val Ala Ala Thr Leu Val Ala Glu Glu Ala Ala Leu Gly
 210 215 220
 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His

```
<210> 114
<211> 241
<212> PRT
<213> Homo sapien
```

<400> 114															
Met	Gln	Cys	Phe	Ser	Phe	Ile	Lys	Thr	Met	Met	Ile	Leu	Phe	Asn	Leu
1				5					10					15	
Leu	Ile	Phe	Leu	Cys	Gly	Ala	Ala	Leu	Leu	Ala	Val	Gly	Ile	Trp	Val
			20					25					30		
Ser	Ile	Asp	Gly	Ala	Ser	Phe	Leu	Lys	Ile	Phe	Gly	Pro	Leu	Ser	Ser
		35					40					45			
Ser	Ala	Met	Gln	Phe	Val	Asn	Val	Gly	Tyr	Phe	Leu	Ile	Ala	Ala	Gly
	50					55					60				
Val	Val	Val	Phe	Ala	Leu	Gly	Phe	Leu	Gly	Cys	Tyr	Gly	Ala	Lys	Thr
65					70					75					80

Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile
 85 90 95
 Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr
 100 105 110
 Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
 115 120 125
 Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
 130 135 140
 Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
 145 150 155 160
 Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
 165 170 175
 Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
 180 185 190
 His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
 195 200 205
 Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
 210 215 220
 Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu
 225 230 235 240
 Gln

<210> 115
 <211> 366
 <212> DNA
 <213> Homo sapien

<400> 115
 gctctttctc tcccctctc tgaatttaac tctttcaact tgcaatttgc aaggattaca 60
 catttcaactg tgatgtatat tgtgttgcaa aaaaaaaaaa gtgtctttgt ttaaaattac 120
 ttggtttgtg aatccatctt gctttttccc catttggaact agtcattaac ccatctctga 180
 actggtagaa aaacatctga agagctagtc tatcagcatc tgacagggtga attggatggt 240
 tctcagaacc atttcaccca gacagcctgt ttctatcctg ttttaataaat tagtttgggt 300
 tctctacatg cataacaaac cctgctccaa tctgtccatc aaaagtctgt gacttgaagt 360
 ttagtc 366

<210> 116
 <211> 282
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(282)
 <223> n = A,T,C or G

<400> 116
 acaaagatga accatttctt atattatagc aaaattaaaa tctaccogta ttctaattatt 60
 gagaaatgag atnaaacaca atnttataaa gtctacttag agaagatcaa gtgacctcaa 120
 agactttact attttcatat tttaagacac atgatttata ctatttttagt aacctgggtc 180
 atacgttaaa caaaggataa tgtgaacagc agagaggatt tgttggcaga aaatctatgt 240
 tcaatctnga actatctana tcacagacat ttctatttct tt 282

<210> 117
 <211> 305
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(305)
 <223> n = A,T,C or G

<400> 117
 acacatgtcg cttcactgcc ttcttagatg cttctggtca acatanagga acagggacca 60
 tatttatcct ccctcctgaa acaattgcaa aataanacaa aatatatgaa acaattgcaa 120
 aataaggcaa aatatatgaa acaacaggtc tcgagatatt ggaaatcagt caatgaagga 180
 tactgatccc tgatcactgt cctaattgcag gatgtgggaa acagatgagg tcacctctgt 240
 gactgcccc gcttactgcc tgtagagagt ttctangctg cagttcagac agggagaaat 300
 tgggt 305

<210> 118
 <211> 71
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(71)
 <223> n = A,T,C or G

<400> 118
 accaagggtg ntgaatctct gacgtgggga tctctgattc ccgcacaatc tgagtggaaa 60
 aantcctggg t 71

<210> 119
 <211> 212
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(212)
 <223> n = A,T,C or G

<400> 119
 actccggttg gtgtcagcag cacgtggcat tgaacatngc aatgtggagc ccaaaccaca 60
 gaaaatgggg tgaaattggc caactttcta tnaacttatg ttggcaantt tgccaccaac 120
 agtaagctgg cccttctaataaaaagaaaat tgaaagggtt ctcactaanc ggaattaant 180
 aatggantca aganactccc aggcctcagc gt 212

<210> 120
 <211> 90
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(90)
 <223> n = A,T,C or G

<400> 120
 actcggttgca natcaggggc cccccagagt caccgttgca ggagtccttc tgggtcttgcc 60
 ctccgccggc gcagaacatg ctggggtggt 90

<210> 121
 <211> 218
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(218)
 <223> n = A,T,C or G

<400> 121
 tgtanegtga anacgacaga nagggttgto aaaaatggag aancottgaa gtcattttga 60
 gaataagatt tgcataaaga ttgggggcta aaacatgggt attgggagac atttctgaag 120
 atatncanrt aaattangga atgaattcat gggtcttttg ggaattcctt tacgatngcc 180
 agcatanact tcatgtggag atancagcta ccttgta 218

<210> 122
 <211> 171
 <212> DNA
 <213> Homo sapien

<400> 122
 taggggtgta tgcactgta aggacaaaaa ttgagactca actggcttaa ccaataaagg 60
 catttgtag ctcatggaac aggaagtcgg atgggtggggc atcttcagtg ctgcatgagt 120
 caccaccccg ggggggtcat ctgtgccaca ggtccctggt gacagtgcgg t 171

<210> 123
 <211> 76
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(76)
 <223> n = A,T,C or G

<400> 123
 tgtagcgtga agacnacaga atgggtgtgtg ctgtgctatc caggaacaca ttattatca 60
 ttatcaanta ttgtgt 76

<210> 124
 <211> 131
 <212> DNA
 <213> Homo sapien

<400> 124
 acctttcccc aaggccaatg tctgtgtgta taactggcgg gctgcaggac agctgcaatt 60
 caatgtgctg ggtcatatgg aggggaggag actctaaaaat agccaatttt attctcttgg 120
 ttaagatttg t 131

<210> 125
 <211> 432
 <212> DNA
 <213> Homo sapien

<400> 125
 acatttatcta ctggctatga aatagatggg ggaaaattgc gttaccaact ataccaactgg 60
 cttgaaaaag aggtgatagc tcttcagagg acttgtagact ttgtctcaga tgctgaagaa 120

```

ctacagtctg catttggcag aaatgaagat gaatttggat taaatgagga tgctgaagat 180
ttgcctcacc aaacaaaagt gaaacaactg agagaaaatt ttcaggaaaa aagacagtgg 240
ctcttgaagt atcagtcact tttgagaatg tttcttagtt actgcatact tcatggatcc 300
catggtgggg gtcttgcacg tgtaagaatg gaattgattt tgcttttgca agaattctcag 360
caggaacat cagaaccact attttctagc cctctgtcag agcaaacctc agtgcctctc 420
ctctttgctt gt 432

```

```

<210> 126
<211> 112
<212> DNA
<213> Homo sapien

```

```

<400> 126
acacaacttg aatagtaaaa tagaaactga gctgaaattt ctaattcact ttctaaccat 60
agtaagaatg atatttcccc ccagggatca ccaaatattt ataaaaattt gt 112

```

```

<210> 127
<211> 54
<212> DNA
<213> Homo sapien

```

```

<400> 127
accacgaaac cacaacaag atggaagcat caatccactt gccaagcaca gcag 54

```

```

<210> 128
<211> 323
<212> DNA
<213> Homo sapien

```

```

<400> 128
acctcattag taattgtttt gttgtttcat ttttttctaa tgtctcccct ctaccagctc 60
acctgagata acagaatgaa aatggaagga cagccagatt tctcctttgc tctctgctca 120
ttctctctga agtctagggt acccattttg gggacccatt ataggcaata aacacagttc 180
ccaaagcatt tggacagttt cttgttgtgt tttagaatgg ttttcctttt tcttagcctt 240
ttcctgcaaa aggetcactc agtcccttgc ttgctcagtg gactgggctc cccagggcct 300
aggctgcctt cttttccatg tcc 323

```

```

<210> 129
<211> 192
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(192)
<223> n = A,T,C or G

```

```

<400> 129
acatacatgt gtgtatatatt ttaaatatca cttttgtatc actctgactt tttagcatac 60
tgaaaacaca ctaacataat ttntgtgaac catgatcaga tacaacccaa atcattcatc 120
tagcacattc atctgtgata naaagatagg tgagtttcat ttccttcacg ttggccaatg 180
gataaacaaa gt 192

```

```

<210> 130
<211> 362
<212> DNA
<213> Homo sapien

```


<220>
 <221> misc_feature
 <222> (1)...(362)
 <223> n = A,T,C or G

<400> 130
 ccctttttta tggaaatgagt agactgtatg tttgaanatt tanccacaac ctcttttgaca 60
 tataatgacg caacaaaaag gtgctgttta gtcttatggg tcagtttatg cccctgacaa 120
 gtttccattg tgttttgccg atcttctggc taatcgtggg atcctccatg ttattagtaa 180
 ttctgtattc cattttgtta acgcttggtg gatgtaacct gctangaggc taactttata 240
 ttaattaaa agctcttatt ttgtgggtcat taaaatggca atttatgtgc agcactttat 300
 tgcagcagga agcacgtgtg ggttggttgt aaagctcttc gctaattctta aaaagtaatg 362
 gg

<210> 131
 <211> 332
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(332)
 <223> n = A,T,C or G

<400> 131
 ctttttgaaa gatcgtgtcc actcctgtgg acatcttggg ttaatggagt ttcccatgca 60
 gtangactgg tatggttgca gctgtccaga taaaaacatt tgaagagctc caaaatgaga 120
 gtctctccag gttcgccctg ctgctccaag tctcagcagc agcctctttt aggaggcatc 180
 ttctgaacta gattaaggca gcttgtaaatt ctgatgtgat ttgggtttatt atccaactaa 240
 cttccatctg ttatcactgg agaaagccca gactccccan gacnggtacg gattgtgggc 300
 atanaaggat tgggtgaagc tggcgttgtg gt 332

<210> 132
 <211> 322
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(322)
 <223> n = A,T,C or G

<400> 132
 actttttgcc ttttgtatat ataaacaatc ttgggacatt ctcttgaaaa ctaggtgtcc 60
 agtggctaag agaactcgat ttcaagcaat tctgaaagga aaaccagcat gacacagaat 120
 ctcaaattcc caaacagggg ctctgtggga aaaatgaggg aggacctttg tatctcgggt 180
 tttagcaagt taaaatgaan atgacaggaa aggcctatctt atcaacaaag agaagagttg 240
 ggatgcttct aaaaaaaact ttggtagaga aaataggaat gctnaatcct agggaagcct 300
 gtaacaatct acaattgggtc ca 322

<210> 133
 <211> 278
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(278)

<223> n = A,T,C or G

<400> 133
 acaagccttc acaagtttaa ctaaattggg attaatcttt ctgtanttat ctgcataatt 60
 cttgtttttc tttccatctg gctcctgggt tgacaatttg tggaaacaac tctattgcta 120
 ctattttaaa aaaatcacaa atctttccct ttaagctatg ttnaattcaa actattcctg 180
 ctattcctgt tttgtcaaag aaattatatt tttcaaaata tgtntatttg tttgatgggt 240
 cccacgaaac actaataaaa accacagaga ccagcctg 278

<210> 134

<211> 121

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(121)

<223> n = A,T,C or G

<400> 134
 gtttanaaaa cttgttttagc tccatagagg aaagaatggt aaactttgta ttttaaaaca 60
 tgattctctg aggttaaact tggttttcaa atgttatatt tacttgtatt ttgcttttgg 120
 t 121

<210> 135

<211> 350

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(350)

<223> n = A,T,C or G

<400> 135
 acttanaacc atgcctagca catcagaatc cctcaaagaa catcagtata atcctataacc 60
 atancaagtg gtgactggtt aagcgtgcga caaaggctcag ctggcacatt acttgtgtgc 120
 aaacttgata cttttgttct aagtaggaac tagtatacag tncctaggan tggtagtcca 180
 ggggtgcccc caactcctgc agccgtcct ctgtgccagn ccctgnaagg aactttcgt 240
 ccacctcaat caagccctgg gccatgctac ctgcaattgg ctgaacaaac gtttgctgag 300
 ttcccaagga tgcaaagcct ggtgctcaac tctggggcg tcaactcagt 350

<210> 136

<211> 399

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(399)

<223> n = A,T,C or G

<400> 136
 tgtaccgtga agacgacaga agttgcatgg cagggacagg gcagggccga ggccagggtt 60
 gctgtgattg tatccgaata ntccctgtga gaaaagataa tgagatgacg tgagcagcct 120
 gcagacttgt gtctgccttc aanaagccag acaggaaggc cctgcctgcc ttggtcttga 180
 cctggcgccc agccagccag ccacaggtgg gcttcttccct tttgtggtga caacnccaag 240
 aaaactgcag aggccaggg tcaggtgtna gtgggtangt gaccataaaa caccagggtgc 300

tccacgggaac ccggggcaaag gccatcccca cctacagcca gcatgccac tggcgtgatg 360
 ggagcagang gatgaagcag ccagntgttc tgcgtgtgt 399

<210> 137

<211> 165

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(165)

<223> n = A,T,C or G

<400> 137

actgggtgttg tnggggggtga tgcgtgtgtg anaagttgan gtgacttcan gatgggtgtgt 60
 ggaggaagtg tgtgaacgta gggatgtaga ngttttggcc gtgctaaatg agcttcggga 120
 ttggctgttc ccactgggtg tcaactgtcat tggtaggggtt cctgt 165

<210> 138

<211> 338

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(338)

<223> n = A,T,C or G

<400> 138

actcaactgga atgccacatt cacaacagaa tcagaggtct gtgaaaacat taatggctcc 60
 ttaacttctc cagtaagaat cagggacttg aaatggaaac gttaacagcc acatgcccaa 120
 tgcgtgggcag tctcccatgc ctccacaggt gaaagggctt gagaaaaatc acatccaatg 180
 tcatgtgttt ccagccacac caaaaggtgc ttgggggtgga gggctggggg catananggt 240
 cagcctcag gaagcctcaa gttccattca gctttgccac tgtacattcc ccatntttaa 300
 aaaaactgat gccttttttt tttttttttg taaaattc 338

<210> 139

<211> 382

<212> DNA

<213> Homo sapien

<400> 139

gggaatcttg gtttttggca tctggtttgc ctatagccga ggccactttg acagaacaaa 60
 gaaagggact tcgagtaaga aggtgattta cagccagcct agtgcccgaa gtgaaggaga 120
 attcaaacag acctcgtcat tcttggtgtg agcctggctg gctcacgcc tatcatctgc 180
 atttgccita ctacaggtgct accggactct ggccctgat gtctgtagt tcaacaggatg 240
 ccttatttgt cttctacacc ccacagggcc cctacttct tcggatgtgt ttttaataat 300
 gtcagctatg tgccccatcc tccttcatgc cctccctccc tttcctacca ctgctgagt 360
 gcctggaact tgtttaaagt gt 382

<210> 140

<211> 200

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(200)

<223> n = A,T,C or G

<400> 140
 accaaanctt ctttctgttg tgttngattt tactataggg gtttngcttn ttctaaanatt 60
 acttttctatt taacancctt tgttaagtgt caggetgcac tttgctccat anaattattg 120
 ttttcacatt tcaacttgta tgtgtttgtc tcttanagca ttggtgaaat cacatatttt 180
 atattcagca taaaggagaa 200

<210> 141
 <211> 335
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(335)
 <223> n = A,T,C or G

<400> 141
 acttttattt caaaacactc atatgttgca aaaaacacat agaaaaataa agtttggtgg 60
 ggggtgctgac taaacttcaa gtcacagact tttatgtgac agattggagc agggtttgtt 120
 atgcatgtag agaaccctaaa ctaattttatt aaacaggata gaaacaggct gtctgggtga 180
 aatggttctg agaaccatcc aattcacctg tcagatgctg atanactagc tcttcagatg 240
 tttttctacc agttcagaga tnggttaatg actanttcca atgggggaaa agcaagatgg 300
 attcacaac caagtaattt taaacaaaga cactt 335

<210> 142
 <211> 459
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(459)
 <223> n = A,T,C or G

<400> 142
 accagggttaa tattgccaca tatatccttt ccaattgcgg gctaaacaga cgtgtattta 60
 ggggttgttta aagacaaccc agcttaatat caagagaaat tgtgacctt catggagtat 120
 ctgatggaga aaacactgag ttttgacaaa tcttatttta ttcagatagc agtctgatca 180
 cacatgggtcc aacaacactc aaataataaa tcaaatatna tcagatgtta aagattggtc 240
 ttcaaacatc atagccaatg atgccccgct tgcctataat ctctccgaca taaaaccaca 300
 tcaacacctc agtggccacc aaaccattca gcacagcttc cttaactgtg agctgtttga 360
 agctaccagt ctgagcacta ttgactatnt ttttcangct ctgaatagct ctagggatct 420
 cagcangggg gggaggaacc agctcaacct tggcgctant 459

<210> 143
 <211> 140
 <212> DNA
 <213> Homo sapien

<400> 143
 acatttcctt ccaccaagtc aggactcctg gcttctgtgg gagttcttat cacctgaggg 60
 aaatccaaac agtctctcct agaaaggaat agtgtcacca accccaccca tctccctgag 120
 accatccgac ttcctgtgtg 140

<210> 144
 <211> 164

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(164)

<223> n = A,T,C or G

<400> 144

acttcagtaa caacatacaa taacaacatt aagtgtatat tgccatcttt gtcattttct	60
atctatacca ctctcccttc tgaaaacaan aatcactanc caatcactta taaaatttg	120
aggcaattaa tccatatttg ttttcaataa ggaaaaaaag atgt	164

<210> 145

<211> 303

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(303)

<223> n = A,T,C or G

<400> 145

acgtagacca tccaactttg tatttgtaat ggcaaacatc cagnagcaat tcttaaacia	60
actggagggt atttataccc aattatocca ttcattaaca tgccctcctc ctcaggctat	120
gcaggacagc tatcataagt cgcccagggc atccagatac taccatttgt ataaacttca	180
gtaggggagt ccatccaagt gacaggtcta atcaaaggag gaaatggaac ataagcccag	240
tagtaaaatn ttgcttagct gaaacagcca caaaagactt accgccgtgg tgattaccat	300
caa	303

<210> 146

<211> 327

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(327)

<223> n = A,T,C or G

<400> 146

actgcagctc aattagaagt ggtctctgac tttcatcanc ttctccctgg gctccatgac	60
actggcctgg agtgactcat tgctctggtt ggttgagaga gctcctttgc caacaggcct	120
ccaagtcagg gctgggattt gtttccttcc cacattctag caacaatatg ctggccactt	180
cctgaacagg gaggggtggga ggagccagca tggaacaagc tgccactttc taaagtagcc	240
agacttgccc ctgggcctgt cacacctact gatgaccttc tgtgcctgca ggatggaatg	300
taggggtgag ctgtgtgact ctatggt	327

<210> 147

<211> 173

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(173)

<223> n = A,T,C or G

<400> 147
acattgtttt tttgagataa agcattgana gagctctcct taacgtgaca caatggaagg 60
actggaacac ataccacat ctttgttctg agggataatt ttctgataaa gtcttgctgt 120
atattcaagc acatatgtta tatattatc agttccatgt ttatagccta gtt 173

<210> 148
<211> 477
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(477)
<223> n = A,T,C or G

<400> 148
acaaccactt tatctcatcg aatttttaac ccaaactcac tcaactgtgcc tttctatcct 60
atgggatata ttatttgatg ctccatttca tcacacatat atgaataata cactcatact 120
gccctactac ctgctgcaat aatcacattc ccttctctgc ctgaccctga agccattggg 180
gtggctctag tggccatcag tccangcctg caccttgagc ccttgagctc cattgctcac 240
nccanccac ctcaccgacc ccatcctctt acacagctac ctccttgctc tctaaccaca 300
tagattatnt ccaaattcag tcaattaagt tactattaac actctaccg acatgtccag 360
caccactggt aagccttctc cagccaacac acacacacac acacncacac acacacatat 420
ccaggcag gctacctcat cttcacaatc acccctttaa ttaccatgct atggtgg 477

<210> 149
<211> 207
<212> DNA
<213> Homo sapien

<400> 149
acagttgtat tataatatca agaaataaac ttqcaatgag agcatttaag agggaagaac 60
taacgtatatt tagagagcca aggaaggttt ctgtggggag tgggatgtaa ggtggggcct 120
gatgataaat aagagtcagc caggtaagtg ggtggtgtgg tatgggcaca gtgaagaaca 180
tttcaggcag agggaacagc agtgaaa 207

<210> 150
<211> 111
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(111)
<223> n = A,T,C or G

<400> 150
accttgattt cattgctgct ctgatggaaa cccaactatc taatttagct aaaacatggg 60
cacttaaatg tggtcagtgt ttggacttgt taactantgg catctttggg t 111

<210> 151
<211> 196
<212> DNA
<213> Homo sapien

<400> 151
agcgcggcag gtcatttga acattccaga tacctatcat tactcgatgc tgttgataac 60

```

adcaagatgg ctttgaactc agggtoacca ccagctattg gaccttacta tgaaaaccat 120
ggataaccaac cggaaaaccc ctatcccgca cagcccactg tggccccac tgtetaagag 180
gtgcatacgg ctcagt 196

```

```

<210> 152
<211> 132
<212> DNA
<213> Homo sapien

```

```

<400> 152
acagcacttt cacatgtaag aaggagaaaa ttccataatg taggagaaag ataacagaac 60
cttccccctt tcatctagt gtggaaacct gatgctttat gttgacagga atagaaccag 120
gagggagttt gt 132

```

```

<210> 153
<211> 285
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(285)
<223> n = A,T,C or G

```

```

<400> 153
acaanacca nganaggcca ctggccgtgg tgctcatggcc tccaaacatg aaagtgtcag 60
cttctgctct tatgtcctca tctgacaact ctttaccatt tttatcctcg ctcagcagga 120
gcacatcaat aaagtccaaa gtcttggaact tggccttggc ttggaggaag tcatcaacac 180
cctggctagt gaggggtgagg cgccgtcctt ggatgaaggc atctgtgaag tctgtcacca 240
gtctgcaggc cctgtggaag cgccgtccac acggagtnag gaatt 285

```

```

<210> 154
<211> 333
<212> DNA
<213> Homo sapien

```

```

<400> 154
accacagtcc tgttgggcca gggcttcatg accctttctg tgaaaagcca tattatcacc 60
accccaaatt tttccttaaa tatctttaac tgaaggggtc agcctcttga ctgcaaagac 120
cctaagccgg ttacacagct aactcccaact ggccctgatt tgtgaaattg ctgctgcctg 180
attggcacag gattcgaagg tgttcagctc cctcctccg tggaaagaga ctctgatttg 240
agtttcacaa attctcgggc cacctcgtca ttgtcctct gaaataaaat cgggagaatg 300
gtcaggcctg tctcatccat atggatcttc cgg 333

```

```

<210> 155
<211> 308
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(308)
<223> n = A,T,C or G

```

```

<400> 155
actggaaata ataaaaccca catcacagt ttgtgtcaaa gatcatcagg gcatggatgg 60
gaaagtgtct tgggaactgt aaagtgccta acacatgatc gatgattttt gttataatat 120
ttgaatcaag gtgcatacaa actctcctgc ctgctcctcc tgggccccag cccagcccc 180

```

atcacagctc actgctctgt tcatccaggc ccagcatgta gtggctgatt cttcttggt	240
gcttttagcc tccanaagtt tctctgaagc caaccaaac tctangtga aggcattgtg	300
gccttggt	308

<210> 156
 <211> 295
 <212> DNA
 <213> Homo sapien

<400> 156	
accttgctcg gtgcttgga catattagga actcaaaata tgagatgata acagtgccta	60
ttattgatta ctgagagaac tgtagacat ttagttgaag attttctaca caggaactga	120
gaataggaga ttatgtttgg cctcatatt ctctcctatc ctcttgctt cattctatgt	180
ctaatatatt ctcaatcaaa taaggttagc ataatcagga aatcgaccaa ataccaatat	240
aaaaccagat gtctatcctt aagattttca aatagaaaac aaattaacag actat	295

<210> 157
 <211> 126
 <212> DNA
 <213> Homo sapien

<400> 157	
acaagtttaa atagtgtgt cactgtgcat gtgctgaaat gtgaaatcca ccacatttct	60
gaagagcaaa acaaattctg tcatgtaatc tctatcttgg gtcgtgggta tatctgtccc	120
cttagt	126

<210> 158
 <211> 442
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(442)
 <223> n = A,T,C or G

<400> 158	
accactgggt ctgggaaaca cccatcctta atacgatgat ttttctgtcg tgtgaaaatg	60
aanccagcag gctgccccta gtcagtcctt ccttccagag aaaaagagat ttgagaaagt	120
gcctgggtaa ttcaccatta atttctccc ccaaactctc tgagtcttcc cttaatat	180
ctgggtggtc tgaccaaagc aggtcatggt ttgttgagca tttgggatcc cagtgaagta	240
natgtttgta gccttgcata cttagccctt cccacgcaca aacggagtgg cagagtggg	300
ccaacctgt tttccagtc cacgtagaca gattcacagt gcggaattct ggaagctgga	360
nacagacggg ctctttgcag agccgggact ctgagangga catgagggcc tctgcctctg	420
tggtcattct ctgatgtcct gt	442

<210> 159
 <211> 498
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(498)
 <223> n = A,T,C or G

<400> 159	
acttccaggt aacgttgttg tttccgttga gcctgaactg atgggtgacg ttgtagggtc	60


```

tccaaacaaga actgaggttg cagagcgggt agggaagagt gctgttccag ttgcacctgg      120
gctgctgtgg actgttgttg attcctcact acggcccaag gttgtggaac tggcanaaaag      180
gtgtgttgtt gganttgago tggggcggct gtggtagggt gtgggctctt caacaggggc      240
tgetgtgttg cggggangtg aangtgttgt gtcacttgag cttggccagc tctggaaagt      300
antanattct tcttgaaggc cagcgtttgt ggagctggca ngggtcantg ttgtgtgtaa      360
cgaacaaagt ctgctgtggg tgggtgtana tcttccacaa agcctgaagt tatggtgtcn      420
tcaggttaana atgtggtttc agtgcctctg ggcngctgtg gaaggttgta nattgtcacc      480
aagggaataa gctgttgtt                                     498

```

<210> 160

<211> 380

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(380)

<223> n = A,T,C or G

<400> 160

```

acctgcatcc agcttccctg ccaaactcac aaggagacat caacctctag acagggaaac      60
agcttcagga tacttccagg agacagagcc accagcagca aaacaaatat tcccatgcct      120
ggagcatggc atagaggaag ctganaaatg tgggggtctga ggaagccatt tgagtctggc      180
cactagacat ctcatcagcc acttgtgtga agagatgccc catgaccca gatgcctctc      240
ccacccttac ctccatctca cacacttgag ctttccactc tgtataattc taacatcctg      300
gagaaaaatg gcagtttgac cgaacctgtt cacaacggta gaggctgatt tctaacgaaa      360
ctgttagaat gaagcctgga                                     380

```

<210> 161

<211> 114

<212> DNA

<213> Homo sapien

<400> 161

```

actccacatc cctcttgagc aggcggttgt cgttcaaggt gtatttggcc ttgcctgtca      60
cactgtccac tggcccctta tccacttggg gcttaatccc tcgaaagagc atgt      114

```

<210> 162

<211> 177

<212> DNA

<213> Homo sapien

<400> 162

```

actttctgaa tcgaatcaaa tgatacttag tgtagtttta atatcctcat atatatcaaa      60
gttttactac tctgataatt ttgtaaacca ggtaaccaga acatccagtc atacagcttt      120
tggltgatata taacttggca ataaccagc ctggtgatac ataaaactac tcaactgt      177

```

<210> 163

<211> 137

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(137)

<223> n = A,T,C or G

<400> 163

```

catttatata gacaggcggtg aagacattca cgacaaaaac gcgaaattct atcccgtagac      60
canagaaggc agctacggct actcctacat cctggcggtg gtggccttcg cctgcacctt      120
catcagcggc atgatgt                                     137

```

```

<210> 164
<211> 469
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(469)
<223> n = A,T,C or G

```

```

<400> 164
cttatcacia tgaatgttct cctgggcagc gttgtgatct ttgccacctt cgtgacttta      60
tgcaatgcat catgctatct cctacctaata gagggagttc caggagattc aaccaggaaa      120
tgcattggatc tcaaaggaaa caaacaccca ataaactcgg agtggcagac tgacaactgt      180
gagacatgca cttgctacga aacagaaatt tcatgttgca cccttgtttc tacacctgtg      240
ggttatgaca aagacaactg ccaaagaatc ttcaagaagg aggactgcaa gtatatcgtg      300
gtggagaaga aggacccaaa aaagacctgt tctgtcagtg aatggataat ctaatgtgct      360
tctagtaggc acagggctcc caggccaggc ctcattctcc tctggcctct aatagtcaat      420
gattgtgtag ccattgcctat cagtaaaaag atntttgagc aaacacttt                469

```

```

<210> 165
<211> 195
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(195)
<223> n = A,T,C or G

```

```

<400> 165
acagtttttt atanatatcg acattgcggg cacttgtggt cagtttcata aagctgggtg      60
atccgctgtc atccactatt ccttggctag agtaaaaatt attcttatag cccatgtccc      120
tgcaggccgc ccgcccgtag ttctcgttcc agtcgtcttg gcacacaggg tgccaggact      180
tcctctgaga tgagt                                     195

```

```

<210> 166
<211> 383
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(383)
<223> n = A,T,C or G

```

```

<400> 166
acatcttagt agtgtggcac atcagggggc catcagggtc acagtcactc atagcctcgc      60
cgaggctcga gtccacacca ccggtgtagg tgtgtcfaat cttgggcttg gcgcccacct      120
ttggagaagg gatatgctgc acacacatgt ccacaaagcc tgtgaactcg ccaaagaatt      180
tttgagacc agcctgagca aggggcggat gttcagcttc agctcctcct tcgtcagggtg      240
gatgccaaac tcgtctangg tccgtgggaa gctgggtgcc acntcaccta caacctgggc      300
gangatctta taaagaggct ccnagataaa ctccacgaaa cttctctggg agctgctagt      360
nggggccttt ttggtgaact ttc                                     383

```

<210> 167
 <211> 247
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(247)
 <223> n = A,T,C or G

<400> 167
 acagagccag accttggcca taaatgaanc agagattaag actaaacccc aagtcganat 60
 tggagcagaa actggagcaa gaagtgggcc tggggctgaa gtagagacca agggcactgc 120
 tatanccata cacagagcca actctcaggc caaggcnatg gttggggcag anccagagac 180
 tcaatctgan tccaaagtgg tggctggaac actggtcatg acanaggcag tgactctgac 240
 tgangtc 247

<210> 168
 <211> 273
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(273)
 <223> n = A,T,C or G

<400> 168
 acttctaagt tttctagaag tggaaggatt gtantcatcc tgaaaatggg tttacttcaa 60
 aatccctcan ccttgttctt cactactgtc tatactgana gtgtcatgtt tccacaaagg 120
 gctgacacct gagcctgnat tttcactcat ccctgagaag ccctttccag taggggtgggc 180
 gattcccaac ttccttgcca caagcttccc aggctttctc ccctggaaaa ctccagcttg 240
 agtccagat acactcatgg gctgccctgg gca 247

<210> 169
 <211> 431
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(431)
 <223> n = A,T,C or G

<400> 169
 acagccttgg ctcccccaaa ctccacagtc tcagtgcaga aagatcatct tccagcagtc 60
 agctcagacc aggttcaaag gatgtgacat caacagtttc tggtttcaga acaggttcta 120
 ctactgtcaa atgacccccc atacttcctc aaaggctgtg gtaagttttg cacaggtgag 180
 ggcagcagaa aggggggtant tactgatgga caccatcttc tctgtatact ccacactgac 240
 cttgccatgg gcaaaggccc ctaccacaaa aacaatagga tcaactgctg gcaccagctc 300
 acgcacatca ctgacaaccg ggatggaaaa agaantgcc aactttcatac atccaactgg 360
 aaaqtgatct gatactggat tcttaattac cttcaaaaagc ttctgggggc catcagctgc 420
 tccgaacactg a 431

<210> 170
 <211> 266
 <212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(266)

<223> n = A,T,C or G

<400> 170

acctgtgggc	tgggctgtta	tgccctgtgcc	ggctgctgaa	agggagttca	gaggtggagc	60
tcaaggagct	ctgcaggcat	tttgccaanc	ctctccanag	canagggagc	aacctacact	120
ccccgctaga	aagacaccag	attggagtcc	tgggaggggg	agttgggggtg	ggcatttgat	180
gtatacttgt	cacctgaatg	aangagccag	agaggaanga	gacgaanatg	anattggcct	240
tcaaagctag	gggtctggca	ggtgga				266

<210> 171

<211> 1248

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1248)

<223> n = A,T,C or G

<400> 171

ggcagccaaa	tcataaacgg	cgaggactgc	agcccgcact	cgcagccctg	gcaggcggca	60
ctgggtcatgg	aaaacgaatt	gttctgctcg	ggcgtcctgg	tgcatccgca	gtgggtgctg	120
tcagccgcac	actgtttcca	gaagtgagtg	cagagctcct	acaccatcgg	gctgggcctg	180
cacagtcttg	aggccgacca	agagccaggg	agccagatgg	tggaggccag	cctctccgta	240
cggaaccag	agtacaacag	acccttgctc	gctaacgacc	tcattgctcat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcggggaaact	cttgccctcg	ttctggctgg	ggtctgctgg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcggtggtg	tctgaggagg	tctgcagtaa	gctctatqac	480
ccgctgtacc	accccagcat	gttctgcgcc	ggcggagggc	aagaccagaa	ggactcctgc	540
aacggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgaggggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agtgtgcgtg	ccagggtgtc	acaccaacct	ctgcaaattc	660
actgagtggg	tagagaaaac	cgtccaggcc	agttaaactc	ggggactggg	aacccatgaa	720
attgaccccc	aaatacatcc	tgcggaagga	attcaggaat	atctgttccc	agcccctcct	780
ccctcaggcc	caggagtcca	ggcccccagc	ccctcctccc	tcaaaccaag	ggtacagatc	840
cccagcccct	cctccctcag	accagggagt	ccagaccccc	cagcccctcc	tccctcagac	900
ccaggagtcc	agcccctcct	ccctcagacc	caggagtcca	gacccccag	cccctcctcc	960
ctcagaccca	ggggtccagg	cccccaaccc	ctcctcctcc	agactcagag	gtccaagccc	1020
ccaaccntc	attccccaga	cccagaggtc	cagggtccag	cccctcntcc	ctcagaccca	1080
gcgggtccaat	gccacctaga	ctntccctgt	acacagtgcc	cccttggtgg	acgttgaccc	1140
aaccttacca	gttggttttt	catttttngt	ccctttcccc	tagatccaga	aataaagttt	1200
aagagaagng	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1248

<210> 172

<211> 159

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(159)

<223> Xaa = Any Amino Acid

<400> 172

```

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
 1      5      10      15
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
 20      25      30
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
 35      40      45
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 50      55      60
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
 65      70      75      80
Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe
 85      90      95
Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser
100      105      110
Gly Gly Ile Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe
115      120      125
Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn
130      135      140
Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
145      150      155

```

```

<210> 173
<211> 1265
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(1265)
<223> n = A,T,C or G

```

```

<400> 173
ggcagccccc actgcagccc ctggcaggcg gcactgggtc tggaaaacga attgtttctgc      60
tcggggcgctc tgggtgcatcc gcagtggggtg ctgtcagccg cacactgttt ccagaactcc      120
tacaccatcg ggctgggccc gcacagtctt gagggccgacc aagagccagg gagccagatg      180
gtggagggccg gctctccgtt acggcaccga gactacaaca gaccttgct cgctaaccgac      240
ctcatgtctca tcaagttgga cgaatccgtg tccgagtctg acaccatccg gagcatcagc      300
attgcttcgc agtgccctac cgcggggaac tcttgctctg tttctggctg ggggtctgtg      360
gcgaacgggtg agtcaacggg tgtgtgtctg cctcttcaa ggaggtcctc tgcccagtcg      420
cggggggctga cccagagctc tgcgtcccag gcagaatgcc taccgtgctg cagtgcgtga      480
acgtgtcggt ggtgtctgag gaggtctgca gtaagctcta tgaccgcgtg taccacccca      540
gcattgtctg cgcggcgga gggcaagacc agaaggactc ctgcaacggt gactctgggg      600
ggccctgat ctgcaacggg tacttgagg gccttgctg tttcgaaaa gccccgtgtg      660
gccaaattgg cgtgccagg gtctacacca acctctgcaa attcaactgag tggatagaga      720
aaaccgtcca ggccagttaa ctctggggac tgggaaccca tgaaattgac ccccaaatac      780
atcctgcgga aggaattcag gaatatctgt tcccagcccc tctcctccta ggcccaggag      840
tccaggcccc cagccctcc tccctcaaac caagggtaca gatccccagc cctcctccc      900
tcagacccag gagtccagac cccccagccc ctctcctc agacccagga gtccagcccc      960
tctcctcaca gacccaggag tccagacccc ccagccctc ctccctcaga cccaggggtt      1020
gaggccccca accctcctc cttcagagtc agaggtccaa gcccccaacc cctcgttccc      1080
cagacccaga ggtnnaggtc ccagccctc ttcctcaga cccagnngtc caatgccacc      1140
tagattttcc ctgnacacag tgccctcttg tggngangttg acccaacctt accagttggt      1200
ttttcatttt tngtcccttt cccctagatc cagaaataaa gtttaagaga ngngcaaaaa      1260
aaaaa                                           1265

```

```

<210> 174
<211> 1459
<212> DNA

```

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1459)

<223> n = A,T,C or G

<400> 174

gggcagccgc	acactgtttc	cagaagtgtg	tgcagagctc	ctacaccatc	gggctgggcc	60
tgcacagtct	tgaggccgac	caagagccag	ggagccagat	ggaggaggcc	agcctctccg	120
taaggcaacc	agagtacaac	agacccttgc	tcgctaacga	cctcatgtct	atcaagtgtg	180
acgaatccgt	gtccgagtct	gacaccatcc	ggagcatcag	cattgcttcg	cagtgcctta	240
ccgcggggaa	ctcttgccct	gtttctggct	gggtctgtct	ggcgaacggg	gagctcacgg	300
gtgtgtgtct	gccctcttca	aggaggtcct	ctgcccagtc	gcgggggctg	acccagagct	360
ctgcgtccca	ggcagaatgc	ctaccgtgct	gcagtgcgtg	aacgtgtcgg	tggtgtctga	420
ngaggtctgc	antaagctct	atgacccgct	gtaccacccc	ancatgttct	gcgccggcgg	480
agggcaagac	cagaaggact	cctgcaacgt	gagagagggg	aaaggggagg	gcaggcgact	540
cagggaaggg	tggagaaggg	ggagacagag	acacacaggg	ccgcatggcg	agatgcagag	600
atggagagac	acacagggag	acagtgacaa	ctagagagag	aaactgagag	aaacagagaa	660
ataaacacag	gaataaagag	aagcaaagga	agagagaaac	agaaacagac	atggggaggc	720
agaaacacac	acacatagaa	atgcagttga	ccttccaaca	gcatggggcc	tgagggcggt	780
gacctccacc	caatagaaaa	tcctcttata	acttttgact	ccccaaaaac	ctgactagaa	840
atagcctact	gttgacgggg	agccttacca	ataacataaa	tagtcgattt	atgcatacgt	900
tttatgcatt	catgatatac	ctttgttga	attttttgat	atttctaagc	tacacagttc	960
gtctgtgaat	ttttttaaat	tgttgcaact	ctcctaaaaa	ttttctgatg	tgtttattga	1020
aaaaatccaa	gtataagtgg	acttgtgcat	tcaaaccagg	gttgttcaag	ggtcaactgt	1080
gtacccagag	ggaaacagtg	acacagattc	atagaggtga	aacacgaaga	gaaacaggaa	1140
aaatcaagac	tctacaaaga	ggctgggcag	gggtggtcat	gcctgtaatc	ccagcacttt	1200
gggaggcgag	gcaggcagat	cacttgaggt	aaggagtcca	agaccagcct	ggccaaaatg	1260
gtgaaatcct	gtctgtacta	aaaatacaaa	agttagctgg	atatggtggc	aggcgccctg	1320
aatcccagct	acttggggag	ctgaggcagg	agaattgctt	gaatatggga	ggcagagggt	1380
gaagtgaagt	gagatcacac	cactatactc	cagctggggc	aacagagtaa	gactctgtct	1440
caaaaaaaaa	aaaaaaaaaa					1459

<210> 175

<211> 1167

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1167)

<223> n = A,T,C or G

<400> 175

gcgcagccct	ggcaggcgcc	actggtcatg	gaaaacgaat	tgttctgtct	gggcgtectg	60
gtgcatccgc	agtgggtgct	gtcagccgca	cactgtttcc	agaactccta	caccatcggg	120
ctgggcctgc	acagtcttga	ggccgaccaa	gagccaggga	gccagatggg	ggaggccagc	180
ctctccgtac	ggcaccagga	gtacaacaga	ctcttgctcg	ctaaccagct	catgctcatc	240
aagttggacg	aatccgtgtc	cgagtctgac	accatccgga	gcatcagcat	tgctctgcag	300
tgccttaccc	cggggaactc	ttgcctcgtn	tctggctggg	gtctgctggc	gaacggcaga	360
atgcctaccg	tgtgcaactg	cgtgaacgtg	tcggtggtgt	ctgaggangt	ctgcagtaag	420
ctctatgacc	cgtgtgacca	ccccagcatg	ttctgcgccg	gcggagggca	agaccagaag	480
gactcctgca	acggtgactc	tggggggccc	ctgatctgca	acgggtactt	gcagggcctt	540
gtgtctttcg	gaaaagcccc	gtgtggccaa	cttggcgtgc	cagggtgtcta	caccaacctc	600
tgcaaattca	ctgagtggat	agagaaaacc	gtccagncca	gttaactctg	gggactggga	660
acccatgaaa	ttgacccccca	aatacatcct	gcggaangaa	ttcaggaata	tctgttccca	720
gccccctctc	cctcaggccc	aggagtccag	gccccagcc	cctcctccct	caaaccaagg	780

```

gtatagatcc ccagccccc ctcctcaga cccaggagtc cagacccccc agccccctnt 840
ccctcagacc caggagtcca gcccctctc cntcagaagc aggagtccag acccccacagc 900
ccctcctccg tcagacccag ggggtgcaggc ccccaacccc tctcctcctca gagtcagagg 960
ccagagcccc caacccctcg ttcctcagac ccagaggtnc aggtccccagc cctctctccc 1020
tcagacccag cgggtccaatg ccacctagan tntccctgta cacagtgcgc ccttggtggca 1080
cgttgaccca accctaccag ttgggttttc attttttgtc cctttccctt agatccagaa 1140
ataaagtnta agagaagcgc aaaaaaa 1167

```

<210> 176
 <211> 205
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (1)...(205)
 <223> Xaa = Any Amino Acid

<400> 176

Met	Glu	Asn	Glu	Leu	Phe	Cys	Ser	Gly	Val	Leu	Val	His	Pro	Gln	Trp
1				5					10					15	
Val	Leu	Ser	Ala	Ala	His	Cys	Phe	Gln	Asn	Ser	Tyr	Thr	Ile	Gly	Leu
			20					25					30		
Gly	Leu	His	Ser	Leu	Glu	Ala	Asp	Gln	Glu	Pro	Gly	Ser	Gln	Met	Val
		35					40					45			
Glu	Ala	Ser	Leu	Ser	Val	Arg	His	Pro	Glu	Tyr	Asn	Arg	Leu	Leu	Leu
		50				55					60				
Ala	Asn	Asp	Leu	Met	Leu	Ile	Lys	Leu	Asp	Glu	Ser	Val	Ser	Glu	Ser
65					70				75					80	
Asp	Thr	Ile	Arg	Ser	Ile	Ser	Ile	Ala	Ser	Gln	Cys	Pro	Thr	Ala	Gly
			85						90					95	
Asn	Ser	Cys	Leu	Val	Ser	Gly	Trp	Gly	Leu	Leu	Ala	Asn	Gly	Arg	Met
			100					105					110		
Pro	Thr	Val	Leu	His	Cys	Val	Asn	Val	Ser	Val	Val	Ser	Glu	Xaa	Val
			115				120					125			
Cys	Ser	Lys	Leu	Tyr	Asp	Pro	Leu	Tyr	His	Pro	Ser	Met	Phe	Cys	Ala
130					135						140				
Gly	Gly	Gly	Gln	Asp	Gln	Lys	Asp	Ser	Cys	Asn	Gly	Asp	Ser	Gly	Gly
145					150					155					160
Pro	Leu	Ile	Cys	Asn	Gly	Tyr	Leu	Gln	Gly	Leu	Val	Ser	Phe	Gly	Lys
			165					170						175	
Ala	Pro	Cys	Gly	Gln	Leu	Gly	Val	Pro	Gly	Val	Tyr	Thr	Asn	Leu	Cys
			180					185					190		
Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln	Xaa	Ser			
			195				200					205			

<210> 177
 <211> 1119
 <212> DNA
 <213> Homo sapien

<400> 177

ggcgaactgc	agccctggca	ggcggcactg	gtcatggaaa	acgaattgtt	ctgctcgggc	60
g'cctgggtg	atccgcagtg	ggtgctgtca	gccgcacact	gtttccagaa	ctcctacacc	120
atcgggctgg	gcctgcacag	tcttgaggcc	gaccaagagc	cagggagcca	gatgggtggag	180
gcccacctct	ccgtacggca	cccagagtag	aacagaccct	tgctcgctaa	cgacctcatg	240
ctcatcaagt	tggacgaatc	cgtgtccag	tctgacacca	tccggagcat	cagcattgct	300
tccgagtgcc	ctaccgcggg	gaactcttgc	ctcgtttctg	gctgggggtct	gctggcggaac	360

```

gatgctgtga ttgccatcca gtcccagaact gtgggaggct gggagtgtga gaagctttcc 420
caaccctggc aggggtgtac catttcggca acttccagtg caaggacgtc ctgctgcac 480
ctcactgggt gctcactact gctcactgca tcacccgaa cactgtgac aactagccag 540
caccatagtt ctccgaagtc agactatcat gattactgtg ttgactgtgc tgtctattgt 600
actaaccatg ccgatgttta ggtgaaatta gcgtcacttg gcctcaacca tcttggtatc 660
cagttatcct cactgaattg agatttcctg cttcagtgtc agccattccc acataatttc 720
tgacctacag aggtgaggga tcatatagct cttcaaggat gctggtactc cctcacaaa 780
ttcatttctc ctgtttagt gaaaggtgog cctctggag cctcccaggg tgggtgtgca 840
ggtcacaatg atgaatgtat gatcgtgttc ccattaccca aagcctttaa atccctcatg 900
ctcagtacac cagggcaggt ctagcatttc ttcatttagt gtatgctgtc cattcatgca 960
accacctcag gactcctgga ttctctgcct agttgagctc ctgcatgctg cctccttggg 1020
gaggtgaggg agagggcca tggttcaatg ggatctgtgc agttgtaaca cattaggtgc 1080
ttaataaaca gaagctgtga tgtaaaaaa aaaaaaaaa 1119

```

<210> 178

<211> 164

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(164)

<223> Xaa = Any Amino Acid

<400> 178

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
 1           5           10           15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
          20           25           30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
          35           40           45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
          50           55           60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65           70           75           80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
          85           90           95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val
          100          105          110
Ile Ala Ile Gln Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu
          115          120          125
Ser Gln Pro Trp Gln Gly Cys Thr Ile Ser Ala Thr Ser Ser Ala Arg
          130          135          140
Thr Ser Cys Cys Ile Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser
145          150          155          160
Pro Gly Thr Leu

```

<210> 179

<211> 250

<212> DNA

<213> Homo sapien

<400> 179

```

ctggagtgcc ttggtgtttc aagcccctgc aggaagcaga atgcaccttc tgaggcacct 60
ccagctgccc ccggccgggg gatgcgaggc tcggagcacc cttgcccggc tgtgattgct 120
gccaggcaact gttcatctca gcttttctgt ccttttgctc ccggcaagcg cttctgctga 180
aagttcatat ctggagcctg atgtcttaac gaataaaggt cccatgctcc acccgaaaaa 240

```


aaaaaaaaaa

250

<210> 180
 <211> 202
 <212> DNA
 <213> Homo sapien

<400> 180

actagtcacag	tgtgtgtggaa	ttccattgtg	ttggggcccaa	cacaatggct	acctttaaca	60
tcacccagac	cccgcccctg	cccggtcccc	acgtgtctgc	taacgacagt	atgatgctta	120
ctctgtact	cggaactat	ttttatgtaa	ttaatgtatg	ctttcttgtt	tataaatgcc	180
tgatttaaaa	aaaaaaaaaa	aa				202

<210> 181
 <211> 558
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(558)

<223> n = A,T,C or G

<400> 181

tccttttkt	naggtttkk	agacamccck	agacctwaan	ctgtgtcaca	gacttcyngg	60
aatgtttagg	cagtgtctagt	aatttcytcg	taatgattct	gttattactt	tcctnattct	120
ttattcctct	ttcttctgaa	gattaatgaa	gttgaaaatt	gaggtggata	aatacaaaaa	180
ggtagtgtga	tagtataagt	atctaagtgc	agatgaaagt	gtgttatata	tatccattca	240
aaattatgca	agttagtaat	tactcagggt	taactaaatt	actttaatat	gctgttgaac	300
ctactctgtt	ccttggctag	aaaaaattat	aaacaggact	ttgttagttt	gggaagccaa	360
attgataata	ttctatgttc	taaaagttgg	gctatacata	aattattaag	aaatatggaw	420
ttttattccc	aggaatatgg	kgttcatttt	atgaatatta	cscrggatag	awgtwtgagt	480
aaaaycagtt	ttggtwaata	ygtwaatatg	tcmtaaataa	acaakgcttt	gacttatttc	540
caaaaaaaaa	aaaaaaaaa					558

<210> 182
 <211> 479
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(479)

<223> n = A,T,C or G

<400> 182

acagggwttk	grggatgcta	agsecccrga	rwtygtttga	tccaacctg	gcttwttttc	60
agaggggaaa	atggggccta	gaagttacag	mscatytagy	tggtgcgmg	gcacccctgg	120
cstcacacag	astcccaggt	agctgggact	acaggcacac	agtcactgaa	gcaggccctg	180
ttwgcaattc	acgttgccac	ctccaactta	aacattcttc	atatgtgatg	tccttagtca	240
ctaagggtta	actttccac	ccagaaaagg	caacttagat	aaaatcttag	agtactttca	300
tactmttcta	agtcctcttc	cagcctcact	kkagagctcm	cytggggggt	gataggaant	360
ntctcttggc	tttctcaata	aartctctat	ycatctcatg	tttaatttgg	tacgcataa	420
awtastgara	aaattaaaa	gttctggtty	mactttaaaa	aaaaaaaaa	aaaaaaaaa	479

<210> 183
 <211> 384
 <212> DNA

<213> Homo sapien

<400> 183

aggcgggagc	agaagctaaa	gccaaagccc	aagaagagtg	gcagtgccag	cactggtgcc	60
agtaccagta	ccaataacag	tgccagtgcc	agtgccagca	ccagtgggtgg	cttcagtgtc	120
ggtgccagcc	tgaccgccac	tctcacatth	gggctcttcg	ctggccttgg	tggagctgg	180
gccagcacca	gtggcagctc	tgggtgcctgt	ggtttctcct	acaagtgaga	ttttagatat	240
tgttaatect	gccagtcttt	ctcttcaagc	cagggtgcat	cctcagaaac	ctactcaaca	300
cagcactcta	ggcagccact	atcaatcaat	tgaagttgac	actctgcatt	aratctatth	360
gccatttcaa	aaaaaaaaaa	aaaa				384

<210> 184

<211> 496

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(496)

<223> n = A,T,C or G

<400> 184

accgaattgg	gaccgctggc	ttataagcga	tcatgttynt	ccrgtatcac	ctcaacgagc	60
aggagatcg	agtctatacg	ctgaagaaat	ttgaccgat	gggacaacag	acctgctcag	120
cccatcctgc	tgggttctcc	ccagatgaca	aatactctsg	acaccgaatc	accatcaaga	180
aacgcttcaa	ggtgctcatg	accagcaaac	cgggccctgt	cctctgaggg	tcccttaaac	240
tgatgtcttt	tctgccacct	gttaccacct	ggagactccg	taaccaaact	cttcggactg	300
tgagccctga	tgcctttttg	ccagccatac	tctttggcat	ccagtctctc	gtggcgattg	360
attatgcttg	tgtgaggcaa	tcatggtggc	atcaccata	aagggaacac	atttgacttt	420
tttttctcat	attttaaatt	actacmagaw	tattwmagaw	waaatgawtt	gaaaaactst	480
taaaaaaaaa	aaaaaa					496

<210> 185

<211> 384

<212> DNA

<213> Homo sapien

<400> 185

gctggtagcc	tatggcgkkg	cccacggagg	ggctcctgag	gccacggrac	agtgacttcc	60
caagtatcyt	gcgscgctc	ttctaccgtc	cctacctgca	gatcttcggg	cagattcccc	120
aggaggacat	ggacgtggcc	ctcatggagc	acagcaactg	ytcgctggag	cccggcttct	180
gggcacaccc	tcttggggcc	caggcgggca	cctgcgtctc	ccagtatgcc	aactggcttg	240
tgggtgctgt	cctcgtcctc	ttcctgctcg	tggccaacat	cctgctggtc	aacttgctca	300
ttgccatgtt	cagttacaca	ttcggcaaag	tacagggcaa	cagcgatctc	tactgggaag	360
gcgcagcggt	accgcctcat	ccgg				384

<210> 186

<211> 577

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(577)

<223> n = A,T,C or G

<400> 186

gagtttagctc	ctccacaacc	ttgatgaggt	cgtctgcagt	ggcctctcgc	ttcataccgc	60
-------------	------------	------------	------------	------------	------------	----

```

inccatcgtc atactgtagg ttgtccacca cytcctggca tcttggggcg gentaatatt 120
ccaggaaaact ctcaatcaag tcaccgtoga tgaacctgt gggctgggtc tgtcttcgcg 180
tcggtgtgaa aggatctccc agaaggagtg ctcgatcttc ccacacttt tgaatgacttt 240
attgagtoga ttctgcatgt ccagcaggag gttgtaccag ctctctgaca gtgaggtcac 300
cagccctatc atgccgttga mcgtgccgaa garcaccgag ccttgtgtgg gggkkgaagt 360
ctcaccocaga ttctgcatta ccagagagcc gtggcaaaaag acattgacaa actcgccag 420
gtggaaaaag amcamctcct ggargtgctn gccgtctctc gtcmgttggg ggcagcgctw 480
tctttttgac acacaaaacaa gttaaaggca ttttcagccc ccagaaantt gtcacatccc 540
aagatntcgc acagcactna tccagttggg attaaat 577

```

<210> 187

<211> 534

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(534)

<223> n = A,T,C or G

<400> 187

```

aacatcttcc tgtataatgc tgtgtaatat cgatccgatn ttgtctgstg agaatycatw 60
actkggaaaa gmaacattaa agcctggaca ctggtattaa aattcacaa atgcaacact 120
ttaaacagtg tgtcaatctg ctcccyynac ttgtgcatca ccagtctggg aakaagggtg 180
tgccctattc acacctgtta aaagggcgct aagcattttt gattcaacat cttttttttt 240
gacacaagtc cgaaaaaagc aaaagtaaac agttatyaat ttgttagcca attcactttc 300
ttcatgggac agagccatyt gatttaaaaa gcaaattgca taatattgag cttggggagc 360
tgatatattga gcggaagagt agcctttcta cttcaccaga cacaactccc ttcatattg 420
ggatgttnac naaagtwatg tctctwacag atgggatgct tttgtggcaa ttctgttctg 480
aggatctccc agtttattta ccacttgcac aagaaggcgt tttcttctc aggc 534

```

<210> 188

<211> 761

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(761)

<223> n = A,T,C or G

<400> 188

```

agaaaccagt atctctnaaa acaacctctc ataccttggt gacctaatth tgtgtgcgtg 60
tgtgtgtgcg cgcataattat atagacaggg acatcttttt tacttttgta aaagcttatg 120
cctcttttgg atctatatct gtgaaagttt taatgatctg ccataatgtc ttggggacct 180
ttgtcttctg tgtaaatggt actagagaaa acacctatnt tatgagtcaa tctagttngt 240
tttattcgac atgaaggaaa ttccagatn acaacactna caaactctcc ctkgackarg 300
ggggacaaaag aaaagcaaaa ctgamcataa raaacaatwa cctgggtgaga arttgcataa 360
acagaaaatwr ggtagtatat tgaarnacag catcattaaa rmgtttwktt wttctccctt 420
gcaaaaaaca tgtacngact tcccgttgag taatgccaag ttgttttttt tatnataaaa 480
cttgcccttc attacatggt tnaaagtggg gtggtggggc aaaatattga aatgatggaa 540
ctgactgata aagctgtaca aataagcagt gtgcctaaca agcaacacag taatgttgac 600
atgcttaatt cacaaatgct aatttcatta taaatgtttg ctaaaatata ctttgaacta 660
ttttctgtn ttcccagagc tgagatntta gattttatgt agtatnaagt gaaaaantac 720
gaaaataata acattgaaga aaaananaaa aanaaaaaaa a 761

```

<210> 189

<211> 482

<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(482)
<223> n = A,T,C or G

<400> 189
 tttttttttt tttgccgatn ctactatttt attgcaggan gtgggggtgt atgcaccgca 60
 caccgggggt atnagaagca agaaggaagg agggagggca cagccccttg ctgagcaaca 120
 aagccgctgt ctgccttctc tgtctgtctc ctggtgcagg cacatgggga gaccttcccc 180
 aaggcagggg ccaccagtcc aggggtggga atacaggggg tgggangtgt gcataagaag 240
 tgataggcac aggccaccgc gtacagaccc ctcggtcctt gacaggtnga tttcgaccag 300
 gtcattgtgc cctgcccgagg cacagcggtan atctggaaaa gacagaatgc tttccttttc 360
 aaatttgggt ngctcatngaa ngggcanttt tccaanttng gctnggtctt ggtacncttg 420
 gtteggccca gctccnctgc caaaaantat tcaccennct ccnaattgct tgcnngnccc 480
 cc 482

<210> 190
<211> 471
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(471)
<223> n = A,T,C or G

<400> 190
 tttttttttt ttttaaaaca gtttttcaca acaaaattta ttagaagaat agtggttttg 60
 aaaactctcg catccagtga gaactaccat acaccacatt acagctngga atgtinctca 120
 aatgtctggg caaatgatcc aatgggaacca ttcaatctta cacatgcacg aaagaacaag 180
 cgctttttgac atacaatgca caaaaaaaaa agggggggggg gaccacatgg attaaaattt 240
 taagtactca tcacatacat taagacacag ttctagtcca gtcnaaaatc agaactgcnt 300
 tgaaaaattt catgtatgca atccaaccaa agaacttnat tgggtgatcat gantnctcta 360
 ctacatonac cttgatcatt gccaggaacn aaaagttnaa ancacnngt acaaaaaanaa 420
 tctgtaattn anttcaacct ccgtacngaa aaatnttntt tatacactcc c 471

<210> 191
<211> 402
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(402)
<223> n = A,T,C or G

<400> 191
 gagggattga aggtctgttc tastgtcggm ctgttcagcc accaactcta acaagttgct 60
 gtcttccact cactgtctgt aagcttttta acccagacwg tatcttcata aatagaacaa 120
 attcttcacc agtcacatct tctaggacct ttttggtatc agttagtata agctcttcca 180
 cttcctttgt taagacttca tctggtaaag tcttaagttt tgtagaaagg aattyaattg 240
 ctcgttctct aacaatgtcc tctccttgaa gtatttggct gaacaaccca cctaaagtcc 300
 ctttgtgcat ccatttttaa tatacttaat agggcattgk tncactaggt taaattctgc 360
 aagagtcata tgtctgcaaa agttgcgtta gtatatctgc ca 402

<210> 192
 <211> 601
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(601)
 <223> n = A,T,C or G

<400> 192
 gagctcggat ccaataatct ttgtctgagg gcagcacaca tatncagtgc catggnaact 60
 ggtctacccc acatgggagc agcatgccgt agntatataa ggtcattccc tgagtcagac 120
 atgcytyttt gaytaccgtg tgccaagtgc tgggtgattct yaacacacyt ccatcccgyt 180
 cttttgtgga aaaactggca cttktctgga actagcarga catcacttac aaattcaccc 240
 acgagacact tgaaagggtg aacaaagcga ytcttgcatc gctttttgtc cctccggcac 300
 cagttgtcaa tactaaccog ctggttttgcc tccatcacat ttgtgatctg tagctctgga 360
 tacatctcct gacagtactg aagaacttct tcttttgttt caaaagcarg tcttggtgcc 420
 tgttgatca gggtccatt tcccagtcyg aatgttcaca tggcataatt wacttccac 480
 aaaacattgc gatttgaggc tcagcaacag caaatcctgt tccggcattg gctgcaagag 540
 cctcgatgta gccggccagc gccaaaggcag gcgcggtgag cccaccagc agcagaagca 600
 g 601

<210> 193
 <211> 608
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(608)
 <223> n = A,T,C or G

<400> 193
 atacagccca nateccacca cgaagatgcg cttgttgact gagaacctga tgcggtcact 60
 ggtcccgtg tagccccagc gactctccac ctgctggaag cggttgatgc tgcactcytt 120
 cccaacgcag gcagmagcgg gscgggtcaa tgaactccay tctgtgcttg gggtkgacgg 180
 tkaagtgcag gaagaggctg accacctcgc ggteccaccag gatgcccagc tgtgcgggac 240
 ctgcagcgaa actcctcgat ggtcatgagc gggaagcgaa tgaggcccag ggcttgcgc 300
 agaaccttcc gectgttctc tggcgtaacc tgcagctgct gccgctgaca ctgggcctcg 360
 gaccagcgga caaacggcrt tgaacagccg cactcaccg atgcccagtg tgtcgcgctc 420
 caggammgsc accagcgtgt ccaggtcaat gtccgtgaag cctccgcgg gtrattggcgt 480
 ctgcagtgtt tttgtcgatg ttctccaggc acaggctggc cagctgcggg tcatcgaaga 540
 gtgcgcctg cgtgagcagc atgaaggcgt tgtcggctcg cagttcttct tcaggaaactc 600
 cactgcaat 608

<210> 194
 <211> 392
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(392)
 <223> n = A,T,C or G

<400> 194
 gaacggctgg accttgccctc gcattgtgct tgctggcagg gaataccttg gcaagcagyt 60

ccagtcocgag	cagccccaga	ccgctgccgc	ccgaagctaa	gcctgcctct	ggccttcccc	120
tccgcctcaa	tgcagaacca	gtagtgggag	cactgtgttt	agagttaaga	gtgaacactg	180
tttgatttta	cttggggaatt	tcctctgtta	tatagctttt	cccaatgcta	atttccaaac	240
aacaacaaca	aaataacatg	tttgccgtgt	aagttgtata	aaagtaggtg	attctgtatt	300
taaagaaaaat	attactgtta	catatactgc	ttgcaatttc	tgtatttatt	gktnctstgg	360
aaataaatat	agttattaaa	ggttgtcant	cc			392

<210> 195
 <211> 502
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(502)
 <223> n = A,T,C or G

<400> 195						
ccsttkgagg	ggtkaggkyc	cagttyccga	gtggaagaaa	caggccagga	gaagtgcgtg	60
ccgagctgag	gcagatgttc	ccacagtgc	ccccagagcc	stgggstata	gtytctgacc	120
cctcncaagg	aaagaccacs	ttctggggac	atgggctgga	gggcaggacc	tagaggcacc	180
aagggaaggc	cccatcccg	ggstgttccc	cgaggaggaa	gggaaggggc	tctgtgtgcc	240
ccccasgagg	aagaggccct	gagtcctggg	atcagacacc	ccttcacgtg	tatccccaca	300
caaatgcaag	ctcaccaagg	tcccctctca	gtccccttcc	stacaccctg	amcggccact	360
gscscacacc	caccagagc	acgccaccog	ccatggggar	tgtgctcaag	gartcgcnng	420
gcarcgtgga	catctngtcc	cagaaggggg	cagaatctcc	aatagangga	ctgarcmstt	480
gctnanaaaa	aaaaanaaaa	aa				502

<210> 196
 <211> 665
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(665)
 <223> n = A,T,C or G

<400> 196						
ggttactttgg	tttcattgcc	accacttagt	ggatgtcatt	tagaaccatt	ttgtctgctc	60
cctctggaag	ccttgccgag	agcggacttt	gtaattgttg	gagaataact	gctgaatttt	120
wagctgtttk	gagttgatts	gcaccactgc	accacaaact	tcaatatgaa	aacyawttga	180
actwatthtat	tatcttgtga	aaagtataac	aatgaaaatt	ttgttcatac	tgtattkac	240
aagtatgatg	aaaagcaawa	gatatatatt	cttttattat	gttaaattat	gattgccatt	300
attaatcggc	aaaatgtgga	gtgtatgttc	ttttcacagt	aatatatgcc	ttttgtaact	360
tcacttggtt	atthttattgt	aatgartta	caaaattctt	aatttaagar	aatggatgt	420
watattttatt	tcatttaattt	ctttcctkgt	ttacgtwaat	tttgaaaaga	wtgcatgatt	480
tottgacaga	aatcgatctt	gatgctgtgg	aagtagtttg	accacatcc	ctatgagttt	540
ttcttagaat	gtataaaggt	tgtagcccat	cnaacttcaa	agaaaaaat	gaccacatac	600
tttgcaatca	ggctgaaatg	tggcatgctn	ttctaattcc	aactttataa	actagcaaan	660
aagtg						665

<210> 197
 <211> 492
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(492)
 <223> n = A,T,C or G

<400> 197
 tttntttttt ttttttttgc aggaaggatt ccattttattg tggatgcatt ttcacaatat 60
 atgtttattg gagcgatcca ttatcagtga aaagtatcaa gtgtttataa natttttagg 120
 gaggcagatt cacagaacat gctngtcngc ttgcagtttt acctcgtna gatnacagag 180
 aattatagtc naaccagtaa acnaggaatt tacttttcaa aagattaaat ccaaactgaa 240
 caaaattcta ccttgaaact tactccatcc aaatattgga ataanagtca gcagtgtatc 300
 attctcttct gaacttttaga ttttctagaa aaatatgtaa tagtgatcag gaagagctct 360
 tgttcaaaag tacaacnaag caatgttccc ttaccatagg ccttaattca aactttgatc 420
 catttcactc ccacacggg agtcaatgct acctgggaca cttgtatttt gtcatnctg 480
 anontggctt aa 492

<210> 198
 <211> 478
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(478)
 <223> n = A,T,C or G

<400> 198
 tttnttttgn atttcantct gtannaanta ttttcattat gtttattana aaaatatnaa 60
 tgtntccacn acaaatcatn ttacntnagt aagaggccan ctacattgta caacatacac 120
 tgagtatatt ttgaaaagga caagttttaa gtanacncat attgccganc atancacatt 180
 tatacatggc ttgattgata tttagcacag canaaactga gtgagttacc agaaanaaat 240
 natatatgtc aatcngattt aagatacaaa acagatccta tggtagatan catcntgtag 300
 gagttgtggc tttatgttta ctgaaagtca atgcagttcc tgtacaaaga gatggcogta 360
 agcattctag tacctctact ccattggttaa gaatcgtaca cttatgttta catatgtnc 420
 gggttaagaat tgtgttaagt naanttatgg agaggtccan gagaaaaatt tgaatnaa 478

<210> 199
 <211> 482
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(482)
 <223> n = A,T,C or G

<400> 199
 agtgacttgt cctccaacaa aacccttga tcaagtttgt ggcactgaca atcagacctta 60
 tgctagtcc tgtcatctat tgcctactaa atgcagactg gaggggacca aaaaggggca 120
 tcaactccag ctggattatt ttggagcctg caaatctatt cctacttgta cggactttga 180
 agtgattcag tttcctctac ggatgagaga ctggctcaag aatatcctca tgcagcttta 240
 tgaagccnac tctgaacacg ctggttatct nagatgagaa ncagagaaat aaagtcnaga 300
 aaatttacct ggangaaaag aggccttngg ctggggacca tccattgaa ccttctctta 360
 anggacttta agaanaaact accacatgtn tgtngtatcc tgggtgccngg ccgtttantg 420
 aactngaen nacccttnt ggaatanant cttgaengcn tctgaactt gtcctctgc 480
 ga 482

<210> 200
 <211> 270

```
<220>  
<221> misc_feature  
<222> (1)...(270)  
<223> n = A,T,C or G
```

<400>	200						
cggcgcgcaag	tgcaactcca	gctggggccg	tgcggacgaa	gattctgcc	gcagttggtc		60
cgactcgcac	gacggcgggc	gcgacagtcg	caggtgcagc	gcgggcgcct	ggggctcttc		120
aaggctgagc	tgacgcgcga	gaggtcgtgt	cacgtcccac	gacctgacg	cgctcgggga		180
cagccggaag	agagcccggt	gaangcggga	ggcctcgggg	agcccctcgg	gaaggggggc		240
ccgagagata	cgcaggtgca	ggtggccgcc					270

```
<210> 201
<211> 419
<212> DNA
<213> Homo sapien
```

```
<220>  
<221> misc_feature  
<222> (1)...(419)  
<223> n = A,T,C or G
```

<400> 201						
tttttttttt	ttttggaatc	tactgcgagc	acagcaggtc	agcaacaagt	ttatttttgca	60
gctagcaagg	taacagggtg	gggcatggtt	acatgttcag	gtcaacttcc	tttgtcgtgg	120
ttgattgggt	tgtctttatg	ggggcggggt	ggggtagggg	aaancgaagc	anaantaaca	180
tggagtgggt	gcaccctccc	tgtagaacct	ggttacnaaa	gcttggggca	gttcacctgg	240
tctgtgaccg	tcattttctt	gacatcaatg	ttattagaag	tcaggatatac	ttttagagag	300
tccactgtnt	ctggaggggag	attagggttt	cttgccaana	tccaancaaa	atccacntga	360
aaaagttaga	tgatncanqt	acngaatacc	ganggcatan	ttctcatant	cgggtggcca	419

```
<210> 202
<211> 509
<212> DNA
<213> Homo sapien
```

```
<220>  
<221> misc_feature  
<222> (1)...(509)  
<223> n = A,T,C or G
```

<400> 202						
tttntttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	60
tggcacttaa	tccattttta	tttcaaaatg	tctacaaant	ttnaatncnc	cattatacng	120
gtnattttnc	aaaatctaaa	nnttattcaa	atntnagcca	aantccttac	ncaaatnnaa	180
tacnncnaaa	aatcaaaaat	atacntntct	ttcagcaaac	ttngttacat	aaattaaaaa	240
aatatatacg	gctgggtgtt	tcaaagtaca	attatcttaa	cactgcaaac	atnttttnnaa	300
ggaactaaaa	taaaaaaaaa	cactnccgca	aaggttaaag	ggaacaacaa	attcntttta	360
caacancnnc	nattataaaa	atcatatctc	aaatccttagg	ggaatatata	cttcacacng	420
ggatcttaac	ttttactnca	ctttgtttat	ttttttanaa	ccattgtntt	gggcccaaca	480
caatggnaat	nccnccnenc	tggaactagt				509

<210>	203
<211>	583
<212>	DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(583)

<223> n = A,T,C or G

<400> 203

tttttttttt	ttttttttga	ccccctctt	ataaaaaaca	agttaccatt	ttattttact	60
tacacatatt	tattttataa	ttggtattag	atattcaaaa	ggcagctttt	aaaatcaaac	120
tacatggaaa	ctgccttaga	tacataattc	ttaggaatta	gcttaaaatc	tgcctaaagt	180
gaaatcttc	tctagctctt	ttgactgtaa	atttttgact	cttgtaaaac	atccaaattc	240
atttttcttg	tctttaaaat	tatctaattc	ttccattttt	tccctattcc	aagtcaattt	300
gcttctctaa	cctcatttcc	tagctcttat	ctactattag	taagtggctt	ttttcctaaa	360
agggaaaaaa	ggaagagana	atggcacaca	aaacaaacat	tttatattca	tatttctacc	420
tacgttaata	aaatagcatt	ttgtgaagcc	agctcaaaag	aaggcttaga	tccttttatg	480
tccattttag	tcactaaacg	atatchaaag	tgccagaatg	caaaagggtt	gtgaacattt	540
atcaaaaagc	taataaaga	tatttcacat	actcatcttt	ctg		583

<210> 204

<211> 589

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(589)

<223> n = A,T,C or G

<400> 204

ttttttttnt	tttttttttt	ttttttttct	tttttttttt	ttganaatga	ggatcgagtt	60
tttcactctc	tagatagggc	atgaagaaaa	ctcatctttc	cagcttttaa	ataacaatca	120
aatctcttat	gctatatcat	attttaagtt	aaactaatga	gtcactggct	tatcttctcc	180
tgaagggaat	ctgttcattc	ttctcattca	tatagttata	tcaagtacta	ccttgcatat	240
tgagaggttt	ttcttctcta	tttacacata	tatttccatg	tgaatttgta	tcaaaccctt	300
attttcatgc	aaactagaaa	ataatgtntt	cttttgcata	agagaagaga	acaatatnag	360
cattacaaaa	ctgctcaaat	tgtttggtta	gnttatccat	tataattagt	tnggcaggag	420
ctaatacaaa	tcacattttac	ngacnagcaa	taataaaact	gaagtaccag	ttaaatatcc	480
aaaataatta	aaggaacatt	tttagcctgg	gtataattag	ctaattcact	ttacaagcat	540
ttattnagaa	tgaattcaca	tgttattatt	cctagcccca	acacaatgg		589

<210> 205

<211> 545

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(545)

<223> n = A,T,C or G

<400> 205

tttttttttt	ttttttcagt	aataatcaga	acaatattta	tttttatatt	taaaattcat	60
agaaaagtgc	cttacattta	ataaaagttt	gtttctcaaa	gtgatcagag	gaattagata	120
tngtcttgaa	caccaatatt	aatttgagga	aaatacacca	aaatacatca	agtaaattat	180
ttaagatcat	agagcttgta	agtgaaga	taaaatttga	cctcagaaac	tctgagcatt	240
aaaatccac	tattagcaaa	taaattacta	tggacttctt	gctttaattt	tgtgatgaat	300
atgggggtgc	actggtaaac	caacacattc	tgaaggatac	attacttagt	gatagattct	360

tatgtacttt	gctanatnac	gtggatatga	gttgacaagt	ttctctttct	tcaatctttt	420
aaggggcnga	ngaaatgagg	aagaaaagaa	aaggattacg	catactgttc	tttctatngg	480
aaggattaga	tatgtttcct	ttgccaatat	taaaaaata	ataatgttta	ctactagtga	540
aaccc						545

<210> 206
 <211> 487
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(487)
 <223> n = A,T,C or G

<400> 206						
tttttttttt	tttttttagtc	aagtttctna	tttttattat	aattaaagtc	ttggtcattt	60
cattttattag	ctctgcaact	tacatattta	aattaaagaa	acgttnttag	acaactgtna	120
caattttataa	atgtaagggtg	ccattattga	gtanatatat	tcctccaaga	gtggatgtgt	180
cccttctccc	accaactaat	gaancagcaa	cattagttta	attttattag	tagatnatac	240
actgctgcaa	acgctaattc	tcttctccat	ccccatgtng	atattgtgta	tatgtgtgag	300
ttggtnagaa	tgcatacanca	atctnacaat	caacagcaag	atgaagctag	gcntgggctt	360
tcggtgaaaa	tagactgtgt	ctgtctgaat	caaatgatct	gacctatcct	cggtggcaag	420
aactcttcga	accgcttcct	caaaggcngc	tgccacattt	gtggcntctn	ttgcacttgt	480
ttcaaaa						487

<210> 207
 <211> 332
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(332)
 <223> n = A,T,C or G

<400> 207						
tgaattggct	aaaagactgc	attttttanaa	ctagcaactc	ttatttcttt	cctttaaaaa	60
tacatagcat	taaatcccaa	atcctattta	aagacctgac	agcttgagaa	ggtcactact	120
gcattttatag	gaccttctgg	tggttctgct	gttacntttg	aantctgaca	atccttgana	180
atctttgcat	gcagaggagg	taaaagggtat	tggattttca	cagaggaana	acacagcgca	240
gaaatgaagg	ggccaggctt	actgagcttg	tccactggag	ggctcatggg	tgggacatgg	300
aaaagaaggc	agcctaggcc	ctggggagcc	ca			332

<210> 208
 <211> 524
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(524)
 <223> n = A,T,C or G

<400> 208						
agggcggtggt	gcgaggggcg	ttactgtttt	gtctcagtaa	caataaatac	aaaaagactg	60
gttgtgttcc	ggccccatcc	aaccacgaag	ttgatttctc	ttgtgtgcag	agtgactgat	120
tttaaaggac	atggagcttg	tcacaatgtc	acaatgtcac	agtgtgaagg	gcacactcac	180

```

tcccgcgtga ttcacattta gcaaccaaca atagctcatg agtcataact tgtaaataact 240
tttggcagaa tacttnttga aacttgcaga tgataactaa gatccaagat atttcccaaa 300
gtaaatagaa gtgggtcata atattaatta cctgttcaca tcagcttcca ttacaagtc 360
atgagcccag acactgacat caaactaagc ccacttagac tcctcaccac cagtctgtcc 420
tgtcatcaga caggaggctg tcaccttgac caaattctca ccagtcaate atctatccaa 480
aaaccattac ctgatccact tccggtaatg caccaccttg gtga 524

```

<210> 209

<211> 159

<212> DNA

<213> Homo sapien

<400> 209

```

gggtgaggaa atccagagtt gccatggaga aaattccagt gtcagcattc ttgtctccttg 60
tggccctctc ctacactctg gccagagata ccacagtcaa acctggagcc aaaaaggaca 120
caaaggactc tcgacccaaa ctgcccaga cctctcca 159

```

<210> 210

<211> 256

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(256)

<223> n = A,T,C or G

<400> 210

```

actccctggc agacaaaggc agaggagaga gctctgttag ttctgtgttg ttgaactgcc 60
actgaatttc ttccacttg gactattaca tgccanttga gggactaatg gaaaaacgta 120
tggggagatt ttanccaatt tangtntgta aatggggaga ctggggcagg cgggagagat 180
ttgcaggggtg naaatgggan ggctggtttg ttanatgaac agggacatag gaggtaggca 240
ccaggatgct aatca 256

```

<210> 211

<211> 264

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(264)

<223> n = A,T,C or G

<400> 211

```

acattgtttt tttagataa agcattgaga gagctctcct taacgtgaca caatggaagg 60
actggaacac ataccacat ctttgttctg agggataatt ttctgataaa gtcttgctgt 120
atattcaagc acatatgtta tatattatc agttccatgt ttatagccta gttaaggaga 180
ggggagatac attongaaa aggactgaaa gaaatactca agtnggaaaa cagaaaaaga 240
aaaaaaggag caaatgagaa gcct 264

```

<210> 212

<211> 328

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(328)

<223> n = A,T,C or G

<400> 212

acccaaaaaat	ccaatgctga	atatttggt	tcattattcc	canattcttt	gattgtcaaa	60
ggatttaatg	ttgtctcagc	ttgggcactt	cagttaggac	ctaaggatgc	cagccggcag	120
gtttatatat	gcagcaacaa	tattcaagcg	cgacaacagg	ttattgaact	tgcccgccag	180
ttnaatttca	ttcccattga	cttgggatcc	ttatcatcag	ccagagagat	tgaaaattta	240
cccctacnac	tctttactct	ctgganaggg	ccagtgggtg	tagctataag	cttggccaca	300
tttttttttc	ctttattcct	ttgtcaga				328

<210> 213

<211> 250

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(250)

<223> n = A,T,C or G

<400> 213

acttatgagc	agagcgacat	atccnagtgt	agactgaata	aaactgaatt	ctctccagtt	60
taaagcattg	ctcactgaag	ggatagaagt	gactgccagg	agggaaagta	agccaaggct	120
cattatgccca	aagganatat	acatttcaat	tctccaaact	tcttcctcat	tccaagagtt	180
ttcaatattt	gcatgaacct	gctgataanc	catgttaana	aacaaatata	tctctnacct	240
tctcatcggt						250

<210> 214

<211> 444

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(444)

<223> n = A,T,C or G

<400> 214

accagaatc	caatgctgaa	tatttggtt	cattattccc	agattctttg	attgtcaaag	60
gatttaatgt	tgtctcagct	tgggcacttc	agttaggacc	taaggatgcc	agccggcagg	120
tttatatatg	cagcaacaat	attcaagcgc	gacaacagg	tattgaactt	gcccgccagt	180
tgaatttcat	tccatttgac	ttgggatcct	tatcatcagc	canagagatt	gaaaatttac	240
ccctacgact	ctttactctc	tggagagggc	cagtgggtgt	agctataagc	ttggccacat	300
ttttttttcc	ttttattcctt	tgtcagagat	gcgattcatc	catatgctan	aaaccaacag	360
agtgactttt	acaaaattcc	tataganatt	gtgaataaaa	ccttacctat	agttgccatt	420
actttgctct	ccctaataata	cctc				444

<210> 215

<211> 366

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(366)

<223> n = A,T,C or G

<400> 215
 aattatgagc agagcgacat atccaagtgt anactgaata aaactgaatt ctctccagtt 60
 *aaagcattg ctactgaag ggatagaagt gactgccagg agggaaagta agccaaggct 120
 cattatgcca aagganatat acatttcaat tctccaaact tcttctcat tccaagagtt 180
 tccaatattt gcatgaacct gctgataagc catgttgaga aacaaatato tctctgacct 240
 tctatagggt aagcagaggc tgtaggcaac atggaccata gcgaanaaaa aacttagtaa 300
 tccaagctgt tttctacaat gtaaccaggt ttccaaccaa ggtggaaato tctataactt 360
 ggaggc 366

<210> 216
 <211> 260
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(260)
 <223> n = A,T,C or G

<400> 216
 ctgtataaac agaactccac tgcangaggg agggccgggc caggagaatc tccgcttgtc 60
 caagacaggg gctaaggag ggtctccaca ctgctnntaa ggcctnttnc atttttttat 120
 taataaaaag tnaaaaaggc ctcttctcaa cttttttccc ttnggctgga aaatttataa 180
 atcaaaaatt tctnaagtt ntcaagctat catatatact ntatcctgaa aaagcaacat 240
 aatttctctt tccctctttt 260

<210> 217
 <211> 262
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(262)
 <223> n = A,T,C or G

<400> 217
 acctacgtgg gtaagtttan aaatgttata atttcaggaa naggaacgca tataattgta 60
 tcttgccat aattttctat ttaataagg aaatagcaaa ttgggggtggg gggaatgtag 120
 ggcattctac agtttgagca aaatgcaatt aaatgtggaa ggacagcact gaaaaatttt 180
 atgaataatc tgtatgatta tatgtctcta gagtagattt ataattagcc acttaccccta 240
 atatecttca tgcttgtaaa gt 262

<210> 218
 <211> 205
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(205)
 <223> n = A,T,C or G

<400> 218
 accaaggtgg tgcattaccg gaantggatc aangacacca tegtggccaa cccctgagca 60
 cccctatcaa ctcccttttg tagtaaaactt ggaaccttgg aaatgaccag gccaaagactc 120
 aggcctcccc agttctactg acctttgtcc ttangnttna ngtccagggg tgctaggaaa 180
 anaaatcagc agacacaggt gtaaa 205

<210> 219
 <211> 114
 <212> DNA
 <213> Homo sapien

<400> 219
 tactgttttg tctcagtaac aataaataca aaaagactgg ttgtgttccg gccccatcca 60
 accacgaagt tgattttctct tgtgtgcaga gtgactgatt ttaaaggaca tgga 114

<210> 220
 <211> 93
 <212> DNA
 <213> Homo sapien

<400> 220
 actagccagc acaaaaggca gggtagcctg aattgctttc tgctctttac atttctttta 60
 aaataagcat ttagtgctca gtcctactg agt 93

<210> 221
 <211> 167
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(167)
 <223> n = A,T,C or G

<400> 221
 actangtgca ggtgcgcaca aatatttgct gatattccct tcatcttgga ttccatgagg 60
 tcttttgccc agcctgtggc tctactgtag taagtttctg ctgatgagga gccagnatgc 120
 cccccactac cttccctgac gctcccccana aatcaccacaa cctctgt 167

<210> 222
 <211> 351
 <212> DNA
 <213> Homo sapien

<400> 222
 agggcggtggt gcggagggcg gtactgacct cattagtagg aggatgcatt ctggcacccc 60
 gttcttcacc tgtcccccaa tcottaaaag gccatactgc ataaagtcaa caacagataa 120
 atgtttgctg aattaaagga tggatgaaaa aaattaataa tgaatttttg cataatccaa 180
 ttttctcttt tatatttcta gaagaagttt ctttgagcct attagatccc gggaatcttt 240
 taggtgagca tgattagaga gcttgtaggt tgcttttaca tatatctggc atatttgagt 300
 ctcgatatcaa aacaatagat tggtaaagggt ggtattattg tattgataag t 351

<210> 223
 <211> 383
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(383)
 <223> n = A,T,C or G

<400> 223

```

aaaaaaca aacaaaaaa acaattcttc attcagaaaa attatcttag ggactgatat      60
tggtaattat ggtcaattta atwrtttkt ggggcatttc cttacattgt cttgacaaga      120
ttaaaatgtc tgtgcaaaaa ttttgtattt tatttggaga cttcttatca aaagtaatgc      180
tgcaaaagga agtctaagga attagtagtg ttcccmccac ttgtttggag tgtgctattc      240
taaaagattt tgatttcctg gaatgacaat tatattttta ctttgggtgg ggaaanagtt      300
ataggaccac agtccttcact tctgatactt gtaaattaat cttttattgc acttgttttg      360
accattaagc tatatgttta aaa                                     383

```

<210> 224

<211> 320

<212> DNA

<213> Homo sapien

<400> 224

```

ccccgaagg cttcttggtta gaaaatagta cagttacaac caataggaac aacaaaaaga      60
aaaagtttgt gacattgtag tagggagtgt gtacccctta ctcccatca aaaaaaaat      120
ggatacatgg ttaaaggata raagggcaat attttatcat atgttctaaa agagaaggaa      180
gagaaaatac tactttctcr aaatggaagc ccttaaagggt gctttgatac tgaaggacac      240
aaatgtggcc gtccatcctc ctttaragtt gcatgacttg gacacggtaa ctgttgacgt      300
tttaractcm gcattgtgac                                     320

```

<210> 225

<211> 1214

<212> DNA

<213> Homo sapien

<400> 225

```

gaggactgca gcccgcactc gcagcccttg caggcggcac tggtcattga aaacgaattg      60
ttctgctcgg gcgtcctggt gcateccgag tgggtgctgt cagccgcaca ctgtttccag      120
aactcctaca ccacggggtt gggcctgcac agtcttgagg ccgaccaaga gccaggggagc      180
cagatgggtg aggccagcct ctccgtacgg caccagagat acaacagacc cttgctcgt      240
aacgacctca tgetcatcaa gttggacgaa tccgtgtccg agtctgacac catccggagc      300
atcagcattg cttcgagtg gcctaccgag gggaactctt gctcgtttc ttgctgggggt      360
ctgctggcga acggcagaat gcctaccgtg ctgcagtgcg tgaacgtgtc ggtggtgtct      420
gaggaggtct gcagtaagct ctatgacccg ctgtaccacc ccagcatgtt ctgcgcgggc      480
ggaggggcaag accagaagga ctcttgcaac ggtgactctg gggggccctt gatctgcaac      540
gggtacttgc agggccttgt gtctttcgga aaagccctgt gtggccaagt tggcgtgcca      600
ggtgtctaca ccaacctctg caaattcact gagtggatag agaaaaccgt ccaggccagt      660
taactctggg gactgggaac ccattgaaatt gacccccaaa tacatcctgc ggaaggaatt      720
caggaatate tgttcccagc cctcctctcc tcaggcccag gagtccaggc cccagcccc      780
tctcctca aaccaagggt acagatcccc agccctcct cctcagacc caggagtcca      840
gacccccag cccctcctcc ctccagacca ggagtcagc cctcctctcc tcagaccag      900
gagtccagac cccccagccc ctctcctc agaccagggt gtcaggccc ccaaccctc      960
ctcctcaga ctccagaggt caagccccc accctcctt cccagaccc agaggtccag      1020
gtcccagccc ctctcctc agaccagcg gtccaatgcc acctagacte tccctgtaca      1080
cagtgcctcc ttgtggcacg ttgacccaac cttaccagtt ggtttttcat tttttgtccc      1140
tttcccttag atccagaaat aaagtctaag agaagcgcaa aaaaaaaaaa aaaaaaaaaa      1200
aaaaaaaaaa aaaa                                     1214

```

<210> 226

<211> 119

<212> DNA

<213> Homo sapien

<400> 226

```

accagtatg tgcagggaga cggaacccca tgtgacagcc cactccacca gggttcccaa      60
agaacctggc ccagtcataa tcattcatcc tgacagtggc aataatcacg ataaccagt      119

```

<210> 227
 <211> 818
 <212> DNA
 <213> Homo sapien

<400> 227
 acaattcata gggacgacca atgaggacag ggaatgaacc cggctctccc ccagccctga 60
 tttttgctac atatggggtc ctttttcatt ctttgcaaaa acactgggtt ttctgagaac 120
 acggacgggt cttagcaciaa tttgtgaaat ctgtgtaraa ccgggctttg caggggagat 180
 aattttcctc ctctggagga aagggtggtga ttgacaggca gggagacagt gacaaggcta 240
 gagaaagcca cgctcggcct tctctgaaac aggatggaac ggcagacccc tgaaaacgaa 300
 gcttggtccc ttccaatcag ccaacttctga gaacccccat ctaacttcct actggaaaag 360
 agggcctcct caggagcagt ccaagagttt tcaaagataa cgtgacaact accatctaga 420
 ggaaaggggtg caccctcagc agagaagccg agagcttaac tctggtcggt tccagagaca 480
 acctgctggc tgtcttgagg tgcccagc ctttgagagg ccactacccc atgaacttct 540
 gccatccact ggacatgaag ctgaggacac tgggcttcaa cactgagttg tcatgagagg 600
 gacaggctct gccctcaagc cggctgaggg cagcaaccac tctcctcccc ttctcagcgc 660
 aaagccattc ccacaaatcc agaccatacc atgaagcaac gagacccaaa cagtttggct 720
 caagaggata tgaggactgt ctacgcctgg ctttgggctg acaccatgca cacacacaag 780
 gtccacttct aggttttctag cctagatggg agtcgtgt 818

<210> 228
 <211> 744
 <212> DNA
 <213> Homo sapien

<400> 228
 actggagaca ctggtgaact tgatcaagac ccagaccacc ccaggctctcc ttctgtggat 60
 gtcattgacgt ttgacatacc tttggaacga gcctcctcct tggagatgg aagaccgtgt 120
 tcgtggccga cctggcctct cctggcctgt ttcttaagat gggagtcac atttcaatgg 180
 taggaaaagt ggcttcgtaa aatagaagag cagtcactgt ggaactacca aatggcgaga 240
 tgctcgggtc acattggggg gctttgggat aaaagattta tgagccaact attctctggc 300
 accagattct aggccagttt gttccactga agcttttccc acagcagtc accctctgag 360
 gctggcagct gaatggcttg ccggtggctc tgtggcaaga tcacactgag atcgatgggt 420
 gagaaggcta ggatgcttgt ctagtgttct tagctgtcac gttggctcct tccaggttg 480
 ccagacgggtg ttggccaact cttctaaaaa cacaggcgcc ctctgggtga cagtgaccgc 540
 ccgtgggtatg ccttggccca ttccagcagt ccaggttatg catttcaagt ttgggggttg 600
 ttcttttctg taatgttctt ctgtgttgct agctgtcttc atttctggg ctaagcagca 660
 ttggggagatg tggaccagag atccactcct taagaaccag tggcgaaaga cactttcttt 720
 cttcactctg aagtagctgg tgggt 744

<210> 229
 <211> 300
 <212> DNA
 <213> Homo sapien

<400> 229
 cgagtctggg ttttgtctat aaagtttgat ccctcctttt ctcatccaaa tcatgtgaac 60
 cattacacat cgaaataaaa gaaaggtggc agacttgccc aacgccaggc tgacatgtgc 120
 tgcagggttg ttgtttttta attattattg ttagaaacgt caccacagct ccctgttaat 180
 ttgtatgtga cagccaactc tgagaaggtc ctatttttcc acctgcagag gatccagctc 240
 cactaggctc ctcttggccc tcacactgga gtctccgcca gtgtgggtgc ccactgacat 300

<210> 230
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 230

cagcagaaca aatacaata tgaagagtgc aaagatctca taaaatctat gctgaggaat	60
gagcgacagt tcaaggagga gaagcttgca gagcagctca agcaagctga ggagctcagg	120
aaatataaag tcttggttca cactcaggaa cgagagctga cccagttaag ggagaagttg	180
cggaagggga gagatgcctc cctctcattg aatgagcctc tccaggccct cctcactccg	240
gatgaaccgg acaagtccca ggggcaggac ctccaagaaa cagacctogg ccgcgaccac	300
g	301

<210> 231

<211> 301

<212> DNA

<213> Homo sapien

<400> 231

gcaagcacgc tggcaaactct ctgtcaggtc agctccagag aagccattag tcatttttagc	60
caggaactcc aagtcacat ccttggaac tggggacttg cgcaggttag ccttgaggat	120
ggcaacacgg gacttctcat caggaagtgg gatgtagatg agctgatcaa gacggccagg	180
tctgaggatg gcaggatcaa tgatgtcagg ccggttggtta ccgccaatga tgaacacatt	240
ttttttgtg gacatgccat ccatttctgt caggatctgg ttgatgactc ggtcagcagc	300
c	301

<210> 232

<211> 301

<212> DNA

<213> Homo sapien

<400> 232

agtaggtatt tcgtgagaag ttcaacacca aaactggaac atagttctcc ttcaagtgtt	60
ggcgacagcg gggcttcttg attctggaat ataactttgt gtaaattaac agccacctat	120
agaagagtcc atctgctgtg aaggagagac agagaactct gggttccgtc gtctgtcca	180
cgtgctgtac caagtgttg tgccagcctg ttacctgttc tctgtaaaa tctggctaatt	240
gctcttgtgt atcacttctg attctgacaa tcaatcaatc aatggcctag agcactgact	300
g	301

<210> 233

<211> 301

<212> DNA

<213> Homo sapien

<400> 233

atgactgact tccagtaag gctctctaag gggtaagtag gaggatccac aggatttgag	60
atgctaaggc cccagagatc gtttgatcca accctcttat ttccagaggg gaaaatgggg	120
cctagaagtt acagagcctc tagctgggtc gctggcacc ctaggctcac acagactccc	180
gagtagctgg gactacaggc acacagtcac tgaagcaggc cctgttagca attctatgcg	240
tacaaattaa catgagatga gtagagactt tattgagaaa gcaagagaaa atcctatcaa	300
c	301

<210> 234

<211> 301

<212> DNA

<213> Homo sapien

<400> 234

aggcctaca catcgagact catccatgat tgatatgaat ttaaaaatta caagcaaaga	60
cattttatcc atcatgatgc tttcttttgt ttctcttttt cgttttcttc tttttctttt	120
tcaatttcag caacatactt ctcaatttct tcaggattta aaatcttgag ggattgatct	180
ggcctcatga cagcaagttc aatgtttttg ccacctgact gaaccacttc caggagtgcc	240
ctgatcacca gcttaatggg cagatcatct gcttcaatgg ctctgtcagt atagttcttc	300

t 301

<210> 235
 <211> 283
 <212> DNA
 <213> Homo sapien

<400> 235
 tggggctgtg catcaggcgg gtttgagaaa tattcaattc tcagcagaag ccagaatttg 60
 aattccctca tcttttaggg aatcatttac caggtttgga gaggattcag acagctcagg 120
 tgctttcact aatgtctctg aacttctgtc cctctttgtt catggatagt ccaataaata 180
 atgttatctt tgaactgatg ctcataggag agaataaag aactctgagt gatatcaaca 240
 ttagggattc aaagaaatat tagatttaag ctcacactgg tca 283

<210> 236
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 236
 aggtcctcca ccaactgcct gaagcacggt taaaattggg aagaagtata gtgcagcata 60
 aatactttta aatcgatcag atttccttaa cccacatgca atcttcttca ccagaagagg 120
 tcggagcagc atcataata ccaagcagaa tgcgtaatag ataaatacaa tggatatatag 180
 tgggtagacg gcttcatgag tacagtgtac tgtggatcgc taatctggac ttgggttgta 240
 aagcatcgtg taccagtcag aaagcatcaa tactcgacat gaacgaatat aaagaacacc 300
 a 301

<210> 237
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 237
 cagtggtagt ggtgggtggac gtggcggttg tcgtgggtgcc ttttttggtg cccgtcacaa 60
 actcaatttt tggtcgctcc tttttggcct tttccaattt gtccatctca attttctggg 120
 ccttggctaa tgctcatag taggagtcct cagaccagcc atggggatca aacatatcct 180
 ttgggtagt ttgtgccaagc tcgtcaatgg cacagaatgg atcagcttct cgtaaatacta 240
 gggttccgaa attctttctt cctttggata atgtagttca tatccattcc ctcttttctc 300
 t 301

<210> 238
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 238
 gggcagggtt tttttttttt ttttttgatg gtgcagaccc ttgctttatt tgtctgactt 60
 gttcacagtt cagccccctg ctcagaaaac caacgggcca gctaaggaga ggaggaggca 120
 ccttgagact tccggagtcg aggctctcca gggttcccca gcccatcaat ctttttctgc 180
 accccctgcc tgggaagcag ctccctgggg ggtgggaatg ggtgactaga agggatttca 240
 gtgtgggacc cagggtctgt tcttcacagt aggaggtgga agggatgact aatttcttta 300
 t 301

<210> 239
 <211> 239
 <212> DNA
 <213> Homo sapien

<400> 239

ataagcagct aggggaattct ttatttagta atgtcctaac ataaaagtgc acataactgc	60
ttctgtcaaa ccatgatact gagctttgtg acaaccaga aataactaag agaaggcaaa	120
atagacacct tagagatcaa gaaacattta cacagttcaa ctgtttaaaa atagctcaac	180
attcagccag tgagtagagt gtgaatgccg gcatacacag tatacaggtc cttcaggga	239

<210> 240

<211> 300

<212> DNA

<213> Homo sapien

<400> 240

ggtcctaagt aagcagcagc ttccacattt taacgcaggt ttacgggtgat actgtccttt	60
gggatctgcc ctccagtggg accttttaag gaagaagtgg gcccagcta agttccacat	120
gctgggtgag ccagatgact tctgttcctt ggtaactttt tcaatgggg cgaatggggg	180
ctgccaggtt tttaaaatca tgcttcactt tgaagcacac ggtaacttca cctcctcac	240
gctgtgggtg tactttgatg aaaataccca ctttgttggc ctttctgaag ctataatgtc	300

<210> 241

<211> 301

<212> DNA

<213> Homo sapien

<400> 241

gaggctctggt gctgaggtct ctgggctagg aagaggagtt ctgtggagct ggaagccaga	60
cctcttttga ggaaactcca gcagctatgt tgggtgtctt gagggaatgc aacaaggctg	120
ctcctccatg tattggaaaa ctgcaaaactg gactcaactg gaaggagtg ctgctgccag	180
tgtgaagaac cagcctgagg tgacagaaac ggaagcaaac aggaacagcc agtcttttct	240
tctcctcct gtcatacggg ctctctcaag catcctttgt tgtcaggggc ctaaaaggga	300
g	301

<210> 242

<211> 301

<212> DNA

<213> Homo sapien

<400> 242

ccgaggctct gggatgcaac caatcactct gtttcacgtg acttttatca ccatacaatt	60
tgtggcattt cctcattttc tacattgtag aatcaagagt gtaataaat gtatatcgat	120
gtcttcaaga atatatcatt cttttttcac tagaaccat tcaaaatata agtcaagaat	180
cttaatatca acaaatatat caagcaaaact ggaaggcaga ataactacca taatttagta	240
taagtaccca aagttttata aatcaaaagc cctaatagata accattttta gaattcaatc	300
a	301

<210> 243

<211> 301

<212> DNA

<213> Homo sapien

<400> 243

aggtaagtcc cagtttgaag ctcaaaagat ctgggtatgag cataggctca tcgacgacat	60
ggtggcccaa gctatgaaat cagagggagg ctctcatctg gctgtaaaa actatgatgg	120
tgacgtgcag tcggactctg tggcccaagg gtatggctct ctggcatga tgaccagct	180
gctgatttgt ccagatggca agacagtaga agcagaggct gccacggga ctgtaaccg	240
tcactaccgc atgttcaga aaggacagga gacgtccacc aatccattg cttccatttt	300
t	301

<210> 244

<211> 300
 <212> DNA
 <213> Homo sapien

<400> 244
 gctgggtttgc aagaatgaaa tgaatgattc tacagctagg acttaacott gaaatggaaa 60
 gtcattgcaat ccattttgca ggatctgtct gtgcacatgc ctctgtagag agcagcattc 120
 ccagggacct tggaaacagt tgacactgta aggtgcttgc tccccaaagac acatcctaaa 180
 aggtgttgta atgggtgaaaa cgtcttcott ctttattgcc cttctttatt tatgtgaaca 240
 actgtttgtc ttttgtgtat cttttttaaa ctgttaaagt caattgtgaa aatgaatatc 300

<210> 245
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 245
 gtctgagtat ttaaaatggt attgaaatta tccccacca atgttagaaa agaaagaggt 60
 tatatactta gataaaaaat gaggtgaatt actatccatt gaaatcatgc tcttagaatt 120
 aaggccagga gatattgtca ttaatgtara cttcaggaca ctagagtata gcagccctat 180
 gttttcaaag agcagagatg caattaaata ttgttttagca tcaaaaaggc cactcaatac 240
 agctaataaa atgaaagacc taattttctaa agcaattctt tataatttac aaagtittaa 300
 g 301

<210> 246
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 246
 ggtctgtcct acaatgcctg cttcttgaaa gaagtcggca ctttctagaa tagctaaata 60
 acctgggctt attttaaaga actatttgta gtcagattg gttttcctat ggctaaaata 120
 agtgcttctt gtgaaaatta aataaaacag ttaattcaaa gccttgatat atgttaccac 180
 taacaatcat actaaatata ttttgaagta caaagtttga catgctctaa agtgacaacc 240
 caaatgtgtc ttacaaaaca cgttcctaac aagggtatgt ttacactacc aatgcagaaa 300
 c 301

<210> 247
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 247
 aggtcctttg gcagggtcga tggatcagag ctcaaactgg agggaaaggc atttcgggta 60
 gcctaagagg gcgactggcg gcagcacaac caaggaaggc aagggtgttt cccccaagct 120
 gtgtcctgtg ttcagggtcg acacacaatc ctcatgggaa caggatcacc catgcgctgc 180
 ccttgatgat caaggttggg gcttaagtgg attaaggag gcaagttctg gggtccttgc 240
 cttttcaaac catgaagtca ggctctgtat ccctcctttt cctaactgat attctaacta 300
 a 301

<210> 248
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 248
 aggtccttgg agatgccatt tcagccgaag gactottctw ttcggaagta caccctcaact 60
 attaggaaga ttcttagggg taatttttct gaggaaggag aactagccaa ctttaagaatt 120

acagggaagaa agtgggtttgg aagacagcca aagaaataaa agcagattaa attgtatcag 180
 glacattcca gctgtttggc aactccataa aaacatttca gattttaatc ccgaatttag 240
 ctaatpagac tggatttttg ttttttatgt tgtgtgtgc agagctaaaa actcagttcc 300
 c 301

<210> 249

<211> 301

<212> DNA

<213> Homo sapien

<400> 249

gcccagagga agcacctggt gotgaactag gcttgccctg ctgtgaactt gcacttgag 60
 cctgacqct gctgttctcc ccgaaaaacc cgaccgacct ccgcatctc cgtcccgccc 120
 ccaggagagc acagcagtga ctacagagctg gtgcgacact gtgcctccct cctcacggcc 180
 catcgtaatg atttattttg aaaattaatt ccaccatcct ttcagattct ggatggaaag 240
 actgaatctt tgaatcagaa ttgtttgctg aaaagaatga tgtgacttcc ttagtcattt 300
 a 301

<210> 250

<211> 301

<212> DNA

<213> Homo sapien

<400> 250

ggctctgtgac aaagcacttgc aggcctgtggg aggcaagtga cccctaacac tacacttctc 60
 cttatcttta ttggcttgat aaacataatt atttctaaca ctacgttatt tccagttgcc 120
 cataagcaca tcaatctctt tctctggctg gaatagtaaa ctaaaagtatg gtacatctac 180
 ctaaaagact actatgtgga ataatacata ctaatgaagt attacatgat ttaaagacta 240
 caataaaacc aaacatgctt ataacattaa gaaaaacaat aaagatacat gattgaaacc 300
 a 301

<210> 251

<211> 301

<212> DNA

<213> Homo sapien

<400> 251

gcagaggtcc tacatttggc ccagtttccc cctgcaccc ctccaggggc cctgcctcat 60
 agacaacctc atagagcata ggagaactgg ttgccctggg ggcaggggga ctgtctggat 120
 ggcaggggtc ctcaaaaatg ccactgtcac tgccaggaaa tgcttctgag cagtacacct 180
 cattgggac aatgaaaagc ttcaagaaat cttcaggctc actctcttga aggccggaa 240
 cctctggagg ggggcagtgg aatcccagct ccaggacgga tctgtctgaa aagatatcct 300
 c 301

<210> 252

<211> 301

<212> DNA

<213> Homo sapien

<400> 252

gcaaccaatc actcigtctt acgtgacttt tatcaccata caatttgtgg catttctca 60
 ttttctacat tgtagaatca agagtgtaaa taaatgtata tcgatgtctt caagaatata 120
 tcatctcttt ttcactagga acccattcaa aatataagtc aagaatctta atatcaacaa 180
 atatatcaag caaactggaa ggcagaataa ctaccataat ttagtataag taccacaaagt 240
 ttataaaatc aaaagcccta atgataacca tttttagaat tcaatcatca ctgtagaatc 300
 a 301

<210> 253

<211> 301
 <212> DNA
 <213> Homo sapien

<400> 253
 ttccctaaga agatgttatt ttgttgggtt ttgttccccc tccatctcga ttctcgtacc 60
 caactaaaaa aaaaaaataa agaaaaaatg tgctgcgttc tgaaaaataa ctcccttagct 120
 tggctcgatt gttttcagac cttaaaatat aaacttggtt cacaagcttt aatccatgtg 180
 gatttttttt cttagagaac cacaaaacat aaaaggagca agtcggactg aatacctgtt 240
 tccatagtgc ccacagggtg ttctcacat tttctccata ggaaaatgct ttttcccaag 300
 g 301

<210> 254
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 254
 cgctgcgcct ttcccttggg ggaggggcaa ggccagaggg ggtccaagtg cagcacgagg 60
 aacttgacca attcccttga agcgggtggg ttaaaccctg taaatgggaa caaaatcccc 120
 ccaaactctct tcatcttacc ctggtggact cctgactgta gaattttttg gttgaaacaa 180
 gaaaaaaata agccttttga cttttcaagg ttgcttaaca ggtactgaaa gactggcctc 240
 acttaaaactg agccaggaaa agctgcagat ttattaatgg gtgtgttagt gtgcagtgcc 300
 t 301

<210> 255
 <211> 302
 <212> DNA
 <213> Homo sapien

<400> 255
 agcttttttt tttttttttt tttttttttt ttcattaaaa aatagtgtct tttattataa 60
 attactgaaa tgtttctttt ctgaatataa atataaatat gtgcaaagtt tgacttggat 120
 tgggattttg ttgagttctt caagcatctc ctaataccct caagggcctg agtagggggg 180
 aggaaaaagg actggagggt gaatctttat aaaaaacaag agtgattgag gcagattgta 240
 aacattatta aaaaacaaga aacaaacaaa aaaatagaga aaaaaaccac cccaacacac 300
 aa 302

<210> 256
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 256
 gttccagaaa acattgaagg tggtttccca aagtctaaact agggataccc cctctagcct 60
 aggaccctcc tccccacacc tcaatccacc aaaccatcca taatgcaccc agataggccc 120
 acccccataa gcttgacac cttgagcaca cagttatgac caggacagac tcatctctat 180
 aggcaaatag ctgctggcaa actggcatta cctggtttgt ggggatgggg gggcaagtgt 240
 gtggcctctc ggcttggtta gcaagaacat tcagggtagg cctaagttan tcgtgttagt 300
 t 301

<210> 257
 <211> 301

<212> DNA

<213> Homo sapien

<400> 257

```

gttgtggagg aactctggct tgctcattaa gtctactga ttttcaactat cccctgaatt      60
tcccacactta tttttgtctt tcaactatcgc aggccttaga agaggtctac ctgcctccag      120
tcttaacctag tccagtcctac cccctggagt tagaatggcc atcctgaagt gaaaagtaat      180
gtcacattac tcccttcagt gatttcttgt agaagtgcc atccctgaat gccaccaaga      240
tcttaatctt cacatcttta atcttatctc ttgtactcct ctttacaccg gagaaggctc      300
c                                          301

```

<210> 258

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 258

```

cagcagtagt agatgccgta tgccagcacg cccagcactc ccaggatcag caccagcacc      60
agggggcccag ccaccaggcg cagaagcaag ataaacagta ggctcaagac cagagccacc      120
cccagggcaa caagaatcca ataccaggac tgggcaaaat cttcaaagat cttaacactg      180
atgtctcggg cattgaggct gtcaataana cgctgatccc ctgctgtatg gtggtgtcat      240
tgggtgatccc tgggagcgcc ggtggagtaa cgttgggtcca tggaaagcag cgcccacaac      300
t                                          301

```

<210> 259

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 259

```

tcatatatgc aaacaaatgc agactangcc tcaggcagag actaaaggac atctcttggg      60
gtgtcctgaa gtgatttggg cccctgaggg cagacaccta agtaggaatc ccagtgggaa      120
gcaaagccat aaggaagccc aggattcctt gtgatcagga agtgggcccag gaaggtctgt      180
tccagctcac atctcatctg catgcagcac ggaccggatg cgccactgg gtcttggctt      240
ccctcccac tctcaagca gtgtccttgt tgagccattt gcatecttgg ctccagggtg      300
c                                          301

```

<210> 260

<211> 301

<212> DNA

<213> Homo sapien

<400> 260

```

tttttttct ccctaaggaa aaagaaggaa caagtctcat aaaaccaa atagcaatggt      60
aaggtgtctt aacttgaaaa agattaggag tcaactggttt acaagttata attgaatgaa      120
agaactgtaa cagccacagt tggccatttc atgccaatgg cagcaaacaa caggattaac      180
tagggcaaaa taaataagtg tgtggaagcc ctgataagtg cttaataaac agactgattc      240
actgagacat cagtacctgc ccgggcggcc gctcgagccg aattctgcag atatccatca      300

```

c

301

<210> 261
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 261
 aaatattcga gcaaactctg taactaatgt gtctccataa aaggctttga actcagtga 60
 tctgcttcca tccacgattc tagcaatgac ctctcggaca tcaaagctcc tcttaagggt 120
 agcaccaact attccataca attcatcagc aggaaataaa ggctcttcag aaggttcaat 180
 ggtgacatcc aatttcttct gataatttag attcctcaca accttcctag ttaagtgaag 240
 ggcattgatga tcatccaaag cccagtggtc acttactcca gactttctgc aatgaagatc 300
 a 301

<210> 262
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 262
 gaggagagcc tggtacagca tttgtaagca cagaatactc caggagtatt tgtaattgtc 60
 tgtgagcttc ttgccgcaag tctctcagaa atttaaaaag atgcaaatcc ctgagtcacc 120
 cctagacttc ctaaaccaga tcctctgggg ctggaacctg gcactctgca tttgtaatga 180
 gggctttctg gtgcacacct aattttgtgc atctttgccc taaatcctgg attagtgcc 240
 catcattacc cccacattat aatgggatag attcagagca gatactctcc agcaaagaat 300
 c 301

<210> 263
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 263
 tttagcttgt ggtaaattgac tcacaaaact gattttaaaa tcaagttaat gtgaattttg 60
 aaaattacta cttaattcta attcacaata acaatggcat taaggtttga cttgagttgg 120
 ttcttagtat tatttatggg aaataggctc ttaccacttg caaataactg gccacatcat 180
 taatgactga ctcccagta aggctctcta aggggtaagt angaggatcc acaggatttg 240
 agatgctaag gccccagaga tcgtttgatc caaccctctt attttcagag gggaaaatgg 300
 g 301

<210> 264
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 264
 aaagacgtta aaccactcta ctaccacttg tggaactctc aaagggtaaa tgacaaascc 60
 aatgaatgac tctaaaaaca atatttacat ttaatggttt gtagacaata aaaaaacaag 120
 gtggatagat ctagaattgt aacattttta gaaaaccata scatttgaca gatgagaaag 180
 ctcaattata gatgcaaagt tataactaaa ctactatagt agtaaagaaa tacatttcac 240
 acccttcata taaattcact atcttggcct gaggcactcc ataaaatgta tcacgtgcat 300
 a 301

<210> 265
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 265
 tgcacaagtt atgtgtaagt gtatccgcac ccagaggtaa aactacactg tcattctttgt 60
 cttcttctga cgcagtatct cttctctggg gagaagccgg gaagtcttct cctggctcta 120
 catattcttg gaagtctcta atcaactttt gtccatttg tttcatttct tcaggaggga 180
 ttttcagttt gtcaacatgt tctctaaca cacttgcca tttctgtaa gaatccaaag 240
 caatccaagg ctttgacatg tcaacaacca gcataactag agtatccttc agagatacgg 300
 c 301

<210> 266
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 266
 taccgtctgc ccttctctcc atccaggcca tctggaatc tacatgggtc ctcctattcg 60
 acaccagatc actctttcct ctaccacag gcttgctatg agcaagagac acaacctcct 120
 cttctctgtg ttccagcttc ttttctgtt cttccacccc ctttaagttct attcctgggg 180
 atagagacac caatacccat aacctctctc ctaagcctcc ttataaccca ggggtgcacag 240
 cacagactcc tgacaactgg taaggccaat gaactgggag ctcacagctg gctgtgctg 300
 a 301

<210> 267
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 267
 aaagagcaca ggccagctca gctgcccctg gccatctaga ctcagcctgg ctccatgggg 60
 gtctctcagt ctgagtcctt ccaggaaaag ctcacctaga cttcttgagg ctgaatcttc 120
 atcctcagag gcagcttctg agagcctgat attcctagcc ttgatggctc ggagtaaagc 180
 ctcaattctga ttctctctct tcttttcttt caagttggtt ttctcaccat cctctgttc 240
 aattcgttc agcttgtctg ctttagccct catttcaga agcttcttct ctttggcacc 300
 t 301

<210> 268
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 268
 aatgtctcac tcaactactt cccagcctac cgtggcctaa ttctgggagt tttcttctta 60
 gatcttggga gagctgggtc ttctaaggag aaggaggaag gacagatgta actttggatc 120
 tcgaagagga agtctaattg aagtaattag tcaacggctc ttgttttagac tcttgggaata 180
 tgetgggtgg ctcaagtggc ctttttgag aaagcaagta ttattcttaa ggagtaacca 240
 cttcccattg ttctactttc taccatcacc aattgtatat tatgtattct ttggagaact 300
 a 301

<210> 269
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 269
 taacaatata cactagctat ctttttaact gtccatcatt agcaccaatg aagattcaat 60
 aaaattacct ttattcacac atctcaaaac aattctgcaa attcttagtg aagtttaact 120
 atagtcacag accttaaata ttcacattgt tttctatgtc tactgaaaat aagttcacta 180
 cttttctgga tattctttac aaaatcttat taaaattcct ggtattatca cccccaatta 240
 tacagtagca caaccacctt atgtagtttt tacatgatag ctctgtagaa gtttcacatc 300
 t 301

<210> 270
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 270
 cattgaagag cttttgcgaa acatcagaac acaagtgcctt ataaaattaa ttaagcctta 60
 cacaagaata catattcctt ttattttctaa ggagttaaac atagatgtag ctgatgtgga 120
 gagcttgctg gtgcagtgc tattggataa cactattcat ggccgaattg atcaagtcaa 180
 ccaactcctt gaactggatc atcagaagaa ggggtgtgca cgatatactg cactagataa 240
 tggaccaacc aactaaattc tctcaccagg ctgtatcagt aaactggcctt aacagaaaac 300
 a 301

<210> 271
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 271
 aaaaggttct cataagatta acaatttaaa taaatatttg atagaacatt ctttctcatt 60
 tttatagctc atcttttagg ttgatattca gttcatgctt cccttgctgt tcttgatcca 120
 gaattgcaat cacttcatca gcctgtattc gctccaattc tctataaagt gggccaagg 180
 tgaaccacag agccacagca cacctctttc ccttggtgac tgccttcacc ccatganggt 240
 tctctcctcc agatganaac tgatcatgag ccacattttt ggggtttata gaagcagtca 300
 c 301

<210> 272
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 272
 taaattgcta agccacagat aacaccaatc aaatggaaca aatcactgtc ttcaaatgtc 60
 ttatcagaaa accaaatgag cctggaatct tcataatacc taaacatgcc gtatttagga 120
 tccaataatt ccctcatgat gagcaagaaa aattctttgc gcacccctcc tgcattccaca 180
 gcatcttctc caacaaatat aaccttgagt ggcttcttgt aatctatgtt ctttgttttc 240
 ctaaggactt ccattgcate tcctacaata ttttctctac gcaccactag aattaagcag 300
 g 301

<210> 273
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 273
 acatgtgtgt atgtgtatct ttgggaaaaan aanaagacat cttgtttayt attttttttgg 60
 agagangctg ggacatggat aatcacwtaa tttgctayta tyactttaat ctgactygaa 120
 gaacogtcta aaaaataaaat ttaaccatgct dtatatctct tatagtatgc ttatttcacc 180
 ttytttctgt ccagagagag tatcagtgac ananatttma ggggtgaamac atgmattggg 240
 gggaattnty tttacngagm accctgcccg sgcgccctcg makengantt ccgcsananc 300
 t 301

<210> 274
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 274
 ctatataact ctttctcaga ggcaaaagag gagatgggta atgtagacaa ttcttttgagg 60
 aacagtaaat gattattaga gagaangaat ggaccaagga gacagaaatt aacttgtaaa 120
 tgattctctt tggaatctga atgagatcaa gaggccagct ttagcttggt gaaaagtcca 180
 tctaggtatg gttgcattct cgtcttcttt tctgcagtag ataatgaggt aaccgaaggc 240
 aattgtgctt cttttgataa gaagctttct tggatcatatc aggaaattcc aganaaagtc 300
 c 301

<210> 275
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 275
 tgggtgtcag cagcacgtgg cattgaacat tgcaatgtgg agcccaaacc acagaaaatg 60
 gggtgaaatt ggccaacttt ctattaactt atgttggcaa ttttgccacc aacagtaagc 120
 tggcccttct aataaaagaa aattgaaagg tttctcacta aacggaatta agtagtgag 180
 tcaagagact ccagggcctc agcgtacctg cccggggcggc cgctcgaagc cgaattctgc 240
 agatatccat cacactggcg gncgctcgan catgcatcta gaaggnccaa ttcgccctat 300
 a 301

<210> 276
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 276
 tgtacacata ctcaataaat aaatgactgc attgtggtat tattactata ctgattatat 60
 ctatcatgtg acttctaatt agaaaatgta tccaaaagca aaacagcaga tatacaaaat 120
 taagagagaca gaagatagac attaacagat aaggcaactt atacattgag aatccaaatc 180
 caatccattt aaacatttgg gaaatgaggg ggacaaatgg aagccagatc aaatttgtgt 240

aaaactatttc agtatgtttc ccttgcttca tgtctgagaa ggctctcctt caatggggat 300
g 301

<210> 277
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 277
tttgttgatg tcagtatttt attacttgcg ttatgagtgc tcacctggga aattctaaag 60
atacagagga cttggaggaa gcagagcaac tgaatttaat ttaaaagaag gaaaacattg 120
gaatcatggc actcctgata ctttcccaaa tcaacactct caatgcccc cctcgtcct 180
caccatagtg gggagactaa agtggccacg gatttgcctt anggtgtcag tgcgttctga 240
gttcnctgtc gattacatct gaccagtctc ctttttccga agtcctccg ttcaatcttg 300
c 301

<210> 278
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 278
taccactaca ctccagcctg ggcaacacag caagacctgt ctcaaagcat aaaatggaat 60
aacatatcaa atgaaacagg gaaaatgaag ctgacaattt atggaagcca gggcttgtca 120
cagtccttac tgttattatg cattacctgg gaatttatat aagcccttaa taataatgcc 180
aatgaacatc tcatgtgtgc tcacaatggt ctggcactat tataagtgtc tcacagggtt 240
tatgtgttct tcgtaacttt atggantagg tactcggccg cgaacacgct aagccgaatt 300
c 301

<210> 279
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 279
aaagcaggaa tgacaagact tgcttttctg gtatgttcta ggtgtattgt gacttttact 60
gttatattaa ttgccaatat aagtaaatat agattatata tgtatagtgt ttcacaaagc 120
ttagaccttt acctccagc caccocacag tgcttgatat ttcagagtca gtcattgggt 180
atacatgtgt agttccaaag cacataagct agaanaanaa atatttctag ggagcactac 240
catctgtttt cacatgaaat gccacacaca tagaactcca acatcaattt cattgcacag 300
a 301

<210> 280

<211> 301

<212> DNA

<213> Homo sapien

<400> 280

```

ggtaactggag ttttcctccc ctgtgaaaac gtaactactg ttgggagtga attgaggatg      60
taaaaagggtg gtggaaccaa attgtgggtca atggaaatag gagaatatgg ttctcactct      120
tgagaaaaaaa acctaaagatt agcccaggta gttgcctgta acttcagttt ttctgcctgg      180
gtttgatata gtttaggggtt ggggttagat taagatctaa attacatcag gacaaagaga      240
caqactatta actccacagt taattaagga ggtatgttcc atgtttattt gttaaagcag      300
t

```

301

<210> 281

<211> 301

<212> DNA

<213> Homo sapien

<400> 281

```

aggtacaaga aggggaatgg gaaagagctg ctgctgtggc attgttcaac ttggatattc      60
gccgagcaat ccaaactctg aatgaagggg catcttctga aaaaggagat ctgaatctca      120
atgtggttagc aatggcttta tcgggttata cggatgagaa gaactccctt tggagagaaa      180
tgtgtagcac actgcgatta cagctaaata acccgtattt gtgtgtcatg ttgtcatttc      240
tgacaagtga aacaggatct tacgatggag ttttgtatga aaacaaagtt gcagtacctc      300
g

```

301

<210> 282

<211> 301

<212> DNA

<213> Homo sapien

<400> 282

```

caggtaactac agaattaaaa tactgacaag caagtagttt cttggcgtgc acgaattgca      60
tgcagaaccc aaaaattaag aaattcaaaa agacattttg tgggcacctg ctagcacaga      120
agcgcagaag caaagcccag gcagaacat gctaacctta cagctcagcc tgcacagaag      180
cgcagaagca aagcccaggc agaaccatgc taaccttaca gctcagcctg cacagaagcg      240
cagaagcaaa gccccaggcag aacatgctaa cttacagct cagcctgcac agaagcacag      300
a

```

301

<210> 283

<211> 301

<212> DNA

<213> Homo sapien

<400> 283

```

atctgtatag ggcagacaaa ctttatarag tgtagagagg tgagcgaaa gatgcaaaa      60
cacittgagg gctttataat aatatgctgc ttgaaaaaaa aaatgtgtag ttgatactca      120
gtgcactccc agacatagta aggggttgct ctgaccaatc aggtgatcat tttttctatc      180
acttcccagg ttttatgcaa aaattttgtt aaattctata atggtgatat gcacttttta      240
ggaacatat acatttttta aaatctattt tatgtaagaa ctgacagacg aatttgcttt      300
g

```

301

<210> 284

<211> 301

<212> DNA

<213> Homo sapien

<400> 284

```

caggtaaaaa acgctattaa gtggcttaga atttgaacat ttgtggtctt tatttacttt      60

```

```

gcttcgtgtg tgggcaaagc aacatcttcc ctaaatatat attaccaaga aaagcaagaa      120
gcagattagg tttttgacaa aacaaacagg ccaaaaaggg gctgacctgg agcagagcat      180
ggtgagaggc aaggcatgag agggcaagtt tgttggtggac agatctgtgc ctactttatt      240
actggagtaa aagaaaacaa agttcattga tgtcgaagga tatatacagt gttagaatt      300
a                                          301

```

```

<210> 285
<211> 301
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

```

```

<400> 285
acatcaccat gatcggatcc cccacccatt atacgttgta tgtttacata aatactcttc      60
aatgatcatt agtggtttta aaaaaatact gaaaactcct tctgcatccc aatctctaac      120
caggaaagca aatgctatct acagacctgc aagccctccc tcaaacnaaa ctatttctgg      180
attaaatatg tctgacttct tttgaggtca cagcactagg caaatgctat ttacgatctg      240
caaaagctgt ttgaagagtc aaagccccc tgtgaacacg atttctggac cctgtaacag      300
t                                          301

```

```

<210> 286
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 286
taccactgca ttccagcctg ggtgacagag tgagactccg tctccaaaaa aaactttgct      60
tgtatattat ttttgccctta cagtggatca ttctagtagg aaaggacagt aagatttttt      120
atcaaaatgt gtcatgccag taagagatgt tatattcttt tctcatctct tccccaccca      180
aaaataagct accatatagc ttataagtct caaatttttg ccttttacta aaatgtgatt      240
gtttctgttc attgtgtatg ctccatcacc tatattaggc aaattccatt ttttcccttg      300
t                                          301

```

```

<210> 287
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 287
tacagatctg ggaactaaat attaaaaatg agtgtggctg gatatatgga gaatgttggg      60
cccagaagga acgtagagat cagatattac aacagctttg ttttgagggt tagaaatatg      120
aaatgatttg gttatgaacg cacagtttag gcagcagggc cagaatcctg accctctgcc      180
ccgtgggtat ctccctccca gcttggctgc ctcatgttat cacagtattc cattttgttt      240
gttgcagtgc ttgtgaagcc atcaagattt tctcgtctgt tttcctctca ttggtaatgc      300
t                                          301

```

```

<210> 288
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 288
gtacacctaa ctgcaaggac agctgaggaa tgtaatgggc agccgctttt aaagaagtag      60
agtcaatagg aagacaaatt ccagttccag ctcagctctg gtatctgcaa agctgcaaaa      120

```

```

gaatctttaa gacaatttca agagaatatt tecttaaagt tggcaatttg gagatcatac 180
aaaagcatct gcttttgtga ttttaatttag ctcatctggc cactggaaga atccaaacag 240
ctcccttaa ttttgatga atgcatgatg gaaattcaat aatttagaaa gttaaaaaaa 300
a 301

```

<210> 289

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 289

```

ggtacactgt ttccatgtta tgtttctaca cattgctacc tcagtgtcc tggaaactta 60
gcttttgatg tctccaagta gtccacctc atttaactct ttgaaactgt atcatctttg 120
ccaagtaaga gtggtggcct atttcagctg ctttgacaaa atgactggct cctgacttaa 180
cgttctataa atgaatgtgc tgaagcaaag tgcccatggt ggcggcgaan aagagaaaga 240
tgtgtttgt tttggactct ctgtggtccc ttccaatgct gtgggtttcc aaccagnnga 300
a 301

```

<210> 290

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 290

```

acactgagct cttcttgata aatatacaga atgcttggca tatacaagat tctatactac 60
tgactgatct gttcatttct ctacagctc ttaccccaaa aagcttttcc accctaagtg 120
ttctgacctc cttttctaat cacagtaggg atagaggcag anccacctac aatgaacatg 180
gagttctatc aagaggcaga aacagcacag aatcccagtt ttaccattcg ctagcagtgc 240
tgcttgaac aaaaacattt ctccatgtct cttttcttc atgcctcaag taacagttag 300
a 301

```

<210> 291

<211> 301

<212> DNA

<213> Homo sapien

<400> 291

```

caggtaccaa tttcttctat cctagaaaca tttcatttta tgttggtgaa acataacaac 60
tatatcagct agattttttt totatgcttt acctgctatg gaaaatttga cacattctgc 120
tttactcttt tgtttatagg tgaatcacia aatgtatttt tatgtattct gtagttcaat 180
agccatggct gtttacttca ttttaatttat ttagcataaa gacattatga aaaggcctaa 240
acatgagctt cacttcccca ctaactaatt agcatctggt atttcttaac cgtaatgcct 300
a 301

```

<210> 292

<211> 301

<212> DNA

<213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 292
 accttttagt agtaatgtct aataataaat aagaaatcaa ttttataagg tccatatagc 60
 tgtattaaat aatttttaag tttaaaagat aaaataccat catttttaaat gtgggtattc 120
 aaaaccaaag natataaccg aaaggaaaaa cagatgagac ataaaaatgat ttgcnagatg 180
 ggaaatatag tasttyatga atgttnatta aattccagtt ataatagtgg ctacacactc 240
 tcactacaca cacagacccc acagtcctat atgccacaaa cacatttcca taacttgaaa 300
 a 301

<210> 293
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 293
 ggtaccaagt gctgggtgcc gctgtttacc tgttctcact gaaaagtctg gctaattgctc 60
 ttgtgtagtc acttctgatt ctgacaatca atcaatcaat ggcctagagc actgactggt 120
 aacacaaacg tcactagcaa agtagcaaca gctttaagtc taaatacaaa gctgttctgt 180
 gtgagaattt tttaaaaggc tacttgtata ataacccttg tcattttttaa tgtacctcgg 240
 ccgcgaccac gctaagccga attctgcaga tatccatcac actggcggcc gctcgagcat 300
 g 301

<210> 294
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 294
 tgacccataa caatatacac tagctatctt ttttaactgtc catcattagc accaatgaag 60
 attcaataaa attaccttta ttacacacac tcaaaacaat tctgcaaatt cttagtgaag 120
 ttttaactata gtcacaganc ttaaatattc acattgtttt ctatgtctac tgaaaataag 180
 ttactactt ttctgggata ttctttacaa aatcttatta aaattcctgg tattatcacc 240
 cccaattata cagtagcaca accaccttat gtagttttta catgatagct ctgtagaggt 300
 t 301

<210> 295
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 295
 gtactctttc tctccctcc tctgaattta attctttcaa cttgcaattt gcaaggatta 60
 cacatttccac tgtgatgtat attgtgttgc aaaaaaaaaa gtgtctttgt ttaaaattac 120
 ttgggtttgt aatccatctt gctttttccc cattggaact agtcattaac ccatctctga 180
 actggtagaa aaacrtctga agagctagtc tatcagcatc tgacaggtga attggatggt 240
 tctcagaacc atttcaccca gacagcctgt ttctatcctg tttataaat tagtttgggt 300
 tctct 305

<210> 296
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 296
 aggtactatg ggaagctgct aaaataatat ttgatagtaa aagtatgtaa tgtgctatct 60
 caactagtag taaactaaaa ataaactgaa actttatgga atctgaagtt attttccttg 120
 attaaataga attaataaac caatatgagg aaacatgaaa ccattgcaatc tactatcaac 180
 ttgaaaaaag tgattgaacg aaccacttag ctttcagatg atgaacactg ataagtcatt 240
 tgcattact ataaatttta aaatctgtta ataagatggc ctataggag gaaaaagggg 300
 c 301

<210> 297
 <211> 300
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(300)
 <223> n = A,T,C or G

<400> 297
 actgagtttt aactggacgc caagcaggca aggctggaag gttttgctct ctttgtgcta 60
 aaggttttga aaaccttgaa ggagaatcat ttgacaaga agtacttaag agtctagaga 120
 acaaagangt gaaccagctg aaagctctcg ggggaanctt acatgtgttg ttaggcctgt 180
 tccatcattg gtagtgact ggccatccct caaaatttgt ctgggctggc ctgagtggc 240
 accgcacctc ggccgcgacc acgctaagcc gaattctgca gatatccatc aactggcgg 300

<210> 298
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 298
 tatggggttt gtcacccaaa agctgatgct gagaaaggcc tccctggggc cctcccgcg 60
 ggcactctgag agacctgggtg ttccagtgtt tctggaaatg ggtcccagtg ccgcccggctg 120
 tgaagctctc agatcaatca cgggaagggc ctggcggttg tggccacctg gaaccacct 180
 gtctgtctg ttacatttc actaycaggt tttctctggg cattacnatt tgttccccta 240
 caacagtgac ctgtgcattc tgctgtggcc tgctgtgtct gcaggtggct ctacgcgagg 300
 t 301

<210> 299
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 299
 gttttgagac ggagtttca tcttgttgcc cagactggac tgcaatggca ggtctctgc 60
 tcaactgcacc ctctgcctcc caggttcag caattctct gctcagcct ccaggtagc 120
 tgggattgca ggtcaccgc accataccca gctaattttt ttgtattttt agtagagacg 180
 gagtttcgcc atgttggcca gctggtctca aactcctgac ctcaagcgac ctgcctgcct 240

cggcctccca aagtgtctgga attataggca tgagtcaaca cgcccagcct aaagatatatt 300
t 301

<210> 300
<211> 301
<212> DNA
<213> Homo sapien

<400> 300
attcagtttt atttgctgcc ccagtatctg taaccaggag tgccacaaaa tcttgccaga 60
tatgtcccac acccactggg aaaggtccc acctggctac ttcctctatc agctgggtca 120
gctgcattcc acaaggttct cagcctaatt agtttcacta cctgccagtc tcaaaactta 180
gtaaagcaag accatgacat tccccacgg aaatcagagt ttgcccacc gtcttggtac 240
tataaagcct gcctctaaca gtcttggtt cttcacacca atcccgagcg catcccccat 300
g 301

<210> 301
<211> 301
<212> DNA
<213> Homo sapien

<400> 301
ttaaattttt gagaggataa aaaggacaaa taatctagaa atgtgtcttc ttcagtctgc 60
agaggacccc aggtctccaa gcaaccacat ggtcaagggc atgaataatt aaaagttggt 120
gggaactcac aaagaccctc agagctgaga caccacaaac agtgggagct cacaagacc 180
ctcagagctg agacaccac aacagtggga gtcacaaaag accctcagag ctgagacacc 240
cacaacagca cctcgttcag ctgccacatg tgtgaataag gatgcaatgt ccagaagtgt 300
t 301

<210> 302
<211> 301
<212> DNA
<213> Homo sapien

<400> 302
aggtacacat ttagcttctg gtaaatgact cacaaaactg attttaaaat caagttaatg 60
tgaattttga aaattactac ttaatcctaa ttcacaataa caatggcatt aaggtttgac 120
ttgagttggt tcttagtatt atttatggta aataggctct taccacttgc aaataactgg 180
ccacatcatt aatgactgac ttcccagtaa ggctctctaa ggggtaagta ggaggatcca 240
caggatttga gatgctaagg ccccagagat cgtttgatcc aacctctta ttttcagagg 300
g 301

<210> 303
<211> 301
<212> DNA
<213> Homo sapien

<400> 303
aggtaccaac tgtggaaata ggtagaggat cattttttct ttccatatca actaagttgt 60
atattgtttt ttgacagttt aacacatctt cttctgtcag agattctttc acaatagcac 120
tggctaattg aactaccgct tgcattgtaa aaatgggtgt ttgtgaaatg atcataggcc 180
agtaacgggt atgtttttct aactgatctt ttgctcgttc caaagggacc tcaagacttc 240
catcgatttt atatctgggg tctagaaaag gagttaatct gttttccctc ataaattcac 300
c 301

<210> 304
<211> 301
<212> DNA

<213> Homo sapien

<400> 304

catggatgt tattttgcag actgtcaacc tgaatttgta tttgcttgac attgcctaata	60
tattagtttc agtttcagct tacccacttt ttgtctgcaa catgcaraas agacagtgcc	120
cttttttagtg tatcatatca ggaatcatct cacattgggt tgtgccatta ctgggtgcagt	180
gactttcagc cacttgggta aggtggagtt ggccatatgt ctccactgca aaattactga	240
ttttcctttt gtaattaata agtgtgtgtg tgaagattct ttgagatgag gtatataatc	300
c	301

<210> 305

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 305

gangtacagc gtgggtcaagg taacaagaag aaaaaaatgt gagtggcacc ctgggatgag	60
caggggggaca gacctggaca gacacgttgt catttctgc tgtgggtagg aaaatgggcg	120
taaaggagga gaaacagata caaaatctcc aactcagtat taaggatttc tcatgcctag	180
aattattgta gaaacaagaa tacattcata tggcaataaa ctaaccatgg tggaacaaaa	240
ttctgggatt taagttggat accaangaaa ttgtattaaa agagctgttc atggaataag	300
a	301

<210> 306

<211> 8

<212> PRT

<213> Homo sapien

<400> 306

Val Leu Gly Trp Val Ala Glu Leu
1 5

<210> 307

<211> 637

<212> DNA

<213> Homo sapien

<400> 307

acagggratg aagggaaagg gagaggatga ggaagcccc ctggggattt ggtttgggtcc	60
ttgtgatcag gtgggtctatg gggcttatcc ctacaaagaa gaatccagaa ataggggcac	120
attgaggaat gatacttgag cccaaagagc attcaatcat tgttttattt gccttmtttt	180
cacaccattg gtgagggagg gattaccacc ctggggttat gaagatgggt gaacacccca	240
acatagcac cggagatatg agatcaacag tttcttagcc atagagattc acagcccaga	300
gcaggaggac gcttgcacac catgcaggat gacatggggg atgcgctcgg gattggtgtg	360
aagaagcaag gactgttaga ggcaggcttt atagtaacaa gacgggtggg caaactctga	420
tttccgtggg ggaatgtcat ggtcttgctt tactaagttt tgagactggc aggtagttaa	480
actcattagg ctgagaacct tgtggaatgc acttgaccca scgtgatagag gaagtagcca	540
ggtgggagcc tttcccagtg ggtgtgggac atatctggca agattttgtg gcactcctgg	600
ttacagatac tggggcagca aataaaactg aatcttg	637

<210> 308

<211> 647

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(647)

<223> n = A,T,C or G

<400> 308

acgattttca	ttatcatgta	aatcgggtca	ctcaaggggc	caaccacagc	tgggagccac	60
tgctcagggg	aaggttcata	tgggactttc	tactgcccaa	ggttctatac	aggatataaa	120
ggngcctcac	agtatagatc	tggtagcaaa	gaagaagaaa	caaacactga	tctctttctg	180
ccacccctct	gaccttttgg	aaactcctctg	acccttttaga	acaagcctac	ctaatatctg	240
ctagagaaaa	gaccaacaac	ggcctcaaaag	gatctctttac	catgaagggtc	tcagctaatt	300
cttgggctaag	atgtgggttc	cacattaggt	tctgaatatg	gggggaagg	tcaatttgct	360
catttttgtgt	gtggataaag	tcaggatgcc	caggggccag	agcagggggc	tgcttgcttt	420
gggaacaatg	gctgaqcata	taaccatagg	ttatggggaa	caaaacaaca	tcaaagtcac	480
tgtatcaatt	gccatgaaga	cttgagggac	ctgaatctac	cgattcatct	taaggcagca	540
ggaccagttt	gagtggaac	aatgcagcag	cagaatcaat	ggaaacaaca	gaatgattgc	600
aatgtccttt	ttttctcct	gcttctgact	tgataaaaag	ggaccgt		647

<210> 309

<211> 460

<212> DNA

<213> Homo sapien

<400> 309

actttatagt	ttaggctgga	cattggaaaa	aaaaaaaaagc	cagaacaaca	tgtgatagat	60
aatatgattg	gctgcacact	tccagactga	tgaatgatga	acgtgatgga	ctattgtatg	120
gagcacatct	tcagcaagag	ggggaaatac	tcatactttt	tggccagcag	ttgtttgatc	180
accaaacatc	atgccagaat	actcagcaaa	ccttcttagc	tcttgagaag	tcaaagtcag	240
gggggaattta	ttcctggcaa	ttttaattgg	actccttatg	tgagagcagc	ggctaccag	300
ctgggggtggt	ggagcgaacc	cgtcactagt	ggacatgcag	tggcagagct	cctggtaacc	360
acctayagga	atcacacaggc	acatgtgtga	tgccaagcgt	gacacctgta	gcactcaaat	420
ttgtcttggt	tttgtctttc	ggtgtgtaag	attcttaagt			460

<210> 310

<211> 539

<212> DNA

<213> Homo sapien

<400> 310

acgggactta	tcaaataaag	ataggaaaag	aagaaaactc	aaatattata	ggcagaaatg	60
ctaaaggttt	taaaatatgt	caggattgga	agaaggcatg	gataaagaac	aaagttcagt	120
taggaaaag	aaacacagaa	ggaagagaca	caataaaagt	cattatgtat	tctgtgagaa	180
gtcagacagt	aagatttgtg	ggaatgggt	tggtttgttg	tatggtatgt	attttagcaa	240
taatctttat	ggcagagaaa	gctaaaatcc	tttagcttgc	gtgaatgatc	acttgctgaa	300
ttcctcaagg	taggcatgat	gaaggagggt	ttagaggaga	cacagacaca	atgaactgac	360
ctagatagaa	agccttagta	tactcagcta	ggaatagtga	ttctgagggc	acactgtgac	420
atgattatgt	cattacatgt	atggtagtga	tggggatgat	aggaagggaag	aacttatggc	480
atattttcac	ccccacaaaa	gtcagttaaa	tattgggaca	ctaaccatcc	aggtcaaga	539

<210> 311

<211> 526

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(526)

<223> n = A,T,C or G

<400> 311

caaatttgag ccaatgacat agaattttac aaatcaagaa gcttattctg gggccatttc	60
ttttgacgtt ttctctaaac tactaaagag gcattaatga tccataaatt atattatcta	120
gatttacagc atttaaaatg tgttcagcat gaaatattag ctacagggga agctaaataa	180
attaaacatg gaataaagat ttgtccttaa atataatcta caagaagact ttgatatttg	240
tttttcacaa gtgaagcatt cttataaagt gtcataacct ttttggggaa actatgggaa	300
aaaatgggga aactctgaag ggttttaagt atcttacctg aagctacaga ctccataacc	360
tctttttaca gggagctcct gcagccccta cagaaatgag tggctgagat tcttgattgc	420
acagcaagag cttctcatct aaacccttcc cctttttagt atctgtgtat caagtataaa	480
aqttctataa actgtagtnt acttatttta atccccaaag cacagt	526

<210> 312

<211> 500

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(500)

<223> n = A,T,C or G

<400> 312

cctctctctc cccacccct gactctagag aaactgggtt tctcccagta ctccagcaat	60
tcattttctga aagcagttga gccactttat tccaaagtac actgcagatg ttcaaactct	120
ccattttctct ttcccttcca cctgccagtt ttgctgactc tcaacttgct atgagtgtaa	180
gcattaagga cattatgctt cttcgattct gaagacaggc cctgctcatg gatgactctg	240
gcttcttagg aaaatatatt tcttccaaaa tcagtaggaa atctaaactt atccctctct	300
tgcagatgct tagcagcttc agacatttgg ttaagaacct atgggaaaaa aaaaaatcct	360
tgttaatgtg gtttcctttg taaaccanga ttcttatttg nctggtatag aatatcagct	420
ctgaacgtgt ggtaaagatt tttgtgtttg aatataggag aaatcagttt gctgaaaagt	480
tagtcttaat tatctattgg	500

<210> 313

<211> 718

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(718)

<223> n = A,T,C or G

<400> 313

ggagatttgt gtggtttgca gccgagggag accaggaaga tctgcatggt gggaaggacc	60
tgatgataca gaggtgagaa ataagaaagg ctgctgactt taccatctga ggccacacat	120
ctgctgaaat ggagataatt aacatcacta gaaacagcaa gatgacaata taatgtctaa	180
gtagtacat gtttttgac atttccagcc ctttttaata tccacacaca caggaagcac	240
aaaagggaagc acagagatcc ctgggagaaa tgcccggccg ccactctggg tcatcgatga	300
gcctcgccct gtgcctgntc ccgcttggtg gggaaggaca tttagaaaatg aattgatgtg	360
ttccttaaaag gatggcagga aaacagatcc tgttggtgat atttatttga acgggattac	420
agatttgaaa tgaagtcaca aagtgagcat taccaatgag aggaaaacag acgagaaaat	480
cttgatgggt cacaagacat gcaacaaaca aaatggaata ctgtgatgac acgagcagcc	540
aactggggag gagataccac ggggcagagg tcaggattct ggccctgctg cctaactgtg	600
cgltatacca atcatttcta ttctaccct caaacaagct gtngaataac tgacttacgg	660
ttctnttggc ccacatttcc atnatccacc ccttcttttt aannttantic caaantgt	718

<210> 314
 <211> 358
 <212> DNA
 <213> Homo sapien

<400> 314
 gtttattttac attacagaaa aaacatcaag acaatgtata ctatttcaaa tatatccata 60
 cataatcaaa tatagctgta gtacatgttt tcattggtgt agattaccac aaatgcaagg 120
 caacatgtgt agatctcttg tcttattctt ttgtctataa tactgtattg tgtagtccaa 180
 gctctcggta gtccagccac tgtgaaacat gtcctcttta gattaacctc gtggacgctc 240
 ttgttgatt gctgaactgt agtgccctgt attttgcttc tgtctgtgaa ttctgttgct 300
 tctggggcat ttccttgta tgcagaggac caccacacag atgacagcaa tctgaatt 358

<210> 315
 <211> 341
 <212> DNA
 <213> Homo sapien

<400> 315
 taccacctcc ccgctggcac tgatgagccg catcaccatg gtcaccagca ccatgaaggc 60
 ataggtgatg atgaggacat ggaatgggccc cccaaggatg gtctgtccaa agaagcgagt 120
 gacccccatt ctgaagatgt ctggaacctc taccagcagg atgatgatag ccccaatgac 180
 agtcaccagc tccccgacca gccggatata gtccttaggg gtcatgtagg ctccctgaag 240
 tagcttctgc tgtaagaggg tgttgctccg ggggctcgtg cggttattgg tcctgggctt 300
 gagggggcgg tagatgcagc acatggtgaa gcagatgatg t 341

<210> 316
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 316
 agactgggca agactcttac gccccacact gcaatttggt cttgttgccg tatccattta 60
 tgtgggcctt tctcgagttt ctgattataa acaccactgg agcgatgtgt tgactggact 120
 cattcaggga gctctggttg caatattagt t 151

<210> 317
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 317
 agaactagtg gatcctaatt aaataacctga aacatatatt ggcatttata aatggctcaa 60
 atcttcattt atctctggcc ttaacctgg ctcttgaggg tgcggccagc agatcccagg 120
 ccagggtctt gttcttgcca cacctgctt a 151

<210> 318
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 318
 actggtggga ggcgctgttt agttggctgt ttccagaggg gtctttcgga gggacctcct 60
 gctgcaggct ggagtgtctt tattcctggc gggagaccgc acattccact gctgaggctg 120
 tgggggcggt ttatcaggca gtgataaaca t 151

<210> 319

<211> 151
 <212> DNA
 <213> Homo sapien

<400> 319
 aactagtggga tccagagcta taggtacagt gtgatctcag ctttgcaaac acattttcta 60
 catagatagt actaggtatt aatagatatg taaagaaaga aatcacacca ttaataatgg 120
 taacattggg tttatgtgat tttagtgggt a 151

<210> 320
 <211> 150
 <212> DNA
 <213> Homo sapien

<400> 320
 aactagtggga tccactagtc cagtgtgggt gaattccatt gtgttgggggt tctagatcgc 60
 gagcggctgc cctttttttt tttttttttg ggggggaatt tttttttttt aatagttatt 120
 gagtgttcta cagcttacag taaataccat 150

<210> 321
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 321
 agcaactttg tttttcatcc aggttatatt aggcttagga tttcctctca cactgcagtt 60
 taggggtgca ttgtaaccag ctatggcata ggtgttaacc aaaggctgag taaacatggg 120
 tgctctgag aaatcaaagt cttcatacac t 151

<210> 322
 <211> 151
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(151)
 <223> n = A,T,C or G

<400> 322
 atccagcacc ttctctgtt tcttgccctc cttttttctt ttcttasatt ctgcttgagg 60
 tttgggcttg gtcagtttgc cacagggctt ggagatgggt acagtcttct ggcattcggc 120
 attgtgcagg gctcgttca nacttcag t 151

<210> 323
 <211> 151
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(151)
 <223> n = A,T,C or G

<400> 323
 tgaggacttg tktttttttt cttttttttt aatcctctta ckttgtaa atattgccta 60
 nagactcant tactaccag tttgtgggtt twtgggagaa atgtaactgg acagttagct 120
 qutcaatyaa aaagacactt ancccatgtg g 151

<210> 324
 <211> 461
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(461)
 <223> n = A,T,C or G

<400> 324
 acctgtgtgg aatttcagct ttctcatgc aaaaggattt tgtatccccg gctacttga 60
 agaagtgggc agctaaagga atccagggtt ttgggtggac tgtaataacc ttgatgaaa 120
 agagttacta cgaatcccat cttgggtcca gctatatcac tgacagcatg gtagaagact 180
 gcgaacctca cttctagact ttacagggtg gacgaaacgg gttcagaaac tgccaggggc 240
 ctcatacagg gatatacaaaa taccctttgt gctaccagg ccctggggaa tcagggtgact 300
 cacacaaatg caatagttgg tcaactgcatt ttacctgaa ccaaagctaa acccgggtgt 360
 gccaccatgc accatggcat gccagagttc aacactgttg ctcttgaaaa ttgggtctga 420
 aaaaacgcac aagagccctt gccctgccct agctgangca c 461

<210> 325
 <211> 400
 <212> DNA
 <213> Homo sapien

<400> 325
 acactgtttc catgttatgt ttctacacat tgctacctca gtgtcctgg aaacttagct 60
 ttgatgtct ccaagtagtc caccttcatt taactcttg aaactgtatc atctttgcc 120
 agtaagagt gtggcctatt tcagctgctt tgacaaaatg actggctcct gacttaacgt 180
 tctataaatg aatgtgtga agcaaagtgc ccatgggtggc ggcaagaag agaaagatgt 240
 gttttgtttt ggactctctg tggctccctc caatgctgtg ggtttccaac caggggaagg 300
 gtcccttttg cattggcaag tgccataacc atgagacta cgtaccatg gttctgctc 360
 ctggccaagc aggtctggtt gcaagaatga aatgaatgat 400

<210> 326
 <211> 1215
 <212> DNA
 <213> Homo sapien

<400> 326
 ggaggactgc agccgcact cgcagccctg gcaggcgga ctggtcatgg aaaacgaatt 60
 gttctgctcg ggcgtcctgg tgcatacgca gtgggtgctg tcagccgcac actgtttcca 120
 gaactcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccagggag 180
 ccagatggtg gaggccagcc tctccgtacg gcaccagag tacaacagac ccttgctcgc 240
 taacgacctc atgctcatca agttggaaga atccgtgtcc gactctgaca ccatccggag 300
 catcagcatt gcttcgcagt gccctaccgc ggggaactct tgccctggtt ctggctgggg 360
 tctgctggcg aacggcagaa tgccctaccgt gctgcagtgc gtgaacgtgt cgggtggtgtc 420
 tgaggaggtc tgcagtaagc tctatgaccc gctgtaccac ccagcatgt tctgcgccgg 480
 cggagggcaa gaccagaagg actcctgcaa cggtgactct ggggggcccc tgatctgcaa 540
 cgggtacttg cagggccttg tgtctttcgg aaaagccccg tgtggccaag ttggcgtgcc 600
 aggtgtctac accaacctct gcaaattcac tgagtggata gaaaaaccg tccaggccag 660
 ttaactctgg ggactgggaa cccatgaaat tgaccccaa atacatcctg cgaaggaat 720
 tcaggaatat ctgttccag cccctcctcc ctacggccca ggagtccagg cccccagccc 780
 ctctccctc aaaccaaggg tacagatccc cagccctcc tccctcagac ccaggagtcc 840
 agacccccca gccctcctc cctcagaccc aggagtccag cccctcctcc ctacagacca 900
 ggagtccaga cccccagcc cctcctccct cagaccagc ggtccaggcc cccaaccct 960
 cctccctcag actcagaggt ccaagcccc aaccctcct tccccagacc cagaggtcca 1020


```

ggccccagcc cctcccccct cagacccagc ggtccaatgc cacctagact ctccctgtac 1080
acagtgcgcc cttgtggcac gttgacccaa ccttaccagt tggtttttca ttttttgtec 1140
ctttcccta gatccagaaa taaagtctaa gagaagcgca aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaaa 1215

```

<210> 327
 <211> 220
 <212> PRT
 <213> Homo sapien

```

<400> 327
Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu Val Met
1      5      10      15
Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
20     25     30
Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly
35     40     45
Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu
50     55     60
Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu Ala
65     70     75     80
Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp
85     90     95
Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn
100    105    110
Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met Pro
115    120    125
Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val Cys
130    135    140
Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala Gly
145    150    155    160
Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro
165    170    175
Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys Ala
180    185    190
Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys
195    200    205
Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
210    215    220

```

<210> 328
 <211> 234
 <212> DNA
 <213> Homo sapien

```

<400> 328
cgctcgtctc tggtagctgc agccaaatca taaacggcga ggactgcagc ccgcactcgc 60
agccctggca ggcggcactg gtcattggaaa acgaattgtt ctgctcgggc gtcctggtgc 120
atccgcagtg ggtgctgtca gccacacact gtttccagaa ctctacacc atcgggctgg 180
gcctgcacag tcttgaggcc gaccaagagc cagggagcca gatggtggag gccca 234

```

<210> 329
 <211> 77
 <212> PRT
 <213> Homo sapien

```

<400> 329
Leu Val Ser Gly Ser Cys Ser Gln Ile Ile Asn Gly Glu Asp Cys Ser

```

1	5	10	15
Pro His Ser	Gln Pro Trp Gln Ala	Ala Leu Val Met	Glu Asn Glu Leu
	20	25	30
Phe Cys Ser	Gly Val Leu Val His	Pro Gln Trp Val	Leu Ser Ala Thr
	35	40	45
His Cys Phe	Gln Asn Ser Tyr Thr	Ile Gly Leu Gly	Leu His Ser Leu
	50	55	60
Glu Ala Asp	Gln Glu Pro Gly Ser	Gln Met Val	Glu Ala
65	70	75	

<210> 330
 <211> 70
 <212> DNA
 <213> Homo sapien

<400> 330
 cccaacacaa tggcccgatc ccatccctga ctccgcccctc aggatcgctc gtctctggta 60
 gctgcagcca 70

<210> 331
 <211> 22
 <212> PRT
 <213> Homo sapien

<400> 331
 Gln His Asn Gly Pro Ile Pro Ser Leu Thr Pro Pro Ser Gly Ser Leu
 1 5 10 15
 Val Ser Gly Ser Cys Ser
 20

<210> 332
 <211> 2507
 <212> DNA
 <213> Homo sapien

<400> 332
 tgggtgccgt gcagccggca gagatggttg agtcatgtt cccgctgttg ctctccttc 60
 tgcccttcct tctgtatatg gctgcgcccc aaatcaggaa aatgctgtcc agtgggggtg 120
 gtacatcaac tggtcagctt cctgggaaaag tagttgtggt cacaggagct aatacaggta 180
 tcgggaagga gacagccaaa gagctggctc agagaggagc tcgagtatat ttagcttgcc 240
 gggatgtgga aaagggggaa ttggtggcca aagagatcca gaccacgaca gggaaccagc 300
 aggtgttggg gcggaaaactg gacctgtctg atactaagtc tattcgagct ttgctaagg 360
 gcttccttagc tgaggaaaag cacctccacg ttttgatcaa caatgcagga gtgatgatg 420
 gtccgtactc gaagacagca gatggctttg agatgcacat aggagtcaac cacttgggtc 480
 acttcctcct aacccatctg ctgctagaga aactaaagga atcagcccca tcaaggatag 540
 taaatgtgtc ttccctcgca catcacctgg gaaggatcca cttccataac ctgcaggggc 600
 agaaattcta caatgcaggc ctggcctact gtcacagcaa gctagccaac atcctcttca 660
 ccaggaact ggcccgagga ctaaaaggct ctggcggttac gacgtattct gtacaccctg 720
 gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg tgggtggcttt 780
 tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac tgtgccttaa 840
 cagaaggctc tgagattcta agtgggaatc atttcagtga ctgtcatgtg gcatgggtct 900
 ctgcccgaagc tcgtaatgag actatagcaa ggcggctgtg ggacgtcagt tgtgacctgc 960
 tgggcctccc aatagactaa caggcagtgc cagttggacc caagagaaga ctgcagcaga 1020
 ctacacagta cttcttgtca aaatgattct ccttcaagggt tttcaaaacc tttagcacia 1080
 agagagcaaa acctccagc cttgcctgct tgggtgtccag ttaaaactca gtgtactgcc 1140
 agattcgtct aaatgtctgt catgtccaga tttactttgc ttctgttact gccagagtta 1200
 ctagagatat cataatagga taagaagacc ctcatatgac ctgcacagct cattttcctt 1260
 ctgaaagaaa ctactaccta ggagaatcta agctatagca gggatgattt atgcaaattt 1320

gaaatagctt	ctttgttcac	aattcagttc	ctcccaacca	accagtcttc	acttcaagag	1380
ggccacactg	caacctcagc	ttaacatgaa	taacaaagac	tggctcagga	gcagggcttg	1440
cccaggcatg	gtggatcacc	ggaggtcagt	agttcaagac	cagcctggcc	aacatgggta	1500
aacccacact	ctactaaaaa	ttgtgtatat	ctttgtgtgt	cttcctgttt	atgtgtgcca	1560
agggagtatt	ttcacaaga	tcaaaacagc	cacaataatc	agagatggag	caaaccagt	1620
ccatccagtc	tttatgcaaa	tgaatgctg	caaagggag	cagattctgt	atatgttggt	1680
aactaccac	caagagcaca	tgggtagcag	ggaagaagta	aaaaaagaga	aggagaatac	1740
gggaagataa	tgcacaaaat	gaagggacta	gttaaggatt	aactagccct	ttaaggatta	1800
actagttaag	gattaatagc	aaaagayatt	aaatatgcta	acatagctat	ggagggaattg	1860
agggcaagca	cccaggactg	atgaggtctt	aacaaaaacc	agtgtggcaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaatccta	aaaacaaaca	aacaaaaaaa	acaattcttc	attcagaaaa	1980
attatcttag	ggactgatat	tggttaattat	ggtaaattta	ataatatttt	ggggcatttc	2040
cttacattgt	cttgacaaga	ttaaaatgtc	tgtgccaaaa	ttttgtattt	tatttgagga	2100
cttcttatca	aaagtaatgc	tgcacaaagga	agtotaagga	attagtagtg	ttcccatcac	2160
ttgtttggag	tgtgctatcc	taaaagattt	tgatttcctg	gaatgacaat	tatatattta	2220
ctttgggtgg	ggaaagagtt	ataggaccac	agtcttcact	tctgataact	gtaaattaat	2280
cttttattgc	acttgttttg	accattaagc	tatatgttta	gaaatgggtca	ttttacggaa	2340
aaattagaaa	aattctgata	atagtgcaga	ataaatgaat	taatgtttta	cttaatttat	2400
attgaactgt	caatgacaaa	taaaaattct	ttttgtattt	ttttgtttt	catttaccag	2460
aataaaaacg	taagaattaa	aagtttgatt	acaaaaaaa	aaaaaaa		2507

<210> 333

<211> 3030

<212> DNA

<213> Homo sapien

<400> 333

gcaggcgact	tgcgagctgg	gagcgattta	aaacgctttg	gattcccccg	gcctgggtgg	60
ggagagcgag	ctgggtgccc	cctagattcc	cgcggccgcg	acctcatgag	cgcacctcg	120
gtccatgga	gcccggcaat	tatgccacct	tggatggagc	caaggatata	gaaggcttgc	180
tgggagcggg	agggggcgcg	aatctggctg	ccactcccc	tctgaccagc	caccagcgg	240
cgctacgct	gatgcctgct	gtcaactatg	cccccttggg	tctgccaggc	tcggcgagc	300
ggccaaagca	atgccaccca	tgccttgggg	tgcggcaggg	gacgtcccca	gctccctgce	360
cttatggtta	ctttggaggc	gggtactact	cctgcgaggt	gtcccgagc	tcgctgaaac	420
cctgtgccc	ggcagccacc	ctggcgcgct	acccgcggga	gactccacg	gcggggaag	480
agtacccag	ycgccccact	gagtttgctt	tctatccggg	atataccggg	acctaccagc	540
ctatggccag	ttacctggac	gtgtctgtgg	tgcagactct	gggtgctcct	ggagaaccgc	600
gacatgactc	cctggttgctt	gtggacagtt	accagtcttg	ggctctcgt	ggtggctgga	660
acagccagat	gtgttgccag	ggagaacaga	acccaccagg	tcccttttgg	aaggcagcat	720
ttgcagactc	cagcgggcag	cacctcctg	acgcctgcgc	ctttcgtcgc	ggccgcaaga	780
aacgcattcc	gtacagcaag	gggcagtgc	gggagctgga	gcgggagtat	gcggctaaca	840
agttcatcac	caaggacaag	aggcgcaaga	tctcggcagc	caccagcctc	tcggagcgcc	900
agattaccat	ctggtttcag	aaccgcccgg	tcaaagagaa	gaaggttctc	gccaaggtga	960
agaacagcgc	taccccttaa	gagatctcct	tgcctgggtg	ggaggagcga	aagtgggggt	1020
gtcctgggga	gaccaggaac	ctgccaaagc	caggctgggg	ccaaggactc	tgctgagagg	1080
cccctagaga	caacaccttt	cccaggccac	tggctgctgg	actgttcttc	aggagcggcc	1140
tgggtaccca	gtatgtgcag	ggagacggaa	ccccatgtga	cagcccaactc	caccagggtt	1200
cccaagaac	ctggcccagt	cataatcatt	catcctgaca	gtggcaataa	tcacgataac	1260
cagtactagc	tgccatgata	gttagcctca	tattttctat	ctagagctct	gtagagcact	1320
ttagaaaccg	ctttcatgaa	ttgagctaat	tatgaataaa	tttggaaggc	gatccctttg	1380
cagggaaagct	ttctctcaga	cccccttcca	ttacacctct	cacctgggta	acagcaggaa	1440
gactgaggag	aggggaacgg	gcagattcgt	tgtgtggctg	tgatgtccgt	ttagcatttt	1500
tctcagctga	cagctgggta	ggtggacaat	tgtagaggct	gtctcttctt	ccctccttgt	1560
ccaccccata	gggtgtaccc	actggtcttg	gaagcaccga	tccttaatac	gatgattttt	1620
ctgtcgtgtg	aaaatgaagc	cagcaggctg	cccctagtca	gtccttctct	ccagagaaaa	1680
agagatttga	gaaagtgcct	gggttaattca	ccattaattt	cctcccccaa	actctctgag	1740
tcttccctta	atattttctg	tggttctgac	caaagcaggt	catggtttgt	tgagcatttg	1800
ggatcccagt	gaagtagatg	tttgtagcct	tgcatactta	gcccttccca	ggcacaaacg	1860

gagtggcaga	gtggtgccaa	ccctgttttc	ccagtccacg	tagacagatt	cacagtgcgg	1920
aattctggaa	gctggagaca	gacgggctct	ttgcagagcc	gggactctga	gagggacatg	1980
agggcctctg	cctctgtgtt	cattctctga	tgctctgtac	ctgggctcag	tgcccgggtg	2040
gactcatctc	ctggccgcgc	agcaaagcca	gcgggttcgt	gctggtcctt	cctgcacctt	2100
aggctggggg	tggggggcct	gccggcgcat	tctccacgat	tgagcgcaca	ggcctgaagt	2160
ctggacaacc	cgcagaaccg	aagctccgag	cagcgggtcg	gtggcgagta	gtggggtcgg	2220
tggcgagcag	ttggtggtgg	gccgcggccg	ccactacctc	gaggacattt	ccctcccga	2280
gccagctctc	ctagaaaccc	cgcggcgccc	gccgcagcca	agtgtttatg	gcccgcggtc	2340
gggtgggagc	ctagccctgt	ctectctcct	gggaaggagt	gaggggtggga	cgtgacttag	2400
acacctacaa	atctattttac	caaagaggag	cccgggactg	agggaaaagg	ccaaagagtg	2460
tgagtgcattg	cggactgggg	gttcaggggga	agaggacgag	gaggaggaag	atgaggtcga	2520
tttcttgatt	taaaaaatcg	tccaagcccc	gtggtccagc	ttaaggtcct	cggttacatg	2580
cgcgcctcag	agcaggtcac	tttctgcctt	ccacgtcctc	cttcaaggaa	gccccatgtg	2640
ggtagctttc	aatatcgag	gttcttactc	ctctgcctct	ataagctcaa	acccaccaac	2700
gatcgggcaa	gtaaaccccc	tccctcgccg	acttcggaac	tggcgagagt	tcagcgcaga	2760
tgggcctgtg	gggagggggc	aagatagatg	agggggagcg	gcatggtgcg	gggtgacccc	2820
ttggagagag	gaaaaaggcc	acaagagggg	ctgccaccgc	cactaacgga	gatggccctg	2880
gtagagacct	ttgggggtct	ggaacctctg	gactccccat	gctctaactc	ccacactctg	2940
ctatcagaaa	cttaaaacttg	aggattttct	ctgtttttca	ctcgcaataa	aytcagagca	3000
aacaaaaaaa	aaaaaaaaaa	aaaactcgag				3030

<210> 334

<211> 2417

<212> DNA

<213> Homo sapien

<400> 334

ggcgccgcgt	ctagagctag	tgggatcccc	cgggctgcac	gaattcggca	cgagtgagtt	60
ggagttttac	ctgtattgtt	ttaattttcaa	caagcctgag	gactagccac	aaatgtaccc	120
agttttacaaa	tgaggaaaca	ggtgcaaaaa	ggttggttacc	tgtcaaagg	cgtatgtggc	180
agagccaaga	tttgagccca	gttatgtctg	atgaacttag	cctatgctct	ttaaacttct	240
gaatgctgac	cattgaggat	atctaaactt	agatcaattg	cattttccct	ccaagactat	300
ttactttatca	atacaataat	accaccttta	ccaatctatt	gttttgatac	gagactcaaa	360
tatgccagat	atatgtaaaa	gcaacctaca	agctctctaa	tcatgctcac	ctaaaagatt	420
cccggaatct	aataggctca	aagaaaacttc	ttctagaaat	ataaaagaga	aaattggatt	480
atgcaaaaaat	tcattatttaa	tttttttcat	ccatccttta	attcagcaaa	cattttatctg	540
ttgttgactt	tatgcagtat	ggccttttaa	ggattggggg	acaggtgaag	aacgggggtgc	600
cagaatgcat	cctcctacta	atgaggtcag	tacacatttg	catttttaaaa	tgccctgtcc	660
agctgggcat	ggtggatcat	gcctgtaatc	tcaacatttg	aaggccaagg	caggaggatt	720
gcttcagccc	aggagttcaa	gaccagcctg	ggcaacatag	aaagacccca	tctctcaatc	780
aatcaatcaa	tgccctgtct	ttgaaaataa	aactctttta	gaaaggttta	atgggcaggg	840
tgtggtagct	catgcctata	atacagcact	ttgggaggct	gaggcaggag	gatcacttta	900
gcccagaagt	tcaagaccag	cctgggcaac	aagtgcaccc	tcattctcaat	tttttaataa	960
aatgaatata	tacataagga	aagataaaaa	gaaaagttta	atgaaagaat	acagtataaa	1020
acaaatctct	tggacctaaa	agtatttttg	ttcaagccaa	atattgtgaa	tcacctctct	1080
gtgttgagga	tacagaatat	ctaagcccag	gaaactgagc	agaaaagttca	tgtactaact	1140
aatcaacccg	aggcaaggca	aaaatgagac	taactaatca	atccgaggca	aggggcaaat	1200
tagacggaac	ctgactctgg	tctattaagc	gacaactttc	cctctgttgt	atttttcttt	1260
tattcaatgt	aaaaggataa	aaactctcta	aaactaaaaa	caatgtttgt	caggagttac	1320
aaaccatgac	caactaatta	tggggaatca	taaaatatga	ctgtatgaga	tcttgatggt	1380
ttacaaaagt	taccactgtg	taatcacttt	aaacattaat	gaacttaaaa	atgaatttac	1440
ggagatttga	atgtttcttt	cctgttgtat	tagttggctc	aggctgccat	aacaaaatac	1500
cacagactgg	gaggcttaag	taacagaaat	tcattttctca	cagttctggg	ggctggaagt	1560
ccacgatcaa	ggtgcaggaa	aggcaggctt	cattctgagg	cccctctctt	ggctcacatg	1620
tggccaccct	cccactgcgt	gctcacatga	cctctttgtg	ctcctggaaa	gaggggtgtg	1680
gggacagagg	gaaagagaag	gagagggaac	tctctggtgt	ctcgtctttc	aaggacccta	1740
acctgggcca	cttttgccca	ggcactgtgg	ggtggggggt	tgtggctgct	ctgctctgag	1800
tggccaagat	aaagcaacag	aaaaatgtcc	aaagctgtgc	agcaaagaca	agccaccgaa	1860

cagggatctg	ctcatcagt	tggggacctc	caagtcggcc	accctggagg	caagccccc	1920
cagagcccat	gcaaggtggc	agcagcagaa	gaagggaatt	gtccctgtcc	ttggcacatt	1980
ctcaccgac	ctgggtgatg	tggacactgc	gatgaatggt	aatgtggatg	agaatatgat	2040
ggactccag	aaaaggagac	ccagctgctc	aggtggctgc	aaatcattac	agccttcac	2100
ctggggagga	actggggggc	tggttctggg	tcagagagca	gcccagtgag	ggtgagagct	2160
acagcctgtc	ctgccagctg	gatccccagt	cccggtaaac	cagtaatcaa	ggctgagcag	2220
atcaggcttc	cggagctgg	tcttgggaag	ccagccctgg	ggtgagttgg	ctcctgctgt	2280
agtaactgaga	caatattgtc	ataaattcaa	tgcgcccttg	tatccctttt	tcttttttat	2340
ctgtctacat	ctataatcac	tatgcatact	agtctttgtt	agtgtttcta	ttcmacttaa	2400
taagatatg	ttatact					2417

<210> 335

<211> 2984

<212> DNA

<213> Homo sapien

<400> 335

atccctcctt	ccccactctc	ctttccagaa	ggcaacttggg	gtcttatctg	ttggactctg	60
aaaacacttc	aggcgccctt	ccaaggtctc	cccaaacccc	taagcagccg	cagaagcget	120
cccgagctgc	cttctcccac	actcaggtga	tcgagttgga	gaggaaagttc	agccatcaga	180
agtaactgtc	ggcccttgaa	cgggcccacc	tggccaagaa	cctcaagctc	acggagaccc	240
aagtgaagat	atggttccag	aacagacgct	ataagactaa	gcgaaagcag	ctctcctcgg	300
agctgggaga	cttgagaaag	cactcctctt	tgcgggccct	gaaagaggag	gccttctccc	360
gggcctccct	ggtctccgtg	tataacagct	atccttacta	cccataacctg	tactgcgtgg	420
gcagctggag	cccagctttt	tggtaatgcc	agctcaggtg	acaaccatta	tgatcaaaaa	480
ctgccttccc	caggggtgct	ctatgaaaag	cacaaggggc	caaggtcagg	gagcaagagg	540
tgtgcacacc	aaagctattg	gagatttgcg	tggaaatctc	asattcttca	ctggtgagac	600
aatgaaacaa	cagagacagt	gaaagtttta	atacctaagt	cattccccc	gtgcatactg	660
taggtcattt	tttttgcctc	tggctacctg	tttgaagggg	agagagggaa	aatcaagtgg	720
tattttccag	cactttgtat	gattttggat	gagctgtaca	cccaaggatt	ctgttctgca	780
actccatcct	cctgtgtcac	tgaatatcaa	ctctgaaaga	gcaaacctaa	caggagaaag	840
gacaaccagg	atgaggatgt	caccaactga	attaaactta	agtccagaag	cctcctgttg	900
gccttggaat	atggccaagg	ctctctctgt	ccctgtaaaa	gagaggggca	aatagagagt	960
ctccaagaga	acgccctcat	gctcagcaca	tatttgcattg	ggagggggag	atgggtggga	1020
ggagatgaaa	atatcagctt	ttcttattcc	tttttattcc	ttttaaaatg	gtatgccaac	1080
ttaagtattt	acaggggtggc	ccaaatagaa	caagatgcac	tcgctgtgat	tttaagacaa	1140
gctgtataaa	cagaactcca	ctgcaagagg	gggggcccggg	ccaggagaat	ctccgcttgt	1200
ccaagacagg	ggcctaagga	gggtctccac	actgctgcta	ggggtgttg	cattttttta	1260
ttagtagaaa	gtggaaaggg	ctcttctcaa	cttttttccc	ttgggttgga	gaatttagaa	1320
tcagaagttt	cctggagttt	tcaggctatc	atatatactg	tatcctgaaa	ggcaacataa	1380
ttcttccttc	cctcctttta	aaattttgtg	ttcctttttg	cagcaattac	tcactaaagg	1440
gcttcatttt	agtcacagatt	tttagtctgg	ctgcacctaa	cttatgcctc	gcttatttag	1500
cccgagatct	ggtctttttt	tttttttttt	tttttccgtc	tcccccaggc	tttatctgtc	1560
ttgacttttt	aaaaaagttt	gggggcagat	tctgaattgg	ctaaaagaca	tgcattttta	1620
aaactagcaa	ctcttatttc	tttcttttaa	aaatacatag	cattaaatcc	caaatectat	1680
ttaaagacct	gacagcttga	gaaggtcact	actgcattta	taggaccttc	tggtggttct	1740
gctgttacgt	ttgaagtctg	acaatccttg	agaatctttg	catgcagagg	aggtaagagg	1800
tattggattt	tcacagagga	agaacacagc	gcagaatgaa	gggccaggct	tactgagctg	1860
tccagtggag	ggctcatggg	tgggacatgg	aaaagaaggc	agcctaggcc	ctggggagcc	1920
cagtcactcg	agcaagcaag	ggactgagtg	agccttttgc	aggaaaaggc	taagaaaaag	1980
gaaaaccatt	ctaaaaacaca	acaagaaact	gtccaaatgc	tttgggaact	gtgtttattg	2040
cctataatgg	gtccccaaaa	tgggtaacct	agacttcaga	gagaatgagc	agagagcaaa	2100
ggagaaatct	ggctgtcctt	ccattttcat	tctgttatct	caggtgagct	ggtagagggg	2160
agacattaga	aaaaaatgaa	acaacaaaac	aattactaat	gaggtacgct	gaggcctggg	2220
agtctcttga	ctccactact	taattccggt	tagtgagaaa	cctttcaatt	ttcttttatt	2280
agaagggcca	gcttactgtt	ggtggcaaaa	ttgccaacat	aagttaatat	aaagtgggcc	2340
aatttcaccc	cattttctgt	ggtttgggct	ccacattgca	atgttcaatg	ccacgtgctg	2400
ctgacacoga	ccggagtact	agccagcaca	aaaggcaggg	tagcctgaat	tgctttctgc	2460

```

tctttacatt tcttttaaaa taagcattta gtgctcagtc cctactgagt actctttctc 2520
tccccctcctc tgaatttaat tctttcaact tgcaatttgc aaggattaca catttcactg 2580
tgatgtatat tgtgttgcaa aaaaaaaaaa aagtgtcttt gtttaaaatt acttggtttg 2640
tgaatccatc ttgctttttc cccattggaa ctagtcatta acccatctct gaactggtag 2700
aaaaacatct gaagagctag tctatcagca tctgacaggt gaattggatg gttctcagaa 2760
ccatttcacc cagacagcct gtttctatcc tgtttaataa attagtttgg gttctctaca 2820
tgcataacaa accctgctcc aatctgtcac ataaaagtct gtgacttgaa gtttagtcag 2880
cacccccacc aaactttatt tttctatgtg ttttttgcaa catatgagtg ttttgaaaat 2940
aaagtaccca tgtctttatt agaaaaaaaa aaaaaaaaaa aaaa 2984

```

<210> 336
 <211> 147
 <212> PRT
 <213> Homo sapien

```

<400> 336
Pro Ser Phe Pro Thr Leu Leu Ser Arg Arg His Leu Gly Ser Tyr Leu
1      5      10      15
Leu Asp Ser Glu Asn Thr Ser Gly Ala Leu Pro Arg Leu Pro Gln Thr
20      25      30
Pro Lys Gln Pro Gln Lys Arg Ser Arg Ala Ala Phe Ser His Thr Gln
35      40      45
Val Ile Glu Leu Glu Arg Lys Phe Ser His Gln Lys Tyr Leu Ser Ala
50      55      60
Pro Glu Arg Ala His Leu Ala Lys Asn Leu Lys Leu Thr Glu Thr Gln
65      70      75      80
Val Lys Ile Trp Phe Gln Asn Arg Arg Tyr Lys Thr Lys Arg Lys Gln
85      90      95
Leu Ser Ser Glu Leu Gly Asp Leu Glu Lys His Ser Ser Leu Pro Ala
100     105     110
Leu Lys Glu Glu Ala Phe Ser Arg Ala Ser Leu Val Ser Val Tyr Asn
115     120     125
Ser Tyr Pro Tyr Tyr Pro Tyr Leu Tyr Cys Val Gly Ser Trp Ser Pro
130     135     140
Ala Phe Trp
145

```

<210> 337
 <211> 9
 <212> PRT
 <213> Homo sapien

```

<400> 337
Ala Leu Thr Gly Phe Thr Phe Ser Ala
1      5

```

<210> 338
 <211> 9
 <212> PRT
 <213> Homo sapien

```

<400> 338
Leu Leu Ala Asn Asp Leu Met Leu Ile
1      5

```

<210> 339
 <211> 318

<212> PRT

<213> Homo sapien

<400> 339

```

Met Val Glu Leu Met Phe Pro Leu Leu Leu Leu Leu Leu Pro Phe Leu
 1      5      10      15
Leu Tyr Met Ala Ala Pro Gln Ile Arg Lys Met Leu Ser Ser Gly Val
 20      25      30
Cys Thr Ser Thr Val Gln Leu Pro Gly Lys Val Val Val Val Thr Gly
 35      40      45
Ala Asn Thr Gly Ile Gly Lys Glu Thr Ala Lys Glu Leu Ala Gln Arg
 50      55      60
Gly Ala Arg Val Tyr Leu Ala Cys Arg Asp Val Glu Lys Gly Glu Leu
 65      70      75      80
Val Ala Lys Glu Ile Gln Thr Thr Thr Gly Asn Gln Gln Val Leu Val
 85      90      95
Arg Lys Leu Asp Leu Ser Asp Thr Lys Ser Ile Arg Ala Phe Ala Lys
 100     105     110
Gly Phe Leu Ala Glu Glu Lys His Leu His Val Leu Ile Asn Asn Ala
 115     120     125
Gly Val Met Met Cys Pro Tyr Ser Lys Thr Ala Asp Gly Phe Glu Met
 130     135     140
His Ile Gly Val Asn His Leu Gly His Phe Leu Leu Thr His Leu Leu
 145     150     155     160
Leu Glu Lys Leu Lys Glu Ser Ala Pro Ser Arg Ile Val Asn Val Ser
 165     170     175
Ser Leu Ala His His Leu Gly Arg Ile His Phe His Asn Leu Gln Gly
 180     185     190
Glu Lys Phe Tyr Asn Ala Gly Leu Ala Tyr Cys His Ser Lys Leu Ala
 195     200     205
Asn Ile Leu Phe Thr Gln Glu Leu Ala Arg Arg Leu Lys Gly Ser Gly
 210     215     220
Val Thr Thr Tyr Ser Val His Pro Gly Thr Val Gln Ser Glu Leu Val
 225     230     235     240
Arg His Ser Ser Phe Met Arg Trp Met Trp Trp Leu Phe Ser Phe Phe
 245     250     255
Ile Lys Thr Pro Gln Gln Gly Ala Gln Thr Ser Leu His Cys Ala Leu
 260     265     270
Thr Glu Gly Leu Glu Ile Leu Ser Gly Asn His Phe Ser Asp Cys His
 275     280     285
Val Ala Trp Val Ser Ala Gln Ala Arg Asn Glu Thr Ile Ala Arg Arg
 290     295     300
Leu Trp Asp Val Ser Cys Asp Leu Leu Gly Leu Pro Ile Asp
 305     310     315

```

<210> 340

<211> 483

<212> DNA

<213> Homo sapien

<400> 340

```

gcgcgaggtct gccctcacac ggaggacacg agactgcttc ctcaagggtc cctgcctgcc      60
tggacactgg tgggaggcgc tgtttagttg gctgttttca gaggggtctt tcggagggac      120
ctcctgctgc aggtctggagt gtctttatcc ctggcgggag accgcacatt ccaactgctga      180
ggttgtgggg gcggtttatc aggcagtgat aaacataaga tgtcatttcc ttgactccgg      240
ccttcaattt tctctttggc tgacgacgga gtccgtggtg tcccgatgta actgacccct      300
gctccaaacg tgacatcaat gatgctcttc tcgggggtgc tgatggcccg cttgggtcacg      360
tgcctaatct cgccattoga ctcttgctcc aaactgtatg aagacacctg actgcacggt      420

```

ttttctgggc ttccagaatt taaagtgaag ggcagcactc ctaagctccg actccgatgc 480
ctg 483

<210> 341
<211> 344
<212> DNA
<213> Homo sapien

<400> 341
ctgctgctga gtcacagatt tcattataaa tagcctccct aaggaaaata cactgaatgc 60
tatttttact aaccattcta tttttataga aatagctgag agtttctaaa ccaactctct 120
gctgccttac aagtattaaa tattttactt ctttccataa agagtagctc aaaatatgca 180
attaatttaa taatttctga tgatgggttt atctgcagta atatgtatat catctattag 240
aatttactta atgaaaaact gaagagaaca aaatttgtaa ccactagcac ttaagtactc 300
ctgattctta acattgtctt taatgaccac aagacaacca acag 344

<210> 342
<211> 592
<212> DNA
<213> Homo sapien

<400> 342
acagcaaaaa agaaactgag aagcccaaty tgctttcttg ttaacatcca cttatccaac 60
caatgtggaa acttcttata cttgggtcca ttatgaagtt ggacaattgc tgctatcaca 120
cctggcaggt aaaccaatgc caagagagtg atggaaacca ttggcaagac tttgttgatg 180
accaggattg gaattttata aaaatattgt tgatgggaag ttgctaaagg gtgaattact 240
tccctcagaa gactgtaaag aaaagtcaga gatgctataa tagcagctat ttttaattggc 300
aagtgccact gtggaaaagag ttcctgtgtg tgetgaagtt ctgaagggca gtcaaattca 360
tcagcatggg ctgttttggtg caaatgcaaa agcacaggtc tttttagcat gctgggtctct 420
cccgtgtcct tatgcaaaata atcgtcttct tctaaatttc tcctaggctt cattttccaa 480
agttcttctt ggtttgtgat gtcttttctg ctttccatta attctataaa atagtatggc 540
ttcagccacc cactcttcgc cttagcttga ccgtgagtct cggctgccgc tg 592

<210> 343
<211> 382
<212> DNA
<213> Homo sapien

<400> 343
ttcttgacct cctcctcctt caagctcaaa caccacctcc cttattcagg accggcactt 60
cttaatgttt gtggctttct ctccagcctc tcttaggagg ggtaatggtg gagttggcat 120
cttgtaactc tctttctcc tttcttcccc tttctctgcc cgccttcccc atcctgctgt 180
agacttcttg attgtcagtc tgtgtcacat ccagtgattg ttttggttct tgttcccttt 240
ctgactgcc aaggggctca gaacccagc aatcccttcc tttcactacc ttcttttttg 300
ggggtagttg gaagggactg aaattgtggg gggaaggtag gaggcacatc aataaagagg 360
aaaccaccaa gctgaaaaaa aa 382

<210> 344
<211> 536
<212> DNA
<213> Homo sapien

<400> 344
ctgggcctga agctgtaggg taaatcagag gcaggcttct gagtgatgag agtcctgaga 60
caataggcca cataaacttg gctggatgga acctcacaat aagggtgtca cctcttggtt 120
gtttaggggg atgccaagga taaggccagc tcagttatat gaagagaagc agaacaacaa 180
agtctttcag agaaatggat gcaatcagag tgggatcccc gtcacatcaa ggtcacactc 240
caccttcatg tgcttgaatg gttgccaggt cagaaaaatc cacccttacc gagtgcgggt 300


```

tccaccat atcccccgcc cgcgtccctt tctccataaa attctttotta gtagctatta 360
cctctctatt atttgatcta gaaattgcc tctttttacc cctaccatga gccctacaaa 420
aaactaacct gccactaata gttatgtcat cctctttatt aatcatcatc ctaggccctaa 480
ctctggccta tgagtgacta caaaaaggat tagactgagc cgaataacaa aaaaaa 536

```

<210> 345
 <211> 251
 <212> DNA
 <213> Homo sapien

```

<400> 345
acctttttgag gtctctctca ccacctccac agccaccgtc accgtgggat gtgctggatg 60
tgaatgaagc ccccatcttt gtgcctcctg aaaagagagt ggaagtgtcc gaggactttg 120
gggtggggcca ggaaatcaca tctacactg cccaggagcc agacacattt atggaacaga 180
aaataacata tcggatttgg agagacactg ccaactggct ggagattaat ccggacactg 240
gtgccatttc c 251

```

<210> 346
 <211> 282
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(282)
 <223> n = A,T,C or G

```

<400> 346
cgcgtctctg aactgtgat catgacaggg gttcaaacag aaagtgcctg ggccctcctt 60
ctaagtcttg ttacacaaaa aaggaaaaag aaaagatctt ctcagttaca aattctggga 120
aggagacta tacctggctc ttgccctaag tgagaggtct tccctccgc accaaaaaat 180
agaaaggctt tctatttcac tggcccagggt agggggaagg agagtaactt tgagtctgtg 240
qqlctcattt cccaagggtc cttcaatgct catnaaaacc aa 282

```

<210> 347
 <211> 201
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(201)
 <223> n = A,T,C or G

```

<400> 347
acacacataa tattataaaa tgccatctaa ttggaaggag ctttctatca ttgcaagtca 60
taaataatac ttttaaaana ntactancag cttttaccta ngctcctaaa tgcttgtaaa 120
tctgagactg actggaccca ccagaccca gggcaagat acatgttacc atatcatctt 180
tataaagaat ttttttttgt c 201

```

<210> 348
 <211> 251
 <212> DNA
 <213> Homo sapien

```

<400> 348
ctgttaatca caacatttgt gcatcacttg tgccaagtga gaaaatgttc taaaatcaca 60
agagagaaca gtgccagaat gaaactgacc ctaagtccca ggtgcccctg ggcaggcaga 120

```

aggagacact	cccagcatgg	aggagggttt	atcttttcat	cctagggtcag	gtctacaatg	180
ggggaagggt	ttattataga	actcccaaca	gccacactca	ctcctgccac	ccaccgatg	240
gcctgcctc	c					251

<210> 349
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 349						
taaaaatcaa	gccatttaat	tgtatctttg	aaggtaaaca	atatatggga	gctggatcac	60
aacccttgag	gatgccagag	ctatgggtcc	agaacatggg	gtggatttat	caacagagtt	120
cagaagggtc	tgaactctac	gtgttaccag	agaacataat	gcaattcatg	cattccaatt	180
agcaattttg	taaaatacca	gaaacagacc	ccaagagtct	ttcaagatga	ggaaaattca	240
actcctggtt	t					251

<210> 350
 <211> 908
 <212> DNA
 <213> Homo sapien

<400> 350						
ctggacactt	tgcgaggggt	tttgctggct	gctgctgctg	cccgtcatgc	tactcatcgt	60
agcccgcccg	gtgaagctcg	ctgctttccc	tacctcctta	agtgactgcc	aaacgcccac	120
cggtcggaat	tgcctctggt	atgatgacag	agaaaatgat	ctcttcctct	gtgacaccaa	180
cacctgtaaa	tttgatgggg	aatgtttaag	aattggagac	actgtgactt	gcgtctgtca	240
gttcaagtgc	aacaatgact	atgtgcctgt	gtgtggctcc	aatggggaga	gctaccagaa	300
tgagtgttac	ctgcgacagg	ctgcatgcaa	acagcagagt	gagatacttg	tggtgtcaga	360
aggatcatgt	gccacagtc	atgaaggctc	tggagaaact	agtcaaaagg	agacatccac	420
ctgtgatatt	tgccagtttg	gtgcagaatg	tgacgaagat	gccgaggatg	tctggtgtgt	480
gtgtaaatatt	gactgtttct	aaaccaactt	caatccctc	tgcgtttctg	atgggaaatc	540
ttatgataat	gcatgccaaa	tcaaagaagc	atcgtgtcag	aaacaggaga	aaattgaagt	600
catgtctttg	ggtcgatgtc	aagataaac	aactacaact	actaagtctg	aagatgggca	660
ttatgcaaga	acagattatg	cagagaatgc	taacaaatta	gaagaaagtg	ccagagaaca	720
ccacataacct	tgtccggaac	attacaatgg	cttctgcatg	catgggaagt	gtgagcattc	780
tatcaatatg	caggagccat	cttgagggtg	tgatgtggtg	tatactggac	aacactgtga	840
aaaaaaggac	tacagtgttc	tatacgttgt	tcccggtcct	gtacgatttc	agtatgtctt	900
aatcgcac						908

<210> 351
 <211> 472
 <212> DNA
 <213> Homo sapien

<400> 351						
ccagttattt	gcaagtggta	agagcctatt	taccataaat	aatactaaga	accaactcaa	60
gtcaaacctt	aatgccattg	ttatttgtga	ttaggattaa	gtagtaattt	tcaaaattca	120
cattaacttg	attttaaaat	cagwtttgyg	agtcatttac	cacaagctaa	atgtgtacac	180
tatgataaaa	acaaccattg	tattcctggt	tttctaaaca	gtcctaattt	ctaacactgt	240
atatatcctt	cgacatcaat	gaactttggt	ttcttttact	ccagtaataa	agtaggcaca	300
gatctgtcca	caacaaactt	gccctctcat	gccttgctc	tcaccatget	ctgctccagg	360
tcagccccct	tttgacctgt	ttgttttgc	aaaaacctaa	tctgtttctt	gcttttcttg	420
gtaatatata	tttagggag	atgttgcttt	gccacacac	gaagcaaagt	aa	472

<210> 352
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 352

ctcaaaagcta	atctctcggg	aatcaaacca	gaaaagggca	aggatcttag	gcatgggtgga	60
tgtggataag	gccagggtcaa	tggttgcaag	catgcagaga	aagaggtaca	toggagcgtg	120
caggctgcgt	tcggtcctta	cgatgaagac	cacgatgcag	tttccaaaca	ttgccactac	180
atacatggaa	aggaggggga	agccaacca	gaaatgggct	ttctctaata	ctgggatacc	240
aataagcaca	a					251

<210> 353

<211> 436

<212> DNA

<213> Homo sapien

<400> 353

tttttttttt	tttttttttt	tttttttaca	caatgcagtc	atatttttat	tgagtatgtg	60
cacattatgg	tattattact	atactgatta	tatttatcat	gtgacttcta	attaraaaat	120
gtatccaaaa	gcaaaacagc	agatatacaa	aattaaagag	acagaagata	gacattaaca	180
gataaggcaa	cttataacatt	gacaatccaa	atccaataca	tttaaacatt	tgggaaatga	240
gggggacaaa	tggaagccar	atcaaatttg	tgtaaaacta	ttcagtatgt	ttcccttgc	300
tcatgtctga	raaggctctc	ccttcaatgg	ggatgacaaa	ctccaaatgc	cacacaaatg	360
ttaacagaat	actagattca	cactggaacg	ggggtaaaga	agaaattatt	ttctataaaa	420
gggtccttaa	tgtagt					436

<210> 354

<211> 854

<212> DNA

<213> Homo sapien

<400> 354

cotttttctag	ttcaccagtt	ttctgcaagg	atgctgggta	gggagtgtct	gcaggaggag	60
caagtctgaa	accaaatcta	ggaacacatg	gaaacgagcc	aggcacaggg	ctggtggggc	120
atcagggacc	accctttggg	ttgatatttt	gcttaatctg	catcttttga	gtaagatcat	180
ctggcagtag	aagctgttct	ccaggtagat	ttctctagct	catgtacaaa	aacatcctga	240
aggactttgt	caggtgcctt	gctaaaagcc	agatgcgttc	ggcacttcct	tggtctgagg	300
tttaattgca	acctacaggc	actgggctca	tgctttcaag	tattttgtcc	tcacttttagg	360
gtgagtga	gatccccatt	ataggagcac	ttgggagaga	tcataataaa	gctgactcct	420
gagtacatgc	agtaatgggg	tagatgtgtg	tggtgtgtct	tcattcctgc	aagggtgctt	480
gttagggagt	gtttccagga	ggaacaagtc	tgaacccaat	catgaaataa	atggtaggtg	540
tgaactggaa	aactaattca	aaagagagat	cgtgatatca	gtgtgggtga	tacaccttgg	600
caatatggaa	ggctctaatt	tgcccatatt	tgaataata	attcagcttt	ttgtaataca	660
aaataacaaa	ggattgagaa	tcattggtgtc	taatgtataa	aagaccaggg	aaacataaat	720
atatcaactg	cataaatgta	aaatgcatgt	gacccaagaa	ggcccccagg	tggcagacaa	780
cattgtaccc	attttccctt	ccaaaatgtg	agcggcgggc	ctgctgcttt	caaggctgtc	840
acacgggatg	tcag					854

<210> 355

<211> 676

<212> DNA

<213> Homo sapien

<400> 355

gaaattlaagt	atgagctaaa	ttccctgtta	aaacctctag	gggtgacaga	tctcttcaac	60
caggtcaaaag	ctgatctttc	tggaatgtca	ccaaccaagg	gcctatatatt	atcaaaagcc	120
atccacaagt	catacctgga	tgtcagcgaa	gagggcacgg	aggcagcagc	agccactggg	180
gacagcatcg	ctgtaaaaag	cctaccaatg	agagctcagt	tcaaggcgaa	ccaccccttc	240
ctgtttcttta	taaggcacac	tcataccaac	acgatcctat	tctgtggcaa	gcttgcctct	300
ccctaatacag	atgggggttg	gtaaggctca	gagttgcaga	tgaggtgcag	agacaatcct	360
gtgactttoc	cacggccaaa	aagctgttca	cacctcacgc	acctctgtgc	ctcagtttgc	420

tcattctgcaa	aataggtcta	ggattttcttc	caaccatttc	atgagttgtg	aagctaaggc	480
tttgtaaatc	atggaaaaag	gtagacttat	gcagaaagcc	tttctggctt	tcttatctgt	540
ggtgtctcat	ttgagtgtctg	tccagtgcac	tgatcaagtc	aatgagtaaa	attttaaggg	600
attagatttt	cttgacttgt	atgtatctgt	gagatcttga	ataagtgacc	tgacatctct	660
gcttaaagaa	aaccag					676

<210> 356

<211> 574

<212> DNA

<213> Homo sapien

<400> 356

tttttttttt	tttttcagga	aaacattctc	ttactttatt	tgcattctcag	caaaggttct	60
catgtggcac	ctgactggca	tcaaaccaaa	gttcgtaggc	caacaaagat	gggccactca	120
caagcttccc	attttagat	ctcagtgcct	atgagtatct	gacacctgtt	cctctcttca	180
gtctcttagg	gaggcttaaa	tctgtctcag	gtgtgctaag	agtgccagcc	caaggkggtc	240
aaaagtccac	aaaactgcag	tctttgctgg	gatagtaagc	caagcagtgc	ctggacagca	300
gagttctttt	cttgggcaac	agataaccag	acaggactct	aatcgtgctc	ttattcaaca	360
ttcttctgtc	tctgcctaga	ctggaataaa	aagccaatct	ctctcgtggc	acagggaagg	420
agatacaagc	tcgtttacat	gtgatagatc	taacaaaggc	atctaccgaa	gtctggtctg	480
gatagacggc	acagggagct	cttaggtcag	cgctgctggt	tggaggacat	tcctgagtc	540
agctttgcag	cctttgtgca	acagtacttt	ccca			574

<210> 357

<211> 393

<212> DNA

<213> Homo sapien

<400> 357

tttttttttt	tttttttttt	tttttttttt	tacagaatat	aratgcttta	tcaactgkaet	60
taatatggkg	kottgttcac	tatacttaaa	aatgcaccac	tcataaatat	tttaattcagc	120
aagccacaac	caaracttga	ttttatcaac	aaaaacccct	aaatataaac	ggsaaaaaag	180
atagatatata	ttattccagt	ttttttaaaa	cttaaaaarat	attccattgc	cgaattaara	240
araarataag	tgttatatgg	aaagaagggc	attcaagcac	actaaaraaa	cctgaggkaa	300
gcataatctg	tacaaaatta	aactgtcctt	tttggcattt	taacaaaattt	gcaacgktct	360
tttttttctt	tttctgtttt	tttttttttt	tac			393

<210> 358

<211> 630

<212> DNA

<213> Homo sapien

<400> 358

acagggtaaa	caggaggatc	cttgctctca	cggagcttac	attctagcag	gaggacaata	60
ttaatgttta	taggaaaatg	atgagtttat	gacaaaggaa	gtagatagtg	ttttacaaga	120
gcatagagta	gggaagctaa	tccagcacag	ggaggtcaca	gagacatccc	taaggaagtg	180
gagtttaaac	tgagagaagc	aagtgcctaa	actgaaggat	gtgttgaaga	agaagggaga	240
gtagaacaat	ttgggcagag	ggaaccttat	agaccctaag	gtgggaaggt	tcaaagaact	300
gaaagagagc	tagaacagct	ggagccgttc	tccggtgtaa	agaggagtca	aagagataag	360
attaagatg	tgaagattaa	gatcttggtg	gcattcaggg	attggcactt	ctacaagaaa	420
tactgaagg	gagtaatgtg	acattacttt	tactttcagg	atggccattc	taactccagg	480
gggtagactg	gactaggtaa	gactggaggc	aggtagacct	cttctaaggc	ctgcgatagt	540
gaaagacaaa	aataagtggg	gaaattcagg	ggatagttaa	aatcagtagg	acttaatgag	600
caagccagag	gttcctccac	aacaaccagt				630

<210> 359

<211> 620

<212> DNA

<213> Homo sapien

<400> 359

acagcattcc	aaaatatata	tctagagact	aarrgtaaat	gctctatagt	gaagaagtaa	60
taattaaaaa	atgctactaa	tatagaaaat	ttataatcag	aaaaataaat	attcagggag	120
ctcaccagaa	gaataaagtg	ctctgccagt	tattaaagga	ttactgctgg	tgaattaaat	180
atggcattcc	ccaagggaaa	tagagagatt	ottctggatt	atgttcaata	tttatttcac	240
aggattaact	gttttaggaa	cagatataaa	gcttcgccac	ggaagagatg	gacaaagcac	300
aaagacaaca	tgatacotta	ggaagcaaca	ctaccctttc	aggcataaaa	tttgagagaa	360
tgcaacatta	tgcttcatga	ataatatgta	gaaagaaggt	ctgatgaaaa	tgacatcctt	420
gaagtaagat	aactttataa	gaattctggg	tcaataaaaa	ttctttgaag	aaaacatcca	480
aatgtcattg	acttatcaaa	tactatcttg	gcataatacc	tatgaaggca	aaactaaaca	540
aacaaaaagc	tcacaccaaa	caaaaccatc	aacttatttt	gtattctata	acatacgaga	600
ctgtaagat	gtgacagtgt					620

<210> 360

<211> 431

<212> DNA

<213> Homo sapien

<400> 360

aaaaaaaaaa	agccagaaca	acatgtgata	gataaatatga	ttggctgcac	acttccagac	60
tgatgaatga	tgaacgtgat	ggactattgt	atggagcaca	tcttcagcaa	gagggggaaa	120
tactcatcat	ttttggccag	cagttgtttg	atcaccaaac	atcatgccag	aatactcagc	180
aaaccttctt	agctcttgag	aagtcaaatg	ccgggggaat	ttattcctgg	caattttaat	240
tggactcctt	atgtgagagc	agcggctacc	cagctggggg	ggtggagcga	acccgtcact	300
agtggacatg	cagtggcaga	gctcctggta	accacctaga	ggaatacaca	ggcacatgtg	360
tgatgccaag	cgtgacacct	gtagcactca	aatttgcctt	gtttttgtct	ttcgggtgtg	420
agattcttag	t					431

<210> 361

<211> 351

<212> DNA

<213> Homo sapien

<400> 361

acactgattt	ccgatcaaaa	gaatcatcat	ctttaccttg	acttttcagg	gaattactga	60
actttcttct	cagaagatag	ggcacagcca	ttgccttggc	ctcacttgaa	gggtctgcat	120
ttgggtctct	tggtctcttg	ccaagtcttc	cagccactcg	aggagagaa	atcgggaggt	180
ttgacttctt	ccggggcttt	cccaggggct	tcaccgtgag	ccttgccggc	ctcagggctg	240
caatccttga	ttcaatgtct	gaaacctcgc	tctctgcctg	ctggacttct	gaggccgtca	300
ctgccactct	gtcctccagc	tctgacagct	cctcatctgt	ggctcctgtt	t	351

<210> 362

<211> 463

<212> DNA

<213> Homo sapien

<400> 362

acttcatcag	gccataatgg	gtgcctcccc	tgagaatcca	agcacctttg	gactgcgcga	60
tgtagatgag	ccggctgaag	atcttgccga	tgcgcggctt	cagggcggaag	ttcttgccgc	120
ccccggtcac	agaaatgacc	aggttgggtg	ttttcaggtg	ccagtgcctg	gtcagcagct	180
cgtaaaggat	ttccgcgtcc	gtgtcgcagg	acagacgtat	atacttcctt	ttcttcccca	240
gtgtctcaaa	ctgaatatcc	ccaaaggcgt	cggtaggaaa	ttccttgggt	tgtttcttgt	300
agttccattt	ctcacttttg	ttgatctggg	tgccttccat	gtgctggctc	tgggcatagc	360
gacanttgca	cacattctcc	ctgataagca	cgatggtgtg	gacaggaagg	aaggatttca	420
ttgggctgtc	ttatggaaac	tggtatttgt	agcttaataa	gac		463

<210> 363
 <211> 653
 <212> DNA
 <213> Homo sapien

 <220>
 <221> misc_feature
 <222> (1)...(653)
 <223> n = A,T,C or G

<400> 363
 acccccagagt ncctgncgtgg catactgnga acgaccaacg acacacccaa gctcggcctc 60
 ctcttgngga ttctgggtga catcttcatg aatggcaacc gtgccagwga ggctgtcctc 120
 tgggaggcac tacgcaagat gggactgcgt cctggggtga gacatcctct ccttgagat 180
 ctaacgaaac ttctcaccta tgagttgtaa agcagaaata cctgnactac agacgagtgc 240
 ccaacagcaa cccccggaa gtatgagttc ctctrgggcc tccgttccta ccatgagasc 300
 tagcaagatg naagtgttga gantcattgc agaggttcag aaaagagacc cntcgtgact 360
 ggtctgcaca gttcatggag gctgcagatg aggccttgga tgctctggat gctgctgcag 420
 ctgaggccga agccccgggt gaagcaagaa cccgcattgg aattggagat gaggctgtgt 480
 ntgggccctg gagctgggat gacattgagt ttgagctgct gacctgggat gaggaaggag 540
 attttgaga tcctnggtcc agaattccat ttacctctct ggcagatac caccagaatg 600
 cccgctccag attccctcag acctttgccg gtcccattat tggtcstggt ggt 653

<210> 364
 <211> 401
 <212> DNA
 <213> Homo sapien

<400> 364
 actagaggaa agacgttaaa ccactctact accacttgtg gaactctcaa agggtaaattg 60
 acaaagccaa tgaatgactc taaaaacaat atttacattt aatggtttgt agacaataaa 120
 aaaacaaggt ggatagatct agaattgtaa cattttaaga aaaccatagc atttgacaga 180
 tgagaaagct caattataga tgcaaagtta taactaaact actatagtag taaagaaata 240
 catttcacac ccttcatata aattcactat ctgggcttga ggcactccat aaaatgtatc 300
 acgtgcatag taaatcttta tatttgctat ggcgttgca tagaggactt ggactgcaac 360
 aagtggatgc gcgaaaaatg aaatcttctt caatagccca g 401

<210> 365
 <211> 356
 <212> DNA
 <213> Homo sapien

<400> 365
 ccagtgtcat atttgggctt aaaatttcaa gaagggcact tcaaattggct ttgcatttgc 60
 atgtttcagt gctagagcgt aggaatagac cctggcgctc actgtgagat gttcttcagc 120
 taccagagca tcaagtctct gcagcaggtc attcttgggt aaagaaatga cttccacaaa 180
 ctctccatcc cctggctttg gcttcggcct tgcgttttcg gcatcatctc cgtaaatggt 240
 gactgtcacg atgtgtatag tacagtttga caagcctggg tccatacaga ccgctggaga 300
 acattcggca atgtcccctt ttagccagct ttctttcttc agctcccgga gagcag 356

<210> 366
 <211> 1851
 <212> DNA
 <213> Homo sapien

<400> 366
 tcatcacat tgccagcagc ggcaccgtta gtcaggtttt ctgggaatcc cacatgagta 60
 cttccgtgtt cttcattctt cttcaatagc cataaatctt ctactctgtg ctggctgttt 120

tcacttcctt	taagcctttg	tgactcttcc	tctgatgtca	gctttaagtc	ttgttctgga	180
ttgctgtttt	cagaagagat	ttttaacatc	tgtttttctt	tgtagtcaga	aagtaactgg	240
caaattacat	gatgatgact	agaaacagca	tactctctgg	cogtctttcc	agatcttgag	300
aagatacatc	aacattttgc	tcaagtagag	ggctgactat	acttgotgat	ccacaacata	360
cagcaagtat	gagagcagtt	cttccatata	tatccagcgc	atttaaattc	gcttttttct	420
tgattaaaaa	tttcaccact	tgctgttttt	gtcctgttat	accaagtagc	agtgggtgtga	480
ggccatgctt	gttttttgat	tcgatatcag	caccgtataa	gagcagtgct	ttggccatta	540
atztatcttc	attgtagaca	gcatagtgtg	gagtgggtat	tccatactca	tctggaatat	600
ttggatcagt	gccatgttcc	agcaacatta	acgcacattc	atcttctctg	cattgtacgg	660
cctttgtcag	agctgtcctc	tttttgttgt	caaggacatt	aagttgacat	cgtctgtcca	720
gcacgagttt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	gcagtcctct	780
tttgcttgte	cctcttggtc	acatccgtgt	ccctgagcat	gacgatgaga	tcctttctgg	840
ggactttacc	ccaccaggca	gctctgtgga	gcttgtccag	atcttctcca	tggacgtggg	900
acctgggac	catgaaggcg	ctgtcatcgt	agtctcccca	agcgaccacg	ttgctcttgc	960
cgtccctctg	cagcagggga	agcagtggca	gcaccacttg	cacctcttgc	tcccaagcgt	1020
cttcacagag	gagtcgttgt	ggtctccaga	agtgcaccag	ttgctcttgc	cgtccctct	1080
gtccatccag	ggaggaagaa	atgcaggaaa	tgaaagatgc	atgcacgatg	gtatactcct	1140
cagccatcaa	acttctggac	agcaggtcac	ttccagcaag	gtggagaaag	ctgtccaccc	1200
acagaggatg	agatccagaa	accacaatat	ccattcacaa	acaaacactt	ttcagccaga	1260
cacagggtact	gaaatcatgt	catctgcggc	aacatgggtg	aacctacca	atcacacatc	1320
aagagatgaa	gacatgcag	tatatctgca	caacgtaata	ctcttcatcc	ataacaaaaat	1380
aatataattt	tcctctggag	ccatatggat	gaactatgaa	ggaagaactc	cccgaagaag	1440
ccagtcgcag	agaagccaca	ctgaagctct	gtcctcagcc	atcagcgcca	cggacaggag	1500
tgtgtttctt	ccccagtgat	gcagcctcaa	gttatccga	agctgcgcga	gcacacgggtg	1560
gtccttgaga	aacaccccag	ctcttccggt	ctaacacagg	caagtcaata	aatgtgataa	1620
tcacataaac	agaattaaaa	gcaaagtcac	ataagcatct	caacagacac	agaaaaggca	1680
tttgacaaaa	tccagcatcc	ttgtatttat	tgttgcagtt	ctcagaggaa	atgcttctaa	1740
cttttcccca	tttagtatta	tgttggtgtg	gggtgtgtca	taggtggttt	ttattacttt	1800
aaggatgtgc	ccttctatgc	ctgtttttgt	gagggtttta	attctcgtgc	c	1851

<210> 367

<211> 668

<212> DNA

<213> Homo sapien

<400> 367

cttgagcttc	caaataygga	agactggccc	ttacacasgt	caatgttaaa	atgaatgcac	60
ttcagtattt	tgaagataaa	atttgrtagat	ctataccttg	ttttttgatt	cgatatcagc	120
accrtataag	agcagtgctt	tggccattaa	tttatctttc	attttagaca	gortagtgya	180
gagtgggtat	tccatactca	tctggaatat	ttggatcagt	gccatgttcc	agcaacatta	240
acgcacattc	atcttccctg	cattgtacgg	cctgtcagta	ttagacccaa	aaacaaatta	300
catatcttag	gaattcaaaa	taacattcca	cagctttcac	caactagtta	tatttaaagg	360
agaaaaactca	tttttatgcc	atgtattgaa	atcaaaccce	cctcatgctg	atatagttgg	420
ctactgcata	cctttatcag	agctgtcctc	tttttgttgt	caaggacatt	aagttgacat	480
cgtctgtcca	gcaggagtgt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	540
gcagtcctat	gagagtgaga	agacttttta	ggaaattgta	gtgcactagc	tacagccata	600
gcaatgatcc	atgtaactgc	aaacactgaa	tagcctgcta	ttactctgcc	ttcaaaaaaa	660
aaaaaaaa						668

<210> 368

<211> 1512

<212> DNA

<213> Homo sapien

<400> 368

ggctcgcaca	gggggsgcgt	gggctttcct	cgggtgggtg	tgggttttcc	ctgggtgggg	60
tgggtgggc	trgaatcccc	tgctggggtt	ggcaggtttt	ggctgggatt	gacttttytc	120
ttcaaacaga	ttggaaaccc	ggagttacct	gctagtgggt	gaaactgggt	ggtagacgcg	180

atctgttggc	tactactggc	ttctcctggc	tgttaaaagc	agatgggtgg	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagt	600
gccttcatgg	agcccaggta	ccacgtccgt	ggagaagatc	tggacaagct	ccacagagct	660
gcctgggtggg	gtaaagtccc	cagaaaggat	ctcatcgta	tgctcaggga	cactgacgtg	720
aacaagaagg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcgtt	aatggtgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	aggtatagat	ctactaattt	tatcttcaaa	atactgaaat	gcattcattt	1080
taacattgac	gtgtgtaagg	gccagtcttc	cgtatttggg	agctcaagca	taacttgaat	1140
gaaaatattt	tgaaatgacc	taattatctm	agactttatt	ttaaatattg	ttattttcaa	1200
agaagcatta	gagggtagac	tttttttttt	ttaaatgcac	ttctggtaaa	tacttttggt	1260
gaaaacactg	aatttgtaaa	aggtaatact	tactattttt	caatttttcc	ctcctaggat	1320
ttttttcccc	taatgaatgt	aagatggcaa	aatttgcctt	gaaatagggt	ttacatgaaa	1380
actccaagaa	aagttaaaca	tgtttcagtg	aatagagatc	ctgctccttt	ggcaagttcc	1440
taaaaaacag	taatagatac	gaggtgatgc	gcctgtcagt	ggcaagggtt	aagatatttc	1500
tgatctcgtg	cc					1512

<210> 369

<211> 1853

<212> DNA

<213> Homo sapien

<400> 369

gggtcgccca	gggggsgcgt	gggctttcct	cggttgggtg	tgggttttcc	ctgggtgggg	60
tgggctgggc	trgaatcccc	tgttgggttt	ggcaggtttt	ggctgggatt	gacttttytc	120
itcaaacaga	ttggaaaccc	ggagttacct	gctagttggt	gaaactgggt	ggtagacgcg	180
atctgttggc	tactactggc	ttctcctggc	tgttaaaagc	agatgggtgg	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagy	600
gccttcatgg	akcccaggta	ccacgtccrt	ggagaagatc	tggacaagct	ccacagagct	660
gcctgggtggg	gtaaagtccc	cagaaaggat	ctcatcgta	tgctcaggga	cackgaygtg	720
aacaagargg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcgtt	aatggtgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	agcatggcct	cacaccactg	ytacttggtr	tacatgagca	aaaacagcaa	1080
gtsgtgaaat	ttttaatyaa	gaaaaaagcg	aattttaaatt	gcrctggata	gatatggaag	1140
ractgctctc	atacttgctg	tatgttgtgg	atcagcaagt	atagtcagcc	ytctacttga	1200
gcaaaatrtr	gatgtatctt	ctcaagatct	ggaaagacgg	ccagagagta	tgctgtttct	1260
agtcatcatc	atgtaatttg	ccagttactt	tctgactaca	aagaaaaaca	gatgttaaaa	1320
atctcttctg	aaaacagcaa	tccagaacaa	gacttaaagc	tgacatcaga	ggaagagtca	1380
caaaggctta	aaggaagtga	aaacagccag	ccagaggcat	ggaaactttt	aaatttaaac	1440
ttttgggtta	atgttttttt	tttttgcctt	aataatatta	gatagtccca	aatgaaatwa	1500
cctatgagac	taggctttga	gaatcaatag	attctttttt	taagaatctt	ttggctagga	1560
gcggtgtctc	acgcctgtaa	ttccagcacc	ttgagaggct	gaggtgggca	gatcacgaga	1620
tcaggagatc	gagaccatcc	tggctaacac	ggtgaaaccc	catctctact	aaaaatacaa	1680


```

aaaetttagct ggggtgtgggtg gcgggtgcct gtagtcccag ctactcagga rgetgaggca 1740
ggagaatggc atgaaccccg gsggtggagg ttgcagttag ccgagatccg ccactacact 1800
caactctggg tgacagagca agactctgtc tcaaaaaaaaa aaaaaaaaaa aaa 1853

```

```

<210> 370
<211> 2184
<212> DNA
<213> Homo sapien

```

```

<400> 370
ggcagcagaa ttaaaaccct cagcaaaaaca ggcatagaag ggacatacct taaagtaata 60
aaaaccacct atgacaagcc cacagccaac ataatactaa atggggaaaaa gttagaagca 120
tttccctctga gaactgcaac aataaatata aggatgctgg attttgtcaa atgccttttc 180
tgtgtctgtt gagatgctta tgtgactttg cttttaattc tgtttatgtg attatcacat 240
ttattgactt gcctgtgtta gaccggaaga gctgggggtg ttctcaggag ccaccgtgtg 300
ctgcggcagc ttccgggataa cttgaggctg catcactggg gaagaaaacac aytccgtgtc 360
gtggcgctga tggctgagga cagagcttca gtgtggcttc tctgcgactg gctttctcgg 420
ggagtctctc ctccatagtt catccatatt gctccagagg aaaattatat tattttgtta 480
tggatgaaga gtattacgtt gtgcagatat actgcagtgt cttcatctct tgatgtgtga 540
ttgggtaggt tccaccatgt tgcgcagat gacatgattt cagtacctgt gtctggctga 600
aaagtgtttg tttgtgaatg gatattgttg tttctggatc tcatcctctg tgggtggaca 660
qctttctcca ccttgcctga agtgacctgc tgtccagaag tttgatggct gaggagtata 720
ccatcgtgca tgcattcttc atttccctga tttcttcctc cctggatgga cagggggagc 780
ggcaagagca acgtgggcac ttctggagac cacaacgact cctctgtgaa gacgtttggg 840
agcaagaggt gcaagtgggt ctgccactgc ttccctgctg gcagggggagc ggcaagagca 900
acgtggtcgc ttgggggagac tacgatgaca gcgccttcat ggatcccagg taccacgtcc 960
atggagaaga tctggacaag ctccacagag ctgcctgggt gggtaaaagtc cccagaaaagg 1020
atctcatcgt catgctcagg gacacggatg tgaacaagag ggacaagcaa aagaggactg 1080
ctctacatct ggcctctgcc aatgggaatt cagaagtagt aaaactcgtg ctggacagac 1140
gatgtcaact taatgtcctt gacaacaaaa agaggacagc tctgacaaaag gccgtacaat 1200
gccaggaaga tgaatgtgct ttaatgttgc tggaaacatg cactgatcca aatattccag 1260
atgagtatgg aaataccact ctacactatg ctgtctacaa tgaagataaa ttaatggcca 1320
aagcactgct ctatatacgt gctgatatcg aatcaaaaaa caagcatggc ctcacaccac 1380
tgctacttgg tatacatgag caaaaacagc aagtggtgaa atttttaatc aagaaaaaag 1440
cgaatttaaa tgcgctggat agatatggaa gaactgctct catacttgct gtatgttgtg 1500
gatcagcaag tatagtcagc cctctacttg agcaaaatgt tgatgtatct tctcaagatc 1560
tggaaaagac gccagagagt atgctgtttc tagtcatcat catgtaattt gccagttact 1620
ttctgactac aaagaaaaac agatgtttaa aatctcttct gaaaacagca atccagaaca 1680
agacttaaaag ctgacatcag aggaagagtc acaaaggctt aaaggaaagt aaaacagcca 1740
gccagaggca tggaaacttt taaatttaaa cttttggttt aatgtttttt ttttttgctt 1800
taataatatt agatagtccc aaatgaaatw acctatgaga ctaggctttg agaatcaata 1860
gattcttttt ttaagaatct tttggctagg agcgggtgtc cagcctgta attccagcac 1920
cttgagaggc tgagggtggc agatcacgag atcaggagat cgagaccatc ctggctaaca 1980
cggtgaaacc ccactctctac taaaaatata aaaacttagc tgggtgtggg ggcgggtgcc 2040
tgtagtccca gctactcagg argctgaggc aggagaatgg catgaacccg ggagggtggg 2100
gttgcaagtga gccgagatcc gccactacac tccagcctgg gtgacagagc aagactctgt 2160
ctcaaaaaaa aaaaaaaaaa aaaa 2184

```

```

<210> 371
<211> 1855
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(1855)
<223> n = A,T,C or G

```

<400> 371

tgcacgcatc	ggccagtgtc	tgtgccacgt	acactgacgc	cccctgagat	gtgcacgccg	60
cacgcgcacg	ttgcacgcgc	ggcagcggct	tggtctggctt	gtaacggctt	gcacgcgcac	120
gccgcccccg	cataaccgtc	agactggcct	gtaacggctt	gcaggcgcac	gccgcacgcg	180
cgtaacggct	tggtctggcct	gtaacggctt	gcacgtgcat	gctgcacgcg	cgtaacggc	240
ttggctggca	tgtagccgct	tggtctggct	ttgcatttct	tgtctggctk	ggcgttgkty	300
tcttgatttg	acgtcttctc	cttgatkgac	cgttttctct	ttggatkgac	gtttctytyt	360
tgcgcttctc	ttgctggact	tgacctttty	tctgctgggt	ttggcattcc	tttgggggtg	420
gctgggtgtt	ttctccgggg	gggktkgccc	ttcctggggg	gggcgtgggk	cgcccccagg	480
gggcgtgggc	tttccccggg	tgggtgtggg	ttttcctggg	gtgggggtgg	ctgtgctggg	540
atccccctgc	tgggggtggc	agggattgac	ttttttcttc	aaacagattg	gaaaccgcga	600
gtaacntgct	agttgggtgaa	actggttggt	agacgcgcat	tgctggtaact	actgtttctc	660
ctggctgtta	aaagcagatg	gtggctgagg	ttgattcaat	gccggctgct	tcttctgtga	720
agaagccatt	tggctctcagg	agcaagatgg	gcaagtgggtg	cgccactgct	tccccctgctg	780
caggggggagc	ggcaagagca	acgtgggcac	ttctggagac	cacaacgact	cctctgtgaa	840
gacgcttggg	agcaagaggt	gcaagtgggtg	ctgccactg	cttccccctgc	tgcaggggag	900
cggcaagagc	aacgtgkcg	cttggggaga	ctacgatgac	agcgccttca	tggakcccag	960
gtaccacgtc	crtggagaag	atctggacaa	gctccacaga	gctgcctggt	ggggtaaagt	1020
ccccagaaaag	gatctcatcg	tcatgctcag	ggacactgay	gtgaacaaga	rggacaagca	1080
aaagaggact	gctctacatc	tggcctctgc	caatgggaat	tcagaagtag	taaaactcgt	1140
gctggacaga	cgatgtcaac	ttaatgtcct	tgacaacaaa	aagaggacag	ctctgacaaa	1200
ggcgtacaaa	tgccaggaag	atgaatgtgc	gttaatgttg	ctggaacatg	gcaactgatcc	1260
aaatattcca	gatgagtatg	gaaataccac	tctacactat	gctgtctaca	atgaagataa	1320
attaatggcc	aaagcactgc	tcttatacgg	tgctgatata	gaatcaaaaa	acaaggtata	1380
gatctactaa	ttttatcttc	aaaatactga	aatgcattca	ttttaacatt	gacgtgtgta	1440
agggccagtc	ttccgtatct	ggaagctcaa	gcataaactg	aatgaaaata	ttttgaaatg	1500
acctaattat	ctaagacttt	attttaaata	ttgttatctt	caaagaagca	ttagagggtg	1560
cagttttttt	tttttaaata	cacttctggt	aaatactttt	gttgaaaaca	ctgaatttgt	1620
aaaaggtaat	acttactatt	tttcaatttt	tccctcctag	gatttttttc	ccctaataag	1680
tgtaagatgg	caaaaatttg	cctgaaatag	gttttacatg	aaaactccaa	gaaaagttaa	1740
acatgtttca	gtgaatagag	atcctgctcc	tttggaagt	tcctaaaaaa	cagtaataga	1800
tacgaggtga	tgccgctgtc	agtggcaagg	tttaagatat	ttctgatctc	gtgcc	1855

<210> 372

<211> 1059

<212> DNA

<213> Homo sapien

<400> 372

gcaacgtggg	cacttctgga	gaaccacaacg	actcctctgt	gaagacgctt	gggagcaaga	60
ggtgcaagtg	gtgctgcccc	ctgcttcccc	tgctgcaggg	gagcggcaag	agcaacgtgg	120
gcgcttgrgg	agactmcgat	gacagygcct	tcattggagcc	caggtaccac	gtccgtggag	180
aagatctgga	caagctccac	agagctgccc	tggtggggta	aagtccccag	aaaggatctc	240
atcgtcatgc	tcaggggacac	tgaygtgaac	aagarggaca	agcaaaagag	gactgctcta	300
catctggcct	ctgccaatgg	gaattcagaa	gtagtataaac	tcstgctgga	cagacgatgt	360
caacttaatg	tccttgacaa	caaaaagagg	acagctctga	yaaaggccgt	acaatgccag	420
gaagatgaat	gtgcgttaat	gttgctggaa	catggcactg	atccaaatat	tccagatgag	480
tatggaaata	ccactctrca	ctaygctrct	tayaatgaag	ataaattaat	ggccaaagca	540
ctgctcttat	ayggtgctga	tatcgaatca	aaaaacaagg	tatagatcta	ctaattttat	600
cttcaaaaata	ctgaaatgca	ttcattttta	cattgacgtg	tgtaagggcc	agtcttccgt	660
atgttggaagc	tcaagcataa	cttgaatgaa	aatatttttg	aatgacctaa	ttatctaaaga	720
ctttattttta	aatattgtta	ttttcaaaga	agcattagag	ggtacagttt	ttttttttta	780
aatgcacttc	tggtaaatac	ttttgttgaa	aacactgaat	ttgtaaaagg	taatacttac	840
tatttttcaa	tttttccctc	ctaggatttt	tttcccctaa	tgaatgtaag	atggcaaaat	900
ttgccttgaa	atagggtttta	catgaaaact	ccaagaaaag	ttaaactatg	ttcagtgaat	960
agagatcctg	ctcctttggc	aagttcctaa	aaaacagtaa	tagatacgag	gtgatgcgcc	1020
tgctcagtggc	aagggtttaag	atattttctga	tctcgtgcc			1059

<210> 373
 <211> 1155
 <212> DNA
 <213> Homo sapien

<400> 373
 atggtggttg aggttgattc catgccggct gcctcttctg tgaagaagcc atttggtctc 60
 aggagcaaga tgggcaagtg gtgctgccgt tgcttccctt gctgcaggga gagcggaag 120
 agcaacgtgg gcacttcttg agaccacgac gactctgcta tgaagacact caggagcaag 180
 atgggcaagt ggtgccgcca ctgcttcccc tgctgcaggg ggagtggcaa gagcaacgtg 240
 atgcttcttg gagaccaaga cgaactctgt atgaagacac tcaggaacaa gatgggcaag 300
 tgggtgctgc actgcttccc ctgctgcagg gggagcggca agagcaaggt gggcgcttg 360
 ggagactacg atgacagtgc ctcatggag ccaggtacc acgtccgtgg agaagatctg 420
 gacaagctcc acagagctgc ctgggtgggt aaagtcccca gaaaggatct catcgctcatg 480
 ctcaaggaca ctgacgtgaa caagaaggac aagcaaaaga ggactgctct acatctggcc 540
 tctgccaatg ggaattcaga agtagtaaaa ctctgctgg acagacgatg tcaacttaat 600
 gtcttgaca acaaaaagag gacagctctg ataaaggccg tacaatgcca ggaagatgaa 660
 tgtgcgttaa tgttgctgga acatggcact gatccaaata ttccagatga gtatggaaat 720
 accactctgc actacgctat ctataatgaa gataaattaa tggccaaagc actgctctta 780
 tatggtgctg atatcgaatc aaaaaacaag catggcctca caccactgtt acttggtgta 840
 catgagcaaa aacagcaagt cgtgaaatth ttaatcaaga aaaaagcgaa tttaaatgca 900
 ctggatagat atggaaggac tgctctcata ctgctgtat gttgtggatc agcaagtata 960
 gtcagccttc tacttgagca aaatattgat gtatcttctc aagatctatc tggacagacg 1020
 gccagagagt atgctgtttc tagtcatcat catgtaatth gccagttact ttctgactac 1080
 aaagaaaaac agatgctaaa aatctcttct gaaaacagca atccagaaaa tgtctcaaga 1140
 accagaaata aataa 1155

<210> 374
 <211> 2000
 <212> DNA
 <213> Homo sapien

<400> 374
 atggtggttg aggttgattc catgccggct gcctcttctg tgaagaagcc atttggtctc 60
 aggagcaaga tgggcaagtg gtgctgccgt tgcttccctt gctgcaggga gagcggaag 120
 agcaacgtgg gcacttcttg agaccacgac gactctgcta tgaagacact caggagcaag 180
 atgggcaagt ggtgccgcca ctgcttcccc tgctgcaggg ggagtggcaa gagcaacgtg 240
 atgcttcttg gagaccaaga cgaactctgt atgaagacac tcaggaacaa gatgggcaag 300
 tgggtgctgc actgcttccc ctgctgcagg gggagcggca agagcaaggt gggcgcttg 360
 ggagactacg atgacagtgc ctcatggag ccaggtacc acgtccgtgg agaagatctg 420
 gacaagctcc acagagctgc ctgggtgggt aaagtcccca gaaaggatct catcgctcatg 480
 ctcaaggaca ctgacgtgaa caagaaggac aagcaaaaga ggactgctct acatctggcc 540
 tctgccaatg ggaattcaga agtagtaaaa ctctgctgg acagacgatg tcaacttaat 600
 gtcttgaca acaaaaagag gacagctctg ataaaggccg tacaatgcca ggaagatgaa 660
 tgtgcgttaa tgttgctgga acatggcact gatccaaata ttccagatga gtatggaaat 720
 accactctgc actacgctat ctataatgaa gataaattaa tggccaaagc actgctctta 780
 tatggtgctg atatcgaatc aaaaaacaag catggcctca caccactgtt acttggtgta 840
 catgagcaaa aacagcaagt cgtgaaatth ttaatcaaga aaaaagcgaa tttaaatgca 900
 ctggatagat atggaaggac tgctctcata ctgctgtat gttgtggatc agcaagtata 960
 gtcagccttc tacttgagca aaatattgat gtatcttctc aagatctatc tggacagacg 1020
 gccagagagt atgctgtttc tagtcatcat catgtaatth gccagttact ttctgactac 1080
 aaagaaaaac agatgctaaa aatctcttct gaaaacagca atccagaaaa agacttaag 1140
 ctgacatcag aggaagagtc acaaaggctc aaaggcagtg aaaatagcca gccagagaaa 1200
 atgtctcaag aaccagaaat aaataaggat ggtgatagag aggttgaaaga agaaatgaag 1260
 aagcatgaaa gtaataatgt gggattacta gaaaacctga ctaatggtgt cactgctggc 1320
 aatggtgata atggattaat tcttcaaagg aagagcagaa cacctgaaaa tcagcaattt 1380
 ctgacaacg aaagtgaaga gtatcacaga atttgcgaat tagtttctga ctacaaagaa 1440
 aaacagatgc caaaatactc ttctgaaaaa agcaaccag aacaagactt aaagctgaca 1500

tcagaggaag	agtcacaaag	gcttgagggc	agtgaaaatg	gccagccaga	gctagaaaaat	1560
tttatggcta	tcgaagaaat	gaagaagcac	ggaagtactc	atgtcggatt	cccagaaaac	1620
ctgactaatg	gtgccactgc	tggcaatggg	gatgatggat	taattcctcc	aaggaagagc	1680
agaacacctg	aaagccagca	atttcctgac	actgagaatg	aagagtatca	cagtgcgcaa	1740
caaaatgata	ctcagaagca	attttgtgaa	gaacagaaca	ctggaatatt	acacgatgag	1800
attctgattc	atgaagaaaa	gcagatagaa	gtgggtgaaa	aaatgaattc	tgagctttct	1860
cttagttgta	agaaagaaaa	agacatcttg	catgaaaata	gtacgttgcg	ggaagaaatt	1920
gccatgctaa	gactggagct	agacacaatg	aaacatcaga	gccagctaaa	aaaaaaaaaa	1980
aaaaaaaaaa	aaaaaaaaaa					2000

<210> 375

<211> 2040

<212> DNA

<213> Homo sapien

<400> 375

atggtggttg	agggtgattc	catgccggct	gcctcttctg	tgaagaagcc	atthggtctc	60
aggagcaaga	tgggcaagtg	gtgctgccgt	tgttccccct	gctgcaggga	gagcggcaag	120
agcaacgttg	gcacttctgg	agaccacgac	gactctgcta	tgaagacact	caggagcaag	180
atgggcaagt	ggtgccgcca	ctgcttcccc	tgtcgcaggg	ggagtggcaa	gagcaacgtg	240
ggcgcttctg	gagaccacga	cgactctgct	atgaagacac	tcaggaacaa	gatgggcaag	300
tgggtgctgcc	actgcttccc	ctgctgcagg	gggagcggca	agagcaaggt	ggcgcttgg	360
ggagactacg	atgacagtgc	cttcatggag	cccaggtacc	acgtccgtgg	agaagatctg	420
gacaagctcc	acagagctgc	ctggtggggg	aaagtcccca	gaaaggatct	catcgtcatg	480
ctcagggaca	ctgacgtgaa	caagaaggac	aagcaaaaaga	ggactgctct	acatctggcc	540
tctgccaatg	ggaattcaga	agtagtaaaa	ctcctgctgg	acagacgatg	tcaacttaat	600
gtccttgaca	acaaaaagag	gacagctctg	ataaaggccg	tacaatgcca	ggaagatgaa	660
tgtgcgttaa	tgttgctgga	acatggcact	gatccaaata	ttccagatga	gtatggaaat	720
accactctgc	actacgctat	ctataatgaa	gataaattaa	tggccaaagc	actgctctta	780
tatggtgctg	atatcgaatc	aaaaaacaag	catggcctca	caccactgtt	acttgggtgta	840
catgagcaaa	aacagcaagt	cgtgaaatth	ttaatcaaga	aaaaagcgaa	tttaaatgca	900
ctggatagat	atggaaggac	tgtctctcata	cttgcgtgat	gttgtggatc	agcaagtata	960
gtcagccttc	tacttgagca	aaatattgat	gtatcttctc	aagatctatc	tggacagagc	1020
gccagagagt	atgctgtttc	tagtcatcat	catgtaatth	gccagttact	ttctgactac	1080
aaagaaaaac	agatgctaaa	aatctcttct	gaaaacagca	atccagaaca	agacttaaag	1140
ctgacatcag	aggaagagtc	acaaaggthc	aaaggcagtg	aaaatagcca	gccagagaaa	1200
atgtctcaag	aaccagaaat	aaataaggat	gggtatagag	aggttgaaga	agaaatgaag	1260
aagcatgaaa	gtaataatgt	gggattacta	gaaaacctga	ctaattggtg	cactgctggc	1320
aatggtgata	atggattaat	tcctcaaagg	aagagcagaa	cacctgaaaa	tcagcaatth	1380
cctgacaacg	aaagtgaaga	gtatcacaga	atthgcgaat	tagthtctga	ctacaaagaa	1440
aaacagatgc	caaaatactc	ttctgaaaac	agcaaccag	aacaagactt	aaagctgaca	1500
tcagaggaag	agtcacaaag	gcttgagggc	agtgaaaatg	gccagccaga	gaaaagatct	1560
caagaaccag	aaataaataa	ggatggtgat	agagagctag	aaaatthtat	ggctatcgaa	1620
gaaatgaaga	agcacggaag	tactcatgct	ggattcccag	aaaacctgac	taatggtgcc	1680
actgctggca	atggtgatga	tggattaatth	cctccaagga	agagcagaac	acctgaaagc	1740
cagcaatthc	ctgacactga	gaatgaagag	tatcacagtg	acgaacaaaa	tgatactcag	1800
aagcaattht	gtgaagaaca	gaacactgga	atattacacg	atgagattct	gattcatgaa	1860
gaaaagcaga	tagaagtggg	tgaaaaaatg	aattctgagc	thtctcttag	ttgtaagaaa	1920
gaaaagacaa	tcttgcatga	aaatagtacg	ttgcgggaag	aaattgccat	gctaagactg	1980
gagctagaca	caatgaaaca	tcagagccag	ctaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2040

<210> 376

<211> 329

<212> PRT

<213> Homo sapien

<400> 376

Met Asp Ile Val Val Ser Gly Ser His Pro Leu Trp Val Asp Ser Phe

```

1           5           10           15
Leu His Leu Ala Gly Ser Asp Leu Leu Ser Arg Ser Leu Met Ala Glu
20           25           30
Glu Tyr Thr Ile Val His Ala Ser Phe Ile Ser Cys Ile Ser Ser Ser
35           40           45
Leu Asp Gly Gln Gly Glu Arg Gln Glu Gln Arg Gly His Phe Trp Arg
50           55           60
Pro Gln Arg Leu Leu Cys Glu Asp Ala Trp Glu Gln Glu Val Gln Val
65           70           75           80
Val Leu Pro Leu Leu Pro Leu Leu Gln Gly Ser Gly Lys Ser Asn Val
85           90           95
Val Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe Met Asp Pro Arg Tyr
100          105          110
His Val His Gly Glu Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp
115          120          125
Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp
130          135          140
Val Asn Lys Arg Asp Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser
145          150          155          160
Ala Asn Gly Asn Ser Glu Val Val Lys Leu Val Leu Asp Arg Arg Cys
165          170          175
Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala
180          185          190
Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly
195          200          205
Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr
210          215          220
Ala Val Tyr Asn Glu Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr
225          230          235          240
Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu
245          250          255
Leu Gly Ile His Glu Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys
260          265          270
Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu
275          280          285
Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile Val Ser Pro Leu Leu
290          295          300
Glu Gln Asn Val Asp Val Ser Ser Gln Asp Leu Glu Arg Arg Pro Glu
305          310          315          320
Ser Met Leu Phe Leu Val Ile Ile Met
325

```

<210> 377

<211> 148

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(148)

<223> Xaa = Any Amino Acid

<400> 377

```

Met Thr Xaa Pro Ser Trp Ser Pro Gly Thr Thr Ser Val Glu Lys Ile
1           5           10           15
Trp Thr Ser Ser Thr Glu Leu Pro Trp Trp Gly Lys Val Pro Arg Lys
20           25           30
Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Xaa Asp Lys

```

35 40 45
 Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu
 50 55 60
 Val Val Lys Leu Xaa Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp
 65 70 75 80
 Asn Lys Lys Arg Thr Ala Leu Xaa Lys Ala Val Gln Cys Gln Glu Asp
 85 90 95
 Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro
 100 105 110
 Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Xaa Tyr Asn Glu Asp
 115 120 125
 Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser
 130 135 140
 Lys Asn Lys Val
 145

<210> 378
 <211> 1719
 <212> PRT
 <213> Homo sapien

<400> 378
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
 1 5 10 15
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
 20 25 30
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
 35 40 45
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
 50 55 60
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
 65 70 75 80
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
 85 90 95
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
 100 105 110
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe
 115 120 125
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His
 130 135 140
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met
 145 150 155 160
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala
 165 170 175
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu
 180 185 190
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr
 195 200 205
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met
 210 215 220
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn
 225 230 235 240
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys
 245 250 255
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly
 260 265 270
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val
 275 280 285

Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr
 290 295 300
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile
 305 310 315 320
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu
 325 330 335
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His His Val
 340 345 350
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile
 355 360 365
 Ser Ser Glu Asn Ser Asn Pro Glu Asn Val Ser Arg Thr Arg Asn Lys
 370 375 380
 Pro Arg Thr His Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser
 385 390 395 400
 Ser Val Lys Lys Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys
 405 410 415
 Cys Arg Cys Phe Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly
 420 425 430
 Thr Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys
 435 440 445
 Met Gly Lys Trp Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly
 450 455 460
 Lys Ser Asn Val Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys
 465 470 475 480
 Thr Leu Arg Asn Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys
 485 490 495
 Cys Arg Gly Ser Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp
 500 505 510
 Asp Ser Ala Phe Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu
 515 520 525
 Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp
 530 535 540
 Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln
 545 550 555 560
 Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val
 565 570 575
 Val Lys Leu Leu Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn
 580 585 590
 Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu
 595 600 605
 Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp
 610 615 620
 Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys
 625 630 635 640
 Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys
 645 650 655
 Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys
 660 665 670
 Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala
 675 680 685
 Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly
 690 695 700
 Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser
 705 710 715 720
 Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser
 725 730 735
 His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln
 740 745 750

Met Leu Lys Ile Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys
 755 760 765
 Leu Thr Ser Glu Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser
 770 775 780
 Gln Pro Glu Lys Met Ser Glu Glu Pro Glu Ile Asn Lys Asp Gly Asp
 785 790 795 800
 Arg Glu Val Glu Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly
 805 810 815
 Leu Leu Glu Asn Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn
 820 825 830
 Gly Leu Ile Pro Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe
 835 840 845
 Pro Asp Asn Glu Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser
 850 855 860
 Asp Tyr Lys Glu Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn
 865 870 875 880
 Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu
 885 890 895
 Glu Gly Ser Glu Asn Gly Gln Pro Glu Leu Glu Asn Phe Met Ala Ile
 900 905 910
 Glu Glu Met Lys Lys His Gly Ser Thr His Val Gly Phe Pro Glu Asn
 915 920 925
 Leu Thr Asn Gly Ala Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro
 930 935 940
 Pro Arg Lys Ser Arg Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu
 945 950 955 960
 Asn Glu Glu Tyr His Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe
 965 970 975
 Cys Glu Glu Gln Asn Thr Gly Ile Leu His Asp Glu Ile Leu Ile His
 980 985 990
 Glu Glu Lys Gln Ile Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser
 995 1000 1005
 Leu Ser Cys Lys Lys Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu
 1010 1015 1020
 Arg Glu Glu Ile Ala Met Leu Arg Leu Glu Leu Asp Thr Met Lys His
 1025 1030 1035 1040
 Gln Ser Gln Leu Pro Arg Thr His Met Val Val Glu Val Asp Ser Met
 1045 1050 1055
 Pro Ala Ala Ser Ser Val Lys Lys Pro Phe Gly Leu Arg Ser Lys Met
 1060 1065 1070
 Gly Lys Trp Cys Cys Arg Cys Phe Pro Cys Cys Arg Glu Ser Gly Lys
 1075 1080 1085
 Ser Asn Val Gly Thr Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr
 1090 1095 1100
 Leu Arg Ser Lys Met Gly Lys Trp Cys Arg His Cys Phe Pro Cys Cys
 1105 1110 1115 1120
 Arg Gly Ser Gly Lys Ser Asn Val Gly Ala Ser Gly Asp His Asp Asp
 1125 1130 1135
 Ser Ala Met Lys Thr Leu Arg Asn Lys Met Gly Lys Trp Cys Cys His
 1140 1145 1150
 Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Lys Val Gly Ala Trp
 1155 1160 1165
 Gly Asp Tyr Asp Asp Ser Ala Phe Met Glu Pro Arg Tyr His Val Arg
 1170 1175 1180
 Gly Glu Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val
 1185 1190 1195 1200
 Pro Arg Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys
 1205 1210 1215

Lys Asp Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly
 1220 1225 1230
 Asn Ser Glu Val Val Lys Leu Leu Asp Arg Arg Cys Gln Leu Asn
 1235 1240 1245
 Val Leu Asp Asn Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys
 1250 1255 1260
 Gln Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro
 1265 1270 1275 1280
 Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr
 1285 1290 1295
 Asn Glu Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp
 1300 1305 1310
 Ile Glu Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Val
 1315 1320 1325
 His Glu Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala
 1330 1335 1340
 Asn Leu Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala
 1345 1350 1355 1360
 Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn
 1365 1370 1375
 Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr
 1380 1385 1390
 Ala Val Ser Ser His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr
 1395 1400 1405
 Lys Glu Lys Gln Met Leu Lys Ile Ser Ser Glu Asn Ser Asn Pro Glu
 1410 1415 1420
 Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Phe Lys Gly
 1425 1430 1435 1440
 Ser Glu Asn Ser Gln Pro Glu Lys Met Ser Gln Glu Pro Glu Ile Asn
 1445 1450 1455
 Lys Asp Gly Asp Arg Glu Val Glu Glu Glu Met Lys Lys His Glu Ser
 1460 1465 1470
 Asn Asn Val Gly Leu Leu Glu Asn Leu Thr Asn Gly Val Thr Ala Gly
 1475 1480 1485
 Asn Gly Asp Asn Gly Leu Ile Pro Gln Arg Lys Ser Arg Thr Pro Glu
 1490 1495 1500
 Asn Gln Gln Phe Pro Asp Asn Glu Ser Glu Glu Tyr His Arg Ile Cys
 1505 1510 1515 1520
 Glu Leu Val Ser Asp Tyr Lys Glu Lys Gln Met Pro Lys Tyr Ser Ser
 1525 1530 1535
 Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu
 1540 1545 1550
 Ser Gln Arg Leu Glu Gly Ser Glu Asn Gly Gln Pro Glu Lys Arg Ser
 1555 1560 1565
 Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Leu Glu Asn Phe
 1570 1575 1580
 Met Ala Ile Glu Glu Met Lys Lys His Gly Ser Thr His Val Gly Phe
 1585 1590 1595 1600
 Pro Glu Asn Leu Thr Asn Gly Ala Thr Ala Gly Asn Gly Asp Asp Gly
 1605 1610 1615
 Leu Ile Pro Pro Arg Lys Ser Arg Thr Pro Glu Ser Gln Gln Phe Pro
 1620 1625 1630
 Asp Thr Glu Asn Glu Glu Tyr His Ser Asp Glu Gln Asn Asp Thr Gln
 1635 1640 1645
 Lys Gln Phe Cys Glu Glu Gln Asn Thr Gly Ile Leu His Asp Glu Ile
 1650 1655 1660
 Leu Ile His Glu Glu Lys Gln Ile Glu Val Val Glu Lys Met Asn Ser
 1665 1670 1675 1680

Glu Leu Ser Leu Ser Cys Lys Lys Glu Lys Asp Ile Leu His Glu Asn
 1685 1690 1695
 Ser Thr Leu Arg Glu Glu Ile Ala Met Leu Arg Leu Glu Leu Asp Thr
 1700 1705 1710
 Met Lys His Gln Ser Gln Leu
 1715

<210> 379
 <211> 656
 <212> PRT
 <213> Homo sapien

<400> 379
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
 1 5 10 15
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
 20 25 30
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
 35 40 45
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
 50 55 60
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
 65 70 75 80
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
 85 90 95
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
 100 105 110
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe
 115 120 125
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His
 130 135 140
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met
 145 150 155 160
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala
 165 170 175
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu
 180 185 190
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr
 195 200 205
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met
 210 215 220
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn
 225 230 235 240
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys
 245 250 255
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly
 260 265 270
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val
 275 280 285
 Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr
 290 295 300
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile
 305 310 315 320
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu
 325 330 335
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His His Val
 340 345 350
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile

355 360 365
 Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu
 370 375 380
 Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser Gln Pro Glu Lys
 385 390 395 400
 Met Ser Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Val Glu
 405 410 415
 Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly Leu Leu Glu Asn
 420 425 430
 Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn Gly Leu Ile Pro
 435 440 445
 Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe Pro Asp Asn Glu
 450 455 460
 Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser Asp Tyr Lys Glu
 465 470 475 480
 Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp
 485 490 495
 Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu Glu Gly Ser Glu
 500 505 510
 Asn Gly Gln Pro Glu Leu Glu Asn Phe Met Ala Ile Glu Glu Met Lys
 515 520 525
 Lys His Gly Ser Thr His Val Gly Phe Pro Glu Asn Leu Thr Asn Gly
 530 535 540
 Ala Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro Pro Arg Lys Ser
 545 550 555 560
 Arg Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu Asn Glu Glu Tyr
 565 570 575
 His Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe Cys Glu Glu Gln
 580 585 590
 Asn Thr Gly Ile Leu His Asp Glu Ile Leu Ile His Glu Glu Lys Gln
 595 600 605
 Ile Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser Leu Ser Cys Lys
 610 615 620
 Lys Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu Arg Glu Glu Ile
 625 630 635 640
 Ala Met Leu Arg Leu Glu Leu Asp Thr Met Lys His Gln Ser Gln Leu
 645 650 655

<210> 380

<211> 671

<212> PRT

<213> Homo sapien

<400> 380

Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
 1 5 10 15
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
 20 25 30
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
 35 40 45
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
 50 55 60
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
 65 70 75 80
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
 85 90 95
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
 100 105 110

Gly	Lys	Ser	Lys	Val	Gly	Ala	Trp	Gly	Asp	Tyr	Asp	Asp	Ser	Ala	Phe
		115					120					125			
Met	Glu	Pro	Arg	Tyr	His	Val	Arg	Gly	Glu	Asp	Leu	Asp	Lys	Leu	His
	130					135					140				
Arg	Ala	Ala	Trp	Trp	Gly	Lys	Val	Pro	Arg	Lys	Asp	Leu	Ile	Val	Met
145					150					155					160
Leu	Arg	Asp	Thr	Asp	Val	Asn	Lys	Lys	Asp	Lys	Gln	Lys	Arg	Thr	Ala
			165						170					175	
Leu	His	Leu	Ala	Ser	Ala	Asn	Gly	Asn	Ser	Glu	Val	Val	Lys	Leu	Leu
		180						185					190		
Leu	Asp	Arg	Arg	Cys	Gln	Leu	Asn	Val	Leu	Asp	Asn	Lys	Lys	Arg	Thr
	195						200					205			
Ala	Leu	Ile	Lys	Ala	Val	Gln	Cys	Gln	Glu	Asp	Glu	Cys	Ala	Leu	Met
	210					215					220				
Leu	Leu	Glu	His	Gly	Thr	Asp	Pro	Asn	Ile	Pro	Asp	Glu	Tyr	Gly	Asn
225					230					235					240
Thr	Thr	Leu	His	Tyr	Ala	Ile	Tyr	Asn	Glu	Asp	Lys	Leu	Met	Ala	Lys
			245						250					255	
Ala	Leu	Leu	Leu	Tyr	Gly	Ala	Asp	Ile	Glu	Ser	Lys	Asn	Lys	His	Gly
		260					265						270		
Leu	Thr	Pro	Leu	Leu	Leu	Gly	Val	His	Glu	Gln	Lys	Gln	Gln	Val	Val
	275						280					285			
Lys	Phe	Leu	Ile	Lys	Lys	Lys	Ala	Asn	Leu	Asn	Ala	Leu	Asp	Arg	Tyr
	290					295					300				
Gly	Arg	Thr	Ala	Leu	Ile	Leu	Ala	Val	Cys	Cys	Gly	Ser	Ala	Ser	Ile
305					310					315					320
Val	Ser	Leu	Leu	Leu	Glu	Gln	Asn	Ile	Asp	Val	Ser	Ser	Gln	Asp	Leu
			325						330					335	
Ser	Gly	Gln	Thr	Ala	Arg	Glu	Tyr	Ala	Val	Ser	Ser	His	His	His	Val
			340					345					350		
Ile	Cys	Gln	Leu	Leu	Ser	Asp	Tyr	Lys	Glu	Lys	Gln	Met	Leu	Lys	Ile
	355						360					365			
Ser	Ser	Glu	Asn	Ser	Asn	Pro	Glu	Gln	Asp	Leu	Lys	Leu	Thr	Ser	Glu
	370					375					380				
Glu	Glu	Ser	Gln	Arg	Phe	Lys	Gly	Ser	Glu	Asn	Ser	Gln	Pro	Glu	Lys
385					390					395					400
Met	Ser	Gln	Glu	Pro	Glu	Ile	Asn	Lys	Asp	Gly	Asp	Arg	Glu	Val	Glu
			405						410					415	
Glu	Glu	Met	Lys	Lys	His	Glu	Ser	Asn	Asn	Val	Gly	Leu	Leu	Glu	Asn
		420						425					430		
Leu	Thr	Asn	Gly	Val	Thr	Ala	Gly	Asn	Gly	Asp	Asn	Gly	Leu	Ile	Pro
	435						440					445			
Gln	Arg	Lys	Ser	Arg	Thr	Pro	Glu	Asn	Gln	Gln	Phe	Pro	Asp	Asn	Glu
	450					455					460				
Ser	Glu	Glu	Tyr	His	Arg	Ile	Cys	Glu	Leu	Val	Ser	Asp	Tyr	Lys	Glu
465					470					475					480
Lys	Gln	Met	Pro	Lys	Tyr	Ser	Ser	Glu	Asn	Ser	Asn	Pro	Glu	Gln	Asp
			485						490					495	
Leu	Lys	Leu	Thr	Ser	Glu	Glu	Glu	Ser	Gln	Arg	Leu	Glu	Gly	Ser	Glu
		500						505					510		
Asn	Gly	Gln	Pro	Glu	Lys	Arg	Ser	Gln	Glu	Pro	Glu	Ile	Asn	Lys	Asp
	515							520				525			
Gly	Asp	Arg	Glu	Leu	Glu	Asn	Phe	Met	Ala	Ile	Glu	Glu	Met	Lys	Lys
	530					535					540				
His	Gly	Ser	Thr	His	Val	Gly	Phe	Pro	Glu	Asn	Leu	Thr	Asn	Gly	Ala
545					550					555					560
Thr	Ala	Gly	Asn	Gly	Asp	Asp	Gly	Leu	Ile	Pro	Pro	Arg	Lys	Ser	Arg
			565						570					575	

```
<210> 381
<211> 251
<212> DNA
<213> Homo sapien
```

```

<400> 381
ggagaagcgt ctgctggggc aggaaggggt ttccctgcc tctcacctgt ccctcaccaa 60
ggtaacatgc ttcccctaag ggtatcccaa cccaggggcc tcaccatgac ctctgagggg 120
ccaatatccc aggagaagca ttggggaggt gggggcaggt gaaggaccca ggactcacac 180
atcctggggc tccaaggcag aggagagggg cctcaagaag gtcaggagga aaatccgtaa 240
caagcagtcg g                                     251

```

```
<210> 382
<211> 3279
<212> DNA
<213> Homo sapiens
```

<400>	382						
cttctctgcag	cccccatgct	ggtgagggggc	acggggcagga	acagtgagacc	caacatggaa	60	
atgctgagg	gtgtcaggaa	gtgatcgggc	tctggggcag	ggaggagggg	tggggagtgt	120	
cactgggagg	ggacatcctg	cagaaggtag	gagtgcagca	acacccgctg	caggggagg	180	
gagagccctg	cggcaccttg	gggagcagag	ggagcagcac	ctgcccaggc	ctgggaggag	240	
gggcctggag	ggcgtgagga	ggagcgagg	ggctgcattg	ctggagtgag	ggatcagggg	300	
cagggcgcg	gatggctca	cacagggaag	agagggcccc	tctgcaggg	cctcaccttg	360	
gccacaggag	gacactgctt	ttcctctgag	gagtcaggag	ctgtggatgt	tgctggacag	420	
aagaaggaca	gggcctggct	caggtgtcca	gaggctgtcg	ctggcttccc	tttgggatca	480	
gactgcagg	agggagggcg	gcagggttgt	ggggggagtg	acgatgagga	tgacctgggg	540	
gtggctccag	gccttgcccc	tgccctgggc	ctcaccacgc	ctccctcaca	gtctcctggc	600	
cctcagtcct	tccccctcac	tcctctctcc	atctggcctc	agtgggctcat	tctgatcact	660	
gaactgacca	taccacgccc	tgccacggc	ctcctactgc	tccccaatgc	cctggagagg	720	
ggacatctag	tcagagagta	gtcctgaaga	ggtggcctct	gcgatgtgcc	tgtggggcca	780	
gcactctgca	gatgggtccc	gcctcatccc	tgtctgacct	tctgcaggga	ctgtcctcct	840	
ggaccttgcc	ccttgtgcag	gagctggacc	ctgaagtcct	ctccccatag	gccaaagact	900	
gagccttggt	ccctctgttg	gactccttgc	ccatattctt	gtgggagtg	gttctggaga	960	
catctctgtc	tgttctctgag	agctgggaat	tgtctcagtg	catctgcctg	cgcggttctg	1020	
agagctggag	ttgcctaggc	agttattggg	gccaactctt	ctcactgtgt	ctctcctcct	1080	
ttacctttag	gggtattctg	gggtccact	tgtctgtaat	ggtgtgcttc	aaggtatcac	1140	
atcatggggc	cctgagccat	gtgccctgcc	tgaaaagcct	gctgtgtaca	ccaaggtgg	1200	
gcattaccgg	aagtggatca	aggacaccat	cgcagccaac	ccctgagtgc	ccctgtccca	1260	
ccctacctc	tagtaaattt	aagtccacct	caogttctgg	catcacttgg	cctttctgga	1320	
tgttggaac	ctgaagcttg	gaactcaact	ggcgaagct	cgagcctcct	gagtcctact	1380	
gacctgtgct	ttctgtgtg	gagtcagg	ctgctaggaa	aaggaatggg	cagacacagg	1440	
tgtatgccaa	gtttctgaa	atgggtataa	ttctgtcttc	tccttcggaa	cactggctgt	1500	
ctctgaagac	ttctcgtcca	gtttcagtga	ggacacacac	aagacagctg	gtgacctgt	1560	
tgtttgtggg	gtgcagagat	gggaggggtg	gggccacccc	tgggaagagt	gacagtgaca	1620	

```

caaggtggac actctctaca gatcactgag gataagctgg agccacaatg catgaggcac 1680
acacacagca aggttgacgc tgtaaacata gccacgctg tcttgggggc actgggaagc 1740
ctagataagg ccgtgagcag aaagaagggg aggatcctcc tatgttggtg aaggagggac 1800
tagggggaga aactgaaagc tgattaatta caggaggttt gttcagggtcc cccaaaccac 1860
cgtcagattt gatgatttcc tagcaggact tacagaaata aagagctatc atgctgtggt 1920
ttattatggt ttgttacatt gataggatac atactgaaat cagcaaacaa aacagatgta 1980
tagattagag tgtggagaaa acagaggaaa acttgcagtt acgaagactg gcaacttggc 2040
tttactaagt tttcagactg gcaggaagtc aaacctatta ggctgaggac cttgtggagt 2100
gtagctgac cagctgatag aggaactagc cagggtggggg cctttccctt tggatggggg 2160
gcatatccga cagttattct ctccaagtgg agacttacgg acagcatata attctccctg 2220
caaggatgta tgataatatg tacaaagtaa ttccaactga ggaagctcac ctgatcotta 2280
gtgtccaggg tttttactgg gggctctgtag gacgagtatg gagtacttga ataattgacc 2340
tgaagtcttc agacctgagg ttccctagag ttcaaacaga tacagcatgg tccagagtc 2400
cagatgtaca aaaacaggga ttcatcaca atcccatctt tagcatgaag ggtctggcat 2460
ggcccaaggc cccaagtata tcaaggcact tgggcagaac atgccaagga atcaaagtgc 2520
atctcccagg agttattcaa gggtgagccc tttacttggg atgtacaggc tttgagcagt 2580
gcagggctgc tgagtcaacc ttttattgta caggggatga gggaaagggg gaggatgagg 2640
aagccccctt ggggatttgg tttggtcttg tgatcagggt gtctatgggg ctatccctac 2700
aaagaagaat ccagaaatag gggcacattg aggaatgata ctgagcccaa agagcattca 2760
atcattgttt tatttgcctt cttttcacac cattggtgag ggagggatta ccaccctggg 2820
gttatgaaga tggttgaaca cccacacat agcaccggag atatgagatc aacagtttct 2880
tagccataga gattcacagc ccagagcagg aggacgctgc acaccatgca ggatgacatg 2940
ggggatgcgc tcgggattgg tgtgaagaag caaggactgt tagaggcagg ctttatagta 3000
acaagacggt ggggcaaact ctgatttccg tgggggaatg tcatggtctt gctttactaa 3060
gttttgagac tggcaggtag tgaaactcat taggctgaga accttgtgga atgcagctga 3120
cccagctgat agaggaagta gccaggtggg agcctttccc agtgggtgtg ggacatatct 3180
ggcaagattt tgtggcactc ctggttacag atactggggc agcaaataaa actgaatctt 3240
gttttcagac cttaaaaaaa aaaaaaaaaa aaaagtgtt 3279

```

<210> 383

<211> 154

<212> PRT

<213> Homo sapiens

<400> 383

```

Met Ala Gly Val Arg Asp Gln Gly Gln Gly Ala Arg Trp Pro His Thr
          5                      10                      15

```

```

Gly Lys Arg Gly Pro Leu Leu Gln Gly Leu Thr Trp Ala Thr Gly Gly
          20                      25                      30

```

```

His Cys Phe Ser Ser Glu Glu Ser Gly Ala Val Asp Gly Ala Gly Gln
          35                      40                      45

```

```

Lys Lys Asp Arg Ala Trp Leu Arg Cys Pro Glu Ala Val Ala Gly Phe
          50                      55                      60

```

```

Pro Leu Gly Ser Asp Cys Arg Glu Gly Gly Arg Gln Gly Cys Gly Gly
          65                      70                      75                      80

```

```

Ser Asp Asp Glu Asp Asp Leu Gly Val Ala Pro Gly Leu Ala Pro Ala
          85                      90                      95

```

```

Trp Ala Leu Thr Gln Pro Pro Ser Gln Ser Pro Gly Pro Gln Ser Leu
          100                     105                     110

```

```

Pro Ser Thr Pro Ser Ser Ile Trp Pro Gln Trp Val Ile Leu Ile Thr
          115                     120                     125

```

Leu Thr Ile Pro Ser Pro Ala His Gly Pro Pro Trp Leu Pro Asn
130 135 140

Ala Leu Glu Arg Gly His Leu Val Arg Glu
145 150

<210> 384
<211> 557
<212> DNA
<213> Homo sapiens

<400> 384
ggatcctcta gaggcgcgc ctactactac taaattcgcg gccgcgtcga cgaagaagag 60
aaagatgtgt ttgtttttg actctctgtg gtcccttcca atgctgtggg ttccaacca 120
ggggaagggt ccccttttga ttgccaagt ccataaccat gagcactact ctaccatggg 180
tctgctcctt ggcgaagcag gctggtttgc aagaatgaaa tgaatgattc tacagctagg 240
acttaacctt aaaaatgaaa gtcttgcaat cccatttgca ggatccgtct gtgcacatgc 300
ctctgtagag agcagcattc ccagggaact tggaaacagt tggcactgta aggtgcttgc 360
tccccaagac acatcctaag aggtgtttgta atgggtgaaaa cgtcttcctt ctttattgcc 420
cctttcttatt tatgtgaaca actgtttgtc tttttttgta tcttttttaa actgtaaagt 480
tcaattgtga aaatgatat catgcaaata aattatgcga ttttttttcc aaagtaaaaa 540
aaaaaaaaaa aaaaaaa 557

<210> 385
<211> 337
<212> DNA
<213> Homo sapiens

<400> 385
ttcccagggt atgtgcgagg gaagacacat ttactatcct tgatggggct gattccttta 60
gtttctctag cagcagatgg gttaggagga agtgacccaa gtggttgact cctatgtgca 120
tttcaaagcc atctgctgtc ttcgagtacg gacacatcat cactcctgca ttgttgatca 180
aaacgtggag gtgcttttcc tcagctaaga agcccttagc aaaagctcga atagacttag 240
tatcagacag gtccagtttc cgcaccaaca cctgctggtt ccctgtcgtg gtctggatct 300
ctttggccac caattccccc ttttccacat cccggca 337

<210> 386
<211> 300
<212> DNA
<213> Homo sapiens

<400> 386
gggcccgtca cgggccagg cccgcctcgc cgagtctctc tccccgggtg cctgcccgcga 60
gcccgcctcg cccagagggt gggcgcgggg ctgcctctac cggctggcgg ctgtaactca 120
gcgaccttgg cccgaaggct ctagcaagga cccaccgacc ccagccgcgg cggcggcggc 180
gcggactttg cccggtgtgt gggcgggagc ggactgcgtg tccgcggacg ggcagcgaag 240
atgttagcct tcgtgccag gaccgtggac cgatcccagg gctgtggtgt aacctcagcc 300

<210> 387
<211> 537
<212> DNA
<213> Homo sapiens

<400> 387
gggcccagtc gggcaccaag ggactctttg caggcttctt tccctggatc atcaaggctg 60
ccctcctctg tgccatcatg atcagcacct atgagttcgg caaaagcttc ttccagaggc 120

```

tgaaccagga ccggcttctg ggcggtcgaa aggggcaagg aggcaaggac ccggtctctc 180
ccacggatgg ggagagggca ggaggagacc cagccaagtg ccttttcctc agcactgagg 240
gagggggctt gtttcccttc cctcccggeg acaagctcca gggcagggct gtccctctgg 300
gcgggccagc acttccctcag acacaacttc ttctgtctgc tccagtcgtg gggatcatca 360
cttaccacc cccaagtgc aagaccaaat cttccagctg ccccttctgt gtttccctgt 420
gtttgtctga gctgggcatg tctccaggaa ccaagaagcc ctgagcctgg tgtagtctcc 480
ctgacccttg ttaatttcctt aagtctaaag atgatgaact tcaaaaaaaa aaaaaaaa 537

```

<210> 388

<211> 520

<212> DNA

<213> Homo sapiens

<400> 388

```

aggataattt ttaaaccaat caaatgaaaa aaacaaacaa acaaaaaagg aaatgtcatg 60
tgagggttaa ccagtttgca ttcccctaag gtggaaaaag taagaggact actcagcact 120
gtttgaagat tgccctctct acagcttctg agaattgtgt tatttcaact gccaaagtga 180
ggacccccc cccaacatgc ccagcccac ccctaagcat ggtcccttgt caccaggcaa 240
ccaggaaact gctacttgtg gacctacca gagaccagga gggtttggtt agctcacagg 300
acttccccca cccagaaga ttagcatccc atactagact cataactcaac tcaactaggc 360
tcataactca ttgatgggta ttagacaatt ccatttcttt ctgggttatta taaacagaaa 420
atctttcctc ttctcattac cagtaaaggc tcttgggtatc tttctgttgg aatgatttct 480
atgaacttgt cttattttaa tgggtgggtt tttttctggt 520

```

<210> 389

<211> 365

<212> DNA

<213> Homo sapiens

<400> 389

```

cgttgcccca gtttgacaga aggaaaggcg gagcttattc aaagtctaga gggagtggag 60
gagttaaggc tggatttcag atctgcctgg ttccagccgc agtgtgccct ctgctcccc 120
aacgactttc caaataatct caggagcgcc ttccagctca gggctcctag aagegtcttg 180
aagcctatgg ccagctgtct ttgtgttccc tctcacccgc ctgtccctac agctgagact 240
cccaggaaac cttcagacta ccttccctctg ccttcagcaa ggggcgttgc ccacattctc 300
tgagggtcag tggaagaacc tagactccca ttgctagagg tagaaagggg aagggtgctg 360
gggag

```

<210> 390

<211> 221

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(221)

<223> n = A,T,C or G

<400> 390

```

tgcctctcca tcctggcccc gaattctctg tcaggaaagt ggggatggac cccatctgca 60
tacacggnnt ctcattgggtg tggaacatct ctgcttgccg ttccaggaag gcctctggct 120
gctctangag tctgancnga ntcgttgccc cantntgaca naaggaaagg cggagcttat 180
tcaaagtcta gagggagtgagg aggagttaag gctggatttc a 221

```

<210> 391

<211> 325

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(325)
 <223> n = A,T,C or G

<400> 391
 taagcaggt cccgaggcct ccctagagcc tggggccgac tctgtgncca tgcangcttt 60
 ctctcgccgc cagcctggag ctgctcctgg catctaccaa caatcagncg aggcgagcag 120
 tagccagggc actgctgcc aacagccagtc cnnataccat catgtnaccc ggtgngctct 180
 naanttingat ntccanagcc ctaccatcn tagttctgct ctcccaccgg ntaccagccc 240
 cactgccag gaatcctaca gccagtaccc tgtcccgacg tctctaccta ccagtacgat 300
 gagacctccg gctactacta tgacc 325

<210> 392
 <211> 277
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(277)
 <223> n = A,T,C or G

<400> 392
 atattgttta actccttctt ttatatcttt taacattttc atggngaaaag gttcacatct 60
 agtctcactt nggcnagnn ctctacttg agtctcttcc ccggcctggn ccagtnгнаa 120
 antaccanga accgncatgn cttaanaach ncctggtttn tgggttnntc aatgactgca 180
 tgcagtgcac caccctgtcc actacgtgat gctgtaggat taaagtctca cagtgggcgg 240
 ctgaggatac agcgcccgct cctgtgttgc tggggaa 277

<210> 393
 <211> 566
 <212> DNA
 <213> Homo sapiens

<400> 393
 actagtccag tgtggtggaa ttccgcccgc cgtcgacgga caggtcagct gtctggctca 60
 gtgatctaca ttctgaagtt gtctgaaaat gtcttcctga tttaaattcag cctaaacggt 120
 ttgccgggaa cactgcagag acaatgctgt gagtttccaa ccttagccca tctgcccggca 180
 gagaaggctc agtttgtcca tcagcattat catgatatca ggactggtta cttgggttaag 240
 gaggggtcta ggagatctgt cccttttaga gacaccttac ttataatgaa gtatttggga 300
 ggggtggtttt caaaagtaga aatgtcctgt attccgatga tcatcctgta aacattttat 360
 catltattaa tcatccctgc ctgtgtctat tattatattc atatctctac gctggaaact 420
 ttctgcctca atgtttactg tgcccttgggt tttgctagtt tgtgttgggt aaaaaaaaaa 480
 cattctctgc ctgagtttta atttttgtcc aaagttattt taatctatac aattaaaagc 540
 ttttgccat caaaaaaaaa aaaaaa 566

<210> 394
 <211> 384
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(384)
 <223> n = A,T,C or G

```

<400> 394
gaacatacat gtcccggcac ctgagctgca gtctgacatc atcgccatca cgggcctcgc 60
tgcaaatng gaccgggcca aggctggact gctggagcgt gtgaaggagc tacagggcna 120
gcaggaggac cgggctttta ggagttttta gctgagtgct actgtagacc ccaaatacca 180
tcccaagatt atcgggagaa agggggcagt aattacccaa atccggttgg agcatgacgt 240
gaacatccag tttcctgata aggacgatgg gaaccagccc caggaccaaa ttaccatcac 300
agggtacgaa aagaacacag aagctgccag ggatgctata ctgagaattg tgggtgaact 360
tgagcagatg gtttctgagg acgt 384

```

```

<210> 395
<211> 399
<212> DNA
<213> Homo sapiens

```

```

<400> 395
ggcaaaactg tgtgacctca ataagacctc gcagatccaa ggtcaagtat cagaagtgac 60
tctgaccttg gactccaaga cctacatcaa cagcctggct atattagatg atgagccagt 120
tatcagaggt ttcattcattg cggaaattgt ggagtctaag gaaatcatgg cctctgaagt 180
attcacgtct ttccagtacc ctgagttctc tatagagtgg cctaacacag gcagaattgg 240
ccagctactt gtctgcaatt gtatcttcaa gaataccctg gccatccctt tgactgacgt 300
caagttctct ttggaaagcc tgggcatctc ctactacag acctctgacc atgggacggt 360
gcagcctggt gagaccatcc aatcccaaat aaaatgcac 399

```

```

<210> 396
<211> 403
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(403)
<223> n = A,T,C or G

```

```

<400> 396
tggagttntc agtgcaaaca agccataaag cttcagtagc aaattactgt ctcacagaaa 60
gacattttca acttctgctc cagctgctga taaaacaaat catgtgttta gcttgactcc 120
agacaaggac aacctgttcc ttcataactc tctagagaaa aaaaggagtt gttagtagat 180
actaaaaaaaa gtggatgaat aatctggata tttttcctaa aaagattcct tgaaacacat 240
taggaaaatg gagggcctta tgatcagaat gctagaatta gtccattgtg ctgaagcagg 300
gtttagggga gggagtggag gataaaagaa ggaaaaaaag aagagtgaga aaacctatct 360
atcaaagcag gtgctatcac tcaatgttag gccctgctct ttt 403

```

```

<210> 397
<211> 100
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(100)
<223> n = A,T,C or G

```

```

<400> 397
actagtnacg tgtggtggaa ttgcgggccg cgtcgacctc naanccatct ctatagcaaa 60
tccatccccg ctctggttg gtnacagaat gactgacaaa 100

```

```

<210> 398
<211> 278

```

<212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(278)
 <223> n = A,T,C or G

<400> 398
 gcgggcgcgt cgacagcagt tccgccagcg ctgcgccctg ggtgggggatg tgctgcacgc 60
 ccacctggac atctggaagt cagcggcctg gatgaaagag cggacttcac ctggggcgat 120
 ttaactactgt gacctgacca gtgaggagag ctggaccgac agcgaggtgg actcatcatg 180
 ctccgggcag cccatccacc tgtggcagtt cctcaaggag ttgctactca agccccacag 240
 ctatggccgc ttcattangt ggctcaacaa ggagaagg 278

<210> 399
 <211> 298
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(298)
 <223> n = A,T,C or G

<400> 399
 acggaggtgg aggaagcgnc cctgggatcg anaggatggg tcctgncatt gaccnccctn 60
 ggggtgceng catggagcgc atgggcgcgg gcctgggcca cggcatggat cgcgtgggct 120
 ccgagatcga gcgcattggc ctggtcatgg accgcatggg ctccgtggag cgcattgggt 180
 ccggcattga gcgcattggc ccgctgggccc tcgaccacat ggcctccanc attganccga 240
 tgggccagac catggagcgc attggctctg gcgtggagcn catgggtgcc ggcatggg 298

<210> 400
 <211> 548
 <212> DNA
 <213> Homo sapiens

<400> 400
 acatcaacta ctccctcatt ttaaggtatg gcagttccct tcctcccctt ttctgcctt 60
 gtacatgtac atgtatgaaa ttcccttctc ttaccgaact ctctccacac atcacaaggt 120
 caaagaacca cagccttaga agggttaagag ggcaccctat gaaatgaaat ggtgatttct 180
 tgagtctctt ttttccacgt ttaaggggcc atggcaggac ttagagttgc gagttaagac 240
 tgcagagggc tagagaatta ttcatatagc gctttgaggc caccatgtc acttatcccc 300
 tataccctct caccatcccc ttgtctactc tgatgcccc aagatgcaac tgggcagcta 360
 gttggcccca taattctggg cctttgttgt ttgttttaat tacttgggca tcccaggaag 420
 atttccagtg atctcctacc atgggcccc ctctgggat caagcccctc ccaggccctg 480
 tccccagccc ctctgcccc agcccccccg cttgccttgg tgctcagccc tcccattggg 540
 agcaggtt 548

<210> 401
 <211> 355
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(355)
 <223> n = A,T,C or G

<400> 401

```

actgtttcca tgttatgttt ctacacattg ctacctcagt gtccttgga acttagcttt 60
tgatgtctcc aagtagtcca ccttcattta actctttgaa actgtatcat ctttgccaag 120
taagagtggg ggcctatttc agctgctttg acaaaatgac tggctcctga cttaacgttc 180
tataaatgaa tgtgctgaag caaagtgcc atggtggcgg cgaagaagan aaagatgtgt 240
tttgttttgg actctctgtg gtcccttcca atgctgnngg tttccaacca ggggaagggt 300
cccttttgca ttgccaagt ccataacat gagcactact ctaccatggn tctgc 355

```

<210> 402

<211> 407

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(407)

<223> n = A,T,C or G

<400> 402

```

atggggcaag ctggataaag aaccaagacc cactggagta tgctgtcttc aagaaaccca 60
tctcacatgc ggtggcatac ataggctcaa aataaaggaa tggagaaaaa tatttcaagc 120
aaatggaaaa cagaaaaaag caggtgttgc actcctactt tctgacaaaa cagactatgc 180
gaataaagat aaaaaagaga aggacattac aaaggtggtc ctgacctttg ataaatctca 240
ttgcttgata ccaacctggg ctgttttaat tgcccaaacc aaaaggataa tttgctgagg 300
ttgtggagct tctccctgc agagagtccc tgactctcca aaatttggtt gagatgtaag 360
gntgattttg ctgacaactc cttttctgaa gttttactca tttccaa 407

```

<210> 403

<211> 303

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(303)

<223> n = A,T,C or G

<400> 403

```

cagtatttat agccnaactg aaaagctagt agcaggcaag tctcaaatec aggcacccaa 60
tctaagcaa gagccatggc atggtgaaaa tgcaaaagga gactctggcc aatctacaaa 120
tagagaacaa gacctactca gtcatgaaca aaaaggcaga caccaacatg gatctcatgg 180
gggattggat attgtaatta tagagcagga agatgacagt gatcgtcatt tggcacaaca 240
tcttaacaac gaccgaaacc cattattttac ataaacctcc attcggtaac catgttgaaa 300
gga 303

```

<210> 404

<211> 225

<212> DNA

<213> Homo sapiens

<400> 404

```

aagtgtaaact tttaaaaatt tagtggattt tgaaaattct tagaggaaaag taaaggaaaa 60
attgttaatg cactcattta cttttacatg gtgaaagtgc tctcttgatc ctacaaacag 120
acattttcca ctogtgtttc catagtgtgt aagtgtatca gatgtgttgg gcatgtgaat 180
ctccaagtgc ctgtgtaata aataaagtat ctttatttca ttcat 225

```

<210> 405

<211> 334
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(334)
 <223> n = A,T,C or G

<400> 405
 gagctgttat actgtgagtt ctactaggaa atcatcaaat ctgaggggtg tctggaggac 60
 ttcaataaac cccccccat agtgaatcag cttccagggg gtccagtcct tctccttact 120
 tcatacccat cccatgccaa aggaagaccc tccctccttg gctcacagcc ttctctaggc 180
 ttccagtgct ctccaggaca gagtgggtta tgttttcagc tccatccttg ctgtgagtgt 240
 ctggtgcggt tgtgcctcca gcttctgctc agtgcttcat ggacagtgtc cagcccatgt 300
 cactctccac tctctcanng tggatcccac cccct 334

<210> 406
 <211> 216
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(216)
 <223> n = A,T,C or G

<400> 406
 tttcatacct aatgagggag ttganatnac atnnaaccag gaaatgcatg gatctcaang 60
 gaaacaaaca cccaataaac tcggagtggc agactgacaa ctgtgagaca tgcacttgct 120
 acnaaacaca aatttnatgt tgcacccttg tttctacacc tgtgggttat gacaaagaca 180
 actgccaaag aatnttcaag aaggaggact gccant 216

<210> 407
 <211> 413
 <212> DNA
 <213> Homo sapiens

<400> 407
 gctgacttgc tagtatcatc tgcatttcatt gaagcacaag aacttcatgc cttgactcat 60
 gtaaattgcaa taggattaaa aaataaattt gatatcacat ggaaacagac aaaaaatatt 120
 gtacaacatt gcacccagtg tcagattcta cacctggcca ctgaggaagc aagagttaat 180
 cccagaggtc tatgtcctaa tgtgttatgg caaatggatg tcatgcacgt accttcattt 240
 ggaaaattgt catttgtcca tgtgacagtt gatacttatt cacatttcat atgggcaacc 300
 tgcagacag gagaaagtct tcccatgtta aaagacattt attatcttgt tttcctgtca 360
 tgggagttcc agaaaaagtt aaaacagaca atgggccagg ttctgtagta aag 413

<210> 408
 <211> 183
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(183)
 <223> n = A,T,C or G

<400> 408

```

ggagctngcc ctcaattcct ccatntctat gttancatat ttaatgtctt ttgnnattaa 60
tnccttaacta gttaatcctt aaagggctan ntaatectta actagtcctt ccattgtgag 120
cattatacctt ccagtattcn ccttctnttt tattttactcc ttccctggcta cccatgtact 180
ntt 183

```

```

<210> 409
<211> 250
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(250)
<223> n = A,T,C or G

```

```

<400> 409
cccacgcattg ataagctctt tttttctgta agtcctgcta ggaaatcatc aaatctgacg 60
gtgggtttggg ggacctgaac aaacctcctg taattaatca gctttcagtt tctcccccta 120
gtccctcctt caacaacata ggaggatcct ccccttcttt ctgctcacgg ccttatctag 180
gcttcccatg gcccccagga cagcgtgggc tatgtttaca gcgcntcctt gctggggggg 240
ggccntatgc 250

```

```

<210> 410
<211> 306
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(306)
<223> n = A,T,C or G

```

```

<400> 410
ggctgggtttg caagaatgaa atgaatgatt ctacagctag gacttaacct tgaaatggaa 60
agtcttgcaa tcccatttgc aggatccgtc tgtgcacatg cctctgtaga gagcagcatt 120
cccagggacc ttggaaacag ttggcactgt aagggtgctt ctccccaaga cacatcctaa 180
aagggtgttg aatgggtgaaa accgcttcct tctttattgc cccttcctat ttatgtgaac 240
nactgggttg ctttttttgn atctttttta aactggaaaag ttcaattgng aaaatgaata 300
tentgc 306

```

```

<210> 411
<211> 261
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(261)
<223> n = A,T,C or G

```

```

<400> 411
agagatattn cttaggtnaa agttcataga gttcccatga actatatgac tggccacaca 60
ggatcttttg tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaatgtc tgaaatggaa cagatttcaa aaaaaaaccc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa ggngaggcaa a 261

```

```

<210> 412

```

<211> 241
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(241)
 <223> n = A,T,C or G

<400> 412
 gttcaatggt aactgacatt tctacaacac ccactcacc gatgtattcg ttgccagtg 60
 ggaacatacc agcctgaatt tggaaaaaat aattgtgttt ctgcccagg aaatactacg 120
 actgactttg atggctccac aaacataacc cagtgtaaaa acagaagatg tggaggggag 180
 ctgggagatt tcaactggga cattgaattc ccaactacc cangcaatta ccagccaac 240
 a 241

<210> 413
 <211> 231
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(231)
 <223> n = A,T,C or G

<400> 413
 aactcttaca atccaagtga ctcatctgtg tgcttgaatc ctttcactg tctcatctcc 60
 ctcatccaag tttctagtag ctctcttttg ttgtgaagga taatcaaact gaacaacaaa 120
 aagtttactc tcttcatttg gaacctaaaa actctcttct tcttgggtct gagggctcca 180
 agaatccttg aatcanttct cagatcattg gggacaccan atcaggaacc t 231

<210> 414
 <211> 234
 <212> DNA
 <213> Homo sapiens

<400> 414
 actgtccatg aagcactgag cagaagctgg aggcacaacg caccagacac tcacagcaag 60
 gatggagctg aaaacataac ccactctgtc ctggaggcac tgggaagcct agagaaggct 120
 gtgagccaag gagggagggt ctctcttttg cataggatgg ggatgaagta aggagaggga 180
 ctggaccccc tggaagctga ttcactatgg ggggagggtg attgaagtcc tcca 234

<210> 415
 <211> 217
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(217)
 <223> n = A,T,C or G

<400> 415
 gcataggatt aagactgagt atcttttcta cattctttta actttctaag gggcacttct 60
 caaaacacag accaggtagc aaatctccac tgctctaagg ntctcaccac cactttctca 120
 caactagcaa tagtagaatt cagtcctact tctgaggcca gaagaatggt tcagaaaaat 180
 antggattat aaaaaataac aattaagaaa aataatc 217

<210> 416
 <211> 213
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(213)
 <223> n = A,T,C or G

<400> 416
 atgcataatnt aaagganact gcctcgcttt tagaagacat ctggnetgct ctctgcatga 60
 ggcacagcag taaagctctt tgattcccag aatcaagaac tctccccttc agactattac 120
 cgaatgcaag gtggttaatt gaaggccact aattgatgct caaatagaag gatattgact 180
 atattggaac agatggagtc tctactacaa aag 213

<210> 417
 <211> 303
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(303)
 <223> n = A,T,C or G

<400> 417
 nagtcttcag gcccatcagg gaagttcaca ctggagagaa gtcatacata tgtactgtat 60
 gtgggaaagg ctttactctg agttcaaate ttcaagccca tcagagagtc cacactggag 120
 agaagccata caaatgcaat gagtgtggga agagcttcag gagggattcc cattatcaag 180
 ttcatctagt ggtccacaca ggagagaaac cctataaatg tgagatatgt gggaagggct 240
 tcantcaaaq ttogtatctt caaatccatc ngaaggncca cagtatanan aaacctttta 300
 agt 303

<210> 418
 <211> 328
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(328)
 <223> n = A,T,C or G

<400> 418
 tttttggcgg tgggtggggca gggacgggac angagtctca ctctgttgcc caggctggag 60
 tgcacaggca tgatctcggc tcaactacaac ccctgcctcc catgtocaag cgattcttgt 120
 gcctcagcct tccctgtagc tagaattaca ggcacatgcc accacaccca gctagttttt 180
 gtatttttag tagagacagg gtttcaccat gttggccagg ctggtetcaa actcctnacc 240
 tcagnggtca ggctggtctc aaactcctga cctcaagtga tctgcccacc tcagcctccc 300
 aaagtgctan gattacaggc cgtgagcc 328

<210> 419
 <211> 389
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(389)
 <223> n = A,T,C or G

<400> 419
 cctcctcaag acggcctgtg gtccgcctcc cggcaaccaa gaagcctgca gtgccatattg 60
 acccctgagc catggaactgg agcctgaaag gcagcgtaca cctgctcct gatcttgctg 120
 cttgtttcct ctctgtggct ccattcatag cacagttgtt gcactgaggc ttgtgcaggc 180
 cgagcaaggc caagctggct caaagagcaa ccagtcaact ctgccacggt gtgccaggca 240
 ccggtttctcc agccaccaac ctcaactcgt cccgcaaatg gcacatcagt tcttctaccc 300
 taaaggtagg accaaagggc atctgctttt ctgaagtcc ctgctctatc agccatcaag 360
 tggcagccac tcnggctgtg tcgacgcgg 389

<210> 420
 <211> 408
 <212> DNA
 <213> Homo sapiens

<400> 420
 gttcctccta actcctgcc aaaacagctc tctcaacat gagagctgca cccctcctcc 60
 tggccagggc agcaagcctt agccttggt tcttgtttct gctttttttc tggctagacc 120
 gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
 gtccattga cacttttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
 gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
 gatataaaaa attcttgaat gactcctata aacatgaaca ggtttatatt cgaagcacag 360
 acgttgaccg gactttgatg aagtgcctatg acaaacctgg caagcccg 408

<210> 421
 <211> 352
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(352)
 <223> n = A,T,C or G

<400> 421
 gctcaaaaat ctttttactg atnnggcattg ctacacaatc attgactatt acggaggcca 60
 gaggagaatg aggcctgggc tgggagccct gtgcctacta naagcacatt agattatcca 120
 ttcactgaca gaacaggctc tttttgggtc cttcttctcc accacnatat acttgacgac 180
 ctcttcttg aagattcttt ggcagttgtc tttgtcataa cccacagggtg tagaaacaag 240
 ggtgcaacat gaaatttctg tttcgtagca agtgcattgc tcacaagttg gcangtctgc 300
 cactccgagt ttattgggtg tttgtttcct ttgagatcca tgcatttctt gg 352

<210> 422
 <211> 337
 <212> DNA
 <213> Homo sapiens

<400> 422
 atgccaccat gctggcaatg cagcggggcg tcgaaggcct gcatatccag cccaagctgg 60
 cgtgatcga cggcaaccgt tgcccgaagt tgccgatgcc agccgaagcg gtgggtcaagg 120
 gcatagcaa ggtgcggcg atcgcggcg cgtcaatcct ggccaaggtc agccgtgac 180
 gtgatggc agctgtcgaa ttgatctacc cgggttatgg catcggcggg cataagggct 240
 atcgaacac cgtgcacctg gaagccttgc agcgctggg gccgacgcg attcaccgac 300
 gctcttcg ccggtacggc tggcctatga aaattat 337

<210> 423
 <211> 310
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(310)
 <223> n = A,T,C or G

<400> 423
 gctcaaaaat ctttttactg atatggcatg gctacacaat cattgactat tagaggccag 60
 aggagaatga ggcctggcct gggagccctg tgccactan aagcncatta gattatccat 120
 tcaactgacag aacagggtctt ttttgggtcc ttcttctcca ccacgatata ctgcagtc 180
 tccttcttga agattctttg gcagttgtct ttgtcataac ccacagggtg anaaacaagg 240
 gtgcaacatg aaatttctgt ttcgtagcaa gtgcatgtct cacagttgtc aagtctgccc 300
 tccgagttta 310

<210> 424
 <211> 370
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(370)
 <223> n = A,T,C or G

<400> 424
 gctcaaaaat ctttttactg ataggcatgg ctacacaatc attgactatt agaggccaga 60
 ggagaatgag gcctggcctg ggagccctgt gcctactaga agcacattag attatccatt 120
 cactgacaga acagggtctt tttgggtcct ttcttctccac cacgatatac ttgcagtcct 180
 ccttctttaa gattctttgg cagttgtctt tgtcataacc cacagggtga gaaacatcct 240
 ggttgaatct cctggaactc cctcattagg tatgaaatag catgatgcat tgcataaagt 300
 cacgaagggtg gcaaagatca caacgctgcc cagganaaca ttcattgtga taagcaggac 360
 tccgtcgacg 370

<210> 425
 <211> 216
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(216)
 <223> n = A,T,C or G

<400> 425
 aattgctatn ntttattttg ccaactcaaaa taattaccaa aaaaaaaaaa tnttaaata 60
 taacaacnca acatcaagg aaananaaca ggaatgngtg actntgcata aatnggccga 120
 anattatcca ttatnttaag ggttgacttc aggnacagc acacagacaa acatgcccag 180
 gaggnnttca ggaccgctcg atgtntntg aggagg 216

<210> 426
 <211> 596
 <212> DNA
 <213> Homo sapiens

```

<400> 426
cttccagtga ggataaccct gttgccccgg gccgagggttc tccattagga tctgattgat 60
tggcagtcag tgatggaagg gtgttctgat cattccgaact gccccaaggg tgcgtggcca 120
gctctctgtt ttgctgagtt ggcagtagga cctaatttgt taattaagag tagatgggtga 180
ggtgtccttg tatttttgatt aacctaatgg ccttcccagc acgactcgga ttcagctgga 240
gacatcacgg caacttttaa tgaaatgatt tgaagggccca ttaagaggca cttcccgtta 300
ttaggcagtt catctgcact gataacttct tggcagctga gctggtcgga gctgtggccc 360
aaacgcacac ttggcttttg gttttgagat acaactctta atcttttagt catgcttgag 420
ggtggatggc cttttcagct ttaacccaat ttgcactgcc ttggaagtgt agccaggaga 480
ataactcat atactcgtgg gcttagaggc cacagcagat gtcattggtc tactgcctga 540
ctcccgctgg tcccatccca ggaccttcca tggcgagta cctgggagcc cgtgct 596

```

<210> 427

<211> 107

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(107)

<223> n = A,T,C or G

<400> 427

```

gaagaattca agttaagttt attcaaaggg cttacngaga atcctanacc caggncccag 60
cccgggagca gccttanaga gctcctgttt gactgcccgg ctcagng 107

```

<210> 428

<211> 38

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(38)

<223> n = A,T,C or G

<400> 428

```

gaacttcna anaangactt tattcactat ttacatt 38

```

<210> 429

<211> 544

<212> DNA

<213> Homo sapiens

<400> 429

```

ctttgctgga cggaataaaa gtggacgcaa gcatgacctc ctgatgaggg cgtgcattt 60
attgaagagc ggctgcagcc ctgcggttca gattaaaatc cgagaattgt atagacgccg 120
atatccagca actcttgaag gactttctga tttatccaca atcaaatcat cggttttcag 180
tttggttggt ggtcctacac ctgtagaacc tgacttggcc gtggctggaa tccactcgtt 240
gccttccact tcagttacac ctactcacc atcctctcct gttggttctg tgcgtcttca 300
agatactaag cccacatttg agatgcagca gccatctccc ccaattcttc ctgtccatcc 360
tgatgtgcag ttaaaaaatc tgccctttta tgatgtcctt gatgttctca tcaagccac 420
gagtttagtt caaagcagta ttcagcgatt tcaagagaag ttttttattt ttgctttgac 480
acctcaacaa gtttagagaga tatgcatac cagggatttt ttgccagggt gtaggagaga 540
ttat 544

```

<210> 430

<211> 507
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(507)
 <223> n = A,T,C or G

```
<400> 430
cttatcncaa tggggctccc aaacttggt gtgcagtga aactccggg gaattttgaa 60
gaacactgac acccatcttc caccgcgaca ctctgattta attgggctgc agtgagaaca 120
gagcatcaat ttaaaaagct gcccagaatg ttntcctggg cagcggttg atctttgccn 180
ccttcgtgac tttatgcaat gcatcatgct atttcatacc taatgaggga gttccaggag 240
attcaaccag gatgtttcta cncctgtggg ttatgacaaa gacaactgcc aaagaatntt 300
caagaaggag gactgcaagt atatcgtggt ggagaagaag gacccaaaaa agacctgttc 360
tgtcagtga tggataatct aatgtgcttc tagtaggcac agggctccca ggccaggcct 420
cattctcttc tggcctctaa tagtcaatga ttgtgtagcc atgcctatca gtaaaaagat 480
ttttgagcaa aaaaaaaaaa aaaaaaa
507
```

<210> 431
 <211> 392
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(392)
 <223> n = A,T,C or G

```
<400> 431
gaaaattcag aatggataaa aacaaatgaa gtacaaaata tttcagattt acatagcgat 60
aaacaagaaa gcacttatca ggaggactta caaatggaag tacactctan aaccatcatc 120
tatcatggct aaatgtgaga ttagcacagc tgtattattt gtacattgca aacacctaga 180
aagagatggg aaacaaaatc ccaggagtgt tgtgtgtgga gtcctgggtt ttccaacaga 240
catcattcca gcattctgag attaggngna ttggggatca ttctggagtt ggaatgttca 300
acaaaagtga tgttgtagg taaaatgtac aacttctgga tctatgcaga cattgaaggt 360
gcaatgagtc tggcttttac tctgctgttt ct
392
```

<210> 432
 <211> 387
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(387)
 <223> n = A,T,C or G

```
<400> 432
ggtatcanta cataatcaaa tatagctgta gtacatgttt tcattggngt agattaccac 60
aaatgcaagg caacatgtgt agatctcttg tcttattott ttgtctataa tactgtattg 120
ngtagtccaa gctctcgna gtccagccac tngaaacat gtcctcttta gattaacctc 180
gtggacnctn ttgttgnatt gtctgaactg tagngccctg tattttgctt ctgtctgnga 240
attctgttgc ttctggggca ttctcttgng atgcagagga ccaccacaca gatgacagca 300
atctgaattg ntccaatcac agctgcgatt aagacatact gaaatcgtac aggaccggga 360
acaacgtata gaacactgga gtccttt
387
```

<210> 433
 <211> 281
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(281)
 <223> n = A,T,C or G

<400> 433
 tccaactagc anagaanact gcttcagggn gtgtaaaatg aaaggcttcc acgcagttat 60
 ctgattaaag aacactaaga gagggacaag gctagaagcc gcaggatgtc tacactatag 120
 caggenctat ttgggttggc tggaggagct gtggaaaaca tggagagatt ggcgctggag 180
 atcgccgtgg ctattcctcn ttgntattac accagngagg ntctctgtnt gccactgggt 240
 tnnaaaaccg ntatacaata atgatagaat aggacacaca t 281

<210> 434
 <211> 484
 <212> DNA
 <213> Homo sapiens

<400> 434
 ttttaaaata agcatttagt gctcagtcce tactgagtac tctttctctc ccttcctctg 60
 aatttaattc tttcaacttg caatttgcaa ggattacaca tttcactgtg atgtatatag 120
 tgttgcaaaa aaaaaaaagt gtctttgttt aaaattactt ggtttgtgaa tccatcttgc 180
 tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa acatctgaag 240
 agctagtcta tcagcatctg acaggtgaat tggatggttc tcagaaccat ttcaccacaga 300
 cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca taacaaaccc 360
 tgcctcaatc tgtcacataa aagtctgtga cttgaagtgt agtcagcacc cccaccaaac 420
 tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataaag taccatgtc 480
 tttta 484

<210> 435
 <211> 424
 <212> DNA
 <213> Homo sapiens

<400> 435
 gcgcgcgtca gagcagggtca ctttctgcct tccacgtcct ccttcaagga agccccatgt 60
 gggtagcttt caatatcgca ggttcttact cctctgcctc tataagctca aaccacacaa 120
 cgatcgggca agtaaacccc ctccctcgcc gacttcggaa ctggcgagag ttcagcgcag 180
 atgggcctgt ggggaggggg caagatagat gagggggagc ggcatggtgc ggggtgaccc 240
 cttggagaga ggaaaaaggc cacaagaggg gctgccaccg ccactaacgg agatggccct 300
 ggtagagacc tttgggggtc tggaaacctt ggactcccca tgctetaact cccacactct 360
 gctatcagaa acttaaaactt gaggattttc tctgtttttc actcgcaata aattcagagc 420
 aaac 424

<210> 436
 <211> 667
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(667)
 <223> n = A,T,C or G

<400> 436

```

accttgggaa nactctcaca atataaaggg tcgtagactt tactccaaat tccaaaaagg 60
tcctggccat gtaatcctga aagttttccc aaggtagcta taaaatcctt ataaggggtgc 120
agcctcttct ggaattctct tgatttcaaa gtctcactct caagttcttg aaaacgaggg 180
cagttcctga aaggcaggta tagcaactga tcttcagaaa gaggaactgt gtgcaccggg 240
atgggctgcc agagtaggat aggattccag atgctgacac cttctggggg aaacaggggt 300
gccaggtttg tcatagcaat catcaaagtc cgggtcaacgt ctgtgcttcg aatataaacc 360
tggtcatgtt tataggactc attcaagaat tttctatata tctttcttat atactctcca 420
agttcataat gctgctccat gccagctgg gtgagttggc caaatccttg tggccatgag 480
gattccttta tggggctcagt gggaaaggtg tcaatgggac ttcggtctcc atgccgaaac 540
accaaagtca caaacttcaa ctccctgggt agtacacttc ggtctagcca gaaaaaaagc 600
agaaacaaga agccaaggct aaggcttgct gccctgccag gaggaggggt gcagctctca 660
tgttgag                                     667

```

<210> 437

<211> 693

<212> DNA

<213> Homo sapiens

<400> 437

```

ctacgtctca accctcattt ttaggtaagg aatcttaagt ccaaagatat taagtgactc 60
acacagccag gtaaggaaag ctggattggc acactaggac tctaccatac cgggttttgt 120
taaagctcag gtaggaggc tgataagctt ggaaggaaact tcagacagct ttttcagatc 180
ataaaagata attcttagcc catgttcttc tccagagcag acctgaaatg acagcacagc 240
aggtaactct ctattttcac ccctcttgct tctactctct gccagtcaga cctgtggggag 300
gccatgggag aaagcagctc tctggatggt tgtcacagatc atggactatt ctctgtggac 360
catttctcca ggttacccta ggtgtcacta ttggggggac agccagcatc tttagctttc 420
atttgagttt ctgtctgtct tcagtagagg aaacttttgc tcttcacact tcacatctga 480
acacctaact gctgttgctc ctgaggtggt gaaagacaga tatagagctt acagtattta 540
tcctatttct aggcactgag ggctgtgggg taccttgtgg tgccaaaaca gatcctgttt 600
taaggacatg ttgcttcaga gatgtctgta actatctggg ggctctgttg gctctttacc 660
ctgcatcatg tgctctcttg gctgaaaatg acc                                     693

```

<210> 438

<211> 360

<212> DNA

<213> Homo sapiens

<400> 438

```

ctgcttatca caatgaatgt tctcctgggc agcgttggtga tctttgccac cttcgtgact 60
ttatgcaatg catcatgcta tttcatacct aatgagggag ttccaggaga ttcaaccagg 120
atgtttctac acctgtgggt tatgacaaag acaactgcc aagaatcttc aagaaggagg 180
actgcaagta tatctggttg agaagaagga cccaaaaaag acctgttctg tcagtgaatg 240
gataatctaa tgtgcttcta gtaggcacag ggctcccagg ccaggcctca ttctcctctg 300
gcctctaata gtcaataatt gtgtagccat gcctatcagt aaaaagattt ttgagcaaac 360

```

<210> 439

<211> 431

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(431)

<223> n = A,T,C or G

<400> 439

```

gttcctnnta actcctgcc gaaacagctc tctcaacat gagagctgca cccctcctcc 60

```

```

tggccagggc agcaagcctt agccttggtt tcttggttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
gtccatttga cacttttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccctata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcggccgcg 420
aatttagtag t
431

```

<210> 440

<211> 523

<212> DNA

<213> Homo sapiens

<400> 440

```

agagataaag cttaggtcaa agttcataga gttcccatga actatatgac tggccacaca 60
ggaicttttg tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaatgtc tgaaatggaa cagatttcaa aaaaaaaccc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa ggagaggcaa agaaaggaga tacagtggag acatctggaa agttttcttc 300
actggaaaac tgctactatc tgtttttata tttctgttaa aatatatgag gctacagaac 360
taaaaaattaa aacctctttg tgtcccttgg tcttggaaca tttatgttcc ttttaaagaa 420
acaaaaatca aactttacag aaagatttga tgtatgtaat acatatagca gctcttgaag 480
tatatatatc atagcaaata agtcactctga tgagaacaag cta
523

```

<210> 441

<211> 430

<212> DNA

<213> Homo sapiens

<400> 441

```

gttctctcta actcctgcc aaaaacagctc tctcaacat gagagctgca cccctcctcc 60
tggccagggc agcaagcctt agccttggtt tcttggttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
gtccatttga cacttttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccctata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcggccgcg 420
aatttagtag
430

```

<210> 442

<211> 362

<212> DNA

<213> Homo sapiens

<400> 442

```

ctaaggaatt agtagtggtc ccatcacttg tttggagtgt gctattctaa aagatttttg 60
tttctgggaa tgacaattat attttaactt tgggtgggga aagagttata ggaccacagt 120
cttcacttct gatacttgta aattaatctt ttattgcact tgttttgacc attaagctat 180
atgttttagaa atggtcattt tacggaaaaa ttagaaaaat tctgataata gtgcagaata 240
aatgaattaa tgttttactt aatttatatt gaactgtcaa tgacaaataa aaattctttt 300
tgattatttt ttgttttcat ttaccagaat aaaaactaag aattaaaagt ttgattacag 360
tc
362

```

<210> 443

<211> 624

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(624)

<223> n = A,T,C or G

<400> 443

```

tttttttttt gcaacacaat atacatcaca gtgaaatgtg taatccttgc aaattgcaag 60
ttgaaagaat taaattcaga ggaggggaga gaaagagtag tcagtaggga ctgagcacta 120
aatgcttatt ttaaaaagaaa tgtaaagagc agaaagcaat tcaggctacc ctgccttttg 180
tgctggctag tactccgggc ggtgtcagca gcacgtggca ttgaacattg caatgtggag 240
cccaaaccac agaaaaatggg gtgaaattgg ccaactttct attaacttgg ctccctgttt 300
tataaaatat tgtgaataat atcacctact tcaaagggca gttatgaggc ttaaatgaac 360
taacgcctac aaaacactta aacatagata acataggtgc aagtactatg tatctgtgtac 420
atggtaaaca tccttattat taaagtcaac gctaaaatga atgtgtgtgc atatgctaata 480
agtacagaga gagggcactt aaaccaacta agggcctgga gggaagggtt cctggaaaaga 540
ngatgcttgt gctgggtcca aatcttgggc tactatgacc ttggccaaat tattttaaact 600
ttgtccctat ctgctaaaca gatc 624

```

<210> 444

<211> 425

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(425)

<223> n = A,T,C or G

<400> 444

```

gcacatcatt nntcttgcatt tctttgagaa taagaagatc agtaaatagt tcagaagtgg 60
gaagctttgt ccaggcctgt gtgtgaaccc aatgttttgc ttagaaatag aacaagtaag 120
ttcattgcta tagcataaca caaaatttgc ataagtgtgt gtcagcaaat ccttgaatgc 180
tgcttaatgt gagaggttgg taaaatcctt tgtgcaacac tctaactccc tgaatgtttt 240
gctgtgctgg gacctgtgca tgccagacaa ggccaagctg gctgaaagag caaccagcca 300
cctctgcaat ctgccacctc ctgctggcag gatttgtttt tgcatacctgt gaagagccaa 360
ggaggcacca gggcataagt gagtagactt atgggtcgacg cggccgcgaa tttagtagta 420
gtaga 425

```

<210> 445

<211> 414

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(414)

<223> n = A,T,C or G

<400> 445

```

catgtttatg nttttggatt actttgggca cctagtgttt ctaaatcgtc tatcattctt 60
ttctgttttt caaaagcaga gatggccaga gtctcaacaa actgtatctt caagtctttg 120
tgaaattctt tgcatgtggc agattattgg atgtagtctt ctttaactag catataaata 180
tggtgtgttt cagataaatg aacagcaaaa tgtggtggaa ttaccatttg gaacattgtg 240
aatgaaaaat tgtgtctcta gattatgtaa caaataacta tttcctaacc attgatcttt 300
ggatttttat aatcctactc acaaatgact aggcttctcc tcttgtattt tgaagcagtg 360
tgggtgctgg attgataaaa aaaaaaaaaa tgcacgcggc cggaatttta gtag 414

```

<210> 446

<211> 631
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(631)
 <223> n = A,T,C or G

<400> 446
 acaaattaga anaaagtgcc agagaacacc acataccttg tccggaacat tacaatggct 60
 tctgcatgca tgggaagtgt gagcattcta tcaatatgca ggagccatct tgcagggtgtg 120
 atgctgggta tactggacaa cactgtgaaa aaaaggacta cagtgttcta tacgttggtc 180
 ccggtcctgt acgatttcag tatgtcttaa tgcagctgt gattggaaca attcagattg 240
 ctgtcatctg tgtgggtggc ctctgcatca caagggccaa actttaggta atagcattgg 300
 actgagattt gtaaaccttc caaccttcca ggaaatgcc cagaagcaac agaattcaca 360
 gacagaagca aaatacaggg cactacagtt cagacaatac aacaagagcg tccacgaggt 420
 taatctaaag ggagcatgtt tcacagtggc tggactaccg agagcttggg ctacacaata 480
 cagtattata gacaaaagaa taagacaaga gatctacaca tgttgccttg catttggtgg 540
 aatctacacc aatgaaaaca tgtactacag ctatatattga ttatgtatgg atatatttga 600
 aatagtatac attgtcttga tgtttttct g 631

<210> 447
 <211> 585
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(585)
 <223> n = A,T,C or G

<400> 447
 ccttgggaaa antntcacia tataaagggt cgtagacttt actccaaatt ccaaaaaggt 60
 cctggccatg taatcctgaa agttttccca aggtagctat aaaatcctta taagggtgca 120
 gctcttctg gaattcctct gatttcaaag tctcactctc aagttcttga aaacgagggc 180
 agttcctgaa aggcaggtat agcaactgat cttcagaaag aggaactgtg tgcaccggga 240
 tgggctgcc a gtaggata ggattccaga tgcagacacc ttctggggga aacagggctg 300
 ccagggttgt catagcactc atcaaagtcc ggtcaacgtc tgtgcttcga atataaacct 360
 gttcatgttt ataggactca ttcaagaatt ttctatatct ctttcttata tactctccaa 420
 gttcataatg ctgctccatg ccagctggg tgagttggcc aaatccttgt ggccatgagg 480
 attcctttat ggggtcagtg ggaaaggtgt caatgggact tccgtctcca tgccgaaaca 540
 ccaaagtcac aaacttcaac tccttggcta gtacacttcg gtcta 585

<210> 448
 <211> 93
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(93)
 <223> n = A,T,C or G

<400> 448
 turtcgtggg tcattctgan nncgaaactg accttgccag ccttgccgan ggccnccat 60
 ggtcccttag tgccctggag agganggggc tag 93

<210> 449
<211> 706
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(706)
<223> n = A,T,C or G

<400> 449
ccaagttcat gctntgtgct ggacgctgga caggggggcaa aagcnnttgc tcgtgggtca 60
ttctgancac cgaactgacc atgccagccc tgccgatggt cctccatggc tccctagtgc 120
cctggagagg aggtgtctag tcagagagta gtcctggaag gtggcctctg ngaggagcca 180
cggggacagc atcctgcaga tggtcgggag cgtcccattc gccattcagg ctgcgcaact 240
gttggaagg gcgattgaag cgggcctctt cgctattacg ccagctggcg aaagggggat 300
gtgctgcaag gcgattgaag tgggtaacgc caggggtttc ccagtcncga cgttgtaaaa 360
cgacggccag tgaattgaat ttaggtgacn ctatagaaga gctatgacgt cgcatgcacg 420
cgtacgtaag cttggatcct ctagagcggc cgcctactac tactaaattc gcggccgagt 480
cgacgtggga tcncactga gagagtggag agtgacatgt gctggacnct gtccatgaag 540
cactgagcag aagctggagg cacaacgcnc cagacactca cagctactca ggaggctgag 600
aacaggttga acctgggagg tggaggttgc aatgagctga gatcaggccn ctgcncceca 660
gcatggatga cagagtgaaa ctccatctta aaaaaaaaaa aaaaaa 706

<210> 450
<211> 493
<212> DNA
<213> Homo sapiens

<400> 450
gagacggagt gtcactctgt tgcccaggct ggagtgcagc aagacactgt ctaagaaaaa 60
acagttttta aaggtaaaaac aacataaaaa gaaatatcct atagtggaaa taagagagtc 120
aaatgaggct gagaacttta caaagggatc ttacagacat gtcgccaata tcactgcatg 180
agcctaagta taagaacaac ctttggggag aaaccatcat ttgacagtga ggtacaattc 240
caagtcagggt agtgaaatgg gtggaattaa actcaaatta atcctgccag ctgaaacgca 300
agagacactg tcagagagtt aaaaagttag ttctatccat gaggtgattc cacagtcttc 360
tcaagtcaac acatctgtga actcacagac caagttctta aaccactgtt caaactctgc 420
tacacatcag aatcacctgg agagctttac aaactcccat tgccgagggt cgacgcggcc 480
gcgaatttag tag 493

<210> 451
<211> 501
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(501)
<223> n = A,T,C or G

<400> 451
gggcgcgtcc cattcgccat tcaggctgag caactgttgg gaaggcgcat cggtgcgggc 60
ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct gcaaggcgat taagttgggt 120
aacgccaggg ttttcccagt cncgacgttg taaaacgacg gccagtgaat tgaatttagg 180
tgacnctata gaagagctat gacgtcgcat gcacgcgtac gtaagcttgg atcctctaga 240
gcggegcgct actactacta aattcgcggc cgcgtcgacg tgggatccnc actgagagag 300
tggagagtga catgtgctgg acnctgtcca tgaagcactg agcagaagct ggaggcacia 360
cgcncacagac actcacagct actcaggagg ctgagaacag gttgaacctg ggagggtggag 420

gttgcaatga gctgagatca ggcncctgcn ccccagcatg gatgacagag tgaaactcca 480
 tottaaaaaa aaaaaaaaaa a 501

<210> 452
 <211> 51
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(51)
 <223> n = A,T,C or G

<400> 452
 agacggtttc accnttataa cnccttttag gatgggnntt ggggagcaag c 51

<210> 453
 <211> 317
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(317)
 <223> n = A,T,C or G

<400> 453
 tacatcttgc tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa 60
 acatctgaag agctagtcta tcagcatctg gcaagtgaat tggatggttc tcagaaccat 120
 ttcacccana cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca 180
 taacaaaccc tgctccaatc tgtcacataa aagctctgtga ctggaagttt antcagcacc 240
 cccaccaaac tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataagg 300
 taccatgtc tttatta 317

<210> 454
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 454
 ttcgagggtac aatcaactct cagagtgtag tttccttcta tagatgagtc agcattaata 60
 taagccacgc cagctctttg aaggagtctt gaattctcct ctgctcactc agtagaacca 120
 agaagaccaa attcttctgc atcccagctt gcaaacaaaa ttgttcttct aggtctccac 180
 ccttctcttt tcagtgttcc aaagctcctc acaatttcat gaacaacagc t 231

<210> 455
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 455
 taccaaagag ggcataataa tcagtctcac agtaggggttc accatcctcc aagtgaaaaa 60
 cattgttccg aatgggcttt ccacaggcta cacacacaaa acaggaaaca tgccaagtgtt 120
 guttcaacgc attgatgact tctccaagga tcttcttttg gcatcgacca cattcagggg 180
 caaagaatth ctcatagcac agctcacaat acaggggtcc tttctcctct a 231

<210> 456
 <211> 231

<212> DNA

<213> Homo sapiens

<400> 456

```

ttggcaggta cccttacaaa gaagacacca taccttatgc gttattaggt ggaataatca 60
ttccattcag tattatcggt attattcttg gagaaaccct gtctgtttac tgtaaccttt 120
tgcaactcaaa ttccctttatc aggaataaact acatagccac tatttacaaa gccattggaa 180
cctttttatt tgggtgcagct gctagtcagt cctgactga cattgccaaag t 231

```

<210> 457

<211> 231

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(231)

<223> n = A,T,C or G

<400> 457

```

cgaggtagccc aggggtctga aaatctctnn ttantagtc gatagcaaaa ttgttcatca 60
gcattcctta atatgatctt gctataatta gatttttctc cattagagtt catacagttt 120
tatttgattt tattagcaat ctctttcaga agacccttga gatcattaag ctttgtatcc 180
agttgtctaa atcgatgcct catttctctt gaggtgtcgc tggcttttgt g 231

```

<210> 458

<211> 231

<212> DNA

<213> Homo sapiens

<400> 458

```

aggtctgggt cccccactt ccaactccct ctactctctc taggactggg ctgggccaag 60
agaagagggg tggttaggga agccqttgag acctqaaqcc ccaccctcta ccttccttca 120
acaccctaac cttgggtaac agcatttgga attatcattt gggatgagta gaatttccaa 180
ggtcctgggt taggcatttt ggggggccag accccaggag aagaagattc t 231

```

<210> 459

<211> 231

<212> DNA

<213> Homo sapiens

<400> 459

```

ggtaccgagg ctgctgaca cagagaaacc ccaacgcgag gaaaggaatg gccagccaca 60
ccttcgcgaa acctgtggg gccaccagt cctaacggga caggacagag agacagagca 120
gccctgcaact gttttccctc caccacagcc atcctgtccc tcattggctc tgtgctttcc 180
actatacaca gtcaccgtcc caatgagaaa caagaaggag caccctccac a 231

```

<210> 460

<211> 231

<212> DNA

<213> Homo sapiens

<400> 460

```

gcagggtataa catgctgcaa caacagatgt gactaggaac ggccggtgac atggggaggg 60
cctatcacc cttcttggg ggctgcttct tcacagtgat catgaagcct agcagcaaat 120
cccacctccc cacacgcaca cggccagcct ggagcccaca gaagggtcct cctgcagcca 180
gtggagcttg gtccagcctc cagtccaccc ctaccaggct taaggataga a 231

```

<210> 461
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 461
 cgagggtttga gaagctctaa tgtgcagggg agccgagaag caggcggcct agggagggtc 60
 gcggtgtgctc cagaagagtg tgtgcatgcc agaggggaaa caggcgcctg tgtgtcctgg 120
 gtgggggttca gtgaggagtg ggaaatttgt tcagcagaac caagccgttg ggtgaataag 180
 aggggggattc catggcactg atagagccct atagtttcag agctgggaat t 231

<210> 462
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 462
 aggtaccctc attgtagcca tgggaaaatt gatgttcagt ggggatcagt gaattaaatg 60
 ggggtcatgca agtataaaaa ttaaaaaaaaa aagacttcat gcccaatctc atatgatgtg 120
 gaagaactgt tagagagacc aacagggtag tgggttagag atttccagag tcttacattt 180
 tctagaggag gtatttaatt tcttctcact catccagtgt tgtatttagg a 231

<210> 463
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 463
 tactccagcc tggtagacaga gcgagaccct atcaccgccc cccacccac caaaaaaaaa 60
 actgagtaga caggtgtcct cttggcatgg taagtcttaa gtcccctccc agatctgtga 120
 catttgacag gtgtcttttc ctctggacct cgggtgtccc atctgagtga gaaaaggcag 180
 tggggaggtg gatcttcacg tcgaagcggg atagaagccc gtgtgaaaag c 231

<210> 464
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 464
 gtactctaag attttatcta agttgccttt tctgggtggg aaagttaac cttagtgaact 60
 aaggacatca catatgaaga atgtttaagt tggaggtggc aacgtgaatt gcaaacaggg 120
 cctgcttcag tgactgtgtg cctgtagtcc cagctactcg ggagtctgtg tgaggccagg 180
 ggtgccagcg caccagctag atgctctgta acttctaggc cccattttcc c 231

<210> 465
 <211> 231
 <212> DNA
 <213> Homo sapiens

<400> 465
 catgttggtg tagctgtggt aatgctggct gcactctcaga cagggttaac ttcagctcct 60
 gtggcaaatt agcaacaaat tctgacatca tatttatggt ttctgtatct ttgttgatga 120
 aggatggcac aatttttgct tgtgttcata atatactcag attagtccag ctccatcaga 180
 taaactggag acatgcagga cattagggta gtgtgttagc tctggtaatg a 231

<210> 466
 <211> 231
 <212> DNA

<213> Homo sapiens

<400> 466

```
caggtagctc tttccattgg atactgtgct agcaagcatg ctctccgggg tttttttaat 60
ggccttcgaa cagaacttgc cacataccca ggtataatag tttctaacat ttgccaggga 120
cctgtgcaat caaatattgt ggagaattcc ctagctggag aagtcacaaa gactataggc 180
aataatggag accagtccca caagatgaca accagtcggt gtgtgcggt g 231
```

<210> 467

<211> 311

<212> DNA

<213> Homo sapiens

<400> 467

```
gtacaccctg gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg 60
tgggtggctt tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac 120
tgtgccttaa cagaaggtct tgagattcta agtgggaatc atttcagtga ctgtcatgtg 180
gcatgggtct ctgcccaagc tcgtaatgag actatagcaa ggcggtgtg ggacgtcagt 240
tgtgacctgc tgggcctccc aatagactaa caggcagtgc cagttggacc caagagaaga 300
ctgcagcaga c 311
```

<210> 468

<211> 3112

<212> DNA

<213> Homo sapiens

<400> 468

```
cattgtgttg ggagaaaaac agaggggaga tttgtgtggc tgcagccgag ggagaccagg 60
aagatctgca tgggtgggaag gacctgatga tacagagttt gataggagac aattaaaggc 120
tggaaggcac tggatgcctg atgatgaagt ggactttcaa actggggcac tactgaaacg 180
atgggatggc cagagacaca ggagatgagt tggagcaagc tcaataacaa agtgggtcaa 240
cgaggacttg gaattgcatg gagctggagc tgaagtttag cccaattgtt tactagttag 300
gtgaatgtgg atgattggat gatcatctct catctctgag cctcaggttc cccatccata 360
aaatgggata cacagtatga tctataaagt gggatatagt atgatctact tcaactgggt 420
atttgaagga tgaattgaga taattttatt caggtgccta gaacaatgcc cagattagta 480
catttgggtg aactgagaaa tggcataaca ccaaatttaa tatatgtcag atgttactat 540
gattatcatt caatctcata gttttgtcat ggcccaattt atcctcactt gtgcctcaac 600
aaattgaact gtaacaaaag gaatctctgg tcttgggtta tggctgagca ccactgagca 660
tttccattcc agttggcttc ttgggtttgc tagctgcac actagtcac tttaaataaat 720
gaagttttta catttctcca gtgatttttt tatctcacct ttgaagatac tatgttatgt 780
gattaaataa agaacttgag aagaacaggc ttcatataac ataaatcaa ttagtagcgc 840
aattttctgg atgggcaata cttatgttca caggaaatgc tttaaaatat gcagaagata 900
attaaatggc aatggacaaa gtgaaaaact tagacttttt tttttttttt ggaagtatct 960
ggatgttcct tagtcaacta aaggagaact gaaaaatagc agtgagttcc acataatcca 1020
acctgtgaga ttaaggctct ttgtggggaa ggacaaagat ctgtaaattt acagtttcct 1080
tccaaagcca acgtcgaatt ttgaaacata tcaaagctct tcttcaagac aaataatcta 1140
tagtacatct ttcttatggg atgcacttat gaaaaatggg ggctgtcaac atctagtcac 1200
ttagctctc aaaatgggtc attttaagag aaagtttttag aatctcatat ttattcctgt 1260
ggaaggacag cattgtggct tggactttat aaggtcttta ttcaactaaa taggtgagaa 1320
ataagaaagg ctgctgactt taccatctga ggccacacat ctgctgaaat ggagataatt 1380
aacatcacta gaaacagcaa gatgacaata taatgtctaa gtagtgacat gtttttgcac 1440
atttccagcc cctttaaata tccacacaca caggaaagc aaaaggaagc acagagatcc 1500
ctggggagaaa tgcgccggcc ccatcttggg tcatcgatga gcctcgccct gtgcctgggtc 1560
ccgcttgtga ggaaggaca ttagaaaaatg aattgatgtg ttctttaaag gatgggcagg 1620
aaaacagatc ctgttgtgga tatttatttg aacgggatta cagatttgaa atgaagtcac 1680
aaagtgagca ttaccaatga gaggaaaaca gacgagaaaa tcttgatggc ttcacaagac 1740
atgcaacaaa caaaatggaa tactgtgatg acatgaggca gccaaagctgg ggaggagata 1800
accacggggc agagggtcag gattctggcc ctgctgccta aactgtgcgt tcataaccaa 1860
```

```

atcatttcat atttetaaac ctcaaaacaa agctgttgta atatctgate totacgggttc 1920
ttctgtgggc caacattctc catatatcca gccacactca tttttaatat ttagtctcca 1980
gatctgtact gtagccttct tacactgtag aataacatta ctcatcttct tcaaagacct 2040
tttgtgttgc tgcctaatat gtagctgact gtttttcta aggagtgttc tggcccaggg 2100
gatctgtgaa caggctggga agcatctcaa gatctttcca ggggtatact tactagcaca 2160
cagcatgate attacggagt gaattatcta atcaacatca tcttcagtgt ctttgcccat 2220
actgaaattc atttccact tttgtgccc ttctcaagac ctcaaaatgt cattccatta 2280
atctcacagg attaactttt ttttttaacc tggagaatt caatgttaca tgcagctatg 2340
ggaatttaat tacatatctt gttttccagt gcaaagatga ctaagtcctt tatccctccc 2400
tttgttttga ttttttttcc agtataaagt taaaatgctt agccttgtae tgaggctgta 2460
tadagccaca gctctctccc atccctccag ccttatctgt catcaccatc aaccctccc 2520
ttgaccccaa acaaaatcta acttgtaatt ccttgaacat gtcaggcata cattattcct 2580
tctgcttgag aaactcttcc ttgtctctta aatctagaat gatgtaaagt tttgaataag 2640
ttgactatct tacttcatgc aaagaaggga cacatatgag attcatcatc acatgagaca 2700
gcaaatataa aaagtataat ttgattataa gaggtttagat aaatatatga aatgcaagag 2760
ccacagaggg aatgttttat gggcacgttt gtaagcctgg gatgtgaagc aaaggcaggg 2820
aacctcatag tatcttatat aatatacttc atttctctat ctctatcaca atatccaaca 2880
agcttttccac agaatctatg cagtgcacaa ccccaaaggc aacctttatc catttcatgg 2940
tgagtgcgct ttacaatttt ggcaaatcat actggctact tatctcaact ttgagatgtg 3000
tttgtccttg tanttaattg aaagaaatag ggcactcttg tgagccactt taggggtcac 3060
tcttggaat aaagaattta caaagagcaa aaaaaaaaaa aaaaaaaaaa aa 3112

```

<210> 469

<211> 2229

<212> DNA

<213> Homo sapiens

<400> 469

```

agctctttgt aaattcttla ttgccaggag tgaaccctaa agtggctcac aagagtgcce 60
tatttctttc aaltaactac aaggacaaac acatctcaaa gttgagataa gtgaccagta 120
tgatttgcca aaattctaaa ggcactcac catgaaatgg ataaagggtta cctttgggga 180
tttgactgac atgaattctg tgaaaagctt gttggatatt gtgatagaga tagagaaatg 240
aagtatatta tataagatac tatgagggtc cctgccttg ctccacatcc caggcttaca 300
aacgtgcccc ataaacattc cctctgtggc tcttgcatct catatattta tctaaactct 360
tataatcaaa tacactttta gtatttgctg tctcatgtga tgatgaatct catatgtgtc 420
ccttctttgc atgaagtaag atagtcaact tattcaaaac ttacatcat tctagattta 480
agagacaagg aagagcttct caggcagaag gaataatgta tgctgacat gttcaaggaa 540
ttacaagtta gattttgttt aggtgcatgg gaggggttga tgggtgatgac agataaggct 600
ggaggatgg ggagaggctg tggctgtata cagctcagt acaaggctaa gcattttaac 660
tttatactgg aaaaaaaaaa aaacaaaggg gagggataaa ggacttagtc atctttgcac 720
tggaacacaa aatatgtaat taaattccca tagctgcatg taacattgaa ttcttccagg 780
ttaaaaaaaaa agttaatcct gtgatattaa tggaaatgaca ttttgagggtc ttgagaatgg 840
gcacaaaagt gggaaatgaa ttccagtatg ggcaagaca ctgaggatga tgttgattag 900
ataattcact ccgtaatgat catgctgtgt gctagttaagt ataacctgg aaagatcttg 960
agatgcttcc cagctgttcc acagatcccc tgggcccagaa cactccttag gaaaaacagt 1020
cagctacata ttaggcagca acacgaaggg tctttgaaca aaatgagtaa tgttattcta 1080
cagtgtagaa aggtcacagt acagatctgg gaactaaata ttaaaaatga gtgtggctgg 1140
atatatggag aatgttgggc ccagaaggaa ccgtagagat cagatattac aacagctttg 1200
ttttgagggt tagaaatatg aaatgatttg gttatgaacg cacagtttag gcagcagggc 1260
cagaatcctg acctctgcc ccgtggttat ctctcccca gcttggctgc ctcatgtcat 1320
cacagtatcc cattttgttt gttgcatgtc ttgtgaagcc atcaagattt tctcgtctgt 1380
tttccctcca ttgtaatgc tcactttgtg acttcatttc aaatctgtaa tcccgttcaa 1440
ataaatatcc acaacaggat ctgttttcc tgcctatcct taaggaaacac atcaattcat 1500
tttataatgt ccttccctca caagcgggac caggcacagg gcgaggctca tcgatgaccc 1560
agatggcgg ccgggcattt ctcccaggga tctctgtgct tctttttgtg ctctctgtgt 1620
gtatggatat ttaagggggc tggaaatgtg caaaaacatg tcaactacta gacattatat 1680
tctatcttgg ctgtttctag tgatgttaat tatctccatt tcagcagatg tgtggcctca 1740
gtatgttaag tcagcagcct ttcttatttc tcacctggaa atacatacga ccatttgagg 1800

```

```

agacaaatgg caaggtgtca gcataccctg aacttgagtt gagagctaca cacaatatta 1860
ttggtttccg agcatcacaa acaccctctc tgtttcttca ctgggcacag aattttaata 1920
cttattttcag tgggctgttg gcaggaacaa atgaagcaat ctacataaag tcactagtgc 1980
agtgcctgac acacaccatt ctcttgaggt cccctctaga gatccacag gtcatatgac 2040
ttcttgggga gcagtggctc acacctgtaa tcccagcact ttgggaggct gaggcagggt 2100
ggtcacctga ggtcaggagt tcaagaccag cctggccaat atggtgaaac cccatctcta 2160
ctaaaaatac aaaaattagc tgggcgtgct ggtgcatgcc tgtaatccca gccccaacac 2220
aatggaatt
2229

```

<210> 470

<211> 2426

<212> DNA

<213> Homo sapiens

<400> 470

```

gtaaattctt tattgccagg agtgaaccct aaagtggctc acaagagtgc cctattttctt 60
tcaattaact acaaggacaa acacatctca aagttgagat aagtgaccag tatgatttgc 120
caaaattcta aagcgactc accatgaaat ggataaagg tacccttggg gatttgcact 180
gcatgaattc tgtgaaaagc ttgttgata ttgtgataga gatagagaaa tgaagtatat 240
tatataagat actatgaggt tccctgcctt tgcttcacat cccaggctta caaacgtgcc 300
ccataaacat tccctctgtg gctcttgcac ttcatatatt tatctaaact cttataatca 360
aattacactt ttagtatttg ctgtctcatg tgatgatgaa tctcatatgt gtcccttctt 420
tgcatgaagt aagatagtca acttattcaa aactttacat cattctagat ttaagagaca 480
aggaagagct tctcaggcag aaggaataat gtatgcctga catgttcaag gaattacaag 540
ttagattttg tttaggtgca tgggaggggt tgatggtgat gacagataag gctggaggga 600
tggggagagg ctgtggctgt atacagcctc agtacaaggc taagcatttt aactttatac 660
tgaaaaaaa atcaaacaaa ggggagggat aaaggactta gtcattcttg cactggaaaa 720
caaaatatgt aattaaattc ccatagctgc atgtaacatt gaattcttcc aggttaaaaa 780
aaaaagttaa tctgtgata ttaatggaat gacattttga ggtcttgaga atgggcacaa 840
aagtgggaaa tgaatttcag tatgggcaaa gacactgagg atgatgttga ttagataatt 900
cactccgtaa tgatcatgct gtgtgctagt aagtataacc ctggaaagat cttgagatgc 960
ttcccagcct gttcacagat cccctgggcc agaacactcc ttaggaaaaa cagtcagcta 1020
catattagge aqcaacacga aggtctcttg aacaaaatga gtaatgttat tctacagtgt 1080
agaaaggtca cagtcagat ctgggaacta atatttaaaa atgagtgtgg ctggatatat 1140
ggagaatggt gggcccagaa ggaaccgtag agatcagata ttacaacagc tttgttttga 1200
gggttagaaa tatgaaatga tttggttatg aacgcacagt ttaggcagca gggccagaat 1260
cctgaccctc tgccccgtgg ttatctcctc cccagcttgg ctgcctcatg tcatcacagt 1320
attccatttt gtttgttgca tgtcttgtga agccatcaag attttctcgt ctgttttctt 1380
ctcattggta atgctcactt tgtgacttca ttcaaatct gtaatccgt tcaaataaat 1440
atccacaaca ggatctgttt tctgcccac cctttaagga acacatcaat tcattttcta 1500
atgtccttcc ctcaacagc ggaccaggca cagggcgagg ctcatcgatg acccaagatg 1560
gcgccggggc atttctccca gggatctctg tgcttccctt tgtgcttctt gtgtgtgtgg 1620
atatttaaa gggctgaaa tgtgcaaaaa catgtcacta cttagacatt atattgtcat 1680
cttgctgttt ctagtgatgt taattatctc catttcagca gatgtgtggc ctcagatggt 1740
aaagtcagca gcctttctta tttctcacct ggaaatacat acgaccattt gaggagacaa 1800
atggcaaggt gtcagcatac cctgaacttg agttgagagc tacacacaat attattgtgt 1860
tccgagcatc acaaacaccc tctctgtttc ttcactgggc acagaatttt aatacttatt 1920
tcagtgggct gttggcagga acaaatgaag caatctacat aaagtcacta gtgcagtgcc 1980
tgacacacac cattctcttg aggtccctc tagagatccc acaggtcata tgacttcttg 2040
gggagcagtg gctcacacct gtaatcccag cactttggga ggctgaggca ggtgggtcac 2100
ctgaggtcag gagttcaaga ccagcctggc caatatggtg aaaccccatc tctactaaaa 2160
atacaaaaat tagctgggct tgctggtgca tgcctgtaat cccagctact tgggaggctg 2220
aggcaggaga attgctggaa catgggaggc ggaggttgca gtgagctgta attgtgccat 2280
tgcaactgaa cctgggcgac agagtggaa cctgtttcca aaaaacaaac aaacaaaaaa 2340
ggcatagtca gatacaacgt ggggtgggat tgtaaataga agcaggatat aaagggcagt 2400
gggtgacggg tttgcccac acaatg
2426

```

<210> 471

<211> 812
 <212> DNA
 <213> Homo sapiens

<400> 471

```

gaacaaaatg agtaatgtta ttctacagtg tagaaaggtc acagtacaga tctgggaact 60
aaataattaaa aatgagtggt gctggatata tggagaatgt tgggcccaga aggaaccgta 120
gagatcagat attacaacag ctttggtttg agggttagaa atatgaaatg atttggttat 180
gaacgcacag tttaggcagc agggccagaa tctgaccct ctgcccctg gttatctct 240
ccccagcttg gctgcctcat gtcacacag tattccattt tgtttgttg atgtcttggt 300
aagccatcaa gatcttctcg tctgttttcc tctcatttgt aatgctcact ttgtgacttc 360
atttcaaatc tgaatcccg ttcaataaaa tatccacaac aggatctgtt ttctgccc 420
tctttaagg aacacatcaa ttcattttct aatgtccttc cctcacaagc gggaccaggc 480
acagggcgag gctcctcgat gacccaagat ggcgccggg catttctccc agggatctct 540
gtgcttctt ttgtgcttcc tgtgtgtgtg gatatttaaa ggggctggaa atgtgcaaaa 600
acatgtcact acctagacat tatattgtca tcttgctgtt tctagtgatg ttaattatct 660
ccatttcagc agatgtgtgg cctcagatgg taaagtcagc agcctttctt atttctcacc 720
tctgtatcat caggctcttc ccaccatgca gatcttctg gtctcctcg gctgcagcca 780
cacaaatctc cctctgttt ttctgatgcc ag

```

812

<210> 472
 <211> 515
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(515)

<223> n = A,T,C or G

<400> 472

```

acggagactt attttctgat attgtctgca tatgtatgtt ttttaagagtc tggaaatagt 60
cttatgactt tctatcatg cttattaata aataatacag ccagagaag atgaaaatgg 120
gttcagaat tattggctct tgcagcccg tgaatctcag caagaggaa caccaactga 180
caatcaggat attgaacctg gacaagagag agaaggaca cctccgatcg aagaacgtaa 240
agtagaagg gattgccagg aaatggatct ggaagagact cggagtgagc gtggagatgg 300
ctctgatgta aaagagaaga ctccacctaa tcttaagcat gctaagacta aagaagcagg 360
agatgggcag ccataagtta aaaagaagac aagctgaagc tacacacatg gctgatgtca 420
cattgaaaat gtgactgaaa atttgaaaat tctctcaata aagtttgagt tttctctgaa 480
gaaaaaaaaa naaaaaaaaa aaanaaaan aaaaa

```

515

<210> 473
 <211> 5829
 <212> DNA
 <213> Homo sapiens

<400> 473

```

cgcattgccg ggaagcccaa gctggctcga agagccacca gccacctgtg caagggtggg 60
cctggaccag ttggaccagc caccaagctc acctactcaa ggaagcagg atggccaggt 120
tgcaacagcc tgagtggctg ccacctgata gctgatggag cagaggcctg aggaaaatca 180
gatggcacat ttagctcttt aatggatctt aagttaattt ttctataaag cacatggcac 240
cagtcctatg ctccagagctc gtatggcact gggaccaca gcaggccgag ttcccaggat 300
tgccatccag gggggccttc tgtagccctg gccagacctt gcagagggtg ctgggtgctc 360
tttgagcgag ctgcgcttcc ctggcatgca caggccccag gtactgacac gctgctctga 420
gtgagcttgt cctgccttgg ctgccacctc actgctgatg gagcagcggc cttaggaaaa 480
gcaaatggcg ctgtagccca actttagggt agaagaagat gtaccatgtc cggccgctag 540
ttggtgactg gtgcacctgc tcttgccgta cccttgaga ggtgggtgtg tgcctttgg 600
ccagcttggc cttgcctggc atgcacaagc ctcatgcaa caactgtct acaaatggag 660

```

```

acacagagag gaaacaagca ggggggtcag gagcaggggtg tgtgtgtgct ttgggggtcc 720
agtccatgcc tcgggtcgta tgggtactgca ggcttcttgg ttgccaagag gcggaaccaca 780
ggccttcttg agggaggactt tacgttcaag tgcagaaagc agccaaaatt accatccatg 840
agactaagcc ttctgtggcc ctggcgagac ttaaaatttg tgccaaggca ggacaagctc 900
actcggagca gcgtgtcagt agctggggcc tatgcatgcc gggcagggcc gggctggctg 960
aaggagcaac cagccacctc tgcaaggggtg cgcctagtgc aggcggagca tccaccacct 1020
caccgcctcg aggaagtggg gatggccagg tccccacagc ctgagtgtct gccaccttat 1080
tgctgatgga gcagaggcct taagaaaagc agatggcact gtggccctac ctttaggggtg 1140
gaagaagtga gtacatgtc cggaagctaa ttggtgactg gtacaccggc tctgtctaca 1200
cctttgcaga ggtggctggg tgccttttga gccagcttgt ccttgcccg catgcacaag 1260
tttcagtga acaactttgc cacaatgga gccatataga ggaaacaaga agcaggttca 1320
ggagaagggt gtaccctgcc tttggggctc cagtccatgc ctcaggtgtc acatggcact 1380
gcgggcttct tggttgccag gaggcggacc acaggccatc ttggggagga ctttgtgttc 1440
aagtgcagaa agcagccagg attgccatcc agggggaccc tctatagccc tggccaaacc 1500
ttgcaggggt gtctggttgc tctttgagcc ggcttggcct ccctggcatg cacgggcccc 1560
aggtgctggc agctgtctcc gagtgtgctt gtctgtcctt ggctgccacc tctgggggg 1620
tgctgtgga ggggtggac cgccaccaa ccttaccag tcaaggaaat ggatggccat 1680
gttcccacag cctgaatggc tgccacctga ttgctgatgg agcaaaggcc ttaggaaaag 1740
cagatggccc ttggccctac ctttttgtta gaagaactga tgttccatgt cctgcagcga 1800
gtgaggttgg tggctgtgcc cccagctcct ggcgcgcct cgagaggtg actggttgct 1860
ctttgggccc tcttggcctt gccagcatg cacaagcctc agtgctacta ctgtgctaca 1920
aatggagcca tataggggaa acgagcagcc atctcaggag caaggtgtat gctgcctttg 1980
ggggtccag tcttgccctc aaggtctta tgtcactgtg ggcttcttgg ttgtcaagag 2040
gcagaccata ggcgtcttg agagggactt tatgttcaag tgcagaaagc agccaggatt 2100
gccaccctcg gactctgcc ttctgtggcc ctggccaaac ttagaatttg gccgtagaca 2160
ggacaggctc acttgagta gcgtgtccgt agctggggtc tgtgcatgcc gggcaaggcc 2220
gggctggctc gggagcaac cagccacctc tgcgggggtg cgctggagc aggtggagca 2280
gccaccagct caccactcc aggaagccgg ggtagccagg tcccaaggc ctgagtgggt 2340
gccacctaat ggctgaagaa acagaggcct tgggaaaacc agatggcact gtggccctac 2400
ctttatggta gaagagctga tttagcctga ctggcagcgt gtggggttgg tggctggtct 2460
gcctgctgct ggcgcacccg tgcaaggatg gctggttgcc ctttgagcca gcttgccctt 2520
gcccggcatg cgaagcctc agtgcaacaa ctgtgtgca aatggggcca tatagaggaa 2580
aggagcagct ggctctggag catggtgtgc actcccttgg ggcttccagt ccatgtctca 2640
tgggtcgtat gacactgcgg gcttgttggg tgccaagagg ggccttcagt gtcattctga 2700
ggaggacttt atgttccagt ccagaaagca gccagtggta ccaccaggg gacttgtgct 2760
tctgtgccc ggcagacgt agaatttgac aaagtccagg cggctcagc cagagcggcg 2820
tgtcggtecc cggggcctgt gcatgccggg cagggccggg ctggcttggg gagcaagcag 2880
ccacctctgt taagggtgtg cctggagcag gtggagcagc caccaacctc acgcaactgaa 2940
agaagcagg atggccagg tccaacatcc tgagtggctg ccacctgatg gctgatggag 3000
cagaggcctg aggaaaagca gatggcactg ctttgtagtg ctgttctttg tctctcttga 3060
tctttttcag ttaatgtctg ttttatcaga gactaggatt gcaaacctg ctcttttttg 3120
ctttccattt gcttggtaaa tattcctcca tccctttatt ttaagcctat gtgtgtcttt 3180
gcacatgaga tgggtctcct gaatacagga caacaatggg tctttactct ttatccaact 3240
tgccagtctg tgtcttttaa ctggggcatt tagccattt acatttaagt ttagtattgt 3300
tacatgtgaa atttatcctg tcatgatgtt gctagctttt tatttttccc attagtattg 3360
agtttcttta tagtgtcaat ggtctttaca attogatatg ttttgtagt ttgtaacaca agaattgtga 3480
ggtttttcct ttctacgttt agtgtctcct tcaggagctc ttgtaacaca gactgtattc tatggccttt 3540
tttatttctt gtaaggtaaa tatgtggatt tatttcttgg gataaaaca tttacagcct 3600
accccaagaa tcattacttt ttaaaatgca attcaaatta gcttttggat tattttgtgt 3660
atggaaagcg ttgtggcatt agaatcctta ttataggat cattaattcac cacagccctg 3720
tatggctctt gtcactgagg ccttttgcct taatctccca accagttgga tctgcaggca 3780
aactcttgag tccaagccat attttttcac gttttttttt ttttttgtc gagattatgg 3840
taaggcatca tgcgtggcta ttgctctggc tgatctcaaa tgtttgacct caagggatct ttctgccacg 3900
tgctactgtg ttgctctggc tatatgcatg atacaccatg cctattgtag agtattacat 3960
gcctcctaaa gtgctaggat aagagccatt tattgccttt ggcctaaata actcaatata 4020
tattttcaaa gtcttattgt tgacaaattt tggggcgtga tgatgagaga agggggtttg 4080
atatctctga aacttttttt acttagagcc atttaagaaa ggaaaaaaca caaattatca 4140

```

```

gaaaaacaac agtaagatca agtgcaaaag ttctgtggca aagatgatga gagtaaagaa 4200
tatatgtttg tgactcatgg tggcttttac ttgtttcttg aatttctgag tacgggttaa 4260
tatttaaaga atctacatta tagataacat ttatttgcaa gttaaagtat ttcaaaattt 4320
cttattgggt ttgtatgaga ttattctcag cctacttcat tatcaagcta tattatttta 4380
ttaatgtagt togatgatct tacagcaaag ctgaaagctg tatcttcaaa atatgtctat 4440
ttgactaaaa agttattcaa caggagttat tatctataaa aaaaatacaa caggaatata 4500
aaaaacttga ggataaaaag atgttggaag aagtaatat aaatcttaaa aaacatatgg 4560
aaactacaca atggggaaga cacatgggtg aagtacaaaa atataaattg gatctagaag 4620
aaagggcaat gcaggcaata gaaaaattag tagaaatccc tttaaagggt agtttgtaaa 4680
atcaggtaag tttattttata atttgccttc atttatttca ctgcaaatta tttttggat 4740
atgtatatat attgtgcttc ctctgcctgt cttacagcaa tttgccttgc agagttctag 4800
gaaaaagggt gcatgtgttt ttactttcaa aatattttaa ttccatcat tataacaaaa 4860
tcaatttttc agagtaatga ttctcactgt ggagtcattt gattattaag acccgttggc 4920
ataagattac atcctctgac tataaaaaatc ctggaagaaa acctaggaaa tttcgtctg 4980
gacattgcac ttggcaatga atttatgggt aacctctgat ccactccag tcaactacca 5040
tgagttttta ttccagata catgaaatca tatgagttga aactttcttt tgattgagca 5100
gtttggaac cgtctttttg tagaatctgc aagtggatat ttggaacct ttgaggcta 5160
tgctgaaaaa agaaatatct tcactacatg atgaccacca gcagcagctg gggaaaccag 5220
cacctgtgg aattccatac ggtgcataga atacatcttc ccttcagtcg gcttgggtca 5280
acttaggtca tgggccacct ggtgatagc agtttccaca gaaatgcttc aagatgaaag 5340
tggatgaccg ggccacctc caccactgcc ctgtaagacc atgggacaca caggccacca 5400
gttcttttca tgtggtcatc cctgtttaga tgggagaaaa tacacctgcc tcatttttgt 5460
accttctgtg tgaacattcc acggcagact gtgcctaaat gtggatgaag aattgaatga 5520
atgaatgaat atgagagaaa atgaataaat ggttcagatc ctgggctgga aggcgtgtga 5580
tgaggatggt gggtagagga gggctctgtt ttcttgctt taagtcacta attgtcact 5640
tggggcagga gcacaggctt tgaatgcaga ccgactggac tttaattctg gctttactag 5700
ttgtgattgt gtgacctgtg gaaagttact taaacctct gtgcctgttt ctttatctgt 5760
aaaatggaga taataagatg tcaaaggact gtggaagaa ttaaatgctt taaaaaaaaa 5820
aaaaaaaaa 5829

```

<210> 474

<211> 1594

<212> DNA

<213> Homo sapiens

<400> 474

```

atztatgat cattaatgcc tctttagtag tttagagaaa acgtcaaaag aaatggcccc 60
agaataagct tcttgatttg taaaattcta tgtcattggc tcaaatttgt atagtatctc 120
aaaaatataa tatatagaca tctcagataa tatatttgaa atagcaaatt cctgtagtaa 180
aataatagta cttaactaga tgagaataac aggtcgocat tatttgaatt gtctcctatt 240
cgtttttcat ttgttgtgtt actcatgttt tacttatgag ggatatatat aacttccact 300
gttttcagaa ttattgtatg cagtcagtat gagaatgcaa tttaagtttc cttgatgctt 360
tttcacactt ctattactag aaataagaat acagtaatat tggcaaagaa aattgaccag 420
ttcaataaaa ttttttagta aatctgattg aaaataaaca ttgcttatgg ctttcttaca 480
tcaatattgt tatgtcctag acaccttate tgaaattacg gcttcaaaat tctaattatg 540
tgcaaatgtg taaaatatca atactttatg ttcaagctgg ggctcttca ggcgtcctgg 600
gctgagagag aaagatgcta gtcogcaag ccggagaggg aacaccgcca cattgttaca 660
cggacacacc gccacgtgga cacatgacca gactcacatg tacagacaca cggagacatt 720
accacatgga gacaccgtca cacagtcaca cggacacact ggcatagtc catggacgga 780
cacacagaca tatggagaaa tcacatggac acaccaccac actatcacag ggacacagac 840
acacggagac atcaccacat ggacacactg tcacactacc acagggacac gagacatcac 900
actgtcacat ggacacacca tcacacacat gaacacaccg acacactgcc atatggacac 960
tggcacacac actgccacac tgtcacatgg acacacctcc acaccatcac accaccacac 1020
acactgcctg tggacacaag gacacacaga cactgtcaca cagatacaca aaacactgtc 1080
acacggagac atcaccatgc agatacaca ccaactgtgt gccgtctgaa ttacctgtct 1140
gggtgggacag cagtggcata ctcatgccta agtgactggc ttccaccca gtatgattg 1200
ccctccatca aactgccc cccaggttg gggctacccc agcccatctt tacaaaacag 1260
ggcaagggtga actaatggag tgggtggagg agttggaaga aatcccagcg tcagtcaccg 1320

```

```

ggatagaatt cccaaggaac cctctttttg gaggatgggt tccatttctg gaggcgatct 1380
gccgacaggg tgaatgcctt cttgcttggt ttctggggaa tcagagagag tccgttttgt 1440
gggtgggaaga gtgtggctgt gtactttgaa ctctgtaaa ttctctgact catgtccaca 1500
aaaccaacag ttttgtgaat gtgtctggag gcaaggggag ggccactcag gatctatgtt 1560
gaagggaaga ggctggggc tggagtattc gctt 1594

```

<210> 475

<211> 2414

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (33)

<223> n=A, T, C or G

<400> 475

```

cccaacacaa tggctttata agaatgcttc acntgtgaaa aacaaatata aaagtcttct 60
tgtagattat ttttaaggac aaatctttat tccatgttta atttatttag ctttccctgt 120
agctaataat tcatgctgaa cacattttta atgctgtaaa tgtagataat gtaatttatg 180
tatcattaat gcctcttttag tagtttagag aaaacgtcaa aagaaatggc cccagaataa 240
gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt tgtatagtat ctcaaaatat 300
aaatatatag acatctcaga taatatattt gaaatagcaa attcctgtta gaaaataata 360
gtacttaact agatgagaat aacaggctgc cattatttga attgtctcct attcgttttt 420
catttggtgt gttactcatg ttttacttat ggggggatat atataacttc cgctgttttc 480
agaagtattg tatgcagtca gtatgagaat gcaatttaag ttctcttgat gctttttcac 540
acttctatta ctagaaataa gaatacagta atattggcaa agaaaattga ccagttcaat 600
aaaaattttt agtaaatctg attgaaaata aacattgctt atggctttct tacatcaata 660
ttgttatgtc ctagacacct tatctgaaat tacggcttca aaattctaata tatgtgcaaa 720
tgtgtaaaat atcaatactt tatgttcaag ctggggcctc ttcaggcgctc ctgggctgag 780
agagaaagat gctagctcgc caagccgggg agggacaccc gccacattgt tacatggaca 840
caccgccacg tggacacatg accagactca catgtacaga cacacggaga cattaccaca 900
tggagacacc gtacacacgt cacacgagca cactggcata gtcacatgga cggacacaca 960
gacatatgga gaaatcacac tgacacacca ccactatc acagggacac agacacacgg 1020
agacatcacc acatggacac actgtcacac taccacaggg acacgagaca tcacactgtc 1080
acatggacac accatcacac acatgaacac accgacacac tgccatatgg acaactgccac 1140
acacactgcc acaactgtcac atggacacac ctccatacca tcacaccacc acacacactg 1200
ccatgtggac acaaggacac acagacactg tcacacagat acacaaaaca ctgtcacacg 1260
gagacatcac catgcagata caccaccaca tggacatagc accagacact ctgccacaca 1320
gatacaccac cacacagaaa tgcggacaca ctgccacaca gacaccacca catcgttgcc 1380
acactttcat gtgtcagctg gcggtgtggg cccacgact ctgggctcta atcgagaaat 1440
tacttgga ca tatagtgaag gcaaaatttt tttttatttt ctgggtaacc aagcgcgact 1500
ctgtctcaaa aaaagaaaaa aaaagcaata tactgtgtaa tcgttgacag cataattcac 1560
tattatgtag atcggagagc agaggattct gaatgcatga acatatcatt aacatttcaa 1620
tacattactc ataattactg atgaactaaa gagaaccaa gaaattatgg tgatagttat 1680
attgacctgg agaaatgtag acacaaaaga accgtaagat gagaaatgtg ttaacacagt 1740
ctataagggc atgcaagaat aaaaataggg gagaaaacag gagagttttt caagagcttt 1800
ctggatcatg aagtcaactt gtatcggtta atttttaaaa ggtttattta catgcaataa 1860
actgcacata cttcaattgt acatttttgt aattcttggc atttgtagct ctataaaacc 1920
agcaacatat taaaatagca aacatatcca ttacctttac caccaaagtt ttcttggttt 1980
ttttctactc actttttcct gectatcccc ccatctcttc cacaggtaac cactgatcca 2040
cttccagtc a ctatccatga gtttttattt ccaaatacat gaaatcatat gaatttctgg 2100
tttttctgt tggagcccaa ggagcaaggg cagaatgagg aacatgatgt ttcttwccga 2160
cagttactca tgacgtctcc atccaggact gaggggggca tccttctcca tctaggactg 2220
ggggcatcct tctccatcca gtattggggg tcatccttct ccatccagta ttgggggtca 2280
tcctcctcca tccaggacct gaggggtgtc ctttctgcg cttccttgga tggcagctt 2340
tccttcatg tttatagtra cttaccatta aatcactgtg ccgttttttc ctaaaataaa 2400
aaaaaaaaaa aaaa 2414

```

<210> 476
<211> 3434
<212> DNA
<213> Homo sapiens

<400> 476

```
atgtgctgca aatgggggcca tatagaggaa aggagcagct ggctctggag catggtgtgc 60
actccctttg ggccttcagt ccatgtctca tgggtcgtat gacactgcgg gcttgttggg 120
tgcaagagg cagaccacag gtcattctga ggaggacttt atgttccagt ccagaaagca 180
gocagtggta ccaccaggg gacttgtgct tctgtggccc aggccagacg tagaatttga 240
aaaagtcagg acggtctcag tcagagcagc atgtcgggtcc ccggggcctg tgcattgccgg 300
gcagggccag gctggcttaa ggagcaagca gccacctctg ttaggggtgt gcttggagca 360
ggtggagcag ccaccaacct cacgcactga aagaagcagg gatggccagg ttccaacatc 420
ctgagtggct gccacctgat ggctgatgga gcagaggcct gaggaaaagc agatggcact 480
gctttgtagt gctgttcttt gtctctcttg atctttttca gttaatgtct gttttatcag 540
agactaggat tgcacaacct gctctttttt gctttccatt tgcttggtaa atattcctcc 600
atccctttat ttttaagccta tttatccaac ttgccagtct gtgtctttta actggggcat 720
acaacaatgg gtctttactc tttagtattt gttacatgtg aaatttatcc tgtcatgatg 780
ttagccatt tacatttaag ttttagtatt gcagtttctt tatagtgtca atgggtcttta 840
ttgctagctt tttatttttc ccattagttt gcagtttctt tatagtgtca atgggtcttta 900
caattcgata tgtttttgta gtggctggta ctggtttttc ctttctacgt ttagtgtctc 960
cttcaggagc tcttgaaca caagaatgtg gatttatttc ttgtaaggta aatatgtgga 1020
tttattctgg gactgtattc tatggccttt accccaagaa tcattacttt ttaaaatgca 1080
attcaaatga gcataaaaca tttacagcct atggaaaggc ttgtggcatt agaactccta 1140
tttataggat tttttgtgt ttttttgaga tatggtcttt gtcctcgagg cagaagtgcc 1200
gtggtttgat cataattcac cacagccctg aactcttgag tccaagccat ccttttgctc 1260
taattctcca accagttgga tctacaagca taaggcatca tgcgtggcta attttttcac 1320
gttttttttt tttttgtcga gattatggta tcaactgtgtt gctctggctg atctcaaagt 1380
tttgacctca agggatcttt ctgccacagc ctctctaaagt gctaggatta tatgcatgat 1440
acaccatgcc tattgtagag tattacatta tttctaaagt cttattgtaa gagccattta 1500
ttgccttttg cctaaataac tcaatataat atctctgaaa cttttttttg acaaattttg 1560
ggacgtgatg atgagagaag ggggtttgaa actttctaat aagagttaac ttagagccat 1620
ttagaagaag aaaaaacaca aattatcaga aaaacaacag taagatcaag tgcaaaagtt 1680
ctgtggcaaa gatgatgaga gtaagaata tatgtttgtg actcatggtg gcttttactt 1740
tgttcttgaa tttctgagta cgggttaaca tttaaagaat ctacattata gataacattt 1800
tattgcaagt aaatgtattt caaaatttgt tattggtttt gtatgagatt attctcagcc 1860
tacttcatta tcaagctata ttattttatt aatgtagttc gatgatctta cagcaaagct 1920
gaaagctgta tcttcaaaat atgtctatct gactaaaaag ttattcaaca ggagttatta 1980
tctataaaaa aatacaacag gaatataaaa aactttgagga taaaaagatg ttggaaaaag 2040
taatattaaa tcttaaaaaa catatggaaa ctacacaatg gtgaagacac attggtgaag 2100
tacaataata taaattggat ctagaagaaa gggcaatgca ggcaatagaa aaatttagtag 2160
aaatcccttt aaaggttagt ttgtaaaatc aggttaagttt atttataatt tgctttcatt 2220
tatttactg caaattatat tttggatatg tatatatatt gtgcttccctc tgctgtctct 2280
acagcaattt gccttgagca gttctaggaa aaaggtggca tgggttttta ctttcaaaat 2340
atttaaatat ccattcattat aacaaaatca atttttcaga gtaatgattc tcaactgtgga 2400
gtcatttgat tattaagacc cgttggcata agattacatc ctctgactat aaaaatcctg 2460
gaagaaaacc taggaatat tctgtggac attgcacttg gcaatgaatt tatgggcgct 2520
ttggaatcct gcagatataa taatgataat taacaaaaac actcagagaa actgccaacc 2580
ctaggatgaa gtatattgtt actgtgcttt gggattaaaa taagtaacta cagtattatag 2640
aacttttata ctgatacaca gacactaaaa agggaaaggg tttagatgag aagctctgct 2700
atgcaatcaa gaatctcagc cactcatttc tgtaggggct gcaggagctc cctgtaaaaga 2760
gaggttatgg agtctgtagc ttcaggttaag atacttaaaa cccttcagag tttctccatt 2820
tttcccata gtttcccaa aaaggttatg acactttata agaattgctt acttgtgaaa 2880
aacaatatc aaagtcttct tgtagattat ttttaaggac aaatctttat tccatgttta 2940
ctttatttag ctttccctgt agctaataat tcatgtgaa cacattttta atgctgtaaa 3000
cttagataat gtaatttatg tatcattaat gctcttttag tagtttagag aaaacgtcaa 3060
gagaaatggc ccagaataa gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt
```

```

<400> 477
Met Asp Gly His Thr Asp Ile Trp Arg Asn His Met Asp Thr Pro Pro
                    5                               10                      15

His Tyr His Arg Asp Thr Asp Thr Arg Arg His His His Met Asp Thr
                    20                               25                      30

Leu Ser His Tyr His Arg Asp Thr Arg His His Thr Val Thr Trp Thr
                    35                               40                      45

His His His Thr His Glu His Thr Asp Thr Leu Pro Tyr Gly His Trp
                    50                               55                      60

His Thr His Cys His Thr Val Thr Trp Thr His Leu His Thr Ile Thr
                    65                               70                      75                      80

Pro Pro His Thr Leu Pro Val Asp Thr Arg Thr His Arg His Cys His
                    85                               90                      95

Thr Asp Thr Gln Asn Thr Val Thr Arg Arg His His His Ala Asp Thr
                    100                               105                      110

Pro Pro Leu Trp Cys Arg Leu Asn Tyr Pro Ala Gly Gly Thr Ala Val
                    115                               120                      125

Ala Tyr Ser Cys Leu Ser Asp Trp Leu Ser Pro Gln
                    130                               135                      140

```

```

<400> 478
Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln
          5              10              15

Ser His Gly His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr
          20              25              30

Gly Glu Ile Thr Trp Thr His His Thr Ile Thr Gly Thr Gln Thr
          35              40              45

His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr

```

50 55 60
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr
 65 70 75 80
 Pro Thr His Cys His Met Asp Thr Gly Thr His Thr Ala Thr Leu Ser
 85 90 95
 His Gly His Thr Ser Thr Pro Ser His His His Thr His Cys Leu Trp
 100 105 110
 Thr Gln Gly His Thr Asp Thr Val Thr Gln Ile His Lys Thr Leu Ser
 115 120 125
 His Gly Asp Ile Thr Met Gln Ile His His His Ser Gly Ala Val
 130 135 140

 <210> 479
 <211> 222
 <212> PRT
 <213> Homo sapiens

 <400> 479
 Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln
 5 10 15
 Ser His Glu His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr
 20 25 30
 Gly Glu Ile Thr Leu Thr His His His Thr Ile Thr Gly Thr Gln Thr
 35 40 45
 His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr
 50 55 60
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr
 65 70 75 80
 Pro Thr His Cys His Met Asp Thr Ala Thr His Thr Ala Thr Leu Ser
 85 90 95
 His Gly His Thr Ser Ile Pro Ser His His His Thr His Cys His Val
 100 105 110
 Asp Thr Arg Thr His Arg His Cys His Thr Asp Thr Gln Asn Thr Val
 115 120 125
 Thr Arg Arg His His His Ala Asp Thr Pro Pro His Gly His Ser Thr
 130 135 140
 Arg His Ser Ala Thr Gln Ile His His His Thr Glu Met Arg Thr His
 145 150 155 160
 Cys His Thr Asp Thr Thr Thr Ser Leu Pro His Phe His Val Ser Ala
 165 170 175
 Gly Gly Val Gly Pro Thr Thr Leu Gly Ser Asn Arg Glu Ile Thr Trp

167

180 185 190

Thr Tyr Ser Glu Gly Lys Ile Phe Phe Tyr Phe Leu Gly Asn Gln Ala
195 200 205

Arg Leu Cys Leu Lys Lys Arg Lys Lys Lys Gln Tyr Thr Val
210 215 220

<210> 480
<211> 144
<212> PRT
<213> Homo sapiens

<400> 480

Met Glu Pro Tyr Arg Gly Asn Glu Gln Pro Ser Gln Glu Gln Gly Val
5 10 15

Cys Cys Leu Trp Gly Leu Gln Ser Leu Pro Gln Gly Ser Tyr Val Thr
20 25 30

Val Gly Phe Leu Val Val Lys Arg Gln Thr Ile Gly Arg Leu Glu Arg
35 40 45

Asp Phe Met Phe Lys Cys Arg Lys Gln Pro Gly Leu Pro Pro Ser Gly
50 55 60

Leu Cys Leu Leu Trp Pro Trp Pro Asn Leu Glu Phe Gly Arg Arg Gln
65 70 75 80

Asp Arg Leu Thr Trp Ser Ser Val Ser Val Ala Gly Val Cys Ala Cys
85 90 95

Arg Ala Arg Pro Gly Trp Leu Gly Glu Gln Pro Ala Thr Ser Ala Gly
100 105 110

Val Arg Leu Glu Gln Val Glu Gln Pro Pro Ala His Pro Leu Gln Glu
115 120 125

Ala Gly Val Ala Arg Phe Pro Arg Pro Glu Trp Val Pro Pro Asn Gly
130 135 140

<210> 481
<211> 167
<212> PRT
<213> Homo sapiens

<400> 481

Met His Gly Pro Gln Val Leu Ala Arg Cys Ser Glu Cys Ala Cys Pro
5 10 15

Ala Leu Ala Ala Thr Ser Ala Gly Val Arg Leu Glu Gly Val Asp Arg
20 25 30

168

Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys Ser His Ser
 35 40 45
 Leu Ser Gly Cys His Leu Met Ala Asp Gly Ala Lys Ala Leu Gly Lys
 50 55 60
 Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr Asp Val Pro
 65 70 75 80
 Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser Ser Trp Arg
 85 90 95
 Ala Leu Ala Glu Val Thr Gly Cys Ser Leu Gly Pro Leu Gly Leu Ala
 100 105 110
 Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys Trp Ser His
 115 120 125
 Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr Ala Ala Phe
 130 135 140
 Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu Trp Ala Ser
 145 150 155 160
 Trp Leu Ser Arg Gly Arg Pro
 165

<210> 482

<211> 143

<212> PRT

<213> Homo sapiens

<400> 482

Met Glu Pro Tyr Arg Gly Asn Lys Lys Gln Val Gln Glu Lys Gly Val
 5 10 15
 Pro Cys Leu Trp Gly Ser Ser Pro Cys Leu Arg Cys His Met Ala Leu
 20 25 30
 Arg Ala Ser Trp Leu Pro Gly Gly Gly Pro Gln Ala Ile Leu Gly Arg
 35 40 45
 Thr Leu Cys Ser Ser Ala Glu Ser Ser Gln Asp Cys His Pro Gly Gly
 50 55 60
 Pro Ser Ile Ala Leu Ala Lys Pro Cys Arg Gly Val Trp Leu Leu Phe
 65 70 75 80
 Glu Pro Ala Trp Pro Pro Trp His Ala Arg Ala Pro Gly Ala Gly Thr
 85 90 95
 Leu Leu Arg Val Cys Leu Ser Cys Leu Gly Cys His Leu Cys Gly Gly
 100 105 110
 Ala Ser Gly Gly Gly Gly Pro Ala Thr Asn Leu Thr Gln Ser Arg Lys
 115 120 125

169

Trp Met Ala Met Phe Pro Gln Pro Glu Trp Leu Pro Pro Asp Gly
 130 135 140

<210> 483
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 483
 Met Glu Thr Gln Arg Gly Asn Lys Gln Arg Ala Gln Glu Gln Gly Val
 5 10 15
 Cys Cys Leu Trp Gly Ser Ser Pro Cys Leu Gly Ser Tyr Gly Thr Ala
 20 25 30
 Gly Phe Leu Val Ala Lys Arg Arg Thr Thr Gly Leu Leu Glu Glu Asp
 35 40 45
 Phe Thr Phe Lys Cys Arg Lys Gln Pro Lys Leu Pro Ser Met Arg Leu
 50 55 60
 Ser Leu Leu Trp Pro Trp Arg Asp Leu Lys Phe Val Pro Arg Gln Asp
 65 70 75 80
 Lys Leu Thr Arg Ser Ser Val Ser Val Ala Gly Ala Tyr Ala Cys Arg
 85 90 95
 Ala Gly Pro Gly Trp Leu Lys Glu Gln Pro Ala Thr Ser Ala Arg Val
 100 105 110
 Arg Leu Val Gln Ala Glu His Pro Pro Pro His Pro Leu Glu Glu Val
 115 120 125
 Gly Met Ala Arg Phe Pro Gln Pro Glu Cys Leu Pro Pro Tyr Cys
 130 135 140

<210> 484
 <211> 30
 <212> PRT
 <213> Homo Sapien

<400> 484
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
 1 5 10 15
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile
 20 25 30

<210> 485
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 485
 gggaagctta tcacctatgt gccgcctctg c

31

<210> 486
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 486
 gogaattctc acgctgagta tttggcc 27

<210> 487
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 487
 cccgaattct tancgtgcc a ccgaacgcc ttcatc 36

<210> 488
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 488
 gggaagcttc tccccggct gcaccagctg tgc 33

<210> 489
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 489
 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 1 5 10 15
 Ser Val Ala

<210> 490
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 490
 Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys

BNSDOCID <WO 0151633A3 IA>

20

<210> 495

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 495

Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro	Lys	Pro	Gly	Ala	Pro
1					5				10					15	
Phe	Pro	Asn	Gly												
			20												

<210> 496

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 496

Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser	Gly	Leu	Leu
1				5				10						15	
Pro	Pro	Pro	Pro	Ala											
				20											

<210> 497

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 497

Leu	Leu	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp	Val
1				5				10					15	
Ser	Val	Arg	Val											
			20											

<210> 498

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 498

Asp	Val	Ser	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val
1				5				10						15	
Val	Pro	Gly	Arg												
			20												

<210> 499
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 499
 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp
 1 5 10 15
 Ser Ala Phe Leu
 20

<210> 500
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 500
 Leu Asp Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met
 1 5 10 15
 Gly Ser Ile Val
 20

<210> 501
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 501
 Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met
 1 5 10 15
 Val Ser Ala Ala
 20

<210> 502
 <211> 414
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (1)...(414)
 <223> n=A,T,C or G

<400> 502
 caccatggag acaggcctgc gctggctttt cctggctcgt gtgctcaaag gtgtccaatg 60
 tcagtcggtg gaggagtcgc ggggtcgcct ggtcacgcct gggacacctt tgacantcac 120
 ctgtagagtt tttggaatng acctcagtag caatgcaatg agctgggtcc gccaggctcc 180
 agggaagggg ctggaatgga tcggagccat tgataattgt ccacantacg cgacctgggc 240

```

aaaaggccga ttatnatntt ccaaaacctn gaccacgggtg gatttgaaaa tgaccagtcc 300
gacaaaccgag gacacggcca cctatttttg tggcagaatg aatactggta atagtgggtg 360
aaadaaatatt tggggcccag gcaccctggt caocgtntcc tcaggccaac ctaa 414

```

<210> 503
 <211> 379
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (1)...(379)
 <223> n=A,T,C or G

```

<400> 503
atnccatggt gcttgggtcaa aggtgtccag tgtcagtcgg tggaggagtc cggggggtcgc 60
ctggtcacgc ctgggacacc cctgacactc acctgcaccg tntctggatt ngacatcagt 120
agctatggag tgagctgggt ccgccaggct ccagggaagg ggctggnata catcggatca 180
ttagtagtag tggtagatnt tacgcgagct gggcgaaagg ccgattcacc atttccaaaa 240
ccingaccac ggtggatttg aaaatcacca gtttgacaac cgaggacacg gccacctatt 300
tntgtgccag aggggggttt aattataaag acatttgggg cccaggcacc ctggtcacgc 360
tntccctagg gcaacctaa 379

```

<210> 504
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

```

<400> 504
Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Glu
 1             5             10             15
Asn Ser Ala

```

<210> 505
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

```

<400> 505
Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn Asp Asn Val Thr
 1             5             10             15
Asn Thr Ala Asn
                20

```

<210> 506
 <211> 407
 <212> DNA
 <213> Homo Sapien

<400> 506

```

atggagacag gcttgcgctg gcttctcctg gtcgctgcgc tcaaaggtgt ccagtgtcag      60
tcgctggagg agtccggggg tcgcctggtc acgcctggga caccctgac actcacctgc      120
accgtctctg gattctccct cagtagcaat gcaatgatct gggtcgccca ggctccaggg      180
aaggggctgg aatacatcgg atacattagt tatggtggtg gcgcatacta cgcgagctgg      240
gtgaaaggcc gattcaccat ctccaaaacc tcgaccacgg tggatctgag aatgaccagt      300
ctgacaaccg aggacacggc cacctatttc tgtgccagaa atagtgattt tagtggtatg      360
ttgtggggcc caggcacccct ggtcacccgtc tcctcagggc aacctaa                407

```

<210> 507
 <211> 422
 <212> DNA
 <213> Homo Sapien

```

<400> 507
atggagacag gcttgcgctg gcttctcctg gtcgctgtgc tcaaaggtgt ccagtgtcag      60
tcggtggagg agtccggggg tcgcctggtc acgcctggga caccctgac actcacctgt      120
acagtctctg gattctccct cagcaactac gacctgaact gggtcgccca ggctccaggg      180
aaggggctgg aatggatcgg gatcattaat tatgttggtg ggacggacta cgcgaactgg      240
gcaaaaggcc ggttcaccat ctccaaaacc tcgaccacgg tggatctcaa gatcgccagt      300
ccgacaaccg aggacacggc cacctatttc tgtgccagag ggtggaagtg cgatgagtct      360
ggtccgtgct tgcgcatctg gggcccaggc accctggtca cegtctcctt agggcaacct      420
aa                                                                422

```

<210> 508
 <211> 411
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (1)...(411)
 <223> n=A,T,C or G

```

<400> 508
atggagacag gcttcgctgg cttctcctgg tcgctgtgct caaaggtgtc cagtgtcagt      60
cggtaggagg gtccgggggt cgcttgggtc cgcttgggac acccctgaca ctcacctgca      120
cagtctcttg aatcgacctc agtagctact gcatgagctg ggtccgccag gctccagggg      180
aggggctgga atggatcgga atcattggta ctcttgggtg cacatactac gcgaggtggg      240
cgaaaggccg attcaccatc tccaaaacct cgaccacggg gcatntgaaa atcnccagtc      300
cgacaaccga ggacacggcc acctatttct gtgccagaga tottcgggat ggtagtagta      360
ctggttatta taaaatctgg ggcccaggca ccctgggtcac cgtctccttg g                411

```

<210> 509
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

```

<400> 509
Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
1           5           10           15

```

<210> 510
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Made in a lab

<400> 510

Pro	Glu	Tyr	Asn	Arg	Pro	Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile
1					5				10				15	

<210> 511

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 511

Tyr	His	Pro	Ser	Met	Phe	Cys	Ala	Gly	Gly	Gly	Gln	Asp	Gln	Lys
1				5				10					15	

<210> 512

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 512

Asp	Ser	Gly	Gly	Pro	Leu	Ile	Cys	Asn	Gly	Tyr	Leu	Gln	Gly	Leu
1					5				10				15	

<210> 513

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 513

Ala	Pro	Cys	Gly	Gln	Val	Gly	Val	Pro	Asx	Val	Tyr	Thr	Asn	Leu
1					5				10				15	

<210> 514

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 514

Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln	Ala	Ser
1					5				10				15	

<210> 515

<211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 515
 Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg
 1 5 10 15

<210> 516
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 516
 Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln
 1 5 10 15

<210> 517
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 517
 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met
 1 5 10 15

<210> 518
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 518
 Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly
 1 5 10 15

<210> 519
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 519
 Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg Asn Tyr Asp Glu Gly Cys
 1 5 10 15

Gly

<210> 520
 <211> 25
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 520
 Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr
 1 5 10 15
 Glu Ala Arg Arg His Tyr Asp Glu Gly
 20 25

<210> 521
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 521
 Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu Leu
 1 5 10 15
 Pro Pro Pro Pro Ala
 20

<210> 522
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 522
 Leu Leu Val Val Pro Ala Ile Lys Lys Asp Tyr Gly Ser Gln Glu Asp
 1 5 10 15
 Phe Thr Gln Val
 20

<210> 523
 <211> 254
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<220>
 <221> VARIANT
 <222> (1)...(254)
 <223> Xaa = any amino acid

<400> 523
 Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
 1 5 10 15
 Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
 20 25 30
 Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
 35 40 45
 Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
 50 55 60
 Trp Val Leu Ser Ala Thr His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
 65 70 75 80
 Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
 85 90 95
 Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
 100 105 110
 Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
 115 120 125
 Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
 130 135 140
 Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
 145 150 155 160
 Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
 165 170 175
 Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
 180 185 190
 Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser Gly
 195 200 205
 Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
 210 215 220
 Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
 225 230 235 240
 Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
 245 250

<210> 524
 <211> 765
 <212> DNA
 <213> Homo sapien

<400> 524
 atggccacag caggaaatcc ctggggctgg ttcctgggggt acctcatcct tgggtgtcgca 60
 ggatcgctcg tctctggtag ctgcagccaa atcataaacg gcgaggactg cagcccgcac 120
 tcgcagccct ggcaggcggc actggtcatg gaaaacgaat tggtctgctc gggcgctcctg 180
 gtgcatccgc agtgggtgct gtcagccgca cactgtttcc agaactccta caccatcggg 240
 ctgggcctgc acagtcttga ggccgaccaa gagccaggga gccagatggt ggaggccagc 300
 ctctccgtac ggcacccaga gtacaacaga cccttgctcg ctaacgacct catgctcatc 360
 aagttggacg aatccgtgtc cgagtctgac accatccgga gcatcagcat tgcttcgcag 420
 tgccctaccg cggggaactc ttgcctcggt tctggctggg gtctgctggc gaacggcaga 480
 atgcctaccg tgctgcagtg cgtgaacgtg tcggtggtgt ctgaggaggt ctgcagtaag 540
 ctctatgacc cgctgtacca cccagcatg ttctgcgcgg gcggagggca agaccagaag 600
 gactcctgca acggtgactc tggggggccc ctgatctgca acgggtactt gcagggcctt 660
 gtgtctttcg gaaaagcccc gtgtggccaa gttggcgtgc cagggtgtcta caccaacctc 720
 tgcaaattca ctgagtggat agagaaaacc gtccaggcca gttaa 765

<210> 525
 <211> 254
 <212> PRT
 <213> Homo sapien

<400> 525

Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
 1 5 10 15
 Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
 20 25 30
 Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
 35 40 45
 Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
 50 55 60
 Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
 65 70 75 80
 Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
 85 90 95
 Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
 100 105 110
 Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
 115 120 125
 Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
 130 135 140
 Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
 145 150 155 160
 Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
 165 170 175
 Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
 180 185 190
 Ala Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly
 195 200 205
 Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
 210 215 220
 Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
 225 230 235 240
 Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
 245 250

<210> 526

<211> 963

<212> DNA

<213> Homo sapiens

<400> 526

atgagtctct gcaacttcac acatgccacc tttgtgctta ttggatatccc aggattagag 60
 aaagcccatt tctgggttgg ctccccctc ctttccatgt atgtagtggc aatgtttgga 120
 aactgcacag tgggtcttcat cgtaaggacg gaacgcagcc tgcacgctcc gatgtacctc 180
 tttctctgca tgcttgacgc cattgacctg gccttatcca catccaccat gcctaagatc 240
 ctgccccctt tctgggttga ttcccgagag attagctttg aggcctgtct taccagatg 300
 ttctttatcc atgccccctc agccattgaa tccaccatcc tgcctggccat gccctttgac 360
 cgttatgtgg ccatctgcca cccactgcgc catgctgcag tgcctcaaca tacagtaaca 420
 gccagattg gcatcgtggc tgtggtccgc ggatccctct tttttttccc actgcctctg 480
 ctgatcaagc ggctggcctt ctgccactcc aatgtcctct cgcactccta ttgtgtccac 540
 caggatgtaa tgaagtggc ctatgcagac actttgcccc atgtggtata tggctctact 600
 gccattctgc tggctcatgg cgtaggacgta atgttcatct ccttgctcta tttctgata 660
 atacgaacgg ttctgcaact gccttccaag tcagagcggg ccaaggcctt tggaaacctgt 720
 gtgtcacaca ttgggtgtgt actcgccttc tatgtgccac ttattggcct ctcaattgta 780
 caccgctttg gaaacagcct tcateccatt gtgcgtgttg tcatgggtga catctacctg 840
 ctgctgcctc ctgtcatcaa tcccatcatc tatggtgcca aaaccaaaca gatcagaaca 900
 cgggtgctgg ctatgttcaa gatcagctgt gacaaggact tgcaggctgt gggaggcaag 960
 tga 963

<210> 527

<211> 320

<212> PRT

<213> Homo sapiens

<400> 527

Met Ser Ser Cys Asn Phe Thr His Ala Thr Phe Val Leu Ile Gly Ile
 5 10 15

Pro Gly Leu Glu Lys Ala His Phe Trp Val Gly Phe Pro Leu Leu Ser
 20 25 30

Met Tyr Val Val Ala Met Phe Gly Asn Cys Ile Val Val Phe Ile Val
 35 40 45

Arg Thr Glu Arg Ser Leu His Ala Pro Met Tyr Leu Phe Leu Cys Met
 50 55 60

Leu Ala Ala Ile Asp Leu Ala Leu Ser Thr Ser Thr Met Pro Lys Ile
 65 70 75 80

Leu Ala Leu Phe Trp Phe Asp Ser Arg Glu Ile Ser Phe Glu Ala Cys
 85 90 95

Leu Thr Gln Met Phe Phe Ile His Ala Leu Ser Ala Ile Glu Ser Thr
 100 105 110

Ile Leu Leu Ala Met Ala Phe Asp Arg Tyr Val Ala Ile Cys His Pro
 115 120 125

Leu Arg His Ala Ala Val Leu Asn Asn Thr Val Thr Ala Gln Ile Gly
 130 135 140

Ile Val Ala Val Val Arg Gly Ser Leu Phe Phe Phe Pro Leu Pro Leu
 145 150 155 160

Leu Ile Lys Arg Leu Ala Phe Cys His Ser Asn Val Leu Ser His Ser
 165 170 175

Tyr Cys Val His Gln Asp Val Met Lys Leu Ala Tyr Ala Asp Thr Leu
 180 185 190

Pro Asn Val Val Tyr Gly Leu Thr Ala Ile Leu Leu Val Met Gly Val
 195 200 205

Asp Val Met Phe Ile Ser Leu Ser Tyr Phe Leu Ile Ile Arg Thr Val
 210 215 220

Leu Gln Leu Pro Ser Lys Ser Glu Arg Ala Lys Ala Phe Gly Thr Cys
 225 230 235 240

Val Ser His Ile Gly Val Val Leu Ala Phe Tyr Val Pro Leu Ile Gly
 245 250 255

Leu Ser Val Val His Arg Phe Gly Asn Ser Leu His Pro Ile Val Arg
 260 265 270

Val Val Met Gly Asp Ile Tyr Leu Leu Leu Pro Pro Val Ile Asn Pro
275 280 285

Ile Ile Tyr Gly Ala Lys Thr Lys Gln Ile Arg Thr Arg Val Leu Ala
290 295 300

Met Phe Lys Ile Ser Cys Asp Lys Asp Leu Gln Ala Val Gly Gly Lys
305 310 315 320

<210> 528
<211> 20
<212> DNA
<213> Homo Sapien

<400> 528
actatggtcc agaggctgtg

20

<210> 529
<211> 20
<212> DNA
<213> Homo Sapien

<400> 529
atcacctatg tgccgcctct

20

<210> 530
<211> 1852
<212> DNA
<213> Homo sapiens

<400> 530

```

ggcaccgagaa ttaaaaccct cagcaaaaaca ggcatagaag ggacatacct taaagtaata 60
aaaaccaccc atgacaagcc cacagccaac ataatactaa atggggaaaa gttagaagca 120
tttccctctga gaactgcaac aataaatata aggatgctgg attttgtcaa atgccttttc 180
tgtgtctgtt gagatgctta tgtgactttg cttttaattc tgtttatgtg attatcacat 240
ttattgactt gctgtgttta gaccggaaga gctggggtgt ttctcaggag ccaccgtgtg 300
ctgcccgcagc ttccgggataa cttgaggctg catcactggg gaagaaacac aytccctgtcc 360
gtggcgctga ttgctgagga cagagcttca gtgtggcttc tctgcgactg gcttcttcgg 420
ggagtctctc cttcatagtt catccatatt gctccagagg aaaattatat tattttgtta 480
tggatgaaga gtattacgtt gtgcagatat actgcagtgt cttcatctct tgatgtgtga 540
ttgggtaggt tccaccatgt tgccgcagat gacatgattt cagtacctgt gtctggctga 600
aaagtgtttg tttgtgaatg gatattgtgg tttctggatc tcatcctctg tgggtggaca 660
gctttctcca ccttgctgga agtgacctgc tgtccagaag tttgatggct gaggagtata 720
ccatcgtgca tgcattcttc atttctgca tttcttctc cctggatgga cagggggagc 780
ggcaagagca acgtgggcac ttctggagac cacaacgact cctctgtgaa gacgcttggg 840
agcaagaggt gcaagtgggt ctgccactgc ttccctgct gcagggggag cggcaagagc 900
aacgtggctg cttggggaga ctacgatgac agcgccttca tggatcccag gtaccacgtc 960
catggagaag atctggacaa gctccacaga gctgcctggg ggggtaaagt cccagaaaag 1020
gatctcatcg tcatgctcag ggacacggat gtgaacaaga gggacaagca aaagaggact 1080
gctctacatc tggcctctgc caatgggaat tcagaagtag taaaactcgt gctggacaga 1140
cgatgtcaac ttaatgtcct tgacaacaaa aagaggacag ctctgacaaa gcccgtaaaa 1200
tgccaggaag atgaatgtgc gttaatgttg ctggaacatg gcactgatcc aaatattcca 1260
gatgagtatg gaaataccac tctacactat gctgtctaca atgaagataa attaatggcc 1320
aaagcactgc tcttatacgg tgctgatata gaatcaaaaa acaagcatgg cctcacacca 1380
ctgctacttg gtatacatga gcaaaaaacag caagtgggtg aatttttaaa caagaaaaaa 1440
ccggaatttaa atgcgctgga tagatatgga agaactgtc tcatacttgc tgtatgttgt 1500
ggcagcaaa gtatagtcag cctctacttt gagcaaaatg ttgatgtatc ttctcaagat 1560
ctggaaaagac ggccagagag tatgctgttt ctagtcatca tcatgttaatt tgccagttac 1620

```

```

tttctgacta caaagaaaaa cagatgttaa aaatctcttc tgaaaacagc aatccagaac 1680
aagacttaaa gctgacatca gaggaagagt cacaaaggct taaaggaagt gaaaacagcc 1740
agccagagct agaagattta tggctattga agaagaatga agaacacgga agtactcatg 1800
tgggattccc agaaaacctg actaacgggtg ccgctgctgg caatggtgat ga 1852

```

<210> 531
 <211> 879
 <212> DNA
 <213> Homo sapiens

```

<400> 531
atgcattctt catttctgc atttcttctt ccctggatgg acagggggag cggcaagagc 60
aacgtgggca cttctggaga ccacaacgac tctctgtgga agacgcttgg gagcaagagg 120
tgcaagtggg gctgccactg cttccctctg tgcaggggga gcggaagag caacgtgggtc 180
gcttggggag actacgatga cagcgcttct atggatccca ggtaccacgt ccatggagaa 240
gatctggaca agctccacag agctgcctgg tggggtaaag tcccagaaa ggatctcatc 300
gtcatgctca gggacacgga tgtgaacaag agggacaagc aaaagaggac tgctctacat 360
ctggcctctg ccaatgggaa ttcagaagta gtaaaactcg tgctggacag acgatgtcaa 420
cttaattgtc ttgacaacaa aaagaggaca gctctgacaa aggcctgaca atgccaggaa 480
gatgaatgtg cgtaaatgtt gctggaacat ggcaactgac caaatattcc agatgagtat 540
ggaaatacca ctctacacta tgctgtctac aatgaagata aattaatggc caaagcactg 600
ctcttatacg gtgctgatat cgaatcaaaa aacaagcatg gcctcacacc actgctactt 660
ggtatacatg agcaaaaaca gcaagtgggtg aaatttttaa tcaagaaaaa agcgaattta 720
aatgcgctgg atagatatgg aagaactgct ctcatacttg ctgtatgttg tggatcagca 780
agtatagtca gccctctact tgagcaaaaat gttgatgtat cttctcaaga tctggaaaga 840
cggccagaga gtatgctgtt tctagtcatc atcatgtaa 879

```

<210> 532
 <211> 292
 <212> PRT
 <213> Homo sapiens

```

<400> 532
Met His Leu Ser Phe Pro Ala Phe Leu Pro Pro Trp Met Asp Arg Gly
          5                      10                      15

Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp His Asn Asp Ser Ser
          20                      25                      30

Val Lys Thr Leu Gly Ser Lys Arg Cys Lys Trp Cys Cys His Cys Phe
          35                      40                      45

Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val Val Ala Trp Gly Asp
          50                      55                      60

Tyr Asp Asp Ser Ala Phe Met Asp Pro Arg Tyr His Val His Gly Glu
          65                      70                      75                      80

Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg
          85                      90                      95

Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Arg Asp
          100                     105                     110

Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser
          115                     120                     125

Glu Val Val Lys Leu Val Leu Asp Arg Arg Cys Gln Leu Asn Val Leu

```


130 135 140
 Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala Val Gln Cys Gln Glu
 145 150 155 160
 Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile
 165 170 175
 Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Val Tyr Asn Glu
 180 185 190
 Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu
 195 200 205
 Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Ile His Glu
 210 215 220
 Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu
 225 230 235 240
 Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys
 245 250 255
 Cys Gly Ser Ala Ser Ile Val Ser Pro Leu Leu Glu Gln Asn Val Asp
 260 265 270
 Val Ser Ser Gln Asp Leu Glu Arg Arg Pro Glu Ser Met Leu Phe Leu
 275 280 285
 Val Ile Ile Met
 290

<210> 533
 <211> 801
 <212> DNA
 <213> Homo sapiens

<400> 533
 atgtacaagc ttcagtgc aa caactgtgct acaaatggag ccacagagag gaaacaagca 60
 gcaggctcag gacgagggtg tgcgtgcct tcggctctcc aatccatgcc tcagggtcc 120
 tatgccactg cagcattctt gggtgccaag aggccaaacca caggccatct tgagaaggag 180
 tttatgttcc actgcagaaa gcagccagga tcaccatcca ggggacttgg tcttctgtgg 240
 ccttggccag acatagaatt tgtgccaagg caggacaagc tcaactcagag cagcgtgtta 300
 gtacctcaaa tctgtgcgtg ccagacaagg ccaaactggc tcaatgagca accagccacc 360
 tctgcagggg tgcgtctgga ggaggtggac cagccaccaa ccttaccag tcaaggaagt 420
 ggatggccat gttcccacag cctgagtgcc tgccacctga tggctgatat agcaaaggcc 480
 ttaggaaaag cagatggccc ttggccctac ctttttgta gaagaactga tgttccatgt 540
 cctgcagcga gtgaggttgg tggctgtgcc cccagctcct ggcacacct cgcagaggtg 600
 actggttget ctttgagccc tcttagcctt gccagcatg cacaagcctc agtgctacta 660
 ctgtgctaca aatggagcca tataggggaa acgagcagcc atctcaggag caaggtgtat 720
 gctgcctttg ggggctccag tccttgccctc aagggcttta tgtcactgtg ggcttcttgg 780
 ttgccaaagag gcagaccata g 801

<210> 534
 <211> 266
 <212> PRT
 <213> Homo sapiens

<400> 534

Met Tyr Lys Leu Gln Cys Asn Asn Cys Ala Thr Asn Gly Ala Thr Glu
 5 10 15

Arg Lys Gln Ala Ala Gly Ser Gly Ala Gly Tyr Ala Leu Pro Ser Ala
 20 25 30

Leu Gln Ser Met Pro Gln Gly Ser Tyr Ala Thr Ala Arg Phe Leu Val
 35 40 45

Ala Lys Arg Pro Thr Thr Gly His Leu Glu Lys Glu Phe Met Phe His
 50 55 60

Cys Arg Lys Gln Pro Gly Ser Pro Ser Arg Gly Leu Gly Leu Leu Trp
 65 70 75 80

Pro Trp Pro Asp Ile Glu Phe Val Pro Arg Gln Asp Lys Leu Thr Gln
 85 90 95

Ser Ser Val Leu Val Pro Gln Ile Cys Ala Cys Gln Thr Arg Pro Asn
 100 105 110

Trp Leu Asn Glu Gln Pro Ala Thr Ser Ala Gly Val Arg Leu Glu Glu
 115 120 125

Val Asp Gln Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys
 130 135 140

Ser His Ser Leu Ser Gly Cys His Leu Met Ala Asp Ile Ala Lys Ala
 145 150 155 160

Leu Gly Lys Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr
 165 170 175

Asp Val Pro Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser
 180 185 190

Ser Trp His Thr Leu Ala Glu Val Thr Gly Cys Ser Leu Ser Pro Leu
 195 200 205

Ser Leu Ala Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys
 210 215 220

Trp Ser His Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr
 225 230 235 240

Ala Ala Phe Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu
 245 250 255

Trp Ala Ser Trp Leu Pro Arg Gly Arg Pro
 260 265

<210> 535

<211> 6082

<212> DNA

<213> Homo sapiens

<400> 535

```

cctccactat tacagcttat aggaaattac aatccacttt acaggcctca aagggttcatt 60
ctggcgagag ggacaggcgt ggcgggcgga gcccagcat cctgtctga ggtccaggag 120
cggagcccg ggccactgcc gcctgatcag cgcgaccccg gcccgcgccc gcccgcgccc 180
gcaagatgct gcccggtgac caggagggtga agcccaaccc gctgcaggac gcgaacctct 240
gctcacgcgt gttcttcttg tggtcaatc ccttgtttaa aattggccat aaacggagat 300
tagagggaaga tgatatgtat tcagtgtctc cagaagacgc ctacagcac cttggagagg 360
agttgcaagg gttctgggat aaagaagttt taagagctga gaatgacgca cagaagcctt 420
ctttaacaag agcaatcata aagtgttact ggaaatctta tttagttttg ggaattttta 480
cgttaattga ggaaagtgcc aaagtaatcc agcccatatt tttgggaaaa attattaatt 540
attttgaaaa ttatgatccc atggattctg tggctttgaa cacagcgtac gcctatgcca 600
cgggtgtgac tttttgcacg ctcaattttg ctatactgca tcacttatat ttttatcacg 660
ttcagtgtgc tgggatgagg ttacgagtag ccatgtgcca tatgatttat cggaaaggcac 720
ttcgtcttag taacatggcc atggggaaga caaccacagg ccagatagtc aatctgctgt 780
ccaatgatgt gaacaagttt gatcagggtga cagtgttctt acacttctg tgggcaggac 840
cactgcaggc gatcgcaagt actgccctac tctggatgga gataggaata tcgtgccttg 900
ctgggatggc agttctaact attctcctgc ccttgcaaaag ctgttttggg aagttgttct 960
catcactgag gagtaaaact gcaactttca cggatgccag gatcaggacc atgaatgaag 1020
ttataactgg tataaggata ataaaaatgt acgcctggga aaagtcattt tcaaatctta 1080
ttaccaattt gagaaagaag gagatttcca agattctgag aagttcctgc ctacggggga 1140
tgaatttggc ttcgtttttc agtgcaagca aaatcatcgt gtttgtgacc ttcaccacct 1200
acgtgctcct cggcagtgtg atcacagcca gccgcgtgtt cgtggcagtg acgctgtatg 1260
gggtgtgctg gctgaacggt accctcttct tccctcagc cattgagagg gtgtcagagg 1320
caatcgtcag catccgaaga atccagacct ttttgcact tgatgagata tcacagcgca 1380
accgtcagct gccgtcagat ggtaaaaaga ttgtgcattg gcaggatttt actgcttttt 1440
gggataaggc atcacagacc ccaactctac aaggcctttc ctttactgtc agacctggcg 1500
aattgttagc tgtggtcggc cccgtgggag cagggaagtc atcactgtta agtgccgtgc 1560
tcggggaatt ggccccaagt cacgggctgg tcagcgtgca tggagaatt gcctatgtgt 1620
ctcagcagcc ctgggtgttc tcgggaactc tgaggagtaa tattttattt gggaagaaat 1680
acgaaaagga acgatatgaa aaagtcataa aggcctgtgc tctgaaaaag gatttacagc 1740
tgttggaaga tggatgctg atctgtgat gagatcgggg aaccacgctg agtggagggc 1800
agaaagcacg ggtaaacctt gcaagagcag tgtatcaaga tctgacatc tatctcctgg 1860
acgatcctct cagtgcagta gatgcggaag ttagcagaca cttgttcgaa ctgtgtattt 1920
gtcaaatttt gcatgagaag atcacaattt tagtgactca tcagttgcag tacctcaaag 1980
ctgcaagtea gattctgata ttgaaagatg gtaaaatggt gcagaagggg acttacactg 2040
agttcctaaa atctggtata gattttggct cctttttaa gaaggataat gaggaaagt 2100
aacaacctcc agttccagga actccacac taaggaatcg taccttctca gagtcttcg 2160
tttggctca acaatcttct agacctcct tgaagatgg tgcctggag agccaagata 2220
cagagaatgt cccagttaca ctatcagagg agaaccgttc tgaaggaaaa gttggttttc 2280
aggcctataa gaattacttc agagctgggt ctcactggat tgtcttcatt ttccttattc 2340
tctaaacac tgcagctcag gttgcctatg tcttcaaga ttggtggctt tcatactggg 2400
caaacaacaa aagtatgcta aatgtcactg taaatggagg aggaaatgta accgagaagc 2460
tagatcttaa ctggtactta ggaatttatt caggtttaac tgtagctacc gttctttttg 2520
gcatagcaag atctctattg gtattctacg tcttgttaa ctcttcacaa actttgcaca 2580
acaaaatggt tgagtcaatt ctgaaagctc cggattattt ctttgataga aatccaatag 2640
gaagaatttt aaatcgtttc tccaaagaca ttggacactt ggatgatttg ctgccgtga 2700
cgttttttaga tttcatccag acattgctac aagtggttgg tgtggtctct gtggtgtgg 2760
ccgtgattcc ttggatcgca atacccttgg tcccttggg aatcattttc atttttctc 2820
ggcgatattt tttggaaacg tcaagagatg tgaagcgctt ggaatctaca actcggagtc 2880
cagtgttttc ccactgtca tcttctctcc aggggtctct gaccatccgg gcatacaaa 2940
cagaagagag gtgtcaggaa ctggttgatg cacaccagga tttacattca gaggtttgg 3000
tcttgttttt gacaacgtcc cgctgggttc cgtccgtct ggatgccatc tgtgccatgt 3060
ttgtcatcat cgttgctttt gggtccctga ttctggcaaa aactctggat gccgggcagg 3120
ttggtttggc actgtcctat gccctcagc tcatggggat gtttcagtgg tgtgttcgac 3180
aaagtgtgta agttgagaat atgatgatc cagtgaagag ggtcattgaa tacacagacc 3240
ttgaaaaaga agcaccttgg gaatatcaga aacgccacc accagcctgg cccatgaag 3300
gagtgataat ctttgacaat gtgaacttca tgtacagtc aggtgggctt ctggtactga 3360

```

```

agcatctgac agcactcatt aaatcacaag aaaaggttgg cattgtggga agaaccggag 3420
ctggaaaaag ttccctcatt tcagcccttt ttagattgtc agaaccggaa ggtaaaattt 3480
ggattgataa gatcttgaca actgaaattg gacttcacga ttttaggaag aaaatgtcaa 3540
tcatacctca ggaacctgtt ttgttccact gaacaatgag gaaaaacctg gatcccttta 3600
atgagcacac ggatgaggaa ctgtggaatg ccttacaaga ggtacaactt aaagaaacca 3660
ttgaagatct tcctggtaaa atggatactg aattagcaga atcaggatcc aatttttagtg 3720
ttggacaaag acaactggtg tgccttgcca gggcaattct caggaaaaat cagatattga 3780
ttattgatga agcgacggca aatgtggatc caagaactga tgagttaata caaaaaaat 3840
ccgggagaaa ttgcccact gcaccgtgct aaccattgca cacagattga acaccattat 3900
tgacagcgac aagataatgg ttttagattc aggaagactg aaagaatatg atgagccgta 3960
tgttttgctg caaaataaag agagcctatt ttacaagatg gtgcaacaac tgggcaaggc 4020
agaagccgct gccctcactg aaacagcaaa acaggtatac ttcaaaagaa attatccaca 4080
tattggtcac actgaccaca tggttacaaa cacttccaat ggacagccct cgaccttaac 4140
tattttcgag acagcactgt gaatccaacc aaaatgtcaa gtccgttccg aaggcatttg 4200
ccactagttt ttggactatg taaaccacat tgtactttt tttacttttg caacaaatat 4260
ttatacatat aagatgctag ttcatittgaa ttttctccc aacttatcca aggatctcca 4320
gctctaacia aatggtttat ttttatttaa atgtcaatag ttgtttttta aaatccaaat 4380
cagaggtgca ggcaccagt taaatgccgt ctatcagggt ttgtgcctta agagactaca 4440
gagtcaaagc tcatttttaa aggagtagga cagagttgtc acaggttttt gttgttggtt 4500
ttattgcccc caaaattaca tgttaatttc catttatatc agggattcta tttacttgaa 4560
gactgtgaag ttgccatttt gtctcattgt tttctttgac ataactagga tccattattt 4620
cccctgaagg cttcttgtaa gaaaatagta cagttacaac caataggaac aacaaaaaga 4680
aaaagtttgt gacattgtag tagggagtggt gtacccctta ctccocatca aaaaaaaaaa 4740
tggatacatg gttaaaggat agaagggcaa tattttatca tatgttctaa aagagaagga 4800
agagaaaata ctactttctc aaaatggaag cctttaaagg tgctttgata ctgaaggaca 4860
caaatgtgac cgtccatcct ccttttagagt tgcattgactt ggacacggtg actgttgacg 4920
ttttgactc cgcattgtga cacttcccaa gaggccaaa cctctaaccg acattcctga 4980
aatacgtggc attattcttt tttggatttc tcatttatgg aaggctaacc ctctgttgac 5040
tgtaagcctt ttggtttggg ctgtattgaa atcctttcta aattgcatga ataggctctg 5100
ctaactgat gagacaaact gaaaattatt gcaagcattg actataatta tgcagtacgt 5160
tctcaggatg catccagggg ttcatittca tgagcctgtc cagggttagtt tactcctgac 5220
cactaatagc attgtcattt gggctttctg ttgaatgaat caacaaacca caatacttcc 5280
tgggaccttt tgtactttat ttgaactatg agtctttaat tttcctgat gatgggtggc 5340
tgaatatggt gagttcagtt tactaaaggt tttactatta tggtttgaag tggagtctca 5400
tgacctctca gaataagggt tcacctccct gaaattgcat atatgtatat agacatgcac 5460
acgtgtgcat ttgtttgtat acatatattt gtccttcgta tagcaagttt tttgctcatc 5520
agcagagagc aacagatggt ttattgagtg aagccttaaa aagcacacac cacacacagc 5580
taactgccaa aatacattga ccgtagtagc tgttcaactc ctagtactta gaaatacacg 5640
tatggttaat gttcagtcga acaaaccaca cacagtaaat gtttattaat agtcatgggt 5700
cgtatttttag gtgactgaaa ttgcaacagt gatcataatg aggtttgtta aaatgatagc 5760
tatattcaaa atgtctatat gtttattttg acttttgagg ttaaagacag tcatataaac 5820
gtcctgtttc tgttttaatg ttatcataga attttttaat gaaactaaat tcaattgaaa 5880
taaatgatag ttttcatctc caaaaaaaaaa aaaaaaaagg gcggccgctc gagtctagag 5940
ggcccgttta aaccgcgtga tcagcctcga ctgtgccttc tagttgccag ccactctgtg 6000
tttgcctctc ccccgctgct tccttgacct tggaaggtgc cactccact gtcctttcct 6060
aataaaatga ggaaattgca tc

```

```

<210> 536
<211> 6140
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(6140)
<223> n=A,T,C or G

```

```

<400> 536

```

cagtgggcgca gtctcagctc actgcagcct ccacctctctg tgttcaagca gtcctcctgc 60
 ctacagccacc agactagcag gtctcccccg cctctttctt ggaaggacac ttgccattgg 120
 atttaggacc caottggata atccaggatg atgtcttcac tccaacatcc tcagtttaat 180
 tccatgtgca aatacccttt tcccaaataa cattcaattc tttaccagga aagggtggctc 240
 aatcccttgt ttaaaattgg ccataaacgg agattagagg aagatgatat gtattcagtg 300
 ctgccagaag accgctcaca gcaccttgga gaggagttgc aagggttctg ggataaagaa 360
 gttttaagag ctgagaatga cgcacagaag ccttctttaa caagagcaat cataaagtgt 420
 tactggaaat cttatttagt tttgggaatt tttacgttaa ttgaggaaag tgccaaagta 480
 atccagccca tatttttggg aaaaattatt aattattttg aaaattatga tcccatggat 540
 cctgtggctt tgaacacagc gtacgcctat gccacgggtc tgactttttg caogctcatt 600
 ttggctatac tgcatacact atatttttat cacgttcagt gtgctgggat gaggttacga 660
 gttagccatgt gccatatgat ttatcgggaag gcacttcgtc ttagtaacat ggccatgggg 720
 aagacaacca caggccagat agtcaatctg ctgtccaatg atgtgaacaa gtttgatcag 780
 gtgacagtgt tcttacactt cctgtgggca ggaccactgc aggcgatcgc agtgactgcc 840
 ctactctgga tggagatagg aatatcgtgc cttgtctggga tggcagttct aatcattctc 900
 ctgcccttgc aaagctgttt tgggaagttg ttctcatcac tgaggagtaa aactgcaact 960
 ttacaggatg ccaggatcag gaccatgaat gaagttataa ctggtataag gataataaaa 1020
 atgtacgcct gggaaaagtc attttcaaat cttattacca atttgagaaa gaaggagatt 1080
 tccaagatcc tgagaagttc ctgcctcagg gggatgaatt tggcttcgtt tttcagtgca 1140
 agcaaaatca tctgttttgt gaccttcacc acctacgtgc tctctggcag tgtgatcaca 1200
 gccagccgct tggctcgtggc agtgacgctg tatggggctg tgcggctgac ggttaccctc 1260
 ttcttccctc cagccattga gaggtgtgca gaggcaatcg tcagcatccg aagaatccag 1320
 acctttttgc tacttgatga gatatacag cgcaaccgtc agctgccgtc agatggtaaa 1380
 aagatgggtg atgtgcagga ttttactgct ttttgggata aggcacaga gaccccaact 1440
 ctacaaggcc ttctctttac tgtcagacct ggcgaattgt tagctgtggt cggccccgtg 1500
 ggagcaggga agtcatact gtttaagtgc gtgctcggg aattggccc aagtcacggg 1560
 ctggtcagcg tgcattggaag aattgcctat gtgtctcagc agccctgggt gttctcggga 1620
 actctgagga gtaatatatt atttgggaag aaatacgaaa aggaacgata tgaaaaagtc 1680
 ataaaggctt gtgctctgaa aaaggattta cagctgttgg aggatggtga tctgactgtg 1740
 ataggagatc ggggaaccac gctgagtgga gggcagaaaag cacgggtaaa ccttgcaaga 1800
 gcagtgtatc aagatgctga catctatctc ctggacgatc ctctcagtg agtagatgcg 1860
 gaagttagca gacacttgt cgaactgtgt atttgtcaaa ttttgcatga gaagatcaca 1920
 attttagtgga ctcatacatt gcagtacctt aaagctgcaa gtcagattct gatattgaaa 1980
 gatggtaaaa tgggtgcagaa ggggacttac actgagttcc taaaatctgg tatagatttt 2040
 ggctcccttt taaagaagga taatgaggaa agtgaacaac ctccagttcc aggaactccc 2100
 acactaagga atcgtacctt ctacagagtct tcggtttgggt ctcaacaatc ttctagacct 2160
 tccctgaaag atggtgctct ggagagccaa gatacagaga atgtccagt tacactatca 2220
 gaggagaacc gttctgaagg aaaagttggt tttcaggcct ataagaatta ctacagagct 2280
 ggtgctcact ggattgtctt cattttcctt attctcctaa acactgcagc tcaggttgcc 2340
 tatgtgcttc aagattggtg gctttcatac tgggcaaaca aacaaagtat gctaaatgtc 2400
 actgtaaatg gaggaggaaa tgtaaccgag aagctagatc ttaactggta cttaggaatt 2460
 tattcaggtt taactgtagc taccgttctt tttggcatag caagatctct attggtattc 2520
 tacgtccttg ttaactcttc acaaactttg cacaacaaaa tgtttgagtc aattctgaaa 2580
 gctccggtat tattctttga tagaaatcca ataggaagaa ttttaaactc tttctccaaa 2640
 gacattggac acttggtatga tttgctgccg ctgacgtttt tagatttcat ccagacattg 2700
 ctacaagtgg ttggtgtggt ctctgtggct gtggccgtga ttccttggtat cgcaataccc 2760
 ttggttcccc ttggaatcat tttcattttt ctccggcgat attttttggga aacgtcaaga 2820
 gatgtgaagc gcttgaatc tacaactcgg agtccagtg tttcccactt gtcacttctc 2880
 ctccaggggc tctggacct ccgggcatac aaagcagaag agaggtgtca ggaactgttt 2940
 gatgcacacc aggatattaca ttcagaggct tgggtcttgt ttttgacaac gtcccgtcg 3000
 ttgcgcgtcc gtctggatgc catctgtgcc atgtttgtca tcatcgttgc ctttgggtcc 3060
 ctgattctgg caaaaactct ggatgccggg cagggttgggt tggcactgtc ctatgccctc 3120
 acgctcatgg ggatgtttca gtggtgtgtt cgacaaagtg ctgaagttga gaatatgatg 3180
 atctcagtag aaagggtcat tgaatacaca gaccttgaaa aagaagcacc ttgggaatat 3240
 cagaaacgcc caccaccagc ctggcccatc gaaggagtga taatctttga caatgtgaac 3300
 tccatgtaca gtccaggtg gctctgtgta ctgaagcatc tgacagcaat cattaaatca 3360
 caagaaaagg ttggcattgt gggaagaacc ggagctggaa aaagttccct catctcagcc 3420
 ctttttagat tgtcagaacc cgaaggtaaa atttggattg ataagatctt gacaactgaa 3480

```

attggacttc acgattttaag gaagaaaatg tcaatcatac ctcaggaacc tgttttgttc 3540
actggaacaa tgaggaaaaa cctggatccc tttaatgagc acacggatga ggaactgtgg 3600
aatgccttac aagagggtaca acttaaagaa accattgaag atcttcctgg taaaatggat 3660
actgaattag cagaatcagg atccaatttt agtggttgac aaagacaact ggtgtgcctt 3720
gccagggcaa ttctcaggaa aaatcagata ttgattattg atgaagcgac ggcaaatgtg 3780
gatccaagaa ctgatgagtt aatacaaaaa aaaatccggg agaaatttgc ccactgcacc 3840
gtgctaacca ttgcacacag attgaacacc attattgaca gcgacaagat aatggtttta 3900
gattcaggaa gactgaaaga atatgatgag ccgtatgttt tgctgcaaaa taaagagagc 3960
ctatttttaca agatgggtgca acaactgggc aaggcagaag ccgctgccct cactgaaaca 4020
gcaaaacaga gatgggggttt caccatgttg gccaggctgg tctcaaaact ctgacctcaa 4080
gtgatccacc tgccttggtc tcccaaaact ctgagattac aggtgtgagc caccacgccc 4140
agcctgagta tacttcaaaa gaaattatcc acatattggt cacactgacc acatggttac 4200
aaacacttcc aatggacagc cctcgacctt aactattttc gagacagcac tgtgaatcca 4260
accaaaatgt caagtcctgt ccgaaggcat ttgccactag tttttggact atgtaaacca 4320
cattgtactt ttttttactt tggcaacaaa tatattataca tacaagatgc tagttcattt 4380
gaatattttc cccaacttat ccaaggatct ccagctctaa caaaatggtt tatttttatt 4440
taaattgtcaa tagtkgkttt ttaaaatcca aatcagaggt gcaggccacc agttaaatgc 4500
cgtctatcag gttttgtgccc ttaagagact acagnagtca gaagctcatt tttaaaggag 4560
taggacagag ttgtcacagg tttttgttgg tgtttktatt gccccaaaaa ttacatgtta 4620
atttccattt atatcagggg attctatttt cttgaagact gtgaagttgc cattttgtct 4680
cattgttttc tttgacatam ctaggatcca ttatttcccc tgaaggcttc ttgkagaaaa 4740
tagtacagtt acaaccaata ggaactamca aaaagaaaaa gtttgtgaca ttgtagtagg 4800
gagtgtgtac cccttactcc ccatcaaaaa aaaaaatgga tacatggtta aaggatagaa 4860
gggcaatatt ttatcatatg ttctaaaaga gaaggaagag aaaatactac tttctcaaaa 4920
tggaagccct taaaggtgct ttgatactga aggacacaaa tgtgaccgtc catctcctt 4980
tagagttgca tgacttggac acggtaactg ttgcagtttt agactcagca ttgtgacact 5040
tcccaagaag gccaacctc taaccgacat tcttgaaata cgtggcatta ttcttttttg 5100
gattttctcat ttaggaagge taaccctctg ttgamtgtam kctttttggt ttgggctgta 5160
ttgaaatcct ttctaaattg catgaatagg ctctgctaac cgtgatgaga caaactgaaa 5220
attattgcaa gcattgacta taattatgca gtacgttctc aggatgcac caggggttca 5280
ttttcatgag cctgtccagg ttagtttact cctgaccact aatagcattg tcatttgggc 5340
tttctgttga atgaatcaac aaaccacaat acttccctggg acctttttgta ctttatttga 5400
actatgagtc ttttaattttt cctgatgatg gtggtgtgaa tatgttgagt tcagtttact 5460
aaaggtttta ctattatggt ttgaaggag tctcatgacc tctcagaaaa ggtgcacctc 5520
cctgaaattg catatatgta tatagacatg cacacgtgtg catttgtttg tatacatata 5580
tttgccttc gtatagcaag tttttgtctc atcagcagag agcaacagat gttttattga 5640
gtgaagcctt aaaaagcaca caccacacac agctaactgc caaaatacat tgaccgtagt 5700
agctgttcaa ctctagtagc ttagaaatac acgtatggtt aatgttcagt ccaacaaacc 5760
acacacagta aatgtttatt aatagtcatt gttcgtattt taggtgactg aaattgcaac 5820
agtgatcata atgaggtttg ttaaaatgat agctatatatc aaaatgtcta tatgtttatt 5880
tggaactttt aggttaaaga cagtcataata aacgtcctgt ttctgtttta atgttatcat 5940
agaatttttt aatgaaacta aattcaattg aaataaatga tagttttcat ctccaaaaaa 6000
aaaaaaaag ggcggccgc tcgagtctag agggcccggt ttaaaccgcg tgatcgcct 6060
cgactgtgcc ttctagtgtc cagccatctg ttgtttggcc ctcccccggt ccttccttga 6120
ccctggaagg ggccactccc                                     6140

```

<210> 537

<211> 1228

<212> PRT

<213> Homo sapiens

<400> 537

Met Leu Pro Val Tyr Gln Glu Val Lys Pro Asn Pro Leu Gln Asp Ala
5 10 15

Asn Leu Cys Ser Arg Val Phe Phe Trp Trp Leu Asn Pro Leu Phe Lys
20 25 30

Ile Gly His Lys Arg Arg Leu Glu Glu Asp Asp Met Tyr Ser Val Leu
 35 40 45
 Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu Leu Gln Gly Phe Trp
 50 55 60
 Asp Lys Glu Val Leu Arg Ala Glu Asn Asp Ala Gln Lys Pro Ser Leu
 65 70 75 80
 Thr Arg Ala Ile Ile Lys Cys Tyr Trp Lys Ser Tyr Leu Val Leu Gly
 85 90 95
 Ile Phe Thr Leu Ile Glu Glu Ser Ala Lys Val Ile Gln Pro Ile Phe
 100 105 110
 Leu Gly Lys Ile Ile Asn Tyr Phe Glu Asn Tyr Asp Pro Met Asp Ser
 115 120 125
 Val Ala Leu Asn Thr Ala Tyr Ala Tyr Ala Thr Val Leu Thr Phe Cys
 130 135 140
 Thr Leu Ile Leu Ala Ile Leu His His Leu Tyr Phe Tyr His Val Gln
 145 150 155 160
 Cys Ala Gly Met Arg Leu Arg Val Ala Met Cys His Met Ile Tyr Arg
 165 170 175
 Lys Ala Leu Arg Leu Ser Asn Met Ala Met Gly Lys Thr Thr Thr Gly
 180 185 190
 Gln Ile Val Asn Leu Leu Ser Asn Asp Val Asn Lys Phe Asp Gln Val
 195 200 205
 Thr Val Phe Leu His Phe Leu Trp Ala Gly Pro Leu Gln Ala Ile Ala
 210 215 220
 Val Thr Ala Leu Leu Trp Met Glu Ile Gly Ile Ser Cys Leu Ala Gly
 225 230 235 240
 Met Ala Val Leu Ile Ile Leu Leu Pro Leu Gln Ser Cys Phe Gly Lys
 245 250 255
 Leu Phe Ser Ser Leu Arg Ser Lys Thr Ala Thr Phe Thr Asp Ala Arg
 260 265 270
 Ile Arg Thr Met Asn Glu Val Ile Thr Gly Ile Arg Ile Ile Lys Met
 275 280 285
 Tyr Ala Trp Glu Lys Ser Phe Ser Asn Leu Ile Thr Asn Leu Arg Lys
 290 295 300
 Lys Glu Ile Ser Lys Ile Leu Arg Ser Ser Cys Leu Arg Gly Met Asn
 305 310 315 320
 Leu Ala Ser Phe Phe Ser Ala Ser Lys Ile Ile Val Phe Val Thr Phe
 325 330 335
 Thr Thr Tyr Val Leu Leu Gly Ser Val Ile Thr Ala Ser Arg Val Phe

340	345	350
Val Ala Val Thr Leu Tyr Gly	Ala Val Arg Leu Thr Val Thr Leu Phe	
355	360	365
Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala Ile Val Ser Ile Arg		
370	375	380
Arg Ile Gln Thr Phe Leu Leu Asp Glu Ile Ser Gln Arg Asn Arg		
385	390	395
Gln Leu Pro Ser Asp Gly Lys Lys Met Val His Val Gln Asp Phe Thr		
405	410	415
Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr Leu Gln Gly Leu Ser		
420	425	430
Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val Val Gly Pro Val Gly		
435	440	445
Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu Gly Glu Leu Ala Pro		
450	455	460
Ser His Gly Leu Val Ser Val His Gly Arg Ile Ala Tyr Val Ser Gln		
465	470	475
Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser Asn Ile Leu Phe Gly		
485	490	495
Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val Ile Lys Ala Cys Ala		
500	505	510
Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly Asp Leu Thr Val Ile		
515	520	525
Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln Lys Ala Arg Val Asn		
530	535	540
Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile Tyr Leu Leu Asp Asp		
545	550	555
Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg His Leu Phe Glu Leu		
565	570	575
Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr Ile Leu Val Thr His		
580	585	590
Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile Leu Ile Leu Lys Asp		
595	600	605
Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu Phe Leu Lys Ser Gly		
610	615	620
Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn Glu Glu Ser Glu Gln		
625	630	635
Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn Arg Thr Phe Ser Glu		
645	650	655

Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro Ser Leu Lys Asp Gly
 660 665 670
 Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro Val Thr Leu Ser Glu
 675 680 685
 Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln Ala Tyr Lys Asn Tyr
 690 695 700
 Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile Phe Leu Ile Leu Leu
 705 710 715 720
 Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln Asp Trp Trp Leu Ser
 725 730 735
 Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val Thr Val Asn Gly Gly
 740 745 750
 Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp Tyr Leu Gly Ile Tyr
 755 760 765
 Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly Ile Ala Arg Ser Leu
 770 775 780
 Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln Thr Leu His Asn Lys
 785 790 795 800
 Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu Phe Phe Asp Arg Asn
 805 810 815
 Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys Asp Ile Gly His Leu
 820 825 830
 Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe Ile Gln Thr Leu Leu
 835 840 845
 Gln Val Val Gly Val Val Ser Val Ala Val Ala Val Ile Pro Trp Ile
 850 855 860
 Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe Ile Phe Leu Arg Arg
 865 870 875 880
 Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg Leu Glu Ser Thr Thr
 885 890 895
 Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser Leu Gln Gly Leu Trp
 900 905 910
 Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys Gln Glu Leu Phe Asp
 915 920 925
 Ala His Gln Asp Leu His Ser Glu Ala Trp Phe Leu Phe Leu Thr Thr
 930 935 940
 Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile Cys Ala Met Phe Val
 945 950 955 960

Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala Lys Thr Leu Asp Ala
 965 970 975
 Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu Thr Leu Met Gly Met
 980 985 990
 Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val Glu Asn Met Met Ile
 995 1000 1005
 Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu Glu Lys Glu Ala Pro
 1010 1015 1020
 Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp Pro His Glu Gly Val
 1025 1030 1035 1040
 Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser Pro Gly Gly Pro Leu
 1045 1050 1055
 Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser Gln Glu Lys Val Gly
 1060 1065 1070
 Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser Leu Ile Ser Ala Leu
 1075 1080 1085
 Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp Ile Asp Lys Ile Leu
 1090 1095 1100
 Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys Lys Met Ser Ile Ile
 1105 1110 1115 1120
 Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met Arg Lys Asn Leu Asp
 1125 1130 1135
 Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp Asn Ala Leu Gln Glu
 1140 1145 1150
 Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro Gly Lys Met Asp Thr
 1155 1160 1165
 Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val Gly Gln Arg Gln Leu
 1170 1175 1180
 Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn Gln Ile Leu Ile Ile
 1185 1190 1195 1200
 Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr Asp Glu Leu Ile Gln
 1205 1210 1215
 Lys Lys Ser Gly Arg Asn Leu Pro Thr Ala Pro Cys
 1220 1225
 <210> 538
 <211> 1261
 <212> PRT
 <213> Homo sapiens
 <400> 538
 Met Tyr Ser Val Leu Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu

5					10					15						
Leu	Gln	Gly	Phe	Trp	Asp	Lys	Glu	Val	Leu	Arg	Ala	Glu	Asn	Asp	Ala	
20					25					30						
Gln	Lys	Pro	Ser	Leu	Thr	Arg	Ala	Ile	Ile	Lys	Cys	Tyr	Trp	Lys	Ser	
35					40					45						
Tyr	Leu	Val	Leu	Gly	Ile	Phe	Thr	Leu	Ile	Glu	Glu	Ser	Ala	Lys	Val	
50					55					60						
Ile	Gln	Pro	Ile	Phe	Leu	Gly	Lys	Ile	Ile	Asn	Tyr	Phe	Glu	Asn	Tyr	
65					70					75					80	
Asp	Pro	Met	Asp	Ser	Val	Ala	Leu	Asn	Thr	Ala	Tyr	Ala	Tyr	Ala	Thr	
85					90					95						
Val	Leu	Thr	Phe	Cys	Thr	Leu	Ile	Leu	Ala	Ile	Leu	His	His	Leu	Tyr	
100					105					110						
Phe	Tyr	His	Val	Gln	Cys	Ala	Gly	Met	Arg	Leu	Arg	Val	Ala	Met	Cys	
115					120					125						
His	Met	Ile	Tyr	Arg	Lys	Ala	Leu	Arg	Leu	Ser	Asn	Met	Ala	Met	Gly	
130					135					140						
Lys	Thr	Thr	Thr	Gly	Gln	Ile	Val	Asn	Leu	Leu	Ser	Asn	Asp	Val	Asn	
145					150					155					160	
Lys	Phe	Asp	Gln	Val	Thr	Val	Phe	Leu	His	Phe	Leu	Trp	Ala	Gly	Pro	
165					170					175						
Leu	Gln	Ala	Ile	Ala	Val	Thr	Ala	Leu	Leu	Trp	Met	Glu	Ile	Gly	Ile	
180					185					190						
Ser	Cys	Leu	Ala	Gly	Met	Ala	Val	Leu	Ile	Ile	Leu	Leu	Pro	Leu	Gln	
195					200					205						
Ser	Cys	Phe	Gly	Lys	Leu	Phe	Ser	Ser	Leu	Arg	Ser	Lys	Thr	Ala	Thr	
210					215					220						
Phe	Thr	Asp	Ala	Arg	Ile	Arg	Thr	Met	Asn	Glu	Val	Ile	Thr	Gly	Ile	
225					230					235					240	
Arg	Ile	Ile	Lys	Met	Tyr	Ala	Trp	Glu	Lys	Ser	Phe	Ser	Asn	Leu	Ile	
245					250					255						
Thr	Asn	Leu	Arg	Lys	Lys	Glu	Ile	Ser	Lys	Ile	Leu	Arg	Ser	Ser	Cys	
260					265					270						
Leu	Arg	Gly	Met	Asn	Leu	Ala	Ser	Phe	Phe	Ser	Ala	Ser	Lys	Ile	Ile	
275					280					285						
Val	Phe	Val	Thr	Phe	Thr	Thr	Tyr	Val	Leu	Leu	Gly	Ser	Val	Ile	Thr	
290					295					300						
Ala	Ser	Arg	Val	Phe	Val	Ala	Val	Thr	Leu	Tyr	Gly	Ala	Val	Arg	Leu	
305					310					315					320	

Thr Val Thr Leu Phe Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala
 325 330 335
 Ile Val Ser Ile Arg Arg Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile
 340 345 350
 Ser Gln Arg Asn Arg Gln Leu Pro Ser Asp Gly Lys Lys Met Val His
 355 360 365
 Val Gln Asp Phe Thr Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr
 370 375 380
 Leu Gln Gly Leu Ser Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val
 385 390 395 400
 Val Gly Pro Val Gly Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu
 405 410 415
 Gly Glu Leu Ala Pro Ser His Gly Leu Val Ser Val His Gly Arg Ile
 420 425 430
 Ala Tyr Val Ser Gln Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser
 435 440 445
 Asn Ile Leu Phe Gly Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val
 450 455 460
 Ile Lys Ala Cys Ala Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly
 465 470 475 480
 Asp Leu Thr Val Ile Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln
 485 490 495
 Lys Ala Arg Val Asn Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile
 500 505 510
 Tyr Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg
 515 520 525
 His Leu Phe Glu Leu Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr
 530 535 540
 Ile Leu Val Thr His Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile
 545 550 555 560
 Leu Ile Leu Lys Asp Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu
 565 570 575
 Phe Leu Lys Ser Gly Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn
 580 585 590
 Glu Glu Ser Glu Gln Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn
 595 600 605
 Arg Thr Phe Ser Glu Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro
 610 615 620

Ser Leu Lys Asp Gly Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro
 625 630 635 640
 Val Thr Leu Ser Glu Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln
 645 650 655
 Ala Tyr Lys Asn Tyr Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile
 660 665 670
 Phe Leu Ile Leu Leu Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln
 675 680 685
 Asp Trp Trp Leu Ser Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val
 690 695 700
 Thr Val Asn Gly Gly Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp
 705 710 715 720
 Tyr Leu Gly Ile Tyr Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly
 725 730 735
 Ile Ala Arg Ser Leu Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln
 740 745 750
 Thr Leu His Asn Lys Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu
 755 760 765
 Phe Phe Asp Arg Asn Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys
 770 775 780
 Asp Ile Gly His Leu Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe
 785 790 795 800
 Ile Gln Thr Leu Leu Gln Val Val Gly Val Val Ser Val Ala Val Ala
 805 810 815
 Val Ile Pro Trp Ile Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe
 820 825 830
 Ile Phe Leu Arg Arg Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg
 835 840 845
 Leu Glu Ser Thr Thr Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser
 850 855 860
 Leu Gln Gly Leu Trp Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys
 865 870 875 880
 Gln Glu Leu Phe Asp Ala His Gln Asp Leu His Ser Glu Ala Trp Phe
 885 890 895
 Leu Phe Leu Thr Thr Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile
 900 905 910
 Cys Ala Met Phe Val Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala
 915 920 925
 Lys Thr Leu Asp Ala Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu

930	935	940
Thr Leu Met Gly Met Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val		
945	950	955 960
Glu Asn Met Met Ile Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu		
	965	970 975
Glu Lys Glu Ala Pro Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp		
	980	985 990
Pro His Glu Gly Val Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser		
	995	1000 1005
Pro Gly Gly Pro Leu Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser		
	1010	1015 1020
Gln Glu Lys Val Gly Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser		
	1025	1030 1035 1040
Leu Ile Ser Ala Leu Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp		
	1045	1050 1055
Ile Asp Lys Ile Leu Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys		
	1060	1065 1070
Lys Met Ser Ile Ile Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met		
	1075	1080 1085
Arg Lys Asn Leu Asp Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp		
	1090	1095 1100
Asn Ala Leu Gln Glu Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro		
	1105	1110 1115 1120
Gly Lys Met Asp Thr Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val		
	1125	1130 1135
Gly Gln Arg Gln Leu Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn		
	1140	1145 1150
Gln Ile Leu Ile Ile Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr		
	1155	1160 1165
Asp Glu Leu Ile Gln Lys Lys Ile Arg Glu Lys Phe Ala His Cys Thr		
	1170	1175 1180
Val Leu Thr Ile Ala His Arg Leu Asn Thr Ile Ile Asp Ser Asp Lys		
	1185	1190 1195 1200
Ile Met Val Leu Asp Ser Gly Arg Leu Lys Glu Tyr Asp Glu Pro Tyr		
	1205	1210 1215
Val Leu Leu Gln Asn Lys Glu Ser Leu Phe Tyr Lys Met Val Gln Gln		
	1220	1225 1230
Leu Gly Lys Ala Glu Ala Ala Ala Leu Thr Glu Thr Ala Lys Gln Arg		
	1235	1240 1245

Trp Gly Phe Thr Met Leu Ala Arg Leu Val Ser Asn Ser
 1250 1255 1260

<210> 539
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 539
 Cys Leu Ser His Ser Val Ala Val Val Thr
 1 5 10

<210> 540
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 540
 Ala Val Val Thr Ala Ser Ala Ala Leu
 1 5

<210> 541
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 541
 Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu
 5 10

<210> 542
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 542
 Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala
 5 10 15

<210> 543
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 543
 Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val
 5 10

<210> 544
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 544
 Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val Glu Glu Lys Phe
 5 10 15

Met Thr

<210> 545
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 545
 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 5 10 15

Ser Val

<210> 546
 <211> 29
 <212> PRT
 <213> Homo sapiens

<400> 546
 Phe Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly
 5 10 15

Thr Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg Met
 20 25

<210> 547
 <211> 58
 <212> PRT
 <213> Homo sapiens

<400> 547
 Val Ala Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu
 5 10 15

Ser Ala Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu
 20 25 30

Ala Phe Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys
 35 40 45

Cys Arg Met Pro Arg Thr Leu Arg Arg Leu
 50 55

<210> 548
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 548
 Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu
 5 10 15

Glu Cys

<210> 549
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 549
 Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg
 5 10 15

Gln Ala

<210> 550
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 550
 Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe
 5 10

<210> 551
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 551
 Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala
 5 10

<210> 552
 <211> 2577
 <212> DNA
 <213> Homo sapiens

<400> 552
 agcatatgta acatgacctg tgcttcagtg ttctttttgtg atcaaaaatt ccttactttt 60
 agt+ttttat ctatggtaga accacccaga gcaggggtcc tcaactccca ggccacagac 120
 ncataccagt ccaaggacta ttatgaacca caccacacag gaggaggtga gcactaggca 180
 agccaaggaa gcttcacctg tacttacagc cacacgccat ggctcatatt acagocctgaa 240

```

ctctgcctcc actcagatca gtgataacat tagaaactca ttggagcacg aacctgtgtg 300
tgaactgcct atccgaagga tctaggttgt gtgcttcgta tgagaatcta atgccagatg 360
atctatcatt gtctcacttt gccccagat aagaccatct agttgcagaa aaataagctc 420
agagcttcca ctgattctac attatggata tgtgcccgcg aagcaagcac aaagccctac 480
ttttacacat gcctagtgat gcttcagtga caaggettgg ctctgttgag tccaactaac 540
ctacctgaga ttctgagatt tctcttcaat ggcttcctgt gagctagagt ttgaaaatat 600
cttaaaatct tgagctagag atggaagtag cttggacgat tttcattatc atgtaaatcg 660
ggtcactcaa ggggccaacc acagctggga gccactgctc aggggaaggt tcatatggga 720
ctttctactg cccaaggttc tatacaggat ataaagggtc ctcacagtat agatctggta 780
gcaaagaaga agaaacaaac actgatctct ttctgccacc cctctgacct tttggaactc 840
ctctgacctt ttagaacaag cctacctaat atctgctaga gaaaagacca acaacggcct 900
caaaggatct cttaccatga aggtctcagc taattcttgg ctaagatgtg ggtccacat 960
taggttctga atatgggggg aagggtcaat ttgctcattt tgtgtgtgga taaagtccagg 1020
atgcccaggg gccagagcag ggggctgctg ctttgggaac aatggctgag catataacca 1080
taggtatggg aacaaaaaac atcaaagtca ctgtatcaat tgccatgaag actcgaggga 1140
cctgaatcta ccgattcatc ttaaggcagc aggaccagtt tgagtggcaa caatgcagca 1200
gcagaatcaa tggaacaac agaattgttg caatgtcctt tttttctcc tccttctgac 1260
ttgataaaag ggaccgtctt ccttggtatt agtgaacccc tttggttctt gaaaaattca 1320
aggagtatct aggacatagt cccagaaga cagtacaaga ctttctgata aactggacat 1380
ttcaagrccc aaataactaa tcagaaaaat caaagatgtg atactatctt ttatcccatg 1440
cataggtgct acacttggat caaatgaaca atgttgggat ctytatggat aaaggctcta 1500
aaagtccctg gataaagaat cctgcaccca ctggtacttc taacttgtct tgtttttgt 1560
ctgwtttctg gctgatgcag gggactaact cactgccacg cgaaaactac ctgaactgaa 1620
ctatgacatc tcacctgata tgtaagatgt aactgttata attattttaa acctcaattt 1680
agcattaact agccttttaa tgtaaacact tacacattat gaygactaga aacgcatac 1740
tctctggccg tctgtccaga tagatcttga gaagatacat caatgttttg ctcaagtaga 1800
aggctgacta tacttgccga tccacaacat acagcaagta tgagagcagt tctaaaatga 1860
cagagatagg aacagtaata aagttattkt aaaagcta at ttgatatact ttaccaattt 1920
aacatcttgc ctgtccgtgc agaatcaaac atttacatgc actaaaagac ataagcatct 1980
tcagtgtcga agtggttcac tttgtaaaat accaccaagg ttaaaaggaa gggacaaaaa 2040
aaaaaaaacc tcttatctca gtgggttatt gcatagcaga agctactaat ttgaagtcct 2100
ttgatggaca agaaacaata ttagggccac ttatctgaaa tgaacaaaga ttaagtga 2160
gatttcatca cagcttccct agactgatat gctgtaatag aaaatcagct agggggtaaa 2220
ataaataaga gctctctgca tgctgaaagc aagtaagatt aataataatg gtaagaatag 2280
tagtcacagg agtttcagtt aatgatgcca ataagcatgt gctaggcact gaattaaatg 2340
ccacatatat ctttcttatg cgcagcaaac tttgaaggat atattctcct acttttcata 2400
tatgacaaca tatttgggtg taaataacgt tcccaaggtc acacacctag caagtaagaa 2460
agttaggaat taaaccaggt attgtgtgaa tctaaagcct aacttttttc tctttatcac 2520
ccacctacgg cttgtcttca ttaaaggaaa agtgtatcca cttaaaaaaa aaaaaaa 2577

```

<210> 553

<211> 58

<212> PRT

<213> Homo sapiens

<400> 553

Ser Ile Cys Asn Met Thr Cys Ala Ser Val Phe Phe Cys Asp Gln Lys
5 10 15

Phe Leu Thr Phe Ser Phe Leu Ser Met Val Glu Pro Pro Arg Ala Gly
20 25 30

Val Leu Asn Ser Gln Ala Thr Asp Ser Tyr Gln Ser Thr Asp Tyr Tyr
35 40 45

Glu Pro His His Thr Gly Gly Gly Glu His
50 55

<210> 554
 <211> 59
 <212> PRT
 <213> Homo sapiens

<400> 554
 Leu Gln Lys Asn Lys Leu Arg Ala Ser Thr Asp Ser Thr Leu Trp Ile
 5 10 15
 Cys Ala Ala Glu Ala Ser Thr Lys Pro Tyr Phe Tyr Thr Cys Leu Val
 20 25 30
 Met Leu His Gly Gln Gly Leu Ala Leu Leu Ser Pro Thr Asn Leu Pro
 35 40 45
 Glu Ile Leu Arg Phe Leu Phe Asn Gly Phe Leu
 50 55

<210> 555
 <211> 71
 <212> PRT
 <213> Homo sapiens

<400> 555
 Leu Gly Arg Phe Ser Leu Ser Cys Lys Ser Gly His Ser Arg Gly Gln
 5 10 15
 Pro Gln Leu Gly Ala Thr Ala Gln Gly Lys Val His Met Gly Leu Ser
 20 25 30
 Thr Ala Gln Gly Ser Ile Gln Asp Ile Lys Val Pro His Ser Ile Asp
 35 40 45
 Leu Val Ala Lys Lys Lys Lys Gln Thr Leu Ile Ser Phe Cys His Pro
 50 55 60
 Ser Asp Pro Leu Glu Leu Leu
 65 70

<210> 556
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 556
 Asn His Pro Glu Gln Gly Ser Ser Thr Pro Arg Pro Gln Thr His Thr
 5 10 15
 Ser Pro Arg Thr Ile Met Asn His Thr Thr Gln Glu Glu Val Ser Thr
 20 25 30
 Arg Gln Ala Lys Glu Ala Ser Pro Val Leu Thr Ala Thr Arg His Gly
 35 40 45
 Ser Tyr Tyr Ser Leu Asn Ser Ala Ser Thr Gln Ile Ser Asp Asn Ile

Ile

Gly Phe His Ile Arg Phe
50

Pro Ser Tyr Leu Ser Gly Val Leu His Ser Arg Ser Tyr
65 70 75

<213> Homo sapiens

<400> 559

```

Thr Leu Pro Pro Leu Arg Ser Val Ile Thr Leu Glu Thr His Trp Ser
              5              10              15

Thr Asn Pro Val Val Asn Cys Leu Ser Glu Gly Ser Arg Leu Cys Ala
              20              25              30

Ser Tyr Glu Asn Leu Met Pro Asp Asp Leu Ser Leu Ser His Phe Ala
              35              40              45

Pro Arg
              50

```

<210> 560

<211> 56

<212> PRT

<213> Homo sapiens

<400> 560

```

Ile Gly Ser Leu Lys Gly Pro Thr Thr Ala Gly Ser His Cys Ser Gly
              5              10              15

Glu Gly Ser Tyr Gly Thr Phe Tyr Cys Pro Arg Phe Tyr Thr Gly Tyr
              20              25              30

Lys Gly Ala Ser Gln Tyr Arg Ser Gly Ser Lys Glu Glu Glu Thr Asn
              35              40              45

Thr Asp Leu Phe Leu Pro Pro Leu
              50              55

```

<210> 561

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(57)

<223> Xaa = Any amino acid

<400> 561

```

Val Leu His Leu Asp Gln Met Asn Asn Val Gly Ile Xaa Met Asp Lys
              5              10              15

Gly Leu Lys Ser Pro Glu Ile Lys Asn Pro Ala Pro Thr Gly Thr Ser
              20              25              30

Asn Leu Ser Cys Phe Leu Ser Xaa Phe Trp Leu Met Gln Gly Thr Asn
              35              40              45

Ser Leu Pro Arg Glu Asn Tyr Leu Asn
              50              55

```

<210> 562
 <211> 59
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> (1)...(59)
 <223> Xaa = Any amino acid

<400> 562
 Asp Leu Tyr Pro Xaa Arg Ser Gln His Cys Ser Phe Asp Pro Ser Val
 5 10 15
 Ala Pro Met His Gly Ile Lys Asn Ser Ile Thr Ser Leu Ile Phe Leu
 20 25 30
 Ile Ser Tyr Leu Xaa Leu Glu Met Ser Ser Leu Ser Glu Ser Leu Val
 35 40 45
 Leu Ser Ser Gly Asp Tyr Val Leu Asp Thr Pro
 50 55

<210> 563
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 563
 Cys Phe Leu Phe Pro Tyr Leu Trp Leu Tyr Ala Gln Pro Leu Phe Pro
 5 10 15
 Lys Gln Gln Pro Pro Ala Leu Ala Pro Gly His Pro Asp Phe Ile His
 20 25 30
 Thr Gln Asn Glu Gln Ile Asp Pro Ser Pro His Ile Gln Asn Leu Met
 35 40 45
 Trp Asn Pro His Leu Ser Gln Glu Leu Ala Glu Thr Phe Met Val Arg
 50 55 60
 Asp Pro Leu Arg Pro Leu Leu Val Phe Ser Leu Ala Asp Ile Arg
 65 70 75

<210> 564
 <211> 64
 <212> PRT
 <213> Homo sapiens

<400> 564
 Ala Cys Ser Lys Gly Ser Glu Glu Phe Gln Arg Val Arg Gly Val Ala
 5 10 15
 Glu Arg Asp Gln Cys Leu Phe Leu Leu Cys Tyr Gln Ile Tyr Thr
 20 25 30

Val Arg His Leu Tyr Ile Leu Tyr Arg Thr Leu Gly Ser Arg Lys Ser
 35 40 45

His Met Asn Leu Pro Leu Ser Ser Gly Ser Gln Leu Trp Leu Ala Pro
 50 55 60

<210> 565

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(57)

<223> Xaa = Any amino acid

<400> 565

Leu Tyr Tyr Cys Ser Tyr Leu Cys His Phe Arg Thr Ala Leu Ile Leu
 5 10 15

Ala Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln
 20 25 30

Asn Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu
 35 40 45

Tyr Ala Val Ser Ser Xaa His Asn Val
 50 55

<210> 566

<211> 55

<212> PRT

<213> Homo sapiens

<400> 566

Ile Leu Leu Glu Phe Phe Arg Asn Gln Arg Gly Ser Leu Asn Pro Arg
 5 10 15

Lys Thr Val Pro Phe Ile Lys Ser Glu Gly Gly Glu Lys Lys Gly His
 20 25 30

Cys Asn His Ser Val Val Ser Ile Asp Ser Ala Ala Ala Leu Leu Pro
 35 40 45

Leu Lys Leu Val Leu Leu Pro
 50 55

<210> 567

<211> 51

<212> PRT

<213> Homo sapiens

<400> 567

Tyr Ser Asp Phe Asp Val Phe Cys Ser His Thr Tyr Gly Tyr Met Leu

5 10 15
 Ser His Cys Ser Gln Ser Ser Ser Pro Leu Leu Trp Pro Leu Gly Ile
 20 25 30
 Leu Thr Leu Ser Thr His Lys Met Ser Lys Leu Thr Leu Pro Pro Ile
 35 40 45
 Phe Arg Thr
 50

<210> 568
 <211> 75
 <212> PRT
 <213> Homo sapiens

<400> 568
 Lys Val Gly Glu Tyr Ile Leu Gln Ser Leu Leu Arg Ile Arg Lys Ile
 5 10 15
 Tyr Val Ala Phe Asn Ser Val Pro Ser Thr Cys Leu Leu Ala Ser Leu
 20 25 30
 Thr Glu Thr Pro Val Thr Thr Ile Leu Thr Ile Ile Ile Asn Leu Thr
 35 40 45
 Cys Phe Gln His Ala Glu Ser Ser Tyr Leu Phe Tyr Pro Leu Ala Asp
 50 55 60
 Phe Leu Leu Gln His Ile Ser Leu Gly Lys Leu
 65 70 75

<210> 569
 <211> 4809
 <212> DNA
 <213> Homo sapiens

<400> 569
 gcatccagag tgggtggactg gttacaggct atgaacctac actgatgcgg caccaccacc 60
 cagagtccac rggttatggt gggtcacatt tactcttgct gtggtatggt ctatagggtt 120
 ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtcttgtagg 180
 aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctgt 240
 tttcagttgc ttttctaatt ctctcttctc gtttacctca aaatcttctc gaggtctcgc 300
 ttctttttaa aatccttgct tactttgcag catcactctg acactcccat tgattcctca 360
 gcacctactg actacacggt taggagtgcaggaggtagaat tcatgtttta ttcattctttg 420
 ggtctgtagc acccagcaaa gtgctcagta aatgcgcagt aattgatttg acctctgaac 480
 aaatacacac tgtactaaga atctacacac cgaaagacaa aaacaagaca aatttgagtg 540
 ctacagggtgt cagccttggc atcacacatg tgccctgtgta ttctcttagg tggttaccag 600
 gagctctgcc actgcatgct cactagtgcagggttcgctc caccaccca gctgggtagc 660
 cgctgctctc acataagggg tccaattaaa attgccagga ataaattccc ccggactttg 720
 acttctcaag agctaagaag gtttgctgag tattctggca tgatgtttgg tgatcaaaaca 780
 actgctggcc aaaaatgatg agtatttccc cctcttgctg aagatgtgct ccatacaata 840
 gtccatcaca ttcattcattc atcagtctgg aagtgtgcag aacaacatgt aatagataat 900
 atgattggct gcacacttcc agactgatga atgatgaatg tgatggacta ttgtatggag 960
 cacatcttca gcaagagggg gaaatactca tcattttatc tattacatgt tgttctggtt 1020


```

ttttttttt tccaatgtcc agcctaaact ataaagtact ttgagaacgc acagtgagcc 1080
ataagcttgc caataaagag tccctctgtg tatggaactg gcttatttca tacacaatct 1140
acaaacaatg agggcaactat tggaaacata ctgtgctgca cagagcattt acaccgctta 1200
tctttaatct tccccagcaa tcccttgettt gtgcgcattt atgacccctg ctctcagaag 1260
tccacataact tttccccaac cgtaacaaat tatttaactc atctaagtta tgtatgtccg 1320
agcagctctga aaacagtaat tgtcccttggg aagaagtgag ttttaagagag ctctagggca 1380
ctcatcacaac ctccagccctt gccctccatg tggtagcagc tcttttggact ggggctaagt 1440
gcttattctt gtgcttccat cctggtaagc tcaattttct taccttagga taactttgct 1500
ggaaaagggc tcagattcag ccgaccattg tggcctctgt ggctgtcaca gcttgtccct 1560
gacatgctat gatgttgggt ccccttctca tcccttggg atttcttctg ctggcccaca 1620
gcccagaaca ctaggccttt tactccacca tcccttgggt tcttttgggt tctgttgtaa 1680
tactcaatcc tctaccatc catgcatagc aattttctaaa aactgaattt caagagcagt 1740
atctgaagaa acaaacatga tttgttccct ttagtaaaaa gaataaattt taataaatca 1800
actttgaaat agttgtaaqa gttaagaaaa agcacaacaa tgagatcacc agagcagctt 1860
ggcctcaaaq aacaggcagc aggattctac aggggtttgag ccttcctaag tgaagctgtt 1920
tccctgcaggc tccctgtctc aagctcctag ctaacagccc cttctccccc gattggcaac 1980
aaagagcaaa aataaacttt tacttgatgc tgagtcagtg taaaaagcca taaaaaatc 2040
cctctaaatg taaaatgtt tgcctccttt gaggttctc tccctcactt ggtctcgat 2100
aaatttagca tggcttata ttgagtcaca gatctggggt ctgccacaga gagcttctc 2160
ctagtgtgtg atgtttttt tccaaactat tgatacaaaa tgcaactggaa tagaaatcaa 2220
cagaaactgg tcaaaagtgt ggcatacaca ttctcatgta gatgtaaaagc tgtgcttaga 2280
atccctttgt gtttctgtt ttggcttggg ttttcttggg gtttgattca tttttttacg 2340
taaattacaa aaacctccca cattttcttca tggattgtat tagtccatgt tctccagaga 2400
agcagaacga gttgagatga tgttttggaa gagattatga ggaaccggct catgtgatga 2460
aggaggttga gtttctctgt gctctgccat ctgcaagctg aagacctgga aagctgaggg 2520
tgtggctcca gctctgagct gaaggcccaa aaccaacggt gtagattcca 2580
ggttgaaggc aggaagaagat ggatgtccca gctcagcagg caggcaggaa gcaaatggg 2640
taaattctct cttctccccc cttttgttcc attcaggcct tcaacagatt ggatgagcgc 2700
ccccccaccc ccacactagg gagggccatc tgctttactg agtcggctga gtcaagtgcc 2760
agcctcatcc caaacacatc tccagacaca cgcagaaatg tttcatctgg gcacctgtg 2820
gccagtcatg ctgacacaca gaactaacca tgacatggat tcttcttaaa gcagtgatag 2880
gagcgaacga aaacattttc ataattttca attattttta atgaaaaacta tatctgatgg 2940
aattgtttta accctagtct gccacacatt atttcttggg accgcccctc cttcaatccc 3000
ttggacactg atgactttat gccagatta cactggaggc ctgtgctgat tttctaacac 3060
atccctgcaa ctgagctggc aaaaagaaaa ctaggcaagt atgacagata catgatgcac 3120
aggctaagtg caaaggaaag aaaaacacca actgcaggga tgagggactc acccctttag 3180
aagtttctac ttgagcagct agaagactac aatgccactc atcaaaacag tgactcaggg 3240
ggagtatttg ggataaagga ggaatctgat gttggaagtc aaatttgaag tgtctttaag 3300
acctacaggt aacgagacag ctggacaaac acatggaaact caggacaaag gctctaagga 3360
cagcacagca gctgacatcc tgtgtgacag ccttgaaagc agcaggcccg ccgctcacat 3420
tttggaaagg aaaaatgggt caatgttgtc tgccactttg gggccttctt gggtcacatg 3480
cattttacat ttatgcagtt gatataatga tgtttcctgg gtcttttata cattagacac 3540
catgattctc aatcctttgt tattttgtat tacaataaagc tgaattatta tttcaaatat 3600
gggcaaatga gagccttcca tattgccaaq gtgtatcaac cacactgata ycaygatctc 3660
tcttttgaat tagttttcca gttcacacct accattttat tcatgattgg tttcagactt 3720
gttccctctg gaaacactcc ctaacaagca ccttgcagg aatgaagaca caccacacac 3780
atctacccca ttaactgcag tactcaagag tcagctttta tatgatctct cccaagtgtc 3840
cctataatgg ggtatcttca ctcaccctaa agtgaggaca aaataacttga aagcatgagc 3900
ccagtgcctg taggtgtgca attaacctca gaccaaggaa gtgccgaacg catctggctt 3960
ttagcaaggc acctgacaaa gtccctcagg atgtttttgt acatgagcta gagaaatgta 4020
cctggagaaq agcttctact gccagatgat cttactcaaa agatgcagat taagcaaaat 4080
atcaacccaa aggggtggct ctgatggccc accagcccct gtgcctggct cgtttcctat 4140
gttccctaga tttggtttca gaactgtctc tccctgcagac actccctaac cagcatcctt 4200
gcagaaaact ggtgaactag aaaaggcctg tgtgggtcac gtggccaccc aacaccacag 4260
cagtgtctaa ggtatgcctg ggagcctgca cagcaggagc ggggtcttct ggagacccgc 4320
atgagatgca aagggcagtg gacaaggagc caagggaggt ggctctagtc acgctgggat 4380
agcgcagct tgaagatgt gggcaagtcc cgagccgtct gccttctag taccacagtt 4440
accactgtct gttacctgcg gagttcaagt gcttcacgtg agacagctac gagacaggcc 4500

```

```

cctggaaact ggaaaaatgcy aagtaaatgt catgcacaat tgttggttcac attttatctc 4560
aatcactttt accaaatcag gctaaaccct gggattcat aacgtcttgg gctgtacaaa 4620
ttgttccttg aaatgactca gagacatttt ctgaattggc tccatcagc caagcatttc 4680
ttcagaactg gaaaaatgct ttaaatttgg ctttgtcatg attattaaaa cactctgtac 4740
attttttatt attgaaatta acacattgcc tactttttaa aaattggaaa aagaaaaaaa 4800
aaaaaaaaa 4809

```

<210> 570

<211> 951

<212> DNA

<213> Homo sapiens

<400> 570

```

aaaattgaat attgagatac cattcttttag tgttaccttt tttaccacaca tgtgtttctg 60
aaaatatttg aattttattc atcttaaaaa ttggaccgg ccttatttac catctttaat 120
ccatttttagt actatgggtg agtacatgga attgaagtct ggcttaaatc ttcagaaagt 180
tatatatcta ttttatttta tttttttgag acagagtctc gctgtgtcac ccaggctgga 240
gtgcggtgcc acaatcttgg ctcaactgcaa cctctgagtc ccaggttcaa gcgatactca 300
tgcttcggcc tcttgagtag ctgggactac aggcgtgcac caccacatct ggctaactct 360
tttttgattt tttagtagag acggggtttc actgtggtct ccatctcctg acctcgtgat 420
ccgcctgcct cccaaagtgc tgggattaca ggcatgagcc accgcacaca gctgggactg 480
ggtaatttat aaagaaaaga ggtttaatga ctacagttc cgcatggctg gagaggcctc 540
aggaaactta caatcatggt ggaaggcgaa ggggaagcaa ggcacgtctt acatgggtggc 600
aggagagaac gagtgagggg ggagactgcc aaaaactttt tttttttgag acaagagtct 660
ggccctgttg cccaggctgg agtgacgtgg catgatctca gctcaactgca acctctgcct 720
cacaggttca agcaattctc atgcctcagc ctcccgcata gctgggacca caggtatgca 780
ccaccacacc tagctaattt ttgtagtttt agtagagatg ggtctcact atgttgctca 840
ggctggtcta aaactcctgg gctccagcaa tccgcctgcc ttggcctccc aaagtgcctg 900
ggttacaggc ataagccacc acatccagcc tgccacatac ttttaacta t 951

```

<210> 571

<211> 819

<212> DNA

<213> Homo sapiens

<400> 571

```

cagcttaaaa atgggtttctt gaaatcagtg attagcattc actcaccagt acccctacta 60
aggggtaggc actgggtttgt actcctggga atacaggagt acaccagaat ttattttctgc 120
ttattgcttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagagggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttaa cctgcattct 240
gaaagatgtt tctcaggttt ttcccttgacg attttcttct tttctgattc tgacaatgtt 300
ttaaatcatt gtactgtggt tatcatttct ctgcatttat tttaccatc ttcctttgta 360
acttgtccta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcacggtg gctcacatct 480
gtaatcccag cactttgggg aggcctgagac ggggtggatca cttgaggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatccgtt ttactaaaa atacaaaaat taccagggca 600
tgggtggcgg cgctgtaat cccaggtaact cgggaggctg agggaggaga atcgcttgaa 660
cctggggagg tgagggagga gaatcgcttg aaccggggag gcagaggttg cagtgaaccg 720
agatcatgtt gctgcactcc agcctggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaaacaaac aaaacagaga gattttgct 819

```

<210> 572

<211> 203

<212> DNA

<213> Homo sapiens

<400> 572

```

tatagaatac tcaagctatg catcaagctt ggtaccgagc tcggatccac tattttacggc 60

```

```
<210> 573
<211> 132
<212> PRT
<213> Homo sapiens
```

```

<400> 573
Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
          5                      10                      15

Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg
          20                      25                      30

Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu
          35                      40                      45

Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu
          50                      55                      60

Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala
          65                      70                      75                      80

Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly
          85                      90                      95

Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro
          100                      105                      110

Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile
          115                      120                      125

Leu Leu Asn Tyr
          130

```

```
<210> 574
<211> 62
<212> PRT
<213> Homo sapiens
```

<400> 574
Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
5 10 15
His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
20 25 30
Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
35 40 45
Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
50 55 60

<210> 575

211

<211> 76
 <212> PRT
 <213> Homo sapiens

<400> 575
 Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp
 5 10 15
 Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu
 20 25 30
 Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly
 35 40 45
 Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp
 50 55 60
 Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys
 65 70 75

<210> 576
 <211> 68
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> (1)...(68)
 <223> Xaa = Any Amino Acid

<400> 576
 Met Leu Gly Lys Ser Arg Ala Val Cys Leu Pro Ser Thr Thr Val Thr
 5 10 15
 Thr Val Cys Tyr Leu Ala Ser Ser Ser Ala Ser Arg Glu Thr Ala Thr
 20 25 30
 Arg Gln Ala Pro Gly Asn Trp Lys Met Xaa Ser Lys Cys His Ala Gln
 35 40 45
 Leu Leu Phe Thr Phe Tyr Leu Asn His Phe Tyr Gln Ile Arg Leu Asn
 50 55 60
 Pro Gly Tyr Ser
 65

<210> 577
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 577
 Met Tyr Leu Glu Asn Ser Phe Tyr Cys Gln Met Ile Leu Leu Lys Arg
 5 10 15
 Cys Arg Leu Ser Lys Ile Ser Thr Gln Arg Val Val Pro Asp Gly Pro

20 25 30
 Pro Ala Pro Val Pro Gly Ser Phe Pro Met Phe Pro Arg Phe Gly Phe
 35 40 45

Arg Leu Ala Pro Pro Ala Asp Thr Pro
 50 55

<210> 578
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 578
 Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu Leu Tyr Ile Arg His
 5 10 15

His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr Lys Lys Leu Asn Tyr
 20 25 30

Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His Ile Ala Lys Val Tyr
 35 40 45

Gln Pro His
 50

<210> 579
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 579
 Met His Phe Thr Phe Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu
 5 10 15

Leu Tyr Ile Arg His His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr
 20 25 30

Lys Lys Leu Asn Tyr Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His
 35 40 45

Ile Ala Lys Val Tyr Gln Pro His
 50 55

<210> 580
 <211> 67
 <212> PRT
 <213> Homo sapiens

<400> 580
 Met Glu Leu Arg Thr Lys Ala Leu Arg Thr Ala Gln Gln Leu Thr Ser
 5 10 15

Cys Val Thr Ala Leu Lys Ala Ala Gly Pro Pro Leu Thr Phe Trp Lys
 20 25 30

213

Gly Lys Trp Val Gln Cys Cys Leu Pro Leu Trp Gly Leu Leu Gly Ser
 35 40 45

His Ala Phe Tyr Ile Tyr Ala Val Asp Ile Phe Met Phe Pro Gly Ser
 50 55 60

Phe Ile His
 65

<210> 581

<211> 77

<212> PRT

<213> Homo sapiens

<400> 581

Met Leu Glu Val Lys Phe Glu Val Ser Leu Arg Pro Thr Gly Asn Glu
 5 10 15

Thr Ala Gly Gln Thr His Gly Thr Gln Asp Lys Gly Ser Lys Asp Ser
 20 25 30

Thr Ala Ala Asp Ile Leu Cys Asp Ser Leu Glu Ser Ser Arg Pro Ala
 35 40 45

Ala His Ile Leu Glu Gly Lys Met Gly Thr Met Leu Ser Ala Thr Leu
 50 55 60

Gly Pro Ser Trp Val Thr Cys Ile Leu His Leu Cys Ser
 65 70 75

<210> 582

<211> 51

<212> PRT

<213> Homo sapiens

<400> 582

Met Leu Phe Leu Gln Thr Ile Asp Thr Lys Cys Thr Gly Ile Glu Ile
 5 10 15

Asn Arg Asn Trp Ser Lys Val Trp His Thr His Ser His Val Asp Val
 20 25 30

Lys Leu Cys Leu Glu Phe Leu Cys Gly Val Trp Phe Gly Leu Gly Phe
 35 40 45

Leu Gly Val
 50

<210> 583

<211> 60

<212> PRT

<213> Homo sapiens

<400> 583

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 5 10 15

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 20 25 30

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 35 40 45

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 50 55 60

<210> 584
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 584
 Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
 5 10 15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 20 25 30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 35 40 45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 50 55 60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 65 70 75

<210> 585
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 585
 Met Val Tyr Arg Phe Gly Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu
 5 10 15

Ala Ser Leu Gly Ser Ser Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp
 20 25 30

Arg Gln Ala Asp Pro Ser Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu
 35 40 45

Leu Phe
 50

<210> 586
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 586

Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
 5 10 15

Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
 20 25 30

Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser
 35 40 45

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
 50 55 60

<210> 587

<211> 1408

<212> DNA

<213> Homo sapiens

<400> 587

ctggacactt tgcgagggct tttgctggct gctgctgctg cccgtcatgc tactcatcgt 60
 agcccgcccg gtgaagctcg ctgctttccc tacctcctta agtgactgcc aaacgcccac 120
 cggttggaat tgctctggtt atgatgacag agaaaatgat ctcttcctct gtgacaccaa 180
 cacctgtaaa tttgatggg aatgtttaag aattggagac actgtgactt gcgtctgtca 240
 gttcaagtgc aacaatgact atgtgcctgt gtgtggctcc aatggggaga gctaccagaa 300
 tgagtgttac ctgcgacagg ctgcatgcaa acagcagagt gagatacttg tgggtgcaga 360
 aggatcatgt gccacagatg caggatcagg atctggagat ggagtccatg aaggctctgg 420
 agaaactagt caaaaggaga catccacctg tgatatttgc cagtttggtg cagaatgtga 480
 cgaagatgcc gaggatgtct ggtgtgtgtg taatattgac tgttctcaa ccaacttcaa 540
 tccccctctgc gcttctgatg ggaaatctta tgataatgca tgccaaatca aagaagcatc 600
 gtgtcagaaa caggagaaaa ttgaagtcac gtctttgggt cgatgtcaag ataacacaac 660
 tacaactact aagtctgaag atgggcatca tgcaagaaca gattatgcag agaatgctaa 720
 caaattagaa gaaagtgcc gagaacacca cataccttgt ccggaacatt acaatggctt 780
 ctgcatgcat gggaagtgtg agcattctat caatatgcag gagccatctt gcagggtgtga 840
 tgctggttat actggacaac actgtgaaaa aaaggactac agtgttctat acgttgttcc 900
 cggtcctgta cgatttcagt atgtcttaac cgcagctgtg attggaacaa ttcagattgc 960
 tgtcatctgt gtggtggtcc tctgcatcac aaggaaatgc cccagaagca acagaattca 1020
 cagacagaag caaaatacag ggcactacag ttcagacaat acaacaagag cgtccacgag 1080
 gttaatctaa agggagcatg ttccacagtg gctggactac cgagagcttg gactacacaa 1140
 tacagtatta tagacaaaag aataagacaa gagatctaca catgttgctt tgcatttgtg 1200
 gtaatctaca ccaatgaaaa catgtactac agctatatatt gattatgtat ggatatattt 1260
 gaaatagtat acattgtctt gatgtttttt ctgtaatgta aataaactat ttatatcaca 1320
 caatawagtt ttttctttcc catgtatttg ttatatataa taaatactca gtgatgagaa 1380
 aaaaaaaaaa aaaaaaaaaa rwmgaccc 1408

<210> 588

<211> 81

<212> PRT

<213> Homo sapiens

<400> 588

Met Pro Gln Lys Gln Gln Asn Ser Gln Thr Glu Ala Lys Tyr Arg Ala
 5 10 15

Leu Gln Phe Arg Gln Tyr Asn Lys Ser Val His Glu Val Asn Leu Lys
 20 25 30

Gly Ala Cys Phe Thr Val Ala Gly Leu Pro Arg Ala Trp Thr Thr Gln
 35 40 45
 Tyr Ser Ile Ile Asp Lys Arg Ile Arg Gln Glu Ile Tyr Thr Cys Cys
 50 55 60
 Leu Ala Phe Val Val Ile Tyr Thr Asn Glu Asn Met Tyr Tyr Ser Tyr
 65 70 75 80

Ile

<210> 589
 <211> 157
 <212> PRT
 <213> Homo sapiens

<400> 589
 Met Thr Met Cys Leu Cys Val Ala Pro Met Gly Arg Ala Thr Arg Met
 5 10 15
 Ser Val Thr Cys Asp Arg Leu His Ala Asn Ser Arg Val Arg Tyr Leu
 20 25 30
 Trp Cys Gln Lys Asp His Val Pro Gln Met Gln Asp Gln Asp Leu Glu
 35 40 45
 Met Glu Ser Met Lys Ala Leu Glu Lys Leu Val Lys Arg Arg His Pro
 50 55 60
 Pro Val Ile Phe Ala Ser Leu Val Gln Asn Val Thr Lys Met Pro Arg
 65 70 75 80
 Met Ser Gly Val Cys Val Ile Leu Thr Val Leu Lys Pro Thr Ser Ile
 85 90 95
 Pro Ser Ala Leu Leu Met Gly Asn Leu Met Ile Met His Ala Lys Ser
 100 105 110
 Lys Lys His Arg Val Arg Asn Arg Arg Lys Leu Lys Ser Cys Leu Trp
 115 120 125
 Val Asp Val Lys Ile Thr Gln Leu Gln Leu Leu Ser Leu Lys Met Gly
 130 135 140
 Ile Met Gln Glu Gln Ile Met Gln Arg Met Leu Thr Asn
 145 150 155

<210> 590
 <211> 347
 <212> PRT
 <213> Homo sapiens

<400> 590
 Met Leu Leu Ile Val Ala Arg Pro Val Lys Leu Ala Ala Phe Pro Thr
 5 10 15

Ser Leu Ser Asp Cys Gln Thr Pro Thr Gly Trp Asn Cys Ser Gly Tyr
 20 25 30
 Asp Asp Arg Glu Asn Asp Leu Phe Leu Cys Asp Thr Asn Thr Cys Lys
 35 40 45
 Phe Asp Gly Glu Cys Leu Arg Ile Gly Asp Thr Val Thr Cys Val Cys
 50 55 60
 Gln Phe Lys Cys Asn Asn Asp Tyr Val Pro Val Cys Gly Ser Asn Gly
 65 70 75 80
 Glu Ser Tyr Gln Asn Glu Cys Tyr Leu Arg Gln Ala Ala Cys Lys Gln
 85 90 95
 Gln Ser Glu Ile Leu Val Val Ser Glu Gly Ser Cys Ala Thr Asp Ala
 100 105 110
 Gly Ser Gly Ser Gly Asp Gly Val His Glu Gly Ser Gly Glu Thr Ser
 115 120 125
 Gln Lys Glu Thr Ser Thr Cys Asp Ile Cys Gln Phe Gly Ala Glu Cys
 130 135 140
 Asp Glu Asp Ala Glu Asp Val Trp Cys Val Cys Asn Ile Asp Cys Ser
 145 150 155 160
 Gln Thr Asn Phe Asn Pro Leu Cys Ala Ser Asp Gly Lys Ser Tyr Asp
 165 170 175
 Asn Ala Cys Gln Ile Lys Glu Ala Ser Cys Gln Lys Gln Glu Lys Ile
 180 185 190
 Glu Val Met Ser Leu Gly Arg Cys Gln Asp Asn Thr Thr Thr Thr Thr
 195 200 205
 Lys Ser Glu Asp Gly His Tyr Ala Arg Thr Asp Tyr Ala Glu Asn Ala
 210 215 220
 Asn Lys Leu Glu Glu Ser Ala Arg Glu His His Ile Pro Cys Pro Glu
 225 230 235 240
 His Tyr Asn Gly Phe Cys Met His Gly Lys Cys Glu His Ser Ile Asn
 245 250 255
 Met Gln Glu Pro Ser Cys Arg Cys Asp Ala Gly Tyr Thr Gly Gln His
 260 265 270
 Cys Glu Lys Lys Asp Tyr Ser Val Leu Tyr Val Val Pro Gly Pro Val
 275 280 285
 Arg Phe Gln Tyr Val Leu Ile Ala Ala Val Ile Gly Thr Ile Gln Ile
 290 295 300
 Ala Val Ile Cys Val Val Val Leu Cys Ile Thr Arg Lys Cys Pro Arg
 305 310 315 320

Ser Asn Arg Ile His Arg Gln Lys Gln Asn Thr Gly His Tyr Ser Ser
 325 330 335

Asp Asn Thr Thr Arg Ala Ser Thr Arg Leu Ile
 340 345

<210> 591
 <211> 565
 <212> DNA
 <213> Homo sapien

<400> 591
 actaaagcaa atgaacaagc tgacttgcta gtatcatctg cattcattga agcacaagaa 60
 cttcatgcct tgactcatgt aaatgcaata ggattaaaaa ataaatttga tatcacatgg 120
 aaacagacaa aaaatattgt acaacattgc acccagtgtc agattctaca cctggccact 180
 caggaagcaa gagttaatcc cagaggtcta tgtcctaattg tgttatggca aatggatgtc 240
 atgcacgtac cttcatttgg aaaattgtca tttgtccatg tgacagttga tacttattca 300
 catttcatat gggcaacctg ccagacagga gaaagtactt cccatgttaa aagacattta 360
 ttatcttgtt ttccgtgcat gggagttcca gaaaaagtta aaacagacaa tggggccaggt 420
 tactgtagta aagcatttca aaaattctta aatcagtgga aaattacaca tacaatagga 480
 attctctata attcccaagg acaggccata attgaaggaa ctaatagaac actcaaagct 540
 caattgggta aacaaaaaaa aaaaa 565

<210> 592
 <211> 188
 <212> PRT
 <213> Homo sapien

<400> 592
 Thr Lys Ala Asn Glu Gln Ala Asp Leu Leu Val Ser Ser Ala Phe Ile
 1 5 10 15
 Glu Ala Gln Glu Leu His Ala Leu Thr His Val Asn Ala Ile Gly Leu
 20 25 30
 Lys Asn Lys Phe Asp Ile Thr Trp Lys Gln Thr Lys Asn Ile Val Gln
 35 40 45
 His Cys Thr Gln Cys Gln Ile Leu His Leu Ala Thr Gln Glu Ala Arg
 50 55 60
 Val Asn Pro Arg Gly Leu Cys Pro Asn Val Leu Trp Gln Met Asp Val
 65 70 75 80
 Met His Val Pro Ser Phe Gly Lys Leu Ser Phe Val His Val Thr Val
 85 90 95
 Asp Thr Tyr Ser His Phe Ile Trp Ala Thr Cys Gln Thr Gly Glu Ser
 100 105 110
 Thr Ser His Val Lys Arg His Leu Ser Cys Phe Pro Val Met Gly
 115 120 125
 Val Pro Glu Lys Val Lys Thr Asp Asn Gly Pro Gly Tyr Cys Ser Lys
 130 135 140
 Ala Phe Gln Lys Phe Leu Asn Gln Trp Lys Ile Thr His Thr Ile Gly
 145 150 155 160
 Ile Leu Tyr Asn Ser Gln Gly Gln Ala Ile Ile Glu Gly Thr Asn Arg
 165 170 175
 Thr Leu Lys Ala Gln Leu Val Lys Gln Lys Lys Lys
 180 185

<210> 593
 <211> 271

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(271)

<223> n = A,T,C or G

<400> 593

actttatgtt	cnagtgcana	aanccncctg	gattgccacc	ntactctcag	ggctgtgant	60
tgtgcnccca	nagcaacctg	ggcacgcggg	gacagggggg	ccnacaattg	agggagcggg	120
gtccctagct	gggtctata	catgncnggg	naagggcngc	tgagtnccat	nagcaaagga	180
nctagnatnt	gcgggggtgc	ggcctgggcc	taccctttna	agcatccntn	gatccactcc	240
angaanccng	gggtagncac	gtttncaca	a			271

<210> 594

<211> 376

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(376)

<223> n = A,T,C or G

<400> 594

cctttggggg	nggggggaac	ctttaccatt	gtncctcttt	atttcatttg	gttnggggtc	60
gcgcctcnn	ggccaacaa	agttatcgtn	nttgaagaga	anattttttt	ggnttngncc	120
cgattaagcg	ncaaatgtgt	agcaaaangc	cgtgccactt	gtggcgtagc	tncgtcgggt	180
cgattcgacg	acaaggcgtn	gcgcgntanc	gttagtctcn	aatngaccn	gtggcatgag	240
cccacgangg	nttcgtgtcg	tcacatggnc	tctagacata	acgcnccn	ttttttncag	300
agggggntgc	cgcccttagg	gagggnaggg	tggggacact	agccaancca	nantctnacc	360
ccattgaaga	aaaggn					376

<210> 595

<211> 242

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(242)

<223> n = A,T,C or G

<400> 595

agnctgctgn	tcgtncctn	tatgtggctt	catnntgagg	acaanagtng	cactgaggct	60
tgngnatgcc	aggcaaggnc	aagctggctc	aaaaagcatc	caccacctc	tgnaangggg	120
atgccangag	cangtgcacc	agteccaact	angagnccn	ggcatgntac	atcttcttcc	180
acccctnaaa	ntttnggcta	caangnccat	ttttcttttt	ctcttaaggg	ncnctgggt	240
tc						242

<210> 596

<211> 535

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(535)

<223> n = A,T,C or G

<400> 596

accagttgga	tactgctaaa	nagatattta	tgcagcctca	tatgttaagt	cgtatatttt	60
gaaagctttt	taaatttttt	ctttaagaag	atttttagatg	cttatcactg	agtaccagag	120
ggatgtaggc	tgatgccctt	atcaacaaag	tcaggggactg	tggcacacaa	ggattgacta	180
ctgcagacac	ggccacaatg	ctacctctag	agggcctgaa	tccccctgcc	ctctctggtg	240
gggagaaggg	ctggcagagc	cattagcatg	ggctccggcc	aatcctggcc	actttgacac	300
lccctggtgt	gacccagggt	cctggaggaa	gggatgaggt	gggcagtaga	gatgctcagg	360
gcagtggccc	ctttccatcc	acactggaac	tatttcagta	ttttaccacc	aattcagcca	420
ttcccttgta	cgtctggctga	acatcagccc	tgctccaggt	ctcagtttcc	cctttgtaaa	480
gggaaagctc	tggattcagg	gagtgatgaa	gaggtcatca	tggctctgag	aattc	535

<210> 597

<211> 257

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(257)

<223> n = A,T,C or G

<400> 597

tttctnatacc	caaaaantacc	ccatattang	accanacatt	tgtctnngaa	aaattaccat	60
tntntaant	ttgggccacc	tgagannaaa	tgggtgtaat	ncatgataag	atggancagn	120
atttctctta	agatnngatn	agaccccggt	tttcacggaa	catatccaag	nacccaatag	180
gnaacaagcc	acgggngggag	tcacaaacat	atattcttta	ctctcataat	ccgtnnccaca	240
naactnttgn	acttgac					257

<210> 598

<211> 222

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(222)

<223> n = A,T,C or G

<400> 598

nntggntacc	gtcnaaactt	nncttggtac	ccgagctcgg	atccactagt	ccagtgtggt	60
ggaattccat	tgtgttgggc	tataagctgt	aatagtggag	ncgtgctngg	ttcattgcan	120
nagnccctcc	gcanncaacn	ttgnnacaac	ctgtgagnag	gcnataaatt	attcacataa	180
tcctcactgc	atgaanctga	ctcaaacgca	tccacntaca	cc		222

<210> 599

<211> 238

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(238)

<223> n = A,T,C or G

<400> 599

gcatgacatc	ancgatgtnt	ttggnnacct	ganattngct	aaaactngng	natgccgggn	60
atgnaggttt	ggtantgatc	tatgcactca	catctcatgg	ggacgtttca	tgtggagtgn	120
tcgacaangt	tgctgnancn	gagaagtgat	gatctcagtt	gaaagggcca	tgtgaataca	180
cnttacactt	gaaaaagaag	cacattggga	atatcacgaa	acgnccacca	acatcctg	238

<210> 600

<211> 232

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(232)

<223> n = A,T,C or G

<400> 600

cgaactat	agactaccta	ggaaaattat	tttagtatca	gaagaatata	aggggtgtag	60
tactcatcag	agctaaatga	gagcgcttta	aaaatgttag	tttgtcttcc	gccatttcta	120
cagaaagctg	caatttcagg	ttttcaacct	aataggtgat	atttaaaaaa	aaaaaaaagc	180
aatcgcaaat	agccccactg	cttttacaaa	tcattttttc	cccaacacaa	tg	232

<210> 601

<211> 547

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(547)

<223> n = A,T,C or G

<400> 601

cattgtgttg	gggaaaaaat	gatttgtata	agcagtgggg	ctatttgcca	ttgctttttt	60
tttttcttaa	atatcaccta	ttaggttgaa	aacctgaaat	tgcagcttcc	tglagaaalg	120
gcggaagaca	aactaacatt	tttaaagcgc	tctcatttag	ctctgatgag	tactacaccc	180
ctnatattct	tctgatacta	aaataatttt	cctagtgtag	tctaaacttt	tttaaaaaga	240
catgtaatcc	gcggagttag	taactcaaaa	cgagtgcata	tnggaagtat	cgcagccggt	300
nctggatnaa	attcccagct	tgctngcttg	ctnagccggg	gggcggtnaa	aaaaacatct	360
gcagcccnng	ggnaaaaacc	ttcgcattgt	tcttacgtgt	ttacgttatt	ttatttcctt	420
nnagcaaggc	nggganttgg	ggactcgaaa	tggtacagtt	gggctgggga	tcgcccttgt	480
tacataaaag	ncgtccagaa	gagggacggt	tacaggcnng	ganctccaaa	ggtcagtcct	540
tgccatt						547

<210> 602

<211> 826

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(826)

<223> n = A,T,C or G

<400> 602

cgggggggnt	tacgtctctc	tggacgcttt	tattgtacca	gggcgatccc	agcccaactg	60
taccattcga	gtccctaactc	ctgccttgct	ctagggaat	aaaataacgt	aaacacgtaa	120
gaacaatgcg	aaagcgtttt	cttccctagg	ctgcagattg	tcttcttcac	cgcacctgct	180
tagctagcta	gctagctggg	aatttaatcc	agaaacggct	tgcgatacct	cctagatgca	240

```

ctcgtttttga gttacaaact ccgoggatta catgtctttt taaaaaagtt tagactacac 300
tagggaaaaat tattttagta tcagaagaat atcaggggggt gtagtactca tcagagctna 360
atgagagcgcc tttaaaaatg ttagtttgto ttccgccatt tctacagaaa gctgcaattt 420
cagggttttca nctaatagg tgatatntaa gaaaaaaaaa acaatogcan atagccact 480
gctttttacaa atcatttttc tcttctaggt atagcctgtc aggtggccta atgtattttt 540
gacatctcta ggaattttta tagaccagaa atgggtgccg gagatatgcc tgcactaatc 600
ttaagtgggg atttatgtat ttctcaanca agtgattaaa gcaaaactag gcacgaatga 660
aatcaagatc tttaggccag aaatcatgaa nanttttana attattttan gaatctgtgg 720
cttctcttct taaaatngaa aaaaaaattg tttaaacca naaggtctga ataccaagc 780
nccctgaacn anagaacaan gccggagcac cccctcccaa atcccc 826

```

<210> 603

<211> 817

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(817)

<223> n = A,T,C or G

<400> 603

```

nnangacttt tgtggnttta tacaattntt ttttctattt ctatgaagag aaagccacag 60
agtccataaaa taattctaaa actcatcatg actttcttgc ctaaaagatc ttgatttcaa 120
tcgtgcctag ttttgcttta atcacttget tgagaaatac ataaatcccc acttaagatt 180
agtgcaggca tatctctggc acccatttct ggttctatta aaattcctag agatgtcaaa 240
aattacatta ggccacctga caggctatac ctagaagaga aaaaatgatt tgtaaaagca 300
gtggggctat ttgcgattgc tttttttttt tcttaaatat cacctattag gttgaaaacc 360
tgaaattgca gctttctgta gaaatggcgg aagacaaact aacattttta aagcgtctct 420
atttagctct gatgagtact acacccctga tattcttctg atactaaaat aatttttcta 480
gtgtagtcta aactttttta aaaagacatg taatccgagg agtttgtaac tcaaaacgag 540
tgcacttagg aggtatcgca agccgtttct ggattaaatt ccagctagc ttgcttgctt 600
agcagggggc ggnaaanaag acatctgcag cctagggaag aaaaaccttc gcattgttct 660
tacgtgttta cgttatttta tttcctanaa caaggcngaa ttgggaactc aatgggttcag 720
ttgggggtgg ggatccctg gtncataaaa ngtcanaaag anggtacagg cggaacncca 780
agggtcgtcc tgcatttana ctcggaattt tgggtgcc 817

```

<210> 604

<211> 694

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(694)

<223> n = A,T,C or G

<400> 604

```

cttttcaaat ctttttinct cttctaggtat tancctgtca ggtggcctaa tgtaattttt 60
gacatctcta ngaattttta tagaaccaga aatgggtgcc agagatatgc ctgcactaat 120
cttaagtggg gatattatgta tttctcaagc aagtgattaa agcaaaacta ggcacgattg 180
aaatcaagat cttttaggca anaaagtcac gatgagtttt agaattattt taggactctg 240
tggctttctc ttcatagaaa tagaaaaaaa aattgtataa aaccacaaaa ggtcctgaat 300
agccaaagca acactganca aaaagaacan agcagggaag caacacacta ccngaattca 360
aattatacta ccagggtgta gtaaccacaaa cagcattcta ttggcataaa atagacacca 420
agaccaatgg ancagaataa agaaccacac aaataaatcc atatatntac cgccanctga 480
ttatcaataa cnaacaccaa gaacatatnt taagggaent nctattcaat aantagtgtc 540
ggnaaaaaact gggaaatcca tatgcagaaa naatgaaact agaccctat ccctcaccat 600

```

acgcaaannt caacttcgga atgggattac aaaacttaag acattccaac ccaagaaact 660
atnaaancta ctattaagaa aacagatcnc nccc 694

<210> 605

<211> 678

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(678)

<223> n = A,T,C or G

<400> 605

taaaaatcta	gactacacta	ggaaattatt	ttantatcag	aagaatatca	ggggtgtagt	60
actcatcana	octaaatgag	agcgttttaa	aaatgttagt	ttgtcttcg	ccatttctac	120
agaaagctgc	aatttcaggt	tttcaacct	ataggtgata	tttaagaaaa	aaaaaaagca	180
atcgcaaat	qccccactgc	ttttacaaat	cattttttct	cttctaggta	tagcctgtca	240
ggtggcctaa	tgtaatTTTT	gacatctcta	ggaattttta	tagaaccaga	aatgggtgcc	300
agagatatgc	ctgcactaat	cttaagtggg	gatttatgta	tttctcaagc	aagtgattaa	360
agcaaaacta	gjcacgattg	aaatcaanat	cttttaggca	agaaagtcac	gatgagtttt	420
anaattatTT	taggactctg	tggttttctc	ttcatagaaa	tagaaaaaaa	aaattgtata	480
aaaaccacaa	aaqgtcctga	atagcccaaa	gcaacactga	acaaaangaa	caaagcagga	540
agcaacacac	taccggaatt	caattatact	accaaggtgt	antaacccaa	acagcattct	600
attgggcata	aaatagacca	aagaccagtg	ggaaacagaa	taaagaancc	caaaataaat	660
cctatatTTA	cngccnc					678

<210> 606

<211> 263

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(263)

<223> n = A,T,C or G

<400> 606

gtgggggtcng	cancageccaa	ctcagettcc	tttcgggctt	tgtttagcaga	cggatcatcc	60
tctagtccac	tgtgntcaaa	ttccattgtg	tgggggccnc	tcgcctcggc	canagatctg	120
agtgancana	cntgtcccca	ctgaggtgcc	ccacagcngn	ttgtnttcag	cangggctna	180
caactcgacc	ggcagcgan	ggctggcaga	antgngcgcc	tnnctcatte	ctacgcngtn	240
ngccgcagga	aggangacag	gcc				263

<210> 607

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 607

ccatgtgggt	cccggttgtc	tt	22
------------	------------	----	----

<210> 608

<211> 22

<212> DNA

<213> Artificial Sequence

<220>
<223> Primer

<400> 608
gataggggtg ctcaggggtt gg 22

<210> 609
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 609
gctggacagg gggcaaaagc tggggcagtg aacctatgtgc 40

<210> 610
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 610
ccttgtccag atagcccagt agctgac 27

<210> 611
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 611
gatagagaaa accgtccagg ccagtattgt gggaggctgg gagtgc 46

<210> 612
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 612
gcacatgggt cactgcccc a gcttttgccc cctgtccagc 40

<210> 613
<211> 38
<212> DNA
<213> Artificial Sequence

<220>

<223> Primer

<400> 613

gccgctcgag ttagaattcg gggttggcca cgatggtg

38

<210> 614

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 614

cggcgggcat atgcatcacc atcaccatca catcataaac ggcgaggact gca

53

<210> 615

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 615

gcactccag cctcccacaa tactggcctg gacggttttc tctatc

46

<210> 616

<211> 1350

<212> DNA

<213> Homo sapien

<400> 616

atgcatcacc	atcaccatca	catcataaac	ggcgaggact	gcagcccgc	ctcgcagccc	60
tggcaggcgg	cactgggtcat	ggaaaacgaa	ttgtttctgt	cggggtctct	ggtgcatccg	120
cagtgggtgc	tgtcagccgc	acactgtttc	cagaactcct	acaccatcgg	gctgggcctg	180
cacagtcttg	aggccgacca	agagccaggg	agccagatgg	tggaggccag	cctctccgta	240
cggcaccacg	agtacaacag	acccttgctc	gctaacgacc	tcatgtctat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcggggaact	cttgcctcgt	ttctggctgg	ggtctgtctg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcggtggtg	tctgaggagg	tctgcagtaa	gctctatgac	480
ccgctgtacc	accccagcat	gttctgcgcc	ggcggagggc	aagaccagaa	ggactcctgc	540
aacgggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgcagggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agttggcgtg	ccagggtgtc	acaccaacct	ctgcaaattc	660
actgagtggg	tagagaaaac	cgtccaggcc	agtattgtgg	gaggctggga	gtgcgagaag	720
cattcccaac	cctggcaggt	gcttgtggcc	tctcgtggca	gggcagttct	cggcgggtgt	780
ctggtgcacc	cccagtgggt	cctcacagct	gcccactgca	tcaggaacaa	aagcgtgac	840
ttgctgggtc	ggcacagcct	gtttcatcct	gaagacacag	gccagggtatt	tcaggtcagc	900
cacagcttcc	caaccccgct	ctacgatatg	agcctcctga	agaatcgatt	cctcaggcca	960
ggtgatgact	ccagccacga	cctcatgctg	ctccgcctgt	cagagcctgc	cgagctcacg	1020
gatgctgtga	aggtcatgga	cctgccacc	caggagccag	cactggggac	cacctgctac	1080
gcctcaggct	ggggcagcat	tgaaccagag	gagttcttga	cccaaagaa	acttcagtgt	1140
gtggacctcc	atgttatttc	caatgacgtg	tgtgcgcaag	ttcaccctca	gaaggtgacc	1200
aagttcatgc	tgtgtgctgg	acgctggaca	gggggcaaaa	gctggggcag	tgaacctatg	1260
gccctgcccg	aaaggccttc	cctgtacacc	aaggtggtgc	attaccggaa	gtggatcaag	1320
gacaccatcg	tggccaaccc	cgaattctaa				1350

<210> 617

<211> 241

<212> PRT

<213> Homo sapiens

<400> 699

```

Met Gln His His His His His His Leu Arg Val Pro Glu Pro Arg Pro
 1           5           10           15
Gly Glu Ala Lys Ala Glu Gly Ala Ala Pro Pro Thr Pro Ser Lys Pro
      20           25           30
Leu Thr Ser Phe Leu Ile Gln Asp Ile Leu Arg Asp Gly Ala Gln Arg
      35           40           45
Gln Gly Gly Arg Thr Ser Ser Gln Arg Gln Arg Asp Pro Glu Pro Glu
      50           55           60
Pro Glu Pro Glu Pro Glu Gly Gly Arg Ser Arg Ala Gly Ala Gln Asn
      65           70           75           80
Asp Gln Leu Ser Thr Gly Pro Arg Ala Ala Pro Glu Glu Ala Glu Thr
      85           90           95
Leu Ala Glu Thr Glu Pro Glu Arg His Leu Gly Ser Tyr Leu Leu Asp
      100          105          110
Ser Glu Asn Thr Ser Gly Ala Leu Pro Arg Leu Pro Gln Thr Pro Lys
      115          120          125
Gln Pro Gln Lys Arg Ser Arg Ala Ala Phe Ser His Thr Gln Val Ile
      130          135          140
Glu Leu Glu Arg Lys Phe Ser His Gln Lys Tyr Leu Ser Ala Pro Glu
      145          150          155          160
Arg Ala His Leu Ala Lys Asn Leu Lys Leu Thr Glu Thr Gln Val Lys
      165          170          175
Ile Trp Phe Gln Asn Arg Arg Tyr Lys Thr Lys Arg Lys Gln Leu Ser
      180          185          190
Ser Glu Leu Gly Asp Leu Glu Lys His Ser Ser Leu Pro Ala Leu Lys
      195          200          205
Glu Glu Ala Phe Ser Arg Ala Ser Leu Val Ser Val Tyr Asn Ser Tyr
      210          215          220
Pro Tyr Tyr Pro Tyr Leu Tyr Cys Val Gly Ser Trp Ser Pro Ala Phe
      225          230          235          240
Trp

```

<210> 700

<211> 729

<212> DNA

<213> Homo sapiens

<400> 700

```

atgcagcatc accaccatca ccacctcagg gttccggagc cgcgggcccg ggaggcgaaa      60
gcgagggggg ccgcgcgcgc gaacccgtcc aagccgctca cgtccttcc catccaggac      120
atcctgcggg acggcgcgca gcggaaggc ggccgcacga gcagccagag acagcgcgac      180
ccggagccgg agccagagcc agagccagag ggaggacgca gccgcgcggg ggcgcgagaac      240
gaccagctga gcaccggggc ccgcgcgcgc ccggatgagg ccgagacgct ggcagagacc      300
gagccagaaa ggcacttggg gtcttatctg ttggactctg aaaacacttc aggcgcctt      360
ccaaggcttc cccaaacccc taagcagccg cagaagcgct cccgagctgc cttctccac      420
actcaggtga tggagttgga gaggaagttc agccatcaga agtacctgtc ggccccgaa      480
cgggccacc tggccaagaa cctcaagctc acggagaccc aagtgaagat atggttccag      540
aacagacgct ataagactaa gcgaaagcag ctctcctcgg agctgggaga cttggagaag      600
cactcctttt tgccggccct gaaagaggag gccttctccc gggcctccct ggtctccgtg      660
tataacagct atccttacta cccatacctg cactgcgtgg gcagctggag ccagctttt      720
tggtaatga

```

277

<210> 701
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 701
 ctactaagcg ctggagtgag ggatcag

27

<210> 702
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 702
 catcgagaat tcactactct ctgactagat gtc

33

<210> 703
 <211> 161
 <212> PRT
 <213> Homo sapiens

<400> 703
 Met Gln His His His His His His Ala Gly Val Arg Asp Gln Gly Gln
 1 5 10 15
 Gly Ala Arg Trp Pro His Thr Gly Lys Arg Gly Pro Leu Leu Gln Gly
 20 25 30
 Leu Thr Trp Ala Thr Gly Gly His Cys Phe Ser Ser Glu Glu Ser Gly
 35 40 45
 Ala Val Asp Gly Ala Gly Gln Lys Lys Asp Arg Ala Trp Leu Arg Cys
 50 55 60
 Pro Glu Ala Val Ala Gly Phe Pro Leu Gly Ser Asp Cys Arg Glu Gly
 65 70 75 80
 Gly Arg Gln Gly Cys Gly Gly Ser Asp Asp Glu Asp Asp Leu Gly Val
 85 90 95
 Ala Pro Gly Leu Ala Pro Ala Trp Ala Leu Thr Gln Pro Pro Ser Gln
 100 105 110
 Ser Pro Gly Pro Gln Ser Leu Pro Ser Thr Pro Ser Ser Ile Trp Pro
 115 120 125
 Gln Trp Val Ile Leu Ile Thr Glu Leu Thr Ile Pro Ser Pro Ala His
 130 135 140
 Gly Pro Pro Trp Leu Pro Asn Ala Leu Glu Arg Gly His Leu Val Arg
 145 150 155 160
 Glu

<210> 704
 <211> 489
 <212> DNA
 <213> Homo sapiens

<400> 704
 atgcaacatc accaccatca ccacgctgga gtgagggatc aggggcaggg cgcgagatgg 60
 cctcacacag ggaagagagg gccctcctg cagggcctca cctgggccac aggaggacac 120
 tgcctttcct ctgaggagtc aggagctgtg gatggtgctg gacagaagaa ggacagggcc 180
 tggctcaggt gtccagaggc tgcgctggc ttccctttgg gatcagactg caggagagga 240
 gggcggcagg gttgtggggg gagtgacgat gaggatgacc tgggggtggc tccaggcctt 300
 gccctgcct gggccctcac ccagcctccc tcacagtctc ctggccctca gtctctcccc 360
 tccactccat cctccatctg gcctcagtgg gtcattctga tccactgaact gaccataccc 420
 agcctgccc acggccctcc atggctcccc aatgccttg agaggggaca tctagtcaga 480
 agtagtga 489

<210> 705
 <211> 132
 <212> PRT
 <213> Homo sapiens

<400> 705
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
 1 5 10 15
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser
 20 25 30
 Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly
 35 40 45
 Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val
 50 55 60
 Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val
 65 70 75 80
 Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala
 85 90 95
 Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Trp
 100 105 110
 Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu
 115 120 125
 Gly Pro Pro Ala
 130

<210> 706
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 706
 ggggaattca tcacctatgt gccgcctctg c

31

<210> 707
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 707
gggctcgagt cactcgccca cgaaatccgt gtaaaacagc

40

<210> 708
<211> 1203
<212> DNA
<213> Homo sapiens

<400> 708
atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60
cagggatctg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120
accgttcata tcgggcctac cgccttcctc ggcttggtg ttgtcgacaa caacggcaac 180
ggcgacagag tccaacgcgt ggtcgggagc gctcgggcg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcacatcc cggtgacgtc atctcgggtga cctggcaaac caagtccggc 360
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catcacctat 420
gtgcgcctc tgctgctgga agtgggggta gaggagaagt tcatgaccat ggtgctgggc 480
attggctccag tgctgggcct ggtctgtgtc ccgtcctag gctcagccag tgaccactgg 540
cgtggacgct atggccgccc cgggcccttc atctgggcac tgccttggg catcctgtg 600
agcctcttcc tcatcccaag ggccggctgg ctacagggc tgctgtgccc ggatcccagg 660
cccctggagc tggcactgct catcctgggc gtggggctgc tggacttctg tggccagggtg 720
tgcttcaact cactggaggc cctgctctct gacctcttcc gggaccgga ccactgtcgc 780
caggcctaact ctgtctatgc cttcatgatc agtcttgggg gctgcctggg ctacctctg 840
cctgccattg actgggacac cagtgcctg gccccctacc tgggcaccca ggaggagtgc 900
ctctttggcc tgctcaccct catcttcctc acctgcgtag cagccacact gctggtggct 960
gaggaggcag cgctgggccc caccgagcca gcagaagggc tgcggcccc ctccttgtcg 1020
ccccactgct gtccatgcgc ggcccgcttg gctttccgga acctgggcgc cctgcttccc 1080
cggctgcacc agctgtgctg ccgcacgtgc cgcacctgc gccggctctt cgtggctgag 1140
ctgtgcagct ggatggcact catgaccttc acgctgtttt acacggattt cgtgggcgag 1200
tga 1203

<210> 709
<211> 400
<212> PRT
<213> Homo sapiens

<400> 709
Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
5 10 15
Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala
20 25 30
Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
35 40 45
Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
50 55 60
Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
65 70 75 80
Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
85 90 95
Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser

100	105	110	
Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr			
115	120	125	
Leu Ala Glu Gly Pro Pro Ala Glu Phe Ile Thr Tyr Val Pro Pro Leu			
130	135	140	
Leu Leu Glu Val Gly Val Glu Glu Lys Phe Met Thr Met Val Leu Gly			
145	150	155	160
Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser Ala			
165	170	175	
Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp			
180	185	190	
Ala Leu Ser Leu Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala			
195	200	205	
Gly Trp Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu			
210	215	220	
Ala Leu Leu Ile Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val			
225	230	235	240
Cys Phe Thr Pro Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro			
245	250	255	
Asp His Cys Arg Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu			
260	265	270	
Gly Gly Cys Leu Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser			
275	280	285	
Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu			
290	295	300	
Leu Thr Leu Ile Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala			
305	310	315	320
Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala			
325	330	335	
Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe			
340	345	350	
Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg			
355	360	365	
Met Pro Arg Thr Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp			
370	375	380	
Met Ala Leu Met Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu			
385	390	395	400

281

<210> 710
<211> 20
<212> PRT
<213> Homo sapiens

<400> 710
Leu Leu Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val
 5 10 15

Ser Val Arg Val
 20

<210> 711
<211> 60
<212> DNA
<213> Homo sapiens

<400> 711
ctgctccac ctccaccgc gctctgcggg gcctctgect gtgatgtctc cgtacgtgtg 60

<210> 712
<211> 10
<212> PRT
<213> Homo sapiens

<400> 712
Ala Ser Ala Cys Asp Val Ser Val Arg Val
 5 10

<210> 713
<211> 30
<212> DNA
<213> Homo sapiens

<400> 713
gcctctgect gtgatgtctc cgtacgtgtg 30

<210> 714
<211> 9
<212> PRT
<213> Homo sapiens

<400> 714
Ala Ser Ala Cys Asp Val Ser Val Arg
1 5

<210> 715
<211> 9
<212> PRT
<213> Homo sapiens

<400> 715
Ser Ala Cys Asp Val Ser Val Arg Val
 5

<210> 716
<211> 27

<212> DNA
 <213> Homo sapiens

<400> 716
 tctgcctgtg atgtctccgt acgtgtg

27

<210> 717
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 717
 Gly Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser
 5 10 15

Ala Ser Asp

<210> 718
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 718
 Val Pro Pro Leu Leu Leu Glu Val Gly Val Glu Glu Lys Phe Met Thr
 5 10 15

Met Val Leu

<210> 719
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 719
 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
 5 10 15

Gln Leu Leu

<210> 720
 <211> 57
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(57)
 <223> n = A,T,C or G

<400> 720
 ggnathggnc cngtnytngg nytngtntgy gtnccnytny tnggnwsngc nwsngay

57

<210> 721
<211> 57
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(57)
<223> n = A,T,C or G

<400> 721
gtncncncny tnytnytnga rgtnggngtn gargaraart tyatgacnat ggtnytn 57

<210> 722
<211> 57
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(57)
<223> n = A,T,C or G

<400> 722
atggtnccarm gnytnrtgggt nwsnmgnytn ytnmgncaym gnaargcnca rytnytn 57

<210> 723
<211> 9
<212> PRT
<213> Homo sapiens

<400> 723
Val Leu Gln Cys Val Asn Val Ser Val
1 5

<210> 724
<211> 9
<212> PRT
<213> Homo sapiens

<400> 724
Arg Met Pro Thr Val Leu Gln Cys Val
1 5

<210> 725
<211> 9
<212> PRT
<213> Homo sapiens

<400> 725
Asn Leu Cys Lys Phe Thr Glu Trp Ile
1 5

<210> 726
<211> 9
<212> PRT

<213> Homo sapiens

<400> 726

Met Leu Ile Lys Leu Asp Glu Ser Val
1 5

<210> 727

<211> 9

<212> PRT

<213> Homo sapiens

<400> 727

Leu Leu Ala Asn Asp Leu Met Leu Ile
1 5

<210> 728

<211> 10

<212> PRT

<213> Homo sapiens

<400> 728

Leu Leu Ala Asn Gly Arg Met Pro Thr Val
1 5 10

<210> 729

<211> 10

<212> PRT

<213> Homo sapiens

<400> 729

Leu Met Leu Ile Lys Leu Asp Glu Ser Val
1 5 10

<210> 730

<211> 10

<212> PRT

<213> Homo sapiens

<400> 730

Val Leu Gln Cys Val Asn Val Ser Val Val
1 5 10

<210> 731

<211> 10

<212> PRT

<213> Homo sapiens

<400> 731

Gly Leu Leu Ala Asn Gly Arg Met Pro Thr
1 5 10

<210> 732

<211> 10

<212> PRT

<213> Homo sapiens

<400> 732

Thr Val Leu Gln Cys Val Asn Val Ser Val

285

1 5 10
 <210> 733
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 733
 Gly Val Leu Val His Pro Gln Trp Val
 1 5

<210> 734
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 734
 Val Leu Val His Pro Gln Trp Val Leu
 1 5

<210> 735
 <211> 1195
 <212> DNA
 <213> Homo sapiens

<400> 735
 ccgagactca cggcgaagct aaggcgaaga gtgggtggct gaagccatac tattttatag 60
 aattaatgga aagcagaaaa gacatcacaa accaagaaga actttggaaa atgaagccta 120
 ggagaaattht agaagaagac gattatttgc ataaggacac gggagagacc agcatgctaa 180
 aaagacctgt gcttttgcac ttgcacccaa cagcccatgc tgatgaattt gactgccctt 240
 cagaacttca gcacacacag gaactctttc cacagtggca cttgcccaatt aaaatagctg 300
 ctattatagc atctctgact tttctttaca ctcttctgag ggaagtaatt caccctttag 360
 caacttccca tcaacaatat ttttataaaa ttccaatcct ggtcatcaac aaagtcttgc 420
 caatggtttc catcactctc ttggcattgg ttacctgcc aggtgtgata gcagcaattg 480
 tccaacttca taatggaacc aagtataaga agtttccaca ttggttgat aagtggatgt 540
 taacaagaaa gcagtttggg cttctcagtt tcttttttgc tgtactgcat gcaatttata 600
 gtctgtctta cccaatgagg cgatcctaca gatacaagtt gctaaactgg gcatatcaac 660
 aggtccaaca aaataaagaa gatgcctgga ttgagcatga tgtttggaga atggagattt 720
 atgtgtctct gggaaattgt ggattggcaa tactggctct gttggctgtg acatctattc 780
 catctgtgag tgactctttg acatggagag aatttcacta tattcagagc aagctaggaa 840
 ttgtttccct tctactgggc acaatacacg cattgatttt tgcctggaat aagtggatag 900
 atataaaaca atttgtatgg tatacacctc caacttttat gatagctgtt ttccttccaa 960
 ttgttgtcct gatatttaaa agcatactat tcctgccatg cttgaggaag aagatactga 1020
 agattagaca tgggtgggaa gacgtcacca aaattaacaa aactgagata tgttcccagt 1080
 tgtagaatta ctgtttacac acatttttgt tcaatattga tatattttat caccaacatt 1140
 tcaagtttgt atttgtaat aaaatgatta ttcaaggaaa aaaaaaaaaa aaaaa 1195

<210> 736
 <211> 339
 <212> PRT
 <213> Homo sapiens

<400> 736
 Met Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met
 5 10 15

Lys Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp Thr
 20 25 30
 Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His Gln
 35 40 45
 Thr Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His Thr
 50 55 60
 Gln Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala Ile
 65 70 75 80
 Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile His
 85 90 95
 Pro Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile Leu
 100 105 110
 Val Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu Leu Ala Leu
 115 120 125
 Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Val Gln Leu His Asn Gly
 130 135 140
 Thr Lys Tyr Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr
 145 150 155 160
 Arg Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala
 165 170 175
 Ile Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu
 180 185 190
 Leu Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp
 195 200 205
 Ile Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly Ile
 210 215 220
 Val Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro Ser
 225 230 235 240
 Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys
 245 250 255
 Leu Gly Ile Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe
 260 265 270
 Ala Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro
 275 280 285
 Pro Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe
 290 295 300
 Lys Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys Ile
 305 310 315 320
 Arg His Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile Cys

325

330

335

Ser Gln Leu

<210> 737

<211> 2172

<212> DNA

<213> Homo sapiens

<400> 737

```

aaaattgaat attgagatac cattctttag tgttacottt tttaccacaca tgtgtttctg 60
aaaatatattg aatttttattc atcttaaaaa ttggaccggg ccttattttac catctttaat 120
ccatttttagt actatgggtg agtacatgga attgaagtct ggcttaaate ttcagaaagt 180
tatatatcta ttttatttta tttttttgag acagagtctc gctgtgtcac ccaggctgga 240
gtgcggtgcc acaatcttgg ctcaactgcaa cctctgagtc ccaggttcaa gcgataactca 300
tgccctggcc tctgagtag ctgggactac aggcgtgcac caccacatct ggctaactct 360
tttttgtatt tttagtagag acggggtttc actgtggtct ccatctcctg acctcgtgat 420
ccgcctgcct cccaaagtgc tgggattaca ggcattgagcc accgcacaca gctgggactg 480
ggtaattttat aaagaaaaga ggtttaatga ctccacagttc cgcattggctg gagaggcctc 540
aggaaactta caatcatggt ggaaggcgaa ggggaagcaa ggcacgtctt acatggtggc 600
aggagagaac gagtgagggg ggagactgcc acaaactttt tttttttgag acaagagtct 660
ggccctgttg cccaggctgg agtgagtggt catgatctca gctcaactgca acctctgcct 720
cacaggttca aqcaattctc atgcctcagc ctcccgcata gctgggacca caggatgca 780
ccaccacacc tagctaattt ttgtagtttt agtagagatg ggggtctcact atgttgctca 840
ggctggtcta aaactcctgg gctccagcaa tccgcctgcc ttggcctccc aaagtgtg 900
ggttacagge ataagccacc acatccagcc tgccacatac ttttaaaacta tcaggtctca 960
tgagaactca tgcactatca caagaatagc atggggaaaaa tccccccat aatccaatca 1020
cctcccacca ggtctcctcc gacacgtggg attgggtggg gacacagagc caaacctgat 1080
cagatgctgc aggggctggg gacactgaga ccactcagac ctgggtgtctc tgtcactctt 1140
ctgggctctg tctgtctcca ggacctccct ccccttccat ggtatagaag gaaagtgtg 1200
taaggtgcaa attgcacagg aactccttaa gacatacata atccactcag cagtttttag 1260
ttcgagcaa aatggagtgg aaggaacaga aatttcctgt gcacccctcc ccgctgtctc 1320
cgccatatcg gcatcctgca tccagagtgg tggactggtt acaggctatg aacctacact 1380
gatgcgccac caccacccag agtccacggg ttatgttggg tcacattttac tcttgetgtg 1440
gtatggtcta taggtttgga cagatgtccg ataactcctt ttacattttg gcatccttgg 1500
gtagctcgtc ttgtaggaaat ggacttgctt caaagtggag gcaggcagat ccttcagacg 1560
ggtatatgga gccctgtttt cagttgcttt tctaattctc tcttatcgtt tacctcaaaa 1620
tcttctgag gtctcgtctc cttttaaaat ccttgtctac tttgcagcat cactctgaca 1680
ctccattgat tctcagcac ctactgacta cacggttagg agtgcaaggg tagaattcat 1740
gttttattca tctttgggtc tgtagcacc agcaaagtgc tcagtaaatt cgcagtaatt 1800
gatttgacct ctgaacaaat acacactgta ctaagaatct acacaccgaa agacaaaaac 1860
aagacaaatt tgagtgtctac aggtgtcacg cttggcatca cacatgtgcc tgtgtattcc 1920
tctaggtggg taccaggagc tctgccactg catgtccact agtgacgggt tcgctccacc 1980
acccagctg ggtagccgct gctctcacat aaggggtcca attaaaattg ccaggaataa 2040
attcccccg actttgactt ctcaagagct aagaagggtt gctgagtatt ctggcatgat 2100
gtttggtgat caaacaactg ctggccaaaa atgatgagta tttccccctc ttgctgaaga 2160
tgtgtccat ac 2172

```

<210> 738

<211> 2455

<212> DNA

<213> Homo sapiens

<400> 738

```

cagcttaaaa atggttttctt gaaatcagtg attagcatte actcaccagt acccctacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttattttctg 120

```

```

ttttgtttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagaggggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaagatggt tctcagggtt ttcccttgacg atttctctct tttctgattc tgacaatggt 300
ttaaatacatt gtactgtggg tatcatttct ctgcatttat tttaccatc ttcccttcta 360
acttgctcta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcacgggtg gctcacatct 480
gtaatcccag cactttgggg aggtgagac ggggtgatca cttgaggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatcccg ttactaaaa atacaaaaat taccaggca 600
tggtggcggg cgctgtaat ccaggtact cgggaggctg agggaggaga atcgcttgaa 660
cctgggaggg tgaggaggga gaatcgctg aaccgggag gcagaggttg cagtgaaccg 720
agatcatggt gctgcactcc agcctggtea acagagcaag actctgcctc aaaaacaaac 780
aataaaciaa acaaacacaa aaaaacagaga gattttgctg caatgtacaa ggagcaattt 840
gctcctttta aaaaataatt tttggccagg cacagtggct cacacctgta atcccagcac 900
tttgggaagg caaggtgggt ggatcatttg aggtcaggag tttgagatca gcctggccaa 960
catggtgaaa cactatctct attaaaaata caaaaatgtg ctcagtgtgg tgggtgcacat 1020
ctgtaatctc agcctccgc atagctggga ccacaggtat gcaccaccac acctagctaa 1080
ttttgtagt ttagtagag atgggtctc actatgttg tcaggctggt ctaaaactcc 1140
tgggtccag caatccgct gccctggcct cccaaagtgc tgggttaca ggcataagcc 1200
accacatcca gctgccaca tacttttaa ctatcaggtc tcatgagaac tcatgacta 1260
tcacaagaat agcatggga aaatccccc cataatcaa tcacctcca ccaggtctcc 1320
tccgacacgt gggattgggt ggggacacag agccaaaccg tatcagatgc tgcaggggt 1380
ggggacactg agaccactca gacctggtgt ctctgtcact cttctgggt ctgtctgtct 1440
ccaggacctc cctcccttc catggtatag aaggaaagt ctgtaagggt caaattgcac 1500
aggaaactct taagacatac atcatccact cagcagtttt aggttcgcag caaatggag 1560
tggaaggaac agaaatttc tgtgcacccc tcccgcgtgt ctccgccata tgggcactct 1620
gcacccagag tgggtgactg gttacaggct atgaacctac actgatgcgg caccaccacc 1680
cagagtccac aggttatgtt ggttcacatt tactcttgct gtggtatggt ctataggttt 1740
ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtcttgtagg 1800
aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctg 1860
tttcagttgc ttttctaatt ctctcttate gtttacctca aaatcttct gaggtctgc 1920
ttccttttaa aatccttgct tactttgcag catcactctg acactccatt gattctcag 1980
cacctactga ctacacgggt aggagtgc aa gggtagaatt catgttttat tcatctttg 2040
gtctgtagca ccagcaaaag tgctcagtaa atgcgcagta attgatttga cctctgaaca 2100
aatacacact gtactaagaa tctacacacc gaaagacaaa aacaagacaa atttgagtgc 2160
tacaggtgtc acgcttgga tcacacatg gctgtgtat tctctaggt ggttaccagg 2220
agctctgcca ctgcatgtcc actagtgaag ggttcgctcc accaccccag ctgggtagcc 2280
actgctctca cataaggggt ccaattaaaa ttgccaggaa taaattcccc cggactttga 2340
cttctcaaga gctaagaagg tttgctgagt attctggcat gatgtttggt gatcaacaa 2400
ctgctggcca aaaatgatga gtatttcccc ctcttgctga agatgtgctc catac 2455

```

<210> 739

<211> 2455

<212> DNA

<213> Homo sapiens

<400> 739

```

cagcttaaaa atggtttctt gaaatcagtg attagcattc actcaccagt acccctaacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttatttctgc 120
ttattgcttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagaggggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaaagatggt tctcagggtt ttcccttgacg atttctctct tttctgattc tgacaatggt 300
ttaaatacatt gtactgtggg tatcatttct ctgcatttat tttaccatc ttcccttcta 360
acttgctcta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcacgggtg gctcacatct 480
gtaatcccag cactttgggg aggtgagac ggggtgatca cttgaggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatcccg ttactaaaa atacaaaaat taccaggca 600
tggtggcggg cgctgtaat ccaggtact cgggaggctg agggaggaga atcgcttgaa 660
cctgggaggg tgaggaggga gaatcgctg aaccgggag gcagaggttg cagtgaaccg 720

```

```

agatcatggt gctgcactcc agcctgggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaaaacaaac aaacacagaga gattttgctg caatgtacaa ggagcaattt 840
gctccttttaa aaaaataaatt tttggccagg cacagtggct cacacctgta atcccagcac 900
tttggaagc caaggtgggt ggatcatttg aggtcaggag tttgagatca gcctggccaa 960
catggtgaaa cactatctct attaaaaata caaaaatgtg ctcagtgtgg tgggtgcacat 1020
ctgtaatctc agcctcccgc atagctggga ccacaggtat gcaccaccac acctagctaa 1080
ttttttagt tttagtagag atgggggtctc actatgttgc tcaggctggg ctaaaactcc 1140
tgggctccag caatccgcct gccttggcct cccaaagtgc tggggttaca ggcataagcc 1200
accacatcca gcctgccaca tacttttaaa ctatcaggtc tcatgagaac tcatgcacta 1260
tcacaagaat agcatgggga aaatccccc cataatccaa tcacctcca ccaggtctcc 1320
tcogacactg gggattgggt ggggacacag agccaaaccg tatcagatgc tgcaggggct 1380
ggggacactg agaccactca gacctgggt ctctgtcact cttctgggct ctgtctgtct 1440
ccaggacctc cctccccttc catggtatag aaggaaagt ctgtaagggt caaattgcac 1500
aggaactcct taagacatac atcatccact cagcagtttt aggttcgcag caaatggag 1560
tggaaggaa agaaatttcc tgtgcacccc tcccgcgtgt ctccgccata tcggcatcct 1620
gcatccagag tgggtggactg gttacaggct atgaacctac actgatgcgg caccaccacc 1680
cagagtccac aggttatgtt ggttcacatt tactcttgc gtggtatggt ctatagggtt 1740
ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtctttagg 1800
aatggacttg cttcaaagt gaggcaggca gatccttcag acgggtatat ggagccctgt 1860
tttcagttgc ttttctaatt ctctcttacc gtttacctca aaatcttcc gaggtctcgc 1920
ttccttttaa aatccttgc tactttgcag catcactctg acactccatt gattcctcag 1980
cacctactga ctacacggtt aggagtgc aa gggtagaatt catgttttat tcatctttg 2040
gtctgtagca ccagcaaaag tgcctagtaa atgcgcagta attgatttga cctctgaaca 2100
aatacacact gtactaagaa tctacacacc gaaagacaaa aacaagacaa atttgagtgc 2160
tacaggtgtc acgcttggca tcacacatgt gcctgtgtat tcccttaggt ggttaccagg 2220
agctctgcca ctgcatgtcc actagtgcg ggttcgctcc accacccag ctgggtagcc 2280
gctgctctca cataaggggt ccaattaaaa ttgccaggaa taaattcccc cggactttga 2340
cttctcaaga gctaagaagg tttgctgagt attctggcat gatgtttggt gatcaaacia 2400
ctgctggcca aaaaatgatga gtatttcccc ctcttgcctga agatgtgctc catac 2455

```

<210> 740

<211> 62

<212> PRT

<213> Homo sapiens

<400> 740

```

Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
              5                      10                      15

```

```

His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
              20                      25                      30

```

```

Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
              35                      40                      45

```

```

Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
              50                      55                      60

```

<210> 741

<211> 135

<212> PRT

<213> Homo sapiens

<400> 741

```

Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
              5                      10                      15

```


Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg
 20 25 30
 Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu
 35 40 45
 Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu
 50 55 60
 Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala
 65 70 75 80
 Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly
 85 90 95
 Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro
 100 105 110
 Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile
 115 120 125
 Leu Leu Asn Tyr Gln Val Ser
 130 135

<210> 742
 <211> 77
 <212> PRT
 <213> Homo sapiens

<400> 742
 Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro Ile Ile Gln
 5 10 15
 Ser Pro Pro Thr Arg Ser Pro Pro Thr Arg Gly Ile Gly Trp Gly His
 20 25 30
 Arg Ala Lys Pro Tyr Gln Met Leu Gln Gly Leu Gly Thr Leu Arg Pro
 35 40 45
 Leu Arg Pro Gly Val Ser Val Thr Leu Leu Gly Ser Val Cys Leu Gln
 50 55 60
 Asp Leu Pro Pro Leu Pro Trp Tyr Arg Arg Lys Val Leu
 65 70 75

<210> 743
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 743
 Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
 5 10 15
 Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
 20 25 30

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
50 55 60

<213> Homo sapiens

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
5 10 15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
20 25 30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
35 40 45
Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
50 55 60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
65 70 75

<213> Homo sapiens

Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp
5 10 15

Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu
20 25 30

Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly
35 40 45

Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp
50 55 60

Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys
65 70 75

<213> Homo sapiens

Met Leu Leu His Ser Ser Leu Val Asn Arg Ala Arg Leu Cys Leu Lys

				5					10					15				
Asn	Lys	Gln	Ile	Asn	Lys	Gln	Thr	Asn	Lys	Thr	Glu	Arg	Phe	Cys	Cys			
20								25					30					
Asn	Val	Gln	Gly	Ala	Ile	Cys	Ser	Phe	Lys	Lys	Ile	Ile	Phe	Gly	Gln			
35								40					45					
Ala	Gln	Trp	Leu	Thr	Pro	Val	Ile	Pro	Ala	Leu	Trp	Glu	Ala	Lys	Val			
50								55					60					
Gly	Gly	Ser	Phe	Glu	Val	Arg	Ser	Leu	Arg	Ser	Ala	Trp	Pro	Thr	Trp			
65								70					75					
												80						

<210> 749
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 749
 Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
 5 10 15
 Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
 20 25 30
 Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser
 35 40 45
 Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
 50 55 60

<210> 750
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 750
 Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
 5 10 15
 Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 20 25 30
 Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 35 40 45
 Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 50 55 60
 Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 65 70 75

<210> 751
 <211> 2479
 <212> DNA
 <213> Homo sapiens

<400> 751
 gtcatatatga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
 ctttgaactc aggggtcacca ccagctattg gaccttacta tgaaaacccat ggataccaac 120
 cggaaaaccc ctatcccgca cagccactg tggccccac tgtctacgag gtgcatccgg 180
 ctccagtacta cccgtccccc gtgccccagt acgccccgag ggctcctgacg caggcttcca 240
 accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
 agaaagcact gtgcatcacc ttgacctggt ggaccttccct cgtgggagct gcgctggccg 360
 ctggcctact ctggaagttc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
 cctcagggtac ctgcatcaac ccctctaact ggtgtgatgg cgtgtcacac tgccccggcg 480
 gggaggacga gaatcggtgt gttcgctctc acggaccaaa cttcctcctt cagatgtact 540
 catctcagag gaagtctgtg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600

```

ggggggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
ataaaaaaact gtaccacagt gatgcctgtt cttcaaaaagc agtgggtttct ttacgctgtt 780
tagcctgctg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840
cgctcccggg ggctggccc tggcaggtca gcctgcacgt ccagaacgtc cacgtgtgcg 900
gaggtcccat catcaccccc gagtggatcg tgacagccgc ccaactgctg gaaaaacctc 960
taacaatcc atggcatttg acggcatttg cggggatttt gagacaatct ttcattgttct 1020
atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080
agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gaactagtga 1140
aaccagtgtg tctgccccac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200
cgggtggggg ggccaccgag gagaaaggga agacctcaga agtgcagaac gctgccaagg 1260
tgcttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320
cagccatgat ctgtgccggc ttctgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380
gagggcctct ggtcacttcg aacaacaata tctggtggct gataggggat acaagctggg 1440
gttctggctg tgccaaagct tacagaccag gactgtacgg gaatgtgatg gtattcacgg 1500
actggattta tcgacaaatg aaggcaaacg gctaattccac atggtcttcg tccttgacgt 1560
cgttttaciaa gaaaacaatg gggctggttt tgcttccccg tgcattgattt actcttagag 1620
atgattcaga ggtcacttca tttttattaa acagtgaact tgcctggctt tggcactctc 1680
tgccatactg tgcaggctgc agtggctccc ctgcccagcc tgctctccct aacccttgt 1740
ccgcaagggg tgatggccgg ctggttggtg gcactggcgg tcaattgtgg aagggaagg 1800
gttgagggtt gccccattg agatcttctt gctgagtcct ttccaggggc caattttgga 1860
tgagcatgga gctgtcactt ctgagctgct ggatgacttg agatgaaaaa ggagagacat 1920
ggaaaggggg acagccaggt ggcacctgca gcggctgccc tctggggcca cttggtagt 1980
tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040
gatggtggcc agaaataaag ggaccagccc ttcattgggtg gtgacgtggt agtcacttgt 2100
aaggggaaca gaaacatttt tgttcttatg gggtgagaat atagacagtg cccttggtgc 2160
gaggggaagca attgaaaagg aactgcctt ggcactcct ggtgcaggtc tccacctgca 2220
cattgggtgg ggtcctggtg agggagactc agccttcttc ctcactcctc ctgacctgc 2280
tctagcacc ctggagagtg aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340
atgtcgccct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400
atgctcagtt taaggtacac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460
ctgagttcaa agccatctt
2479

```

<210> 752

<211> 492

<212> PRT

<213> Homo sapiens

<400> 752

```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
      5              10              15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
      20              25              30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
      35              40              45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
      50              55              60

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
      65              70              75              80

Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
      85              90              95

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys

```

100					105					110					
Cys	Ser	Asn	Ser	Gly	Ile	Glu	Cys	Asp	Ser	Ser	Gly	Thr	Cys	Ile	Asn
		115					120					125			
Pro	Ser	Asn	Trp	Cys	Asp	Gly	Val	Ser	His	Cys	Pro	Gly	Gly	Glu	Asp
		130				135					140				
Glu	Asn	Arg	Cys	Val	Arg	Leu	Tyr	Gly	Pro	Asn	Phe	Ile	Leu	Gln	Met
		145				150					155				160
Tyr	Ser	Ser	Gln	Arg	Lys	Ser	Trp	His	Pro	Val	Cys	Gln	Asp	Asp	Trp
			165						170					175	
Asn	Glu	Asn	Tyr	Gly	Arg	Ala	Ala	Cys	Arg	Asp	Met	Gly	Tyr	Lys	Asn
			180					185					190		
Asn	Phe	Tyr	Ser	Ser	Gln	Gly	Ile	Val	Asp	Asp	Ser	Gly	Ser	Thr	Ser
		195					200					205			
Phe	Met	Lys	Leu	Asn	Thr	Ser	Ala	Gly	Asn	Val	Asp	Ile	Tyr	Lys	Lys
		210					215					220			
Leu	Tyr	His	Ser	Asp	Ala	Cys	Ser	Ser	Lys	Ala	Val	Val	Ser	Leu	Arg
		225				230					235				240
Cys	Leu	Ala	Cys	Gly	Val	Asn	Leu	Asn	Ser	Ser	Arg	Gln	Ser	Arg	Ile
				245					250					255	
Val	Gly	Gly	Glu	Ser	Ala	Leu	Pro	Gly	Ala	Trp	Pro	Trp	Gln	Val	Ser
			260					265					270		
Leu	His	Val	Gln	Asn	Val	His	Val	Cys	Gly	Gly	Ser	Ile	Ile	Thr	Pro
		275					280					285			
Glu	Trp	Ile	Val	Thr	Ala	Ala	His	Cys	Val	Glu	Lys	Pro	Leu	Asn	Asn
		290				295					300				
Pro	Trp	His	Trp	Thr	Ala	Phe	Ala	Gly	Ile	Leu	Arg	Gln	Ser	Phe	Met
		305				310					315				320
Phe	Tyr	Gly	Ala	Gly	Tyr	Gln	Val	Gln	Lys	Val	Ile	Ser	His	Pro	Asn
			325					330					335		
Tyr	Asp	Ser	Lys	Thr	Lys	Asn	Asn	Asp	Ile	Ala	Leu	Met	Lys	Leu	Gln
			340					345					350		
Lys	Pro	Leu	Thr	Phe	Asn	Asp	Leu	Val	Lys	Pro	Val	Cys	Leu	Pro	Asn
		355					360					365			
Pro	Gly	Met	Met	Leu	Gln	Pro	Glu	Gln	Leu	Cys	Trp	Ile	Ser	Gly	Trp
		370				375					380				
Gly	Ala	Thr	Glu	Glu	Lys	Gly	Lys	Thr	Ser	Glu	Val	Leu	Asn	Ala	Ala
		385				390					395				400
Lys	Val	Leu	Leu	Ile	Glu	Thr	Gln	Arg	Cys	Asn	Ser	Arg	Tyr	Val	Tyr
				405				410						415	

Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
420 425 430

Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
435 440 445

Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
450 455 460

Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
465 470 475 480

Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly
485 490

<210> 753

<211> 683

<212> DNA

<213> Homo sapiens

<400> 753

```
gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaacccat ggataccaac 120
cggaaaaccc ctatcccgcg cagcccactg tggccccac tgtctacgag gtgcatccgg 180
ctcagtacta cccgtccccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
accccgctgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgaccctgg ggaccttcct cgtgggagct gcgctggccg 360
ctggcctact ctggaagtgc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
cctcagggtac ctgcatcaac cctctaaact ggtgtgatgg cgtgtcacac tgccccggcg 480
gggaggacga gaatcgggtgt gttcgccctc acggacaaaa cttcctcctt cagatgtact 540
catctcagag gaagtcctgg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600
gggcggcctg cagggacatg ggtataaga ataattttta ctctagccaa ggaatagtgg 660
atgacagcgg atccaccagc ttt                                     683
```

<210> 754

<211> 209

<212> PRT

<213> Homo sapiens

<400> 754

```
Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
1 5 10 15
Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
20 25 30
Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
35 40 45
Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
50 55 60
Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
65 70 75 80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
85 90 95
```

297

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
 100 105 110
 Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
 115 120 125
 Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
 130 135 140
 Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met
 145 150 155 160
 Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
 165 170 175
 Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
 180 185 190
 Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
 195 200 205
 Phe

<210> 755
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 755
 Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr
 1 5 10 15
 Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg
 20 25

<210> 756
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 756
 ggatccgccg ccaccatgtc actttctagc ctgct

35

<210> 757
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 757
 gtcgactcag ctggaccaca gccgcag

27

<210> 758
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 758
 agatccgcgcg ccaccatggg ctgcaggetg ctct

34

<210> 759
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> PCR primer

<400> 759
 gtgcactcag aaatccttcc tcttgac

27

<210> 760
 <211> 936
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...()
 <223> n = A,T,C or G

<400> 760
 atgggctgca ggctgntctg ctgtgcgggt ctctgtctcc tgggagcggg ccccatggaa 60
 acgggagttta cgcagacacc aagacacctg gtcattggga tgacaaataa gaagtctttg 120
 aaatgtgaac aacatctggg tcataacgct atgtattggg acaagcaaag tgctaagaag 180
 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240
 agtcgcttct cactgaatg ccccaacagc tctcacttat tcttcacct acacaccctg 300
 cagccagaag actcggccct gtatctctgc gccagcagcc aagaccggac aagcagctcc 360
 tacgagcagt acttcgggac gggcaccagg ctacagggtc cagaggacct gaaaaacgtg 420
 ttcaccaccg aggtcgctgt gtttgagcca tcagaagcag agatctcca caccacaaag 480
 gccacactgg tgtgcctggc cacaggcttc taccaccgac acgtggagct gagctggtgg 540
 gtgaatggga aggaggtgca cagtgggggtc agcacagacc cgcagccctc caaggagcag 600
 ccgcccctca atgactccag atactgcctg agcagccgcc tgagggtctc ggccaccttc 660
 tggcagaacc ccgcaacca ctccgctgt caagtccagt tctacgggt ctcgagaaat 720
 gacgagtggg ccaggatag ggccaaacct gtcaccaga tcgtcagcgc cgaggcctgg 780
 ggtagagcag actgtggtt cactccgag tcttaccagc aaggggtcct gtctgccacc 840
 atcctctatg agatcttgc aggggaaggcc acctgtatg ccgtgctggt cagtgccttc 900
 gtgctgatgg ccattggtcaa gagaaaggat ttctga 936

<210> 761
 <211> 834
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...()
 <223> n = A,T,C or G

<400> 761
 atgtcacttt ctagectgct naaggtgggt acagcttcac tgtggctagg acctggcatt 60
 gccacagaaga taactcaaac ccaaccagga atgttcgtgc aggaaaagga ggctgtgact 120
 ctggaactgca catatgacac cagtgatcaa agttatgggt tcttctggta caagcagccc 180

```

agcagtgggg aaatgatttt tcttatttat caggggtctt atgacgagca aaatgcaaca 240
gaaggtcgct actcattgaa tttccagaag gcaagaaaat cgcacaacct tgtcatctcc 300
gcttcacaac tgggggactc agcaatgtat ttctgtgcaa tgagagaggg cgcgggagga 360
ggaaacaaac tcacctttgg gacaggcact cagctaaaag tggaactcaa tatccagaac 420
cctgaccctg ccgtgtacca gctgagagac tctaaatcca gtgacaagtc tgtctgccta 480
ttcaccgatt ttgattctca aacaaatgtg tcacaaagta aggattctga tgtgtatata 540
acagacaaaa ctgtgctaga catgaggtct atggacttca agagcaacag tgctgtggcc 600
tggagcaaca aatctgactt tgcattgtgca aacgccttca acaacagcat tattccagaa 660
gacacettct tccccagccc agaaagttcc tgtgatgtca agctggtcga gaaaagcttt 720
gaaacagata cgaacctaaa ctttcaaaac ctgtcagtga ttgggttccg aatcctctct 780
ctgaaagtgg ccgggtttaa tctgctcatg acgctgcggc tgtggtccag ctga      834

```

<210> 762

<211> 311

<212> PRT

<213> Homo sapiens

<220>

<221> variant

<222> (1)...(311)

<223> Xaa = Any amino acid

<400> 762

```

Met Gly Cys Arg Leu Xaa Cys Cys Ala Val Leu Cys Leu Leu Gly Ala
                    5                                10                        15

```

```

Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met
                    20                                25                        30

```

```

Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His
                    35                                40                        45

```

```

Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu
                    50                                55                        60

```

```

Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro
                    65                                70                        75                        80

```

```

Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His
                    85                                90                        95

```

```

Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser
                    100                                105                        110

```

```

Ser Gln Asp Arg Thr Ser Ser Ser Tyr Glu Gln Tyr Phe Gly Pro Gly
                    115                                120                        125

```

```

Thr Arg Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu
                    130                                135                        140

```

```

Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys
                    145                                150                        155                        160

```

```

Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu
                    165                                170                        175

```

```

Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr
                    180                                185                        190

```

300

Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr
 195 200 205
 Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro
 210 215 220
 Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn
 225 230 235 240
 Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser
 245 250 255
 Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr
 260 265 270
 Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly
 275 280 285
 Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala
 290 295 300
 Met Val Lys Arg Lys Asp Phe
 305 310

<210> 763
 <211> 277
 <212> PRT
 <213> Homo sapiens

<400> 763
 Met Ser Leu Ser Ser Leu Leu Lys Val Val Thr Ala Ser Leu Trp Leu
 5 10 15
 Gly Pro Gly Ile Ala Gln Lys Ile Thr Gln Thr Gln Pro Gly Met Phe
 20 25 30
 Val Gln Glu Lys Glu Ala Val Thr Leu Asp Cys Thr Tyr Asp Thr Ser
 35 40 45
 Asp Gln Ser Tyr Gly Leu Phe Trp Tyr Lys Gln Pro Ser Ser Gly Glu
 50 55 60
 Met Ile Phe Leu Ile Tyr Gln Gly Ser Tyr Asp Glu Gln Asn Ala Thr
 65 70 75 80
 Glu Gly Arg Tyr Ser Leu Asn Phe Gln Lys Ala Arg Lys Ser Ala Asn
 85 90 95
 Leu Val Ile Ser Ala Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe Cys
 100 105 110
 Ala Met Arg Glu Gly Ala Gly Gly Gly Asn Lys Leu Thr Phe Gly Thr
 115 120 125
 Gly Thr Gln Leu Lys Val Glu Leu Asn Ile Gln Asn Pro Asp Pro Ala
 130 135 140

Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu
 145 150 155 160

Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser
 165 170 175

Asp Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp
 180 185 190

Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala
 195 200 205

Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe
 210 215 220

Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe
 225 230 235 240

Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe
 245 250 255

Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu
 260 265 270

Arg Leu Trp Ser Ser
 275

<210> 764

<211> 1536

<212> DNA

<213> Homo sapiens

<400> 764

```

atgtacaacc tggtgctgtc ctacgacaga catgggggacc acctgcagcc cctggacctc 60
gtgcccacac accagggtct cacccttttc aagctggctg gaggaggagg taacactgtg 120
atgtttcagc acctgatgca gaagcgggag cacaccaggt ggacgtatgg accactgacc 180
tcgactctct atgacctcac agagatcgac tcctcagggg atgagcagtc cctgctggaa 240
cttatcatca ccaccaagaa gcgggagggt cgccagatcc tggaccagac gccggtgaag 300
gagctggtga gcctcaagt gaagcgggtac gggcgggcgt acttctgcat gctgggtgcc 360
atatatctgc tgtacatcat ctgcttcacc atgtgctgca tctaccgccc cctcaagccc 420
aggaccaata accgcacgag cccccgggac aacacctctt tacagcagaa gctacttcag 480
gaagcctaca tgacctctaa ggacgatatc cggttggtcg gggagctggt gactgtcatt 540
ggggctatca tcatctgctt ggtagaggtt ccagacatct tcagaatggg ggtcactcgc 600
ttctttggac agaccatcct tggggggcca ttccatgtcc tcatcatcac ctatgccttc 660
atggtgctgg tgacctggt gatgcggctc atcagtgcca ggggggaggt ggtacctatg 720
tcctttgcac tcgtgctggg ctggtgcaac gtcattgtact tcgcccagag attccagatg 780
ctaggccctt tcacctcat gattcagaag atgatttttg ggcacctgat gcgattctgc 840
tggctgatgg ctgtggtcat cctgggcttt gcttcagcct tctatatcat cttccagaca 900
gaggaccccg aggagctagg ccacttctac gactacccca tggccctggt cagcaccttc 960
gagctgttcc ttacctcat cgatggccca gccaaactaca acgtggacct gcccttcatt 1020
tacagcatca cctatgctgc ctttgccatc atcgccacac tgcctcatgt caacctcttc 1080
attgccatga tggcgacac tcaactggcg gtggcccatg agcgggatga gctgtggagg 1140
gccagattg tggccaccac ggtgatgctg gaggcgaagc tgcctcgctg cctgtggcct 1200
cgctccggga tctgcggacg ggagtatggc ctgggagacc gctgggttct gcgggtggaa 1260
gacaggcaag atctcaaccg gcagcggatc caacgctacg cacaggcctt ccacaccg 1320
ggctctgagg atttgacaa agactcagtg gaaaaactag agctgggctg tcccttcagc 1380

```

```

ccccacctgt cccttccat gcccctcagtg tctcgaagta cctccccgag cagtgccaat 1440
tgggaaaggc ttgggcaagg gaccctgagg agagacctgc gtgggataat caacaggggt 1500
ctggaggacg gggagagctg ggaatatcag atctga 1536

```

<210> 765

<211> 1533

<212> DNA

<213> Homo sapiens

<400> 765

```

atgtacaacc tgttgcgtgc ctacgacaga catggggacc acctgcagcc cctggacctc 60
gtgcccatac accaggggtc cacccttttc aagctggctg gactggagg taacactgtg 120
atgtttcagc acctgatgca gaagcggaag cacaccagc ggacgtatgg accactgacc 180
tcgactctct atgacctcac agagatcgac tctcagggg atgagcagtc cctgctggaa 240
cttatcatca ccaccaagaa gcgggaggct cgcagatcc tggaccagac gccggtgaag 300
gagctgggtga gctcaagtg gaagcggtac gggcgccgt acttctgcat gctgggtgcc 360
atatatctgc tgtacatcat ctgcttcacc atgtgctgca tctaccgccc cctcaagccc 420
aggaccaata accgcacgag cccccgggac aacacctct tacagcagaa gctacttcag 480
gaagccatac tgaccctaa ggacgatac cggctggctg gggagctggt gactgtcatt 540
ggggctatca tcatcctgct ggtagagggt ccagacatct tcagaatggg ggtcactcgc 600
ttctttggac agaccatcct tgggggccc ttccatgtcc tcatcatcac ctatgccttc 660
atggtgctgg tgaccatggt gatgcggctc atcagtgcc a gcggggagggt ggtacctatg 720
tcctttgcac tcgtgctggg ctggtgcaac gtcattgact tcgcccagg attccagatg 780
ctaggccctc tcaccatcat gattcagaag atgatttttg gcgacctgat gcgattctgc 840
tggtgatgg ctgtggtcat cctgggcttt gcttcagcct tctatatcat ctccagaca 900
gaggaccccg aggagctagg ccacttctac gactacccca tggccctgtt cagcaccttc 960
gagctgttcc ttaccatcat cgaatggcca gccaaactaca acgtggacct gcccttcatt 1020
tacagcatca cctatgctgc ctttgccatc atcgccacac tgctcatgct caacctctc 1080
attgccatga tggcgacac tcaactggcg gtggcccatg agcgggatga gctgtggagg 1140
gccagattg tggccaccac ggtgatgctg gagcggaagc tgccctcgtg cctgtggcct 1200
cgctccggga tctgcggac ggagtatggc ctgggagacc gctgggttct gcgggtggaa 1260
gacaggcaag atctcaacc gcagcggatc caacgctacg cacaggcctt ccacaccgg 1320
ggctctgagg atttgacaa agactcagtg gaaaaactag agctgggctg tcccttcagc 1380
ccccacctgt cccttccat gccctcagtg tctcgaagta cctccccgag cagtgccaat 1440
tgggaaaggc ttgggcaagg gaccctgagg agagacctgc gtgggataat caacaggggt 1500
ctggaggacg gggagagctg ggaatatcag atc 1536

```

<210> 766

<211> 511

<212> PRT

<213> Homo sapiens

<400> 766

```

Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg His Gly Asp His Leu Gln
      5                      10                      15

Pro Leu Asp Leu Val Pro Asn His Gln Gly Leu Thr Pro Phe Lys Leu
      20                      25                      30

Ala Gly Val Glu Gly Asn Thr Val Met Phe Gln His Leu Met Gln Lys
      35                      40                      45

Arg Lys His Thr Gln Trp Thr Tyr Gly Pro Leu Thr Ser Thr Leu Tyr
      50                      55                      60

Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp Glu Gln Ser Leu Leu Glu
      65                      70                      75                      80

```

Leu	Ile	Ile	Thr	Thr	Lys	Lys	Arg	Glu	Ala	Arg	Gln	Ile	Leu	Asp	Gln
				85					90						
Thr	Pro	Val	Lys	Glu	Leu	Val	Ser	Leu	Lys	Trp	Lys	Arg	Tyr	Gly	Arg
				100					105						
Pro	Tyr	Phe	Cys	Met	Leu	Gly	Ala	Ile	Tyr	Leu	Leu	Tyr	Ile	Ile	Cys
				115					120						
Phe	Thr	Met	Cys	Cys	Ile	Tyr	Arg	Pro	Leu	Lys	Pro	Arg	Thr	Asn	Asn
				130					135						
Arg	Thr	Ser	Pro	Arg	Asp	Asn	Thr	Leu	Leu	Gln	Gln	Lys	Leu	Leu	Gln
				145					150						
Glu	Ala	Tyr	Met	Thr	Pro	Lys	Asp	Asp	Ile	Arg	Leu	Val	Gly	Glu	Leu
				165					170						
Val	Thr	Val	Ile	Gly	Ala	Ile	Ile	Ile	Leu	Leu	Val	Glu	Val	Pro	Asp
				180					185						
Ile	Phe	Arg	Met	Gly	Val	Thr	Arg	Phe	Phe	Gly	Gln	Thr	Ile	Leu	Gly
				195					200						
Gly	Pro	Phe	His	Val	Leu	Ile	Ile	Thr	Tyr	Ala	Phe	Met	Val	Leu	Val
				210					215						
Thr	Met	Val	Met	Arg	Leu	Ile	Ser	Ala	Ser	Gly	Glu	Val	Val	Pro	Met
				225					230						
Ser	Phe	Ala	Leu	Val	Leu	Gly	Trp	Cys	Asn	Val	Met	Tyr	Phe	Ala	Arg
				245					250						
Gly	Phe	Gln	Met	Leu	Gly	Pro	Phe	Thr	Ile	Met	Ile	Gln	Lys	Met	Ile
				260					265						
Phe	Gly	Asp	Leu	Met	Arg	Phe	Cys	Trp	Leu	Met	Ala	Val	Val	Ile	Leu
				275					280						
Gly	Phe	Ala	Ser	Ala	Phe	Tyr	Ile	Ile	Phe	Gln	Thr	Glu	Asp	Pro	Glu
				290					295						
Glu	Leu	Gly	His	Phe	Tyr	Asp	Tyr	Pro	Met	Ala	Leu	Phe	Ser	Thr	Phe
				305					310						
Glu	Leu	Phe	Leu	Thr	Ile	Ile	Asp	Gly	Pro	Ala	Asn	Tyr	Asn	Val	Asp
				325					330						
Leu	Pro	Phe	Met	Tyr	Ser	Ile	Thr	Tyr	Ala	Ala	Phe	Ala	Ile	Ile	Ala
				340					345						
Thr	Leu	Leu	Met	Leu	Asn	Leu	Leu	Ile	Ala	Met	Met	Gly	Asp	Thr	His
				355					360						
Trp	Arg	Val	Ala	His	Glu	Arg	Asp	Glu	Leu	Trp	Arg	Ala	Gln	Ile	Val
				370					375						
Ala	Thr	Thr	Val	Met	Leu	Glu	Arg	Lys	Leu	Pro	Arg	Cys	Leu	Trp	Pro

385 390 395 400
 Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly Leu Gly Asp Arg Trp Phe
 405 410 415
 Leu Arg Val Glu Asp Arg Gln Asp Leu Asn Arg Gln Arg Ile Gln Arg
 420 425 430
 Tyr Ala Gln Ala Phe His Thr Arg Gly Ser Glu Asp Leu Asp Lys Asp
 435 440 445
 Ser Val Glu Lys Leu Glu Leu Gly Cys Pro Phe Ser Pro His Leu Ser
 450 455 460
 Leu Pro Met Pro Ser Val Ser Arg Ser Thr Ser Arg Ser Ser Ala Asn
 465 470 475 480
 Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg Arg Asp Leu Arg Gly Ile
 485 490 495
 Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser Trp Glu Tyr Gln Ile
 500 505 510

 <210> 767
 <211> 134
 <212> PRT
 <213> Homo sapiens

 <400> 767
 Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg His Gly Asp His Leu Gln
 5 10 15
 Pro Leu Asp Leu Val Pro Asn His Gln Gly Leu Thr Pro Phe Lys Leu
 20 25 30
 Ala Gly Val Glu Gly Asn Thr Val Met Phe Gln His Leu Met Gln Lys
 35 40 45
 Arg Lys His Thr Gln Trp Thr Tyr Gly Pro Leu Thr Ser Thr Leu Tyr
 50 55 60
 Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp Glu Gln Ser Leu Leu Glu
 65 70 75 80
 Leu Ile Ile Thr Thr Lys Lys Arg Glu Ala Arg Gln Ile Leu Asp Gln
 85 90 95
 Thr Pro Val Lys Glu Leu Val Ser Leu Lys Trp Lys Arg Tyr Gly Arg
 100 105 110
 Pro Tyr Phe Cys Met Leu Gly Ala Ile Tyr Leu Leu Tyr Ile Ile Cys
 115 120 125
 Phe Thr Met Cys Cys Ile
 130

305

<210> 768

<211> 55

<212> PRT

<213> Homo sapiens

<400> 768

Ala Tyr Arg Pro Leu Lys Pro Arg Thr Asn Asn Arg Thr Ser Pro Arg
 5 10 15

Asp Asn Thr Leu Leu Gln Gln Lys Leu Leu Gln Glu Ala Tyr Met Thr
 20 25 30

Pro Lys Asp Asp Ile Arg Leu Val Gly Glu Leu Val Thr Val Ile Gly
 35 40 45

Ala Ile Ile Ile Leu Leu Val
 50 55

<210> 769

<211> 39

<212> PRT

<213> Homo sapiens

<400> 769

Glu Val Pro Asp Ile Phe Arg Met Gly Val Thr Arg Phe Phe Gly Gln
 5 10 15

Thr Ile Leu Gly Gly Pro Phe His Val Leu Ile Ile Thr Tyr Ala Phe
 20 25 30

Met Val Leu Val Thr Met Val
 35

<210> 770

<211> 19

<212> PRT

<213> Homo sapiens

<400> 770

Met Arg Leu Ile Ser Ala Ser Gly Glu Val Val Pro Met Ser Phe Ala
 5 10 15

Leu Val Leu

<210> 771

<211> 52

<212> PRT

<213> Homo sapiens

<400> 771

Gly Trp Cys Asn Val Met Tyr Phe Ala Arg Gly Phe Gln Met Leu Gly
 5 10 15

Pro Phe Thr Ile Met Ile Gln Lys Met Ile Phe Gly Asp Leu Met Arg

20 25 30
 Phe Cys Trp Leu Met Ala Val Val Ile Leu Gly Phe Ala Ser Ala Phe
 35 40 45
 Tyr Ile Ile Phe
 50

 <210> 772
 <211> 213
 <212> PRT
 <213> Homo sapiens

 <400> 772
 Gln Thr Glu Asp Pro Glu Glu Leu Gly His Phe Tyr Asp Tyr Pro Met
 5 10 15
 Ala Leu Phe Ser Thr Phe Glu Leu Phe Leu Thr Ile Ile Asp Gly Pro
 20 25 30
 Ala Asn Tyr Asn Val Asp Leu Pro Phe Met Tyr Ser Ile Thr Tyr Ala
 35 40 45
 Ala Phe Ala Ile Ile Ala Thr Leu Leu Met Leu Asn Leu Leu Ile Ala
 50 55 60
 Met Met Gly Asp Thr His Trp Arg Val Ala His Glu Arg Asp Glu Leu
 65 70 75 80
 Trp Arg Ala Gln Ile Val Ala Thr Thr Val Met Leu Glu Arg Lys Leu
 85 90 95
 Pro Arg Cys Leu Trp Pro Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly
 100 105 110
 Leu Gly Asp Arg Trp Phe Leu Arg Val Glu Asp Arg Gln Asp Leu Asn
 115 120 125
 Arg Gln Arg Ile Gln Arg Tyr Ala Gln Ala Phe His Thr Arg Gly Ser
 130 135 140
 Glu Asp Leu Asp Lys Asp Ser Val Glu Lys Leu Glu Leu Gly Cys Pro
 145 150 155 160
 Phe Ser Pro His Leu Ser Leu Pro Met Pro Ser Val Ser Arg Ser Thr
 165 170 175
 Ser Arg Ser Ser Ala Asn Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg
 180 185 190
 Arg Asp Leu Arg Gly Ile Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser
 195 200 205
 Trp Glu Tyr Gln Ile
 210

<210> 773
 <211> 1302
 <212> DNA
 <213> Homo sapiens

<400> 773
 tggacaaagg gggtcacaca ttcccttccat acggttgagc ctctacctgc ctggtgctgg 60
 tcacagttca gcttcttcat gatggtggat cccaatggca atgaatccag tgetacatac 120
 ttcatcctaa taggcctccc tggtttagaa gaggtcagc tctggttggc cttcccattg 180
 tgctccctct accttattgc tgtgctaggt aacttgacaa tcatctacat tgtgaggact 240
 gagcacagcc tgcattgagcc catgtatata ttcttttgc tgccttcagg cattgacatc 300
 ctcatctcca cctcatccat gcccaaaatg ctggccatct tctggttcaa ttccactacc 360
 atccagtttg atgcttgtct gctacagatg tttgccatcc actccttata tggcatggaa 420
 tccacagtgc tgcctggccat ggcttttgac cgctatgtgg ccatctgtca cccactgcgc 480
 catgccacag tacttacgtt gcctcgtgtc accaaaattg gtgtggctgc tgtggtgagg 540
 ggggctgcac tgatggcacc ccttcctgtc ttcatcaagc agctgccctt ctgccgctcc 600
 aatatacctt cccatttcta ctgcctacac caagatgtca tgaagctggc ctgtgatgat 660
 atccgggtca atgtcgtcta tggccttata gtcatcatct ccgccattgg cctggactca 720
 cttctcatct cttctcata tctgcttatt ctttaagactg tgttgggctt gacacgtgaa 780
 gccaggcca aggcatttgg cacttgcgtc tctcatgtgt gtgctgtgtt catattctat 840
 gtaccctttc ttggattgtc catggtgcat cgctttagca agcggcgtga ctctccgctg 900
 cccgtcatct tggccaatat ctatctgctg gttcctcctg tgctcaacc aattgtctat 960
 ggagtgaaga caaaggagat tcgacagcgc atccttcgac ttttccatgt ggccacacac 1020
 gcttcagagc cctaggtgtc agtgatcaaa ctcttttcc attcagagtc ctctgattca 1080
 gatttttaatg ttaacatttt ggaagacagt attcagaaaa aaaatttcct taataaaaaat 1140
 acaactcaga tccttcaaat atgaaactgg ttggggaatc tccatttttt caatattatt 1200
 ttcttctttg ttttcttgc acatataatt attaataccc tgactaggtt gtggttttag 1260
 ggttattact tttcatttta ccatgcagtc caaatctaaa ct 1302

<210> 774
 <211> 2061
 <212> DNA
 <213> Homo sapiens

<400> 774
 acgattcgac agcgcctcct tcgacttttc catgtggcca cacacgcttc agagccctag 60
 gtgtcagtag tcaaaacttct ttccatttca gactcctctg attcagattt taatgttaac 120
 attttggaag acagatttca gaaaaaaat ttcttaata aaaatacaac tcagatcctt 180
 caaatatgaa actggttggg gaatctccat tttttcaata ttattttctt ctttgttttc 240
 ttgtacata taattattaa taccctgact aggttgtggt tggagggtta ttacttttca 300
 ttttaccatg cagtccaaat ctaaaactgt tctactgatg gtttacagca ttctgagata 360
 agaattgtac atctagagaa catttgccaa aggcctaagc acggcaaagg aaaataaaca 420
 cagaatataa taaaatgaga taatctagct taaaactata acttctctt cagaactccc 480
 aaccacattg gatctcagaa aaatgctgtc ttcaaaatga cttctacaga gaagaaataa 540
 tttttcctct ggacactagc acttaagggg aagattggaa gtaaagcctt gaaaagagta 600
 catttaccta cgttaatgaa agttgacaca ctgttctgag agttttcaca gcatatggac 660
 cctgtttttc ctatttaatt ttcttatcaa ccttttaatt aggcagaagat attattagta 720
 cctcattgt agccatggga aaattgatgt tcagtgggga tcagtgaatt aaatggggtc 780
 atacaagtat aaaaattaaa aaaaaaggac ttcatgccc atctcatatg atgtggaaga 840
 actgttagag agaccaacag ggtagtgggt tagagatttc cagagtctta ctttttctag 900
 aggaggtatt taatttcttc tactcatcc agtggtgtat ttaggaattt cctggcaaca 960
 gaactcatgg ctttaatccc actagctatt gcttattgtc ctggtccaat tgccaattac 1020
 ctgtgtcttg gaagaagtga ttcttaggtt caccattatg gaagattctt attcagaaag 1080
 tctgcatagg gcttatagca agttatttat ttttaaaagt tccatagggt attctgatag 1140
 gcagtgggt tagggagcca ccagttatga tgggaagtat ggaatggcag gtcttgaaga 1200
 taacattggc cttttgagtg tgaactcgtag ctggaaagt agggaatctt caggaccatg 1260
 ctttatttgg ggctttgtgc agtatggaac agggactttg agaccaggaa agcaatctga 1320

```

ataggcatg ggaatcagga atttttgctt ctgaggggct attaccaagg gttaataggt 1380
ttcatcttca acaggatatg acaacagtgt taaccaagaa actcaaatta caaataactaa 1440
acatgtgat catatatgtg gtaagtttca ttttcttttt caatctcag gtccctgat 1500
atgattcct ataacatgct ttcacccct tttgtaatgg atatcatatt tggaaatgcc 1560
tatttaatac ttgtatttgc tgcctggactg taagcccatg agggcactgt ttattattga 1620
atgtcatctc tgttcacat tgaactgctt ttgtcatca ttgaatcccc cagcaaagtg 1680
cctagaacat aatagtgtt atgcttgaca ccggttattt ttcacaaac ctgattcctt 1740
atgtcctgaa cacatagcca ggcaattttc cagccttctt tgagttgggt attattaaat 1800
ctgggccatt acttccaatg tgagtggag tgacatgtgc aatttctata cctggctcat 1860
aaacccctcc catgtgcagc ctttcatgtt gacattaaat gtgacttggg aagctatgtg 1920
ctacacagag taaatcaca gaagcctgga tttctgaaaa aactgtgcag agccaaacct 1980
ctgcatttg caactccac ttgtatttgt acgaggcagt tggataagtg aaaaaataag 2040
tactatttgg tcaagtctct g
2061

```

<210> 775

<211> 957

<212> DNA

<213> Homo sapiens

<400> 775

```

atgatggtgg atcccaatgg caatgaatcc agtgetacat acttcacct aataggcctc 60
cctgggttag aagaggctca gttctggttg gccttcccat tgtgtccct ctaccttatt 120
gctgtgctag gtaacttgac aatcatctac attgtgcgga ctgagcacag cctgcatgag 180
cccatgtata tatttctttg catgctttca ggcattgaca tctcatctc cacctcatcc 240
atgccccaaa tgcctggccat cttctggttc aattccacta ccatccagtt tgatgcttgt 300
ctgctacaga tgtttgccat ccactcctta tctggcatgg aatccacagt gctgctggcc 360
atggcttttg accgctatgt ggcatctgt caccactgc gccatgccac agtacttacg 420
ttgctctgtg tcacccaaat tgggtgtggt gctgtggtgc ggggggctgc actgatggca 480
cccttctctg tcttcatcaa gcagctgccc ttctgcccgt ccaatatcct ttccattcc 540
tactgcttac accaagatgt catgaagctg gcctgtgatg atatccgggt caatgtcgtc 600
tatggcctta tgcctcatcat ctccgccatt ggctggact cacttctcat ctcttctca 660
tatctgctta ttcttaagac tgtgttgggc ttgacacgtg aagcccaggc caaggcattt 720
ggcacttgcg tctctcatgt gtgtgctgtg ttcataattct atgtacctt cattggattg 780
tccatggtgc atcgctttag caagcggcgt gactctccgc tgcccgtcat cttggccaat 840
atctatctgc tggttcctcc tgtgtccaac ccaattgtct atggagtga gacaaaggag 900
atcagacagc gcatccttcg acttttccat gtggccacac acgcttcaga gccttag 957

```

<210> 776

<211> 954

<212> DNA

<213> Homo sapiens

<400> 776

```

atgatggtgg atcccaatgg caatgaatcc agtgetacat acttcacct aataggcctc 60
cctgggttag aagaggctca gttctggttg gccttcccat tgtgtccct ctaccttatt 120
gctgtgctag gtaacttgac aatcatctac attgtgcgga ctgagcacag cctgcatgag 180
cccatgtata tatttctttg catgctttca ggcattgaca tctcatctc cacctcatcc 240
atgccccaaa tgcctggccat cttctggttc aattccacta ccatccagtt tgatgcttgt 300
ctgctacaga tgtttgccat ccactcctta tctggcatgg aatccacagt gctgctggcc 360
atggcttttg accgctatgt ggcatctgt caccactgc gccatgccac agtacttacg 420
ttgctctgtg tcacccaaat tgggtgtggt gctgtggtgc ggggggctgc actgatggca 480
cccttctctg tcttcatcaa gcagctgccc ttctgcccgt ccaatatcct ttccattcc 540
tactgcttac accaagatgt catgaagctg gcctgtgatg atatccgggt caatgtcgtc 600
tatggcctta tgcctcatcat ctccgccatt ggctggact cacttctcat ctcttctca 660
tatctgctta ttcttaagac tgtgttgggc ttgacacgtg aagcccaggc caaggcattt 720
ggcacttgcg tctctcatgt gtgtgctgtg ttcataattct atgtacctt cattggattg 780
tccatggtgc atcgctttag caagcggcgt gactctccgc tgcccgtcat cttggccaat 840

```

atctatctgc tggttcctcc tgtgctcaac ccaattgtct atggagtga gacaaaggag 900
 attcgacagc gcatccttcg acttttccat gtggccacac acgcttcaga gccc 954

<210> 777

<211> 318

<212> PRT

<213> Homo sapiens

<400> 777

Met	Met	Val	Asp	Pro	Asn	Gly	Asn	Glu	Ser	Ser	Ala	Thr	Tyr	Phe	Ile	
				5					10						15	
Leu	Ile	Gly	Leu	Pro	Gly	Leu	Glu	Glu	Ala	Gln	Phe	Trp	Leu	Ala	Phe	
			20					25						30		
Pro	Leu	Cys	Ser	Leu	Tyr	Leu	Ile	Ala	Val	Leu	Gly	Asn	Leu	Thr	Ile	
		35					40					45				
Ile	Tyr	Ile	Val	Arg	Thr	Glu	His	Ser	Leu	His	Glu	Pro	Met	Tyr	Ile	
	50						55				60					
Phe	Leu	Cys	Met	Leu	Ser	Gly	Ile	Asp	Ile	Leu	Ile	Ser	Thr	Ser	Ser	
	65				70					75					80	
Met	Pro	Lys	Met	Leu	Ala	Ile	Phe	Trp	Phe	Asn	Ser	Thr	Thr	Ile	Gln	
				85					90					95		
Phe	Asp	Ala	Cys	Leu	Leu	Gln	Met	Phe	Ala	Ile	His	Ser	Leu	Ser	Gly	
			100					105						110		
Met	Glu	Ser	Thr	Val	Leu	Leu	Ala	Met	Ala	Phe	Asp	Arg	Tyr	Val	Ala	
		115					120					125				
Ile	Cys	His	Pro	Leu	Arg	His	Ala	Thr	Val	Leu	Thr	Leu	Pro	Arg	Val	
	130					135					140					
Thr	Lys	Ile	Gly	Val	Ala	Ala	Val	Val	Arg	Gly	Ala	Ala	Leu	Met	Ala	
	145				150					155					160	
Pro	Leu	Pro	Val	Phe	Ile	Lys	Gln	Leu	Pro	Phe	Cys	Arg	Ser	Asn	Ile	
			165						170					175		
Leu	Ser	His	Ser	Tyr	Cys	Leu	His	Gln	Asp	Val	Met	Lys	Leu	Ala	Cys	
			180					185					190			
Asp	Asp	Ile	Arg	Val	Asn	Val	Val	Tyr	Gly	Leu	Ile	Val	Ile	Ile	Ser	
		195					200					205				
Ala	Ile	Gly	Leu	Asp	Ser	Leu	Leu	Ile	Ser	Phe	Ser	Tyr	Leu	Leu	Ile	
	210					215					220					
Leu	Lys	Thr	Val	Leu	Gly	Leu	Thr	Arg	Glu	Ala	Gln	Ala	Lys	Ala	Phe	
	225				230					235					240	
Gly	Thr	Cys	Val	Ser	His	Val	Cys	Ala	Val	Phe	Ile	Phe	Tyr	Val	Pro	
				245					250					255		

Phe Ile Gly Leu Ser Met Val His Arg Phe Ser Lys Arg Arg Asp Ser
 260 265 270

Pro Leu Pro Val Ile Leu Ala Asn Ile Tyr Leu Leu Val Pro Pro Val
 275 280 285

Leu Asn Pro Ile Val Tyr Gly Val Lys Thr Lys Glu Ile Arg Gln Arg
 290 295 300

Ile Leu Arg Leu Phe His Val Ala Thr His Ala Ser Glu Pro
 305 310 315

<210> 778

<211> 28

<212> PRT

<213> Homo sapiens

<400> 778

Met Met Val Asp Pro Asn Gly Asn Glu Ser Ser Ala Thr Tyr Phe Ile
 5 10 15

Leu Ile Gly Leu Pro Gly Leu Glu Glu Ala Gln Phe
 20 25

<210> 779

<211> 9

<212> PRT

<213> Homo sapiens

<400> 779

Arg Thr Glu His Ser Leu His Glu Pro
 5

<210> 780

<211> 21

<212> PRT

<213> Homo sapiens

<400> 780

Lys Met Leu Ala Ile Phe Trp Phe Asn Ser Thr Thr Ile Gln Phe Asp
 5 10 15

Ala Cys Leu Leu Gln
 20

<210> 781

<211> 20

<212> PRT

<213> Homo sapiens

<400> 781

Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg His Ala Thr Val Leu
 5 10 15

311

Thr Leu Pro Arg
20

<210> 782
<211> 37
<212> PRT
<213> Homo sapiens

<400> 782
Phe Ile Lys Gln Leu Pro Phe Cys Arg Ser Asn Ile Leu Ser His Ser
5 10 15
Tyr Cys Leu His Gln Asp Val Met Lys Leu Ala Cys Asp Asp Ile Arg
20 25 30

Val Asn Val Val Tyr
35

<210> 783
<211> 13
<212> PRT
<213> Homo sapiens

<400> 783
Lys Thr Val Leu Gly Leu Thr Arg Glu Ala Gln Ala Lys
5 10

<210> 784
<211> 10
<212> PRT
<213> Homo sapiens

<400> 784
Val His Arg Phe Ser Lys Arg Arg Asp Ser
5 10

<210> 785
<211> 22
<212> PRT
<213> Homo sapiens

<400> 785
Lys Thr Lys Glu Ile Arg Gln Arg Ile Leu Arg Leu Phe His Val Ala
5 10 15

Thr His Ala Ser Glu Pro
20

<210> 786
<211> 3245
<212> DNA
<213> Homo sapiens

ENCLOSURE NO. 117-34A

<210> 787
 <211> 1479
 <212> DNA
 <213> Homo sapiens

<400> 787
 atggctttga actcagggtc accaccagct attggacctt actatgaaaa ccatggatac 60
 caaccggaaa acccctatcc cgcacagccc actgtgtgcc ccactgtcta cgagggtgcat 120
 ccggctcagt actaccgctc ccccggtgcc cagtaagccc cgagggtcct gacgcaggct 180
 tccaaccccg tcgtctgcac gcagcccaaa tccccatccg ggacagtgtg cacctcaaag 240
 actaagaaaag cactgtgcat caccttgacc ctggggacct tcctcgtggg agctgcgctg 300
 gccgctggcc tactctggaa gttcatgggc agcaagtgtc ccaactctgg gatagagtgc 360
 gactcctcag gtacctgcat caaccctctt aactggtgtg atggcgtgtc aactgcccc 420
 ggcgggggagg acgagaatcg gtgtgttcgc ctctacggat caaacttcat ccttcagggtg 480
 tactcatctc agaggaagtc ctggcaccct gtgtgccaa acgactggaa cgagaactac 540
 gggcgggcg cctgcaggga catgggctat aagaataatt ttactctag ccaaggaata 600
 gtggatgaca gcggatccac cagctttatg aaactgaaca caagtgccgg caatgtcgat 660
 atctataaaa aactgtacca cagtgtatgcc tgttcttcaa aagcagtggg ttctttacgc 720
 tgtatagcct gcgggggtcaa cttgaactca agccgccaga gcaggattgt gggcgggcgag 780
 agcgcgctcc cgggggcctg gccctggcag gtcagcctgc acgtccagaa cgtccacgtg 840
 tgcggaggct ccacatcac ccccgagtgg atcgtgacag ccgcccactg cgtggaaaaa 900
 cctcttaaca atccatggca ttggacggca tttgcgggga ttttgagaca atctttcatg 960
 ttctatggag ccggatacca agtagaaaaa gtgatttctc atccaaatta tgactccaag 1020
 accaagaaca atgacattgc gctgatgaag ctgcagaagc ctctgacttt caacgacctt 1080
 gtgaaaccag tgtgtctgcc caaccaggc atgatgctgc agccagaaca gctctgctgg 1140
 atttccgggt ggggggccac cgaggagaaa gggaagacct cagaagtgtc gaacgctgcc 1200
 aaggtgcttc tcattgagac acagagatgc aacagcagat atgtctatga caacctgatc 1260
 acaccagcca tgatctgtgc cggcttctctg caggggaacg tcgattcttg ccagggtgac 1320
 agtggagggc ctctggtcac ttogaagaac aatatctggt ggctgatagg ggatacaagc 1380
 tggggttctg gctgtgccaa agcttacaga ccaggagtgt acgggaatgt gatgggtattc 1440
 acggactgga tttatcgaca aatgagggca gacggctaa 1479

<210> 788
 <211> 1476
 <212> DNA
 <213> Homo sapiens

<400> 788
 atggctttga actcagggtc accaccagct attggacctt actatgaaaa ccatggatac 60
 caaccggaaa acccctatcc cgcacagccc actgtgtgcc ccactgtcta cgagggtgcat 120
 ccggctcagt actaccgctc ccccggtgcc cagtaagccc cgagggtcct gacgcaggct 180
 tccaaccccg tcgtctgcac gcagcccaaa tccccatccg ggacagtgtg cacctcaaag 240
 actaagaaaag cactgtgcat caccttgacc ctggggacct tcctcgtggg agctgcgctg 300
 gccgctggcc tactctggaa gttcatgggc agcaagtgtc ccaactctgg gatagagtgc 360
 gactcctcag gtacctgcat caaccctctt aactggtgtg atggcgtgtc aactgcccc 420
 ggcgggggagg acgagaatcg gtgtgttcgc ctctacggat caaacttcat ccttcagggtg 480
 tactcatctc agaggaagtc ctggcaccct gtgtgccaa acgactggaa cgagaactac 540
 gggcgggcg cctgcaggga catgggctat aagaataatt ttactctag ccaaggaata 600
 gtggatgaca gcggatccac cagctttatg aaactgaaca caagtgccgg caatgtcgat 660
 atctataaaa aactgtacca cagtgtatgcc tgttcttcaa aagcagtggg ttctttacgc 720
 tgtatagcct gcgggggtcaa cttgaactca agccgccaga gcaggattgt gggcgggcgag 780
 agcgcgctcc cgggggcctg gccctggcag gtcagcctgc acgtccagaa cgtccacgtg 840
 tgcggaggct ccacatcac ccccgagtgg atcgtgacag ccgcccactg cgtggaaaaa 900
 cctcttaaca atccatggca ttggacggca tttgcgggga ttttgagaca atctttcatg 960
 ttctatggag ccggatacca agtagaaaaa gtgatttctc atccaaatta tgactccaag 1020
 accaagaaca atgacattgc gctgatgaag ctgcagaagc ctctgacttt caacgacctt 1080
 gtgaaaccag tgtgtctgcc caaccaggc atgatgctgc agccagaaca gctctgctgg 1140


```

atitccgggt ggggggcccac cgaggagaaa gggaagacct cagaagtgt gaacgtgtcc 1200
aaggtgcttc tcattgagac acagagatgc aacagcagat atgtctatga caacctgac 1260
acaccagcca tgatctgtgc cggcttcttg caggggaacg tcgattcttg ccaggggtgac 1320
agtggagggc ctctggtcac ttccaagaac aatatctggg ggctgatagg ggatacaagc 1380
tggggttctg gctgtgccaa agcttacaga ccaggagtgt acgggaatgt gatggtattc 1440
acggactgga tttatcgaca aatgagggca gacggc 1476

```

<210> 789

<211> 492

<212> PRT

<213> Homo sapiens

<400> 789

```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
      5              10              15
Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
      20              25              30
Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
      35              40              45
Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
      50              55              60
Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
      65              70              75              80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
      85              90              95
Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
      100             105             110
Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
      115             120             125
Pro Ser Asp Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
      130             135             140
Glu Asn Arg Cys Val Arg Leu Tyr Gly Ser Asn Phe Ile Leu Gln Val
      145             150             155             160
Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
      165             170             175
Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
      180             185             190
Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
      195             200             205
Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys
      210             215             220
Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg
      225             230             235             240
Cys Ile Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile
      245             250             255
Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser
      260             265             270
Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro
      275             280             285
Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn
      290             295             300
Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met
      305             310             315             320
Phe Tyr Gly Ala Gly Tyr Gln Val Glu Lys Val Ile Ser His Pro Asn
      325             330             335
Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln
      340             345             350

```

Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn
 355 360 365
 Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp
 370 375 380
 Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala
 385 390 395 400
 Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr
 405 410 415
 Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
 420 425 430
 Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
 435 440 445
 Lys Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
 450 455 460
 Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
 465 470 475 480
 Thr Asp Trp Ile Tyr Arg Gln Met Arg Ala Asp Gly
 485 490

<210> 790

<211> 100

<212> PRT

<213> Homo sapiens

<400> 790

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
 5 10 15
 Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
 20 25 30
 Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
 35 40 45
 Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
 50 55 60
 Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
 65 70 75 80
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
 85 90 95
 Gly Ala Ala Leu
 100

<210> 791

<211> 393

<212> PRT

<213> Homo sapiens

<400> 791

Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys Cys Ser Asn
 5 10 15
 Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn Pro Ser Asn
 20 25 30
 Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp Glu Asn Arg
 35 40 45
 Cys Val Arg Leu Tyr Gly Ser Asn Phe Ile Leu Gln Val Tyr Ser Ser
 50 55 60
 Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp Asn Glu Asn
 65 70 75 80

Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn Asn Phe Tyr
 85 90 95
 Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser Phe Met Lys
 100 105 110
 Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys Leu Tyr His
 115 120 125
 Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg Cys Ile Ala
 130 135 140
 Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile Val Gly Gly
 145 150 155 160
 Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser Leu His Val
 165 170 175
 Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro Glu Trp Ile
 180 185 190
 Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn Pro Trp His
 195 200 205
 Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met Phe Tyr Gly
 210 215 220
 Ala Gly Tyr Gln Val Glu Lys Val Ile Ser His Pro Asn Tyr Asp Ser
 225 230 235 240
 Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln Lys Pro Leu
 245 250 255
 Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn Pro Gly Met
 260 265 270
 Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp Gly Ala Thr
 275 280 285
 Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala Lys Val Leu
 290 295 300
 Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr Asp Asn Leu
 305 310 315 320
 Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly Asn Val Asp
 325 330 335
 Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser Lys Asn Asn
 340 345 350
 Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly Cys Ala Lys
 355 360 365
 Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe Thr Asp Trp
 370 375 380
 Ile Tyr Arg Gln Met Arg Ala Asp Gly
 385 390

<210> 792

<211> 595

<212> PRT

<213> Homo sapiens

<400> 792

Met Ser Phe Leu Asn Phe Thr Ala Val Leu Phe Ala Ala Ser Ser Ala
 1 5 10 15
 Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile
 20 25 30
 Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe Asp
 35 40 45
 Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe
 50 55 60
 Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser
 65 70 75 80

Leu	Glu	Lys	Arg	Glu	Ala	Glu	Ala	Met	Val	Leu	Gly	Ile	Gly	Pro	Val
				85					90					95	
Leu	Gly	Leu	Val	Cys	Val	Pro	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp
			100					105					110		
Arg	Gly	Arg	Tyr	Gly	Arg	Arg	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu
			115				120					125			
Gly	Ile	Leu	Leu	Ser	Leu	Phe	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala
			130			135					140				
Gly	Leu	Leu	Cys	Pro	Asp	Pro	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile
145					150					155					160
Leu	Gly	Val	Gly	Leu	Leu	Asp	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro
				165					170					175	
Leu	Glu	Ala	Leu	Leu	Ser	Asp	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg
			180					185					190		
Gln	Ala	Tyr	Ser	Val	Tyr	Ala	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu
		195					200					205			
Gly	Tyr	Leu	Leu	Pro	Ala	Ile	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro
		210				215						220			
Tyr	Leu	Gly	Thr	Gln	Glu	Glu	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile
225					230					235					240
Phe	Leu	Thr	Cys	Val	Ala	Ala	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala
				245						250				255	
Leu	Gly	Pro	Thr	Glu	Pro	Ala	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser
			260					265						270	
Pro	His	Cys	Cys	Pro	Cys	Arg	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly
		275					280					285			
Ala	Leu	Leu	Pro	Arg	Leu	His	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr
		290				295					300				
Leu	Arg	Arg	Leu	Phe	Val	Ala	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met
305					310					315					320
Thr	Phe	Thr	Leu	Phe	Tyr	Thr	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln
				325					330					335	
Gly	Val	Pro	Arg	Ala	Glu	Pro	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp
			340					345					350		
Glu	Gly	Val	Arg	Met	Gly	Ser	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile
		355					360					365			
Ser	Leu	Val	Phe	Ser	Leu	Val	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly
		370				375					380				
Thr	Arg	Ala	Val	Tyr	Leu	Ala	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala
385					390					395					400
Gly	Ala	Thr	Cys	Leu	Ser	His	Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala
				405					410					415	
Ala	Leu	Thr	Gly	Phe	Thr	Phe	Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr
			420					425					430		
Leu	Ala	Ser	Leu	Tyr	His	Arg	Glu	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr
		435					440					445			
Arg	Gly	Asp	Thr	Gly	Gly	Ala	Ser	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser
		450				455					460				
Phe	Leu	Pro	Gly	Pro	Lys	Pro	Gly	Ala	Pro	Phe	Pro	Asn	Gly	His	Val
465					470					475					480
Gly	Ala	Gly	Gly	Ser	Gly	Leu	Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly
				485					490					495	
Ala	Ser	Ala	Cys	Asp	Val	Ser	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr
			500					505					510		
Glu	Ala	Arg	Val	Val	Pro	Gly	Arg	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile
		515					520					525			
Leu	Asp	Ser	Ala	Phe	Leu	Leu	Ser	Gln	Val	Ala	Pro	Ser	Leu	Phe	Met
							535					540			

Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser
545 550 555 560
Ala Ala Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val
565 570 575
Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala Gly Gly His His His
580 585 590
His His His
595

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51633 A3

(51) International Patent Classification: **C12N 15/12**,
15/11, 1/21, 5/10, C07K 14/47, 16/18, 19/00, A61K 38/17,
48/00, G01N 33/68, C12Q 1/68, C12N 5/08

(21) International Application Number: PCT/US01/01574

(22) International Filing Date: 16 January 2001 (16.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/488,672 14 January 2000 (14.01.2000) US

(71) Applicant, for all designated States except US: **CORINA CORPORATION** [US/US], 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US)

(72) Inventors: and


(75) Inventors/Applicants, for US only: **XU, Jiangchun** [US/US], 18808 S.E. 43rd Place, Bellevue, WA 98006 (US); **DILLON, David, C.** [US/US], 18112 N.W. Montreux Drive, Issaquah, WA 98027 (US); **MITCHAM,**

Jennifer, L. [US/US], 16677 N.E. 88th Street, Redmond, WA 98052 (US); **HARLOCKER, Susan, L.** [US/US], 7522 13th Avenue W., Seattle, WA 98117 (US); **JIANG, Yuqiu** [CN/US], 5001 South 232nd Street, Kent, WA 98032 (US); **REED, Steven, G.** [US/US], 2843 122nd Place N.E., Bellevue, WA 98005 (US); **KALOS, Michael, D.** [US/US], 8116 Dayton Ave., N., Seattle, WA 98103 (US); **FANGER, Gary, Richard** [US/US], 15906 29th Drive S.E., Mill Creek, WA 98012 (US); **DAY, Craig, H.** [US/US], 11501 Stone Ave., N., C122, Seattle, WA 98133 (US); **RETTTER, Marc, W.** [US/US], 33402 N.E. 43rd Place, Carnation, WA 98104 (US); **STOLK, John, A.** [US/US], 7436 Northeast 144th Place, Bothell, WA 98011 (US); **SKEIKY, Yasir, A.W.** [LB/US], 15106 S.E. 47th Place, Bellevue, WA 98006 (US); **WANG, Aijun** [CN/US], 3106 213th Place S.E., Issaquah, WA 98029 (US); **MEAGHER, Madeleine, Joy** [US/US], 507 N.E. 71st, #1, Seattle, WA 98115 (US).

(74) Agents: **POTTER, Jane, E.R.**; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 et al. (US).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER



(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

WO 01/51633 A3



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report:

20 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Inter. Patent Application No.

PCT/US 01/01574

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/11 C12N1/21 C12N5/10 C07K14/47
 C07K16/18 C07K19/00 A61K38/17 A61K48/00 G01N33/68
 C12Q1/68 C12N5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched - classification system followed by classification symbols.

IPC 7 C12N A61K C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used):

EPO-Internal, EMBL, BIOSIS, WPI Data, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
----------	--	-----------------------

X	WO 98 37093 A (CORIXA CORP) 27 August 1998 (1998-08-27)	1-5,7,9, 12-14
Y	the whole document	6,10,11, 15-18

X	WO 98 37418 A (CORIXA CORP) 27 August 1998 (1998-08-27)	1-6,9, 15-17
Y	the whole document	6,15-17

A	WO 97 33909 A (CORIXA CORP) 18 September 1997 (1997-09-18)	

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search:

4 September 2001

Date of mailing of the international search report

10.01.02

Name and mailing address of the ISA

European Patent Office - P.B. 5518 Patentaan 2
 NL-2280 HV Rijswijk
 Tel: (+31-70) 340-2040 Ex. 11651 epo.nl
 Fax: (+31-70) 340-3016

Authorized officer

VAN DER SCHAAL C.A.

Form PCT/ISA 210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/US 01/01574

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SJOGREN H O: "Therapeutic immunization against cancer antigens using genetically engineered cells" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV. NL, vol. 3, no. 3, 1 October 1997 (1997-10-01), pages 161-172, XP004097000 ISSN: 1380-2933 the whole document ---	10,11,18
P,X	WO 00 04149 A (CORIXA CORP) 27 January 2000 (2000-01-27) the whole document ---	1-7,9-18
E	WO 01 25272 A (CORIXA CORP ; REED STEVEN G (US); XU JIANGCHUN (US); CHEEVER MARTIN) 12 April 2001 (2001-04-12) SEQ ID NO 1 claims ---	1-7,9-18
E	WO 01 34802 A (HARLOCKER SUSAN L ; CORIXA CORP (US); DAY CRAIG H (US); JIANG YUQIU) 17 May 2001 (2001-05-17) SEQ ID NO 1 claims -----	1-7,9-18

Form PCT/ISA 210 (continuation of second sheet) (July 1992)

page 2 of 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/01574

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 10 13 14 and 18 are (partially) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

Claims 1-7, 9-18 partially.
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: Claims 1-7 9-18 partially

A polypeptide comprising at least an immunogenic portion of a prostate tumor protein encoded by SEQ ID 1 (according to the Description of the Sequence Identifiers), fragments and variants thereof, fusion proteins comprising it, polynucleotides or oligonucleotides derived therefrom, antibodies binding to the polypeptide, their use in the treatment of cancer, in methods for diagnosing cancer, or for expanding and/or stimulating T-cells.

2. Claims: Inventions 2-527: Claims 1-18 partially and as far as applicable

As for subject 1 but concerning respectively SEQ IDs
2-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328,
330, 332-335, 340-375, 381, 382, 384-476, 524, 526, 530, 531, 533, 535
536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-6
55, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 76
5, 773-776 and 786-788

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 01/01574

Patent document cited in search report		Publication date	Patent family members)	Publication date
WO 9837093	A	27-08-1998	US 6261562 B1	17-07-2001
			AU 731840 B2	05-04-2001
			AU 6181898 A	09-09-1998
			BR 9808881 A	11-09-2001
			CN 1252837 T	10-05-2000
			EP 1005546 A2	07-06-2000
			HU 0002095 A2	28-10-2000
			NO 994069 A	22-10-1999
			PL 335348 A1	25-04-2000
			TR 9902053 T2	21-04-2000
			US 6262245 B1	17-07-2001
			WO 9837093 A2	27-08-1998
			US 6329505 B1	11-12-2001
			ZA 9801585 A	04-09-1998
WO 9837418	A	27-08-1998	AU 6536898 A	09-09-1998
			BR 9807734 A	31-10-2000
			EP 0972201 A2	19-01-2000
			JP 2001513886 T	04-09-2001
			WO 9837418 A2	27-08-1998
			ZA 9801536 A	08-01-1999
WO 9733909	A	18-09-1997	AU 728186 B2	04-01-2001
			AU 2329597 A	01-10-1997
			BR 9708082 A	27-07-1999
			CA 2249742 A1	18-09-1997
			EP 0914335 A2	12-05-1999
			NO 984229 A	13-11-1998
			WO 9733909 A2	18-09-1997
			US 6034218 A	07-03-2000
WO 0004149	A	27-01-2000	AU 5314899 A	07-02-2000
			CN 1315998 T	03-10-2001
			EP 1097208 A2	09-05-2001
			NO 20010196 A	12-03-2001
			WO 0004149 A2	27-01-2000
			US 6329505 B1	11-12-2001
WO 0125272	A	12-04-2001	AU 7994200 A	10-05-2001
			WO 0125272 A2	12-04-2001
WO 0134802	A	17-05-2001	US 6329505 B1	11-12-2001
			AU 1656501 A	06-06-2001
			AU 6158700 A	30-01-2001
			WO 0104143 A2	18-01-2001
			WO 0134802 A2	17-05-2001

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2001 (19.07.2001)

(10) International Publication Number
PCT
WO 01/051633 A3

(51) International Patent Classification: C12N 15/12,
15/11, 1/21, 5/10, C07K 14/47, 16/18, 19/00, A61K 38/17,
48/00, G01N 33/68, C12Q 1/68, C12N 5/08

(21) International Application Number: PCT/US01/01574

(22) International Filing Date: 16 January 2001 (16.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/483,672 14 January 2000 (14.01.2000) US

(71) Applicant (for all designated States except US): CORIXA
CORPORATION [US/US]: 1124 Columbia Street, Suite
200, Seattle, WA 98104 (US)


(72) Inventors; and

(75) Inventors/Applicants (for US only): XU, Jiangchun
[US/US]: 15805 S.E. 43rd Place, Bellevue, WA 98006

(US). DILLON, Davin, C. [US/US]: 18112 N.W. Mont-
treux Drive, Issaquah, WA 98027 (US). MITCHAM,
Jennifer, L. [US/US]: 16677 N.E. 88th Street, Redmond,
WA 98052 (US). HARLOCKER, Susan, L. [US/US]:
7522 13th Avenue W., Seattle, WA 98117 (US). JIANG,
Yugu [CN/US]: 5001 South 232nd Street, Kent, WA
98032 (US). REED, Steven, G. [US/US]: 2843 122nd
Place N.E., Bellevue, WA 98005 (US). KALOS, Michael,
D. [US/US]: 8116 Dayton Ave. N., Seattle, WA 98103
(US). FANGER, Gary, Richard [US/US]: 15906 29th
Drive S.E., Mill Creek, WA 98012 (US). DAY, Craig,
H. [US/US]: 11501 Stone Ave. N., C122, Seattle, WA
98133 (US). RETTER, Marc, W. [US/US]: 33402 N.E.
43rd Place, Carnation, WA 98104 (US). STOLK, John,
A. [US/US]: 7436 Northeast 144th Place, Bothell, WA
98011 (US). SKEIKY, Yasir, A.W. [LB/US]: 15106 S.E.
47th Place, Bellevue, WA 98006 (US). WANG, Aijun
[CN/US]: 3106 213th Place S.E., Issaquah, WA 98029
(US). MEAGHER, Madeleine, Joy [US/US]: 507 N.E.
71st, #1, Seattle, WA 98115 (US).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER



(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

WO 01/051633 A3



(74) **Agents:** POTTER, Jane, E.R., Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 et al. (US).

Published:

with international search report

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(88) **Date of publication of the international search report:**

20 June 2002

(48) **Date of publication of this corrected version:**

31 October 2002

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(15) **Information about Correction:**

see PCT Gazette No. 44/2002 of 31 October 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER

5 TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to therapy and diagnosis of cancer, such as prostate cancer. The invention is more specifically related to polypeptides, comprising at least a portion of a prostate-specific protein, and to polynucleotides encoding such polypeptides. Such polypeptides and polynucleotides
10 are useful in pharmaceutical compositions, *e.g.*, vaccines, and other compositions for the diagnosis and treatment of prostate cancer.

BACKGROUND OF THE INVENTION

Cancer is a significant health problem throughout the world. Although Cancer is a significant health problem throughout the world. Although advances have
15 been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention or treatment is currently available. Current therapies, which are generally based on a combination of chemotherapy or surgery and radiation, continue to prove inadequate in many patients.

Prostate cancer is the most common form of cancer among males, with
20 an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.

25 In spite of considerable research into therapies for the disease, prostate cancer remains difficult to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins - prostate specific antigen (PSA)

and prostatic acid phosphatase (PAP) - have limited therapeutic and diagnostic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with prostate volume, and do not indicate the level of metastasis.

In spite of considerable research into therapies for these and other cancers, prostate cancer remains difficult to diagnose and treat effectively. Accordingly, there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

10 SUMMARY OF THE INVENTION

In one aspect, the present invention provides polynucleotide compositions comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375,

381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, under moderately stringent conditions;

5 (e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

10 (f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

15 (g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

20 In one preferred embodiment, the polynucleotide compositions of the invention are expressed in at least about 20%, more preferably in at least about 30%, and most preferably in at least about 50% of prostate tissue samples tested, at a level that is at least about 2-fold, preferably at least about 5-fold, and most preferably at least about 10-fold higher than that for other normal tissues.

25 The present invention, in another aspect, provides polypeptide compositions comprising an amino acid sequence that is encoded by a polynucleotide sequence described above.

The present invention further provides polypeptide compositions comprising an amino acid sequence selected from the group consisting of sequences
30 recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383,

477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

In certain preferred embodiments, the polypeptides and/or
5 polynucleotides of the present invention are immunogenic, *i.e.*, they are capable of eliciting an immune response, particularly a humoral and/or cellular immune response, as further described herein.

The present invention further provides fragments, variants and/or derivatives of the disclosed polypeptide and/or polynucleotide sequences, wherein the
10 fragments, variants and/or derivatives preferably have a level of immunogenic activity of at least about 50%, preferably at least about 70% and more preferably at least about 90% of the level of immunogenic activity of a polypeptide sequence set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-
15 629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 or 789-791, or a polypeptide sequence encoded by a polynucleotide sequence set forth in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626,
20 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

The present invention further provides polynucleotides that encode a polypeptide described above, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

25 Within other aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

Within a related aspect of the present invention, pharmaceutical compositions, *e.g.*, vaccine compositions, are provided for prophylactic or therapeutic
30 applications. Such compositions generally comprise an immunogenic polypeptide or

polynucleotide of the invention and an immunostimulant, such as an adjuvant, together with a physiologically acceptable carrier.

The present invention further provides pharmaceutical compositions that comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to
5 a polypeptide of the present invention, or a fragment thereof; and (b) a physiologically acceptable carrier.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) a pharmaceutically acceptable carrier or excipient. Illustrative
10 antigen presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

Within related aspects, pharmaceutical compositions are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

15 The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, *e.g.*, vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. The fusions proteins may comprise multiple immunogenic
20 polypeptides or portions/variants thereof, as described herein, and may further comprise one or more polypeptide segments for facilitating and/or enhancing the expression, purification and/or immunogenicity of the polypeptide(s).

Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human
25 patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

Within further aspects, the present invention provides methods for
30 inhibiting the development of a cancer in a patient, comprising administering to a

patient a pharmaceutical composition as recited above. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

The present invention further provides, within other aspects, methods for
5 removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the polypeptide from the sample.

Within related aspects, methods are provided for inhibiting the
10 development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a
15 polynucleotide encoding such a polypeptide; and (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

Within further aspects, the present invention provides methods for
20 inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with one or more of: (i) a polypeptide
25 comprising at least an immunogenic portion of polypeptide disclosed herein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

Within further aspects, the present invention provides methods for determining the presence or absence of a cancer, preferably a prostate cancer, in a patient comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody.

The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide of the present invention, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to an inventive polynucleotide, or a complement of such a polynucleotide.

In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

Within further aspects, the present invention provides antibodies, such as monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

Figure 1 illustrates the ability of T cells to kill fibroblasts expressing the representative prostate-specific polypeptide P502S, as compared to control fibroblasts. The percentage lysis is shown as a series of effector:target ratios, as indicated.

Figures 2A and 2B illustrate the ability of T cells to recognize cells expressing the representative prostate-specific polypeptide P502S. In each case, the number of γ -interferon spots is shown for different numbers of responders. In Figure 2A, data is presented for fibroblasts pulsed with the P2S-12 peptide, as compared to fibroblasts pulsed with a control E75 peptide. In Figure 2B, data is presented for fibroblasts expressing P502S, as compared to fibroblasts expressing HER-2/*neu*.

Figure 3 represents a peptide competition binding assay showing that the P1S#10 peptide, derived from P501S, binds HLA-A2. Peptide P1S#10 inhibits HLA-A2 restricted presentation of fluM58 peptide to CTL clone D150M58 in TNF release

bioassay. D150M58 CTL is specific for the HLA-A2 binding influenza matrix peptide fluM58.

Figure 4 illustrates the ability of T cell lines generated from P1S#10 immunized mice to specifically lyse P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat A2Kb targets, as compared to EGFP-transduced Jurkat A2Kb. The percent lysis is shown as a series of effector to target ratios, as indicated.

Figure 5 illustrates the ability of a T cell clone to recognize and specifically lyse Jurkat A2Kb cells expressing the representative prostate-specific polypeptide P501S, thereby demonstrating that the P1S#10 peptide may be a naturally processed epitope of the P501S polypeptide.

Figures 6A and 6B are graphs illustrating the specificity of a CD8⁺ cell line (3A-1) for a representative prostate-specific antigen (P501S). Figure 6A shows the results of a ⁵¹Cr release assay. The percent specific lysis is shown as a series of effector:target ratios, as indicated. Figure 6B shows the production of interferon-gamma by 3A-1 cells stimulated with autologous B-LCL transduced with P501S, at varying effector:target ratios as indicated.

Figure 7 is a Western blot showing the expression of P501S in baculovirus.

Figure 8 illustrates the results of epitope mapping studies on P501S.

Figure 9 is a schematic representation of the P501S protein showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Figure 10 is a genomic map showing the location of the prostate genes P775P, P704P, B305D, P712P and P774P within the Cat Eye Syndrome region of chromosome 22q11.2

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S.

SEQ ID NO: 1 is the determined cDNA sequence for F1-13

SEQ ID NO: 2 is the determined 3' cDNA sequence for F1-12

SEQ ID NO: 3 is the determined 5' cDNA sequence for F1-12

SEQ ID NO: 4 is the determined 3' cDNA sequence for F1-16
SEQ ID NO: 5 is the determined 3' cDNA sequence for H1-1
SEQ ID NO: 6 is the determined 3' cDNA sequence for H1-9
SEQ ID NO: 7 is the determined 3' cDNA sequence for H1-4
5 SEQ ID NO: 8 is the determined 3' cDNA sequence for J1-17
SEQ ID NO: 9 is the determined 5' cDNA sequence for J1-17
SEQ ID NO: 10 is the determined 3' cDNA sequence for L1-12
SEQ ID NO: 11 is the determined 5' cDNA sequence for L1-12
SEQ ID NO: 12 is the determined 3' cDNA sequence for N1-1862
10 SEQ ID NO: 13 is the determined 5' cDNA sequence for N1-1862
SEQ ID NO: 14 is the determined 3' cDNA sequence for J1-13
SEQ ID NO: 15 is the determined 5' cDNA sequence for J1-13
SEQ ID NO: 16 is the determined 3' cDNA sequence for J1-19
SEQ ID NO: 17 is the determined 5' cDNA sequence for J1-19
15 SEQ ID NO: 18 is the determined 3' cDNA sequence for J1-25
SEQ ID NO: 19 is the determined 5' cDNA sequence for J1-25
SEQ ID NO: 20 is the determined 5' cDNA sequence for J1-24
SEQ ID NO: 21 is the determined 3' cDNA sequence for J1-24
SEQ ID NO: 22 is the determined 5' cDNA sequence for K1-58
20 SEQ ID NO: 23 is the determined 3' cDNA sequence for K1-58
SEQ ID NO: 24 is the determined 5' cDNA sequence for K1-63
SEQ ID NO: 25 is the determined 3' cDNA sequence for K1-63
SEQ ID NO: 26 is the determined 5' cDNA sequence for L1-4
SEQ ID NO: 27 is the determined 3' cDNA sequence for L1-4
25 SEQ ID NO: 28 is the determined 5' cDNA sequence for L1-14
SEQ ID NO: 29 is the determined 3' cDNA sequence for L1-14
SEQ ID NO: 30 is the determined 3' cDNA sequence for J1-12
SEQ ID NO: 31 is the determined 3' cDNA sequence for J1-16
SEQ ID NO: 32 is the determined 3' cDNA sequence for J1-21
30 SEQ ID NO: 33 is the determined 3' cDNA sequence for K1-48

- SEQ ID NO: 34 is the determined 3' cDNA sequence for K1-55
SEQ ID NO: 35 is the determined 3' cDNA sequence for L1-2
SEQ ID NO: 36 is the determined 3' cDNA sequence for L1-6
SEQ ID NO: 37 is the determined 3' cDNA sequence for N1-1858
5 SEQ ID NO: 38 is the determined 3' cDNA sequence for N1-1860
SEQ ID NO: 39 is the determined 3' cDNA sequence for N1-1861
SEQ ID NO: 40 is the determined 3' cDNA sequence for N1-1864
SEQ ID NO: 41 is the determined cDNA sequence for P5
SEQ ID NO: 42 is the determined cDNA sequence for P8
10 SEQ ID NO: 43 is the determined cDNA sequence for P9
SEQ ID NO: 44 is the determined cDNA sequence for P18
SEQ ID NO: 45 is the determined cDNA sequence for P20
SEQ ID NO: 46 is the determined cDNA sequence for P29
SEQ ID NO: 47 is the determined cDNA sequence for P30
15 SEQ ID NO: 48 is the determined cDNA sequence for P34
SEQ ID NO: 49 is the determined cDNA sequence for P36
SEQ ID NO: 50 is the determined cDNA sequence for P38
SEQ ID NO: 51 is the determined cDNA sequence for P39
SEQ ID NO: 52 is the determined cDNA sequence for P42
20 SEQ ID NO: 53 is the determined cDNA sequence for P47
SEQ ID NO: 54 is the determined cDNA sequence for P49
SEQ ID NO: 55 is the determined cDNA sequence for P50
SEQ ID NO: 56 is the determined cDNA sequence for P53
SEQ ID NO: 57 is the determined cDNA sequence for P55
25 SEQ ID NO: 58 is the determined cDNA sequence for P60
SEQ ID NO: 59 is the determined cDNA sequence for P64
SEQ ID NO: 60 is the determined cDNA sequence for P65
SEQ ID NO: 61 is the determined cDNA sequence for P73
SEQ ID NO: 62 is the determined cDNA sequence for P75
30 SEQ ID NO: 63 is the determined cDNA sequence for P76

SEQ ID NO: 64 is the determined cDNA sequence for P79

SEQ ID NO: 65 is the determined cDNA sequence for P84

SEQ ID NO: 66 is the determined cDNA sequence for P68

SEQ ID NO: 67 is the determined cDNA sequence for P80 (also referred

5 to as P704P)

SEQ ID NO: 68 is the determined cDNA sequence for P82

SEQ ID NO: 69 is the determined cDNA sequence for U1-3064

SEQ ID NO: 70 is the determined cDNA sequence for U1-3065

SEQ ID NO: 71 is the determined cDNA sequence for V1-3692

10 SEQ ID NO: 72 is the determined cDNA sequence for 1A-3905

SEQ ID NO: 73 is the determined cDNA sequence for V1-3686

SEQ ID NO: 74 is the determined cDNA sequence for R1-2330

SEQ ID NO: 75 is the determined cDNA sequence for 1B-3976

SEQ ID NO: 76 is the determined cDNA sequence for V1-3679

15 SEQ ID NO: 77 is the determined cDNA sequence for 1G-4736

SEQ ID NO: 78 is the determined cDNA sequence for 1G-4738

SEQ ID NO: 79 is the determined cDNA sequence for 1G-4741

SEQ ID NO: 80 is the determined cDNA sequence for 1G-4744

SEQ ID NO: 81 is the determined cDNA sequence for 1G-4734

20 SEQ ID NO: 82 is the determined cDNA sequence for 1H-4774

SEQ ID NO: 83 is the determined cDNA sequence for 1H-4781

SEQ ID NO: 84 is the determined cDNA sequence for 1H-4785

SEQ ID NO: 85 is the determined cDNA sequence for 1H-4787

SEQ ID NO: 86 is the determined cDNA sequence for 1H-4796

25 SEQ ID NO: 87 is the determined cDNA sequence for 1I-4807

SEQ ID NO: 88 is the determined cDNA sequence for 1I-4810

SEQ ID NO: 89 is the determined cDNA sequence for 1I-4811

SEQ ID NO: 90 is the determined cDNA sequence for 1J-4876

SEQ ID NO: 91 is the determined cDNA sequence for 1K-4884

30 SEQ ID NO: 92 is the determined cDNA sequence for 1K-4896

- SEQ ID NO: 93 is the determined cDNA sequence for 1G-4761
SEQ ID NO: 94 is the determined cDNA sequence for 1G-4762
SEQ ID NO: 95 is the determined cDNA sequence for 1H-4766
SEQ ID NO: 96 is the determined cDNA sequence for 1H-4770
5 SEQ ID NO: 97 is the determined cDNA sequence for 1H-4771
SEQ ID NO: 98 is the determined cDNA sequence for 1H-4772
SEQ ID NO: 99 is the determined cDNA sequence for 1D-4297
SEQ ID NO: 100 is the determined cDNA sequence for 1D-4309
SEQ ID NO: 101 is the determined cDNA sequence for 1D-1-4278
10 SEQ ID NO: 102 is the determined cDNA sequence for 1D-4288
SEQ ID NO: 103 is the determined cDNA sequence for 1D-4283
SEQ ID NO: 104 is the determined cDNA sequence for 1D-4304
SEQ ID NO: 105 is the determined cDNA sequence for 1D-4296
SEQ ID NO: 106 is the determined cDNA sequence for 1D-4280
15 SEQ ID NO: 107 is the determined full length cDNA sequence for F1-12
(also referred to as P504S)
SEQ ID NO: 108 is the predicted amino acid sequence for F1-12
SEQ ID NO: 109 is the determined full length cDNA sequence for J1-17
SEQ ID NO: 110 is the determined full length cDNA sequence for L1-12
20 (also referred to as P501S)
SEQ ID NO: 111 is the determined full length cDNA sequence for N1-
1862 (also referred to as P503S)
SEQ ID NO: 112 is the predicted amino acid sequence for J1-17
SEQ ID NO: 113 is the predicted amino acid sequence for L1-12 (also
25 referred to as P501S)
SEQ ID NO: 114 is the predicted amino acid sequence for N1-1862 (also
referred to as P503S)
SEQ ID NO: 115 is the determined cDNA sequence for P89
SEQ ID NO: 116 is the determined cDNA sequence for P90
30 SEQ ID NO: 117 is the determined cDNA sequence for P92

SEQ ID NO: 118 is the determined cDNA sequence for P95
SEQ ID NO: 119 is the determined cDNA sequence for P98
SEQ ID NO: 120 is the determined cDNA sequence for P102
SEQ ID NO: 121 is the determined cDNA sequence for P110
5 SEQ ID NO: 122 is the determined cDNA sequence for P111
SEQ ID NO: 123 is the determined cDNA sequence for P114
SEQ ID NO: 124 is the determined cDNA sequence for P115
SEQ ID NO: 125 is the determined cDNA sequence for P116
SEQ ID NO: 126 is the determined cDNA sequence for P124
10 SEQ ID NO: 127 is the determined cDNA sequence for P126
SEQ ID NO: 128 is the determined cDNA sequence for P130
SEQ ID NO: 129 is the determined cDNA sequence for P133
SEQ ID NO: 130 is the determined cDNA sequence for P138
SEQ ID NO: 131 is the determined cDNA sequence for P143
15 SEQ ID NO: 132 is the determined cDNA sequence for P151
SEQ ID NO: 133 is the determined cDNA sequence for P156
SEQ ID NO: 134 is the determined cDNA sequence for P157
SEQ ID NO: 135 is the determined cDNA sequence for P166
SEQ ID NO: 136 is the determined cDNA sequence for P176
20 SEQ ID NO: 137 is the determined cDNA sequence for P178
SEQ ID NO: 138 is the determined cDNA sequence for P179
SEQ ID NO: 139 is the determined cDNA sequence for P185
SEQ ID NO: 140 is the determined cDNA sequence for P192
SEQ ID NO: 141 is the determined cDNA sequence for P201
25 SEQ ID NO: 142 is the determined cDNA sequence for P204
SEQ ID NO: 143 is the determined cDNA sequence for P208
SEQ ID NO: 144 is the determined cDNA sequence for P211
SEQ ID NO: 145 is the determined cDNA sequence for P213
SEQ ID NO: 146 is the determined cDNA sequence for P219
30 SEQ ID NO: 147 is the determined cDNA sequence for P237

SEQ ID NO: 148 is the determined cDNA sequence for P239
SEQ ID NO: 149 is the determined cDNA sequence for P248
SEQ ID NO: 150 is the determined cDNA sequence for P251
SEQ ID NO: 151 is the determined cDNA sequence for P255
5 SEQ ID NO: 152 is the determined cDNA sequence for P256
SEQ ID NO: 153 is the determined cDNA sequence for P259
SEQ ID NO: 154 is the determined cDNA sequence for P260
SEQ ID NO: 155 is the determined cDNA sequence for P263
SEQ ID NO: 156 is the determined cDNA sequence for P264
10 SEQ ID NO: 157 is the determined cDNA sequence for P266
SEQ ID NO: 158 is the determined cDNA sequence for P270
SEQ ID NO: 159 is the determined cDNA sequence for P272
SEQ ID NO: 160 is the determined cDNA sequence for P278
SEQ ID NO: 161 is the determined cDNA sequence for P105
15 SEQ ID NO: 162 is the determined cDNA sequence for P107
SEQ ID NO: 163 is the determined cDNA sequence for P137
SEQ ID NO: 164 is the determined cDNA sequence for P194
SEQ ID NO: 165 is the determined cDNA sequence for P195
SEQ ID NO: 166 is the determined cDNA sequence for P196
20 SEQ ID NO: 167 is the determined cDNA sequence for P220
SEQ ID NO: 168 is the determined cDNA sequence for P234
SEQ ID NO: 169 is the determined cDNA sequence for P235
SEQ ID NO: 170 is the determined cDNA sequence for P243
SEQ ID NO: 171 is the determined cDNA sequence for P703P-DE1
25 SEQ ID NO: 172 is the predicted amino acid sequence for P703P-DE1
SEQ ID NO: 173 is the determined cDNA sequence for P703P-DE2
SEQ ID NO: 174 is the determined cDNA sequence for P703P-DE6
SEQ ID NO: 175 is the determined cDNA sequence for P703P-DE13
SEQ ID NO: 176 is the predicted amino acid sequence for P703P-DE13
30 SEQ ID NO: 177 is the determined cDNA sequence for P703P-DE14

SEQ ID NO: 178 is the predicted amino acid sequence for P703P-DE14

SEQ ID NO: 179 is the determined extended cDNA sequence for 1G-

4736

SEQ ID NO: 180 is the determined extended cDNA sequence for 1G-

5 4738

SEQ ID NO: 181 is the determined extended cDNA sequence for 1G-

4741

SEQ ID NO: 182 is the determined extended cDNA sequence for 1G-

4744

10 SEQ ID NO: 183 is the determined extended cDNA sequence for 1H-

4774

SEQ ID NO: 184 is the determined extended cDNA sequence for 1H-

4781

SEQ ID NO: 185 is the determined extended cDNA sequence for 1H-

15 4785

SEQ ID NO: 186 is the determined extended cDNA sequence for 1H-

4787

SEQ ID NO: 187 is the determined extended cDNA sequence for 1H-

4796

20 SEQ ID NO: 188 is the determined extended cDNA sequence for 1I-

4807

SEQ ID NO: 189 is the determined 3' cDNA sequence for 1I-4810

SEQ ID NO: 190 is the determined 3' cDNA sequence for 1I-4811

SEQ ID NO: 191 is the determined extended cDNA sequence for 1J-

25 4876

SEQ ID NO: 192 is the determined extended cDNA sequence for 1K-

4884

SEQ ID NO: 193 is the determined extended cDNA sequence for 1K-

4896

- SEQ ID NO: 194 is the determined extended cDNA sequence for 1G-
4761
- SEQ ID NO: 195 is the determined extended cDNA sequence for 1G-
4762
- 5 SEQ ID NO: 196 is the determined extended cDNA sequence for 1H-
4766
- SEQ ID NO: 197 is the determined 3' cDNA sequence for 1H-4770
SEQ ID NO: 198 is the determined 3' cDNA sequence for 1H-4771
SEQ ID NO: 199 is the determined extended cDNA sequence for 1H-
10 4772
- SEQ ID NO: 200 is the determined extended cDNA sequence for 1D-
4309
- SEQ ID NO: 201 is the determined extended cDNA sequence for 1D.1-
4278
- 15 SEQ ID NO: 202 is the determined extended cDNA sequence for 1D-
4288
- SEQ ID NO: 203 is the determined extended cDNA sequence for 1D-
4283
- SEQ ID NO: 204 is the determined extended cDNA sequence for 1D-
20 4304
- SEQ ID NO: 205 is the determined extended cDNA sequence for 1D-
4296
- SEQ ID NO: 206 is the determined extended cDNA sequence for 1D-
4280
- 25 SEQ ID NO: 207 is the determined cDNA sequence for 10-d8fwd
SEQ ID NO: 208 is the determined cDNA sequence for 10-H10con
SEQ ID NO: 209 is the determined cDNA sequence for 11-C8rev
SEQ ID NO: 210 is the determined cDNA sequence for 7.g6fwd
SEQ ID NO: 211 is the determined cDNA sequence for 7.g6rev
30 SEQ ID NO: 212 is the determined cDNA sequence for 8-b5fwd

SEQ ID NO: 213 is the determined cDNA sequence for 8-b5rev
SEQ ID NO: 214 is the determined cDNA sequence for 8-b6fwd
SEQ ID NO: 215 is the determined cDNA sequence for 8-b6 rev
SEQ ID NO: 216 is the determined cDNA sequence for 8-d4fwd
5 SEQ ID NO: 217 is the determined cDNA sequence for 8-d9rev
SEQ ID NO: 218 is the determined cDNA sequence for 8-g3fwd
SEQ ID NO: 219 is the determined cDNA sequence for 8-g3rev
SEQ ID NO: 220 is the determined cDNA sequence for 8-h11rev
SEQ ID NO: 221 is the determined cDNA sequence for g-f12fwd
10 SEQ ID NO: 222 is the determined cDNA sequence for g-f3rev
SEQ ID NO: 223 is the determined cDNA sequence for P509S
SEQ ID NO: 224 is the determined cDNA sequence for P510S
SEQ ID NO: 225 is the determined cDNA sequence for P703DE5
SEQ ID NO: 226 is the determined cDNA sequence for 9-A11
15 SEQ ID NO: 227 is the determined cDNA sequence for 8-C6
SEQ ID NO: 228 is the determined cDNA sequence for 8-H7
SEQ ID NO: 229 is the determined cDNA sequence for JPTPN13
SEQ ID NO: 230 is the determined cDNA sequence for JPTPN14
SEQ ID NO: 231 is the determined cDNA sequence for JPTPN23
20 SEQ ID NO: 232 is the determined cDNA sequence for JPTPN24
SEQ ID NO: 233 is the determined cDNA sequence for JPTPN25
SEQ ID NO: 234 is the determined cDNA sequence for JPTPN30
SEQ ID NO: 235 is the determined cDNA sequence for JPTPN34
SEQ ID NO: 236 is the determined cDNA sequence for PTPN35
25 SEQ ID NO: 237 is the determined cDNA sequence for JPTPN36
SEQ ID NO: 238 is the determined cDNA sequence for JPTPN38
SEQ ID NO: 239 is the determined cDNA sequence for JPTPN39
SEQ ID NO: 240 is the determined cDNA sequence for JPTPN40
SEQ ID NO: 241 is the determined cDNA sequence for JPTPN41
30 SEQ ID NO: 242 is the determined cDNA sequence for JPTPN42

SEQ ID NO: 243 is the determined cDNA sequence for JPTPN45
SEQ ID NO: 244 is the determined cDNA sequence for JPTPN46
SEQ ID NO: 245 is the determined cDNA sequence for JPTPN51
SEQ ID NO: 246 is the determined cDNA sequence for JPTPN56
5 SEQ ID NO: 247 is the determined cDNA sequence for PTPN64
SEQ ID NO: 248 is the determined cDNA sequence for JPTPN65
SEQ ID NO: 249 is the determined cDNA sequence for JPTPN67
SEQ ID NO: 250 is the determined cDNA sequence for JPTPN76
SEQ ID NO: 251 is the determined cDNA sequence for JPTPN84
10 SEQ ID NO: 252 is the determined cDNA sequence for JPTPN85
SEQ ID NO: 253 is the determined cDNA sequence for JPTPN86
SEQ ID NO: 254 is the determined cDNA sequence for JPTPN87
SEQ ID NO: 255 is the determined cDNA sequence for JPTPN88
SEQ ID NO: 256 is the determined cDNA sequence for JP1F1
15 SEQ ID NO: 257 is the determined cDNA sequence for JP1F2
SEQ ID NO: 258 is the determined cDNA sequence for JP1C2
SEQ ID NO: 259 is the determined cDNA sequence for JP1B1
SEQ ID NO: 260 is the determined cDNA sequence for JP1B2
SEQ ID NO: 261 is the determined cDNA sequence for JP1D3
20 SEQ ID NO: 262 is the determined cDNA sequence for JP1A4
SEQ ID NO: 263 is the determined cDNA sequence for JP1F5
SEQ ID NO: 264 is the determined cDNA sequence for JP1E6
SEQ ID NO: 265 is the determined cDNA sequence for JP1D6
SEQ ID NO: 266 is the determined cDNA sequence for JP1B5
25 SEQ ID NO: 267 is the determined cDNA sequence for JP1A6
SEQ ID NO: 268 is the determined cDNA sequence for JP1E8
SEQ ID NO: 269 is the determined cDNA sequence for JP1D7
SEQ ID NO: 270 is the determined cDNA sequence for JP1D9
SEQ ID NO: 271 is the determined cDNA sequence for JP1C10
30 SEQ ID NO: 272 is the determined cDNA sequence for JP1A9

SEQ ID NO: 273 is the determined cDNA sequence for JP1F12
SEQ ID NO: 274 is the determined cDNA sequence for JP1E12
SEQ ID NO: 275 is the determined cDNA sequence for JP1D11
SEQ ID NO: 276 is the determined cDNA sequence for JP1C11
5 SEQ ID NO: 277 is the determined cDNA sequence for JP1C12
SEQ ID NO: 278 is the determined cDNA sequence for JP1B12
SEQ ID NO: 279 is the determined cDNA sequence for JP1A12
SEQ ID NO: 280 is the determined cDNA sequence for JP8G2
SEQ ID NO: 281 is the determined cDNA sequence for JP8H1
10 SEQ ID NO: 282 is the determined cDNA sequence for JP8H2
SEQ ID NO: 283 is the determined cDNA sequence for JP8A3
SEQ ID NO: 284 is the determined cDNA sequence for JP8A4
SEQ ID NO: 285 is the determined cDNA sequence for JP8C3
SEQ ID NO: 286 is the determined cDNA sequence for JP8G4
15 SEQ ID NO: 287 is the determined cDNA sequence for JP8B6
SEQ ID NO: 288 is the determined cDNA sequence for JP8D6
SEQ ID NO: 289 is the determined cDNA sequence for JP8F5
SEQ ID NO: 290 is the determined cDNA sequence for JP8A8
SEQ ID NO: 291 is the determined cDNA sequence for JP8C7
20 SEQ ID NO: 292 is the determined cDNA sequence for JP8D7
SEQ ID NO: 293 is the determined cDNA sequence for P8D8
SEQ ID NO: 294 is the determined cDNA sequence for JP8E7
SEQ ID NO: 295 is the determined cDNA sequence for JP8F8
SEQ ID NO: 296 is the determined cDNA sequence for JP8G8
25 SEQ ID NO: 297 is the determined cDNA sequence for JP8B10
SEQ ID NO: 298 is the determined cDNA sequence for JP8C10
SEQ ID NO: 299 is the determined cDNA sequence for JP8E9
SEQ ID NO: 300 is the determined cDNA sequence for JP8E10
SEQ ID NO: 301 is the determined cDNA sequence for JP8F9
30 SEQ ID NO: 302 is the determined cDNA sequence for JP8H9

- SEQ ID NO: 303 is the determined cDNA sequence for JP8C12
SEQ ID NO: 304 is the determined cDNA sequence for JP8E11
SEQ ID NO: 305 is the determined cDNA sequence for JP8E12
SEQ ID NO: 306 is the amino acid sequence for the peptide PS2#12
5 SEQ ID NO: 307 is the determined cDNA sequence for P711P
SEQ ID NO: 308 is the determined cDNA sequence for P712P
SEQ ID NO: 309 is the determined cDNA sequence for CLONE23
SEQ ID NO: 310 is the determined cDNA sequence for P774P
SEQ ID NO: 311 is the determined cDNA sequence for P775P
10 SEQ ID NO: 312 is the determined cDNA sequence for P715P
SEQ ID NO: 313 is the determined cDNA sequence for P710P
SEQ ID NO: 314 is the determined cDNA sequence for P767P
SEQ ID NO: 315 is the determined cDNA sequence for P768P
SEQ ID NO: 316-325 are the determined cDNA sequences of previously
15 isolated genes
SEQ ID NO: 326 is the determined cDNA sequence for P703PDE5
SEQ ID NO: 327 is the predicted amino acid sequence for P703PDE5
SEQ ID NO: 328 is the determined cDNA sequence for P703P6.26
SEQ ID NO: 329 is the predicted amino acid sequence for P703P6.26
20 SEQ ID NO: 330 is the determined cDNA sequence for P703PX-23
SEQ ID NO: 331 is the predicted amino acid sequence for P703PX-23
SEQ ID NO: 332 is the determined full length cDNA sequence for
P509S
SEQ ID NO: 333 is the determined extended cDNA sequence for P707P
25 (also referred to as 11-C9)
SEQ ID NO: 334 is the determined cDNA sequence for P714P
SEQ ID NO: 335 is the determined cDNA sequence for P705P (also
referred to as 9-F3)
SEQ ID NO: 336 is the predicted amino acid sequence for P705P
30 SEQ ID NO: 337 is the amino acid sequence of the peptide P1S#10

- SEQ ID NO: 338 is the amino acid sequence of the peptide p5
- SEQ ID NO: 339 is the predicted amino acid sequence of P509S
- SEQ ID NO: 340 is the determined cDNA sequence for P778P
- SEQ ID NO: 341 is the determined cDNA sequence for P786P
- 5 SEQ ID NO: 342 is the determined cDNA sequence for P789P
- SEQ ID NO: 343 is the determined cDNA sequence for a clone showing
homology to Homo sapiens MM46 mRNA
- SEQ ID NO: 344 is the determined cDNA sequence for a clone showing
homology to Homo sapiens TNF-alpha stimulated ABC protein (ABC50) mRNA
- 10 SEQ ID NO: 345 is the determined cDNA sequence for a clone showing
homology to Homo sapiens mRNA for E-cadherin
- SEQ ID NO: 346 is the determined cDNA sequence for a clone showing
homology to Human nuclear-encoded mitochondrial serine hydroxymethyltransferase
(SHMT)
- 15 SEQ ID NO: 347 is the determined cDNA sequence for a clone showing
homology to Homo sapiens natural resistance-associated macrophage protein2
(NRAMP2)
- SEQ ID NO: 348 is the determined cDNA sequence for a clone showing
homology to Homo sapiens phosphoglucomutase-related protein (PGMRP)
- 20 SEQ ID NO: 349 is the determined cDNA sequence for a clone showing
homology to Human mRNA for proteosome subunit p40
- SEQ ID NO: 350 is the determined cDNA sequence for P777P
- SEQ ID NO: 351 is the determined cDNA sequence for P779P
- SEQ ID NO: 352 is the determined cDNA sequence for P790P
- 25 SEQ ID NO: 353 is the determined cDNA sequence for P784P
- SEQ ID NO: 354 is the determined cDNA sequence for P776P
- SEQ ID NO: 355 is the determined cDNA sequence for P780P
- SEQ ID NO: 356 is the determined cDNA sequence for P544S
- SEQ ID NO: 357 is the determined cDNA sequence for P745S
- 30 SEQ ID NO: 358 is the determined cDNA sequence for P782P

SEQ ID NO: 359 is the determined cDNA sequence for P783P

SEQ ID NO: 360 is the determined cDNA sequence for unknown 17984

SEQ ID NO: 361 is the determined cDNA sequence for P787P

SEQ ID NO: 362 is the determined cDNA sequence for P788P

5 SEQ ID NO: 363 is the determined cDNA sequence for unknown 17994

SEQ ID NO: 364 is the determined cDNA sequence for P781P

SEQ ID NO: 365 is the determined cDNA sequence for P785P

SEQ ID NO: 366-375 are the determined cDNA sequences for splice variants of B305D.

10 SEQ ID NO: 376 is the predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 366.

SEQ ID NO: 377 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 372.

SEQ ID NO: 378 is the predicted amino acid sequence encoded by the
15 sequence of SEQ ID NO: 373.

SEQ ID NO: 379 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 374.

SEQ ID NO: 380 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 375.

20 SEQ ID NO: 381 is the determined cDNA sequence for B716P.

SEQ ID NO: 382 is the determined full-length cDNA sequence for P711P.

SEQ ID NO: 383 is the predicted amino acid sequence for P711P.

SEQ ID NO: 384 is the cDNA sequence for P1000C.

25 SEQ ID NO: 385 is the cDNA sequence for CGI-82.

SEQ ID NO:386 is the cDNA sequence for 23320.

SEQ ID NO:387 is the cDNA sequence for CGI-69.

SEQ ID NO:388 is the cDNA sequence for L-iditol-2-dehydrogenase.

SEQ ID NO:389 is the cDNA sequence for 23379.

30 SEQ ID NO:390 is the cDNA sequence for 23381.

SEQ ID NO:391 is the cDNA sequence for KIAA0122.

SEQ ID NO:392 is the cDNA sequence for 23399.

SEQ ID NO:393 is the cDNA sequence for a previously identified gene.

SEQ ID NO:394 is the cDNA sequence for HCLBP.

5 SEQ ID NO:395 is the cDNA sequence for transglutaminase.

SEQ ID NO:396 is the cDNA sequence for a previously identified gene.

SEQ ID NO:397 is the cDNA sequence for PAP.

SEQ ID NO:398 is the cDNA sequence for Ets transcription factor

PDEF.

10 SEQ ID NO:399 is the cDNA sequence for hTGR.

SEQ ID NO:400 is the cDNA sequence for KIAA0295.

SEQ ID NO:401 is the cDNA sequence for 22545.

SEQ ID NO:402 is the cDNA sequence for 22547.

SEQ ID NO:403 is the cDNA sequence for 22548.

15 SEQ ID NO:404 is the cDNA sequence for 22550.

SEQ ID NO:405 is the cDNA sequence for 22551.

SEQ ID NO:406 is the cDNA sequence for 22552.

SEQ ID NO:407 is the cDNA sequence for 22553 (also known as

P1020C).

20 SEQ ID NO:408 is the cDNA sequence for 22558.

SEQ ID NO:409 is the cDNA sequence for 22562.

SEQ ID NO:410 is the cDNA sequence for 22565.

SEQ ID NO:411 is the cDNA sequence for 22567.

SEQ ID NO:412 is the cDNA sequence for 22568.

25 SEQ ID NO:413 is the cDNA sequence for 22570.

SEQ ID NO:414 is the cDNA sequence for 22571.

SEQ ID NO:415 is the cDNA sequence for 22572.

SEQ ID NO:416 is the cDNA sequence for 22573.

SEQ ID NO:417 is the cDNA sequence for 22573.

30 SEQ ID NO:418 is the cDNA sequence for 22575.

SEQ ID NO:419 is the cDNA sequence for 22580.
SEQ ID NO:420 is the cDNA sequence for 22581.
SEQ ID NO:421 is the cDNA sequence for 22582.
SEQ ID NO:422 is the cDNA sequence for 22583.
5 SEQ ID NO:423 is the cDNA sequence for 22584.
SEQ ID NO:424 is the cDNA sequence for 22585.
SEQ ID NO:425 is the cDNA sequence for 22586.
SEQ ID NO:426 is the cDNA sequence for 22587.
SEQ ID NO:427 is the cDNA sequence for 22588.
10 SEQ ID NO:428 is the cDNA sequence for 22589.
SEQ ID NO:429 is the cDNA sequence for 22590.
SEQ ID NO:430 is the cDNA sequence for 22591.
SEQ ID NO:431 is the cDNA sequence for 22592.
SEQ ID NO:432 is the cDNA sequence for 22593.
15 SEQ ID NO:433 is the cDNA sequence for 22594.
SEQ ID NO:434 is the cDNA sequence for 22595.
SEQ ID NO:435 is the cDNA sequence for 22596.
SEQ ID NO:436 is the cDNA sequence for 22847.
SEQ ID NO:437 is the cDNA sequence for 22848.
20 SEQ ID NO:438 is the cDNA sequence for 22849.
SEQ ID NO:439 is the cDNA sequence for 22851.
SEQ ID NO:440 is the cDNA sequence for 22852.
SEQ ID NO:441 is the cDNA sequence for 22853.
SEQ ID NO:442 is the cDNA sequence for 22854.
25 SEQ ID NO:443 is the cDNA sequence for 22855.
SEQ ID NO:444 is the cDNA sequence for 22856.
SEQ ID NO:445 is the cDNA sequence for 22857.
SEQ ID NO:446 is the cDNA sequence for 23601.
SEQ ID NO:447 is the cDNA sequence for 23602.
30 SEQ ID NO:448 is the cDNA sequence for 23605.

- SEQ ID NO:449 is the cDNA sequence for 23606.
SEQ ID NO:450 is the cDNA sequence for 23612.
SEQ ID NO:451 is the cDNA sequence for 23614.
SEQ ID NO:452 is the cDNA sequence for 23618.
5 SEQ ID NO:453 is the cDNA sequence for 23622.
SEQ ID NO:454 is the cDNA sequence for folate hydrolase.
SEQ ID NO:455 is the cDNA sequence for LIM protein.
SEQ ID NO:456 is the cDNA sequence for a known gene.
SEQ ID NO:457 is the cDNA sequence for a known gene.
10 SEQ ID NO:458 is the cDNA sequence for a previously identified gene.
SEQ ID NO:459 is the cDNA sequence for 23045.
SEQ ID NO:460 is the cDNA sequence for 23032.
SEQ ID NO:461 is the cDNA sequence for clone 23054.
SEQ ID NO:462-467 are cDNA sequences for known genes.
15 SEQ ID NO:468-471 are cDNA sequences for P710P.
SEQ ID NO:472 is a cDNA sequence for P1001C.
SEQ ID NO: 473 is the determined cDNA sequence for a first splice
variant of P775P (referred to as 27505).
SEQ ID NO: 474 is the determined cDNA sequence for a second splice
20 variant of P775P (referred to as 19947).
SEQ ID NO: 475 is the determined cDNA sequence for a third splice
variant of P775P (referred to as 19941).
SEQ ID NO: 476 is the determined cDNA sequence for a fourth splice
variant of P775P (referred to as 19937).
25 SEQ ID NO: 477 is a first predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 474.
SEQ ID NO: 478 is a second predicted amino acid sequence encoded by
the sequence of SEQ ID NO: 474.
SEQ ID NO: 479 is the predicted amino acid sequence encoded by the
30 sequence of SEQ ID NO: 475.

SEQ ID NO: 480 is a first predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 481 is a second predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

5 SEQ ID NO: 482 is a third predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 483 is a fourth predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

10 SEQ ID NO: 484 is the first 30 amino acids of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 485 is the PCR primer AW025.

SEQ ID NO: 486 is the PCR primer AW003.

SEQ ID NO: 487 is the PCR primer AW027.

SEQ ID NO: 488 is the PCR primer AW026.

15 SEQ ID NO: 489-501 are peptides employed in epitope mapping studies.

SEQ ID NO: 502 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody 20D4.

SEQ ID NO: 503 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody JA1.

20 SEQ ID NO: 504 & 505 are peptides employed in epitope mapping studies.

SEQ ID NO: 506 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 8H2.

25 SEQ ID NO: 507 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 7H8.

SEQ ID NO: 508 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 2D4.

SEQ ID NO: 509-522 are peptides employed in epitope mapping studies.

30 SEQ ID NO: 523 is a mature form of P703P used to raise antibodies against P703P.

SEQ ID NO: 524 is the putative full-length cDNA sequence of P703P.

SEQ ID NO: 525 is the predicted amino acid sequence encoded by SEQ ID NO: 524.

SEQ ID NO: 526 is the full-length cDNA sequence for P790P.

5 SEQ ID NO: 527 is the predicted amino acid sequence for P790P.

SEQ ID NO: 528 & 529 are PCR primers.

SEQ ID NO: 530 is the cDNA sequence of a splice variant of SEQ ID NO: 366.

10 SEQ ID NO: 531 is the cDNA sequence of the open reading frame of SEQ ID NO: 530.

SEQ ID NO: 532 is the predicted amino acid encoded by the sequence of SEQ ID NO: 531.

SEQ ID NO: 533 is the DNA sequence of a putative ORF of P775P.

15 SEQ ID NO: 534 is the predicted amino acid sequence encoded by SEQ ID NO: 533.

SEQ ID NO: 535 is a first full-length cDNA sequence for P510S.

SEQ ID NO: 536 is a second full-length cDNA sequence for P510S.

SEQ ID NO: 537 is the predicted amino acid sequence encoded by SEQ ID NO: 535.

20 SEQ ID NO: 538 is the predicted amino acid sequence encoded by SEQ ID NO: 536.

SEQ ID NO: 539 is the peptide P501S-370.

SEQ ID NO: 540 is the peptide P501S-376.

SEQ ID NO: 541-551 are epitopes of P501S.

25 SEQ ID NO: 552 is an extended cDNA sequence for P712P.

SEQ ID NO: 553-568 are the amino acid sequences encoded by predicted open reading frames within SEQ ID NO: 552.

SEQ ID NO: 569 is an extended cDNA sequence for P776P.

30 SEQ ID NO: 570 is the determined cDNA sequence for a splice variant of P776P referred to as contig 6.

SEQ ID NO: 571 is the determined cDNA sequence for a splice variant of P776P referred to as contig 7.

SEQ ID NO: 572 is the determined cDNA sequence for a splice variant of P776P referred to as contig 14.

5 SEQ ID NO: 573 is the amino acid sequence encoded by a first predicted ORF of SEQ ID NO: 570.

SEQ ID NO: 574 is the amino acid sequence encoded by a second predicted ORF of SEQ ID NO: 570.

10 SEQ ID NO: 575 is the amino acid sequence encoded by a predicted ORF of SEQ ID NO: 571.

SEQ ID NO: 576-586 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 569.

SEQ ID NO: 587 is a DNA consensus sequence of the sequences of P767P and P777P.

15 SEQ ID NO: 588-590 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 587.

SEQ ID NO: 591 is an extended cDNA sequence for P1020C.

SEQ ID NO: 592 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: P1020C.

20 SEQ ID NO: 593 is a splice variant of P775P referred to as 50748.

SEQ ID NO: 594 is a splice variant of P775P referred to as 50717.

SEQ ID NO: 595 is a splice variant of P775P referred to as 45985.

SEQ ID NO: 596 is a splice variant of P775P referred to as 38769.

SEQ ID NO: 597 is a splice variant of P775P referred to as 37922.

25 SEQ ID NO: 598 is a splice variant of P510S referred to as 49274.

SEQ ID NO: 599 is a splice variant of P510S referred to as 39487.

SEQ ID NO: 600 is a splice variant of P504S referred to as 5167.16.

SEQ ID NO: 601 is a splice variant of P504S referred to as 5167.1.

SEQ ID NO: 602 is a splice variant of P504S referred to as 5163.46.

30 SEQ ID NO: 603 is a splice variant of P504S referred to as 5163.42.

- SEQ ID NO: 604 is a splice variant of P504S referred to as 5163.34.
- SEQ ID NO: 605 is a splice variant of P504S referred to as 5163.17.
- SEQ ID NO: 606 is a splice variant of P501S referred to as 10640.
- SEQ ID NO: 607-615 are the sequences of PCR primers.
- 5 SEQ ID NO: 616 is the determined cDNA sequence of a fusion of P703P and PSA.
- SEQ ID NO: 617 is the amino acid sequence of the fusion of P703P and PSA.
- SEQ ID NO: 618 is the cDNA sequence of the gene DD3.
- 10 SEQ ID NO: 619 is an extended cDNA sequence for P714P.
- SEQ ID NO: 620-622 are the cDNA sequences for splice variants of P704P.
- SEQ ID NO: 623 is the cDNA sequence of a splice variant of P553S referred to as P553S-14.
- 15 SEQ ID NO: 624 is the cDNA sequence of a splice variant of P553S referred to as P553S-12.
- SEQ ID NO: 625 is the cDNA sequence of a splice variant of P553S referred to as P553S-10.
- SEQ ID NO: 626 is the cDNA sequence of a splice variant of P553S referred to as P553S-6.
- 20 SEQ ID NO: 627 is the amino acid sequence encoded by SEQ ID NO: 626.
- SEQ ID NO: 628 is a first amino acid sequence encoded by SEQ ID NO: 623.
- 25 SEQ ID NO: 629 is a second amino acid sequence encoded by SEQ ID NO: 623.
- SEQ ID NO: 630 is a first full-length cDNA sequence for prostate-specific transglutaminase gene (also referred to herein as P558S).
- 30 SEQ ID NO: 631 is a second full-length cDNA sequence for prostate-specific transglutaminase gene.

SEQ ID NO: 632 is the amino acid sequence encoded by the sequence of SEQ ID NO: 630.

SEQ ID NO: 633 is the amino acid sequence encoded by the sequence of SEQ ID NO: 631.

5 SEQ ID NO: 634 is the full-length cDNA sequence for P788P.

SEQ ID NO: 635 is the amino acid sequence encoded by SEQ ID NO: 634.

SEQ ID NO: 636 is the determined cDNA sequence for a polymorphic variant of P788P.

10 SEQ ID NO: 637 is the amino acid sequence encoded by SEQ ID NO: 636.

SEQ ID NO: 638 is the amino acid sequence of peptide 4 from P703P.

SEQ ID NO: 639 is the cDNA sequence that encodes peptide 4 from P703P.

15 SEQ ID NO: 640-655 are cDNA sequences encoding epitopes of P703P.

SEQ ID NO: 656-671 are the amino acid sequences of epitopes of P703P.

SEQ ID NO: 672 and 673 are PCR primers.

20 SEQ ID NO: 674 is the cDNA sequence encoding an N-terminal portion of P788P expressed in *E. coli*.

SEQ ID NO: 675 is the amino acid sequence of the N-terminal portion of P788P expressed in *E. coli*.

SEQ ID NO: 676 is the amino acid sequence of the *M. tuberculosis* antigen Ra12.

25 SEQ ID NO: 677 and 678 are PCR primers.

SEQ ID NO: 679 is the cDNA sequence for the Ra12-P510S-C construct.

SEQ ID NO: 680 is the cDNA sequence for the P510S-C construct.

SEQ ID NO: 681 is the cDNA sequence for the P510S-E3 construct.

SEQ ID NO: 682 is the amino acid sequence for the Ra12-P510S-C construct.

SEQ ID NO: 683 is the amino acid sequence for the P510S-C construct.

SEQ ID NO: 684 is the amino acid sequence for the P510S-E3 construct.

5 SEQ ID NO: 685-690 are PCR primers.

SEQ ID NO: 691 is the cDNA sequence of the construct Ra12-P775P-ORF3.

SEQ ID NO: 692 is the amino acid sequence of the construct Ra12-P775P-ORF3.

10 SEQ ID NO: 693 and 694 are PCR primers.

SEQ ID NO: 695 is the determined amino acid sequence for a P703P His tag fusion protein.

SEQ ID NO: 696 is the determined cDNA sequence for a P703P His tag fusion protein.

15 SEQ ID NO: 697 and 698 are PCR primers.

SEQ ID NO: 699 is the determined amino acid sequence for a P705P His tag fusion protein.

SEQ ID NO: 700 is the determined cDNA sequence for a P705P His tag fusion protein.

20 SEQ ID NO: 701 and 702 are PCR primers.

SEQ ID NO: 703 is the determined amino acid sequence for a P711P His tag fusion protein.

SEQ ID NO: 704 is the determined cDNA sequence for a P711P His tag fusion protein.

25 SEQ ID NO: 705 is the amino acid sequence of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 706 and 707 are PCR primers.

SEQ ID NO: 708 is the determined cDNA sequence for the construct Ra12-P501S-E2.

SEQ ID NO: 709 is the determined amino acid sequence for the construct Ra12-P501S-E2.

SEQ ID NO: 710 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 711 is the DNA sequence encoding SEQ ID NO: 710.

5 SEQ ID NO: 712 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 713 is the DNA sequence encoding SEQ ID NO: 712.

SEQ ID NO: 714 is a peptide employed in epitope mapping studies.

SEQ ID NO: 715 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 716 is the DNA sequence encoding SEQ ID NO: 715.

10 SEQ ID NO: 717-719 are the amino acid sequences for CD4 epitopes of P501S.

SEQ ID NO: 720-722 are the DNA sequences encoding the sequences of SEQ ID NO: 717-719.

15 SEQ ID NO: 723-734 are the amino acid sequences for putative CTL epitopes of P703P.

SEQ ID NO: 735 is the full-length cDNA sequence for P789P.

SEQ ID NO: 736 is the amino acid sequence encoded by SEQ ID NO: 735.

20 SEQ ID NO: 737 is the determined full-length cDNA sequence for the splice variant of P776P referred to as contig 6.

SEQ ID NO: 738-739 are determined full-length cDNA sequences for the splice variant of P776P referred to as contig 7.

SEQ ID NO: 740-744 are amino acid sequences encoded by SEQ ID NO: 737.

25 SEQ ID NO: 745-750 are amino acid sequences encoded by the splice variant of P776P referred to as contig 7.

SEQ ID NO: 751 is the full-length cDNA sequence for human transmembrane protease serine 2.

30 SEQ ID NO: 752 is the amino acid sequence encoded by SEQ ID NO: 751.

SEQ ID NO: 753 is the cDNA sequence encoding the first 209 amino acids of human transmembrane protease serine 2.

SEQ ID NO: 754 is the first 209 amino acids of human transmembrane protease serine 2.

5 SEQ ID NO: 755 is the amino acid sequence of peptide 296-322 of P501S.

SEQ ID NO: 756-759 are PCR primers.

SEQ ID NO: 760 is the determined cDNA sequence of the Vb chain of a T cell receptor for the P501S-specific T cell clone 4E5.

10 SEQ ID NO: 761 is the determined cDNA sequence of the Va chain of a T cell receptor for the P501S-specific T cell clone 4E5.

SEQ ID NO: 762 is the amino acid sequence encoded by SEQ ID NO 760.

15 SEQ ID NO: 763 is the amino acid sequence encoded by SEQ ID NO 761.

SEQ ID NO: 764 is the full-length open reading frame for P768P including stop codon.

SEQ ID NO: 765 is the full-length open reading frame for P768P without stop codon.

20 SEQ ID NO: 766 is the amino acid sequence encoded by SEQ ID NO: 765.

SEQ ID NO: 767-772 are the amino acid sequences for predicted domains of P768P.

SEQ ID NO: 773 is the full-length cDNA sequence of P835P.

25 SEQ ID NO: 774 is the cDNA sequence of the previously identified clone FLJ13581.

SEQ ID NO: 775 is the cDNA sequence of the open reading frame for P835P with stop codon.

30 SEQ ID NO: 776 is the cDNA sequence of the open reading frame for P835P without stop codon.

SEQ ID NO: 777 is the full-length amino acid sequence for P835P.

SEQ ID NO: 778-785 are the amino acid sequences of extracellular and intracellular domains of P835P.

SEQ ID NO: 786 is the full-length cDNA sequence for P1000C.

5 SEQ ID NO: 787 is the cDNA sequence of the open reading frame for P1000C, including stop codon.

SEQ ID NO: 788 is the cDNA sequence of the open reading frame for P1000C, without stop codon.

SEQ ID NO: 789 is the full-length amino acid sequence for P1000C.

10 SEQ ID NO: 790 is amino acids 1-100 of SEQ ID NO: 789.

SEQ ID NO: 791 is amino acids 100-492 of SEQ ID NO: 789.

SEQ ID NO: 792 is the amino acid sequence of an α prepro-P501S recombinant protein.

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed generally to compositions and their use in the therapy and diagnosis of cancer, particularly prostate cancer. As described further below, illustrative compositions of the present invention include, but are not restricted to, polypeptides, particularly immunogenic polypeptides, polynucleotides encoding such
20 polypeptides, antibodies and other binding agents, antigen presenting cells (APCs) and immune system cells (*e.g.*, T cells).

The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of
25 the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, et al. Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al. Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid

Hybridization (B. Hames & S. Higgins, eds., 1985); Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, **A Practical Guide to Molecular Cloning** (1984).

All publications, patents and patent applications cited herein, whether
5 supra or infra, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

Polypeptide Compositions

10 As used herein, the term "polypeptide" " is used in its conventional meaning, *i.e.*, as a sequence of amino acids. The polypeptides are not limited to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-
15 expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising epitopes, *i.e.*, antigenic
20 determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of evoking an immune response.

Particularly illustrative polypeptides of the present invention comprise those encoded by a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382
25 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, or a sequence that hybridizes under moderately stringent conditions, or, alternatively, under highly stringent conditions, to a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175,

177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788. In specific embodiments, the polypeptides of the invention
5 comprise amino acid sequences as set forth in any one of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

10 The polypeptides of the present invention are sometimes herein referred to as prostate-specific proteins or prostate-specific polypeptides, as an indication that their identification has been based at least in part upon their increased levels of expression in prostate tissue samples. Thus, a "prostate-specific polypeptide" or "prostate-specific protein," refers generally to a polypeptide sequence of the present
15 invention, or a polynucleotide sequence encoding such a polypeptide, that is expressed in a substantial proportion of prostate tissue samples, for example preferably greater than about 20%, more preferably greater than about 30%, and most preferably greater than about 50% or more of prostate tissue samples tested, at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in other
20 normal tissues, as determined using a representative assay provided herein. A prostate-specific polypeptide sequence of the invention, based upon its increased level of expression in tumor cells, has particular utility both as a diagnostic marker as well as a therapeutic target, as further described below.

In certain preferred embodiments, the polypeptides of the invention are
25 immunogenic, *i.e.*, they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with prostate cancer. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, *Antibodies: A Laboratory*
30 *Manual*, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a

polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

- 5 As would be recognized by the skilled artisan, immunogenic portions of the polypeptides disclosed herein are also encompassed by the present invention. An "immunogenic portion," as used herein, is a fragment of an immunogenic polypeptide of the invention that itself is immunologically reactive (*i.e.*, specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide.
- 10 Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they
- 15 specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques.

- In one preferred embodiment, an immunogenic portion of a polypeptide of the present invention is a portion that reacts with antisera and/or T-cells at a level that
- 20 is not substantially less than the reactivity of the full-length polypeptide (*e.g.*, in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that
- 25 have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, *e.g.*, having greater than about 100% or 150% or more immunogenic activity.

- In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain
- 30 has been deleted. Other illustrative immunogenic portions will contain a small N-

and/or C-terminal deletion (e.g., 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

In another embodiment, a polypeptide composition of the invention may also comprise one or more polypeptides that are immunologically reactive with T cells
5 and/or antibodies generated against a polypeptide of the invention, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.

In another embodiment of the invention, polypeptides are provided that comprise one or more polypeptides that are capable of eliciting T cells and/or antibodies
10 that are immunologically reactive with one or more polypeptides described herein, or one or more polypeptides encoded by contiguous nucleic acid sequences contained in the polynucleotide sequences disclosed herein, or immunogenic fragments or variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

15 The present invention, in another aspect, provides polypeptide fragments comprising at least about 5, 10, 15, 20, 25, 50, or 100 contiguous amino acids, or more, including all intermediate lengths, of a polypeptide composition set forth herein, such as those set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568,
20 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791, or those encoded by a polynucleotide sequence set forth in a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591,
25 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

In another aspect, the present invention provides variants of the polypeptide compositions described herein. Polypeptide variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%,
30 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity

(determined as described below), along its length, to a polypeptide sequence set forth herein.

In one preferred embodiment, the polypeptide fragments and variants provided by the present invention are immunologically reactive with an antibody and/or
5 T-cell that reacts with a full-length polypeptide specifically set forth herein.

In another preferred embodiment, the polypeptide fragments and variants provided by the present invention exhibit a level of immunogenic activity of at least about 50%, preferably at least about 70%, and most preferably at least about 90% or more of that exhibited by a full-length polypeptide sequence specifically set forth
10 herein.

A polypeptide "variant," as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of
15 the above polypeptide sequences of the invention and evaluating their immunogenic activity as described herein using any of a number of techniques well known in the art.

For example, certain illustrative variants of the polypeptides of the invention include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other illustrative variants
20 include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

In many instances, a variant will contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide
25 chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, *e.g.*, with immunogenic characteristics. When it is
30 desired to alter the amino acid sequence of a polypeptide to create an equivalent, or

even an improved, immunogenic variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.

For example, certain amino acids may be substituted for other amino
5 acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence
10 substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

TABLE 1

Amino Acids			Codons					
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Cysteine	Cys	C	UGC	UGU				
Aspartic acid	Asp	D	GAC	GAU				
Glutamic acid	Glu	E	GAA	GAG				
Phenylalanine	Phe	F	UUC	UUU				
Glycine	Gly	G	GGA	GGC	GGG	GGU		
Histidine	His	H	CAC	CAU				
Isoleucine	Ile	I	AUA	AUC	AUU			
Lysine	Lys	K	AAA	AAG				
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU
Methionine	Met	M	AUG					
Asparagine	Asn	N	AAC	AAU				
Proline	Pro	P	CCA	CCC	CCG	CCU		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Valine	Val	V	GUA	GUC	GUG	GUU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				

In making such changes, the hydrophatic index of amino acids may be considered. The importance of the hydrophatic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydrophatic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydrophatic index on the basis of its

hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5);
5 glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are
10 within ± 2 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of
15 its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine
20 (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2
25 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that
30 take various of the foregoing characteristics into consideration are well known to those

of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition, any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of
5 flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

10 Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values
15 include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a
20 preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

25 As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For
30 example, a polypeptide may be conjugated to an immunoglobulin Fc region.

When comparing polypeptide sequences, two sequences are said to be "identical" if the sequence of amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

- Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics

Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

In one preferred approach, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Within other illustrative embodiments, a polypeptide may be a fusion polypeptide that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known

tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological
5 and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the polypeptide or to enable the polypeptide to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the polypeptide.

Fusion polypeptides may generally be prepared using standard
10 techniques, including chemical conjugation. Preferably, a fusion polypeptide is expressed as a recombinant polypeptide, allowing the production of increased levels, relative to a non-fused polypeptide, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one
15 polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion polypeptide that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and
20 second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a
25 secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as
30 linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al.,

Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to
5 separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and
10 transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

The fusion polypeptide can comprise a polypeptide as described herein together with an unrelated immunogenic protein, such as an immunogenic protein capable of eliciting a recall response. Examples of such proteins include tetanus,
15 tuberculosis and hepatitis proteins (*see*, for example, Stoute et al. *New Engl. J. Med.*, 336:86-91, 1997).

In one preferred embodiment, the immunological fusion partner is derived from a *Mycobacterium* sp., such as a *Mycobacterium tuberculosis*-derived Ra12 fragment. Ra12 compositions and methods for their use in enhancing the expression
20 and/or immunogenicity of heterologous polynucleotide/polypeptide sequences is described in U.S. Patent Application 60/158,585, the disclosure of which is incorporated herein by reference in its entirety. Briefly, Ra12 refers to a polynucleotide region that is a subsequence of a *Mycobacterium tuberculosis* MTB32A nucleic acid. MTB32A is a serine protease of 32 KD molecular weight encoded by a gene in virulent
25 and avirulent strains of *M. tuberculosis*. The nucleotide sequence and amino acid sequence of MTB32A have been described (for example, U.S. Patent Application 60/158,585; *see also*, Skeiky et al., *Infection and Immun.* (1999) 67:3998-4007, incorporated herein by reference). C-terminal fragments of the MTB32A coding sequence express at high levels and remain as a soluble polypeptides throughout the
30 purification process. Moreover, Ra12 may enhance the immunogenicity of heterologous

immunogenic polypeptides with which it is fused. One preferred Ra12 fusion polypeptide comprises a 14 KD C-terminal fragment corresponding to amino acid residues 192 to 323 of MTB32A. Other preferred Ra12 polynucleotides generally comprise at least about 15 consecutive nucleotides, at least about 30 nucleotides, at least about 60 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, or at least about 300 nucleotides that encode a portion of a Ra12 polypeptide. Ra12 polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a Ra12 polypeptide or a portion thereof) or may comprise a variant of such a sequence. Ra12 polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not substantially diminished, relative to a fusion polypeptide comprising a native Ra12 polypeptide. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native Ra12 polypeptide or a portion thereof.

Within other preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza B* (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (*e.g.*, the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine

amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been
5 exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (*see Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion polypeptide. A repeat portion is found in the C-terminal region starting at
10 residue 178. A particularly preferred repeat portion incorporates residues 188-305.

Yet another illustrative embodiment involves fusion polypeptides, and the polynucleotides encoding them, wherein the fusion partner comprises a targeting signal capable of directing a polypeptide to the endosomal/lysosomal compartment, as described in U.S. Patent No. 5,633,234. An immunogenic polypeptide of the invention,
15 when fused with this targeting signal, will associate more efficiently with MHC class II molecules and thereby provide enhanced in vivo stimulation of CD4⁺ T-cells specific for the polypeptide.

Polypeptides of the invention are prepared using any of a variety of well known synthetic and/or recombinant techniques, the latter of which are further
20 described below. Polypeptides, portions and other variants generally less than about 150 amino acids can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. In one illustrative example, such polypeptides are synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a
25 growing amino acid chain. *See* Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

In general, polypeptide compositions (including fusion polypeptides) of
30 the invention are isolated. An "isolated" polypeptide is one that is removed from its

original environment. For example, a naturally-occurring protein or polypeptide is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are also purified, *e.g.*, are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99%
5 pure.

Polynucleotide Compositions

The present invention, in other aspects, provides polynucleotide compositions. The terms "DNA" and "polynucleotide" are used essentially interchangeably herein to refer to a DNA molecule that has been isolated free of total
10 genomic DNA of a particular species. "Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA molecule does not contain large portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA molecule as originally isolated, and does not exclude
15 genes or coding regions later added to the segment by the hand of man.

As will be understood by those skilled in the art, the polynucleotide compositions of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may
20 be naturally isolated, or modified synthetically by the hand of man.

As will be also recognized by the skilled artisan, polynucleotides of the invention may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules may include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-
25 to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a polypeptide/protein of the invention or a portion thereof) or may comprise a sequence that encodes a variant or derivative, preferably an immunogenic variant or derivative, of such a sequence.

5 Therefore, according to another aspect of the present invention, polynucleotide compositions are provided that comprise some or all of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 10 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, complements of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 15 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, and degenerate variants of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 20 773-776 and 786-788. In certain preferred embodiments, the polynucleotide sequences set forth herein encode immunogenic polypeptides, as described above.

In other related embodiments, the present invention provides polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332- 25 335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a 30 polynucleotide sequence of this invention using the methods described herein, (*e.g.*,

BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

Typically, polynucleotide variants will contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenicity of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth herein). The term "variants" should also be understood to encompass homologous genes of xenogenic origin.

In additional embodiments, the present invention provides polynucleotide fragments comprising various lengths of contiguous stretches of sequence identical to, or complementary to, one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-60°C, 5 X SSC, overnight; followed by washing twice at 65°C for

20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, *e.g.*, to 60-65°C or 65-70°C.

In certain preferred embodiments, the polynucleotides described above, *e.g.*, polynucleotide variants, fragments and hybridizing sequences, encode polypeptides that are immunologically cross-reactive with a polypeptide sequence specifically set forth herein. In other preferred embodiments, such polynucleotides encode polypeptides that have a level of immunogenic activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein.

The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

When comparing polynucleotide sequences, two sequences are said to be "identical" if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison

“window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, preferably 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

- 5 Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships.
- 10 In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson,
- 15 E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

- Alternatively, optimal alignment of sequences for comparison may be
- 20 conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics
- 25 Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

- One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402
- 30 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST

2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for
5 nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments;
10 or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and
15 a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5
20 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the
25 reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal
30 homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides

that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions
5 and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Therefore, in another embodiment of the invention, a mutagenesis approach, such as site-specific mutagenesis, is employed for the preparation of
10 immunogenic variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence can be made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more
15 nucleotide sequence changes into the polynucleotide.

Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on
20 both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

In certain embodiments of the present invention, the inventors
25 contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the immunogenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA
30 molecule. In such embodiments, a primer comprising typically about 14 to about 25

nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

As used herein, the term "oligonucleotide directed mutagenesis procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable
5 signal, such as amplification. As used herein, the term "oligonucleotide directed mutagenesis procedure" is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known
10 rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

15 In another approach for the production of polypeptide variants of the present invention, recursive sequence recombination, as described in U.S. Patent No. 5,837,458, may be employed. In this approach, iterative cycles of recombination and screening or selection are performed to "evolve" individual polynucleotide variants of the invention having, for example, enhanced immunogenic activity.

20 In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15 contiguous nucleotides that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence
25 disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

The ability of such nucleic acid probes to specifically hybridize to a
30 sequence of interest will enable them to be of use in detecting the presence of

complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

Polynucleotide molecules having sequence regions consisting of
5 contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, *e.g.*, Southern and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in
10 various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger
15 contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 15 bases in
20 length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

25 Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various

factors. For example, one may wish to employ primers from towards the termini of the total sequence.

Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly
5 practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR™ technology of U. S. Patent 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular
10 biology.

The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of
15 selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate
20 little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be
25 needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered
30 more stringent by the addition of increasing amounts of formamide, which serves to

destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

According to another embodiment of the present invention, polynucleotide compositions comprising antisense oligonucleotides are provided. Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, provide a therapeutic approach by which a disease can be treated by inhibiting the synthesis of proteins that contribute to the disease. The efficacy of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA_A receptor and human EGF (Jaskulski *et al.*, Science. 1988 Jun 10;240(4858):1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989;1(4):225-32; Peris *et al.*, Brain Res Mol Brain Res. 1998 Jun 15;57(2):310-20; U. S. Patent 5,801,154; U.S. Patent 5,789,573; U. S. Patent 5,718,709 and U.S. Patent 5,610,288). Antisense constructs have also been described that inhibit and can be used to treat a variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S. Patent 5,591,317 and U. S. Patent 5,783,683).

Therefore, in certain embodiments, the present invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary,

and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein. Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence and determination of secondary structure, T_m ,
5 binding energy, and relative stability. Antisense compositions may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell. Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which are substantially complementary
10 to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software and/or the BLASTN 2.0.5 algorithm software (Altschul *et al.*, Nucleic Acids Res. 1997 Sep 1;25(17):3389-402).

The use of an antisense delivery method employing a short peptide
15 vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, Nucleic Acids Res. 1997 Jul 15;25(14):2730-6). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered
20 into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane.

According to another embodiment of the invention, the polynucleotide compositions described herein are used in the design and preparation of ribozyme
25 molecules for inhibiting expression of the tumor polypeptides and proteins of the present invention in tumor cells. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc Natl Acad Sci U S A. 1987 Dec;84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24;49(2):211-20). For
30 example, a large number of ribozymes accelerate phosphoester transfer reactions with a

high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, Cell. 1981 Dec;27(3 Pt 2):487-96; Michel and Westhof, J Mol Biol. 1990 Dec 5;216(3):585-610; Reinhold-Hurek and Shub, Nature. 1992 May 14;357(6374):173-6). This specificity has been attributed to the requirement
5 that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general,
10 enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to
15 cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over many
20 technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of
25 target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action
30 (Woolf *et al.*, Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7305-9). Thus, the

specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA
5 guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* Nucleic Acids Res. 1992 Sep 11;20(17):4559-65. Examples of hairpin motifs are described by Hampel *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry 1989 Jun 13;28(12):4929-33; Hampel *et al.*, Nucleic
10 Acids Res. 1990 Jan 25;18(2):299-304 and U. S. Patent 5,631,359. An example of the hepatitis δ virus motif is described by Perrotta and Been, Biochemistry. 1992 Dec 1;31(47):11843-52; an example of the RNaseP motif is described by Guerrier-Takada *et al.*, Cell. 1983 Dec;35(3 Pt 2):849-57; Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and Collins, Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8826-30; Collins and Olive,
15 Biochemistry. 1993 Mar 23;32(11):2795-9); and an example of the Group I intron is described in (U. S. Patent 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an
20 RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as
25 described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that
30 prevent their degradation by serum ribonucleases (see *e.g.*, Int. Pat. Appl. Publ. No. WO

92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells. Ribozymes

expressed from such promoters have been shown to function in mammalian cells. Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

In another embodiment of the invention, peptide nucleic acids (PNAs) compositions are provided. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, *Antisense Nucleic Acid Drug Dev.* 1997 7(4) 431-37). PNA is able to be utilized in a number of methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (*Trends Biotechnol* 1997 Jun;15(6):224-9). As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen *et al.*, *Science* 1991 Dec 6;254(5037):1497-500; Hanvey *et al.*, *Science*. 1992 Nov 27;258(5087):1481-5; Hyrup and Nielsen, *Bioorg Med Chem.* 1996 Jan;4(1):5-23). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc or Fmoc protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used.

PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*,

Bioorg Med Chem. 1995 Apr;3(4):437-45). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

As with peptide synthesis, the success of a particular PNA synthesis will
5 depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed
10 by the purification of PNAs by reverse-phase high-pressure liquid chromatography, providing yields and purity of product similar to those observed during the synthesis of peptides.

Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that
15 contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and
20 utilized modifications of PNAs (for example, Norton *et al.*, Bioorg Med Chem. 1995 Apr;3(4):437-45; Petersen *et al.*, J Pept Sci. 1995 May-Jun;1(3):175-83; Orum *et al.*, Biotechniques. 1995 Sep;19(3):472-80; Footer *et al.*, Biochemistry. 1996 Aug 20;35(33):10673-9; Griffith *et al.*, Nucleic Acids Res. 1995 Aug 11;23(15):3003-8; Pardridge *et al.*, Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5592-6; Boffa *et al.*,
25 Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1901-5; Gambacorti-Passerini *et al.*, Blood. 1996 Aug 15;88(4):1411-7; Armitage *et al.*, Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12320-5; Seeger *et al.*, Biotechniques. 1997 Sep;23(3):512-7). U.S. Patent No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to
30 therapeutics.

Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (Anal Chem. 1993 Dec 15;65(24):3545-9) and Jensen *et al.* (Biochemistry. 1997 Apr 22;36(16):5072-7). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen *et al.* using BIAcore™ technology.

Other applications of PNAs that have been described and will be apparent to the skilled artisan include use in DNA strand invasion, antisense inhibition, mutational analysis, enhancers of transcription, nucleic acid purification, isolation of transcriptionally active genes, blocking of transcription factor binding, genome cleavage, biosensors, *in situ* hybridization, and the like.

Polynucleotide Identification, Characterization and Expression

Polynucleotide compositions of the present invention may be identified, prepared and/or manipulated using any of a variety of well established techniques (see generally, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989, and other like references). For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using the microarray technology of Affymetrix, Inc. (Santa Clara, CA) according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as tumor cells.

Many template dependent processes are available to amplify a target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by

reference in its entirety. Briefly, in PCRTM, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present
5 in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse
10 transcription and PCRTM amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

Any of a number of other template dependent processes, many of which are variations of the PCRTM amplification technique, are readily known and available in
15 the art. Illustratively, some such methods include the ligase chain reaction (referred to as LCR), described, for example, in Eur. Pat. Appl. Publ. No. 320,308 and U.S. Patent No. 4,883,750; Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880; Strand Displacement Amplification (SDA) and Repair Chain Reaction (RCR). Still other amplification methods are described in Great Britain Pat.
20 Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025. Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. Eur. Pat. Appl. Publ. No. 329,822 describes a nucleic acid amplification process involving cyclically synthesizing single-stranded
25 RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA). PCT Intl. Pat. Appl. Publ. No. WO 89/06700 describes a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. Other amplification methods such as "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara,
30 1989) are also well-known to those of skill in the art.

An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (e.g., a tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification.

5 Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ^{32}P) using well known techniques. A bacterial or

10 bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may

15 be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can

20 then be assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (see Triglia et al., *Nucl. Acids Res.*

25 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a

30 known region. The amplified sequences are typically subjected to a second round of

amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic. 1*:111-19, 1991) and walking PCR (Parker et al., *Nucl. Acids. Res. 19*:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (*e.g.*, NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.) or other comparable techniques available in the art. The composition of the synthetic peptides may be

confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, **may be altered during direct synthesis and/or combined using chemical methods with** sequences from other proteins, or any part thereof, to produce a variant polypeptide.

5 In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing
10 sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et
15 al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York. N.Y.

A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid,
20 or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids); or animal cell systems.

25 The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription
30 and translation elements, including constitutive and inducible promoters, may be used.

For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORT1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses
5 are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

In bacterial systems, any of a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example,
10 when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with
15 sequences for the amino-terminal Met and the subsequent 7 residues of .beta.-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are
20 soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

25 In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of
30 sequences encoding polypeptides may be driven by any of a number of promoters. For

example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) *Proc. Natl. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which

successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of

skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

5 A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal
10 antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions
20 thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used
25 include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

 Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained
30 intracellularly depending on the sequence and/or the vector used. As will be understood

by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMLAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

Antibody Compositions, Fragments Thereof and Other Binding Agents

According to another aspect, the present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that exhibit immunological binding to a tumor polypeptide disclosed herein, or to a portion, variant or derivative thereof. An antibody, or antigen-binding fragment thereof, is said to "specifically bind," "immunologically bind," and/or is "immunologically reactive" to a polypeptide of the invention if it reacts at a detectable level (within, for example, an ELISA assay) with the polypeptide, and does not react detectably with unrelated polypeptides under similar conditions.

Immunological binding, as used in this context, generally refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K_d) of the interaction, wherein a smaller K_d represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and on geometric parameters that equally influence the rate in both directions. Thus, both the "on rate constant" (K_{on}) and the "off rate constant" (K_{off}) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of K_{off}/K_{on} enables cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant K_d . See, generally, Davies et al. (1990) Annual Rev. Biochem. 59:439-473.

An "antigen-binding site," or "binding portion" of an antibody refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable regions" which are interposed between more conserved flanking stretches known as

"framework regions," or "FRs". Thus the term "FR" refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs."

Binding agents may be further capable of differentiating between patients with and without a cancer, such as prostate cancer, using the representative assays provided herein. For example, antibodies or other binding agents that bind to a tumor protein will preferably generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (*e.g.*, blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. Preferably, a statistically significant number of samples with and without the disease will be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation

of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (*e.g.*, mice, rats, rabbits, sheep
5 or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule
10 incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest
15 may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as
20 described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid
25 cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

A number of therapeutically useful molecules are known in the art which comprise antigen-binding sites that are capable of exhibiting immunological binding properties of an antibody molecule. The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the "F(ab)" fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the "F(ab')₂" fragment which comprises both antigen-binding sites. An "Fv" fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecule. Fv fragments are, however, more commonly derived using recombinant techniques known in the art. The Fv fragment includes a non-covalent V_H::V_L heterodimer including an antigen-binding site which retains much of the antigen recognition and binding capabilities of the native antibody molecule. Inbar et al. (1972) Proc. Nat. Acad. Sci. USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; and Ehrlich et al. (1980) Biochem 19:4091-4096.

A single chain Fv ("sFv") polypeptide is a covalently linked V_H::V_L heterodimer which is expressed from a gene fusion including V_H- and V_L-encoding genes linked by a peptide-encoding linker. Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883. A number of methods have been described to discern chemical structures for converting the naturally aggregated--but chemically separated--light and heavy polypeptide chains from an antibody V region into an sFv molecule which will fold into a three dimensional structure substantially similar to the structure of an

antigen-binding site. See, *e.g.*, U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

Each of the above-described molecules includes a heavy chain and a light chain CDR set, respectively interposed between a heavy chain and a light chain FR set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. As used herein, the term "CDR set" refers to the three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as "CDR1," "CDR2," and "CDR3" respectively. An antigen-binding site, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. A polypeptide comprising a single CDR, (*e.g.*, a CDR1, CDR2 or CDR3) is referred to herein as a "molecular recognition unit." Crystallographic analysis of a number of antigen-antibody complexes has demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units are primarily responsible for the specificity of an antigen-binding site.

As used herein, the term "FR set" refers to the four flanking amino acid sequences which frame the CDRs of a CDR set of a heavy or light chain V region. Some FR residues may contact bound antigen; however, FRs are primarily responsible for folding the V region into the antigen-binding site, particularly the FR residues directly adjacent to the CDRs. Within FRs, certain amino residues and certain structural features are very highly conserved. In this regard, all V region sequences contain an internal disulfide loop of around 90 amino acid residues. When the V regions fold into a binding-site, the CDRs are displayed as projecting loop motifs which form an antigen-binding surface. It is generally recognized that there are conserved structural regions of FRs which influence the folded shape of the CDR loops into certain "canonical" structures--regardless of the precise CDR amino acid sequence. Further, certain FR residues are known to participate in non-covalent interdomain contacts which stabilize the interaction of the antibody heavy and light chains.

A number of "humanized" antibody molecules comprising an antigen-binding site derived from a non-human immunoglobulin have been described, including **chimeric antibodies having rodent V regions and their associated CDRs fused to human constant domains** (Winter et al. (1991) Nature 349:293-299; Lobuglio et al. (1989) Proc. Nat. Acad. Sci. USA 86:4220-4224; Shaw et al. (1987) J Immunol. 138:4534-4538; and Brown et al. (1987) Cancer Res. 47:3577-3583), rodent CDRs grafted into a human supporting FR prior to fusion with an appropriate human antibody constant domain (Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536; and Jones et al. (1986) Nature 321:522-525), and rodent CDRs supported by recombinantly veneered rodent FRs (European Patent Publication No. 519,596, published Dec. 23, 1992). These "humanized" molecules are designed to minimize unwanted immunological response toward rodent antihuman antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.

As used herein, the terms "veneered FRs" and "recombinantly veneered FRs" refer to the selective replacement of FR residues from, *e.g.*, a rodent heavy or light chain V region, with human FR residues in order to provide a xenogeneic molecule comprising an antigen-binding site which retains substantially all of the native FR polypeptide folding structure. Veneering techniques are based on the understanding that the ligand binding characteristics of an antigen-binding site are determined primarily by the structure and relative disposition of the heavy and light chain CDR sets within the antigen-binding surface. Davies et al. (1990) Ann. Rev. Biochem. 59:439-473. Thus, antigen binding specificity can be preserved in a humanized antibody only wherein the CDR structures, their interaction with each other, and their interaction with the rest of the V region domains are carefully maintained. By using veneering techniques, exterior (*e.g.*, solvent-accessible) FR residues which are readily encountered by the immune system are selectively replaced with human residues to provide a hybrid molecule that comprises either a weakly immunogenic, or substantially non-immunogenic veneered surface.

The process of veneering makes use of the available sequence data for human antibody variable domains compiled by Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S. Dept. of Health and Human Services, U.S. Government Printing Office, 1987), updates to the Kabat database, and other accessible U.S. and foreign databases (both nucleic acid and protein). Solvent accessibilities of V region amino acids can be deduced from the known three-dimensional structure for human and murine antibody fragments. There are two general steps in veneering a murine antigen-binding site. Initially, the FRs of the variable domains of an antibody molecule of interest are compared with corresponding FR sequences of human variable domains obtained from the above-identified sources. The most homologous human V regions are then compared residue by residue to corresponding murine amino acids. The residues in the murine FR which differ from the human counterpart are replaced by the residues present in the human moiety using recombinant techniques well known in the art. Residue switching is only carried out with moieties which are at least partially exposed (solvent accessible), and care is exercised in the replacement of amino acid residues which may have a significant effect on the tertiary structure of V region domains, such as proline, glycine and charged amino acids.

In this manner, the resultant "veneered" murine antigen-binding sites are thus designed to retain the murine CDR residues, the residues substantially adjacent to the CDRs, the residues identified as buried or mostly buried (solvent inaccessible), the residues believed to participate in non-covalent (*e.g.*, electrostatic and hydrophobic) contacts between heavy and light chain domains, and the residues from conserved structural regions of the FRs which are believed to influence the "canonical" tertiary structures of the CDR loops. These design criteria are then used to prepare recombinant nucleotide sequences which combine the CDRs of both the heavy and light chain of a murine antigen-binding site into human-appearing FRs that can be used to transfect mammalian cells for the expression of recombinant human antibodies which exhibit the antigen specificity of the murine antibody molecule.

In another embodiment of the invention, monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in

this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{211}At , and ^{212}Bi . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred
5 toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a
10 substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an
15 antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which
20 otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups,
25 sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of
30 different cleavable linker groups have been described. The mechanisms for the

intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by
5 serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody.
10 Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent
15 bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for
20 radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For
25 example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

T Cell Compositions

The present invention, in another aspect, provides T cells specific for a tumor polypeptide disclosed herein, or for a variant or derivative thereof. Such cells

may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

T cells may be stimulated with a polypeptide, polynucleotide encoding a polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide of interest. Preferably, a tumor polypeptide or polynucleotide of the invention is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a polypeptide of the present invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., *Cancer Res.* 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a tumor polypeptide (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 days will typically result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (see Coligan et

al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a tumor polypeptide, polynucleotide or polypeptide-expressing APC may be CD4⁺ and/or CD8⁺. Tumor polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to a tumor polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a tumor polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of the tumor polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

Pharmaceutical Compositions

In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell and/or antibody compositions disclosed herein in pharmaceutically-acceptable carriers for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

It will be understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, such as, *e.g.*, other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as

described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

Therefore, in another aspect of the present invention, pharmaceutical compositions are provided comprising one or more of the polynucleotide, polypeptide, antibody, and/or T-cell compositions described herein in combination with a physiologically acceptable carrier. In certain preferred embodiments, the pharmaceutical compositions of the invention comprise immunogenic polynucleotide and/or polypeptide compositions of the invention for use in prophylactic and therapeutic vaccine applications. Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Generally, such compositions will comprise one or more polynucleotide and/or polypeptide compositions of the present invention in combination with one or more immunostimulants.

It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable salts of the polynucleotides and polypeptides of the invention. Such salts can be prepared, for example, from pharmaceutically acceptable non-toxic bases, including organic bases (*e.g.*, salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (*e.g.*, sodium, potassium, lithium, ammonium, calcium and magnesium salts).

In another embodiment, illustrative immunogenic compositions, *e.g.*, vaccine compositions, of the present invention comprise DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the polynucleotide may be administered within any of a variety of delivery systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable promoter and terminating signal). Alternatively, bacterial delivery systems may involve

the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (*e.g.*, U.S. Pat. No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A. D. (1990) *Human Gene Therapy* 1:5-14; Scarpa et al. (1991) *Virology* 180:849-852; Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109.

In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett et al. (1993) *J. Virol.* 67:5911-5921; Mittereder et al. (1994) *Human Gene Therapy* 5:717-729; Seth et al. (1994) *J. Virol.* 68:933-940; Barr et al. (1994) *Gene Therapy* 1:51-58; Berkner, K. L. (1988) *BioTechniques* 6:616-629; and Rich et al. (1993) *Human Gene Therapy* 4:461-476).

Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, *e.g.*, U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines 90* (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129;

Kotin, R. M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; and Zhou et al. (1994) J. Exp. Med. 179:1867-1875.

Additional viral vectors useful for delivering the polynucleotides encoding polypeptides of the present invention by gene transfer include those derived from the pox family of viruses, such as vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK.sup.(-) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, *e.g.*, Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al. Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.

Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer

protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant

5 Avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, *e.g.*, WO 91/12882; WO 89/03429; and WO 92/03545.

Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in

10 U.S. Patent Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Patent Nos. 5,505,947 and 5,643,576.

Moreover, molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al. *J. Biol. Chem.* (1993) 268:6866-6869 and Wagner et

15 al. *Proc. Natl. Acad. Sci. USA* (1992) 89:6099-6103, can also be used for gene delivery under the invention.

Additional illustrative information on these and other known viral-based delivery systems can be found, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al.,

25 *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993.

In certain embodiments, a polynucleotide may be integrated into the genome of a target cell. This integration may be in a specific location and orientation *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the

30 polynucleotide may be stably maintained in the cell as a separate, episomal segment of

DNA. Such polynucleotide segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. The manner in which the expression construct is delivered to a cell and where in the cell the polynucleotide remains is dependent on the type of expression
5 construct employed.

In another embodiment of the invention, a polynucleotide is administered/delivered as "naked" DNA, for example as described in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable
10 beads, which are efficiently transported into the cells.

In still another embodiment, a composition of the present invention can be delivered via a particle bombardment approach, many of which have been described. In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK)
15 and Powderject Vaccines Inc. (Madison, WI), some examples of which are described in U.S. Patent Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device,
20 propelling the particles into a target tissue of interest.

In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include those provided by Bioject, Inc. (Portland, OR), some examples of which are described in U.S. Patent Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639
25 and 5,993,412.

According to another embodiment, the pharmaceutical compositions described herein will comprise one or more immunostimulants in addition to the immunogenic polynucleotide, polypeptide, antibody, T-cell and/or APC compositions of this invention. An immunostimulant refers to essentially any substance that enhances
30 or potentiates an immune response (antibody and/or cell-mediated) to an exogenous

antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins.

5 Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated

10 sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Within certain embodiments of the invention, the adjuvant composition

15 is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (*e.g.*, IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as

20 provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman,

25 *Ann. Rev. Immunol.* 7:145-173, 1989.

Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL[®] adjuvants are available from Corixa Corporation (Seattle, WA; *see*, for example, US

30 Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing

oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by
5 Sato et al., *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example
10 combinations of at least two of the following group comprising QS21, QS7, Quil A, β -escin, or digitonin.

Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix,
15 particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or
20 suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol^R to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.


In one preferred embodiment, the adjuvant system includes the
25 combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL[®] adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-

MPL[®] adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 is disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn[®]; Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula



wherein, n is 1-50, A is a bond or $-\text{C}(\text{O})-$, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12th edition: entry 7717). These adjuvant molecules are described in WO

99/52549. The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

5 According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or
10 maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

15 Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (*see* Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In
20 general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex*
25 *vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see* Zitvogel et al., *Nature Med.* 4:594-600, 1998).

 Dendritic cells and progenitors may be obtained from peripheral blood,
30 bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph

nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from
5 peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature"
10 cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature
15 phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide of the
20 invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a pharmaceutical composition comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be
25 administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or
30 progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or

RNA; or with antigen-expressing recombinant bacterium or viruses (*e.g.*, vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (*e.g.*, a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will typically vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

Carriers for use within such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release. In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such compositions is well within the level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (*e.g.*, a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (*see e.g.*, U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

In another illustrative embodiment, biodegradable microspheres (*e.g.*, polylactate polyglycolate) are employed as carriers for the compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763;

5.814,344, 5,407,609 and 5,942,252. Modified hepatitis B core protein carrier systems, such as described in WO/99 40934, and references cited therein, will also be useful for many applications. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Patent No. 5 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

The pharmaceutical compositions of the invention will often further comprise one or more buffers (*e.g.*, neutral buffered saline or phosphate buffered saline), carbohydrates (*e.g.*, glucose, mannose, sucrose or dextrans), mannitol, proteins, 10 polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (*e.g.*, aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate.

15 The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition 20 may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, parenteral, intravenous, intranasal, and intramuscular administration and 25 formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they

may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (see, for example, Mathiowitz *et al.*, Nature 1997 Mar 27;386(6623):410-4; Hwang *et al.*, Crit Rev Ther Drug Carrier Syst 1998;15(3):243-84; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451). Tablets, troches, pills, capsules and the like may also contain any of a variety of additional components, for example, a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.

Typically, these formulations will contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

For oral administration, the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. Alternatively, the active ingredient may be incorporated into an oral solution such as
5 one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

10 In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363. In certain embodiments, solutions of the active compounds
15 as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

20 Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U. S. Patent 5,466,468). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and
25 storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as
30 lecithin, by the maintenance of the required particle size in the case of dispersion and/or

by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- 5 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered
10 isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml
15 of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations will of course preferably meet sterility, pyrogenicity, and the general safety and purity
20 standards as required by FDA Office of Biologics standards.

In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for
25 example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be

administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption
5 delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. The phrase
10 "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the
15 lungs *via* nasal aerosol sprays has been described, *e.g.*, in U. S. Patent 5,756,353 and U. S. Patent 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, *J Controlled Release* 1998 Mar 2;52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871) are also well-known in the pharmaceutical arts. Likewise, illustrative transmucosal drug delivery in the form of
20 a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045.

In certain embodiments, liposomes, nanocapsules, microparticles, lipid particles, vesicles, and the like, are used for the introduction of the compositions of the present invention into suitable host cells/organisms. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid
25 particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like. Alternatively, compositions of the present invention can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

The formation and use of liposome and liposome-like preparations as potential drug carriers is generally known to those of skill in the art (see for example,
30 Lasic, *Trends Biotechnol* 1998 Jul;16(7):307-21; Takakura, *Nippon Rinsho* 1998

Mar;56(3):691-5; Chandran *et al.*, Indian J Exp Biol. 1997 Aug;35(8):801-9; Margalit, Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61; U.S. Patent 5,567,434; U.S. Patent 5,552,157; U.S. Patent 5,565,213; U.S. Patent 5,738,868 and U.S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

5 Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, J Biol Chem. 1990 Sep 25;265(27):16337-42; Muller *et al.*, DNA Cell Biol. 1990 Apr;9(3):221-9). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery
10 systems. Liposomes have been used effectively to introduce genes, various drugs, radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, the use of liposomes does not appear to be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

15 In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)).

 Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the
20 present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (see, for example, Quintanar-Guerrero *et al.*, Drug Dev Ind Pharm. 1998 Dec;24(12):1113-28). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) may be designed using polymers able to be degraded *in vivo*. Such particles can be made as described, for
25 example, by Couvreur *et al.*, Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20; zur Muhlen *et al.*, Eur J Pharm Biopharm. 1998 Mar;45(2):149-55; Zambaux *et al.* J Controlled Release. 1998 Jan 2;50(1-3):31-40; and U. S. Patent 5,145,684.

Cancer Therapeutic Methods

In further aspects of the present invention, the pharmaceutical compositions described herein may be used for the treatment of cancer, particularly for the immunotherapy of prostate cancer. Within such methods, the pharmaceutical compositions described herein are administered to a patient, typically a warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. As discussed above, administration of the pharmaceutical compositions may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The

polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (*see*, for example, Cheever et al., *Immunological Reviews* 157:177, 1997).

Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g.*, intracutaneous,

intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25 μ g to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

Cancer Detection and Diagnostic Compositions, Methods and Kits

In general, a cancer may be detected in a patient based on the presence of one or more prostate tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies)

obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as prostate cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a prostate tumor sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue

There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. *See, e.g.,* Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length prostate tumor proteins and polypeptide portions thereof to which the binding agent binds, as described above.

The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μ g, and preferably about 100 ng to about 1 μ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (*see, e.g.,* Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized

on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of
5 detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically
10 blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact
15 time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve
20 equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM. The second
25 antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of
30 binding that occurs over a period of time. Unbound detection reagent is then removed

and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

10 To determine the presence or absence of a cancer, such as prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with
15 samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985,
20 p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a
25 signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such tumor protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (e.g., 5 - 25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of tumor polypeptide to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a tumor protein of the invention that is at least 10

nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence as disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (*see*, for example, Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the

cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound
5 binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific
10 for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

15 The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a tumor protein.
20 Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

25 Alternatively, a kit may be designed to detect the level of mRNA encoding a tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be

present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a tumor protein.

The following Examples are offered by way of illustration and not by way of limitation.

5

EXAMPLES

EXAMPLE 1

ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC POLYPEPTIDES

10

This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library was constructed from prostate tumor poly A⁺ RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A⁺ RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, CA) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax *E. coli* DH10B cells (BRL Life Technologies) by electroporation.

Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis.

30

The prostate tumor library contained 1.64×10^7 independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained 3.3×10^6 independent colonies, with 69% of clones having inserts and the average insert size being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.

cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara *et al.* (*Blood*, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70 μ g) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 μ l of H₂O, heat-denatured and mixed with 100 μ l (100 μ g) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 μ l) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 μ l H₂O to form the driver DNA.

To form the tracer DNA, 10 μ g prostate tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 μ l H₂O. Tracer DNA was mixed with 15 μ l driver DNA and 20 μ l of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 μ l H₂O, mixed with 8 μ l driver DNA and 20 μ l of 2 x hybridization buffer, and subjected to a hybridization at 68

32 P for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK⁺ (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax *E. coli* DH10B cells by electroporation to generate a prostate tumor specific subtracted
5 cDNA library (referred to as "prostate subtraction 1").

To analyze the subtracted cDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems
10 Division Automated Sequencer Model 373A (Foster City, CA). Six cDNA clones, hereinafter referred to as F1-13, F1-12, F1-16, H1-1, H1-9 and H1-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3' and 5' cDNA sequences for F1-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3' cDNA sequences for F1-13, F1-16, H1-1, H1-9 and H1-4 being provided
15 in SEQ ID NO: 1 and 4-7, respectively.

The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, F1-13, F1-16, H1-1, and H1-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA),
20 human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. H1-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for F1-12 were found.

Subsequent studies led to the isolation of a full-length cDNA sequence
25 for F1-12 (also referred to as P504S). This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108. cDNA splice variants of P504S are provided in SEQ ID NO: 600-605.

To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described
30 above with the normal pancreas cDNA library and with the three most abundant genes

in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1 μ g each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNA3.1 were added to the
5 driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the "subtracted prostate tumor specific cDNA library with spike".

Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3' and 5' cDNA sequences for
10 the clones referred to as J1-17, L1-12, N1-1862, J1-13, J1-19, J1-25, J1-24, K1-58, K1-63, L1-4 and L1-14 are provided in SEQ ID NOS: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-27 and 28-29, respectively. The determined 3' cDNA sequences for the clones referred to as J1-12, J1-16, J1-21, K1-48, K1-55, L1-2, L1-6, N1-1858, N1-1860, N1-1861, N1-1864 are provided in SEQ ID NOS: 30-40,
15 respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (J1-17, L1-12 and N1-1862; SEQ ID NOS: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (J1-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein,
20 and the other (K1-48; SEQ ID NO:33) was determined to have some homology to *R. norvegicus* mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (J1-16, K1-55, L1-6 and N1-1864; SEQ ID NOS:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (J1-21 and N1-1860;
25 SEQ ID NOS: 32 and 38, respectively) were found to show some homology to non-human sequences, and two (L1-2 and N1-1861; SEQ ID NOS: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides J1-13, J1-19, J1-24, J1-25, K1-58, K1-63, L1-4, L1-14 (SEQ ID NOS: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29,
30 respectively).

Subsequent studies led to the isolation of full length cDNA sequences for J1-17, L1-12 and N1-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114. L1-12 is also referred to as P501S. A cDNA splice variant of P501S is provided in SEQ ID NO: 606.

5 In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (referred to as "prostate subtraction 2"). The determined cDNA sequences for these clones, hereinafter referred to as U1-3064, U1-3065, V1-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively.

10 Comparison of the determined sequences with those in the gene bank revealed no significant homologies to U1-3065.

A second subtraction with spike (referred to as "prostate subtraction spike 2") was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, J1-17, pulmonary surfactant-associated protein, mitochondrial DNA, cytochrome c oxidase subunit II, N1-1862, autonomously replicating sequence, L1-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as V1-3686, R1-2330, 1B-3976 and V1-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO:73-76, respectively. Comparison of these sequences

15 with those in the gene bank revealed no significant homologies to V1-3686 and R1-2330.

Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones, referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4810, 1I-4811, 1J-4876, 1K-4884 and 1K-4896. The determined cDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 1I-4807, 1J-4876 and

25 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively). Further analysis of the

30

isolated clones led to the determination of extended cDNA sequences for 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4807, 1J-4876, 1K-4884 and 1K-4896, provided in SEQ ID NOS: 179-188 and 191-193, respectively, and to the determination of additional partial cDNA sequences for 1I-4810
5 and 1I-4811, provided in SEQ ID NOS: 189 and 190, respectively.

Additional studies with prostate subtraction spike 2 resulted in the isolation of three more clones. Their sequences were determined as described above and compared to the most recent GenBank. All three clones were found to have homology to known genes, which are Cysteine-rich protein, KIAA0242, and KIAA0280
10 (SEQ ID NO: 317, 319, and 320, respectively). Further analysis of these clones by Synteni microarray (Synteni, Palo Alto, CA) demonstrated that all three clones were over-expressed in most prostate tumors and prostate BPH, as well as in the majority of normal prostate tissues tested, but low expression in all other normal tissues.

An additional subtraction was performed by subtracting a normal
15 prostate cDNA library with normal pancreas cDNA (referred to as "prostate subtraction 3"). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively). Further analysis of the
20 isolated clones led to the determination of extended cDNA sequences for 1G-4761, 1G-4762, 1H-4766 and 1H-4772 provided in SEQ ID NOS: 194-196 and 199, respectively, and to the determination of additional partial cDNA sequences for 1H-4770 and 1H-4771, provided in SEQ ID NOS: 197 and 198, respectively.

Subtraction of a prostate tumor cDNA library, prepared from a pool of
25 polyA+ RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS:
30 103 and 104, respectively). Further analysis of the isolated clones led to the

determination of extended cDNA sequences for 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280, provided in SEQ ID NOS: 200-206, respectively.

cDNA clones isolated in prostate subtraction 1 and prostate subtraction 2, described above, were colony PCR amplified and their mRNA expression levels in prostate tumor, normal prostate and in various other normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted onto slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested, reverse transcribed, and fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity. Two clones (referred to as P509S and P510S) were found to be over-expressed in prostate tumor and normal prostate and expressed at low levels in all other normal tissues tested (liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon). The determined cDNA sequences for P509S and P510S are provided in SEQ ID NO: 223 and 224, respectively. Comparison of these sequences with those in the gene bank as described above, revealed some homology to previously identified ESTs.

Additional, studies led to the isolation of the full-length cDNA sequence for P509S. This sequence is provided in SEQ ID NO: 332, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 339. Two variant full-length cDNA sequences for P510S are provided in SEQ ID NO: 535 and 536, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 537 and 538, respectively. Additional splice variants of P510S are provided in SEQ ID NO: 598 and 599.

EXAMPLE 2

DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE-SPECIFIC POLYPEPTIDES

Using gene specific primers, mRNA expression levels for the
5 representative prostate-specific polypeptides F1-16, H1-1, J1-17 (also referred to as P502S), L1-12 (also referred to as P501S), F1-12 (also referred to as P504S) and N1-1862 (also referred to as P503S) were examined in a variety of normal and tumor tissues using RT-PCR.

Briefly, total RNA was extracted from a variety of normal and tumor
10 tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 μ g of total RNA with SuperScript II reverse transcriptase (BRL Life Technologies) at 42 °C for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, β -actin was used as an internal control for each of the tissues examined. First, serial dilutions of the
15 first strand cDNAs were prepared and RT-PCR assays were performed using β -actin specific primers. A dilution was then chosen that enabled the linear range amplification of the β -actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the β -actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was
20 minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.

mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver,
25 lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. F1-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. H1-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon
30 and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin,

small intestine, bone marrow, and was not detected in the other tissues tested. J1-17 (P502S) and L1-12 (P501S) appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in prostate tumor and normal prostate but at low to undetectable levels in all the other tissues examined. N1-1862 (P503S) was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that F1-16, H1-1, J1-17 (P502S), N1-1862 (P503S) and L1-12 (P501S) are either prostate specific or are expressed at significantly elevated levels in prostate.

Further RT-PCR studies showed that F1-12 (P504S) is over-expressed in 60% of prostate tumors, detectable in normal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. U1-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not detectable in normal tissues.

RT-PCR characterization of R1-2330, U1-3064 and 1D-4279 showed that these three antigens are over-expressed in prostate and/or prostate tumors.

Northern analysis with four prostate tumors, two normal prostate samples, two BPH prostates, and normal colon, kidney, liver, lung, pancreas, skeletal muscle, brain, stomach, testes, small intestine and bone marrow, showed that L1-12 (P501S) is over-expressed in prostate tumors and normal prostate, while being undetectable in other normal tissues tested. J1-17 (P502S) was detected in two prostate tumors and not in the other tissues tested. N1-1862 (P503S) was found to be over-expressed in three prostate tumors and to be expressed in normal prostate, colon and kidney, but not in other tissues tested. F1-12 (P504S) was found to be highly expressed in two prostate tumors and to be undetectable in all other tissues tested.

The microarray technology described above was used to determine the expression levels of representative antigens described herein in prostate tumor, breast tumor and the following normal tissues: prostate, liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon. L1-12 (P501S) was found to be

over-expressed in normal prostate and prostate tumor, with some expression being detected in normal skeletal muscle. Both J1-12 and F1-12 (P504S) were found to be over-expressed in prostate tumor, with expression being lower or undetectable in all other tissues tested. N1-1862 (P503S) was found to be expressed at high levels in prostate tumor and normal prostate, and at low levels in normal large intestine and normal colon, with expression being undetectable in all other tissues tested. R1-2330 was found to be over-expressed in prostate tumor and normal prostate, and to be expressed at lower levels in all other tissues tested. 1D-4279 was found to be over-expressed in prostate tumor and normal prostate, expressed at lower levels in normal spinal cord, and to be undetectable in all other tissues tested.

Further microarray analysis to specifically address the extent to which P501S (SEQ ID NO: 110) was expressed in breast tumor revealed moderate over-expression not only in breast tumor, but also in metastatic breast tumor (2/31), with negligible to low expression in normal tissues. This data suggests that P501S may be over-expressed in various breast tumors as well as in prostate tumors.

The expression levels of 32 ESTs (expressed sequence tags) described by Vasmatzis *et al.* (*Proc. Natl. Acad. Sci. USA* 95:300-304, 1998) in a variety of tumor and normal tissues were examined by microarray technology as described above. Two of these clones (referred to as P1000C and P1001C) were found to be over-expressed in prostate tumor and normal prostate, and expressed at low to undetectable levels in all other tissues tested (normal aorta, thymus, resting and activated PBMC, epithelial cells, spinal cord, adrenal gland, fetal tissues, skin, salivary gland, large intestine, bone marrow, liver, lung, dendritic cells, stomach, lymph nodes, brain, heart, small intestine, skeletal muscle, colon and kidney. The determined cDNA sequences for P1000C and P1001C are provided in SEQ ID NO: 384 and 472, respectively. The sequence of P1001C was found to show some homology to the previously isolated Human mRNA for JM27 protein. Subsequent comparison of the sequence of SEQ ID NO: 384 with sequences in the public databases, led to the identification of a full-length cDNA sequence of P1000C (SEQ ID NO: 786), which encodes a 492 amino acid sequence. Analysis of the amino acid sequence using the PSORT II program led to the

identification of a putative transmembrane domain from amino acids 84-100. The cDNA sequence of the open reading frame of P1000C, including the stop codon, is provided in SEQ ID NO: 787, with the open reading frame without the stop codon being provided in SEQ ID NO: 788. The full-length amino acid sequence of P1000C is provided in SEQ ID NO: 789. SEQ ID NO: 790 and 791 represent amino acids 1-100 and 100-492 of P1000C, respectively.

The expression of the polypeptide encoded by the full length cDNA sequence for F1-12 (also referred to as P504S; SEQ ID NO: 108) was investigated by immunohistochemical analysis. Rabbit-anti-P504S polyclonal antibodies were generated against the full length P504S protein by standard techniques. Subsequent isolation and characterization of the polyclonal antibodies were also performed by techniques well known in the art. Immunohistochemical analysis showed that the P504S polypeptide was expressed in 100% of prostate carcinoma samples tested (n=5).

The rabbit-anti-P504S polyclonal antibody did not appear to label benign prostate cells with the same cytoplasmic granular staining, but rather with light nuclear staining. Analysis of normal tissues revealed that the encoded polypeptide was found to be expressed in some, but not all normal human tissues. Positive cytoplasmic staining with rabbit-anti-P504S polyclonal antibody was found in normal human kidney, liver, brain, colon and lung-associated macrophages, whereas heart and bone marrow were negative.

This data indicates that the P504S polypeptide is present in prostate cancer tissues, and that there are qualitative and quantitative differences in the staining between benign prostatic hyperplasia tissues and prostate cancer tissues, suggesting that this polypeptide may be detected selectively in prostate tumors and therefore be useful in the diagnosis of prostate cancer.

EXAMPLE 3

ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC
POLYPEPTIDES BY PCR-BASED SUBTRACTION

5 A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The
10 resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, WI) and transformed into XL-1 Blue MRF' *E. coli* (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.

 Fifty-nine positive clones were sequenced. Comparison of the DNA
15 sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, P18, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79 and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO: 41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID
20 NO: 46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate.

 Further studies employing the sequence of SEQ ID NO: 67 as a probe in standard full-length cloning methods, resulted in the isolation of three cDNA sequences
25 which appear to be splice variants of P80 (also known as P704P). These sequences are provided in SEQ ID NO: 620-622.

 Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant homologies to known sequences. The determined cDNA
30 sequences for these clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145,

147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. Larger cDNA clones containing the P20 sequence represent splice variants of a gene referred to as P703P. The determined DNA sequence for the variants referred to as DE1, DE13 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The determined cDNA sequence for an extended spliced form of P703 is provided in SEQ ID NO: 225. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.

mRNA Expression levels for representative clones in tumor tissues (prostate (n=5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n=2), ovary (n=2), skeletal muscle, skin, stomach, small intestine and brain), and activated and non-activated PBMC was determined by RT-PCR as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.

P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed comparable expression. P20, a portion of the P703P gene, was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of P18 was found in normal prostate, prostate tumor and breast tumor compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal prostate and prostate tumor, compared to six of twelve other normal tissues tested.

Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to the majority of normal tissues. However, substantial expression of P29 was observed in normal colon and
5 normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.

Further studies resulted in the isolation of twelve additional clones, hereinafter referred to as 10-d8, 10-h10, 11-c8, 7-g6, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3, 8-
10 h11, 9-f12 and 9-f3. The determined DNA sequences for 10-d8, 10-h10, 11-c8, 8-d4, 8-d9, 8-h11, 9-f12 and 9-f3 are provided in SEQ ID NO: 207, 208, 209, 216, 217, 220, 221 and 222, respectively. The determined forward and reverse DNA sequences for 7-g6, 8-b5, 8-b6 and 8-g3 are provided in SEQ ID NO: 210 and 211; 212 and 213; 214 and 215; and 218 and 219, respectively. Comparison of these sequences with those in
15 the gene bank revealed no significant homologies to the sequence of 9-f3. The clones 10-d8, 11-c8 and 8-h11 were found to show some homology to previously isolated ESTs, while 10-h10, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3 and 9-f12 were found to show some homology to previously identified genes. Further characterization of 7-G6 and 8-G3 showed identity to the known genes PAP and PSA, respectively.

20 mRNA expression levels for these clones were determined using the micro-array technology described above. The clones 7-G6, 8-G3, 8-B5, 8-B6, 8-D4, 8-D9, 9-F3, 9-F12, 9-H3, 10-A2, 10-A4, 11-C9 and 11-F2 were found to be over-expressed in prostate tumor and normal prostate, with expression in other tissues tested being low or undetectable. Increased expression of 8-F11 was seen in prostate tumor
25 and normal prostate, bladder, skeletal muscle and colon. Increased expression of 10-H10 was seen in prostate tumor and normal prostate, bladder, lung, colon, brain and large intestine. Increased expression of 9-B1 was seen in prostate tumor, breast tumor, and normal prostate, salivary gland, large intestine and skin, with increased expression of 11-C8 being seen in prostate tumor, and normal prostate and large intestine.

An additional cDNA fragment derived from the PCR-based normal prostate subtraction, described above, was found to be prostate specific by both microarray technology and RT-PCR. The determined cDNA sequence of this clone (referred to as 9-A11) is provided in SEQ ID NO: 226. Comparison of this sequence with those
5 in the public databases revealed 99% identity to the known gene HOXB13.

Further studies led to the isolation of the clones 8-C6 and 8-H7. The determined cDNA sequences for these clones are provided in SEQ ID NO: 227 and 228, respectively. These sequences were found to show some homology to previously isolated ESTs.

10 PCR and hybridization-based methodologies were employed to obtain longer cDNA sequences for clone P20 (also referred to as P703P), yielding three additional cDNA fragments that progressively extend the 5' end of the gene. These fragments, referred to as P703PDE5, P703P6.26, and P703PX-23 (SEQ ID NO: 326, 328 and 330, with the predicted corresponding amino acid sequences being provided in
15 SEQ ID NO: 327, 329 and 331, respectively) contain additional 5' sequence. P703PDE5 was recovered by screening of a cDNA library (#141-26) with a portion of P703P as a probe. P703P6.26 was recovered from a mixture of three prostate tumor cDNAs and P703PX_23 was recovered from cDNA library (#438-48). Together, the additional sequences include all of the putative mature serine protease along with part of
20 the putative signal sequence. The full-length cDNA sequence for P703P is provided in SEQ ID NO: 524, with the corresponding amino acid sequence being provided in SEQ ID NO: 525.

Using computer algorithms, the following regions of P703P were predicted to represent potential HLA A2-binding CTL epitopes: amino acids 164-172
25 of SEQ ID NO: 525 (SEQ ID NO: 723); amino acids 160-168 of SEQ ID NO: 525 (SEQ ID NO: 724); amino acids 239-247 of SEQ ID NO: 525 (SEQ ID NO: 725); amino acids 118-126 of SEQ ID NO: 525 (SEQ ID NO: 726); amino acids 112-120 of SEQ ID NO: 525 (SEQ ID NO: 727); amino acids 155-164 of SEQ ID NO: 525 (SEQ ID NO: 728); amino acids 117-126 of SEQ ID NO: 525 (SEQ ID NO: 729); amino acids
30 164-173 of SEQ ID NO: 525 (SEQ ID NO: 730); amino acids 154-163 of SEQ ID NO:

525 (SEQ ID NO: 731); amino acids 163-172 of SEQ ID NO: 525 (SEQ ID NO: 732); amino acids 58-66 of SEQ ID NO: 525 (SEQ ID NO: 733); and amino acids 59-67 of SEQ ID NO: 525 (SEQ ID NO: 734).

P703P was found to show some homology to previously identified
5 proteases, such as thrombin. The thrombin receptor has been shown to be preferentially expressed in highly metastatic breast carcinoma cells and breast carcinoma biopsy samples. Introduction of thrombin receptor antisense cDNA has been shown to inhibit the invasion of metastatic breast carcinoma cells in culture. Antibodies against thrombin receptor inhibit thrombin receptor activation and thrombin-induced platelet
10 activation. Furthermore, peptides that resemble the receptor's tethered ligand domain inhibit platelet aggregation by thrombin. P703P may play a role in prostate cancer through a protease-activated receptor on the cancer cell or on stromal cells. The potential trypsin-like protease activity of P703P may either activate a protease-activated receptor on the cancer cell membrane to promote tumorigenesis or activate a protease-
15 activated receptor on the adjacent cells (such as stromal cells) to secrete growth factors and/or proteases (such as matrix metalloproteinases) that could promote tumor angiogenesis, invasion and metastasis. P703P may thus promote tumor progression and/or metastasis through the activation of protease-activated receptor. Polypeptides and antibodies that block the P703P-receptor interaction may therefore be usefully
20 employed in the treatment of prostate cancer.

To determine whether P703P expression increases with increased severity of Gleason grade, an indicator of tumor stage, quantitative PCR analysis was performed on prostate tumor samples with a range of Gleason scores from 5 to > 8. The mean level of P703P expression increased with increasing Gleason score, indicating that
25 P703P expression may correlate with increased disease severity.

Further studies using a PCR-based subtraction library of a prostate tumor pool subtracted against a pool of normal tissues (referred to as JP: PCR subtraction) resulted in the isolation of thirteen additional clones, seven of which did not share any significant homology to known GenBank sequences. The determined cDNA sequences
30 for these seven clones (P711P, P712P, novel 23, P774P, P775P, P710P and P768P) are

provided in SEQ ID NO: 307-311, 313 and 315, respectively. The remaining six clones (SEQ ID NO: 316 and 321-325) were shown to share some homology to known genes. By microarray analysis, all thirteen clones showed three or more fold over-expression in prostate tissues, including prostate tumors, BPH and normal prostate as compared to
5 normal non-prostate tissues. Clones P711P, P712P, novel 23 and P768P showed over-expression in most prostate tumors and BPH tissues tested (n=29), and in the majority of normal prostate tissues (n=4), but background to low expression levels in all normal tissues. Clones P774P, P775P and P710P showed comparatively lower expression and expression in fewer prostate tumors and BPH samples, with negative to low expression
10 in normal prostate.

Further studies led to the isolation of an extended cDNA sequence for P712P (SEQ ID NO: 552). The amino acid sequences encoded by 16 predicted open reading frames present within the sequence of SEQ ID NO: 552 are provided in SEQ ID NO: 553-568.

15 The full-length cDNA for P711P was obtained by employing the partial sequence of SEQ ID NO: 307 to screen a prostate cDNA library. Specifically, a directionally cloned prostate cDNA library was prepared using standard techniques. One million colonies of this library were plated onto LB/Amp plates. Nylon membrane filters were used to lift these colonies, and the cDNAs which were picked up by these
20 filters were denatured and cross-linked to the filters by UV light. The P711P cDNA fragment of SEQ ID NO: 307 was radio-labeled and used to hybridize with these filters. Positive clones were selected, and cDNAs were prepared and sequenced using an automatic Perkin Elmer/Applied Biosystems sequencer. The determined full-length sequence of P711P is provided in SEQ ID NO: 382, with the corresponding predicted
25 amino acid sequence being provided in SEQ ID NO: 383.

Using PCR and hybridization-based methodologies, additional cDNA sequence information was derived for two clones described above, 11-C9 and 9-F3, herein after referred to as P707P and P714P, respectively (SEQ ID NO: 333 and 334). After comparison with the most recent GenBank, P707P was found to be a splice
30 variant of the known gene HoxB13. In contrast, no significant homologies to P714P

were found. Further studies employing the sequence of SEQ ID NO: 334 as a probe in standard full-length cloning methods, resulted in an extended cDNA sequence for P714P. This sequence is provided in SEQ ID NO: 619. This sequence was found to show some homology to the gene that encodes human ribosomal L23A protein.

5 Clones 8-B3, P89, P98, P130 and P201 (as disclosed in U.S. Patent Application No. 09/020,956, filed February 9, 1998) were found to be contained within one contiguous sequence, referred to as P705P (SEQ ID NO: 335, with the predicted amino acid sequence provided in SEQ ID NO: 336), which was determined to be a splice variant of the known gene NKX 3.1.

10 Further studies on P775P resulted in the isolation of four additional sequences (SEQ ID NO: 473-476) which are all splice variants of the P775P gene. The sequence of SEQ ID NO: 474 was found to contain two open reading frames (ORFs). The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 477 and 478. The cDNA sequence of SEQ ID NO: 475 was found to contain an
15 ORF which encodes the amino acid sequence of SEQ ID NO: 479. The cDNA sequence of SEQ ID NO: 473 was found to contain four ORFs. The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 480-483. Additional splice variants of P775P are provided in SEQ ID NO: 593-597.

Subsequent studies led to the identification of a genomic region on
20 chromosome 22q11.2, known as the Cat Eye Syndrome region, that contains the five prostate genes P704P, P712P, P774P, P775P and B305D. The relative location of each of these five genes within the genomic region is shown in Fig. 10. This region may therefore be associated with malignant tumors, and other potential tumor genes may be contained within this region. These studies also led to the identification of a potential
25 open reading frame (ORF) for P775P (provided in SEQ ID NO: 533), which encodes the amino acid sequence of SEQ ID NO: 534.

Comparison of the clone of SEQ ID NO: 325 (referred to as P558S) with sequences in the GenBank and GeneSeq DNA databases showed that P558S is identical to the prostate-specific transglutaminase gene, which is known to have two forms. The
30 full-length sequences for the two forms are provided in SEQ ID NO: 630 and 631, with

the corresponding amino acid sequences being provided in SEQ ID NO: 632 and 633, respectively. The cDNA sequence of SEQ ID NO: 631 has a 15 pair base insert, resulting in a 5 amino acid insert in the corresponding amino acid sequence (SEQ ID NO: 633). This insert is not present in the sequence of SEQ ID NO: 630.

5 Further studies on P768P (SEQ ID NO: 315) led to the identification of the putative full-length open reading frame (ORF). The cDNA sequence of the ORF with stop codon is provided in SEQ ID NO: 764. The cDNA sequence of the ORF without stop codon is provided in SEQ ID NO: 765, with the corresponding amino acid sequence being provided in SEQ ID NO: 766. This sequence was found to show 86%
10 identity to a rat calcium transporter protein, indicating that P768P may represent a human calcium transporter protein. The locations of transmembrane domains within P768P were predicted using the PSORT II computer algorithm. Six transmembrane domains were predicted at amino acid positions 118-134, 172-188, 211-227, 230-246, 282-298 and 348-364. The amino acid sequences of SEQ ID NO: 767-772 represent
15 amino acids 1-134, 135-188, 189-227, 228-246, 247-298 and 299-511 of P768P, respectively.

EXAMPLE 4

SYNTHESIS OF POLYPEPTIDES

20

Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems 430A peptide synthesizer using Fmoc chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of
25 conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid
30 (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of

0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

5

EXAMPLE 5

FURTHER ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC POLYPEPTIDES BY PCR-BASED SUBTRACTION

10 A cDNA library generated from prostate primary tumor mRNA as described above was subtracted with cDNA from normal prostate. The subtraction was performed using a PCR-based protocol (Clontech), which was modified to generate larger fragments. Within this protocol, tester and driver double stranded cDNA were separately digested with five restriction enzymes that recognize six-nucleotide
15 restriction sites (MluI, MscI, PvuII, SalI and StuI). This digestion resulted in an average cDNA size of 600 bp, rather than the average size of 300 bp that results from digestion with RsaI according to the Clontech protocol. This modification did not affect the subtraction efficiency. Two tester populations were then created with different adapters, and the driver library remained without adapters.

20 The tester and driver libraries were then hybridized using excess driver cDNA. In the first hybridization step, driver was separately hybridized with each of the two tester cDNA populations. This resulted in populations of (a) unhybridized tester cDNAs, (b) tester cDNAs hybridized to other tester cDNAs, (c) tester cDNAs hybridized to driver cDNAs and (d) unhybridized driver cDNAs. The two separate
25 hybridization reactions were then combined, and rehybridized in the presence of additional denatured driver cDNA. Following this second hybridization, in addition to populations (a) through (d), a fifth population (e) was generated in which tester cDNA with one adapter hybridized to tester cDNA with the second adapter. Accordingly, the second hybridization step resulted in enrichment of differentially expressed sequences
30 which could be used as templates for PCR amplification with adaptor-specific primers.

The ends were then filled in, and PCR amplification was performed using adaptor-specific primers. Only population (e), which contained tester cDNA that did not hybridize to driver cDNA, was amplified exponentially. A second PCR amplification step was then performed, to reduce background and further enrich
5 differentially expressed sequences.

This PCR-based subtraction technique normalizes differentially expressed cDNAs so that rare transcripts that are overexpressed in prostate tumor tissue may be recoverable. Such transcripts would be difficult to recover by traditional subtraction methods.

10 In addition to genes known to be overexpressed in prostate tumor, seventy-seven further clones were identified. Sequences of these partial cDNAs are provided in SEQ ID NO: 29 to 305. Most of these clones had no significant homology to database sequences. Exceptions were JPTPN23 (SEQ ID NO: 231; similarity to pig valosin-containing protein), JPTPN30 (SEQ ID NO: 234; similarity to rat mRNA for
15 proteasome subunit), JPTPN45 (SEQ ID NO: 243; similarity to rat *norvegicus* cytosolic NADP-dependent isocitrate dehydrogenase), JPTPN46 (SEQ ID NO: 244; similarity to human subclone H8 4 d4 DNA sequence), JP1D6 (SEQ ID NO: 265; similarity to *G. gallus* dynein light chain-A), JP8D6 (SEQ ID NO: 288; similarity to human BAC clone RG016J04), JP8F5 (SEQ ID NO: 289; similarity to human subclone H8 3 b5 DNA
20 sequence), and JP8E9 (SEQ ID NO: 299; similarity to human Alu sequence).

Additional studies using the PCR-based subtraction library consisting of a prostate tumor pool subtracted against a normal prostate pool (referred to as PT-PN PCR subtraction) yielded three additional clones. Comparison of the cDNA sequences of these clones with the most recent release of GenBank revealed no significant
25 homologies to the two clones referred to as P715P and P767P (SEQ ID NO: 312 and 314). The remaining clone was found to show some homology to the known gene KIAA0056 (SEQ ID NO: 318). Using microarray analysis to measure mRNA expression levels in various tissues, all three clones were found to be over-expressed in prostate tumors and BPH tissues. Specifically, clone P715P was over-expressed in most
30 prostate tumors and BPH tissues by a factor of three or greater, with elevated expression

seen in the majority of normal prostate samples and in fetal tissue, but negative to low expression in all other normal tissues. Clone P767P was over-expressed in several prostate tumors and BPH tissues, with moderate expression levels in half of the normal prostate samples, and background to low expression in all other normal tissues tested.

5 Further analysis, by microarray as described above, of the PT-PN PCR subtraction library and of a DNA subtraction library containing cDNA from prostate tumor subtracted with a pool of normal tissue cDNAs, led to the isolation of 27 additional clones (SEQ ID NO: 340-365 and 381) which were determined to be over-expressed in prostate tumor. The clones of SEQ ID NO: 341, 342, 345, 347, 348, 349,
10 351, 355-359, 361, 362 and 364 were also found to be expressed in normal prostate. Expression of all 26 clones in a variety of normal tissues was found to be low or undetectable, with the exception of P544S (SEQ ID NO: 356) which was found to be expressed in small intestine. Of the 26 clones, 11 (SEQ ID NO: 340-349 and 362) were found to show some homology to previously identified sequences. No significant
15 homologies were found to the clones of SEQ ID NO: 350, 351, 353-361, and 363-365.

Comparison of the sequence of SEQ ID NO: 362 with sequences in the GenBank and GeneSeq DNA databases showed that this clone (referred to as P788P) is identical to GeneSeq Accession No. X27262, which encodes a protein found in the GeneSeq protein Accession No. Y00931. The full length cDNA sequence of P788P is
20 provided in SEQ ID NO: 634, with the corresponding predicted amino acid being provided in SEQ ID NO: 635. Subsequently, a full-length cDNA sequence for P788P that contains polymorphisms not found in the sequence of SEQ ID NO: 634, was cloned multiple times by PCR amplification from cDNA prepared from several RNA templates from three individuals. This determined cDNA sequence of this polymorphic variant of
25 P788P is provided in SEQ ID NO: 636, with the corresponding amino acid sequence being provided in SEQ ID NO: 637. The sequence of SEQ ID NO: 637 differs from that of SEQ ID NO: 635 by six amino acid residues. The P788P protein has 7 potential transmembrane domains at the C-terminal portion and is predicted to be a plasma membrane protein with an extracellular N-terminal region.

Further studies on the clone of SEQ ID NO: 352 (referred to as P790P) led to the isolation of the full-length cDNA sequence of SEQ ID NO: 526. The corresponding predicted amino acid is provided in SEQ ID NO: 527. Data from two quantitative PCR experiments indicated that P790P is over-expressed in 11/15 tested prostate tumor samples and is expressed at low levels in spinal cord, with no expression being seen in all other normal samples tested. Data from further PCR experiments and microarray experiments showed over-expression in normal prostate and prostate tumor with little or no expression in other tissues tested. P790P was subsequently found to show significant homology to a previously identified G-protein coupled prostate tissue receptor.

Additional studies on the clone of SEQ ID NO: 354 (referred to as P776P) led to the isolation of an extended cDNA sequence, provided in SEQ ID NO: 569. The determined cDNA sequences of three additional splice variants of P776P are provided in SEQ ID NO: 570-572. The amino acid sequences encoded by two predicted open reading frames (ORFs) contained within SEQ ID NO: 570, one predicted ORF contained within SEQ ID NO: 571, and 11 predicted ORFs contained within SEQ ID NO: 569, are provided in SEQ ID NO: 573-586, respectively. Further studies led to the isolation of the full-length sequence for the clone of SEQ ID NO: 570 (provided in SEQ ID NO: 737). Full-length cloning efforts on the clone of SEQ ID NO: 571 led to the isolation of two sequences (provided in SEQ ID NO: 738 and 739), representing a single clone, that are identical with the exception of a polymorphic insertion/deletion at position 1293. Specifically, the clone of SEQ ID NO: 739 (referred to as clone F1) has a C at position 1293. The clone of SEQ ID NO: 738 (referred to as clone F2) has a single base pair deletion at position 1293. The predicted amino acid sequences encoded by 5 open reading frames located within SEQ ID NO: 737 are provided in SEQ ID NO: 740-744, with the predicted amino acid sequences encoded by the clone of SEQ ID NO: 738 and 739 being provided in SEQ ID NO: 745-750.

Comparison of the cDNA sequences for the clones P767P (SEQ ID NO: 314) and P777P (SEQ ID NO: 350) with sequences in the GenBank human EST database showed that the two clones matched many EST sequences in common,

suggesting that P767P and P777P may represent the same gene. A DNA consensus sequence derived from a DNA sequence alignment of P767P, P777P and multiple EST clones is provided in SEQ ID NO: 587. The amino acid sequences encoded by three putative ORFs located within SEQ ID NO: 587 are provided in SEQ ID NO: 588-590.

5 The clone of SEQ ID NO: 342 (referred to as P789P) was found to show homology to a previously identified gene. The full length cDNA sequence for P789P and the corresponding amino acid sequence are provided in SEQ ID NO: 735 and 736, respectively.

10

EXAMPLE 6

PEPTIDE PRIMING OF MICE AND PROPAGATION OF CTL LINES

6.1. This Example illustrates the preparation of a CTL cell line specific for cells expressing the P502S gene.

15

Mice expressing the transgene for human HLA A2Kb (provided by Dr L. Sherman, The Scripps Research Institute, La Jolla, CA) were immunized with P2S#12 peptide (VLGWVAEL; SEQ ID NO: 306), which is derived from the P502S gene (also referred to herein as J1-17, SEQ ID NO: 8), as described by Theobald et al., *Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995 with the following modifications. Mice were
20 immunized with 100µg of P2S#12 and 120µg of an I-A^b binding peptide derived from hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and using a nylon mesh single cell suspensions prepared. Cells were then resuspended at 6×10^6 cells/ml in complete media (RPMI-1640; Gibco BRL, Gaithersburg, MD) containing 10% FCS, 2mM Glutamine (Gibco BRL), sodium
25 pyruvate (Gibco BRL), non-essential amino acids (Gibco BRL), 2×10^{-5} M 2-mercaptoethanol, 50U/ml penicillin and streptomycin, and cultured in the presence of irradiated (3000 rads) P2S#12-pulsed (5mg/ml P2S#12 and 10mg/ml β 2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7µg/ml dextran sulfate and 25µg/ml LPS for 3 days). Six days later, cells (5×10^5 /ml) were
30 restimulated with 2.5×10^6 /ml peptide pulsed irradiated (20,000 rads) EL4A2Kb cells

(Sherman et al, *Science* 258:815-818, 1992) and 3×10^6 /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20U/ml IL-2. Cells continued to be restimulated on a weekly basis as described, in preparation for cloning the line.

P2S#12 line was cloned by limiting dilution analysis with peptide pulsed
5 EL4 A2Kb tumor cells (1×10^4 cells/ well) as stimulators and A2 transgenic spleen cells as feeders (5×10^5 cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, clones that were growing were isolated and maintained in culture. Several of these clones demonstrated significantly higher reactivity (lysis) against human fibroblasts (HLA A2Kb expressing) transduced with
10 P502S than against control fibroblasts. An example is presented in Figure 1.

This data indicates that P2S #12 represents a naturally processed epitope of the P502S protein that is expressed in the context of the human HLA A2Kb molecule.

15 6.2. This Example illustrates the preparation of murine CTL lines and CTL clones specific for cells expressing the P501S gene.

This series of experiments were performed similarly to that described above. Mice were immunized with the P1S#10 peptide (SEQ ID NO: 337), which is
20 derived from the P501S gene (also referred to herein as L1-12, SEQ ID NO: 110). The P1S#10 peptide was derived by analysis of the predicted polypeptide sequence for P501S for potential HLA-A2 binding sequences as defined by published HLA-A2 binding motifs (Parker, KC, et al, *J. Immunol.*, 152:163, 1994). P1S#10 peptide was synthesized as described in Example 4, and empirically tested for HLA-A2 binding
25 using a T cell based competition assay. Predicted A2 binding peptides were tested for their ability to compete HLA-A2 specific peptide presentation to an HLA-A2 restricted CTL clone (D150M58), which is specific for the HLA-A2 binding influenza matrix peptide fluM58. D150M58 CTL secretes TNF in response to self-presentation of peptide fluM58. In the competition assay, test peptides at 100-200 μ g/ml were added to
30 cultures of D150M58 CTL in order to bind HLA-A2 on the CTL. After thirty minutes,

CTL cultured with test peptides, or control peptides, were tested for their antigen dose response to the fluM58 peptide in a standard TNF bioassay. As shown in Figure 3, peptide P1S#10 competes HLA-A2 restricted presentation of fluM58, demonstrating that peptide P1S#10 binds HLA-A2.

5 Mice expressing the transgene for human HLA A2Kb were immunized as described by Theobald et al. (*Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995) with the following modifications. Mice were immunized with 62.5µg of P1S #10 and 120µg of an I-A^b binding peptide derived from Hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and single
10 cell suspensions prepared using a nylon mesh. Cells were then resuspended at 6×10^6 cells/ml in complete media (as described above) and cultured in the presence of irradiated (3000 rads) P1S#10-pulsed (2µg/ml P1S#10 and 10mg/ml β2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7µg/ml dextran sulfate and 25µg/ml LPS for 3 days). Six days later cells (5×10^5 /ml) were restimulated
15 with 2.5×10^6 /ml peptide-pulsed irradiated (20,000 rads) EL4A2Kb cells, as described above, and 3×10^6 /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20 U/ml IL-2. Cells were restimulated on a weekly basis in preparation for cloning. After three rounds of *in vitro* stimulations, one line was generated that recognized P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat targets as
20 shown in Figure 4.

A P1S#10-specific CTL line was cloned by limiting dilution analysis with peptide pulsed EL4 A2Kb tumor cells (1×10^4 cells/ well) as stimulators and A2 transgenic spleen cells as feeders (5×10^5 cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, viable clones were
25 isolated and maintained in culture. As shown in Figure 5, five of these clones demonstrated specific cytolytic reactivity against P501S-transduced Jurkat A2Kb targets. This data indicates that P1S#10 represents a naturally processed epitope of the P501S protein that is expressed in the context of the human HLA-A2.1 molecule.

EXAMPLE 7

PRIMING OF CTL *IN VIVO* USING NAKED DNA IMMUNIZATION

WITH A PROSTATE ANTIGEN

The prostate-specific antigen L1-12, as described above, is also referred
5 to as P501S. HLA A2Kb Tg mice (provided by Dr L. Sherman, The Scripps Research
Institute, La Jolla, CA) were immunized with 100 µg P501S in the vector VR1012
either intramuscularly or intradermally. The mice were immunized three times, with a
two week interval between immunizations. Two weeks after the last immunization,
immune spleen cells were cultured with Jurkat A2Kb-P501S transduced stimulator
10 cells. CTL lines were stimulated weekly. After two weeks of *in vitro* stimulation, CTL
activity was assessed against P501S transduced targets. Two out of 8 mice developed
strong anti-P501S CTL responses. These results demonstrate that P501S contains at
least one naturally processed HLA-A2-restricted CTL epitope.

15

EXAMPLE 8

ABILITY OF HUMAN T CELLS TO RECOGNIZE PROSTATE-SPECIFIC POLYPEPTIDES

This Example illustrates the ability of T cells specific for a prostate
tumor polypeptide to recognize human tumor.

20 Human CD8⁺ T cells were primed *in vitro* to the P2S-12 peptide (SEQ
ID NO: 306) derived from P502S (also referred to as J1-17) using dendritic cells
according to the protocol of Van Tsai et al. (*Critical Reviews in Immunology* 18:65-75,
1998). The resulting CD8⁺ T cell microcultures were tested for their ability to
recognize the P2S-12 peptide presented by autologous fibroblasts or fibroblasts which
25 were transduced to express the P502S gene in a γ -interferon ELISPOT assay (see
Lalvani et al., *J. Exp. Med.* 186:859-865, 1997). Briefly, titrating numbers of T cells
were assayed in duplicate on 10⁴ fibroblasts in the presence of 3 µg/ml human β 2-
microglobulin and 1 µg/ml P2S-12 peptide or control E75 peptide. In addition, T cells
were simultaneously assayed on autologous fibroblasts transduced with the P502S gene
30 or as a control, fibroblasts transduced with HER-2/*neu*. Prior to the assay, the

fibroblasts were treated with 10 ng/ml γ -interferon for 48 hours to upregulate class I MHC expression. One of the microcultures (#5) demonstrated strong recognition of both peptide pulsed fibroblasts as well as transduced fibroblasts in a γ -interferon ELISPOT assay. Figure 2A demonstrates that there was a strong increase in the number of γ -interferon spots with increasing numbers of T cells on fibroblasts pulsed with the P2S-12 peptide (solid bars) but not with the control E75 peptide (open bars). This shows the ability of these T cells to specifically recognize the P2S-12 peptide. As shown in Figure 2B, this microculture also demonstrated an increase in the number of γ -interferon spots with increasing numbers of T cells on fibroblasts transduced to express the P502S gene but not the HER-2/*neu* gene. These results provide additional confirmatory evidence that the P2S-12 peptide is a naturally processed epitope of the P502S protein. Furthermore, this also demonstrates that there exists in the human T cell repertoire, high affinity T cells which are capable of recognizing this epitope. These T cells should also be capable of recognizing human tumors which express the P502S gene.

EXAMPLE 9

ELICITATION OF PROSTATE ANTIGEN-SPECIFIC CTL RESPONSES

IN HUMAN BLOOD

This Example illustrates the ability of a prostate-specific antigen to elicit a CTL response in blood of normal humans.

Autologous dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal donors by growth for five days in RPMI medium containing 10% human serum, 50 ng/ml GMCSF and 30 ng/ml IL-4. Following culture, DC were infected overnight with recombinant P501S-expressing vaccinia virus at an M.O.I. of 5 and matured for 8 hours by the addition of 2 micrograms/ml CD40 ligand. Virus was inactivated by UV irradiation, CD8⁺ cells were isolated by positive selection using magnetic beads, and priming cultures were initiated in 24-well plates. Following five stimulation cycles using autologous fibroblasts

retrovirally transduced to express P501S and CD80, CD8+ lines were identified that specifically produced interferon-gamma when stimulated with autologous P501S-transduced fibroblasts. The P501S-specific activity of cell line 3A-1 could be maintained following additional stimulation cycles on autologous B-LCL transduced with P501S. Line 3A-1 was shown to specifically recognize autologous B-LCL transduced to express P501S, but not EGFP-transduced autologous B-LCL, as measured by cytotoxicity assays (^{51}Cr release) and interferon-gamma production (Interferon-gamma Elispot; *see above and Lalvani et al., J. Exp. Med. 186:859-865, 1997*). The results of these assays are presented in Figures 6A and 6B.

10

EXAMPLE 10

IDENTIFICATION OF A NATURALLY PROCESSED CTL EPITOPE CONTAINED WITHIN THE
PROSTATE-SPECIFIC ANTIGEN P703P

The 9-mer peptide p5 (SEQ ID NO: 338) was derived from the P703P antigen (also referred to as P20). The p5 peptide is immunogenic in human HLA-A2 donors and is a naturally processed epitope. Antigen specific human CD8+ T cells can be primed following repeated *in vitro* stimulations with monocytes pulsed with p5 peptide. These CTL specifically recognize p5-pulsed and P703P-transduced target cells in both ELISPOT (as described above) and chromium release assays. Additionally, immunization of HLA-A2Kb transgenic mice with p5 leads to the generation of CTL lines which recognize a variety of HLA-A2Kb or HLA-A2 transduced target cells expressing P703P.

Initial studies demonstrating that p5 is a naturally processed epitope were done using HLA-A2Kb transgenic mice. HLA-A2Kb transgenic mice were immunized subcutaneously in the footpad with 100 μg of p5 peptide together with 140 μg of hepatitis B virus core peptide (a Th peptide) in Freund's incomplete adjuvant. Three weeks post immunization, spleen cells from immunized mice were stimulated *in vitro* with peptide-pulsed LPS blasts. CTL activity was assessed by chromium release assay five days after primary *in vitro* stimulation. Retrovirally transduced cells expressing the

control antigen P703P and HLA-A2Kb were used as targets. CTL lines that specifically recognized both p5-pulsed targets as well as P703P-expressing targets were identified.

Human *in vitro* priming experiments demonstrated that the p5 peptide is immunogenic in humans. Dendritic cells (DC) were differentiated from monocyte
5 cultures derived from PBMC of normal human donors by culturing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, the DC were pulsed with 1 ug/ml p5 peptide and cultured with CD8+ T cell enriched PBMC. CTL lines were restimulated on a weekly basis with p5-pulsed monocytes. Five to six weeks after initiation of the CTL cultures,
10 CTL recognition of p5-pulsed target cells was demonstrated. CTL were additionally shown to recognize human cells transduced to express P703P, demonstrating that p5 is a naturally processed epitope.

Studies identifying a further peptide epitope (referred to as peptide 4) derived from the prostate tumor-specific antigen P703P that is capable of being
15 recognized by CD4 T cells on the surface of cells in the context of HLA class II molecules were carried out as follows. The amino acid sequence for peptide 4 is provided in SEQ ID NO: 638, with the corresponding cDNA sequence being provided in SEQ ID NO: 639.

Twenty 15-mer peptides overlapping by 10 amino acids and derived
20 from the carboxy-terminal fragment of P703P were generated using standard procedures. Dendritic cells (DC) were derived from PBMC of a normal female donor using GM-CSF and IL-4 by standard protocols. CD4 T cells were generated from the same donor as the DC using MACS beads and negative selection. DC were pulsed overnight with pools of the 15-mer peptides, with each peptide at a final concentration
25 of 0.25 microgram/ml. Pulsed DC were washed and plated at 1×10^4 cells/well of 96-well V-bottom plates and purified CD4 T cells were added at 1×10^5 /well. Cultures were supplemented with 60 ng/ml IL-6 and 10 ng/ml IL-12 and incubated at 37 °C. Cultures were restimulated as above on a weekly basis using DC generated and pulsed as above as antigen presenting cells, supplemented with 5 ng/ml IL-7 and 10 u/ml IL-2.
30 Following 4 *in vitro* stimulation cycles, 96 lines (each line corresponding to one well) were tested for specific proliferation and cytokine production in response to the

stimulating pools with an irrelevant pool of peptides derived from mammaglobin being used as a control.

One line (referred to as 1-F9) was identified from pool #1 that demonstrated specific proliferation (measured by ³H proliferation assays) and cytokine production (measured by interferon-gamma ELISA assays) in response to pool #1 of P703P peptides. This line was further tested for specific recognition of the peptide pool, specific recognition of individual peptides in the pool, and in HLA mismatch analyses to identify the relevant restricting allele. Line 1-F9 was found to specifically proliferate and produce interferon-gamma in response to peptide pool #1, and also to peptide 4 (SEQ ID NO: 638). Peptide 4 corresponds to amino acids 126-140 of SEQ ID NO: 327. Peptide titration experiments were conducted to assess the sensitivity of line 1-F9 for the specific peptide. The line was found to specifically respond to peptide 4 at concentrations as low as 0.25 ng/ml, indicating that the T cells are very sensitive and therefore likely to have high affinity for the epitope.

To determine the HLA restriction of the P703P response, a panel of antigen presenting cells (APC) was generated that was partially matched with the donor used to generate the T cells. The APC were pulsed with the peptide and used in proliferation and cytokine assays together with line 1-F9. APC matched with the donor at HLA-DRB0701 and HLA-DQB02 alleles were able to present the peptide to the T cells, indicating that the P703P-specific response is restricted to one of these alleles.

Antibody blocking assays were utilized to determine if the restricting allele was HLA-DR0701 or HLA-DQ02. The anti-HLA-DR blocking antibody L243 or an irrelevant isotype matched IgG2a were added to T cells and APC cultures pulsed with the peptide RMPTVLQCVNVS VVS (SEQ ID NO: 638) at 250 ng/ml. Standard interferon-gamma and proliferation assays were performed. Whereas the control antibody had no effect on the ability of the T cells to recognize peptide-pulsed APC, in both assays the anti-HLA-DR antibody completely blocked the ability of the T cells to specifically recognize peptide-pulsed APC.

To determine if the peptide epitope RMPTVLQCVNVS VVS (SEQ ID NO: 638) was naturally processed, the ability of line 1-F9 to recognize APC pulsed with recombinant P703P protein was examined. For these experiments a number of

recombinant P703P sources were utilized; *E. coli*-derived P703P, Pichia-derived P703P and baculovirus-derived P703P. Irrelevant protein controls used were *E. coli*-derived L3E (a lung-specific antigen) and baculovirus-derived mammaglobin. In interferon-gamma ELISA assays, line 1-F9 was able to efficiently recognize both *E. coli* forms of P703P as well as Pichia-derived recombinant P703P, while baculovirus-derived P703P was recognized less efficiently. Subsequent Western blot analysis revealed that the *E. coli* and Pichia P703P protein preparations were intact while the baculovirus P703P preparation was approximately 75% degraded. Thus, peptide RMPTVLQCVNVS VVS (SEQ ID NO: 638) from P703P is a naturally processed peptide epitope derived from P703P and presented to T cells in the context of HLA-DRB-0701

In further studies, twenty-four 15-mer peptides overlapping by 10 amino acids and derived from the N-terminal fragment of P703P (corresponding to amino acids 27-154 of SEQ ID NO: 525) were generated by standard procedures and their ability to be recognized by CD4 cells was determined essentially as described above. DC were pulsed overnight with pools of the peptides with each peptide at a final concentration of 10 microgram/ml. A large number of individual CD4 T cell lines (65/480) demonstrated significant proliferation and cytokine release (IFN-gamma) in response to the P703P peptide pools but not to a control peptide pool. The CD4 T cell lines which demonstrated specific activity were restimulated on the appropriate pool of P703P peptides and reassayed on the individual peptides of each pool as well as a peptide dose titration of the pool of peptides in a IFN-gamma release assay and in a proliferation assay.

Sixteen immunogenic peptides were recognized by the T cells from the entire set of peptide antigens tested. The amino acid sequences of these peptides are provided in SEQ ID NO: 656-671, with the corresponding cDNA sequences being provided in SEQ ID NO: 640-655, respectively. In some cases the peptide reactivity of the T cell line could be mapped to a single peptide, however some could be mapped to more than one peptide in each pool. Those CD4 T cell lines that displayed a representative pattern of recognition from each peptide pool with a reasonable affinity for peptide were chosen for further analysis (I-1A, -6A; II-4C, -5E; III-6E, IV-4B, -3F, -9B, -10F, V-5B, -4D, and -10F). These CD4 T cells lines were restimulated on the

appropriate individual peptide and reassayed on autologous DC pulsed with a truncated form of recombinant P703P protein made in *E. coli* (a.a. 96 - 254 of SEQ ID NO: 525), full-length P703P made in the baculovirus expression system, and a fusion between influenza virus NS1 and P703P made in *E. coli*. Of the T cell lines tested, line I-1A
5 recognized specifically the truncated form of P703P (*E. coli*) but no other recombinant form of P703P. This line also recognized the peptide used to elicit the T cells. Line 2-4C recognized the truncated form of P703P (*E. coli*) and the full length form of P703P made in baculovirus, as well as peptide. The remaining T cell lines tested were either peptide-specific only (II-5E, II-6F, IV-4B, IV-3F, IV-9B, IV-10F, V-5B and V-4D) or
10 were non-responsive to any antigen tested (V-10F). These results demonstrate that the peptide sequence RPLLANDLMLIKLDE (SEQ ID NO: 671; corresponding to a.a. 110-124 of SEQ ID NO: 525) recognized by the T cell line I-1A, and the peptide sequences SVSESDTIRSISIAS (SEQ ID NO: 668; corresponding to a.a. 125-139 of SEQ ID NO: 525) and ISIASQCPTAGNSCL (SEQ ID NO: 667; corresponding to a.a. 135-149 of
15 SEQ ID NO: 525) recognized by the T cell line II-4C may be naturally processed epitopes of the P703P protein.

EXAMPLE 11

EXPRESSION OF A BREAST TUMOR-DERIVED ANTIGEN

IN PROSTATE

20

Isolation of the antigen B305D from breast tumor by differential display is described in US Patent Application No. 08/700,014, filed August 20, 1996. Several different splice forms of this antigen were isolated. The determined cDNA sequences
25 for these splice forms are provided in SEQ ID NO: 366-375, with the predicted amino acid sequences corresponding to the sequences of SEQ ID NO: 292, 298 and 301-303 being provided in SEQ ID NO: 299-306, respectively. In further studies, a splice variant of the cDNA sequence of SEQ ID NO: 366 was isolated which was found to contain an additional guanine residue at position 884 (SEQ ID NO: 530), leading to a
30 frameshift in the open reading frame. The determined DNA sequence of this ORF is

provided in SEQ ID NO: 531. This frameshift generates a protein sequence (provided in SEQ ID NO: 532) of 293 amino acids that contains the C-terminal domain common to the other isoforms of B305D but that differs in the N-terminal region.

The expression levels of B305D in a variety of tumor and normal tissues were examined by real time PCR and by Northern analysis. The results indicated that B305D is highly expressed in breast tumor, prostate tumor, normal prostate and normal testes, with expression being low or undetectable in all other tissues examined (colon tumor, lung tumor, ovary tumor, and normal bone marrow, colon, kidney, liver, lung, ovary, skin, small intestine, stomach). Using real-time PCR on a panel of prostate tumors, expression of B305D in prostate tumors was shown to increase with increasing Gleason grade, demonstrating that expression of B305D increases as prostate cancer progresses.

EXAMPLE 12

15 GENERATION OF HUMAN CTL *IN VITRO* USING WHOLE GENE PRIMING AND STIMULATION TECHNIQUES WITH THE PROSTATE-SPECIFIC ANTIGEN P501S

Using *in vitro* whole-gene priming with P501S-vaccinia infected DC (see, for example, Yee et al, *The Journal of Immunology*, 157(9):4079-86, 1996), human CTL lines were derived that specifically recognize autologous fibroblasts transduced with P501S (also known as L1-12), as determined by interferon- γ ELISPOT analysis as described above. Using a panel of HLA-mismatched B-LCL lines transduced with P501S, these CTL lines were shown to be likely restricted to HLAB class I allele. Specifically, dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal human donors by growing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, DC were infected overnight with recombinant P501S vaccinia virus at a multiplicity of infection (M.O.I) of five, and matured overnight by the addition of 3 μ g/ml CD40 ligand. Virus was inactivated by UV irradiation. CD8+ T cells were isolated using a magnetic bead system, and priming cultures were initiated

using standard culture techniques. Cultures were restimulated every 7-10 days using autologous primary fibroblasts retrovirally transduced with P501S and CD80. Following four stimulation cycles, CD8+ T cell lines were identified that specifically produced interferon- γ when stimulated with P501S and CD80-transduced autologous fibroblasts. A panel of HLA-mismatched B-LCL lines transduced with P501S were generated to define the restriction allele of the response. By measuring interferon- γ in an ELISPOT assay, the P501S specific response was shown to be likely restricted by HLA B alleles. These results demonstrate that a CD8+ CTL response to P501S can be elicited.

To identify the epitope(s) recognized, cDNA encoding P501S was fragmented by various restriction digests, and sub-cloned into the retroviral expression vector pBIB-KS. Retroviral supernatants were generated by transfection of the helper packaging line Phoenix-Ampho. Supernatants were then used to transduce Jurkat/A2Kb cells for CTL screening. CTL were screened in IFN- γ ELISPOT assays against these A2Kb targets transduced with the "library" of P501S fragments. Initial positive fragments P501S/H3 and P501S/F2 were sequenced and found to encode amino acids 106-553 and amino acids 136-547, respectively, of SEQ ID NO: 113. A truncation of H3 was made to encode amino acid residues 106-351 of SEQ ID NO: 113, which was unable to stimulate the CTL, thus localizing the epitope to amino acid residues 351-547. Additional fragments encoding amino acids 1-472 (Fragment A) and amino acids 1-351 (Fragment B) were also constructed. Fragment A but not Fragment B stimulated the CTL thus localizing the epitope to amino acid residues 351-472. Overlapping 20-mer and 18-mer peptides representing this region were tested by pulsing Jurkat/A2Kb cells versus CTL in an IFN- γ assay. Only peptides P501S-369(20) and P501S-369(18) stimulated the CTL. Nine-mer and 10-mer peptides representing this region were synthesized and similarly tested. Peptide P501S-370 (SEQ ID NO: 539) was the minimal 9-mer giving a strong response. Peptide P501S-376 (SEQ ID NO: 540) also gave a weak response, suggesting that it might represent a cross-reactive epitope.

In subsequent studies, the ability of primary human B cells transduced with P501S to prime MHC class I-restricted, P501S-specific, autologous CD8 T cells was examined. Primary B cells were derived from PBMC of a homozygous HLA-A2 donor by culture in CD40 ligand and IL-4, transduced at high frequency with recombinant P501S in the vector pBIB, and selected with blastocidin-S. For *in vitro* priming, purified CD8+ T cells were cultured with autologous CD40 ligand + IL-4 derived, P501S-transduced B cells in a 96-well microculture format. These CTL microcultures were re-stimulated with P501S-transduced B cells and then assayed for specificity. Following this initial screen, microcultures with significant signal above background were cloned on autologous EBV-transformed B cells (BLCL), also transduced with P501S. Using IFN-gamma ELISPOT for detection, several of these CD8 T cell clones were found to be specific for P501S, as demonstrated by reactivity to BLCL/P501S but not BLCL transduced with control antigen. It was further demonstrated that the anti-P501S CD8 T cell specificity is HLA-A2-restricted. First, antibody blocking experiments with anti-HLA-A,B,C monoclonal antibody (W6.32), anti-HLA-B,C monoclonal antibody (B1.23.2) and a control monoclonal antibody showed that only the anti-HLA-A,B,C antibody blocked recognition of P501S-expressing autologous BLCL. Secondly, the anti-P501S CTL also recognized an HLA-A2 matched, heterologous BLCL transduced with P501S, but not the corresponding EGFP transduced control BLCL.

A naturally processed, CD8, class I-restricted peptide epitope of P501S was identified as follows. Dendritic Cells (DC) were isolated by Percol gradient followed by differential adherence, and cultured for 5 days in the presence of RPMI medium containing 1% human serum, 50ng/ml GM-CSF and 30ng/ml IL-4. Following culture, DC were infected for 24 hours with P501S-expressing adenovirus at an MOI of 10 and matured for an additional 24 hours by the addition of 2ug/ml CD40 ligand. CD8 cells were enriched for by the subtraction of CD4+, CD14+ and CD16+ populations from PBMC with magnetic beads. Priming cultures containing 10,000 P501S-expressing DC and 100,000 CD8+ T cells per well were set up in 96-well V-bottom plates with RPMI containing 10% human serum, 5ng/ml IL-12 and 10ng/ml IL-6. Cultures were stimulated every 7 days using autologous fibroblasts retrovirally

transduced to express P501S and CD80, and were treated with IFN-gamma for 48-72 hours to upregulate MHC Class I expression. 10u/ml IL-2 was added at the time of stimulation and on days 2 and 5 following stimulation. Following 4 stimulation cycles, one P501S-specific CD8+ T cell line (referred to as 2A2) was identified that produced IFN-gamma in response to IFN-gamma-treated P501S/CD80 expressing autologous fibroblasts, but not in response to IFN-gamma-treated P703P/CD80 expressing autologous fibroblasts in a γ -IFN Elispot assay. Line 2A2 was cloned in 96-well plates with 0.5 cell/well or 2 cells/well in the presence of 75,000 PBMC/well, 10,000 B-LCL/well, 30ng/ml OKT3 and 50u/ml IL-2. Twelve clones were isolated that showed strong P501S specificity in response to transduced fibroblasts.

Fluorescence activated cell sorting (FACS) analysis was performed on P501S-specific clones using CD3-, CD4- and CD8-specific antibodies conjugated to PercP, FITC and PE respectively. Consistent with the use of CD8 enriched T cells in the priming cultures, P5401S-specific clones were determined to be CD3+, CD8+ and CD4-.

To identify the relevant P501S epitope recognized by P501S specific CTL, pools of 18-20 mer or 30-mer peptides that spanned the majority of the amino acid sequence of P501S were loaded onto autologous B-LCL and tested in γ -IFN Elispot assays for the ability to stimulate two P501S-specific CTL clones, referred to as 4E5 and 4E7. One pool, composed of five 18-20 mer peptides that spanned amino acids 411-486 of P501S (SEQ ID NO: 113), was found to be recognized by both P501S-specific clones. To identify the specific 18-20 mer peptide recognized by the clones, each of the 18-20 mer peptides that comprised the positive pool were tested individually in γ -IFN Elispot assays for the ability to stimulate the two P501S-specific CTL clones, 4E5 and 4E7. Both 4E5 and 4E7 specifically recognized one 20-mer peptide (SEQ ID NO: 710; cDNA sequence provided in SEQ ID NO: 711) that spanned amino acids 453-472 of P501S. Since the minimal epitope recognized by CD8+ T cells is almost always either a 9 or 10-mer peptide sequence, 10-mer peptides that spanned the entire sequence of SEQ ID NO: 710 were synthesized that differed by 1 amino acid. Each of these 10-mer peptides was tested for the ability to stimulate two P501S-specific clones, (referred to as 1D5 and 1E12). One 10-mer peptide (SEQ ID NO: 712; cDNA sequence provided in

SEQ ID NO: 713) was identified that specifically stimulated the P501S-specific clones. This epitope spans amino acids 463-472 of P501S. This sequence defines a minimal 10-mer epitope from P501S that can be naturally processed and to which CTL responses can be identified in normal PBMC. Thus, this epitope is a candidate for use as a vaccine moiety, and as a therapeutic and/or diagnostic reagent for prostate cancer.

To identify the class I restriction element for the P501S-derived sequence of SEQ ID NO: 712, HLA blocking and mismatch analyses were performed. In γ -IFN Elispot assays, the specific response of clones 4A7 and 4E5 to P501S-transduced autologous fibroblasts was blocked by pre-incubation with 25ug/ml W6/32 (pan-Class I blocking antibody) and B1.23.2 (HLA-B/C blocking antibody). These results demonstrate that the SEQ ID NO: 712-specific response is restricted to an HLA-B or HLA-C allele.

For the HLA mismatch analysis, autologous B-LCL (HLA-A1,A2,B8,B51, Cw1, Cw7) and heterologous B-LCL (HLA-A2,A3,B18,B51,Cw5,Cw14) that share the HLAB51 allele were pulsed for one hour with 20ug/ml of peptide of SEQ ID NO: 712, washed, and tested in γ -IFN Elispot assays for the ability to stimulate clones 4A7 and 4E5. Antibody blocking assays with the B1.23.2 (HLA-B/C blocking antibody) were also performed. SEQ ID NO: 712-specific response was detected using both the autologous (D326) and heterologous (D107) B-LCL, and furthermore the responses were blocked by pre-incubation with 25ug/ml of B1.23.2 HLA-B/C blocking antibody. Together these results demonstrate that the P501S-specific response to the peptide of SEQ ID NO: 712 is restricted to the HLA-B51 class I allele. Molecular cloning and sequence analysis of the HLA-B51 allele from D3326 revealed that the HLA-B51 subtype of D326 is HLA-B51011.

Based on the 10-mer P501S-derived epitope of SEQ ID NO: 712, two 9-mers with the sequences of SEQ ID NO: 714 and 715 were synthesized and tested in Elispot assays for the ability to stimulate two P501S-specific CTL clones derived from line 2A2. The 10-mer peptide of SEQ ID NO: 712, as well as the 9-mer peptide of SEQ ID NO: 715, but not the 9-mer peptide of SEQ ID NO: 714, were capable of stimulating the P501S-specific CTL to produce IFN-gamma. These results demonstrate that the peptide of SEQ ID NO: 715 is a 9-mer P501S-derived epitope recognized by P501S-

specific CTL. The DNA sequence encoding the epitope of SEQ ID NO: 715 is provided in SEQ ID NO: 716.

To identify the class I restricting allele for the P501S-derived peptide of SEQ ID NO: 712 and 715 specific response, each of the HLA B and C alleles were
5 cloned from the donor used in the *in vitro* priming experiment. Sequence analysis indicated that the relevant alleles were HLA-B8, HLA-B51, HLA-Cw01 and HLA-Cw07. Each of these alleles were subcloned into an expression vector and co-transfected together with the P501S gene into VA-13 cells. Transfected VA-13 cells were then tested for the ability to specifically stimulate the P501S-specific CTL in
10 ELISPOT assays. VA-13 cells transfected with P501S and HLA-B51 were capable of stimulating the P501S-specific CTL to secrete gamma-IFN. VA-13 cells transfected with HLA-B51 alone or P501S + the other HLA-alleles were not capable of stimulating the P501S-specific CTL. These results demonstrate that the restricting allele for the P501S-specific response is the HLAB51 allele. Sequence analysis revealed that the
15 subtype of the relevant restricting allele is HLA-B51011.

To determine if the P501S-specific CTL could recognize prostate tumor cells that express P501S, the P501S-positive lines LnCAP and CRL2422 (both expressing "moderate" amounts of P501S mRNA and protein), and PC-3 (expressing low amounts of P501S mRNA and protein), plus the P501S-negative cell line DU-145
20 were retrovirally transduced with the HLA-B51011 allele that was cloned from the donor used to generate the P501S-specific CTL. HLA-B51011- or EGFP-transduced and selected tumor cells were treated with gamma-interferon and androgen (to upregulate stimulatory functions and P501S, respectively) and used in gamma-interferon Elispot assays with the P501S-specific CTL clones 4E5 and 4E7. Untreated
25 cells were used as a control.

Both 4E5 and 4E7 efficiently and specifically recognized LnCAP and CRL2422 cells that were transduced with the HLA-B51011 allele, but not the same cell lines transduced with EGFP. Additionally, both CTL clones specifically recognized PC-3 cells transduced with HLA-B51011, but not the P501S-negative tumor cell line
30 DU-145. Treatment with gamma-interferon or androgen did not enhance the ability of CTL to recognize tumor cells. These results demonstrate that P501S-specific CTL,

generated by *in vitro* whole gene priming, specifically and efficiently recognize prostate tumor cell lines that express P501S.

A naturally processed CD4 epitope of P501S was identified as follows.

CD4 cells specific for P501S were prepared as described above. A series
5 of 16 overlapping peptides were synthesized that spanned approximately 50% of the amino terminal portion of the P501S gene (amino acids 1- 325 of SEQ ID NO: 113). For priming, peptides were combined into pools of 4 peptides, pulsed at 4 µg/ml onto dendritic cells (DC) for 24 hours, with TNF-alpha. DC were then washed and mixed with negatively selected CD4+ T cells in 96 well U-bottom plates. Cultures were re-
10 stimulated weekly on fresh DC loaded with peptide pools. Following a total of 4 stimulation cycles, cells were rested for an additional week and tested for specificity to APC pulsed with peptide pools using γ-IFN ELISA and proliferation assays. For these assays, adherent monocytes loaded with either the relevant peptide pool at 4ug/ml or an irrelevant peptide at µg/ml were used as APC. T cell lines that demonstrated either
15 specific cytokine secretion or proliferation were then tested for recognition of individual peptides that were present in the pool. T cell lines could be identified from pools A and B that recognized individual peptides from these pools.

From pool A, lines AD9 and AE10 specifically recognized peptide 1 (SEQ ID NO: 719), and line AF5 recognized peptide 39 (SEQ ID NO: 718). From pool B, line BC6 could be identified that recognized peptide 58 (SEQ ID NO: 717). Each of these lines were stimulated on the specific peptide and tested for specific recognition of the peptide in a titration assay as well as cell lysates generated by infection of HEK 293 cells with adenovirus expressing either P501S or an irrelevant antigen. For these assays, APC-adherent monocytes were pulsed with either 10, 1, or 0.1 µg/ml individual P501S peptides, and DC were pulsed overnight with a 1:5 dilution of adenovirally infected cell lysates. Lines AD9, AE10 and AF5 retained significant recognition of the relevant P501S-derived peptides even at 0.1 mg/ml. Furthermore, line AD9 demonstrated significant (8.1 fold stimulation index) specific activity for lysates from adenovirus-P501S infected cells. These results demonstrate that high affinity CD4 T cell lines can be generated toward P501S-derived epitopes, and that at least a subset of these T cells specific for the P501S derived sequence of SEQ ID NO: 719 are specific for an epitope that is naturally processed by human cells. The DNA sequences encoding the amino acid sequences of SEQ ID NO: 717-719 are provided in SEQ ID NO: 720-722, respectively.

To further characterize the P501S-specific activity of AD9, the line was cloned using anti-CD3. Three clones, referred to as 1A1, 1A9 and 1F5, were identified that were specific for the P501S-1 peptide (SEQ ID NO: 719). To determine the HLA restriction allele for the P501S-specific response, each of these clones was tested in class II antibody blocking and HLA mismatch assays using proliferation and gamma-interferon assays. In antibody blocking assays and measuring gamma-interferon production using ELISA assays, the ability of all three clones to recognize peptide pulsed APC was specifically blocked by co-incubation with either a pan-class II blocking antibody or a HLA-DR blocking antibody, but not with a HLA-DQ or an irrelevant antibody. Proliferation assays performed simultaneously with the same cells confirmed these results. These data indicate that the P501S-specific response of the clones is restricted by an HLA-DR allele. Further studies demonstrated that the restricting allele for the P501S-specific response is HLA-DRB1501.

EXAMPLE 13

IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS
BY MICROARRAY ANALYSIS

5 This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

 A human prostate tumor cDNA expression library as described above was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to
10 non-prostate normal tissues (not including testis). 372 clones were identified, and 319 were successfully sequenced. Table I presents a summary of these clones, which are shown in SEQ ID NOs:385-400. Of these sequences SEQ ID NOs:386, 389, 390 and 392 correspond to novel genes, and SEQ ID NOs: 393 and 396 correspond to previously identified sequences. The others (SEQ ID NOs:385, 387, 388, 391, 394, 395 and 397-
15 400) correspond to known sequences, as shown in Table I.

Table I
Summary of Prostate Tumor Antigens

Known Genes	Previously Identified Genes	Novel Genes
T-cell gamma chain	P504S	23379 (SEQ ID NO:38)
Kallikrein	P1000C	23399 (SEQ ID NO:39)
Vector	P501S	23320 (SEQ ID NO:38)
CGI-82 protein mRNA (23319; SEQ ID NO:385)	P503S	23381 (SEQ ID NO:390)
PSA	P510S	
Ald. 6 Dehyd.	P784P	
L-Iditol-2 dehydrogenase (23376; SEQ ID NO:388)	P502S	
Ets transcription factor PDEF (22672; SEQ ID NO:398)	P706P	
hTGR (22678; SEQ ID NO:399)	19142.2, bangur.seq (22621; SEQ ID NO:396)	
KIAA0295(22685; SEQ ID NO:400)	5566.1 Wang (23404; SEQ ID NO:393)	
Prostatic Acid Phosphatase(22655; SEQ ID NO:397)	P712P	
transglutaminase (22611; SEQ ID NO:395)	P778P	
HDLBP (23508; SEQ ID NO:394)		
CGI-69 Protein(23367; SEQ ID NO:387)		
KIAA0122(23383; SEQ ID NO:391)		
TEEG		

CGI-82 showed 4.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 43% of prostate tumors, 25% normal prostate, not detected in other normal tissues tested. L-idoitol-2 dehydrogenase showed 4.94 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 90% of prostate tumors, 100% of normal prostate, and not detected in other normal tissues tested. Ets transcription factor PDEF showed 5.55 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% prostate tumors, 25% normal prostate and not detected in other normal tissues tested. hTGR1 showed 9.11 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 63% of prostate tumors and is not detected in normal tissues tested including normal prostate. KIAA0295 showed 5.59 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% of prostate tumors, low to undetectable in normal tissues tested including normal prostate tissues. Prostatic acid phosphatase showed 9.14 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 67% of prostate tumors, 50% of normal prostate, and not detected in other normal tissues tested. Transglutaminase showed 14.84 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 30% of prostate tumors, 50% of normal prostate, and is not detected in other normal tissues tested. High density lipoprotein binding protein (HDLBP) showed 28.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% of normal prostate, and is undetectable in all other normal tissues tested. CGI-69 showed 3.56 fold over-expression in prostate tissues as compared to other normal tissues tested. It is a low abundant gene, detected in more than 90% of prostate tumors, and in 75% normal prostate tissues. The expression of this gene in normal tissues was very low. KIAA0122 showed 4.24 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 57% of prostate tumors, it was undetectable in all normal tissues tested including normal prostate tissues. 19142.2 bangur showed 23.25 fold over-expression in prostate tissues as compared to other

normal tissues tested. It was over-expressed in 97% of prostate tumors and 100% of normal prostate. It was undetectable in other normal tissues tested. 5566.1 Wang showed 3.31 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% normal prostate and was also over-expressed in normal bone marrow, pancreas, and activated PBMC. Novel clone 23379 (also referred to as P553S) showed 4.86 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in 97% of prostate tumors and 75% normal prostate and is undetectable in all other normal tissues tested. Novel clone 23399 showed 4.09 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 27% of prostate tumors and was undetectable in all normal tissues tested including normal prostate tissues. Novel clone 23320 showed 3.15 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in all prostate tumors and 50% of normal prostate tissues. It was also expressed in normal colon and trachea. Other normal tissues do not express this gene at high level.

Subsequent full-length cloning studies on P553S, using standard techniques, revealed that this clone is an incomplete spliced form of P501S. The determined cDNA sequences for four splice variants of P553S are provided in SEQ ID NO: 623-626. An amino acid sequence encoded by SEQ ID NO: 626 is provided in SEQ ID NO: 627. The cDNA sequence of SEQ ID NO: 623 was found to contain two open reading frames (ORFs). The amino acid sequences encoded by these two ORFs are provided in SEQ ID NO: 628 and 629.

EXAMPLE 14

IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY ELECTRONIC SUBTRACTION

This Example describes the use of an electronic subtraction technique to identify prostate-specific antigens.

Potential prostate-specific genes present in the GenBank human EST database were identified by electronic subtraction (similar to that described by Vasmatizis et al., *Proc. Natl. Acad. Sci. USA* 95:300-304, 1998). The sequences of EST clones (43,482) derived from various prostate libraries were obtained from the GenBank public human EST database. Each prostate EST sequence was used as a query sequence in a BLASTN (National Center for Biotechnology Information) search against the human EST database. All matches considered identical (length of matching sequence >100 base pairs, density of identical matches over this region > 70%) were grouped (aligned) together in a cluster. Clusters containing more than 200 ESTs were discarded since they probably represented repetitive elements or highly expressed genes such as those for ribosomal proteins. If two or more clusters shared common ESTs, those clusters were grouped together into a "supercluster," resulting in 4,345 prostate superclusters.

Records for the 479 human cDNA libraries represented in the GenBank release were downloaded to create a database of these cDNA library records. These 479 cDNA libraries were grouped into three groups: Plus (normal prostate and prostate tumor libraries, and breast cell line libraries, in which expression was desired), Minus (libraries from other normal adult tissues, in which expression was not desirable), and Other (libraries from fetal tissue, infant tissue, tissues found only in women, non-prostate tumors and cell lines other than prostate cell lines, in which expression was considered to be irrelevant). A summary of these library groups is presented in Table II.

Table IIProstate cDNA Libraries and ESTs

Library	# of Libraries	# of ESTs
Plus	25	43,482
Normal	11	18,875
Tumor	11	21,769
Cell lines	3	2,838
Minus	166	
Other	287	

- 5 Each supercluster was analyzed in terms of the ESTs within the supercluster. The tissue source of each EST clone was noted and used to classify the superclusters into four groups: Type 1- EST clones found in the Plus group libraries only; no expression detected in Minus or Other group libraries; Type 2- EST clones derived from the Plus and Other group libraries only; no expression detected in the
- 10 Minus group; Type 3- EST clones derived from the Plus, Minus and Other group libraries, but the number of ESTs derived from the Plus group is higher than in either the Minus or Other groups; and Type 4- EST clones derived from Plus, Minus and Other group libraries, but the number derived from the Plus group is higher than the number derived from the Minus group. This analysis identified 4,345 breast clusters
- 15 (*see* Table III). From these clusters, 3,172 EST clones were ordered from Research Genetics, Inc., and were received as frozen glycerol stocks in 96-well plates.

Table IIIProstate Cluster Summary

Type	# of Superclusters	# of ESTs Ordered
1	688	677
2	2899	2484
3	85	11
4	673	0
Total	4345	3172

5 The EST clone inserts were PCR-amplified using amino-linked PCR primers for Synteni microarray analysis. When more than one PCR product was obtained for a particular clone, that PCR product was not used for expression analysis. In total, 2,528 clones from the electronic subtraction method were analyzed by microarray analysis to identify electronic subtraction breast clones that had high levels
10 of tumor vs. normal tissue mRNA. Such screens were performed using a Synteni (Palo Alto, CA) microarray, according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Within these analyses, the clones were arrayed on the chip, which was then probed with fluorescent probes
15 generated from normal and tumor prostate cDNA, as well as various other normal tissues. The slides were scanned and the fluorescence intensity was measured.

Clones with an expression ratio greater than 3 (*i.e.*, the level in prostate tumor and normal prostate mRNA was at least three times the level in other normal tissue mRNA) were identified as prostate tumor-specific sequences (Table IV). The
20 sequences of these clones are provided in SEQ ID NO: 401-453, with certain novel sequences shown in SEQ ID NO: 407, 413, 416-419, 422, 426, 427 and 450.

Table IV
Prostate-tumor Specific Clones

SEQ ID NO.	Sequence Designation	Comments
401	22545	previously identified P1000C
402	22547	previously identified P704P
403	22548	known
404	22550	known
405	22551	PSA
406	22552	prostate secretory protein 94
407	22553	novel
408	22558	previously identified P509S
409	22562	glandular kallikrein
410	22565	previously identified P1000C
411	22567	PAP
412	22568	B1006C (breast tumor antigen)
413	22570	novel
414	22571	PSA
415	22572	previously identified P706P
416	22573	novel
417	22574	novel
418	22575	novel
419	22580	novel
420	22581	PAP
421	22582	prostatic secretory protein 94
422	22583	novel
423	22584	prostatic secretory protein 94
424	22585	prostatic secretory protein 94
425	22586	known
426	22587	novel
427	22588	novel
428	22589	PAP
429	22590	known
430	22591	PSA
431	22592	known
432	22593	Previously identified P777P
433	22594	T cell receptor gamma chain
434	22595	Previously identified P705P
435	22596	Previously identified P707P
436	22847	PAP
437	22848	known
438	22849	prostatic secretory protein 57

439	22851	PAP
440	22852	PAP
441	22853	PAP
442	22854	previously identified P509S
443	22855	previously identified P705P
444	22856	previously identified P774P
445	22857	PSA
446	23601	previously identified P777P
447	23602	PSA
448	23605	PSA
449	23606	PSA
450	23612	novel
451	23614	PSA
452	23618	previously identified P1000C
453	23622	previously identified P705P

Further studies on the clone of SEQ ID NO: 407 (also referred to as P1020C) led to the isolation of an extended cDNA sequence provided in SEQ ID NO: 591. This extended cDNA sequence was found to contain an open reading frame that
5 encodes the predicted amino acid sequence of SEQ ID NO: 592. The P1020C cDNA and amino acid sequences were found to show some similarity to the human endogenous retroviral HERV-K pol gene and protein.

EXAMPLE 15

10 FURTHER IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY MICROARRAY ANALYSIS

This Example describes the isolation of additional prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library as described above
15 was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to non-prostate normal tissues (not including testis). 142 clones were identified and sequenced. Certain of these clones are shown in SEQ ID NO: 454-467. Of these sequences, SEQ ID NO: 459-460 represent novel genes. The others (SEQ ID NO: 454-
20 458 and 461-467) correspond to known sequences. Comparison of the determined

cDNA sequence of SEQ ID NO: 461 with sequences in the Genbank database using the BLAST program revealed homology to the previously identified transmembrane protease serine 2 (TMPRSS2). The full-length cDNA sequence for this clone is provided in SEQ ID NO: 751, with the corresponding amino acid sequence being
5 provided in SEQ ID NO: 752. The cDNA sequence encoding the first 209 amino acids of TMPRSS2 is provided in SEQ ID NO: 753, with the first 209 amino acids being provided in SEQ ID NO: 754.

The sequence of SEQ ID NO: 462 (referred to as P835P) was found to correspond to the previously identified clone FLJ13518 (Accession AK023643; SEQ ID
10 NO: 774), which had no associated open reading frame (ORF). This clone was used to search the Geneseq DNA database and matched a clone previously identified as a G protein-coupled receptor protein (DNA Geneseq Accession A09351; amino acid Geneseq Accession Y92365), that is characterized by the presence of seven transmembrane domains. The sequences of fragments between these domains are
15 provided in SEQ ID NO: 778-785, with SEQ ID NO: 778, 780, 782 and 784 representing extracellular domains and SEQ ID NO: 779, 781, 783 and 785 representing intracellular domains. SEQ ID NO: 778-785 represent amino acids 1-28, 53-61, 83-103, 124-143, 165-201, 226-238, 263-272 and 297-381, respectively, of P835P. The full-length cDNA sequence for P835P is provided in SEQ ID NO: 773. The cDNA
20 sequence of the open reading frame for P835P, including stop codon, is provided in SEQ ID NO: 775, with the open reading frame without stop codon being provided in SEQ ID NO: 776 and the corresponding amino acid sequence being provided in SEQ ID NO: 777.

25

EXAMPLE 16

FURTHER CHARACTERIZATION OF PROSTATE-SPECIFIC ANTIGEN P710P

This Example describes the full length cloning of P710P.

The prostate cDNA library described above was screened with the P710P
30 fragment described above. One million colonies were plated on LB/Ampicillin plates.

Nylon membrane filters were used to lift these colonies, and the cDNAs picked up by these filters were then denatured and cross-linked to the filters by UV light. The P710P fragment was radiolabeled and used to hybridize with the filters. Positive cDNA clones were selected and their cDNAs recovered and sequenced by an automatic Perkin Elmer/Applied Biosystems Division Sequencer. Four sequences were obtained, and are presented in SEQ ID NO: 468-471. These sequences appear to represent different splice variants of the P710P gene. Subsequent comparison of the cDNA sequences of P710P with those in Genbank revealed homology to the DD3 gene (Genbank accession numbers AF103907 & AF103908). The cDNA sequence of DD3 is provided in SEQ ID NO: 618.

EXAMPLE 17

PROTEIN EXPRESSION OF PROSTATE-SPECIFIC ANTIGENS

This example describes the expression and purification of prostate-specific antigens in *E. coli*, baculovirus, mammalian and yeast cells.

a) Expression of P501S in *E. coli*

Expression of the full-length form of P501S was attempted by first cloning P501S without the leader sequence (amino acids 36-553 of SEQ ID NO: 113) downstream of the first 30 amino acids of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) in pET17b. Specifically, P501S DNA was used to perform PCR using the primers AW025 (SEQ ID NO: 485) and AW003 (SEQ ID NO: 486). AW025 is a sense cloning primer that contains a HindIII site. AW003 is an antisense cloning primer that contains an EcoRI site. DNA amplification was performed using 5 μ l 10X Pfu buffer, 1 μ l 20 mM dNTPs, 1 μ l each of the PCR primers at 10 μ M concentration, 40 μ l water, 1 μ l Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1 μ l DNA at 100 ng/ μ l. Denaturation at 95°C was performed for 30 sec, followed by 10 cycles of 95°C for 30 sec, 60°C for 1 min and by 72°C for 3 min. 20 cycles of 95°C for 30 sec, 65°C for 1 min and by 72°C for 3 min, and lastly by 1 cycle of 72°C for 10 min. The PCR product was

cloned to Ra12m/pET17b using HindIII and EcoRI. The sequence of the resulting fusion construct (referred to as Ra12-P501S-F) was confirmed by DNA sequencing.

The fusion construct was transformed into BL21(DE3)pLysE, pLysS and CodonPlus *E. coli* (Stratagene) and grown overnight in LB broth with kanamycin. The
5 resulting culture was induced with IPTG. Protein was transferred to PVDF membrane and blocked with 5% non-fat milk (in PBS-Tween buffer), washed three times and incubated with mouse anti-His tag antibody (Clontech) for 1 hour. The membrane was washed 3 times and probed with HRP-Protein A (Zymed) for 30 min. Finally, the membrane was washed 3 times and developed with ECL (Amersham). No expression
10 was detected by Western blot. Similarly, no expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage (Invitrogen).

An N-terminal fragment of P501S (amino acids 36-325 of SEQ ID NO: 113) was cloned down-stream of the first 30 amino acids of the *M. tuberculosis* antigen Ra12 in pET17b as follows. P501S DNA was used to perform PCR using the primers
15 AW025 (SEQ ID NO: 485) and AW027 (SEQ ID NO: 487). AW027 is an antisense cloning primer that contains an EcoRI site and a stop codon. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The fusion construct (referred to as
20 Ra12-P501S-N) was confirmed by DNA sequencing.

The Ra12-P501S-N fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, essentially as described above. Using Western blot analysis, protein bands were observed at the expected molecular weight of 36 kDa. Some high molecular weight bands were also observed, probably due to
25 aggregation of the recombinant protein. No expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage.

A fusion construct comprising a C-terminal portion of P501S (amino acids 257-553 of SEQ ID NO: 113) located down-stream of the first 30 amino acids of
30 the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) was prepared as follows. P501S

DNA was used to perform PCR using the primers AW026 (SEQ ID NO: 488) and AW003 (SEQ ID NO: 486). AW026 is a sense cloning primer that contains a HindIII site. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The
5 sequence for the fusion construct (referred to as Ra12-P501S-C) was confirmed.

The Ra12-P501S-C fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, as described above. A small amount of protein was detected by Western blot, with some molecular weight aggregates also being observed. Expression was also detected by Western blot when the Ra12-P501S-C
10 fusion was used for expression in BL21CodonPlus induced by CE6 phage.

A fusion construct comprising a fragment of P501S (amino acids 36-298 of SEQ ID NO: 113) located down-stream of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 705) was prepared as follows. P501S DNA was used to perform PCR using the primers AW042 (SEQ ID NO: 706) and AW053 (SEQ ID NO: 707). AW042 is a sense
15 cloning primer that contains a EcoRI site. AW053 is an antisense primer with stop and Xho I sites. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the EcoRI and Xho I sites. The resulting fusion construct (referred to as Ra12-P501S-E2) was expressed in B834 (DE3) pLys S *E. coli* host cells in TB media for 2 h at room temperature. Expressed protein
20 was purified by washing the inclusion bodies and running on a Ni-NTA column. The purified protein stayed soluble in buffer containing 20 mM Tris-HCl (pH 8), 100 mM NaCl, 10 mM β -Me and 5% glycerol. The determined cDNA and amino acid sequences for the expressed fusion protein are provided in SEQ ID NO: 708 and 709, respectfully.

25 b) Expression of P501S in Baculovirus

The Bac-to-Bac baculovirus expression system (BRL Life Technologies, Inc.) was used to express P501S protein in insect cells. Full-length P501S (SEQ ID NO: 113) was amplified by PCR and cloned into the XbaI site of the donor plasmid pFastBac1. The recombinant bacmid and baculovirus were prepared according to the

manufacturer's instructions. The recombinant baculovirus was amplified in Sf9 cells and the high titer viral stocks were utilized to infect High Five cells (Invitrogen) to make the recombinant protein. The identity of the full-length protein was confirmed by N-terminal sequencing of the recombinant protein and by Western blot analysis (Figure 7). Specifically, 0.6 million High Five cells in 6-well plates were infected with either the unrelated control virus BV/ECD_PD (lane 2), with recombinant baculovirus for P501S at different amounts or MOIs (lanes 4-8), or were uninfected (lane 3). Cell lysates were run on SDS-PAGE under reducing conditions and analyzed by Western blot with the anti-P501S monoclonal antibody P501S-10E3-G4D3 (prepared as described below). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

The localization of recombinant P501S in the insect cells was investigated as follows. The insect cells overexpressing P501S were fractionated into fractions of nucleus, mitochondria, membrane and cytosol. Equal amounts of protein from each fraction were analyzed by Western blot with a monoclonal antibody against P501S. Due to the scheme of fractionation, both nucleus and mitochondria fractions contain some plasma membrane components. However, the membrane fraction is basically free from mitochondria and nucleus. P501S was found to be present in all fractions that contain the membrane component, suggesting that P501S may be associated with plasma membrane of the insect cells expressing the recombinant protein.

c) Expression of P501S in Mammalian Cells

Full-length P501S (553 amino acids; SEQ ID NO: 113) was cloned into various mammalian expression vectors, including pCEP4 (Invitrogen), pVR1012 (Vical, San Diego, CA) and a modified form of the retroviral vector pBMN, referred to as pBIB. Transfection of P501S/pCEP4 and P501S/pVR1012 into HEK293 fibroblasts was carried out using the Fugene transfection reagent (Boehringer Mannheim). Briefly, 2 ul of Fugene reagent was diluted into 100 ul of serum-free media and incubated at room temperature for 5-10 min. This mixture was added to 1 ug of P501S plasmid DNA, mixed briefly and incubated for 30 minutes at room temperature. The

Fugene/DNA mixture was added to cells and incubated for 24-48 hours. Expression of recombinant P501S in transfected HEK293 fibroblasts was detected by means of Western blot employing a monoclonal antibody to P501S.

Transfection of p501S/pCEP4 into CHO-K cells (American Type Culture Collection, Rockville, MD) was carried out using GenePorter transfection reagent (Gene Therapy Systems, San Diego, CA). Briefly, 15 µl of GenePorter was diluted in 500 µl of serum-free media and incubated at room temperature for 10 min. The GenePorter/media mixture was added to 2 µg of plasmid DNA that was diluted in 500 µl of serum-free media, mixed briefly and incubated for 30 min at room temperature. CHO-K cells were rinsed in PBS to remove serum proteins, and the GenePorter/DNA mix was added and incubated for 5 hours. The transfected cells were then fed an equal volume of 2x media and incubated for 24-48 hours.

FACS analysis of P501S transiently infected CHO-K cells, demonstrated surface expression of P501S. Expression was detected using rabbit polyclonal antisera raised against a P501S peptide, as described below. Flow cytometric analysis was performed using a FaCScan (Becton Dickinson), and the data were analyzed using the Cell Quest program.

d) Expression of P501S in *S. cerevisiae*

P501S was expressed in yeast, directed in membranes, using the yeast α prepro signal sequence. The natural signal sequence and first luminal domain of P501S was deleted in order to conserve the natural positioning of the expressed P501S protein.

Specifically, the α prepro signal sequence of *S. cerevisiae* linked to amino acids 55-553 of SEQ ID NO: 113 with a His tag tail was cloned into the plasmid pRIT15068 with the CUP1 promoter and transfected into *S. cerevisiae* strain Y1790. The Y1790 strain is Leu⁺ and His⁻. Expression of protein was induced by addition of either 500 µM or 250 µM of CuSO₄ at 30 °C in minimal medium supplemented with histidine. Cells were harvested 24 hours after induction. Extracts were prepared by growing cells to a concentration of OD600 5.0 in 50 mM citrate phosphate buffer (pH 4.0) plus 130 mM NaCl supplemented with protease inhibitors. Cells were disrupted

using glass beads and centrifuged for 20 min at 15,000 g. The recombinant protein was found to be 100% pellet associated.

Expression of the recombinant protein (molecular weight 63 kD) was demonstrated by Western blot analysis, using the anti-P501S monoclonal antibody 10E-
5 D4-G3 described below. The amino acid sequence of the expressed protein is provided in SEQ ID NO: 792.

Fermentation processes for the production of the α prepro-P501S-His tag recombinant protein in *S. cerevisiae* (strain Y1790 – CUP1 inducible promoter) were evaluated as follows. One hundred μ l of a master seed containing 2.5×10^8 cells/ml of
10 transformed *S. cerevisiae* Y1790 were spread on FSC004AA solid medium. The composition of the FSC004AA medium is as follows: glucose 10 g/l; $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ 0.0002 g/l; folic acid 0.000064 g/l; KH_2PO_4 1 g/l; $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 0.0004 g/l; Inositol 0.064 g/l; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.5 g/l; H_3BO_3 0.0005 g/l; Pyridoxine 0.008 g/l; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.00009 g/l;
15 Niacin 0.000032 g/l; $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ 0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0.0004 g/l; $(\text{NH}_4)_2\text{SO}_4$ 5 g/l; agar 18 g/l; Histidine 0.1 g/l.

Two plates were incubated for 26 h at 30 °C. These solid pre-cultures were harvested in 5 ml of liquid medium FSC007AA and 0.5 ml (or 9.3×10^7 cells) of
20 this suspension was used to inoculate 2 liquid pre-cultures.

The composition of the FSC007AA medium is as follows: Glucose 10 g/l; $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ 0.0002 g/l; folic acid 0.000064 g/l; KH_2PO_4 1 g/l; $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 0.0004 g/l; Inositol 0.064 g/l; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.5 g/l; H_3BO_3 0.0005 g/l; Pyridoxine 0.008 g/l; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$
25 0.00009 g/l; Niacine 0.000032 g/l; $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ 0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0.0004 g/l; $(\text{NH}_4)_2\text{SO}_4$ 5 g/l; Histidine 0.1 g/l.

These pre-cultures were run for 20 hours in 2L flasks containing 400 ml
30 of medium FSC007AA in order to obtain an OD of 1.8. The other characteristics of
these pre-cultures are as follows: pH 2.8; glucose 2.3 g/L; ethanol 3.4 g/L.

The best timing for liquid pre-cultures for strain Y1790 was determined in preliminary experiments. Liquid pre-cultures containing 400 ml of medium and inoculated with various volumes of Master Seed (0.25, 0.5, 1 or 2 ml) were monitored in order to identify the best inoculum size and timing. Glucose, ethanol, pH, OD and
 5 cell number (determined by flow cytometry) were followed between 16 and 23 hours of culture. Glucose exhaustion and maximal biomass were obtained after 20 hour incubation with 0.5 inoculum. These conditions were adopted for transferring the pre-culture into fermentation.

In total, 800ml of pre-culture were used to inoculate a 20 L fermenter
 10 containing 5L of medium FSC002AA. Three ml of irradiated antifoam were added before inoculation. The composition of the FSC002AA medium is as follows:
 (NH₄)₂SO₄ 6.4 g/l; Na₂MoO₄.2H₂O 2.05 mg/l; folic acid 0.54 mg/l; KH₂PO₄ 8.25 g/l;
 MnSO₄.H₂O 4.1 mg/l; inositol 540 mg/l; MgSO₄.7H₂O 4.69 g/l; H₃BO₃ 5.17 mg/l;
 pyridoxine 68 mg/l; CaCl₂.2H₂O 0.92 g/l; KI 1.03 mg/l; thiamine 68 mg/l; NaCl 0.06g/l;
 15 CoCl₂.6H₂O 0.92 mg/l; Niacine 0.27 mg/l; HCl 1 ml/l; FeCl₃.6H₂O 9.92 mg/l;
 Riboflavin 0.13 mg/l; CuSO₄.5H₂O 0.41 mg/l; Glucose 0.14 g/l; Panthotenate Ca 68
 mg/l; ZnSO₄.7H₂O 4.1 mg/l; Biotin 0.54 mg/l; para-aminobenzoic acid 0.13 mg/l;
 Histidine 0.3 g/l

The carbon source (glucose) was supplemented by a continuous feeding
 20 of FFB004AA medium. The composition of the FFB004AA medium is as follows:
 glucose 350 g/l; Na₂MoO₄.2H₂O 5.15 mg/l; folic acid 1.36 mg/l; KH₂PO₄ 20.6 g/l;
 MnSO₄.H₂O 10.3 mg/l; inositol 1350 mg/l; MgSO₄.7H₂O 11.7 g/l; H₃BO₃ 12.9 mg/l;
 pyridoxine 170 mg/l; CaCl₂.2H₂O 2.35 g/l; KI 2.6 mg/l; thiamine 170 g/l; NaCl 0.15 g/l;
 CoCl₂.6H₂O 2.3 mg/l; niacine 0.67 mg/l; HCl 2.5 ml/l; FeCl₃.6H₂O 24.8 mg/l;
 25 riboflavin; 0.33 mg/l; CuSO₄.5H₂O 1.03 mg/l; biotin 1.36 mg/l; panthotenate Ca 170
 mg/l; ZnSO₄.7H₂O 10.3 mg/l; para-aminobenzoic acid: 0.33 mg/l; histidine 5.35 g/l.

The residual glucose concentration was maintained very low (□50 mg/L) in order to minimize ethanol production by fermentation. This was achieved by limiting the development of the microorganism using a limited glucose feed rate. The Standard
 30 biomass content (OD 80-90) was reached in fermentation after 44 hour growth phase.

CUP1 promoter was then induced by adding 500μM CuSO₄ in order to

produce P501S antigen. CuSO_4 addition was followed by ethanol accumulation (up to 6 g/L), and the glucose feeding rate was then reduced in order to consume the ethanol. The copper available for the microorganism was monitored by testing Cu ion concentration in the broth supernatant using a spectrophotometric copper assay (DETC
5 method). The fermentation was then supplemented by CuSO_4 throughout the induction phase in order to maintain its concentration between 150 and 250 μM in the supernatant. The biomass reached an OD of 100 at the end of induction. Cells were harvested after 8 hours of induction.

Cell homogenate was prepared and analysed by SDS-PAGE and Western
10 Blot using standard protocols. A major protein band with the expected molecular weight of 62KD was detected by Western blot using anti-P501S monoclonal antibodies. Western blot analysis also showed that the major 62KD band was progressively produced from 30 minutes of induction on, and reached a maximum after 3 hours. No more antigen seemed to be produced between 3 and 12 hours of induction.

15 The number of passages through a French Press necessary to extract all the antigen from the cells was evaluated. One, three and five passages were tested and total cell lysates, supernatants and pellets of cell lysates were analysed by Western blot. Three passages through a French Press were sufficient to completely extract the antigen. The antigen was present in the insoluble fraction.

20

e) Expression of P703P in Baculovirus

The cDNA for full-length P703P-DE5 (SEQ ID NO: 326), together with several flanking restriction sites, was obtained by digesting the plasmid pCDNA703 with restriction endonucleases Xba I and Hind III. The resulting restriction fragment
25 (approx. 800 base pairs) was ligated into the transfer plasmid pFastBacI which was digested with the same restriction enzymes. The sequence of the insert was confirmed by DNA sequencing. The recombinant transfer plasmid pFBP703 was used to make recombinant bacmid DNA and baculovirus using the Bac-To-Bac Baculovirus expression system (BRL Life Technologies). High Five cells were infected with the
30 recombinant virus BVP703, as described above, to obtain recombinant P703P protein.

e) Expression of P788P in *E. Coli*

A truncated, N-terminal portion, of P788P (residues 1-644 of SEQ ID NO: 777; referred to as P788P-N) fused with a C-terminal 6xHis Tag was expressed in *E. coli* as follows. P788P cDNA was amplified using the primers AW080 and AW081 (SEQ ID NO: 672 and 673). AW080 is a sense cloning primer with an NdeI site. AW081 is an antisense cloning primer with a XhoI site. The PCR-amplified P788P, as well as the vector pCRX1, were digested with NdeI and XhoI. Vector and insert were ligated and transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. P788P-N clone #6 was confirmed to be identical to the designed construct. The expression construct P788P-N #6/pCRX1 was transformed into *E. coli* BL21 CodonPlus-RIL competent cells. After induction, most of the cells grew well, achieving OD600 of greater than 2.0 after 3 hr. Coomassie stained SDS-PAGE showed an over-expressed band at about 75 kD. Western blot analysis using a 6xHisTag antibody confirmed the band was P788P-N. The determined cDNA sequence for P788P-N is provided in SEQ ID NO: 674, with the corresponding amino acid sequence being provided in SEQ ID NO: 675.

f) Expression of P510S in *E. Coli*

The P510S protein has 9 potential transmembrane domains and is predicted to be located at the plasma membrane. The C-terminal protein of this protein, as well as the predicted third extracellular domain of P510S were expressed in *E. coli* as follows.

The expression construct referred to as Ra12-P501S-C was designed to have a 6 HisTag at the N-terminal end, followed by the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and then the C-terminal portion of P510S (amino residues 1176-1261 of SEQ ID NO: 538). Full-length P510S was used to amplify the P510S-C fragment by PCR using the primers AW056 and AW057 (SEQ ID NO: 677 and 678, respectively). AW056 is a sense cloning primer with an EcoRI site. AW057 is an antisense primer with stop and XhoI sites. The amplified P501S fragment and Ra12/pCRX1 were digested with EcoRI and XhoI and then purified. The insert and

vector were ligated together and transformed into NovaBlue. Colonies were randomly screened for insert and sequences. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. A mini-induction screen was performed to optimize the expression conditions. After induction
5 the cells grew well, achieving OD 600 nm greater than 2.0 after 3 hours. Coomassie stain SDS-PAGE showed a highly over-expressed band at approx. 30 kD. Though this is higher than the expected molecular weight, western blot analysis was positive, showing this band to be the His tag-containing protein. The optimized culture conditions are as follows. Dilute overnight culture/daytime culture (LB + kanamycin +
10 chloramphenicol) into 2xYT (with kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2xYT. Allow to grow at 37 °C until OD600 = 0.6. Take an aliquot out as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3 sample, spin down cells and store at -80 °C. The determined cDNA and amino acid sequences for the Ra12-P510S-C construct are provided in SEQ ID NO: 679 and 682,
15 respectively.

The expression construct P510S-C was designed to have a 5' added start codon and a glycine (GGA) codon and then the P510S C terminal fragment followed by the in frame 6x histidine tag and stop codon from the pET28b vector. The cloning strategy is similar to that used for Ra12-P510S-C, except that the PCR primers employed were
20 those shown in SEQ ID NO: 685 and 686, respectively and the NcoI/XhoI cut in pET28b was used. The primer of SEQ ID NO: 685 created a 5' NcoI site and added a start codon. The antisense primer of SEQ ID NO: 686 creates a XhoI site on P510S C terminal fragment. Clones were confirmed by sequencing. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL
25 competent cells. An OD600 of greater than 2.0 was obtained 30 hours after induction. Coomassie stained SDS-PAGE showed an over-expressed band at about 11 kD. Western blot analysis confirmed that the band was P510S-C, as did N-terminal protein sequencing. The optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (+ kanamycin
30 and chloramphenicol) at a ratio of 25 mL culture to 1 liter 2x YT, and allow to grow at

37 °C until an OD 600 of about 0.5 is reached. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P510S-C construct are shown in SEQ ID NO: 680 and 683, respectively.

5 The predicted third extracellular domain of P510S (P510S-E3; residues 328-676 of SEQ ID NO: 538) was expressed in *E. coli* as follows. The P510S fragment was amplified by PCR using the primers shown in SEQ ID NO: 687 and 688. The primer of SEQ ID NO: 687 is a sense primer with an NdeI site for use in ligating into pPDM. The primer of SEQ ID NO: 688 is an antisense primer with an added XhoI site
10 for use in ligating into pPDM. The resulting fragment was cloned to pPDM at the NdeI and XhoI sites. Clones were confirmed by sequencing. For protein expression, the clone was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. After induction, an OD600 of greater than 2.0 was achieved after 3 hours. Coomassie stained SDS-PAGE showed an over-expressed band at about 39 kD, and N-terminal sequencing
15 confirmed the N-terminal to be that of P510S-E3. Optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2x YT. Allow to grow at 37 °C until OD 600 equals 0.6. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3
20 sample, spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P501S-E3 construct are provided in SEQ ID NO: 681 and 684, respectively.

g) Expression of P775S in *E. Coli*

25 The antigen P775P contains multiple open reading frames (ORF). The third ORF, encoding the protein of SEQ ID NO: 483, has the best motif score. An expression fusion construct containing the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and P775P-ORF3 with an N-terminal 6x HisTag was prepared as follows. P775P-ORF3 was amplified using the sense PCR primers of SEQ ID NO: 689 and the anti-sense PCR primer of SEQ ID NO: 690. The PCR amplified fragment of P775P and

Ra12/pCRX1 were digested with the restriction enzymes EcoRI and XhoI. Vector and insert were ligated and then transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. A clone having the desired sequence was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. Two hours after induction, the cell density peaked at OD600 of approximately 1.8. Coomassie stained SDS-PAGE showed an over-expressed band at about 31 kD. Western blot using 6x HisTag antibody confirmed that the band was Ra12-P775P-ORF3. The determined cDNA and amino acid sequences for the fusion construct are provided in SEQ ID NO: 691 and 692, respectively.

10

H) EXPRESSION OF A P703P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P703P was prepared by PCR using the primers of SEQ ID NO: 693 and 694. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P703P are provided in SEQ ID NO: 695 and 696, respectively.

20

I) EXPRESSION OF A P705P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P705P was prepared by PCR using the primers of SEQ ID NO: 697 and 698. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P705P are provided in SEQ ID NO: 699 and 700, respectively.

30

J) EXPRESSION OF A P711P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P711P was prepared by PCR using the primers of SEQ ID NO: 701 and 702. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P711P are provided in SEQ ID NO: 703 and 704, respectively.

10

EXAMPLE 18

PREPARATION AND CHARACTERIZATION OF ANTIBODIES

AGAINST PROSTATE-SPECIFIC POLYPEPTIDES

15

a) Preparation and Characterization of Polyclonal Antibodies against P703P,

P504S and P509S

Polyclonal antibodies against P703P, P504S and P509S were prepared as follows.

Each prostate tumor antigen expressed in an *E. coli* recombinant expression system was grown overnight in LB broth with the appropriate antibiotics at 37°C in a shaking incubator. The next morning, 10 ml of the overnight culture was added to 500 ml to 2x YT plus appropriate antibiotics in a 2L-baffled Erlenmeyer flask. When the Optical Density (at 560 nm) of the culture reached 0.4-0.6, the cells were induced with IPTG (1 mM). Four hours after induction with IPTG, the cells were harvested by centrifugation. The cells were then washed with phosphate buffered saline and centrifuged again. The supernatant was discarded and the cells were either frozen for future use or immediately processed. Twenty ml of lysis buffer was added to the cell pellets and vortexed. To break open the *E. coli* cells, this mixture was then run

20
25

through the French Press at a pressure of 16,000 psi. The cells were then centrifuged again and the supernatant and pellet were checked by SDS-PAGE for the partitioning of the recombinant protein. For proteins that localized to the cell pellet, the pellet was resuspended in 10 mM Tris pH 8.0, 1% CHAPS and the inclusion body pellet was washed and centrifuged again. This procedure was repeated twice more. The washed inclusion body pellet was solubilized with either 8 M urea or 6 M guanidine HCl containing 10 mM Tris pH 8.0 plus 10 mM imidazole. The solubilized protein was added to 5 ml of nickel-chelate resin (Qiagen) and incubated for 45 min to 1 hour at room temperature with continuous agitation. After incubation, the resin and protein mixture were poured through a disposable column and the flow through was collected. The column was then washed with 10-20 column volumes of the solubilization buffer. The antigen was then eluted from the column using 8M urea, 10 mM Tris pH 8.0 and 300 mM imidazole and collected in 3 ml fractions. A SDS-PAGE gel was run to determine which fractions to pool for further purification.

As a final purification step, a strong anion exchange resin such as HiPrepQ (Biorad) was equilibrated with the appropriate buffer and the pooled fractions from above were loaded onto the column. Each antigen was eluted off the column with a increasing salt gradient. Fractions were collected as the column was run and another SDS-PAGE gel was run to determine which fractions from the column to pool. The pooled fractions were dialyzed against 10 mM Tris pH 8.0. The proteins were then vialled after filtration through a 0.22 micron filter and the antigens were frozen until needed for immunization.

Four hundred micrograms of each prostate antigen was combined with 100 micrograms of muramyl dipeptide (MDP). Every four weeks rabbits were boosted with 100 micrograms mixed with an equal volume of Incomplete Freund's Adjuvant (IFA). Seven days following each boost, the animal was bled. Sera was generated by incubating the blood at 4°C for 12-4 hours followed by centrifugation.

Ninety-six well plates were coated with antigen by incubating with 50 microliters (typically 1 microgram) of recombinant protein at 4 °C for 20 hours. 250 microliters of BSA blocking buffer was added to the wells and incubated at room

temperature for 2 hours. Plates were washed 6 times with PBS/0.01% Tween. Rabbit sera was diluted in PBS. Fifty microliters of diluted sera was added to each well and incubated at room temperature for 30 min. Plates were washed as described above before 50 microliters of goat anti-rabbit horse radish peroxidase (HRP) at a 1:10000 dilution was added and incubated at room temperature for 30 min. Plates were again washed as described above and 100 microliters of TMB microwell peroxidase substrate was added to each well. Following a 15 min incubation in the dark at room temperature, the colorimetric reaction was stopped with 100 microliters of 1N H₂SO₄ and read immediately at 450 nm. All polyclonal antibodies showed immunoreactivity to the appropriate antigen.

b) Preparation and Characterization of Antibodies against P501S

A murine monoclonal antibody directed against the carboxy-terminus of the prostate-specific antigen P501S was prepared as follows.

A truncated fragment of P501S (amino acids 355-526 of SEQ ID NO: 113) was generated and cloned into the pET28b vector (Novagen) and expressed in *E. coli* as a thioredoxin fusion protein with a histidine tag. The trx-P501S fusion protein was purified by nickel chromatography, digested with thrombin to remove the trx fragment and further purified by an acid precipitation procedure followed by reverse phase HPLC.

Mice were immunized with truncated P501S protein. Serum bleeds from mice that potentially contained anti-P501S polyclonal sera were tested for P501S-specific reactivity using ELISA assays with purified P501S and trx-P501S proteins. Serum bleeds that appeared to react specifically with P501S were then screened for P501S reactivity by Western analysis. Mice that contained a P501S-specific antibody component were sacrificed and spleen cells were used to generate anti-P501S antibody producing hybridomas using standard techniques. Hybridoma supernatants were tested for P501S-specific reactivity initially by ELISA, and subsequently by FACS analysis of reactivity with P501S transduced cells. Based on these results, a monoclonal hybridoma referred to as 10E3 was chosen for further subcloning. A number of subclones were

generated, tested for specific reactivity to P501S using ELISA and typed for IgG isotype. The results of this analysis are shown below in Table V. Of the 16 subclones tested, the monoclonal antibody 10E3-G4-D3 was selected for further study.

5

Table V

Isotype analysis of murine anti-P501S monoclonal antibodies

Hybridoma clone	Isotype	Estimated [Ig] in supernatant ($\mu\text{g/ml}$)
4D11	IgG1	14.6
1G1	IgG1	0.6
4F6	IgG1	72
4H5	IgG1	13.8
4H5-E12	IgG1	10.7
4H5-EH2	IgG1	9.2
4H5-H2-A10	IgG1	10
4H5-H2-A3	IgG1	12.8
4H5-H2-A10-G6	IgG1	13.6
4H5-H2-B11	IgG1	12.3
10E3	IgG2a	3.4
10E3-D4	IgG2a	3.8
10E3-D4-G3	IgG2a	9.5
10E3-D4-G6	IgG2a	10.4
10E3-E7	IgG2a	6.5
8H12	IgG2a	0.6

The specificity of 10E3-G4-D3 for P501S was examined by FACS analysis. Specifically, cells were fixed (2% formaldehyde, 10 minutes), permeabilized (0.1% saponin, 10 minutes) and stained with 10E3-G4-D3 at 0.5 – 1 $\mu\text{g/ml}$, followed by incubation with a secondary, FITC-conjugated goat anti-mouse Ig antibody (Pharmingen, San Diego, CA). Cells were then analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. For analysis of infected cells, B-LCL were infected with a vaccinia vector that expresses P501S. To demonstrate specificity in these assays, B-LCL transduced with a different antigen (P703P) and uninfected B-LCL vectors were utilized. 10E3-G4-D3 was shown to bind with P501S-transduced B-

LCL and also with P501S-infected B-LCL, but not with either uninfected cells or P703P-transduced cells.

To determine whether the epitope recognized by 10E3-G4-D3 was found on the surface or in an intracellular compartment of cells, B-LCL were transduced with
5 P501S or HLA-B8 as a control antigen and either fixed and permeabilized as described above or directly stained with 10E3-G4-D3 and analyzed as above. Specific recognition of P501S by 10E3-G4-D3 was found to require permeabilization, suggesting that the epitope recognized by this antibody is intracellular.

The reactivity of 10E3-G4-D3 with the three prostate tumor cell lines
10 Lncap, PC-3 and DU-145, which are known to express high, medium and very low levels of P501S, respectively, was examined by permeabilizing the cells and treating them as described above. Higher reactivity of 10E3-G4-D3 was seen with Lncap than with PC-3, which in turn showed higher reactivity than DU-145. These results are in agreement with the real time PCR and demonstrate that the antibody specifically
15 recognizes P501S in these tumor cell lines and that the epitope recognized in prostate tumor cell lines is also intracellular.

Specificity of 10E3-G4-D3 for P501S was also demonstrated by Western blot analysis. Lysates from the prostate tumor cell lines Lncap, DU-145 and PC-3, from P501S-transiently transfected HEK293 cells, and from non-transfected HEK293 cells
20 were generated. Western blot analysis of these lysates with 10E3-G4-D3 revealed a 46 kDa immunoreactive band in Lncap, PC-3 and P501S-transfected HEK cells, but not in DU-145 cells or non-transfected HEK293 cells. P501S mRNA expression is consistent with these results since semi-quantitative PCR analysis revealed that P501S mRNA is expressed in Lncap, to a lesser but detectable level in PC-3 and not at all in DU-145
25 cells. Bacterially expressed and purified recombinant P501S (referred to as P501SStr2) was recognized by 10E3-G4-D3 (24 kDa), as was full-length P501S that was transiently expressed in HEK293 cells using either the expression vector VR1012 or pCEP4. Although the predicted molecular weight of P501S is 60.5 kDa, both transfected and "native" P501S run at a slightly lower mobility due to its hydrophobic nature.

Immunohistochemical analysis was performed on prostate tumor and a panel of normal tissue sections (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder, ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). Tissue samples were fixed in formalin solution for 24 hours and embedded in paraffin before being sliced into 10 micron sections. Tissue sections were permeabilized and incubated with 10E3-G4-D3 antibody for 1 hr. HRP-labeled anti-mouse followed by incubation with DAB chromogen was used to visualize P501S immunoreactivity. P501S was found to be highly expressed in both normal prostate and prostate tumor tissue but was not detected in any of the other tissues tested.

To identify the epitope recognized by 10E3-G4-D3, an epitope mapping approach was pursued. A series of 13 overlapping 20-21 mers (5 amino acid overlap; SEQ ID NO: 489-501) was synthesized that spanned the fragment of P501S used to generate 10E3-G4-D3. Flat bottom 96 well microtiter plates were coated with either the peptides or the P501S fragment used to immunize mice, at 1 microgram/ml for 2 hours at 37 °C. Wells were then aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature, and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified antibody 10E3-G4-D3 was added at 2 fold dilutions (1000 ng – 16 ng) in PBST and incubated for 30 minutes at room temperature. This was followed by washing 6 times with PBST and subsequently incubating with HRP-conjugated donkey anti-mouse IgG (H+L) Affinipure F(ab') fragment (Jackson ImmunoResearch, West Grove, PA) at 1:20000 for 30 minutes. Plates were then washed and incubated for 15 minutes in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As shown in Fig. 8, reactivity was seen with the peptide of SEQ ID NO: 496 (corresponding to amino acids 439-459 of P501S) and with the P501S fragment but not with the remaining peptides, demonstrating that the epitope recognized by 10E3-G4-D3 is localized to amino acids 439-459 of SEQ ID NO: 113.

In order to further evaluate the tissue specificity of P501S, multi-array immunohistochemical analysis was performed on approximately 4700 different human tissues encompassing all the major normal organs as well as neoplasias derived from

these tissues. Sixty-five of these human tissue samples were of prostate origin. Tissue sections 0.6 mm in diameter were formalin-fixed and paraffin embedded. Samples were pretreated with HIER using 10 mM citrate buffer pH 6.0 and boiling for 10 min. Sections were stained with 10E3-G4-D3 and P501S immunoreactivity was visualized with HRP. All the 65 prostate tissues samples (5 normal, 55 untreated prostate tumors, 5 hormone refractory prostate tumors) were positive, showing distinct perinuclear staining. All other tissues examined were negative for P501S expression.

c) Preparation and Characterization of Antibodies against P503S

A fragment of P503S (amino acids 113-241 of SEQ ID NO: 114) was expressed and purified from bacteria essentially as described above for P501S and used to immunize both rabbits and mice. Mouse monoclonal antibodies were isolated using standard hybridoma technology as described above. Rabbit monoclonal antibodies were isolated using Selected Lymphocyte Antibody Method (SLAM) technology at Immgenics Pharmaceuticals (Vancouver, BC, Canada). Table VI, below, lists the monoclonal antibodies that were developed against P503S.

Table VI

Antibody	Species
20D4	Rabbit
JA1	Rabbit
1A4	Mouse
1C3	Mouse
1C9	Mouse
1D12	Mouse
2A11	Mouse
2H9	Mouse
4H7	Mouse
8A8	Mouse
8D10	Mouse
9C12	Mouse
6D12	Mouse

The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 20D4 and JA1 were determined and are provided in SEQ ID NO: 502 and 503, respectively.

5 In order to better define the epitope binding region of each of the antibodies, a series of overlapping peptides were generated that span amino acids 109-213 of SEQ ID NO: 114. These peptides were used to epitope map the anti-P503S monoclonal antibodies by ELISA as follows. The recombinant fragment of P503S that was employed as the immunogen was used as a positive control. Ninety-six well
10 microtiter plates were coated with either peptide or recombinant antigen at 20 ng/well overnight at 4 °C. Plates were aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature then washed in PBS containing 0.1% Tween 20 (PBST). Purified rabbit monoclonal antibodies diluted in PBST were added to the wells and incubated for 30 min at room temperature. This was
15 followed by washing 6 times with PBST and incubation with Protein-A HRP conjugate at a 1:2000 dilution for a further 30 min. Plates were washed six times in PBST and incubated with tetramethylbenzidine (TMB) substrate for a further 15 min. The reaction was stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. ELISA with the mouse monoclonal antibodies was performed with
20 supernatants from tissue culture run neat in the assay.

All of the antibodies bound to the recombinant P503S fragment, with the exception of the negative control SP2 supernatant. 20D4, JA1 and 1D12 bound strictly to peptide #2101 (SEQ ID NO: 504), which corresponds to amino acids 151-169 of SEQ ID NO: 114. 1C3 bound to peptide #2102 (SEQ ID NO: 505), which corresponds
25 to amino acids 165-184 of SEQ ID NO: 114. 9C12 bound to peptide #2099 (SEQ ID NO: 522), which corresponds to amino acids 120-139 of SEQ ID NO: 114. The other antibodies bind to regions that were not examined in these studies.

Subsequent to epitope mapping, the antibodies were tested by FACS analysis on a cell line that stably expressed P503S to confirm that the antibodies bind to
30 cell surface epitopes. Cells stably transfected with a control plasmid were employed as

a negative control. Cells were stained live with no fixative. 0.5 ug of anti-P503S monoclonal antibody was added and cells were incubated on ice for 30 min before being washed twice and incubated with a FITC-labelled goat anti-rabbit or mouse secondary antibody for 20 min. After being washed twice, cells were analyzed with an Excalibur
5 fluorescent activated cell sorter. The monoclonal antibodies 1C3, 1D12, 9C12, 20D4 and JA1, but not 8D3, were found to bind to a cell surface epitope of P503S.

In order to determine which tissues express P503S, immunohistochemical analysis was performed, essentially as described above, on a panel of normal tissues (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder,
10 ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). HRP-labeled anti-mouse or anti-rabbit antibody followed by incubation with TMB was used to visualize P503S immunoreactivity. P503S was found to be highly expressed in prostate tissue, with lower levels of expression being observed in cervix, colon, ileum and kidney, and no expression being observed in adrenal, breast, duodenum, gall
15 bladder, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis.

Western blot analysis was used to characterize anti-P503S monoclonal antibody specificity. SDS-PAGE was performed on recombinant (rec) P503S expressed in and purified from bacteria and on lysates from HEK293 cells transfected with full length P503S. Protein was transferred to nitrocellulose and then Western blotted with
20 each of the anti-P503S monoclonal antibodies (20D4, JA1, 1D12, 6D12 and 9C12) at an antibody concentration of 1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to either a goat anti-mouse monoclonal antibody or to protein A-sepharose. The monoclonal antibody 20D4 detected the appropriate molecular weight 14 kDa recombinant P503S (amino acids 113-241) and the 23.5 kDa
25 species in the HEK293 cell lysates transfected with full length P503S. Other anti-P503S monoclonal antibodies displayed similar specificity by Western blot.

d) Preparation and Characterization of Antibodies against P703P

Rabbits were immunized with either a truncated (P703Ptr1; SEQ ID NO: 172) or full-length mature form (P703Pfl; SEQ ID NO: 523) of recombinant P703P

protein was expressed in and purified from bacteria as described above. Affinity purified polyclonal antibody was generated using immunogen P703Pfl or P703Ptrl attached to a solid support. Rabbit monoclonal antibodies were isolated using SLAM technology at Immgenics Pharmaceuticals. Table VII below lists both the polyclonal and monoclonal antibodies that were generated against P703P.

Table VII

Antibody	Immunogen	Species/type
Aff. Purif. P703P (truncated); #2594	P703Ptrl	Rabbit polyclonal
Aff. Purif. P703P (full length); #9245	P703Pfl	Rabbit polyclonal
2D4	P703Ptrl	Rabbit monoclonal
8H2	P703Ptrl	Rabbit monoclonal
7H8	P703Ptrl	Rabbit monoclonal

The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 8H2, 7H8 and 2D4 were determined and are provided in SEQ ID NO: 506-508, respectively.

Epitope mapping studies were performed as described above. Monoclonal antibodies 2D4 and 7H8 were found to specifically bind to the peptides of SEQ ID NO: 509 (corresponding to amino acids 145-159 of SEQ ID NO: 172) and SEQ ID NO: 510 (corresponding to amino acids 11-25 of SEQ ID NO: 172), respectively. The polyclonal antibody 2594 was found to bind to the peptides of SEQ ID NO: 511-514, with the polyclonal antibody 9427 binding to the peptides of SEQ ID NO: 515-517.

The specificity of the anti-P703P antibodies was determined by Western blot analysis as follows. SDS-PAGE was performed on (1) bacterially expressed recombinant antigen; (2) lysates of HEK293 cells and Ltk^{-/-} cells either untransfected or transfected with a plasmid expressing full length P703P; and (3) supernatant isolated from these cell cultures. Protein was transferred to nitrocellulose and then Western blotted using the anti-P703P polyclonal antibody #2594 at an antibody concentration of 1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to an anti-rabbit antibody. A 35 kDa immunoreactive band could be observed with

recombinant P703P. Recombinant P703P runs at a slightly higher molecular weight since it is epitope tagged. In lysates and supernatants from cells transfected with full length P703P, a 30 kDa band corresponding to P703P was observed. To assure specificity, lysates from HEK293 cells stably transfected with a control plasmid were
5 also tested and were negative for P703P expression. Other anti-P703P antibodies showed similar results.

Immunohistochemical studies were performed as described above, using anti-P703P monoclonal antibody. P703P was found to be expressed at high levels in normal prostate and prostate tumor tissue but was not detectable in all other tissues
10 tested (breast tumor, lung tumor and normal kidney).

e) Preparation and Characterization of Antibodies against P504S

Full-length P504S (SEQ ID NO: 108) was expressed and purified from bacteria essentially as described above for P501S and employed to raise rabbit monoclonal antibodies using Selected Lymphocyte Antibody Method (SLAM)
15 technology at Immgenics Pharmaceuticals (Vancouver, BC, Canada). The anti-P504S monoclonal antibody 13H4 was shown by Western blot to bind to both expressed recombinant P504S and to native P504S in tumor cells.

Immunohistochemical studies using 13H4 to assess P504S expression in various prostate tissues were performed as described above. A total of 104 cases,
20 including 65 cases of radical prostatectomies with prostate cancer (PC), 26 cases of prostate biopsies and 13 cases of benign prostate hyperplasia (BPH), were stained with the anti-P504S monoclonal antibody 13H4. P504S showed strongly cytoplasmic granular staining in 64/65 (98.5%) of PCs in prostatectomies and 26/26 (100%) of PCs in prostatic biopsies. P504S was stained strongly and diffusely in carcinomas (4+ in
25 91.2% of cases of PC; 3+ in 5.5%; 2+ in 2.2% and 1+ in 1.1%) and high grade prostatic intraepithelial neoplasia (4+ in all cases). The expression of P504S did not vary with Gleason score. Only 17/91 (18.7%) of cases of NP/BPH around PC and 2/13 (15.4%) of BPH cases were focally (1+, no 2+ to 4+ in all cases) and weakly positive for P504S in large glands. Expression of P504S was not found in small atrophic glands, postatrophic
30 hyperplasia, basal cell hyperplasia and transitional cell metaplasia in either biopsies or

prostatectomies. P504S was thus found to be over-expressed in all Gleason scores of prostate cancer (98.5 to 100% of sensitivity) and exhibited only focal positivities in large normal glands in 19/104 of cases (82.3% of specificity). These findings indicate that P504S may be usefully employed for the diagnosis of prostate cancer.

5

EXAMPLE 19

CHARACTERIZATION OF CELL SURFACE EXPRESSION AND
CHROMOSOME LOCALIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10 This example describes studies demonstrating that the prostate-specific antigen P501S is expressed on the surface of cells, together with studies to determine the probable chromosomal location of P501S.

The protein P501S (SEQ ID NO: 113) is predicted to have 11 transmembrane domains. Based on the discovery that the epitope recognized by the anti-
15 P501S monoclonal antibody 10E3-G4-D3 (described above in Example 17) is intracellular, it was predicted that following transmembrane determinants would allow the prediction of extracellular domains of P501S. Fig. 9 is a schematic representation of the P501S protein showing the predicted location of the transmembrane domains and the intracellular epitope described in Example 17. Underlined sequence represents the
20 predicted transmembrane domains, bold sequence represents the predicted extracellular domains, and italicized sequence represents the predicted intracellular domains. Sequence that is both bold and underlined represents sequence employed to generate polyclonal rabbit serum. The location of the transmembrane domains was predicted using HHMTOP as described by Tusnady and Simon (Principles Governing Amino
25 Acid Composition of Integral Membrane Proteins: Applications to Topology Prediction, *J. Mol. Biol.* 283:489-506, 1998).

Based on Fig. 9, the P501S domain flanked by the transmembrane domains corresponding to amino acids 274-295 and 323-342 is predicted to be extracellular. The peptide of SEQ ID NO: 518 corresponds to amino acids 306-320 of
30 P501S and lies in the predicted extracellular domain. The peptide of SEQ ID NO: 519,

which is identical to the peptide of SEQ ID NO: 518 with the exception of the substitution of the histidine with an asparagine, was synthesized as described above. A Cys-Gly was added to the C-terminus of the peptide to facilitate conjugation to the carrier protein. Cleavage of the peptide from the solid support was carried out using the following cleavage mixture: trifluoroacetic acid:ethanediol:thioanisol:water:phenol (40:1:2:2:3). After cleaving for two hours, the peptide was precipitated in cold ether. The peptide pellet was then dissolved in 10% v/v acetic acid and lyophilized prior to purification by C18 reverse phase hplc. A gradient of 5-60% acetonitrile (containing 0.05% TFA) in water (containing 0.05% TFA) was used to elute the peptide. The purity of the peptide was verified by hplc and mass spectrometry, and was determined to be >95%. The purified peptide was used to generate rabbit polyclonal antisera as described above.

Surface expression of P501S was examined by FACS analysis. Cells were stained with the polyclonal anti-P501S peptide serum at 10 µg/ml, washed, incubated with a secondary FITC-conjugated goat anti-rabbit Ig antibody (ICN), washed and analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. To demonstrate specificity in these assays, B-LCL transduced with an irrelevant antigen (P703P) or nontransduced were stained in parallel. For FACS analysis of prostate tumor cell lines, Lncap, PC-3 and DU-145 were utilized. Prostate tumor cell lines were dissociated from tissue culture plates using cell dissociation medium and stained as above. All samples were treated with propidium iodide (PI) prior to FACS analysis, and data was obtained from PI-excluding (*i.e.*, intact and non-permeabilized) cells. The rabbit polyclonal serum generated against the peptide of SEQ ID NO: 519 was shown to specifically recognize the surface of cells transduced to express P501S, demonstrating that the epitope recognized by the polyclonal serum is extracellular.

To determine biochemically if P501S is expressed on the cell surface, peripheral membranes from Lncap cells were isolated and subjected to Western blot analysis. Specifically, Lncap cells were lysed using a dounce homogenizer in 5 ml of homogenization buffer (250 mM sucrose, 10 mM HEPES, 1mM EDTA, pH 8.0, 1

complete protease inhibitor tablet (Boehringer Mannheim)). Lysate samples were spun at 1000 g for 5 min at 4 °C. The supernatant was then spun at 8000g for 10 min at 4 °C. Supernatant from the 8000g spin was recovered and subjected to a 100,000g spin for 30 min at 4 °C to recover peripheral membrane. Samples were then separated by SDS-
5 PAGE and Western blotted with the mouse monoclonal antibody 10E3-G4-D3 (described above in Example 17) using conditions described above. Recombinant purified P501S, as well as HEK293 cells transfected with and over-expressing P501S were included as positive controls for P501S detection. LCL cell lysate was included as a negative control. P501S could be detected in Lncap total cell lysate, the 8000g
10 (internal membrane) fraction and also in the 100,000g (plasma membrane) fraction. These results indicate that P501S is expressed at, and localizes to, the peripheral membrane.

To demonstrate that the rabbit polyclonal antiserum generated to the peptide of SEQ ID NO: 519 specifically recognizes this peptide as well as the
15 corresponding native peptide of SEQ ID NO: 518, ELISA analyses were performed. For these analyses, flat-bottomed 96 well microtiter plates were coated with either the peptide of SEQ ID NO: 519, the longer peptide of SEQ ID NO: 520 that spans the entire predicted extracellular domain, the peptide of SEQ ID NO: 521 which represents the epitope recognized by the P501S-specific antibody 10E3-G4-D3, or a P501S fragment
20 (corresponding to amino acids 355-526 of SEQ ID NO: 113) that does not include the immunizing peptide sequence, at 1 µg/ml for 2 hours at 37 °C. Wells were aspirated, blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified anti-P501S polyclonal rabbit serum was added at 2 fold dilutions (1000 ng -
25 125 ng) in PBST and incubated for 30 min at room temperature. This was followed by washing 6 times with PBST and incubating with HRP-conjugated goat anti-rabbit IgG (H+L) Affinipure F(ab') fragment at 1:20000 for 30 min. Plates were then washed and incubated for 15 min in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As
30 shown in Fig. 11, the anti-P501S polyclonal rabbit serum specifically recognized the

peptide of SEQ ID NO: 519 used in the immunization as well as the longer peptide of SEQ ID NO: 520, but did not recognize the irrelevant P501S-derived peptides and fragments.

In further studies, rabbits were immunized with peptides derived from the P501S sequence and predicted to be either extracellular or intracellular, as shown in Fig. 9. Polyclonal rabbit sera were isolated and polyclonal antibodies in the serum were purified, as described above. To determine specific reactivity with P501S, FACS analysis was employed, utilizing either B-LCL transduced with P501S or the irrelevant antigen P703P, of B-LCL infected with vaccinia virus-expressing P501S. For surface expression, dead and non-intact cells were excluded from the analysis as described above. For intracellular staining, cells were fixed and permeabilized as described above. Rabbit polyclonal serum generated against the peptide of SEQ ID NO: 548, which corresponds to amino acids 181-198 of P501S, was found to recognize a surface epitope of P501S. Rabbit polyclonal serum generated against the peptide SEQ ID NO: 551, which corresponds to amino acids 543-553 of P501S, was found to recognize an epitope that was either potentially extracellular or intracellular since in different experiments intact or permeabilized cells were recognized by the polyclonal sera. Based on similar deductive reasoning, the sequences of SEQ ID NO: 541-547, 549 and 550, which correspond to amino acids 109-122, 539-553, 509-520, 37-54, 342-359, 295-323, 217-274, 143-160 and 75-88, respectively, of P501S, can be considered to be potential surface epitopes of P501S recognized by antibodies.

In further studies, mouse monoclonal antibodies were raised against amino acids 296 to 322 to P501S, which are predicted to be in an extracellular domain. A/J mice were immunized with P501S/adenovirus, followed by subsequent boosts with an *E. coli* recombinant protein, referred to as P501N, that contains amino acids 296 to 322 of P501S, and with peptide 296-322 (SEQ ID NO: 755) coupled with KLH. The mice were subsequently used for splenic B cell fusions to generate anti-peptide hybridomas. The resulting 3 clones, referred to as 4F4 (IgG1,kappa), 4G5 (IgG2a,kappa) and 9B9 (IgG1,kappa), were grown for antibody production. The 4G5 mAb was purified by passing the supernatant over a Protein A-sepharose column,

followed by antibody elution using 0.2M glycine, pH 2.3. Purified antibody was neutralized by the addition of 1M Tris, pH 8, and buffer exchanged into PBS.

For ELISA analysis, 96 well plates were coated with P501S peptide 296-322 (referred to as P501-long), an irrelevant P775 peptide, P501S-N, P501TR2, P501S-long-KLH, P501S peptide 306-319 (referred to as P501-short)-KLH, or the irrelevant peptide 2073-KLH, all at a concentration of 2 ug/ml and allowed to incubate for 60 minutes at 37 °C. After coating, plates were washed 5X with PBS + 0.1% Tween and then blocked with PBS, 0.5% BSA, 0.4% Tween20 for 2 hours at room temperature. Following the addition of supernatants or purified mAb, the plates were incubated for 60 minutes at room temperature. Plates were washed as above and donkey anti-mouse IgHRP-linked secondary antibody was added and incubated for 30 minutes at room temperature, followed by a final washing as above. TMB peroxidase substrate was added and incubated 15 minutes at room temperature in the dark. The reaction was stopped by the addition of 1N H₂SO₄ and the OD was read at 450 nM. All three hybrid clones secreted mAb that recognized peptide 296-322 and the recombinant protein P501N.

For FACS analysis, HEK293 cells were transiently transfected with a P501S/VR1012 expression constructs using Fugene 6 reagent. After 2 days of culture, cells were harvested and washed, then incubated with purified 4G5 mAb for 30 minutes on ice. After several washes in PBS, 0.5% BSA, 0.01% azide, goat anti-mouse Ig-FITC was added to the cells and incubated for 30 minutes on ice. Cells were washed and resuspended in wash buffer including 1% propidium iodide and subjected to FACS analysis. The FACS analysis confirmed that amino acids 296-322 of P501S are in an extracellular domain and are cell surface expressed.

The chromosomal location of P501S was determined using the GeneBridge 4 Radiation Hybrid panel (Research Genetics). The PCR primers of SEQ ID NO: 528 and 529 were employed in PCR with DNA pools from the hybrid panel according to the manufacturer's directions. After 38 cycles of amplification, the reaction products were separated on a 1.2% agarose gel, and the results were analyzed through the Whitehead Institute/MIT Center for Genome Research web server

(<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>) to determine the probable chromosomal location. Using this approach, P501S was mapped to the long arm of chromosome 1 at WI-9641 between q32 and q42. This region of chromosome 1 has been linked to prostate cancer susceptibility in hereditary prostate cancer (Smith *et al.* *Science* 274:1371-1374, 1996 and Berthon *et al.* *Am. J. Hum. Genet.* 62:1416-1424, 1998). These results suggest that P501S may play a role in prostate cancer malignancy.

EXAMPLE 20

REGULATION OF EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10

Steroid (androgen) hormone modulation is a common treatment modality in prostate cancer. The expression of a number of prostate tissue-specific antigens have previously been demonstrated to respond to androgen. The responsiveness of the prostate-specific antigen P501S to androgen treatment was examined in a tissue culture system as follows.

15

Cells from the prostate tumor cell line LNCaP were plated at 1.5×10^6 cells/T75 flask (for RNA isolation) or 3×10^5 cells/well of a 6-well plate (for FACS analysis) and grown overnight in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum (BRL Life Technologies, Gaithersburg, MD). Cell culture was continued for an additional 72 hours in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum, with 1 nM of the synthetic androgen Methyltrienolone (R1881; New England Nuclear) added at various time points. Cells were then harvested for RNA isolation and FACS analysis at 0, 1, 2, 4, 8, 16, 24, 28 and 72-hours post androgen addition. FACS analysis was performed using the anti-P501S antibody 10E3-G4-D3 and permeabilized cells.

25

For Northern analysis, 5-10 micrograms of total RNA was run on a formaldehyde denaturing gel, transferred to Hybond-N nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ), cross-linked and stained with methylene blue. The filter was then prehybridized with Church's Buffer (250 mM Na_2HPO_4 , 70 mM H_3PO_4 , 1 mM EDTA, 1% SDS, 1% BSA in pH 7.2) at 65 °C for 1 hour. P501S DNA was

30

labeled with ^{32}P using High Prime random-primed DNA labeling kit (Boehringer Mannheim). Unincorporated label was removed using MicroSpin S300-HR columns (Amersham Pharmacia Biotech). The RNA filter was then hybridized with fresh Church's Buffer containing labeled cDNA overnight, washed with 1X SCP (0.1 M NaCl, 0.03 M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 0.001 M Na_2EDTA), 1% sarkosyl (n-lauroylsarcosine) and exposed to X-ray film.

Using both FACS and Northern analysis, P501S message and protein levels were found to increase in response to androgen treatment.

10

EXAMPLE 20

PREPARATION OF FUSION PROTEINS OF PROSTATE-SPECIFIC ANTIGENS

The example describes the preparation of a fusion protein of the prostate-specific antigen P703P and a truncated form of the known prostate antigen PSA. The truncated form of PSA has a 21 amino acid deletion around the active serine site. The expression construct for the fusion protein also has a restriction site at 3' end, immediately prior to the termination codon, to aid in adding cDNA for additional antigens.

The full-length cDNA for PSA was obtained by RT-PCR from a pool of RNA from human prostate tumor tissues using the primers of SEQ ID NO: 607 and 608, and cloned in the vector pCR-Blunt II-TOPO. The resulting cDNA was employed as a template to make two different fragments of PSA by PCR with two sets of primers (SEQ ID NO: 609 and 610; and SEQ ID NO: 611 and 612). The PCR products having the expected size were used as templates to make truncated forms of PSA by PCR with the primers of SEQ ID NO: 611 and 613, which generated PSA (delta 208-218 in amino acids). The cDNA for the mature form of P703P with a 6X histidine tag at the 5' end, was prepared by PCR with P703P and the primers of SEQ ID NO: 614 and 615. The cDNA for the fusion of P703P with the truncated form of PSA (referred to as FOPP) was then obtained by PCR using the modified P703P cDNA and the truncated form of PSA cDNA as templates and the primers of SEQ ID NO: 614 and 615. The FOPP

cDNA was cloned into the NdeI site and XhoI site of the expression vector pCRX1, and confirmed by DNA sequencing. The determined cDNA sequence for the fusion construct FOPP is provided in SEQ ID NO: 616, with the amino acid sequence being provided in SEQ ID NO: 617.

5 The fusion FOPP was expressed as a single recombinant protein in *E. coli* as follows. The expression plasmid pCRX1FOPP was transformed into the *E. coli* strain BL21-CodonPlus RIL. The transformant was shown to express FOPP protein upon induction with 1 mM IPTG. The culture of the corresponding expression clone was inoculated into 25 ml LB broth containing 50 ug/ml kanamycin and 34 ug/ml
10 chloramphenicol, grown at 37 °C to OD600 of about 1, and stored at 4 °C overnight. The culture was diluted into 1 liter of TB LB containing 50 ug/ml kanamycin and 34 ug/ml chloramphenicol, and grown at 37 °C to OD600 of 0.4. IPTG was added to a final concentration of 1 mM, and the culture was incubated at 30 °C for 3 hours. The cells were pelleted by centrifugation at 5,000 RPM for 8 min. To purify the protein, the
15 cell pellet was suspended in 25 ml of 10 mM Tris-Cl pH 8.0, 2mM PMSF, complete protease inhibitor and 15 ug lysozyme. The cells were lysed at 4 °C for 30 minutes, sonicated several times and the lysate centrifuged for 30 minutes at 10,000 x g. The precipitate, which contained the inclusion body, was washed twice with 10 mM Tris-Cl pH 8.0 and 1% CHAPS. The inclusion body was dissolved in 40 ml of 10 mM Tris-Cl
20 pH 8.0, 100 mM sodium phosphate and 8 M urea. The solution was bound to 8 ml Ni-NTA (Qiagen) for one hour at room temperature. The mixture was poured into a 25 ml column and washed with 50 ml of 10 mM Tris-Cl pH 6.3, 100 mM sodium phosphate, 0.5% DOC and 8M urea. The bound protein was eluted with 350 mM imidazole, 10 mM Tris-Cl pH 8.0, 100 mM sodium phosphate and 8 M urea. The fractions containing
25 FOPP proteins were combined and dialyzed extensively against 10 mM Tris-Cl pH 4.6, aliquoted and stored at - 70 °C.

EXAMPLE 21

REAL-TIME PCR CHARACTERIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S IN
PERIPHERAL BLOOD OF PROSTATE CANCER PATIENTS

- 5 Circulating epithelial cells were isolated from fresh blood of normal individuals and metastatic prostate cancer patients, mRNA isolated and cDNA prepared using real-time PCR procedures. Real-time PCR was performed with the TaqmanTM procedure using both gene specific primers and probes to determine the levels of gene expression.
- 10 Epithelial cells were enriched from blood samples using an immunomagnetic bead separation method (Dynal A.S., Oslo, Norway). Isolated cells were lysed and the magnetic beads removed. The lysate was then processed for poly A+ mRNA isolation using magnetic beads coated with Oligo(dT)25. After washing the beads in buffer, bead/poly A+ RNA samples were suspended in 10 mM Tris HCl pH 8.0
- 15 and subjected to reversed transcription. The resulting cDNA was subjected to real-time PCR using gene specific primers. Beta-actin content was also determined and used for normalization. Samples with P501S copies greater than the mean of the normal samples + 3 standard deviations were considered positive. Real time PCR on blood samples was performed using the TaqmanTM procedure but extending to 50 cycles using
- 20 forward and reverse primers and probes specific for P501S. Of the eight samples tested, 6 were positive for P501S and β -actin signal. The remaining 2 samples had no detectable β -actin or P501S. No P501S signal was observed in the four normal blood samples tested.

25

EXAMPLE 22

EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGENS P703P AND P501S IN
SCID MOUSE-PASSAGED PROSTATE TUMORS

- When considering the effectiveness of antigens in the treatment of
- 30 prostate cancer, the continued presence of the antigens in tumors during androgen

ablation therapy is important. The presence of the prostate-specific antigens P703P and P501S in prostate tumor samples grown in SCID mice in the presence of testosterone was evaluated as follows.

Two prostate tumors that had metastasized to the bone were removed
5 from patients, implanted into SCID mice and grown in the presence of testosterone. Tumors were evaluated for mRNA expression of P703P, P501S and PSA using quantitative real time PCR with the SYBR green assay method. Expression of P703P and P501S in a prostate tumor was used as a positive control and the absence in normal intestine and normal heart as negative controls. In both cases, the specific mRNA was
10 present in late passage tumors. Since the bone metastases were grown in the presence of testosterone, this implies that the presence of these genes would not be lost during androgen ablation therapy.

EXAMPLE 23

15 ANTI-P503S MONOCLONAL ANTIBODY INHIBITS TUMOR GROWTH *IN VIVO*

The ability of the anti-P503S monoclonal antibody 20D4 to suppress tumor formation in mice was examined as follows.

Ten SCID mice were injected subcutaneously with HEK293 cells that expressed P503S. Five mice received 150 micrograms of 20D4 intravenously at day 0
20 (time of tumor cell injection), day 5 and day 9. Tumor size was measured for 50 days. Of the five animals that received no 20D4, three formed detectable tumors after about 2 weeks which continued to enlarge throughout the study. In contrast, none of the five mice that received 20D4 formed tumors. These results demonstrate that the anti-P503S Mab 20D4 displays potent anti-tumor activity *in vivo*.

25

EXAMPLE 24

CHARACTERIZATION OF A T CELL RECEPTOR CLONE FROM A P501S-SPECIFIC T CELL CLONE

30 T cells have a limited lifespan. However, cloning of T cell receptor (TCR) chains and subsequent transfer essentially enables infinite propagation of the T

cell specificity. Cloning of tumor-antigen TCR chains allows the transfer of the specificity into T cells isolated from patients that share the TCR MHC-restricting allele. Such T cells could then be expanded and used in adoptive transfer settings to introduce the tumor antigen specificity into patients carrying tumors that express the antigen. T
5 cell receptor alpha and beta chains from a CD8 T cell clone specific for the prostate-specific antigen P501S were isolated and sequenced as follows.

Total mRNA from 2×10^6 cells from CTL clone 4E5 (described above in Example 12) was isolated using Trizol reagent and cDNA was synthesized. To determine Va and Vb sequences in this clone, a panel of Va and Vb subtype-specific
10 primers was synthesized and used in RT-PCR reactions with cDNA generated from each of the clones. The RT-PCR reactions demonstrated that each of the clones expressed a common Vb sequence that corresponded to the Vb7 subfamily. Furthermore, using cDNA generated from the clone, the Va sequence expressed was determined to be Va6. To clone the full TCR alpha and beta chains from clone 4E5,
15 primers were designed that spanned the initiator and terminator-coding TCR nucleotides. The primers were as follows: TCR Valpha-6 5'(sense): GGATCC---GCCGCCACC---ATGTCACCTTTCTAGCCTGCT (SEQ ID NO: 756) BamHI site Kozak TCR alpha sequence TCR alpha 3' (antisense): GTCGAC---TCAGCTGGACCACAGCCGCAG (SEQ ID NO: 757) Sall site TCR alpha constant
20 sequence TCR Vbeta-7. 5'(sense): GGATCC---GCCGCCACC--ATGGGCTGCAGGCTGCTCT (SEQ ID NO: 758) BamHI site. Kozak TCR alpha sequence TCR beta 3' (antisense): GTCGAC---TCAGAAATCCTTTCTCTTGAC (SEQ ID NO: 759) Sall site TCR beta constant sequence. Standard 35 cycle RT-PCR reactions were established using cDNA synthesized from the CTL clone and the above
25 primers, employing the proofreading thermostable polymerase PWO (Roche, Nutley, NJ).

The resultant specific bands (approx. 850 bp for alpha and approx. 950 for beta) were ligated into the PCR blunt vector (Invitrogen) and transformed into *E. coli*. *E. coli* transformed with plasmids containing full-length alpha and beta chains
30 were identified, and large scale preparations of the corresponding plasmids were generated. Plasmids containing full-length TCR alpha and beta chains were submitted

for sequencing. The sequencing reactions demonstrated the cloning of full-length TCR alpha and beta chains with the determined cDNA sequences for the Vb and Va chains being shown in SEQ ID NO: 760 and 761, respectively. The corresponding amino acid sequences are shown in SEQ ID NO: 762 and 763, respectively. The Va sequence was
5 shown by nucleotide sequence alignment to be 99% identical (347/348) to Va6.2, and the Vb to be 99% identical to Vb7 (336/338).

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration,
10 various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is Claimed:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788 under moderately stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-

375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

(g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(b) sequences having at least 70% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(c) sequences having at least 90% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-

629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

- (d) sequences encoded by a polynucleotide of claim 1;
- (e) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and
- (f) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. A host cell transformed or transfected with an expression vector according to claim 3.

5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7. A fusion protein comprising at least one polypeptide according to claim 2.